PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gershon, D				Gershon, D			Canada catalyses health research with thirteen virtual institutes	NATURE			English	Editorial Material																		2000, NATURE, V406, P445	1	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					113	114		10.1038/35024216	http://dx.doi.org/10.1038/35024216			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993084				2022-12-28	WOS:000089124000057
J	Gershon, D				Gershon, D			Research gets a new lease of life as Canada takes the initiative	NATURE			English	Editorial Material																			0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					113	114		10.1038/35024216	http://dx.doi.org/10.1038/35024216			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993084				2022-12-28	WOS:000089124000056
J	Leung, WC; Whitty, P				Leung, WC; Whitty, P			Is evidence based medicine neglected by royal college examinations? A descriptive study of their syllabuses	BRITISH MEDICAL JOURNAL			English	Article									Newcastle City Hlth Trust, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Newcastle Upon Tyne, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Leung, WC (corresponding author), Newcastle City Hlth Trust, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.							*GEN MED COUNC, 1993, TOM DOCT REC UND MED; McAlister FA, 1999, J GEN INTERN MED, V14, P236, DOI 10.1046/j.1525-1497.1999.00323.x; Molesworth N, 1998, BRIT MED J, V317, P1720, DOI 10.1136/bmj.317.7174.1720a; Norman GR, 1998, CAN MED ASSOC J, V158, P177; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					603	604		10.1136/bmj.321.7261.603	http://dx.doi.org/10.1136/bmj.321.7261.603			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977836	Bronze, Green Published			2022-12-28	WOS:000089243200020
J	Pascual, M; Rodo, X; Ellner, SP; Colwell, R; Bouma, MJ				Pascual, M; Rodo, X; Ellner, SP; Colwell, R; Bouma, MJ			Cholera dynamics and El Nino-Southern Oscillation	SCIENCE			English	Article							INTRASEASONAL OSCILLATIONS; GLOBAL ATMOSPHERE; TIME-SERIES; HEMISPHERE; CHAOS; LIMA; PERU	Analysis of a monthly 18-year cholera time series from Bangladesh shows that the temporal variability of cholera exhibits an interannual component at the dominant frequency of El Nino-Southern Oscillation (ENSO). Results from nonlinear time series analysis support a role for both ENSO and previous disease Levels in the dynamics of cholera. Cholera patterns are Linked to the previously described changes in the atmospheric circulation of south Asia and, consistent with these changes, to regional temperature anomalies.	Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Columbus Ctr, Baltimore, MD 21202 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA; Univ Barcelona, Dept Ecol, E-08028 Barcelona, Catalunya, Spain; PCB Univ Barcelona, Climat Res Grp, E-08028 Barcelona, Catalunya, Spain; Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; Univ Maryland, Dept Cell & Mol Biol, College Pk, MD 20742 USA; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University System of Maryland; University of Maryland Baltimore; Woods Hole Oceanographic Institution; University of Barcelona; Cornell University; University System of Maryland; University of Maryland College Park; University of London; London School of Hygiene & Tropical Medicine	Pascual, M (corresponding author), Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Columbus Ctr, 701 E Pratt St,Suite 236, Baltimore, MD 21202 USA.		Rodó, Xavier/F-7663-2017	Rodó, Xavier/0000-0003-4843-6180				BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; BRYDEN JL, 1871, EPIDEMIC CHOLERA BEN; Casdagli M., 1992, NONLINEAR MODELING F; Checkley W, 2000, LANCET, V355, P442, DOI 10.1016/S0140-6736(00)82010-3; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; EPSTEIN PR, 1993, LANCET, V342, P1216, DOI 10.1016/0140-6736(93)92191-U; Finkenstadt B, 1998, P ROY SOC B-BIOL SCI, V265, P753, DOI 10.1098/rspb.1998.0357; Franco AA, 1997, AM J EPIDEMIOL, V146, P1067, DOI 10.1093/oxfordjournals.aje.a009235; GHIL M, 1991, J ATMOS SCI, V48, P752, DOI 10.1175/1520-0469(1991)048<0752:IOITGA>2.0.CO;2; GHIL M, 1991, J ATMOS SCI, V48, P780, DOI 10.1175/1520-0469(1991)048<0780:IOITGA>2.0.CO;2; HARRISON EF, 1990, J GEOPHYS RES-ATMOS, V95, P18687, DOI 10.1029/JD095iD11p18687; Klein SA, 1999, J CLIMATE, V12, P917, DOI 10.1175/1520-0442(1999)012<0917:RSSTVD>2.0.CO;2; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; NYCHKA D, 1992, J ROY STAT SOC B MET, V54, P399; ROSSOW WB, 1991, B AM METEOROL SOC, V72, P2, DOI 10.1175/1520-0477(1991)072<0002:ICDP>2.0.CO;2; SalazarLindo E, 1997, LANCET, V350, P1597, DOI 10.1016/S0140-6736(05)64013-5; SCHAFFER WM, 1990, UBIQUITY OF CHAOS, P138; SCHMETZ J, 1995, ADV SPACE RES, V16, P69, DOI 10.1016/0273-1177(95)00382-O; SCHWARTZ IB, 1992, J MATH BIOL, V30, P473, DOI 10.1007/BF00160532; SCHWARTZ IB, 1983, J MATH BIOL, V18, P233, DOI 10.1007/BF00276090; Soden BJ, 1996, J GEOPHYS RES-ATMOS, V101, P9333, DOI 10.1029/96JD00280; Takens F., 1981, DYNAMICAL SYSTEMS TU, V898, P366, DOI [10.1007/bfb0091924, DOI 10.1007/BFB0091924, 10.1007/BFb0091924]; VAUTARD R, 1989, PHYSICA D, V35, P395, DOI 10.1016/0167-2789(89)90077-8	24	361	370	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1766	1769		10.1126/science.289.5485.1766	http://dx.doi.org/10.1126/science.289.5485.1766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976073				2022-12-28	WOS:000089195200051
J	Roberts, G; Scully, C; Shotts, R				Roberts, G; Scully, C; Shotts, R			ABC of oral health - Dental emergencies	BRITISH MEDICAL JOURNAL			English	Review							HEAD-INJURY; ADMISSIONS; ASSAULT		Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England	University of London; University College London	Roberts, G (corresponding author), Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England.							ANDREASEN JO, 1994, TXB COLOUR ATLAS TRA; Bishop BG, 1997, MIL MED, V162, P130, DOI 10.1093/milmed/162.2.130; Gilthorpe MS, 1999, BRIT J ORAL MAX SURG, V37, P294, DOI 10.1054/bjom.1998.0039; Moles DR, 1999, BRIT J ORAL MAX SURG, V37, P301, DOI 10.1054/bjom.1998.0040; Muthukrishnan A, 1996, Dent Update, V23, P316; Nelson Linda P., 1997, Current Opinion in Pediatrics, V9, P242, DOI 10.1097/00008480-199706000-00010; Roberts G, 1996, ORAL DENT TRAUMA CHI; Sheller B, 1997, Pediatr Dent, V19, P470	8	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					559	562		10.1136/bmj.321.7260.559	http://dx.doi.org/10.1136/bmj.321.7260.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968824	Green Published			2022-12-28	WOS:000089174100025
J	Betancourt, JL; Latorre, C; Rech, JA; Quade, J; Rylander, KA				Betancourt, JL; Latorre, C; Rech, JA; Quade, J; Rylander, KA			A 22,000-year record of monsoonal precipitation from Northern Chile's Atacama Desert	SCIENCE			English	Article							ATMOSPHERIC METHANE CONCENTRATION; ABRUPT CLIMATE-CHANGE; LAST GLACIAL MAXIMUM; SOUTHERN GREAT-BASIN; LAKE-TITICACA; CENTRAL ANDES; SUMMERTIME PRECIPITATION; HOLOCENE PALEOHYDROLOGY; BOLIVIAN ALTIPLANO; TROPICAL CLIMATE	Fossil rodent middens and wetland deposits from the central Atacama Desert (22 degrees to 24 degrees S) indicate increasing summer precipitation, grass cover, and groundwater levels from 16.2 to 10.5 calendar kiloyears before present(ky B.P.). Higher elevation shrubs and summer-flowering grasses expanded downslope across what is now the edge of Absolute Desert, a broad expanse now largely devoid of rainfall and vegetation. Paradoxically, this pluvial period coincided with the summer insolation minimum and reduced adiabatic heating over the central Andes. Summer precipitation over the central Andes and central Atacama may depend on remote teleconnections between seasonal insolation forcing in both hemispheres, the Asian monsoon, and Pacific sea surface temperature gradients. A Less pronounced episode of higher groundwater Levels in the central Atacama from 8 to 3 ky B.P. conflicts with an extreme lowstand of Lake Titicaca, indicating either different climatic forcing or different response times and sensitivities to climatic change.	US Geol Survey, Tucson, AZ 85745 USA; Univ Chile, Fac Ciencias, Lab Bot, Santiago, Chile; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA	United States Department of the Interior; United States Geological Survey; Universidad de Chile; University of Arizona	Betancourt, JL (corresponding author), US Geol Survey, 1675 W Anklam Rd, Tucson, AZ 85745 USA.	jlbetanc@usgs.gov	Latorre, Claudio/P-3917-2019; Latorre, Claudio/E-6805-2012	Latorre, Claudio/0000-0003-4708-7599; Latorre, Claudio/0000-0003-4708-7599				Abbott MB, 1997, QUATERNARY RES, V47, P169, DOI 10.1006/qres.1997.1881; Abbott MB, 1997, QUATERNARY RES, V47, P70, DOI 10.1006/qres.1996.1874; ARAVENA R, 1990, WATER RESOUR RES, V26, P2887, DOI 10.1029/WR026i012p02887; ARROYO MTK, 1988, ANN MO BOT GARD, V75, P55, DOI 10.2307/2399466; ARROYO MTK, 1999, GAYANA BOT, V55, P93; BAIED CA, 1993, MT RES DEV, V13, P145, DOI 10.2307/3673632; Baucom PC, 1999, J SEDIMENT RES, V69, P597, DOI 10.2110/jsr.69.597; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Betancourt J.L., 1990, PACKRAT MIDDENS LAST; BILLS BG, 1994, GEOPHYS RES LETT, V21, P293, DOI 10.1029/93GL03544; Blodgett T.A., 1997, EARTH INTERACTIONS, V1; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; CHAPPELLAZ J, 1990, NATURE, V345, P127, DOI 10.1038/345127a0; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CLAPPERTON CM, 1993, PALAEOGEOGR PALAEOCL, V101, P189, DOI 10.1016/0031-0182(93)90012-8; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Colinvaux PA, 1996, SCIENCE, V274, P85, DOI 10.1126/science.274.5284.85; Cross SL, 2000, HOLOCENE, V10, P21, DOI 10.1191/095968300671452546; Garreaud RD, 1999, MON WEATHER REV, V127, P901, DOI 10.1175/1520-0493(1999)127<0901:MAOTSP>2.0.CO;2; Geyh MA, 1999, QUATERNARY RES, V52, P143, DOI 10.1006/qres.1999.2060; Grosjean M, 1997, QUATERNARY RES, V48, P239, DOI 10.1006/qres.1997.1917; GROSJEAN M, 1994, PALAEOGEOGR PALAEOCL, V109, P89, DOI 10.1016/0031-0182(94)90119-8; GROSJEAN M, 1995, J PALEOLIMNOL, V14, P241, DOI 10.1007/BF00682426; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Lenters JD, 1999, MON WEATHER REV, V127, P409, DOI 10.1175/1520-0493(1999)127<0409:SPVOSA>2.0.CO;2; LIU Z, 1999, PAGES NEWSL, V2, P16; Marquet PA, 1998, REV CHIL HIST NAT, V71, P593; Marticorena C., 1998, Gayana Botanica, V55, P23; Martin L, 1997, QUATERNARY RES, V47, P117, DOI 10.1006/qres.1996.1866; Mourguiart P, 1998, PALAEOGEOGR PALAEOCL, V143, P51, DOI 10.1016/S0031-0182(98)00068-6; Quade J, 1998, QUATERNARY RES, V49, P129, DOI 10.1006/qres.1997.1959; QUADE J, 1995, GEOL SOC AM BULL, V107, P213, DOI 10.1130/0016-7606(1995)107<0213:FSDITS>2.3.CO;2; RODBELL DT, IN PRESS QUAT RES; RONDEAU B, 1990, THESIS U QUEBEC MONT; Schwalb A, 1999, PALAEOGEOGR PALAEOCL, V148, P153, DOI 10.1016/S0031-0182(98)00181-3; Seltzer G, 2000, GEOLOGY, V28, P35; Seltzer GO, 1998, GEOLOGY, V26, P167, DOI 10.1130/0091-7613(1998)026<0167:HRSRPF>2.3.CO;2; SERVANT M, 1978, CAHIERS ORSTOM G, V10, P5; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; Sylvestre F, 1999, QUATERNARY RES, V51, P54, DOI 10.1006/qres.1998.2017; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; ValeroGarces BL, 1996, J PALEOLIMNOL, V16, P1; VILLAGRAN C, 1981, VEGETATIO, V48, P3, DOI 10.1007/BF00117356; Villagran C., 1983, REV CHIL HIST NAT, V56, P137; Vuille M, 1999, INT J CLIMATOL, V19, P1579, DOI 10.1002/(SICI)1097-0088(19991130)19:14<1579::AID-JOC441>3.0.CO;2-N; Vuille M, 2000, J GEOPHYS RES-ATMOS, V105, P12447, DOI 10.1029/2000JD900134; WIRRMANN D, 1987, PALAEOGEOGR PALAEOCL, V59, P315, DOI 10.1016/0031-0182(87)90088-5; WIRRMANN D, 1997, QUATERNARY RES, V43, P344	54	246	262	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1542	1546		10.1126/science.289.5484.1542	http://dx.doi.org/10.1126/science.289.5484.1542			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968788				2022-12-28	WOS:000089071700044
J	Dai, PC; Mook, HA; Aeppli, G; Hayden, SM; Dogan, F				Dai, PC; Mook, HA; Aeppli, G; Hayden, SM; Dogan, F			Resonance as a measure of pairing correlations in the high-T-c superconductor YBa2Cu3O6.6	NATURE			English	Article							NEUTRON-SCATTERING; SPIN FLUCTUATIONS; MECHANISM; MODEL; ANTIFERROMAGNETISM; SPECTRA; STATE; GAP	One of the most striking properties of the high-transition-temperature (high-T-c) superconductors is that they are all derived from insulating antiferromagnetic parent compounds. The intimate relationship between magnetism and superconductivity in these copper oxide materials has intrigued researchers from the outset(1-4), because it does not exist in conventional superconductors. Evidence for this link comes from neutron-scattering experiments that show the unambiguous presence of short-range antiferromagnetic correlations (excitations) in the high-T-c superconductors. Even so, the role of such excitations in the pairing mechanism for superconductivity is still a subject of controversy(5). For YBa2Cu3O6+x, where x controls the hole-doping level, the most prominent feature in the magnetic excitation spectrum is a sharp resonance (refs 6-11). Here we show that for underdoped YBa2Cu3O6.6, where x and T-c are below their optimal values, modest magnetic fields suppress the resonance significantly, much more so for fields approximately perpendicular to the CuO2 planes than for parallel fields. Our results indicate that the resonance measures pairing and phase coherence, suggesting that magnetism plays an important role in high-T-c superconductivity. The persistence of a field effect above T-c favours mechanisms in which the superconducting electron pairs are pre-formed in the normal state of underdoped copper oxide superconductors(12-14), awaiting transition to the superconducting state.	Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; NEC Res Inst, Princeton, NJ 08540 USA; Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; NEC Corporation; University of Bristol; University of Washington; University of Washington Seattle	Dai, PC (corresponding author), Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA.	piq@ornl.gov	Dai, Pengcheng/C-9171-2012; Hayden, Stephen M/F-4162-2011	Dai, Pengcheng/0000-0002-6088-3170; Hayden, Stephen M/0000-0002-3209-027X				Aeppli G, 1999, PHYS STATUS SOLIDI B, V215, P519, DOI 10.1002/(SICI)1521-3951(199909)215:1<519::AID-PSSB519>3.0.CO;2-8; ANDERSON PW, 1990, PHYS REV B, V42, P2624, DOI 10.1103/PhysRevB.42.2624; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Arovas DP, 1997, PHYS REV LETT, V79, P2871, DOI 10.1103/PhysRevLett.79.2871; Basov DN, 1999, SCIENCE, V283, P49, DOI 10.1126/science.283.5398.49; Bourges P, 1997, PHYSICA B, V234, P830, DOI 10.1016/S0921-4526(96)01112-X; Chakravarty S, 2000, PHYS REV B, V61, P14821, DOI 10.1103/PhysRevB.61.14821; Dai P, 1996, PHYS REV LETT, V77, P5425, DOI 10.1103/PhysRevLett.77.5425; Dai PC, 1999, SCIENCE, V284, P1344, DOI 10.1126/science.284.5418.1344; Dai PC, 1998, PHYS REV LETT, V80, P1738, DOI 10.1103/PhysRevLett.80.1738; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; EMERY VJ, 1987, PHYS REV LETT, V58, P2794, DOI 10.1103/PhysRevLett.58.2794; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Fong HF, 1997, PHYS REV LETT, V78, P713, DOI 10.1103/PhysRevLett.78.713; Haworth C, 1998, PHYSICA B, V246, P73, DOI 10.1016/S0921-4526(98)00028-3; HIRSCH JE, 1987, PHYS REV LETT, V59, P228, DOI 10.1103/PhysRevLett.59.228; JANKO B, 1999, CONDMAT9912073; Junod A, 1999, PHYSICA C, V317, P333, DOI 10.1016/S0921-4534(99)00077-5; JUNOD A, 1996, STUDIES HIGH TEMPERA, V19, P1; Lee PA, 1997, PHYS REV LETT, V78, P4111, DOI 10.1103/PhysRevLett.78.4111; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; Renner C, 1998, PHYS REV LETT, V80, P149, DOI 10.1103/PhysRevLett.80.149; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Scalapino DJ, 1999, SCIENCE, V284, P1282, DOI 10.1126/science.284.5418.1282; Scalapino DJ, 1998, PHYS REV B, V58, P8222, DOI 10.1103/PhysRevB.58.8222; SCHULZ HJ, 1987, EUROPHYS LETT, V4, P609, DOI 10.1209/0295-5075/4/5/016; TRANQUADA JM, 1988, PHYS REV LETT, V60, P156, DOI 10.1103/PhysRevLett.60.156; Uemura YJ, 1997, PHYSICA C, V282, P194, DOI 10.1016/S0921-4534(97)00194-9; Yin L, 1997, PHYS REV LETT, V78, P3559, DOI 10.1103/PhysRevLett.78.3559	31	172	172	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					965	968		10.1038/35023094	http://dx.doi.org/10.1038/35023094			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984044	Green Submitted			2022-12-28	WOS:000089020200036
J	Sinervo, B; Svensson, E; Comendant, T				Sinervo, B; Svensson, E; Comendant, T			Density cycles and an offspring quantity and quality game driven by natural selection	NATURE			English	Article							SIZE; POPULATION; EVOLUTION; FINCHES; NUMBER; TESTS	A long-standing hypothesis(1,2) posits that natural selection can favour two female strategies when density cycles. At low density, females producing many smaller progeny are favoured when the intrinsic rate of increase, r, governs population growth. At peak density, females producing fewer, high-quality, progeny are favoured when the carrying capacity, K, is exceeded and the population crashes. Here we report on the first example of a genetic r versus K selection(3-5) game that promotes stable population cycles in lizards. Decade-long fitness studies and game theory demonstrated that two throat-colour morphs were refined by selection in which the strength of natural selection varied with density. Orange-throated females, r strategists, produced many eggs and were favoured at low density. Conversely, yellow-throated females, K strategists, produced large eggs and were favoured at high density. Progeny size should also be under negative frequency-dependent selection in that large progeny will have a survival advantage when rare, but the advantage disappears when they become common. We confirmed this prediction by seeding field plots with rare and common giant hatchlings. Thus, intrinsic causes of frequency- and density-dependent selection promotes an evolutionary game with two-generation oscillations.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Sinervo, B (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Earth & Marine Sci Bldg, Santa Cruz, CA 95064 USA.	sinervo@biology.ucsc.edu	Svensson, Erik/E-8324-2010	Svensson, Erik/0000-0001-9006-016X				BOAG PT, 1981, SCIENCE, V214, P82, DOI 10.1126/science.214.4516.82; BROCKELMAN WY, 1975, AM NAT, V109, P677, DOI 10.1086/283037; BRODIE ED, 1992, EVOLUTION, V46, P1284, DOI 10.1111/j.1558-5646.1992.tb01124.x; Chatfield C, 1992, ANAL TIME SERIES INT, P62; Chitty D, 1960, COLD SPRING HARB SYM, V22, P277; CHITTY DENNIS, 1960, CANADIAN JOUR ZOOL, V38, P99, DOI 10.1139/z60-011; Cooper W.E. Jr, 1992, P298; Endler J.A., 1986, Monographs in Population Biology, pviii; GIBBS HL, 1987, NATURE, V327, P511, DOI 10.1038/327511a0; LANDE R, 1983, EVOLUTION, V37, P1210, DOI 10.2307/2408842; MAC ARTHUR ROBERT H., 1967; Maynard Smith J., 1982, pi; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; RICE WR, 1990, BIOMETRICS, V46, P303, DOI 10.2307/2531435; Sinervo B, 1998, MATERNAL EFFECTS AS ADAPTATIONS, P288; SINERVO B, 1990, SCIENCE, V248, P1106, DOI 10.1126/science.248.4959.1106; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Sinervo B, 1996, EVOLUTION, V50, P1299, DOI 10.1111/j.1558-5646.1996.tb02370.x; SINERVO B, 1991, SCIENCE, V252, P1300, DOI 10.1126/science.252.5010.1300; SINERVO B, 1992, SCIENCE, V258, P1927, DOI 10.1126/science.258.5090.1927; Sinervo B, 2000, ADAPTIVE GENETIC VARIATION IN THE WILD, P41; SINERVO B, 1996, ADAPTATION, P148; SINERVO B, MODEL SYSTEMS BEHAV; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Stearns S.C., 1992, pi; SVENSSON E, IN PRESS EVOLUTION; Wallace B., 1970, GENETIC LOAD ITS BIO; Zeng Z, 1998, ECOLOGY, V79, P2193, DOI 10.1890/0012-9658(1998)079[2193:CPDITR]2.0.CO;2	28	322	323	1	138	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					985	988		10.1038/35023149	http://dx.doi.org/10.1038/35023149			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984050				2022-12-28	WOS:000089020200042
J	Hsu, JY; Sun, ZW; Li, XM; Reuben, M; Tatchell, K; Bishop, DK; Grushcow, JM; Brame, CJ; Caldwell, JA; Hunt, DF; Lin, RL; Smith, MM; Allis, CD				Hsu, JY; Sun, ZW; Li, XM; Reuben, M; Tatchell, K; Bishop, DK; Grushcow, JM; Brame, CJ; Caldwell, JA; Hunt, DF; Lin, RL; Smith, MM; Allis, CD			Mitotic phosphorylation of histone H3 is governed by IpI1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes	CELL			English	Article							PROTEIN SERINE/THREONINE PHOSPHATASES; CAENORHABDITIS-ELEGANS EMBRYOS; MEIOTIC CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; C-ELEGANS; S-PHASE; CONDENSATION; GENE; SEGREGATION; MITOSIS	Phosphorylation of histone H3 at serine 10 occurs during mitosis and meiosis in a wide range of eukaryotes and has been shown to be required for proper chromosome transmission in Tetrahymena. Here we report that Ipl1/aurora kinase and its genetically interacting phosphatase, Glc7/PP1, are responsible for the balance of H3 phosphorylation during mitosis in Saccharomyces cerevisiae and Caenorhabditis elegans. In these models, both enzymes are required for H3 phosphorylation and chromosome segregation, although a causal link between the two processes has not been demonstrated. Deregulation of human aurora kinases has been implicated in oncogenesis as a consequence of chromosome missegregation. Our findings reveal an enzyme system that regulates chromosome dynamics and controls histone phosphorylation that is conserved among diverse eukaryotes.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22908 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Virginia; University of Virginia; University of Virginia; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Chicago; University of Chicago	Lin, RL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA.	rlin@hamon.swmed.edu; allis@virginia.edu	Tatchell, Kelly/A-9643-2009; Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920, R01GM040922] Funding Source: NIH RePORTER; NICHD NIH HHS [HD37933] Funding Source: Medline; NIGMS NIH HHS [GM40922, GM28920] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Baker SH, 1997, GENETICS, V145, P615; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; Boxem M, 1999, DEVELOPMENT, V126, P2227; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRENNER S, 1974, GENETICS, V77, P71; CHAN CSM, 1993, GENETICS, V135, P677; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; CREANOR J, 1993, CELL CYCLE, P25; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS R, 1995, GENETICS, V139, P579; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Jones AR, 1996, DEV BIOL, V180, P165, DOI 10.1006/dbio.1996.0293; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KLAPHOLZ S, 1985, GENETICS, V110, P187; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; MARIAN B, 1982, FEBS LETT, V139, P72, DOI 10.1016/0014-5793(82)80490-0; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Roghi C, 1998, J CELL SCI, V111, P557; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SMITH MM, 1991, METHOD CELL BIOL, V35, P485; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; Sweet MT, 1996, J CELL BIOL, V135, P1219, DOI 10.1083/jcb.135.5.1219; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tatsuka M, 1998, CANCER RES, V58, P4811; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Van Hooser A, 1998, J CELL SCI, V111, P3497; Venturi GM, 2000, GENETICS, V155, P69; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Woollard A, 1999, MECH DEVELOP, V82, P95, DOI 10.1016/S0925-4773(99)00020-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	71	685	714	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					279	291		10.1016/S0092-8674(00)00034-9	http://dx.doi.org/10.1016/S0092-8674(00)00034-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975519	Bronze			2022-12-28	WOS:000088625600004
J	Keatinge, WR; Donaldson, GC; Cordioli, EA; Martinelli, M; Kunst, AE; Mackenbach, JP; Nayha, S; Vuori, I				Keatinge, WR; Donaldson, GC; Cordioli, EA; Martinelli, M; Kunst, AE; Mackenbach, JP; Nayha, S; Vuori, I			Heat related mortality in warm and cold regions of Europe: observational study	BRITISH MEDICAL JOURNAL			English	Article							CLIMATE-CHANGE; TEMPERATURE; STRESS	Objectives To assess heat related mortalities in relation to climate within Europe. Design Observational population study. Setting North Finland, south Finland, Baden-Wurttemberg, Netherlands, London, north Italy, and Athens. Subjects People aged 65-74. Main outcome measures Mortalities at temperatures above, below and within each region's temperature band of minimum mortality. Results Mortality was lowest at 14.3-17.3 degrees C in north Finland but at 22.7-25.7 degrees C in Athens. Overall the 3 degrees C minimum mortality temperature bands were significantly higher in regions with higher than lower mean summer temperatures (P = 0.027). This was not due to regional differences in wind speeds, humidity, rain. As a result, regions with hot summers did not have significantly higher annual hear related mortality per million population than cold regions at temperatures above these bands. Mean annual heat related mortalities were 304 (95% confidence interval 126 to 482) in North Finland, 445 (59 to 831) in Athens, and 40 (13 to 68) in London. Cold related mortalities were 2457 (1130 to 3786), 2533 (965 to 4101), and 3129 (2319 to 3939) respectively. Conclusions Populations in Europe have adjusted successfully to mean summer temperatures ranging from 13.5 degrees C to 24.1 degrees C, and can be expected to adjust to global warming predicted for the next half century with little sustained increase in hear related mortality. Active measures to accelerate adjustment to hot weather could minimise temporary rises in heat related mortality, and measures to maintain protection against cold in winter could permit substantial reductions in overall mortality as temperatures rise.	Univ London Queen Mary & Westfield Coll, London E1 4NS, England; Univ Bologna, Postgrad Sch Cardiol, Bologna, Italy; Erasmus Univ, Dept Hlth, Rotterdam, Netherlands; Reg Inst Occupat Hlth, Oulu, Finland; UKK Inst Hlth Promot Res, Tampere, Finland	University of London; Queen Mary University London; University of Bologna; Erasmus University Rotterdam; UKK Institute	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Med Sci Bldg, London E1 4NS, England.		Donaldson, Gavin/M-7992-2017	Kunst, Anton/0000-0002-3313-5273; Donaldson, Gavin/0000-0002-5538-4190				CONN JW, 1996, J CLIN INVEST, V264, P434; DONALDSON GC, 1997, J EPIDEMIOL COMMUNIT, V51, P43; FALCAO JM, 1977, ACTA MEDICA PORT, V10, P537; HULME M, 1998, 1 UKCIP CLIM RES UN, P1; Kalkstein LS, 1997, ENVIRON HEALTH PERSP, V105, P84, DOI 10.2307/3433067; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; KATSOUYANNI K, 1988, LANCET, V2, P575; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; MACFARLANE A, 1976, NATURE, V264, P434, DOI 10.1038/264434a0; Mackenbach JP, 1997, LANCET, V349, P1297, DOI 10.1016/S0140-6736(05)62510-X; Martens WJM, 1998, SOC SCI MED, V46, P331, DOI 10.1016/S0277-9536(97)00162-7; Rooney C, 1998, J EPIDEMIOL COMMUN H, V52, P482, DOI 10.1136/jech.52.8.482; Sartor F, 1995, ENVIRON RES, V70, P105, DOI 10.1006/enrs.1995.1054; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203	16	243	256	0	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					670	673		10.1136/bmj.321.7262.670	http://dx.doi.org/10.1136/bmj.321.7262.670			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987770	Bronze, Green Published			2022-12-28	WOS:000089444100023
J	Lipshultz, SE; Easley, KA; Orav, EJ; Kaplan, S; Starc, TJ; Bricker, JT; Lai, WW; Moodie, DS; Sopko, G; McIntosh, K; Colan, SD				Lipshultz, SE; Easley, KA; Orav, EJ; Kaplan, S; Starc, TJ; Bricker, JT; Lai, WW; Moodie, DS; Sopko, G; McIntosh, K; Colan, SD		Pediat Pulm Cardiac Complications	Absence of cardiac toxicity of zidovudine in infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IDIOPATHIC DILATED CARDIOMYOPATHY; NUCLEOSIDE ANALOGS; CHILDREN; EXPOSURE	Background: Some evidence suggests that perinatal exposure to zidovudine may cause cardiac abnormalities in infants. We prospectively studied left ventricular structure and function in infants born to mothers infected with the human immunodeficiency virus (HIV) in order to determine whether there was evidence of zidovudine cardiac toxicity after perinatal exposure. Methods: We followed a group of infants born to HIV-infected women from birth to five years of age with echocardiographic studies every four to six months. Serial echocardiograms were obtained for 382 infants without HIV infection (36 with zidovudine exposure) and 58 HIV-infected infants (12 with zidovudine exposure). Repeated-measures analysis was used to examine four measures of left ventricular structure and function during the first 14 months of life in relation to zidovudine exposure. Results: Zidovudine exposure was not associated with significant abnormalities in mean left ventricular fractional shortening, end-diastolic dimension, contractility, or mass in either non-HIV-infected or HIV-infected infants. Among infants without HIV infection, the mean fractional shortening at 10 to 14 months was 38.1 percent for those never exposed to zidovudine and 39.0 percent for those exposed to zidovudine (mean difference, -0.9 percentage point; 95 percent confidence interval, -3.1 to 1.3 percentage points; P=0.43). Among HIV-infected infants, the mean fractional shortening at 10 to 14 months was similar in those never exposed to zidovudine (35.4 percent) and those exposed to the drug (35.3 percent) (mean difference, 0.1 percentage point; 95 percent confidence interval, -3.7 to 3.9 percentage points; P=0.95). Zidovudine exposure was not significantly related to depressed fractional shortening (shortening of 25 percent or less) during the first 14 months of life. No child over the age of 10 months had depressed fractional shortening. Conclusions: Zidovudine was not associated with acute or chronic abnormalities in left ventricular structure or function in infants exposed to the drug in the perinatal period. (N Engl J Med 2000;343:759-66.) (C) 2000, Massachusetts Medical Society.	Univ Rochester, Med Ctr, Div Pediat Cardiol, Rochester, NY 14642 USA; Childrens Hosp Strong, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Boston Med Ctr, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pediat, Div Pediat Cardiol, Cleveland, OH 44195 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Calif Los Angeles, Med Ctr, Dept Pediat, Div Pediat Cardiol, Los Angeles, CA USA; Presbyterian Hosp, Dept Pediat, Div Pediat Cardiol, New York, NY USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Columbia Univ, Sch Med, New York, NY USA; Baylor Coll Med, Dept Pediat, Div Pediat Cardiol, Houston, TX 77030 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Cardiol, New York, NY USA; NHLBI, Bethesda, MD 20892 USA	University of Rochester; University of Rochester; University of Rochester; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Boston Medical Center; Boston University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; NewYork-Presbyterian Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Columbia University; Baylor College of Medicine; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lipshultz, SE (corresponding author), Univ Rochester, Med Ctr, Div Pediat Cardiol, 601 Elmwood Ave,Box 631, Rochester, NY 14642 USA.		, 賴吾為/T-8615-2019; Colan, Steven/ABB-4580-2020; Easley, Kirk A/K-6910-2015	, 賴吾為/0000-0001-9174-8310; Easley, Kirk A/0000-0003-4419-2617	DIVISION OF LUNG DISEASES [N01HR096039, N01HR096038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-96039, N01-HR-96038] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Cardoso JS, 1997, CARDIOLOGY, V88, P26, DOI 10.1159/000177305; Chow HH, 1997, DRUG METAB DISPOS, V25, P412; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; DOMANSKI MJ, 1995, J PEDIATR-US, V127, P137, DOI 10.1016/S0022-3476(95)70275-X; Gerschenson M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P386; GERSCHENSON M, 1999, P 2 C GLOB STRAT PRE, P70; GERSCHENSON M, 1998, AM J HUM GENET, V63, pA164; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Lewis W, 1998, CARDIOLOGY IN AIDS, P317; Lipshultz SE, 1998, CIRCULATION, V97, P1246, DOI 10.1161/01.CIR.97.13.1246; LIPSHULTZ SE, 1992, NEW ENGL J MED, V327, P1260, DOI 10.1056/NEJM199210293271802; LIPSHULTZ SE, 1994, J PEDIATR-US, V125, P563, DOI 10.1016/S0022-3476(94)70008-7; LIPSHULTZ SE, IN PRESS CIRCULATION; MarinGarcia J, 1996, J INHERIT METAB DIS, V19, P309, DOI 10.1007/BF01799259; MarinGarcia J, 1996, CARDIOVASC RES, V31, P306; Morris AAM, 1999, LANCET, V354, P1046, DOI 10.1016/S0140-6736(99)00301-3; Patterson TA, 1997, DRUG METAB DISPOS, V25, P453; Schwartz ML, 1996, CIRCULATION, V94, P2021, DOI 10.1161/01.CIR.94.8.2021; STARC TJ, 1999, PEDIATRICS, V104, P219; Stark RI, 1997, J SOC GYNECOL INVEST, V4, P183, DOI 10.1016/S1071-5576(97)00028-2; STARTARI R, 1998, P 2 WORLD C PED CARD, P1156	23	103	106	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					759	766		10.1056/NEJM200009143431102	http://dx.doi.org/10.1056/NEJM200009143431102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984563				2022-12-28	WOS:000089221300002
J	D'Amico, AV; Schultz, D; Loffredo, M; Dugal, R; Hurwitz, M; Kaplan, I; Beard, CJ; Renshaw, AA; Kantoff, PW				D'Amico, AV; Schultz, D; Loffredo, M; Dugal, R; Hurwitz, M; Kaplan, I; Beard, CJ; Renshaw, AA; Kantoff, PW			Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY	Context Combined treatment using radiation therapy (RT) and androgen suppression therapy (AST) is used to treat men with clinically localized adenocarcinoma of the prostate, but outcome using this combined therapy compared with RT alone is not known. Objective To determine the relative efficacy of RT plus AST vs RT alone among men with clinically localized prostate cancer. Design, Setting, and Patients Retrospective cohort study of 1586 men with prostate cancer who were treated between January 1989 and August 1999 using 3-dimensional conformal RT with (n = 276) or without (n = 1310) 6 months of AST. Main Outcome Measure Relative risk (RR) of prostate-specific antigen (PSA) failure (defined according to the American Society for Therapeutic Radiology and Oncology consensus statement), by treatment and high-, intermediate-, or low-risk group based on serum PSA level, biopsy Gleason score, and 1992 American Joint Commission on Cancer clinical tumor category. Results Estimates of 5-year PSA outcome after RT with or without AST were not statistically different among low-risk patients (P = .09), whereas intermediate- and high risk patients treated with RT plus AST had significantly better outcomes than those treated with RT alone (P < .001 and = .009, respectively). The RR of PSA failure in low-risk patients treated with RT plus AST was 0.5 (95% confidence interval [CI], 0.3-1.1) compared with patients treated with RT alone. The RRs of PSA failure in intermediate-risk and high-risk patients treated with RT plus AST compared with RT alone were 0.2 (95% CI, 0.1-0.3) and 0.4 (95% CI, 0.2-0.8), respectively. Conclusions Our data suggest a significant benefit in 5-year PSA outcomes for men with clinically localized prostate cancer in intermediate- and high-risk groups treated with RT plus AST vs those treated with RT alone. Results from prospective randomized trials currently under way are needed to validate these findings.	Brigham & Womens Hosp, Joint Ctr Radiat Therapy, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02115 USA; Millersville Univ, Dept Math, Millersville, PA 17551 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Brigham & Women's Hospital; Pennsylvania State System of Higher Education (PASSHE); Millersville University of Pennsylvania	D'Amico, AV (corresponding author), Brigham & Womens Hosp, Joint Ctr Radiat Therapy, 75 Francis St,L-2 Level, Boston, MA 02115 USA.			Kantoff, Philip/0000-0001-7275-0597				Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; COX DR, 1972, J R STAT SOC B, V34, P187; Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PILEPICH MV, 2000, 42 ANN M AM SOC THER; Pollack A., 1999, International Journal of Radiation Oncology Biology Physics, V45, P146, DOI 10.1016/S0360-3016(99)90022-6; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; SLIVJAK AM, 1998, INT J RADIAT ONCOL, V42, P176; Smith L. G., 1999, International Journal of Radiation Oncology Biology Physics, V45, P218, DOI 10.1016/S0360-3016(99)90157-8; SOLOWAY MS, 1995, J UROLOGY, V154, P424, DOI 10.1016/S0022-5347(01)67067-8	12	128	128	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1280	1283		10.1001/jama.284.10.1280	http://dx.doi.org/10.1001/jama.284.10.1280			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979115	Bronze			2022-12-28	WOS:000089124600035
J	Ito, T; Okazaki, S				Ito, T; Okazaki, S			Pushing the limits of lithography	NATURE			English	Review							RESOLUTION; NM	The phenomenal rate of increase in the integration density of silicon chips has been sustained in large part by advances in optical lithography - the process that patterns and guides the fabrication of the component semiconductor devices and circuitry. Although the introduction of shorter-wavelength light sources and resolution-enhancement techniques should help maintain the current rate of device miniaturization for several more years, a point will be reached where optical lithography can no longer attain the required feature sizes. Several alternative lithographic techniques under development have the capability to overcome these resolution limits but, at present, no obvious successor to optical lithography has emerged.	Fujitsu Labs Ltd, Atsugi, Kanagawa 2430197, Japan; Assoc Super Adv Elect Technol, Atsugi, Kanagawa 2430198, Japan	Fujitsu Ltd; Fujitsu Laboratories Ltd; Association of Super-Advanced Electronics Technology (ASET)	Ito, T (corresponding author), Fujitsu Labs Ltd, 10 Morinosato Wakamiya, Atsugi, Kanagawa 2430197, Japan.							BERGER SD, 1991, J VAC SCI TECHNOL B, V9, P2996, DOI 10.1116/1.585356; BJORKHOLM JE, 1990, J VAC SCI TECHNOL B, V8, P1509, DOI 10.1116/1.585106; DEGUCHI K, 1992, JPN J APPL PHYS 1, V31, P2954, DOI 10.1143/JJAP.31.2954; *INT SEATECH, 1999, INT TECHN ROADM SEM; KINOSHITA H, 1989, J VAC SCI TECHNOL B, V7, P1648, DOI 10.1116/1.584507; Klein M., 1970, ENCY BR; Kubiak GD, 1998, P SOC PHOTO-OPT INS, V3331, P81, DOI 10.1117/12.309560; LEVENSON MD, 1982, IEEE T ELECTRON DEV, V29, P1828, DOI 10.1109/T-ED.1982.21037; MATSUO K, 1991, IEDM, V91, P70; NAKAYAMA Y, 1990, J VAC SCI TECHNOL B, V8, P1836, DOI 10.1116/1.585169; OIZUMI H, IN PRESS JPN J APPL; OKAZAKI S, 1991, J VAC SCI TECHNOL B, V9, P2829, DOI 10.1116/1.585650; PFEIFFER HC, 1995, MICROELECTRON ENG, V27, P143, DOI 10.1016/0167-9317(94)00075-6; Silfvast WT, 1999, P SOC PHOTO-OPT INS, V3676, P272, DOI 10.1117/12.351098; TERASAWA T, 1989, P SOC PHOTO-OPT INS, V1088, P25, DOI 10.1117/12.953131	15	622	647	10	236	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1027	1031		10.1038/35023233	http://dx.doi.org/10.1038/35023233			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984061				2022-12-28	WOS:000089020200054
J	Chai, JJ; Du, CY; Wu, JW; Kyin, S; Wang, XD; Shi, YG				Chai, JJ; Du, CY; Wu, JW; Kyin, S; Wang, XD; Shi, YG			Structural and biochemical basis of apoptotic activation by Smac/DIABLO	NATURE			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; PROCASPASE-9 ACTIVATION; DNA FRAGMENTATION; PROTEIN XIAP; INHIBITOR; OLIGOMERIZATION; CASPASES; APAF-1; DATP	Apoptosis (programmed cell death), an essential process in the development and homeostasis of metazoans, is carried out by caspases. The mitochondrial protein Smac/DIABLO performs a critical function in apoptosis by eliminating the inhibitory effect of IAPs (inhibitor of apoptosis proteins) on caspases. Here we show that Smac/DIABLO promotes not only the proteolytic activation of procaspase-3 but also the enzymatic activity of mature caspase-3, both of which depend upon its ability to interact physically with IAPs. The crystal structure of Smac/DIABLO at 2.2 Angstrom resolution reveals that it homodimerizes through an extensive hydrophobic interface. Missense mutations inactivating this dimeric interface significantly compromise the function of Smac/DIABLO. As in the Drosophila proteins Reaper, Grim and Hid, the amino-terminal amino acids of Smac/DIABLO are indispensable for its function, and a seven-residue peptide derived from the amino terminus promotes procaspase-3 activation in vitro. These results establish an evolutionarily conserved structural and biochemical basis for the activation of apoptosis by Smac/DIABLO.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Princeton University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu		Shi, Yigong/0000-0003-2030-168X; Chai, Jijie/0000-0001-7591-3873				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	37	638	726	18	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					855	862		10.1038/35022514	http://dx.doi.org/10.1038/35022514			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972280				2022-12-28	WOS:000088903600034
J	Bruining, GJ				Bruining, GJ		Netherlands Kolibrie Study Grp Ch	Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2	LANCET			English	Article							CHILDREN; WEIGHT	Secular growth changes have not been linked with type-1 diabetes. Longitudinal growth analysis in prediabetic type-1 children indicated increased body mass Index (BMI) in the first year of life and an increased growth in length in the next 2 years. These heavier and taller children presented with autoantibodies against pancreatic islet tyrosine phosphatases at diagnosis many years later. It is possible that increased BMI during the first year of life and the development of such autoantibodies represents an additional risk marker towards earlier clinical onset of disease.	Erasmus Univ, Med Ctr, Dept Paediat, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands; Dutch Growth Fdn, Rotterdam, Netherlands; TNO, Dept Stat, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Immunohaematol & Bloodtransfus, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bruining, GJ (corresponding author), Sophia Childrens Hosp, Room Sp 3431,Dr Molenwaterplein 60, NL-3015 GJ Rotterdam, Netherlands.		Roep, Bart/AAD-7609-2021					COLE TJ, 1995, ARCH DIS CHILD, V73, P8, DOI 10.1136/adc.73.1.8; Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006; HERNGREEN WP, 1994, ANN HUM BIOL, V21, P449, DOI 10.1080/03014469400003472; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; Sabbah E, 1999, J CLIN ENDOCR METAB, V84, P1534, DOI 10.1210/jc.84.5.1534	5	79	81	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					655	656		10.1016/S0140-6736(00)02612-X	http://dx.doi.org/10.1016/S0140-6736(00)02612-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968443				2022-12-28	WOS:000088884100018
J	Verheugt, FWA; Martin, JF; Ryden, L				Verheugt, FWA; Martin, JF; Ryden, L			European cardiology: 50 years	LANCET			English	Article									Univ Nijmegen, Univ Hosp, Heartctr, Dept Cardiol, NL-6500 HB Nijmegen, Netherlands; UCL, London, England; Karolinska Hosp, S-10401 Stockholm, Sweden	Radboud University Nijmegen; University of London; University College London; Karolinska Institutet; Karolinska University Hospital	Verheugt, FWA (corresponding author), Univ Nijmegen, Univ Hosp, Heartctr, Dept Cardiol, NL-6500 HB Nijmegen, Netherlands.	f.verheugt@cardio.azn.nl	Verheugt, F.W.A./H-8105-2014						0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					671	672		10.1016/S0140-6736(00)02615-5	http://dx.doi.org/10.1016/S0140-6736(00)02615-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968452				2022-12-28	WOS:000088884100040
J	Gottlieb, S				Gottlieb, S			Personalised medicine comes a step closer for asthma	BRITISH MEDICAL JOURNAL			English	News Item																		Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483	1	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					724	724		10.1136/bmj.321.7263.724	http://dx.doi.org/10.1136/bmj.321.7263.724			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999895	Green Published			2022-12-28	WOS:000089546600012
J	Olowokure, B; Hawker, J; Blair, I; Spencer, N				Olowokure, B; Hawker, J; Blair, I; Spencer, N			Decrease in effectiveness of routine surveillance of Haemophilus influenzae disease after introduction of conjugate vaccine: comparison of routine reporting with active surveillance system	BRITISH MEDICAL JOURNAL			English	Article								In October 1992 routine immunisation with Haemophilus influenzae type b conjugate vaccine was introduced in the United Kingdom, and the incidence of disease was subsequently reported to have decreased 15-fold.(1) The surveillance systems in place were primarily routine and were known to underestimate the burden of invasive H influenzae disease.(2) This study aimed to determine whether underreporting continued after introduction of the conjugate vaccine, and how this might affect the reported success of the vaccine. Results of routine surveillance were compared with active surveillance for invasive H influenzae disease in the West Midlands health region of England.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Sandwell Hlth Author, Dept Publ Hlth, W Bromwich B70 9LD, W Midlands, England; Univ Warwick, Postgrad Med Sch, Sect Child Hlth, Coventry CV4 7AL, W Midlands, England	University of Birmingham; University of Warwick	Olowokure, B (corresponding author), W Midlands Heartlands Hosp, Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Birmingham B9 5SS, W Midlands, England.							Hargreaves RM, 1996, BRIT MED J, V312, P160; Macleod C A, 1994, Commun Dis Rep CDR Rev, V4, pR13; Nazareth B, 1992, Commun Dis Rep CDR Rev, V2, pR13; Salisbury DM, 1998, PEDIATR INFECT DIS J, V17, pS136, DOI 10.1097/00006454-199809001-00009; Wise J, 1999, BRIT MED J, V319, P278, DOI 10.1136/bmj.319.7205.278	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					731	732		10.1136/bmj.321.7263.731	http://dx.doi.org/10.1136/bmj.321.7263.731			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999903	Green Published, Bronze			2022-12-28	WOS:000089546600020
J	Chen, G; Bonadeo, NH; Steel, DG; Gammon, D; Katzer, DS; Park, D; Sham, LJ				Chen, G; Bonadeo, NH; Steel, DG; Gammon, D; Katzer, DS; Park, D; Sham, LJ			Optically induced entanglement of excitons in a single quantum dot	SCIENCE			English	Article							COMPUTATION; SHIFTS; LOGIC	Optically induced entanglement is identified by the spectrum of the phase-sensitive homodyne-detected coherent nonlinear optical response in a single gallium arsenide quantum dot. The electron-hole entanglement involves two magneto-excitonic states differing in transition energy and polarization. The strong coupling needed for entanglement is provided through the Coulomb interaction involving the electrons and holes. The result presents a first step toward the optical realization of quantum Logic operations using two or more quantum dots.	Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA; USN, Res Lab, Washington, DC 20375 USA; Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA	University of Michigan System; University of Michigan; United States Department of Defense; United States Navy; Naval Research Laboratory; University of California System; University of California San Diego	Steel, DG (corresponding author), Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA.	dst@eecs.umich.edu	Yang, ZhangQiang/T-4855-2018; Katzer, D. Scott/N-7841-2013	Sham, Lu/0000-0001-5718-2077				Ahn J, 2000, SCIENCE, V287, P463, DOI 10.1126/science.287.5452.463; Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Beterov I. M, 1974, PROGR QUANTUM ELEC 1, V3, P1; Bonadeo NH, 1998, PHYS REV LETT, V81, P2759, DOI 10.1103/PhysRevLett.81.2759; BOTT K, 1993, PHYS REV B, V48, P17418, DOI 10.1103/PhysRevB.48.17418; Brown SW, 1996, PHYS REV B, V54, P17339, DOI 10.1103/PhysRevB.54.R17339; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; Chuang IL, 1998, PHYS REV LETT, V80, P3408, DOI 10.1103/PhysRevLett.80.3408; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Ekert A, 1996, REV MOD PHYS, V68, P733, DOI 10.1103/RevModPhys.68.733; Ferrio KB, 1998, PHYS REV LETT, V80, P786, DOI 10.1103/PhysRevLett.80.786; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; Hagley E, 1997, PHYS REV LETT, V79, P1, DOI 10.1103/PhysRevLett.79.1; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; OSTREICH T, 1995, PHYS REV LETT, V75, P2554, DOI 10.1103/PhysRevLett.75.2554; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; Schrodinger E, 1935, P CAMB PHILOS SOC, V31, P555, DOI 10.1017/S0305004100013554; SHAM LJ, 1966, PHYS REV, V144, P708, DOI 10.1103/PhysRev.144.708; Sieh C, 1999, PHYS REV LETT, V82, P3112, DOI 10.1103/PhysRevLett.82.3112; Spreeuw RJC, 1998, FOUND PHYS, V28, P361, DOI 10.1023/A:1018703709245; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631; Zeilinger A, 1999, REV MOD PHYS, V71, pS288, DOI 10.1103/RevModPhys.71.S288; 1998, PHYS WORLD, V11, P33; 2000, PHYS TODAY, V53, P20	30	234	243	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2000	289	5486					1906	1909		10.1126/science.289.5486.1906	http://dx.doi.org/10.1126/science.289.5486.1906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988065				2022-12-28	WOS:000089355800037
J	Yen, AS; Kim, SS; Hecht, MH; Frant, MS; Murray, B				Yen, AS; Kim, SS; Hecht, MH; Frant, MS; Murray, B			Evidence that the reactivity of the martian soil is due to superoxide ions	SCIENCE			English	Article							OXIDE SURFACES; OXYGEN; PHOTOFORMATION; RESONANCE	The Viking Landers were unable to detect evidence of Life on Mars but, instead, found a chemically reactive soil capable of decomposing organic molecules. This reactivity was attributed to the presence of one or more as-yet-unidentified inorganic superoxides or peroxides in the martian soil. Using electron paramagnetic resonance spectroscopy, we show that superoxide radical ions (O-2(-)) form directly on Mars-analog mineral surfaces exposed to ultraviolet radiation under a simulated martian atmosphere. These oxygen radicals can explain the reactive nature of the soil and the apparent absence of organic material at the martian surface.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Chemot Consulting, Newton, MA 02458 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology	Yen, AS (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.			Hecht, Michael/0000-0002-4114-4583				ANPO M, 1985, J PHYS CHEM-US, V89, P5689, DOI 10.1021/j100272a023; BALLOU EV, 1978, NATURE, V271, P644, DOI 10.1038/271644a0; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Biemann K., 1977, Journal of Geophysical Research, V82, P4641, DOI 10.1029/JS082i028p04641; CHE M, 1982, ADV CATAL, V31, P77, DOI 10.1016/S0360-0564(08)60453-8; CHE M, 1983, ADV CATAL, V32, P1, DOI 10.1016/S0360-0564(08)60439-3; Christensen PR, 1998, SCIENCE, V279, P1692, DOI 10.1126/science.279.5357.1692; CHUN SFS, 1978, NATURE, V274, P875, DOI 10.1038/274875a0; CLARKSON RB, 1978, SURF SCI, V74, P325, DOI 10.1016/0039-6028(78)90029-8; COTTON FA, 1995, BASIC INORGANIC CHEM, P435; GASYMOV AM, 1984, KINET KATAL, V25, P358; HOROWITZ NH, 1986, UTOPIA BACK SEARCH L, P136; HOWE RF, 1982, ADV COLLOID INTERFAC, V18, P1, DOI 10.1016/0001-8686(82)85030-6; HOWE RF, 1993, COLLOID SURFACE A, V72, P353, DOI 10.1016/0927-7757(93)80485-W; HOWE RF, 1986, J CHEM PHYS, V85, P6129, DOI 10.1063/1.451478; HUNTEN DM, 1979, J MOL EVOL, V14, P71, DOI 10.1007/BF01732369; ITO T, 1985, J CHEM SOC FARAD T 1, V81, P2835, DOI 10.1039/f19858102835; Johnston C.L., 1991, GEMS GEMOL, V27, P220, DOI [10.5741/GEMS.27.4.220, DOI 10.5741/GEMS.27.4.220]; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KLEIN HP, 1978, ICARUS, V34, P666, DOI 10.1016/0019-1035(78)90053-2; KLEIN HP, 1976, SCIENCE, V194, P99, DOI 10.1126/science.194.4260.99; KUHN WR, 1979, J MOL EVOL, V14, P57, DOI 10.1007/BF01732367; Levin G. V., 1977, Journal of Geophysical Research, V82, P4663, DOI 10.1029/JS082i028p04663; LUNSFORD JH, 1973, CATAL REV, V8, P135; LUNSFORD JH, 1984, ACS SYM SER, V248, P127; Oyama V. I., 1977, Journal of Geophysical Research, V82, P4669, DOI 10.1029/JS082i028p04669; OYAMA VI, 1977, NATURE, V265, P110, DOI 10.1038/265110a0; ZENT AP, 1994, ICARUS, V108, P146, DOI 10.1006/icar.1994.1047; [No title captured]	29	199	205	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1909	1912		10.1126/science.289.5486.1909	http://dx.doi.org/10.1126/science.289.5486.1909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988066				2022-12-28	WOS:000089355800038
J	Klein, J; Sato, A				Klein, J; Sato, A			The HLA system - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BARE LYMPHOCYTE SYNDROME; MHC CLASS-I; TRANSFERRIN RECEPTOR; PEMPHIGUS-VULGARIS; STRUCTURAL BASIS; MOLECULAR CLUES; SEVERE MALARIA; T-CELLS; GENE; HEMOCHROMATOSIS		Max Planck Inst Biol, Immunogenet Abt, D-72076 Tubingen, Germany	Max Planck Society	Klein, J (corresponding author), Max Planck Inst Biol, Immunogenet Abt, Corrensstr 42, D-72076 Tubingen, Germany.	jan.klein@tuebingen.mpg.de						AHMED AR, 1990, P NATL ACAD SCI USA, V87, P7658, DOI 10.1073/pnas.87.19.7658; Ajioka RS, 1997, AM J HUM GENET, V60, P1439, DOI 10.1086/515466; Altman JD, 1998, SCIENCE, V280, P1821; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Andrews NC, 2000, NEW ENGL J MED, V342, P364; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chong H, 1996, SPRINGER SEMIN IMMUN, V18, P149, DOI 10.1007/BF00820663; Collins EJ, 1998, IMMUNOL REV, V163, P151, DOI 10.1111/j.1600-065X.1998.tb01194.x; COLVIN RB, 1990, ANNU REV MED, V41, P361; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DeSandro A, 1999, AM J HUM GENET, V65, P279, DOI 10.1086/302519; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feltkamp TEW, 1996, IMMUNOL TODAY, V17, P5, DOI 10.1016/0167-5699(96)80559-7; Flavell RA, 1999, CURR OPIN IMMUNOL, V11, P635, DOI 10.1016/S0952-7915(99)00029-1; Furukawa H, 1999, J CLIN INVEST, V103, P755, DOI 10.1172/JCI5335; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Kuhn LC, 1999, TRENDS BIOCHEM SCI, V24, P164, DOI 10.1016/S0968-0004(99)01386-9; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lopez-Botet M, 1999, CURR OPIN IMMUNOL, V11, P301, DOI 10.1016/S0952-7915(99)80048-X; McMichael AJ, 1999, J CLIN INVEST, V104, P1669, DOI 10.1172/JCI8943; NEWTONNASH DK, 1994, HUM IMMUNOL, V41, P105, DOI 10.1016/0198-8859(94)90002-7; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Ogg GS, 1998, CURR OPIN IMMUNOL, V10, P393, DOI 10.1016/S0952-7915(98)80110-6; Raghavan M, 1999, J CLIN INVEST, V103, P595, DOI 10.1172/JCI6455; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Sayegh M H, 1996, Int Rev Immunol, V13, P221, DOI 10.3109/08830189609061749; Simpson E, 1997, CURR OPIN IMMUNOL, V9, P655, DOI 10.1016/S0952-7915(97)80045-3; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Thorsby E, 1997, HUM IMMUNOL, V53, P1, DOI 10.1016/S0198-8859(97)00024-4; Tiwari J.L., 1985, HLA DIS ASS; Udaka K, 1996, J IMMUNOL, V157, P670; Wen L, 2000, J EXP MED, V191, P97, DOI 10.1084/jem.191.1.97; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51	49	272	287	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					782	786		10.1056/NEJM200009143431106	http://dx.doi.org/10.1056/NEJM200009143431106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984567				2022-12-28	WOS:000089221300006
J	Grinspoon, S; Corcoran, C; Parlman, K; Costello, M; Rosenthal, D; Anderson, E; Stanley, T; Schoenfeld, D; Burrows, B; Hayden, D; Basgoz, N; Klibanski, A				Grinspoon, S; Corcoran, C; Parlman, K; Costello, M; Rosenthal, D; Anderson, E; Stanley, T; Schoenfeld, D; Burrows, B; Hayden, D; Basgoz, N; Klibanski, A			Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NANDROLONE DECANOATE; WEIGHT; BODY	Background: Substantial loss of muscle mass occurs among men with AIDS wasting. Objective: To investigate the independent effects of testosterone therapy and progressive resistance training in eugonadal men with AIDS wasting. Design: Randomized, controlled trial. Setting: University hospital. Patients: 54 eugonadal men with AIDS wasting (weight < 90% ideal body weight or weight loss > 10%). Intervention: In a 2 x 2 factorial design, patients were assigned to receive testosterone enanthate (200 mg/wk) or placebo injections and progressive resistance training (three times weekly) or no training for 12 weeks. Measurements: Cross-sectional muscle area and other indices of muscle mass. Results: Cross-sectional muscle area increased in response to training compared with nontraining (change in arm muscle mass, 499 +/- 349 mm(2) vs. 206 +/- 264 mm(2) [P = 0.004]; change in leg muscle mass, 1106 +/- 854 mm(2) vs. 523 +/- 872 mm(2) [P = 0.045]) and in response to testosterone therapy compared with placebo (change in arm muscle mass, 512 +/- 371 mm(2) vs. 194 +/- 215 mm(2) [P < 0.001]; change in leg muscle mass, 1236 +/- 881 mm(2) vs. 399 +/- 729 mm(2) [P = 0.002]). Levels of high-density lipoprotein cholesterol decreased in response to testosterone therapy compared with placebo (-0.03 +/- 0.13 mmol/L vs. 0.05 +/- 0.13 mmol/L [-1 +/- 5 mg/dL vs. 2 +/- 5 mg/dL]; P = 0.011) and increased in response to training compared with nontraining (0.05 +/- 0.13 mmol/L vs. 0.00 +/- 0.16 mmol/L [2 +/- 5 mg/dL vs. 0 +/- 6 mg/dL]; P = 0.052). Conclusions: In contrast to anabolic therapies that may have adverse effects on metabolic variables, supervised exercise effectively increases muscle mass and is associated with significant positive health benefits in eugonadal men with AIDS wasting.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Vet Adm Med Ctr, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B,55 Fruit St, Boston, MA 02114 USA.		Stanley, Takara/GYV-4488-2022	Stanley, Takara/0000-0002-2336-2958	NCRR NIH HHS [M01-RR01066] Funding Source: Medline; NIDDK NIH HHS [R01-DK49302, P32-DK07028] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028, R01DK049302] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM COL SPORTS MED, 1980, GUID GRAD EX TEST EX; ANDRES PL, 1986, NEUROLOGY, V36, P937, DOI 10.1212/WNL.36.7.937; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Finison LJ, 1996, ARCH PHYS MED REHAB, V77, P1251; FISHER A, 1998, 12 WORLD AIDS C GEN, P844; GIBERT CL, 1998, 12 WORLD AIDS C GEN, P554; Gold J, 1996, AIDS, V10, P745, DOI 10.1097/00002030-199606001-00008; Grinspoon S, 1999, J CLIN ENDOCR METAB, V84, P201, DOI 10.1210/jc.84.1.201; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; Hortobagyi T, 1997, MED SCI SPORT EXER, V29, P107, DOI 10.1097/00005768-199701000-00015; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MUNSAT TL, 1989, PHYSICAL MED REHABIL, V3, P188; RIETSCHEL P, IN PRESS CLIN INFECT; Sattler FR, 1999, J CLIN ENDOCR METAB, V84, P1268, DOI 10.1210/jc.84.4.1268; Silva M, 1998, AIDS, V12, P1645, DOI 10.1097/00002030-199813000-00012; Strawford A, 1999, JAMA-J AM MED ASSOC, V281, P1282, DOI 10.1001/jama.281.14.1282; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422	20	147	149	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					348	355		10.7326/0003-4819-133-5-200009050-00010	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979879				2022-12-28	WOS:000089111900004
J	Xavier, RJ; Podolsky, DK				Xavier, RJ; Podolsky, DK			Microbiology - How to get along - Friendly microbes in a hostile world	SCIENCE			English	Editorial Material							PROTEIN		Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Xavier, RJ (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St,GRJ-719, Boston, MA 02114 USA.							Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370; Higgins LM, 1999, SCIENCE, V285, P588, DOI 10.1126/science.285.5427.588; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0	9	43	48	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1483	1484		10.1126/science.289.5484.1483	http://dx.doi.org/10.1126/science.289.5484.1483			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10991734				2022-12-28	WOS:000089071700028
J	Reid, RP; Visscher, PT; Decho, AW; Stolz, JF; Bebout, BM; Dupraz, C; Macintyre, LG; Paerl, HW; Pinckney, JL; Prufert-Bebout, L; Steppe, TF; DesMarais, DJ				Reid, RP; Visscher, PT; Decho, AW; Stolz, JF; Bebout, BM; Dupraz, C; Macintyre, LG; Paerl, HW; Pinckney, JL; Prufert-Bebout, L; Steppe, TF; DesMarais, DJ			The role of microbes in accretion, lamination and early lithification of modern marine stromatolites	NATURE			English	Article							SUBTIDAL STROMATOLITES; EXUMA-CAYS; BAHAMAS; MATS; COMMUNITIES	For three billion years, before the Cambrian diversification of life, laminated carbonate build-ups called stromatolites were widespread in shallow marine seas(1,2). These ancient structures are generally thought to be microbial in origin and potentially preserve evidence of the Earth's earliest biosphere(1-3). Despite their evolutionary significance, little is known about stromatolite formation, especially the relative roles of microbial and environmental factors in stromatolite accretion(1,3). Here we show that growth of modern marine stromatolites represents a dynamic balance between sedimentation and intermittent lithification of cyanobacterial mats. Periods of rapid sediment accretion, during which stromatolite surfaces are dominated by pioneer communities of gliding filamentous cyanobacteria, alternate with hiatal intervals. These discontinuities in sedimentation are characterized by development of surface films of exopolymer and subsequent heterotrophic bacterial decomposition, forming thin crusts of microcrystalline carbonate. During prolonged hiatal periods, climax communities develop, which include endolithic coccoid cyanobacteria. These coccoids modify the sediment, forming thicker lithified laminae. Preservation of lithified layers at depth creates millimetre-scale lamination. This simple model of modern marine stromatolite growth may be applicable to ancient stromatolites.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, MGG, Miami, FL 33149 USA; Univ Connecticut, Dept Marine Sci, Groton, CT 06340 USA; Univ S Carolina, Sch Publ Hlth, Columbia, SC 29208 USA; Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Smithsonian Inst, Natl Museum Nat Hist, Washington, DC 20560 USA; Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA	University of Miami; University of Connecticut; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Duquesne University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Smithsonian Institution; Smithsonian National Museum of Natural History; University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System; Texas A&M University College Station	Reid, RP (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, MGG, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.	preid@rsmas.miami.edu	Decho, Alan W/F-9510-2010; Visscher, Pieter/T-7464-2017	Pinckney, James/0000-0002-6056-6511; Visscher, Pieter/0000-0001-6911-1532				AWRAMIK SM, 1988, P NATL ACAD SCI USA, V85, P1327, DOI 10.1073/pnas.85.5.1327; Bartley JK, 1996, PALAIOS, V11, P571, DOI 10.2307/3515192; CHAFETZ H S, 1992, Palaios, V7, P277, DOI 10.2307/3514973; Decho AW, 1999, BIOTECHNIQUES, V27, P1246; DECHO AW, UNPUB AQUAT MICROB E; DILL RF, 1986, NATURE, V324, P55, DOI 10.1038/324055a0; DRAVIS JJ, 1983, SCIENCE, V219, P385, DOI 10.1126/science.219.4583.385; Golubic S, 2000, MICROBIAL SEDIMENTS, P57; Golubic S., 1996, ALGOLOGICAL STUDIES, P273; Grotzinger JP, 1999, ANNU REV EARTH PL SC, V27, P313, DOI 10.1146/annurev.earth.27.1.313; KRUMBEIN WE, 1977, LIMNOL OCEANOGR, V22, P635, DOI 10.4319/lo.1977.22.4.0635; Lee SJ, 2000, MICROBIAL SEDIMENTS, P16; LOGAN BW, 1961, J GEOL, V69, P517, DOI 10.1086/626769; MACINTYRE IG, IN PRESS SEDIMENTOLO; Monty C.L.V., 1976, STROMATOLITES DEV SE, P193, DOI DOI 10.1016/S0070-4571(08)71137-3; PAERL HW, 1993, LIMNOL OCEANOGR, V38, P1150, DOI 10.4319/lo.1993.38.6.1150; Pinckney JL, 1997, FACIES, V36, P204; REID RP, 1995, FACIES, V33, P1, DOI 10.1007/BF02537442; Reid RP, 2000, J SEDIMENT RES, V70, P24, DOI 10.1306/2DC408FA-0E47-11D7-8643000102C1865D; REID RP, 1999, ATOLL RES B, V466, P1; Riding R, 1994, BIOSTABILIZATION SED, V84, P183; STAL LJ, 1985, FEMS MICROBIOL ECOL, V31, P111, DOI 10.1111/j.1574-6968.1985.tb01138.x; VANGEMERDEN H, 1993, MAR GEOL, V113, P3, DOI 10.1016/0025-3227(93)90146-M; Visscher PT, 1999, APPL ENVIRON MICROB, V65, P3272; Visscher PT, 1998, AM MINERAL, V83, P1482, DOI 10.2138/am-1998-11-1236; VISSCHER PT, IN PRESS GEOLOGY; Walter M. R., 1976, DEV SEDIMENTOL, V20, P251; Walter M.R., 1983, EARTHS EARLIEST BIOS, P187; WALTER MR, 1992, PROTEROZOIC BIOSPHER, P335; [No title captured]	30	562	613	7	161	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					989	992		10.1038/35023158	http://dx.doi.org/10.1038/35023158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984051				2022-12-28	WOS:000089020200043
J	Kleinberg, JM				Kleinberg, JM			Navigation in a small world - It is easier to find short chains between points in some networks than others.	NATURE			English	Article									Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA	Cornell University	Kleinberg, JM (corresponding author), Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA.							Albert R, 1999, NATURE, V401, P130, DOI 10.1038/43601; KILLWORTH PD, 1978, SOC NETWORKS, V1, P159, DOI 10.1016/0378-8733(78)90018-7; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; PELEG D, 1989, J ACM, V36, P510, DOI 10.1145/65950.65953; Pirolli P, 1999, PSYCHOL REV, V106, P643, DOI 10.1037/0033-295X.106.4.643; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; [No title captured]	7	1033	1071	5	104	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					845	845		10.1038/35022643	http://dx.doi.org/10.1038/35022643			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	347AG	10972276	Bronze			2022-12-28	WOS:000088903600028
J	Djulbegovic, B; Lacevic, M; Cantor, A; Fields, KK; Bennett, CL; Adams, JR; Kuderer, NM; Lyman, GH				Djulbegovic, B; Lacevic, M; Cantor, A; Fields, KK; Bennett, CL; Adams, JR; Kuderer, NM; Lyman, GH			The uncertainty principle and industry-sponsored research	LANCET			English	Article; Proceedings Paper	VII Cochrane Colloquium	OCT 05-09, 1999	ROME, ITALY				RANDOMIZED CLINICAL-TRIALS; CONFLICT-OF-INTEREST; ETHICS; EQUIPOISE; QUALITY; DESIGN; DRUGS	Background Reporting of pharmaceutical-industry-sponsored randomised clinical trials often result in biased findings, either due to selective reporting of studies with non-equivalent arms or publication of low-quality papers, wherein unfavourable results are incompletely described. A randomised trial should be conducted only if there is substantial uncertainty about the relative value of one treatment versus another. Studies in which intervention and control are thought to be non-equivalent violates the uncertainty principle. Methods We examined the quality of 136 published randomised trials that focused on one disease category (multiple myeloma) and adherence to the uncertainty principle. To evaluate whether the uncertainty principle was upheld, we compared the number of studies favouring experimental treatments over standard ones. We analysed data according to the source of funding. Findings Trials funded solely or in part by 35 profit-making organisations had a trend toward higher quality scores (mean 2.94 [SD 1.3]; median 3) than randomised trials supported by 95 governmental or other non-profit organisations (2.4 [0.8]; 2; p=0.06). Overall, the uncertainty principle was upheld, with 44% of randomised trials favouring standard treatments and 56% innovative treatments (p=0.17); mean and median preference evaluation scores were 3.7 (1.0) and 4. However, when the analysis was done according to the source of funding, studies funded by non-profit organisations maintained equipoise favouring new therapies over standard ones (47% vs 53%; p=0.608) to a greater extent than randomised trials supported solely or in part by profit-making organisations (74% vs 26%; p=0.004). Interpretation The reported bias in research sponsored by the pharmaceutical industry may be a consequence of violations of the uncertainty principle. Sponsors of clinical trials should be encouraged to report all results and to choose appropriate comparative controls.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Div Blood & Bone Marrow Transplantat, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Div Biostat, Tampa, FL 33612 USA; VA Chicago Hlth Care Syst, Lakeside Div, Chicago, IL USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL USA; Albany Med Coll, Div Hematol Oncol, Albany, NY 12208 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Northwestern University; Albany Medical College	Djulbegovic, B (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Div Blood & Bone Marrow Transplantat, 12902 Magnolia Dr, Tampa, FL 33612 USA.	djulbebm@moffitt.usf.edu	Lyman, Gary H/K-5227-2019; Bennett, Charles L/C-2050-2008; Djulbegovic, Benjamin/I-3661-2012	Lyman, Gary H/0000-0002-0823-8086; Djulbegovic, Benjamin/0000-0003-0671-1447				ATKINS H, 1966, BRIT MED J, V2, P377, DOI 10.1136/bmj.2.5510.377; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Chalmers I, 1997, BRIT MED J, V314, P74, DOI 10.1136/bmj.314.7073.74a; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; Dieppe P, 1999, LANCET, V353, P1626, DOI 10.1016/S0140-6736(05)75755-X; Djulbegovic B, 1999, BLOOD, V94, p399A; Doll R, 1998, BMJ-BRIT MED J, V317, P1217, DOI 10.1136/bmj.317.7167.1217; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; GILBERT JP, 1977, SCIENCE, V198, P684, DOI 10.1126/science.333585; HILL AB, 1987, BRIT MED J, V294, P1419, DOI 10.1136/bmj.294.6584.1419; HILL AB, 1963, BMJ-BRIT MED J, V2, P1043; Horton R, 1999, LANCET, V354, P1138, DOI 10.1016/S0140-6736(99)00328-1; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johansen HK, 1999, JAMA-J AM MED ASSOC, V282, P1752, DOI 10.1001/jama.282.18.1752; Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510; Lilford RJ, 1995, J ROY SOC MED, V88, P552; Machin D, 1997, Clin Oncol (R Coll Radiol), V9, P100; MOHER D, 1999, HLTH TECHNOL ASSES, V3, P19; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Rennie D, 1999, JAMA-J AM MED ASSOC, V282, P1766, DOI 10.1001/jama.282.18.1766; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Sackett DL, 2000, CAN MED ASSOC J, V162, P1311; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Zivin JA, 2000, SCI AM, V282, P69, DOI 10.1038/scientificamerican0400-69; 2000, N ENGL J MED, V342, P42	31	331	339	1	42	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2000	356	9230					635	638		10.1016/S0140-6736(00)02605-2	http://dx.doi.org/10.1016/S0140-6736(00)02605-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	346RD	10968436				2022-12-28	WOS:000088884100011
J	McCarron, P; Peters, TJ; Harvey, I; Brogan, R				McCarron, P; Peters, TJ; Harvey, I; Brogan, R			Letter indicates misreading of our paper on chromium waste	BRITISH MEDICAL JOURNAL			English	Letter									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Greater Glasgow Hlth Board, Glasgow G3 8YZ, Lanark, Scotland	University of Bristol; University of East Anglia	McCarron, P (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.			Peters, Tim/0000-0003-2881-4180				JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; McCarron P, 2000, BMJ-BRIT MED J, V320, P11, DOI 10.1136/bmj.320.7226.11; Moffatt S, 2000, BRIT MED J, V320, P1274, DOI 10.1136/bmj.320.7244.1274; Stewart AL, 1992, MEASURING FUNCTIONIN	4	1	1	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	2000	321	7257					386	386		10.1136/bmj.321.7257.386	http://dx.doi.org/10.1136/bmj.321.7257.386			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QH	10991576	Green Published			2022-12-28	WOS:000088656300060
J	MacMahon, S; Neal, B				MacMahon, S; Neal, B			Differences between blood-pressure-lowering drugs	LANCET			English	Editorial Material							ISOLATED SYSTOLIC HYPERTENSION		Univ Sydney, Inst Int Hlth, Sydney, NSW 1585, Australia	University of Sydney	MacMahon, S (corresponding author), Univ Sydney, Inst Int Hlth, Sydney, NSW 1585, Australia.			Neal, Bruce/0000-0002-0490-7465; MacMahon, Stephen/0000-0003-2064-7699				COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; MACMAHON S, 1994, J HYPERTENS, V12, pS5; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; Yusuf S, 2000, NEW ENGL J MED, V342, P145; YUSUF S, 1989, HYPERTENSION, V0013	10	18	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					352	353		10.1016/S0140-6736(00)02521-6	http://dx.doi.org/10.1016/S0140-6736(00)02521-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972362				2022-12-28	WOS:000088486000002
J	Eagle, KA				Eagle, KA			Update in cardiology	ANNALS OF INTERNAL MEDICINE			English	Review									Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Eagle, KA (corresponding author), Univ Michigan, Med Ctr, 3910 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							Chamberlain DA, 1997, LANCET, V350, P461; Lauriola P, 1998, LANCET, V351, P1180, DOI 10.1016/S0140-6736(05)79124-8; Salo JA, 1999, ANN INTERN MED, V130, P637, DOI 10.7326/0003-4819-130-8-199904200-00003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Wallentin L, 1999, LANCET, V354, P701	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					439	446		10.7326/0003-4819-133-6-200009190-00012	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975962				2022-12-28	WOS:000089329700006
J	Shalala, D				Shalala, D			Protecting research subjects - What must be done	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US Dept HHS, Washington, DC 20201 USA		Shalala, D (corresponding author), US Dept HHS, Washington, DC 20201 USA.							Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; *ASS AM U, 2000, REP U PROT HUM BEI; *DEP HLTH HUM SERV, 1998, I REV BOARDS PROM AP; *DEP HLTH HUM SERV, 2000, PROT HUM RES SUBJ ST; *DEP HLTH HUM SERV, 1998, I REV BOARDS EM IND; *DEP HLTH HUM SERV, 1998, I REV BOARDS TIM REF; *DEP HLTH HUM SERV, 1998, I REV BOARDS THEIR R; Department of Health and Human Services Office of Inspector General, 2000, RECR HUM SUBJ PRESS; HENNEY JE, 2000, ASS AM MED COLL COUN	9	156	157	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					808	810		10.1056/NEJM200009143431112	http://dx.doi.org/10.1056/NEJM200009143431112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984573				2022-12-28	WOS:000089221300012
J	Mulac-Jericevic, B; Mullinax, RA; DeMayo, FJ; Lydon, LP; Conneely, OM				Mulac-Jericevic, B; Mullinax, RA; DeMayo, FJ; Lydon, LP; Conneely, OM			Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform	SCIENCE			English	Article							HUMAN-BREAST-CANCER; EMBRYONIC STEM-CELLS; MOUSE UTERUS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; A-ISOFORM; IMPLANTATION; FORM; ACTIVATION; PROMOTERS	Progesterone regulates reproductive function through two intracellular receptors, progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B), that arise from a single gene and function as transcriptional regulators of progesterone-responsive genes. Although in vitro studies show that PR isoforms can display different transcriptional regulatory activities, their physiological significance is unknown. By selective ablation of PR-A in mice, we show that the PR-B isoform modulates a subset of reproductive functions of progesterone by regulation of a subset of progesterone-responsive target genes. Thus, PR-A and PR-B are functionally distinct mediators of progesterone action in vivo and should provide suitable targets for generation of tissue-selective progestins.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Conneely, OM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019; Mulac-Jericevic, Biserka/S-6034-2018	DeMayo, Francesco/0000-0002-9480-7336; Mulac-Jericevic, Biserka/0000-0001-8418-0712	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032007, R21HD032007] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32007] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abuin A, 1996, MOL CELL BIOL, V16, P1851; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BRANDON DD, 1993, AM J OBSTET GYNECOL, V169, P78, DOI 10.1016/0002-9378(93)90135-6; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; Duffy DM, 1997, BIOL REPROD, V57, P693, DOI 10.1095/biolreprod57.4.693; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Graham JD, 1996, J STEROID BIOCHEM, V56, P93; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; LESSEY BA, 1983, ENDOCRINOLOGY, V112, P1267, DOI 10.1210/endo-112-4-1267; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MCMASTER MT, 1992, MOL ENDOCRINOL, V6, P101, DOI 10.1210/me.6.1.101; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MULACJERICEVIC B, UNPUB; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Paria BC, 1998, ENDOCRINOLOGY, V139, P3958, DOI 10.1210/en.139.9.3958; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SHYAMALA G, 1990, ENDOCRINOLOGY, V126, P2882, DOI 10.1210/endo-126-6-2882; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tibbetts TA, 1999, P NATL ACAD SCI USA, V96, P12021, DOI 10.1073/pnas.96.21.12021; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEIGEL NL, 1993, HORMONES HLTH DIS, P309; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P3923, DOI 10.1210/en.139.9.3923	33	527	553	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1751	1754		10.1126/science.289.5485.1751	http://dx.doi.org/10.1126/science.289.5485.1751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976068				2022-12-28	WOS:000089195200046
J	Gelber, AC; Hochberg, MC; Mead, LA; Wang, NY; Wigley, FM; Klag, MJ				Gelber, AC; Hochberg, MC; Mead, LA; Wang, NY; Wigley, FM; Klag, MJ			Joint injury in young adults and risk for subsequent knee and hip osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	60th National Scientific Meeting of the American-College-of-Rheumatology	OCT 18-22, 1996	ORLANDO, FL	Amer Coll Rheumatol			ARTICULAR-CARTILAGE; UNITED-STATES; ARTHRITIS; WOMEN; MEN; EPIDEMIOLOGY; MENISCECTOMY; ASSOCIATION; PREVALENCE; OBESITY	Background: Knee and hip injuries have been linked with osteoarthritis in cross-sectional and case-control studies, but few prospective studies have examined the relation between injuries in young adults and risk for later osteoarthritis. Objective: To prospectively examine the relation between joint injury and incident knee acid hip osteoarthritis. Design: Prospective cohort study. Setting: Johns Hopkins Precursors Study. Participants: 1321 former medical students. Measurements: Injury status at cohort entry was recorded when the mean age of participants was 22 years. Injury during followup and incident osteoarthritis were determined by using self-administered questionnaires. Osteoarthritis was confirmed by symptoms and radiographic findings. Results: Over a median follow-up of 36 years, 141 participants reported joint injuries (knee alone [n = 111], hip alone [n = 16], or knee and hip [n = 14]) and 96 developed osteoarthritis (knee alone [n = 64], hip alone [n = 27], or knee and hip [n = 5]). The cumulative incidence of knee osteoarthritis by 65 years of age was 13.9% in participants who had a knee injury during adolescence and young adulthood and 6.0% in those who did not (P = 0.0045) (relative risk, 2.95 [95% CI, 1.35 to 6.45]). Joint injury at cohort entry or during follow-up substantially increased the risk for subsequent osteoarthritis at that site (relative risk, 5.17 [CI, 3.07 to 8.71] and 3.50 [CI, 0.84 to 14.69] for knee and hip, respectively). Results were similar for persons with osteoarthritis confirmed by radiographs and symptoms. Conclusions: Young adults with knee injuries are at considerably increased risk for osteoarthritis later in life and should be targeted in the primary prevention of osteoarthritis.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Univ Maryland, Baltimore, MD 21201 USA; Vet Affairs Med Ctr, Baltimore, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gelber, AC (corresponding author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.			Wang, Nae-Yuh/0000-0001-6513-9730	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER; NIAMS NIH HHS [KO8 AR-01939] Funding Source: Medline; NIA NIH HHS [AG-01760] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN RD, 1991, J RHEUMATOL, V18, P10; ALTMAN RD, 1992, ANN RHEUM DIS, V51, P1056, DOI 10.1136/ard.51.9.1056; COMONIHUNTLEY J, 1990, HLTH STATUS WELL BEI; COOPER C, 1994, ANN RHEUM DIS, V53, P90, DOI 10.1136/ard.53.2.90; Cooper C, 1998, AM J EPIDEMIOL, V147, P516; Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7; CREAMER P, 1993, J RHEUMATOL, V20, P1461; CUNNINGHAM LS, 1984, AM J PUBLIC HEALTH, V74, P574, DOI 10.2105/AJPH.74.6.574; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; DECKERS JW, 1990, CIRCULATION, V82, P259; *DEP HLTH HUM SERV, 1980, INT CLASS DIS, V1; Felson DT, 1997, ARTHRITIS RHEUM, V40, P728, DOI 10.1002/art.1780400420; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9; Gabriel SE, 1997, J RHEUMATOL, V24, P719; Gabriel SE, 1997, J RHEUMATOL, V24, P43; Gelber AC, 1999, AM J MED, V107, P542, DOI 10.1016/S0002-9343(99)00292-2; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; Hart DJ, 1999, ARTHRITIS RHEUM, V42, P17, DOI 10.1002/1529-0131(199901)42:1<17::AID-ANR2>3.0.CO;2-E; HELIOVAARA M, 1993, ACTA ORTHOP SCAND, V64, P513, DOI 10.3109/17453679308993681; Hochberg M.C., 1997, OSTEOARTHRITIS PUBLI, P169; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LEQUESNE M, 1994, J RHEUMATOL, V21, P65; Little C, 1997, J RHEUMATOL, V24, P2199; MANKIN HJ, 1974, NEW ENGL J MED, V291, P1285, DOI 10.1056/NEJM197412122912406; MANKIN HJ, 1974, NEW ENGL J MED, V291, P1335, DOI 10.1056/NEJM197412192912507; March LM, 1998, OSTEOARTHR CARTILAGE, V6, P87, DOI 10.1053/joca.1997.0098; *NAT HLTH NUTR EX, 1979, BAS DAT ARTHR KNEE H; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RADIN EL, 1972, LANCET, V1, P519; RALL K L, 1964, Mo Med, V61, P435; Roos H, 1998, ARTHRITIS RHEUM, V41, P687, DOI 10.1002/1529-0131(199804)41:4<687::AID-ART16>3.0.CO;2-2; ROUBENOFF R, 1991, JAMA-J AM MED ASSOC, V266, P3004, DOI 10.1001/jama.266.21.3004; Slemenda C, 1998, ARTHRITIS RHEUM, V41, P1951, DOI 10.1002/1529-0131(199811)41:11<1951::AID-ART9>3.0.CO;2-9; Slemenda C, 1997, ANN INTERN MED, V127, P97, DOI 10.7326/0003-4819-127-2-199707150-00001; Sowers M, 1999, ARTHRITIS RHEUM, V42, P483, DOI 10.1002/1529-0131(199904)42:3<483::AID-ANR13>3.0.CO;2-O; TEPPER S, 1993, AM J EPIDEMIOL, V137, P1081, DOI 10.1093/oxfordjournals.aje.a116611; THOMAS CB, 1951, B JOHNS HOPKINS HOSP, V89, P419; YELIN EH, 1990, ARTHRITIS RHEUM, V33, P750, DOI 10.1002/art.1780330520	42	466	481	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					321	328		10.7326/0003-4819-133-5-200009050-00007	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	350QD	10979876				2022-12-28	WOS:000089111900001
J	Billings, JA				Billings, JA			Recent advances - Palliative care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ILL HOSPITALIZED-PATIENTS; TERMINALLY ILL; DEATH; LIFE; END; MANAGEMENT; ONCOLOGY; OUTCOMES; SUPPORT; TRIAL		Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Billings, JA (corresponding author), Massachusetts Gen Hosp, Palliat Care Serv, Founders 600,55 Fruit St, Boston, MA 02114 USA.	JBillings@partners.org			NCI NIH HHS [R25 CA066818, R25 CA 66818-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA066818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahm JL, 1999, ANN INTERN MED, V131, P37, DOI 10.7326/0003-4819-131-1-199907060-00009; BACKONJA M, 1988, JAMA-J AM MED ASSOC, V280, P1831; Baile WF, 1999, CANCER-AM CANCER SOC, V86, P887, DOI 10.1002/(SICI)1097-0142(19990901)86:5<887::AID-CNCR27>3.0.CO;2-X; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; Billings JA, 1997, JAMA-J AM MED ASSOC, V278, P733, DOI 10.1001/jama.278.9.733; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Bruera E, 1998, CAN MED ASSOC J, V158, P1717; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; DAVIS C, 1995, EUR J PALLIAT CARE, V2, P9; Desbiens NA, 1999, J PAIN SYMPTOM MANAG, V17, P248, DOI 10.1016/S0885-3924(98)00149-3; Field MJ, 1997, APPROACHING DEATH IM; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Foley KM, 1999, ARCH NEUROL-CHICAGO, V56, P413, DOI 10.1001/archneur.56.4.413; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Grant MD, 1998, JAMA-J AM MED ASSOC, V279, P1973, DOI 10.1001/jama.279.24.1973; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krakauer E L, 2000, Oncologist, V5, P53, DOI 10.1634/theoncologist.5-1-53; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; Mazzocato C, 2000, SUPPORT CARE CANCER, V8, P89, DOI 10.1007/s005200050021; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1998, ANN INTERN MED, V128, P552, DOI 10.7326/0003-4819-128-7-199804010-00006; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Rabow MW, 2000, JAMA-J AM MED ASSOC, V283, P771, DOI 10.1001/jama.283.6.771; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Volicer L, 1998, HOSPICE CARE PATIENT; Wineberg H, 2000, ARCH INTERN MED, V160, P21, DOI 10.1001/archinte.160.1.21	40	36	37	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					555	558		10.1136/bmj.321.7260.555	http://dx.doi.org/10.1136/bmj.321.7260.555			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968822	Green Published			2022-12-28	WOS:000089174100024
J	Marquet, PA				Marquet, PA			Ecology - Invariants, scaling laws, and ecological complexity	SCIENCE			English	Editorial Material							BODY-SIZE; POPULATION-DENSITY; ABUNDANCE; PATTERNS; DYNAMICS; EVOLUTION; ANIMALS; LIFE		Pontificia Univ Catolica Chile, Dept Ecol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Marquet, PA (corresponding author), Pontificia Univ Catolica Chile, Dept Ecol, Alameda 340, Santiago, Chile.	pmarquet@genes.bio.puc.cl	Marquet, Pablo A/B-7732-2009	Marquet, Pablo A/0000-0001-6369-9339				BABU GJ, 1992, COMMUN STAT SIMULAT, V21, P533, DOI 10.1080/03610919208813034; Blackburn TM, 1997, J ANIM ECOL, V66, P233, DOI 10.2307/6025; BLACKBURN TM, 1994, TRENDS ECOL EVOL, V9, P471, DOI 10.1016/0169-5347(94)90311-5; Bonner JT., 1988, EVOLUTION COMPLEXITY; Brown J., 2000, SCALING BIOL; Brown J.H., 1995, MACROECOLOGY; Brown JH, 1999, OIKOS, V87, P3, DOI 10.2307/3546991; BROWN JH, 1993, AM NAT, V142, P573, DOI 10.1086/285558; Calder WA., 1984, SIZE FUNCTION LIFE H; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; Enquist BJ, 1999, NATURE, V401, P907, DOI 10.1038/44819; Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; Keitt TH, 1996, J THEOR BIOL, V182, P161, DOI 10.1006/jtbi.1996.0150; Keitt TH, 1998, NATURE, V393, P257, DOI 10.1038/30478; LABARBERA M, 1989, ANNU REV ECOL SYST, V20, P97, DOI 10.1146/annurev.es.20.110189.000525; Lawton JH, 1999, OIKOS, V84, P177, DOI 10.2307/3546712; LAWTON JH, 1990, PHILOS T R SOC B, V330, P283, DOI 10.1098/rstb.1990.0199; LAWTON JH, 1989, OIKOS, V55, P429, DOI 10.2307/3565606; MARQUET PA, 1990, SCIENCE, V250, P1125, DOI 10.1126/science.250.4984.1125; MARQUET PA, 1995, J ANIM ECOL, V64, P325, DOI 10.2307/5894; MAURER MA, 1998, UNTANGLING ECOLOGICA; MAY RM, 1986, ECOLOGY, V67, P1115, DOI 10.2307/1938668; MEDEL RG, AM NAT, V145, P154; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Ritchie ME, 1999, NATURE, V400, P557, DOI 10.1038/23010; Roughgarden J, 1986, COMMUNITY ECOL, P333; Schmid PE, 2000, SCIENCE, V289, P1557, DOI 10.1126/science.289.5484.1557; Schmidt-Neilsen K, 1984, SCALING WHY IS ANIMA; Siemann E, 1996, NATURE, V380, P704, DOI 10.1038/380704a0; Taper ML, 1996, AM NAT, V147, P1072, DOI 10.1086/285893; West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677; YODZIS P, 1992, AM NAT, V139, P1151, DOI 10.1086/285380	33	25	29	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1487	1488		10.1126/science.289.5484.1487	http://dx.doi.org/10.1126/science.289.5484.1487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10991735				2022-12-28	WOS:000089071700030
J	Schieber, J; Krinsley, D; Riciputi, L				Schieber, J; Krinsley, D; Riciputi, L			Diagenetic origin of quartz silt in mudstones and implications for silica cycling	NATURE			English	Article							FOSSIL RECORD; PROVENANCE; DEPOSITION; MUDROCKS; ISOTOPES; OXYGEN	Mudstone-the most abundant sedimentary rock type(1), composed primarily of clay- or silt-sized particles-contains most of the quartz found in sedimentary rocks(2). These quartz grains, which are chemically and mechanically resistant and therefore preserve their characteristics well, have long been considered to be derived from the continental crust(1). Here we analyse quartz silt from black shales in the eastern USA, dating back to the Late Devonian period (about 370 million years ago), using backscattered electron and cathodoluminescence imaging and measure oxygen isotopes with an ion probe. Our results indicate that up to 100% of the quartz silt in our samples does not originate from the continental crust. Instead, it appears to have precipitated early in diagenesis in algal cysts and other pore spaces(3), with silica derived from the dissolution of opaline skeletons of planktonic organisms, such as radiolaria and diatoms. Transformation of early diatoms into in situ quartz silt might explain the time gap between the earliest fossil occurrences of diatoms about 120 Myr ago(4) and molecular evidence for a much earlier appearance between 266 or even 500 Myr ago(5,6). Moreover, if many other mudstone successions show similarly high proportions of in situ precipitated-rather than detrital-quartz silt, the sedimentary record in mudstones may have been misinterpreted in the past, with consequences for our estimates of palaeoproductivity as well as our perceptions of the dynamics and magnitude of global biogeochemical cycling of silica.	Univ Texas, Dept Geol, Arlington, TX 76019 USA; Univ Oregon, Dept Geol Sci, Eugene, OR 97403 USA; Oak Ridge Natl Lab, Div Chem & Analyt Sci, Oak Ridge, TN 37831 USA	University of Texas System; University of Texas Arlington; University of Oregon; United States Department of Energy (DOE); Oak Ridge National Laboratory	Schieber, J (corresponding author), Univ Texas, Dept Geol, Arlington, TX 76019 USA.	schieber@uta.edu	Schieber, Juergen Schieber/A-3001-2013					[Anonymous], 1992, PRODUCTIVITY ACCUMUL; BLATT H, 1987, J SEDIMENT PETROL, V57, P373, DOI 10.1306/212F8B34-2B24-11D7-8648000102C1865D; BLATT H, 1985, J SEDIMENT PETROL, V55, P69; BLATT H, 1981, J SEDIMENT PETROL, V51, P1259; Carroll AR, 1998, GEOLOGY, V26, P1023, DOI 10.1130/0091-7613(1998)026<1023:EDSITU>2.3.CO;2; Ettensohn F.R, 1988, DEVONIAN WORLD, V2, P323; Ettensohn F.R., 1998, SHALES MUDSTONES, VVolume I, P109; FUCHBAUER H, 1988, SEDIMENTE SEDIMENTGE; Hallam A., 1992, PHANEROZOIC SEA LEVE; HATHON C, 1980, FE234661 US DEP EN; Kepferle R. C., 1993, USGS BULL, V1909, pF1, DOI [10.3133 /b1909, DOI 10.3133/B1909]; Kooistra WHCF, 1996, MOL PHYLOGENET EVOL, V6, P391, DOI 10.1006/mpev.1996.0088; MALIVA R G, 1989, Palaios, V4, P519, DOI 10.2307/3514743; MATTER A, 1985, PROVENANCE ARENITES, P191; MILLIKEN KL, 1994, J SEDIMENT RES A, V64, P567, DOI 10.1306/D4267E0B-2B26-11D7-8648000102C1865D; OBrien N.R., 1990, ARGILLACEOUS ROCK AT; Parrish J.T., 1998, INTERPRETING PREQUAT; PHILIPPE H, 1994, J EVOLUTION BIOL, V7, P247, DOI 10.1046/j.1420-9101.1994.7020247.x; Potter P.E., 1980, SEDIMENTOLOGY SHALE; Riciputi LR, 1998, INT J MASS SPECTROM, V178, P81, DOI 10.1016/S1387-3806(98)14088-5; Round F. E., 1990, DIATOMS BIOL MORPHOL; Schieber J, 1999, J SEDIMENT RES, V69, P909, DOI 10.2110/jsr.69.909; Schieber J, 1996, J SEDIMENT RES, V66, P175; Schieber J., 1998, SHALES AND MUDSTONES, V1, P187; Seyedolali A, 1997, GEOLOGY, V25, P787, DOI 10.1130/0091-7613(1997)025<0787:PIOQBS>2.3.CO;2; Tappan H, 1980, PALEOBIOLOGY PLANT P; Tyson R.V., 1991, Geological Society Special Publication, V58, P1; Wollast R., 1983, SILICON GEOCHEMISTRY, P39; WOODROW DL, 1985, CATSKILL DELTA, P51; ZINKERNAGEL U, 1978, CONTRIB SEDIMENTOL, V8	30	164	188	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					981	985		10.1038/35023143	http://dx.doi.org/10.1038/35023143			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984049				2022-12-28	WOS:000089020200041
J	Snieder, R				Snieder, R			The tube worm turns - Science needs a new breed of Renaissance man and woman.	NATURE			English	Editorial Material									Colorado Sch Mines, Dept Geophys, Golden, CO 80401 USA; Colorado Sch Mines, Ctr Wave Phenomena, Golden, CO 80401 USA	Colorado School of Mines; Colorado School of Mines	Snieder, R (corresponding author), Colorado Sch Mines, Dept Geophys, Golden, CO 80401 USA.								0	2	2	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					939	939		10.1038/35023062	http://dx.doi.org/10.1038/35023062			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984030				2022-12-28	WOS:000089020200021
J	Khriachtchev, L; Pettersson, M; Runeberg, N; Lundell, J; Rasanen, M				Khriachtchev, L; Pettersson, M; Runeberg, N; Lundell, J; Rasanen, M			A stable argon compound	NATURE			English	Article							RARE-GAS; INFRARED-SPECTRA; XE; PHOTOLYSIS; CHEMISTRY; MOLECULES; MATRICES; STATES; NEON; KR	The noble gases have a particularly stable electronic configuration, comprising fully filled s and p valence orbitals. This makes these elements relatively non-reactive, and they exist at room temperature as monatomic gases. Pauling predicted(1) in 1933 that the heavier noble gases, whose valence electrons are screened by core electrons and thus less strongly bound, could form stable molecules. This prediction was verified in 1962 by the preparation of xenon hexafluoroplatinate, XePtF6, the first compound to contain a noble-gas atom(2,3). Since then, a range of different compounds containing radon, xenon and krypton have been theoretically anticipated and prepared(4-8). Although the lighter noble gases neon, helium and argon are also expected to be reactive under suitable conditions(9,10), they remain the last three long-lived elements of the periodic table for which no stable compound is known. Here we report that the photolysis of hydrogen fluoride in a solid argon matrix leads to the formation of argon fluorohydride (HArF), which we have identified by probing the shift in the position of vibrational bands on isotopic substitution using infrared spectroscopy. Extensive ab initio calculations indicate that HArF is intrinsically stable, owing to significant ionic and covalent contributions to its bonding, thus confirming computational predictions(11-13) that argon should form a stable hydride species with properties similar to those of the analogous xenon and krypton compounds reported before(14-18).	Univ Helsinki, Dept Chem, FIN-00014 Helsinki, Finland	University of Helsinki	Rasanen, M (corresponding author), Univ Helsinki, Dept Chem, POB 55,AI Virtasen Aukio 1, FIN-00014 Helsinki, Finland.	markku.rasanen@helsinki.fi	Lundell, Jan/AAS-4221-2020	Lundell, Jan/0000-0003-0396-4537; Khriachtchev, Leonid/0000-0002-1146-5212				BARTLETT N, 1962, P CHEM SOC LONDON, P218; BONDYBEY VE, 1971, THESIS U CALIFORNIA; Bressler C, 1996, J CHEM PHYS, V105, P10178, DOI 10.1063/1.472731; Chaban GM, 1999, J CHEM PHYS, V111, P1823, DOI 10.1063/1.479452; DUNNING TH, 1978, J CHEM PHYS, V69, P134, DOI 10.1063/1.436397; Evans CJ, 2000, J CHEM PHYS, V112, P1321, DOI 10.1063/1.480684; Evans CJ, 2000, J CHEM PHYS, V112, P9363, DOI 10.1063/1.481557; FRENKING G, 1988, J AM CHEM SOC, V110, P8007, DOI 10.1021/ja00232a009; FRENKING G, 1990, STRUCT BOND, V73, P17; FRENKING G, 1989, J PHYS CHEM-US, V93, P3410, DOI 10.1021/j100346a008; Graham L, 2000, COORDIN CHEM REV, V197, P321, DOI 10.1016/S0010-8545(99)00190-3; Holloway JH, 1999, ADV INORG CHEM, V46, P51; HUNT RD, 1985, J CHEM PHYS, V82, P4442, DOI 10.1063/1.448747; JOHNS JWC, 1984, J MOL SPECTROSC, V106, P124, DOI 10.1016/0022-2852(84)90087-0; Khriachtchev L, 1998, CHEM PHYS LETT, V288, P727, DOI 10.1016/S0009-2614(98)00295-4; Lorenz M, 2000, J PHYS CHEM A, V104, P3770, DOI 10.1021/jp993891+; NELSON LY, 1967, INORG CHEM, V6, P1758, DOI 10.1021/ic50055a038; Pauling L, 1933, J AM CHEM SOC, V55, P1895, DOI 10.1021/ja01332a016; Pettersson M, 2000, J PHYS CHEM A, V104, P3579, DOI 10.1021/jp9936751; PETTERSSON M, 1995, J CHEM PHYS, V102, P6423, DOI 10.1063/1.469357; Pettersson M, 1997, J CHEM PHYS, V107, P8423, DOI 10.1063/1.475042; Pettersson M, 1999, EUR J INORG CHEM, P729; Pettersson M, 1999, J AM CHEM SOC, V121, P11904, DOI 10.1021/ja9932784; RUNEBERG N, UNPUB J CHEM PHYS; STEIN L, 1973, NATURE, V243, P30, DOI 10.1038/243030a0; THOMPSON CA, 1994, J AM CHEM SOC, V116, P423, DOI 10.1021/ja00080a069; TURNER JJ, 1963, SCIENCE, V140, P974, DOI 10.1126/science.140.3570.974-a; Wong MW, 2000, J AM CHEM SOC, V122, P6289, DOI 10.1021/ja9938175	28	529	534	4	288	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					874	876		10.1038/35022551	http://dx.doi.org/10.1038/35022551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972285				2022-12-28	WOS:000088903600039
J	Macilwain, C				Macilwain, C			Green Bank dish may be last of the giants	NATURE			English	News Item																			0	1	2	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					816	816		10.1038/35022718	http://dx.doi.org/10.1038/35022718			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972259	Bronze			2022-12-28	WOS:000088903600005
J	Cobelens, FGJ; van Deutekom, H; Draayer-Jansen, IWE; Schepp-Beelen, ACHM; van Gerven, PJHJ; van Kessel, RPM; Mensen, MEA				Cobelens, FGJ; van Deutekom, H; Draayer-Jansen, IWE; Schepp-Beelen, ACHM; van Gerven, PJHJ; van Kessel, RPM; Mensen, MEA			Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity	LANCET			English	Article							HEPATITIS-A; TRAVELERS; EPIDEMIOLOGY; PREVENTION; RECOMMENDATIONS; VACCINATION; MALARIA	Background No data exist on risks of infection with Mycobacterium tuberculosis in travellers. We studied incidences of and risk factors for tuberculin skin-test conversion among Dutch long-term travellers to countries of high tuberculosis endemicity. Methods In a multicentre, prospective cohort study based in travel and tuberculosis clinics in the Netherlands, 1072 BCG-naive immunocompetent travellers to countries with an estimated annual risk of M tuberculosis infection of at least 1% were skin tested before departure with 1 tuberculin unit purified protein derivative (PPD) of M tuberculosis in Tween-80. Those with results less than 2 mm were retested 2-4 months after their return with simultaneous testing for cross-sensitivity to environmental mycobacteria (1 tuberculin unit PPD of M scrofulaceum in Tween-80). M tuberculosis infection was defined as a post-travel M tuberculosis tuberculin skin-test result of at least 10 mm that was 3 mm or more larger than the M scrofulaceum result. Findings Post-travel skin-test results were available for 656 (66%) of 988 individuals who were eligible for follow-up. Among these, 12 M tuberculosis infections were identified (1.8%). The overall incidence rate was 3.5 per 1000 person-months of travel (95% CI 2.0-6.2), and 2.8 per 1000 person-months of travel (1.2-5.5) after exclusion of health-care workers. Two had active tuberculosis at the time of testing (incidence rate 0.6 per 1000 person-months of travel [0.3-2.3]). Work in patient care abroad was an independent risk factor (adjusted rate ratio 5.34, p=0.015). Interpretation The risk of M tuberculosis infection in longterm travellers to high-endemicity countries, even if not engaged in health-care work, is substantial and of similar magnitude to the average risk for the local population. BCG vaccination or post-travel tuberculin skin-testing of high-risk travellers should be considered.	Acad Med Ctr, Ctr Trop & Travel Med A01 331, Div Infect Dis Trop Med & AIDS, NL-1100 DE Amsterdam, Netherlands; Municipal Hlth Serv, Dept TB Control, Amsterdam, Netherlands; Municipal Hlth Serv, Dept TB Control, Utrecht, Netherlands; Municipal Hlth Serv, Dept Infect Dis & Hyg, Utrecht, Netherlands; Municipal Hlth Serv, Dept TB Control, The Hague, Netherlands; Municipal Hlth Serv, Dept TB Control, Rotterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Cobelens, FGJ (corresponding author), Acad Med Ctr, Ctr Trop & Travel Med A01 331, Div Infect Dis Trop Med & AIDS, POB 22700, NL-1100 DE Amsterdam, Netherlands.	f.g.cobelens@amc.uva.nl		Cobelens, Frank/0000-0002-4367-1133				BEHRENS RH, 1994, BRIT MED J, V309, P918, DOI 10.1136/bmj.309.6959.918; Bleiker M A, 1989, Bull Int Union Tuberc Lung Dis, V64, P7; BLEIKER MA, 1992, ONDERZOEK NAAR PREVA; Borgdorff M W, 1999, Ned Tijdschr Geneeskd, V143, P1398; BROEKMANS JF, 1993, TUBERCULOSIS COMPREH; BRUINS J, 1998, THESIS ERASMUS U ROT; COBELENS FGJ, 1999, NED TIJDSCHR GENEES, V143, P885; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; EDWARDS LB, 1973, AM REV RESPIR DIS, V108, P1334; Houston, 1997, J Travel Med, V4, P76, DOI 10.1111/j.1708-8305.1997.tb00784.x; Koch, 1994, J Travel Med, V1, P4, DOI 10.1111/j.1708-8305.1994.tb00548.x; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; MORGER H, 1983, BRIT MED J, V286, P184, DOI 10.1136/bmj.286.6360.184; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; PALMER CE, 1968, J AMER MED ASSOC, V205, P167, DOI 10.1001/jama.205.3.167; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RICHARDS NM, 1979, AM REV RESPIR DIS, V120, P59; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; SHOPE RE, 1993, EMERGING VIRUSES; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; Styblo K, 1980, Adv Tuberc Res, V20, P1; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VONREYN CF, 1994, CLIN INFECT DIS, V19, P15, DOI 10.1093/clinids/19.1.15; 1997, CAN COMM DIS RES, V23, P1	29	132	132	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					461	465		10.1016/S0140-6736(00)02554-X	http://dx.doi.org/10.1016/S0140-6736(00)02554-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981889				2022-12-28	WOS:000088657700011
J	Girelli, D; Russo, C; Ferraresi, P; Olivieri, O; Pinotti, M; Friso, S; Manzato, F; Mazzucco, A; Bernardi, F; Corrocher, R				Girelli, D; Russo, C; Ferraresi, P; Olivieri, O; Pinotti, M; Friso, S; Manzato, F; Mazzucco, A; Bernardi, F; Corrocher, R			Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COAGULATION-FACTOR-VII; ISCHEMIC-HEART-DISEASE; TISSUE FACTOR; HEMOSTATIC FACTORS; BLOOD-COAGULATION; FACTOR-V; FIBRINOGEN; THROMBOSIS; REGION; ATHEROSCLEROSIS	Background: High plasma levels of coagulation factor VII have been suggested to be predictors of death due to coronary artery disease. Since polymorphisms in the factor VII gene contribute to variations in factor VII levels, such polymorphisms may be associated with the risk of myocardial infarction, which is precipitated by thrombosis. Methods: We studied a total of 444 patients, 311 of whom had severe, angiographically documented coronary atherosclerosis. Of these 311 patients, 175 had documentation of a previous myocardial infarction. As a control group, 133 patients with normal coronary arteriograms were also included. We measured the levels of activated factor VII and assessed three polymorphisms in the factor VII gene, one involving the promoter (A1 and A2 alleles), one involving the catalytic region (R353Q), and one involving intron 7. Results: Each of the polymorphisms influenced factor VII levels. Patients with the A2A2 and QQ genotypes had the lowest levels of activated factor VII (66 percent and 72 percent lower, respectively, than the levels in patients with the wild-type genotypes). The frequencies of the various genotypes in the patients free of coronary artery disease were similar to those in the entire population of patients with coronary artery disease. In the latter group, there were significantly more heterozygotes and homozygotes for the A2 and Q alleles among those who had not had a myocardial infarction than among those who had had an infarction (P=0.008 for the presence of the promoter polymorphism and P=0.01 for the presence of the R353Q polymorphism by chi-square analysis). The adjusted odds ratio for myocardial infarction among the patients with the A1A2 or RQ genotype was 0.47 (95 percent confidence interval, 0.27 to 0.81). Conclusions: Our findings suggest that certain factor VII genotypes have a role in protection against myocardial infarction. This may explain why some patients do not have myocardial infarction despite the presence of severe coronary atherosclerosis. (N Engl J Med 2000;343:774-80.) (C) 2000, Massachusetts Medical Society.	Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy; Univ Verona, Inst Clin Chem, I-37100 Verona, Italy; Univ Verona, Inst Cardiovasc Surg, I-37100 Verona, Italy; Univ Ferrara, Dept Biochem & Mol Biol, Ferrara, Italy	University of Verona; University of Verona; University of Verona; University of Ferrara	Girelli, D (corresponding author), Univ Verona, Policlin GB Rossi, Dept Clin & Expt Med, I-37134 Verona, Italy.		bernardi, francesco/F-5443-2013; Friso, Simonetta/K-4715-2016; Girelli, Domenico/B-1183-2008; Olivieri, Oliviero/A-9126-2008	Girelli, Domenico/0000-0001-9684-1899; Olivieri, Oliviero/0000-0001-8209-9056; Pinotti, Mirko/0000-0002-4114-7055; FERRARESI, Paolo/0000-0001-6742-7832	Telethon [E.0675] Funding Source: Medline	Telethon(Fondazione Telethon)		Ardissino D, 1999, BLOOD, V94, P46; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72; Bernardi F, 1997, ARTERIOSCL THROM VAS, V17, P2548, DOI 10.1161/01.ATV.17.11.2548; deMaat MPM, 1997, ARTERIOSCL THROM VAS, V17, P1918, DOI 10.1161/01.ATV.17.10.1918; Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P281, DOI 10.1055/s-0037-1615188; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Ghaddar HM, 1998, CIRCULATION, V98, P2815, DOI 10.1161/01.CIR.98.25.2815; Girelli D, 1998, BLOOD, V91, P4158, DOI 10.1182/blood.V91.11.4158.411k23_4158_4163; GREEN F, 1994, BAILLIERE CLIN HAEM, V7, P675, DOI 10.1016/S0950-3536(05)80103-9; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P1392; Hunault M, 1997, ARTERIOSCL THROM VAS, V17, P2825, DOI 10.1161/01.ATV.17.11.2825; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Iacoviello L, 1998, LANCET, V351, P1205; LANDER ES, 1994, SCIENCE, V266, P353; Lane A, 1996, ATHEROSCLEROSIS, V119, P119, DOI 10.1016/0021-9150(95)05638-6; MARCHETTI G, 1993, HUM GENET, V90, P575; Marckmann P, 1998, EUR J CLIN NUTR, V52, P75, DOI 10.1038/sj.ejcn.1600533; Meade TW, 1998, LANCET, V351, P233; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MORRISSEY JH, 1993, BLOOD, V81, P734; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; Redondo M, 1999, ARTERIOSCL THROM VAS, V19, P1020, DOI 10.1161/01.ATV.19.4.1020; Ridker PM, 1999, LANCET, V353, P687, DOI 10.1016/S0140-6736(99)00067-7; Smith FB, 1997, ARTERIOSCL THROM VAS, V17, P3321, DOI 10.1161/01.ATV.17.11.3321; van't Hooft FM, 1999, BLOOD, V93, P3432, DOI 10.1182/blood.V93.10.3432.410k16_3432_3441; Wang XL, 1997, ARTERIOSCL THROM VAS, V17, P246, DOI 10.1161/01.ATV.17.2.246; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	32	190	214	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					774	780		10.1056/NEJM200009143431104	http://dx.doi.org/10.1056/NEJM200009143431104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984565	Bronze			2022-12-28	WOS:000089221300004
J	Lea, DW; Pak, DK; Spero, HJ				Lea, DW; Pak, DK; Spero, HJ			Climate impact of late quaternary equatorial Pacific sea surface temperature variations	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; OXYGEN ISOTOPIC COMPOSITION; PLANKTONIC-FORAMINIFERA; TROPICAL PACIFIC; ICE CORE; RECORD; MAGNESIUM; OCEAN; RECONSTRUCTIONS; DEGLACIATION	Magnesium/calcium data from planktonic foraminifera in equatorial Pacific sediment cores demonstrate that tropical Pacific sea surface temperatures (SSTs) were 2.8 degrees +/- 0.7 degrees C colder than the present at the Last glacial maximum. Glacial-interglacial temperature differences as great as 5 degrees C are observed over the Last 450 thousand years. Changes in SST coincide with changes in Antarctic air temperature and precede changes in continental ice volume by about 3 thousand years, suggesting that tropical cooling played a major role in driving ice-age climate. Comparison of SST estimates from eastern and western sites indicates that the equatorial Pacific zonal SST gradient was similar or somewhat Larger during glacial episodes. Extraction of a salinity proxy from the magnesium/calcium and oxygen isotope data indicates that transport of water vapor into the western Pacific was enhanced during glacial episodes.	Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; Univ Calif Davis, Dept Geol, Davis, CA 95616 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Davis	Lea, DW (corresponding author), Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA.							Andreasen DJ, 1997, PALEOCEANOGRAPHY, V12, P395, DOI 10.1029/97PA00822; Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; Beck JW, 1997, NATURE, V385, P705, DOI 10.1038/385705a0; Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; BERGER WH, 1993, P OCEAN DRILLING PRO, V0130; Broecker WS, 1989, PALEOCEANOGRAPHY, V4, P207, DOI 10.1029/PA004i002p00207; Broecker WS, 1999, PALEOCEANOGRAPHY, V14, P13, DOI 10.1029/1998PA900009; BROECKER WS, 1986, QUATERNARY RES, V26, P121, DOI 10.1016/0033-5894(86)90087-6; Cane MA, 1998, SCIENCE, V282, P59, DOI 10.1126/science.282.5386.59; *CLIMAP, 1981, GEOL SOC AM MAP CHAR; Crowley TJ, 2000, CLIM DYNAM, V16, P241, DOI 10.1007/s003820050325; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; Fairbanks RG, 1997, CORAL REEFS, V16, pS93, DOI 10.1007/s003380050245; FAIRBANKS RG, 1982, NATURE, V298, P841, DOI 10.1038/298841a0; Farrell JW, 1989, PALEOCEANOGRAPHY, V4, P447, DOI 10.1029/PA004i004p00447; Hastings DW, 1998, PALEOCEANOGRAPHY, V13, P161, DOI 10.1029/97PA03147; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Kroenke L. W., 1991, P OCEAN DRILL PROGRA, V130; Le JN, 1992, PALEOCEANOGRAPHY, V7, P21, DOI 10.1029/91PA02854; Lea DW, 1999, GEOCHIM COSMOCHIM AC, V63, P2369, DOI 10.1016/S0016-7037(99)00197-0; Lea DW, 1996, GEOCHIM COSMOCHIM AC, V60, P3143, DOI 10.1016/0016-7037(96)00184-6; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; Levitus S, 1994, WORLD OCEAN ATLAS, V3; LYLE MW, 1992, NATURE, V355, P812, DOI 10.1038/355812a0; MARTIN PA, 1999, 1 GEOCH GEOPHYS GEOS; Martinez JI, 1997, MAR MICROPALEONTOL, V32, P311; Mashiotta TA, 1999, EARTH PLANET SC LETT, V170, P417, DOI 10.1016/S0012-821X(99)00116-8; McCulloch MT, 1999, SCIENCE, V283, P202, DOI 10.1126/science.283.5399.202; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Nurnberg D, 2000, PALEOCEANOGRAPHY, V15, P124, DOI 10.1029/1999PA000370; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; Pelejero C, 1999, PALEOCEANOGRAPHY, V14, P224, DOI 10.1029/1998PA900015; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Pisias NG, 1997, PALEOCEANOGRAPHY, V12, P381, DOI 10.1029/97PA00583; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SHACKLETON NJ, 1992, QUATERNARY SCI REV, V11, P387, DOI 10.1016/0277-3791(92)90021-Y; Stoll HM, 1999, GEOCHIM COSMOCHIM AC, V63, P3535, DOI 10.1016/S0016-7037(99)00129-5; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	43	766	870	4	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1719	1724		10.1126/science.289.5485.1719	http://dx.doi.org/10.1126/science.289.5485.1719			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976060				2022-12-28	WOS:000089195200038
J	Buffetaut, E; Suteethorn, V; Cuny, G; Tong, HY; Le Loeuff, J; Khansubha, S; Jongautchariyakul, S				Buffetaut, E; Suteethorn, V; Cuny, G; Tong, HY; Le Loeuff, J; Khansubha, S; Jongautchariyakul, S			The earliest known sauropod dinosaur	NATURE			English	Article							EVOLUTION; THAILAND	Sauropods were a very successful group of dinosaurs during the Jurassic and Cretaceous periods, but their earlier history is poorly known. Until now, the earliest reported sauropod bones were from the Early Jurassic(1-3), and the only tentative evidence of earlier sauropods was in the form of controversial footprints(4,5). Here we report the discovery of an incomplete sauropod skeleton from the Late Triassic period of Thailand, which provides the first osteological evidence of pre-Jurassic sauropods. This dinosaur is markedly different from prosauropods and substantiates theoretical predictions that there was a fairly long period of sauropod evolution during the Triassic.	CNRS, F-75013 Paris, France; Dept Mineral Resources, Geol Survey Div, Bangkok 10400, Thailand; Musee Dinosaures, F-11260 Esperaza, France; Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	Centre National de la Recherche Scientifique (CNRS); Department of Mineral Resources - Thailand; University of Bristol	Buffetaut, E (corresponding author), CNRS, 16 Cour Liegat, F-75013 Paris, France.	Eric.Buffetaut@wanadoo.fr	Cuny, Gilles/A-4775-2013; Cuny, Gilles/F-8949-2017	Cuny, Gilles/0000-0001-7680-1697; Cuny, Gilles/0000-0001-7680-1697				Avanzini M, 1997, PALAIOS, V12, P538, DOI 10.2307/3515410; Barrett PM, 1999, J VERTEBR PALEONTOL, V19, P785, DOI 10.1080/02724634.1999.10011191; Bonaparte J.F., 1971, OPERA LILLOANA, V22, P1; Bonaparte JF, 1999, AMEGHINIANA, V36, P115; BUFFETAUT E, 1995, GEOL MAG, V132, P739, DOI 10.1017/S0016756800018951; Buffetaut Eric, 1998, P83; Charig A. J., 1965, Proceedings of the Linnean Society of London, V176, P197; COOPER M R, 1984, Palaeontologia Africana, V25, P203; Ellenberger F., 1958, C R SOC GEOL FRANCE, V4, P65; Ellenberger P., 1972, PALAEOVERTEBRATA, P1; Galton P.M., 1990, P320; GALTON PM, 1985, GEOBIOS-LYON, V18, P671, DOI 10.1016/S0016-6995(85)80065-6; Gauffre F-X, 1993, NEUES JB GEOLOGIE PA, V11, P648; GIERLINSKI R, 1998, GEOL Q, V42, P477; Haubold H., 1984, SAURIERFAHRTEN; He X. L., 1998, ACTA GEOLOGICA SICHU, V18, P1; JAIN SL, 1979, 4 INT GONDW S, P204; McIntosh J.S., 1990, P345; Racey A, 1996, J PETROL GEOL, V19, P5, DOI 10.1111/j.1747-5457.1996.tb00511.x; Sues H.-D., 1990, P143; Thulborn T., 1990, DINOSAUR TRACKS; Upchurch P, 1998, ZOOL J LINN SOC-LOND, V124, P43, DOI 10.1111/j.1096-3642.1998.tb00569.x; UPCHURCH P, 1995, PHILOS T R SOC B, V349, P365, DOI 10.1098/rstb.1995.0125; Wellnhofer Peter, 1994, Revue de Paleobiologie Volume Special, V7, P263; Wilson JA, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011115; YADAGIRI P, 1988, RECORDS GEOLOGICAL S, V11, P102; ZHANG FJ, 1989, ACTA MATH APPL SIN-E, V1, P1; Zhang Y, 1983, PALAEONTOLOGICA SI C, V162, P1	28	80	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					72	74		10.1038/35024060	http://dx.doi.org/10.1038/35024060			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993074				2022-12-28	WOS:000089124000043
J	Weiss, SC				Weiss, SC			Parental decisions and physician responsibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Asch A, 1997, HASTINGS CENT REP, V27, P17; 1974, NY TIMES        0612, pA18	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1142	1142		10.1001/jama.284.9.1142	http://dx.doi.org/10.1001/jama.284.9.1142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974697				2022-12-28	WOS:000089037200018
J	Watkinson, AR; Freckleton, RP; Robinson, RA; Sutherland, WJ				Watkinson, AR; Freckleton, RP; Robinson, RA; Sutherland, WJ			Predictions of biodiversity response to genetically modified herbicide-tolerant crops	SCIENCE			English	Article							ABUNDANCE; SCALE; BIRDS	We simulated the effects of the introduction of genetically modified herbicide-tolerant (GMHT) crops on weed populations and the consequences for seed-eating birds. We predict that weed populations might be reduced to Low Levels or practically eradicated, depending on the exact form of management. Consequent effects on the local use of fields by birds might be severe, because such reductions represent a major Loss of food resources. The regional impacts of GMHT crops are shown to depend on whether the adoption of GMHT crops by farmers covaries with current weed levels.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; British Trust Ornithol, Thetford IP24 2PU, Norfolk, England	University of East Anglia; University of East Anglia; British Trust for Ornithology	Watkinson, AR (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.		Robinson, Robert/B-8237-2009; Sutherland, William/B-1291-2013; Watkinson, Andrew R/N-1649-2013; Freckleton, Rob P/B-6455-2013	Robinson, Robert/0000-0003-0504-9906; Sutherland, William/0000-0002-6498-0437; Freckleton, Robert/0000-0002-8338-864X				Clark SJ, 1996, WEED RES, V36, P405, DOI 10.1111/j.1365-3180.1996.tb01670.x; Firbank LG, 1999, NATURE, V399, P727, DOI 10.1038/21516; Freckleton RP, 1998, J APPL ECOL, V35, P904, DOI 10.1111/j.1365-2664.1998.tb00008.x; Freckleton RP, 1998, J APPL ECOL, V35, P340, DOI 10.1046/j.1365-2664.1998.00308.x; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; MOLL S, 1997, BRIGHT CROP PROT C W, P931; READ MA, 1998, ASPECTS APPL BIOL, V52, P401; Robinson R.A., 1997, THESIS U E ANGLIA NO; Robinson RA, 1999, ECOGRAPHY, V22, P447, DOI 10.1111/j.1600-0587.1999.tb00581.x; Sutherland WJ, 1998, J APPL ECOL, V35, P418, DOI 10.1046/j.1365-2664.1998.00320.x; WEVERS JDA, 1998, ASPECTS APPL BIOL, V52, P393; Wilson JD, 1999, AGR ECOSYST ENVIRON, V75, P13, DOI 10.1016/S0167-8809(99)00064-X	12	154	173	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1554	1557		10.1126/science.289.5484.1554	http://dx.doi.org/10.1126/science.289.5484.1554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968791				2022-12-28	WOS:000089071700047
J	Nicoll, RA; Mellor, J; Frerking, M; Schmitz, D				Nicoll, RA; Mellor, J; Frerking, M; Schmitz, D			Neurobiology - Kainate receptors and synaptic plasticity	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL CA3 NEURONS; LTP		Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.		MELLOR, Jack/B-4548-2019	MELLOR, Jack/0000-0002-7706-8105; Schmitz, Dietmar/0000-0003-2741-5241				BAHN S, 1994, J NEUROSCI, V14, P5525; Bortolotto ZA, 1999, NATURE, V402, P297, DOI 10.1038/46290; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; Paternain AV, 2000, J NEUROSCI, V20, P196, DOI 10.1523/JNEUROSCI.20-01-00196.2000; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180	10	24	26	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					957	957		10.1038/35023075	http://dx.doi.org/10.1038/35023075			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984042				2022-12-28	WOS:000089020200033
J	Hiramoto, M; Hiromi, Y; Giniger, E; Hotta, Y				Hiramoto, M; Hiromi, Y; Giniger, E; Hotta, Y			The Drosophila Netrin receptor Frazzled guides axons by controlling Netrin distribution	NATURE			English	Article							C-ELEGANS; COLORECTAL-CANCER; COMMISSURAL AXONS; GENETIC-ANALYSIS; PIONEER NEURONS; NERVOUS-SYSTEM; MOTOR AXONS; GUIDANCE; UNC-6; CNS	Netrin is a secreted protein that can act as a chemotropic axon guidance cue(1,2). Two classes of Netrin receptor, DCC3-5 and UNC-5 (refs 6-9), are required for axon guidance(3,4,6-11) and are thought to mediate Netrin signals in growth cones through their cytoplasmic domains(12,13). However, in the guidance of Drosophila photoreceptor axons, the DCC orthologue Frazzled(3) is required not in the photoreceptor neurons but instead in their targets, indicating that Frazzled also has a non-cell-autonomous function(14). Here we show that Frazzled can capture Netrin and 'present' it for recognition by other receptors. Moreover, Frazzled itself is actively localized within the axon through its cytoplasmic domain, and thereby rearranges Netrin protein into a spatial pattern completely different from the pattern of Netrin gene expression. Frazzled-dependent guidance of one pioneer neuron in the central nervous system can be accounted for solely on the basis of this ability of Frazzled to control Netrin distribution, and not by Frazzled signalling. We propose a model of patterning mechanism in which a receptor rearranges secreted ligand molecules, thereby creating positional information for other receptors.	Natl Inst Genet, Dept Dev Genet, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Dept Genet, Shizuoka 4118540, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Fred Hutchinson Cancer Center; Japan Science & Technology Agency (JST)	Hotta, Y (corresponding author), Natl Inst Genet, Dept Dev Genet, 1111 Yata, Shizuoka 4118540, Japan.		Giniger, Edward/C-1764-2015	Giniger, Edward/0000-0002-8340-6158				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; Gong QZ, 1999, DEVELOPMENT, V126, P1451; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hidalgo A, 1997, DEVELOPMENT, V124, P3253; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JACOBS JR, 1989, J NEUROSCI, V9, P2412; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Przyborski SA, 1998, DEVELOPMENT, V125, P41; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3	30	101	102	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					886	889		10.1038/35022571	http://dx.doi.org/10.1038/35022571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972289				2022-12-28	WOS:000088903600043
J	Gach, JE; Heagerty, A				Gach, JE; Heagerty, A			Crusted scabies looking like psoriasis	LANCET			English	Article							NORWEGIAN SCABIES; PATIENT				Gach, JE (corresponding author), Royal Liverpool Univ Hosp, Dept Dermatol, Liverpool L7 8XP, Merseyside, England.							delGiudice P, 1997, J INFECT DIS, V176, P1090, DOI 10.1086/516518; ESPY PD, 1976, ARCH DERMATOL, V112, P193, DOI 10.1001/archderm.112.2.193; Jaramillo-Ayerbe F, 1998, ARCH DERMATOL, V134, P143, DOI 10.1001/archderm.134.2.143; RAU RC, 1986, J AM ACAD DERMATOL, V15, P1058, DOI 10.1016/S0190-9622(86)80318-8; WOLF R, 1987, J AM ACAD DERMATOL, V17, P434, DOI 10.1016/S0190-9622(87)70225-4	5	23	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					650	650		10.1016/S0140-6736(00)02608-8	http://dx.doi.org/10.1016/S0140-6736(00)02608-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968439				2022-12-28	WOS:000088884100014
J	Lanas, A; Bajador, E; Serrano, P; Fuentes, J; Carreno, S; Guardia, J; Sanz, M; Montoro, M; Sainz, R				Lanas, A; Bajador, E; Serrano, P; Fuentes, J; Carreno, S; Guardia, J; Sanz, M; Montoro, M; Sainz, R			Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEPTIC-ULCER DISEASE; PROPHYLACTIC ASPIRIN; CYCLOOXYGENASE; PERFORATION; PREVENTION; RAT	Background: The relation between medications that release nitric oxide, such as nitroglycerin and other nitrovasodilators, and upper gastrointestinal bleeding is uncertain. In animals, these medications reduce the gastric damage induced by nonsteroidal antiinflammatory drugs. Nitric oxide, however, inhibits platelet aggregation and may contribute to bleeding from an ulcer. Methods: We performed a case-control study to determine the risk of bleeding in patients taking nitrovasodilators, low-dose aspirin, or other nonsteroidal antiinflammatory drugs. The case group was made up of 1122 consecutive patients admitted to one of four hospitals with bleeding from a peptic lesion. The 2231 control subjects were 1109 patients hospitalized for other reasons and 1122 outpatients from the same geographic area. Results: In the week before admission, 520 (46.3 percent) of the patients with bleeding had taken a nonsteroidal antiinflammatory drug other than low-dose aspirin, 120 (10.7 percent) had taken low-dose aspirin (less than or equal to 300 mg per day), 60 (5.3 percent) a nitrovasodilator, and 135 (12.0 percent) an antisecretory agent such as a histamine H-2-receptor antagonist or a proton-pump inhibitor. In multivariate models that adjusted for age, sex, and clinical risk factors, the use of a nonsteroidal antiinflammatory drug other than low-dose aspirin was independently associated with an increased risk of bleeding from a peptic ulcer (odds ratio, 7.4; 95 percent confidence interval, 4.5 to 12.0), as was the use of low-dose aspirin alone (odds ratio, 2.4; 95 percent confidence interval, 1.8 to 3.3). The use of a nitrovasodilator was associated with a decreased risk of bleeding (odds ratio, 0.6; 95 percent confidence interval, 0.4 to 0.9), as was antisecretory therapy (odds ratio, 0.6; 95 percent confidence interval, 0.4 to 0.8). In patients taking any type of nonsteroidal antiinflammatory drug, the use of a nitrovasodilator or antisecretory therapy was independently associated with a decreased risk of bleeding. Conclusions: The use of nitrovasodilator drugs is independently associated with a decreased risk of upper gastrointestinal bleeding. (N Engl J Med 2000;343:834-9.) (C) 2000, Massachusetts Medical Society.	Univ Hosp, Serv Digest Dis, Zaragoza, Spain; Hosp Miguel Servet, Serv Digest Dis, Zaragoza, Spain; Hosp San Jorge, Serv Digest Dis, Huesca, Spain; Hosp San Millan, Serv Digest Dis, Logrono, Spain	Miguel Servet University Hospital; Miguel Servet University Hospital; Hospital Universidad San Jorge	Lanas, A (corresponding author), Hosp Clin Univ, Serv Aparato Digest, Zaragoza 50009, Spain.	alanas@posta.unizar.cs	Montoro, Miguel/M-3631-2013	Montoro, Miguel/0000-0001-7676-9842				BARRACHINA MD, 1995, EUR J PHARMACOL, V281, pR3, DOI 10.1016/0014-2999(95)00399-6; Donnelly MT, 1998, GASTROENTEROLOGY, V114, pA107; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Kelly JP, 1996, LANCET, V348, P1413, DOI 10.1016/S0140-6736(96)01254-8; Lanas A, 1997, GASTROENTEROLOGY, V112, P683, DOI 10.1053/gast.1997.v112.pm9041228; LANAS A, 1992, GASTROENTEROLOGY, V103, P862, DOI 10.1016/0016-5085(92)90018-T; Lanas A, 1998, J INT MED RES, V26, P120, DOI 10.1177/030006059802600302; Lanas AI, 1996, GUT, V39, P654, DOI 10.1136/gut.39.5.654; LOPEZBELMONTE J, 1993, BRIT J PHARMACOL, V108, P73, DOI 10.1111/j.1476-5381.1993.tb13442.x; MCCARTHY DM, 1995, SCAND J GASTROENTERO, V30, P24, DOI 10.3109/00365529509107758; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; PETROSKI D, 1993, CLIN THER, V15, P314; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Rodriguez LAG, 1999, EPIDEMIOLOGY, V10, P228, DOI 10.1097/00001648-199905000-00006; Salvemini D, 1996, J CLIN INVEST, V97, P2562, DOI 10.1172/JCI118704; Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; Taha AS, 1999, GASTROENTEROLOGY, V116, P254, DOI 10.1016/S0016-5085(99)70120-4; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; Wallace JL, 1999, THROMB RES, V93, P43, DOI 10.1016/S0049-3848(98)00134-0; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827	24	324	336	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					834	839		10.1056/NEJM200009213431202	http://dx.doi.org/10.1056/NEJM200009213431202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995862				2022-12-28	WOS:000089355600002
J	Ross, KS; Carter, HB; Pearson, JD; Guess, HA				Ross, KS; Carter, HB; Pearson, JD; Guess, HA			Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; MEN; AGE; POPULATION; MORTALITY	Context Despite widespread use of serum prostate-specific antigen (PSA) testing to detect prostate cancer, the relative effectiveness of different PSA screening strategies is unknown. Objective To compare prostate cancer mortality, PSA testing rates, and biopsy rates using various PSA screening strategies, including the standard strategy of annually testing men aged 50 through 75 years. Design and Setting A Monte-Carlo simulation based on a Markov model was used to simulate the natural history of prostate cancer using different starting ages, testing intervals, and PSA thresholds for prostate biopsy. Age-specific PSA levels and prostate biopsy detection probabilities were determined from population data and surgical series. Main Outcome Measures Numbers of prevented prostate cancer deaths, PSA tests, and prostate biopsies per 1000 men aged 40 through 80 years, compared among 7 different strategies vs no screening. Results Compared with annual PSA testing beginning at age 50 years, the strategy of PSA testing at ages 40 and 45 years followed by biennial testing beginning at age 50 years was estimated to simultaneously reduce prostate cancer mortality and number of PSA tests and biopsies performed per 1000 men. Specifically, compared with no screening, the standard strategy prevents 3.2 deaths, with an additional 10500 PSA tests and 600 prostate biopsies, while the earlier but less frequent strategy prevents 3.3 deaths, with an additional 7500 PSA tests and 450 prostate biopsies. Strategies that lowered the PSA threshold for prostate biopsy to below 4.0 ng/mL or strategies that used age-specific PSA levels were not more efficient than use of a PSA threshold of 4.0 ng/mL, These 2 findings remained true under all sensitivity analyses performed to test assumptions of the model, Conclusion Recognizing that the efficacy of PSA screening is unproved, the standard strategy of annual PSA screening beginning at age 50 years appears to be less effective and more resource intensive compared with a strategy that begins earlier but screens biennially instead of annually.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, James Brady Urol Inst,Dept Urol, Baltimore, MD 21287 USA; Merck Res Labs, Dept Epidemiol, Blue Bell, PA USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins Medicine; Merck & Company	Carter, HB (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, James Brady Urol Inst,Dept Urol, 403 Marburg,600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL CANCER INSTITUTE [T32CA009330, P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236, 5-T32-CA09330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auvinen A, 1996, J Med Screen, V3, P97; BARRY MJ, 1995, UROLOGY, V46, P445, DOI 10.1016/S0090-4295(99)80255-6; BROWN BW, 1993, J NATL CANCER I, V85, P979, DOI 10.1093/jnci/85.12.979; Carter HB, 1999, UROLOGY, V53, P126, DOI 10.1016/S0090-4295(98)00466-X; Carter HB, 1997, JAMA-J AM MED ASSOC, V277, P1456, DOI 10.1001/jama.277.18.1456; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Epstein JI, 1997, J UROLOGY, V158, P1886, DOI 10.1016/S0022-5347(01)64159-4; Etzioni R, 1999, J UROLOGY, V162, P741, DOI 10.1097/00005392-199909010-00032; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; GUESS HA, 1997, J EPIDEMIOL BIOSTAT, V2, P161; Klein EA, 2000, J UROLOGY, V163, P179, DOI 10.1016/S0022-5347(05)67999-2; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; Lu-Yao GL, 1999, UROLOGY, V54, P301, DOI 10.1016/S0090-4295(99)00100-4; MARK DH, 1994, J UROLOGY, V152, P896, DOI 10.1016/S0022-5347(17)32602-2; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Potter SR, 1999, ONCOLOGY-NY, V13, P99; Pound CR, 1997, UROL CLIN N AM, V24, P395, DOI 10.1016/S0094-0143(05)70386-4; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Ries L, 1998, SEER CANC STAT REV 1; Ross Kevin S., 1999, Journal of Urology, V161, P210; Schroder FH, 2000, J UROLOGY, V163, P806, DOI 10.1016/S0022-5347(05)67809-3; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SKATES SJ, 1991, J CLIN EPIDEMIOL, V44, P365, DOI 10.1016/0895-4356(91)90075-K; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Torrance GW, 1996, COST EFFECTIVENESS H, P276; *US C OFF TECHN AS, 1995, COST EFF PROST CANC; Wardle J, 1996, BRIT J HEALTH PSYCH, V1, P1, DOI 10.1111/j.2044-8287.1996.tb00486.x; WHITTEMORE AS, 1995, J NATL CANCER I, V87, P354, DOI 10.1093/jnci/87.5.354; ZHANG YS, 1982, J EPIDEMIOL COMMUNIT, V36, P1	30	103	108	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1399	1405		10.1001/jama.284.11.1399	http://dx.doi.org/10.1001/jama.284.11.1399			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989402	Bronze			2022-12-28	WOS:000089242500034
J	Yuan, CS; Foss, JF				Yuan, CS; Foss, JF			Oral methylnaltrexone for opioid-induced constipation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NALOXONE; CANCER		Univ Chicago, Dept Anesthesia, Chicago, IL 60637 USA; Univ Chicago, Dept Crit Care, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Yuan, CS (corresponding author), Univ Chicago, Dept Anesthesia, Chicago, IL 60637 USA.		Foss, Joseph F/B-8342-2008	Foss, Joseph F/0000-0002-4050-7151	NCI NIH HHS [R01 CA79042] Funding Source: Medline; NCRR NIH HHS [M01 RR00055] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BASILISCO G, 1987, DIGEST DIS SCI, V32, P829, DOI 10.1007/BF01296704; GLARE P, 1992, J PAIN SYMPTOM MANAG, V7, P369, DOI 10.1016/0885-3924(92)90092-V; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; SYKES NP, 1991, LANCET, V337, P1475, DOI 10.1016/0140-6736(91)93162-3; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367	5	60	76	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1383	1384		10.1001/jama.284.11.1383	http://dx.doi.org/10.1001/jama.284.11.1383			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989399				2022-12-28	WOS:000089242500029
J	Kondo, T; Raff, M				Kondo, T; Raff, M			Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; ZONE PROGENITOR CELLS; RAT OPTIC-NERVE; VENTRICULAR ZONE; NEURONAL DIFFERENTIATION; MONOCLONAL-ANTIBODY; ASTROCYTES; LINEAGE; GALACTOCEREBROSIDE; PROLIFERATION	During animal development, cells become progressively more restricted in the cell types to which they can give rise. In the central nervous system (CNS), for example, multipotential stem cells produce various kinds of specified precursors that divide a limited number of times before they terminally differentiate into either neurons OF glial cells. We show here that certain extracellular signals can induce oligodendrocyte precursor cells to revert to multipotential neural stem cells, which can self-renew and give rise to neurons and astrocytes, as well as to oligodendrocytes, Thus, these precursor cells have greater developmental potential than previously thought.	UCL, MRC, Dev Neurobiol Programme, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Kondo, T (corresponding author), UCL, MRC, Dev Neurobiol Programme, Mol Cell Biol Lab, Mortimer St, London WC1E 6BT, England.	tkondo@ucl.ac.uk	Kondo, Toru/F-9420-2012; Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1994, DEVELOPMENT, V120, P1097; BARTLETT PF, 1980, BRAIN RES, V204, P339; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896-6273(00)80193-2; HARDY R, 1991, DEVELOPMENT, V111, P1061; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Li WW, 1998, J NEUROSCI, V18, P8853; Mabie PC, 1997, J NEUROSCI, V17, P4112; NOLL E, 1993, DEVELOPMENT, V118, P563; Palmer TD, 1999, J NEUROSCI, V19, P8487; RAFF MC, 1984, DEV BIOL, V106, P53, DOI 10.1016/0012-1606(84)90060-5; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAFF MC, 1983, NATURE, V303, P396; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Williams BP, 1997, NEURON, V18, P553, DOI 10.1016/S0896-6273(00)80297-4; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; WREN D, 1992, J CELL BIOL, V116, P167, DOI 10.1083/jcb.116.1.167; YU WP, 1994, NEURON, V12, P1353, DOI 10.1016/0896-6273(94)90450-2	28	663	716	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1754	1757		10.1126/science.289.5485.1754	http://dx.doi.org/10.1126/science.289.5485.1754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976069				2022-12-28	WOS:000089195200047
J	Ward, PD; Montgomery, DR; Smith, R				Ward, PD; Montgomery, DR; Smith, R			Altered river morphology in South Africa related to the Permian-Triassic extinction	SCIENCE			English	Article							MASS EXTINCTION; SEDIMENT YIELD; KAROO BASIN; BOUNDARY; END; VEGETATION; AUSTRALIA; PATTERNS; SYSTEMS; MODEL	The Permian-Triassic transition in the Karoo Basin of South Africa was characterized by a rapid and apparently basin-wide change from meandering to braided river systems, as evidenced by preserved sedimentary facies. This radical changeover in river morphology is consistent with geomorphic consequences stemming from a rapid and major die-off of rooted plant Life in the basin. Evidence from correlative nonmarine strata elsewhere in the world containing fluvial Permian-Triassic boundary sections suggests that a catastrophic terrestrial die-off of vegetation was a global event, producing a marked increase in sediment yield as well as contributing to the global delta(13)C excursion across the Permian-Triassic boundary.	Univ Washington, Dept Geol Sci, Seattle, WA 98195 USA; S African Museum, ZA-8000 Cape Town, South Africa	University of Washington; University of Washington Seattle	Ward, PD (corresponding author), Univ Washington, Dept Geol Sci, Seattle, WA 98195 USA.							Anderson JM, 1999, J AFR EARTH SCI, V28, P145, DOI 10.1016/S0899-5362(98)00083-9; [Anonymous], 1957, RIVER CHANNEL PATTER; [Anonymous], 1994, GEOLOGICAL SOC AM ME; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; CAMPBELL IH, 1992, SCIENCE, V258, P1760, DOI 10.1126/science.258.5089.1760; COLLINS BD, 1986, GEOL SOC AM BULL, V97, P986; Cotter E., 1978, CAN SOC PET GEOL MEM, V5, P361; DUNNE T, 1979, J HYDROL, V42, P281, DOI 10.1016/0022-1694(79)90052-0; Eriksson PG, 1998, SEDIMENT GEOL, V120, P5, DOI 10.1016/S0037-0738(98)00026-8; Erwin D. H, 1993, GREAT PALEOZOIC CRIS; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; HARVEY AM, 1991, EARTH SURF PROCESSES, V16, P675, DOI 10.1002/esp.3290160711; HAYES SK, 1999, THESIS U WASHINGTON; JACKSON LE, 1977, US GEOL SURV J RES, V5, P17; Kadomura H., 1983, Z GEOMORPHOL S, V46, P124; KING G M, 1990, Palaeontologia Africana, V27, P31; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; KRAMES JA, 1965, DEPT AGR MISC PUBL, V970, P85; MacLeod KG, 2000, GEOLOGY, V28, P227, DOI 10.1130/0091-7613(2000)28<227:TOMREA>2.0.CO;2; MADER D, 1992, EVOLUTION PALAEOECOL, V1; MAGARITZ M, 1992, AM J SCI, V292, P727, DOI 10.2475/ajs.292.10.727; Morante Richard, 1996, Historical Biology, V11, P289; Murray AB, 1997, EARTH SURF PROC LAND, V22, P1001; PROSSER IP, 1995, WATER RESOUR RES, V31, P2867, DOI 10.1029/95WR02218; PROSSER IP, 1994, GEOLOGY, V22, P1127, DOI 10.1130/0091-7613(1994)022<1127:GFATRO>2.3.CO;2; RAMPINO MR, 1996, HAZARDS DUE ASTEROID, P827; RENNE PR, 1995, SCIENCE, V269, P1413, DOI 10.1126/science.269.5229.1413; Retallack GJ, 1999, AUST J EARTH SCI, V46, P785, DOI 10.1046/j.1440-0952.1999.00745.x; Retallack GJ, 1999, GEOL SOC AM BULL, V111, P52, DOI 10.1130/0016-7606(1999)111<0052:PGPRBE>2.3.CO;2; RUBIDGE B, 1995, GEOL SURV S AFR BIOS, P1; SARTZ RS, 1953, J SOIL WATER CONSERV, V8, P279; SCHUMM SA, 1968, GEOL SOC AM BULL, V79, P1573, DOI 10.1130/0016-7606(1968)79[1573:SCPCOT]2.0.CO;2; SCHUMM SA, 1995, GEOLOGY, V23, P391, DOI 10.1130/0091-7613(1995)023<0391:SYFDES>2.3.CO;2; SCHUMM SA, 1985, ANNU REV EARTH PL SC, V13, P5, DOI 10.1146/annurev.ea.13.050185.000253; Scott K.M., 1978, EROSION SEDIMENT YIE, V1030; SCOTT KM, 1971, 750C US GEOL SURV, P242; SMITH DG, 1976, GEOL SOC AM BULL, V87, P857, DOI 10.1130/0016-7606(1976)87<857:EOVOLM>2.0.CO;2; SMITH ND, 1984, GEOLOGY, V12, P78, DOI 10.1130/0091-7613(1984)12<78:WRAOEO>2.0.CO;2; SMITH RMH, 1995, PALAEOGEOGR PALAEOCL, V117, P81, DOI 10.1016/0031-0182(94)00119-S; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; THACKERAY JF, 1990, NATURE, V347, P751, DOI 10.1038/347751a0; URSIC SJ, 1965, P FEDERAL INT AGENCY; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155	43	273	290	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1740	1743		10.1126/science.289.5485.1740	http://dx.doi.org/10.1126/science.289.5485.1740			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976065				2022-12-28	WOS:000089195200043
J	Morrow, J				Morrow, J			Making mortal decisions at the beginning of life: The case of impaired and imperiled infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BABY DOE		Univ Texas, Med Branch, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Morrow, J (corresponding author), Univ Texas, Med Branch, Galveston, TX 77550 USA.							Affleck G., 1991, INFANTS CRISIS PAREN; AMUNDSEN DW, 1987, EUTHANASIA NEWBORN, P10; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Dworkin R., 1993, LIFES DOMINION; Jones G E, 1990, Pediatrician, V17, P87; KOOP CE, 1989, HASTINGS CENT REP, V19, pS2; MCMILLAN RC, 1987, EUTHANASIA NEWBORN, pR14; More ES, 1994, EMPATHIC PRACTITIONE; MOSKOP JC, 1986, HASTINGS CENT REP, V16, P8, DOI 10.2307/3563084; NOLAN K, 1990, HASTINGS CENT REP, V20, P3; REISER SJ, 1986, J HEALTH POLIT POLIC, V11, P199, DOI 10.1215/03616878-11-2-199; RHODEN NK, 1985, MILBANK FUND Q, V63, P18, DOI 10.2307/3349897; SINCLAIR JC, 1987, EUTHANASIA NEWBORN, P169; Singer P., 1993, PRACTICAL ETHICS; WEIR R, 1992, COMPELLED COMPASSION, P10	15	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1146	1147		10.1001/jama.284.9.1146	http://dx.doi.org/10.1001/jama.284.9.1146			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	349GK	10974700				2022-12-28	WOS:000089037200021
J	Egeland, GM; Skjaerven, R; Irgens, LM				Egeland, GM; Skjaerven, R; Irgens, LM			Birth characteristics of women who develop gestational diabetes: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MELLITUS		Univ Bergen, Dept Publ Hlth & Primary Hlth, Locus Registry Based Epidemiol, N-5021 Bergen, Norway; Univ Bergen, Dept Publ Hlth & Primary Hlth, Sect Med Stat, Bergen, Norway; Univ Bergen, Med Birth Registry Norway, N-5020 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen	Egeland, GM (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth, Locus Registry Based Epidemiol, N-5021 Bergen, Norway.	grace.egeland@isf.uib.no						BARKER DJP, 1995, BRIT MED J, V511, P171; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Melve KK, 1999, AM J EPIDEMIOL, V150, P756; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5	5	82	84	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					546	547		10.1136/bmj.321.7260.546	http://dx.doi.org/10.1136/bmj.321.7260.546			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968815	Green Published, Bronze			2022-12-28	WOS:000089174100020
J	Desai, SA; Bezrukov, SM; Zimmerberg, J				Desai, SA; Bezrukov, SM; Zimmerberg, J			A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite	NATURE			English	Article							PLASMODIUM-FALCIPARUM; TRANSPORT; MEMBRANE; ERYTHROCYTES; PERMEATION; CULTURE	Growth of the malaria parasite in human red blood cells (RBCs) is accompanied by an increased uptake of many solutes including anions(1), sugars(2), purines(3), amino acids(4) and organic cations(5). Although the pharmacological properties and selectivity of this uptake suggest that a chloride channel is involved, the precise mechanism has not been identified. Moreover, the location of this uptake in the infected RBC is unknown because tracer studies are complicated by possible uptake through fluid-phase pinocytosis(6) or membranous ducts(7). Here we have studied the permeability of infected RBCs using the whole-cell voltage-clamp method. With this method, uninfected RBCs had ohmic whole-cell conductances of less than 100 pS, consistent with their low tracer permeabilities(8). In contrast, trophozoite-infected RBCs exhibited voltage-dependent, non-saturating currents that were 150-fold larger, predominantly carried by anions and abruptly abolished by channel blockers. Patch-clamp measurements and spectral analysis confirmed that a small (<10 pS) ion channel on the infected RBC surface, present at about 1,000 copies per cell, is responsible for these currents. Because its pharmacological properties and substrate selectivities match those seen with tracer studies, this channel accounts for the increased uptake of small solutes in infected RBCs. The surface location of this new channel and its permeability to organic solutes needed for parasite growth indicate that it may have a primary role in a sequential diffusive pathway for parasite nutrient acquisition.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Desai, SA (corresponding author), NIAID, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	sdesai@niaid.nih.gov	Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483	Intramural NIH HHS [Z01 AI000882-07] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000241, Z01HD001409, Z01HD000242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000882, Z01AI000841] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BREUER WV, 1987, J CELL PHYSIOL, V133, P55, DOI 10.1002/jcp.1041330107; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; BURNS ER, 1988, IN VITRO CELL DEV B, V24, P481, DOI 10.1007/BF02628503; CABANTCHIK ZI, 1990, BLOOD CELLS, V16, P421; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; CRANDALL I, 1991, PARASITOLOGY, V102, P335, DOI 10.1017/S0031182000064271; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; ELFORD BC, 1995, BIOCHEM J, V308, P361, DOI 10.1042/bj3080361; GINSBURG H, 1985, MOL BIOCHEM PARASIT, V14, P313, DOI 10.1016/0166-6851(85)90059-3; GINSBURG H, 1987, J MEMBRANE BIOL, V96, P1, DOI 10.1007/BF01869329; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hibbs AR, 1997, EUR J CELL BIOL, V72, P182; HUNTER MJ, 1977, J PHYSIOL-LONDON, V268, P35, DOI 10.1113/jphysiol.1977.sp011845; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; KIRK K, 1994, J BIOL CHEM, V269, P3339; Kirk K, 1996, MOL BIOCHEM PARASIT, V82, P195, DOI 10.1016/0166-6851(96)02734-X; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; KUTNER S, 1987, BIOCHEM PHARMACOL, V36, P123, DOI 10.1016/0006-2952(87)90389-3; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; SAUVE R, 1985, J THEOR BIOL, V113, P501, DOI 10.1016/S0022-5193(85)80035-7; Staines HM, 2000, BBA-BIOMEMBRANES, V1463, P88, DOI 10.1016/S0005-2736(99)00187-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UPSTON JM, 1995, BBA-BIOMEMBRANES, V1236, P249, DOI 10.1016/0005-2736(95)00055-8; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109	27	213	223	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					1001	1005		10.1038/35023000	http://dx.doi.org/10.1038/35023000			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984055				2022-12-28	WOS:000089020200047
J	Tyack, PL				Tyack, PL			Dolphins whistle a signature tune	SCIENCE			English	Editorial Material							STABILITY		Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Tyack, PL (corresponding author), Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA.		Tyack, Peter L/D-6209-2013; Tyack, Peter/AAC-4513-2019	Tyack, Peter L/0000-0002-8409-4790; Tyack, Peter/0000-0002-8409-4790				Byrne R., 1988, MACHIAVELLIAN INTELL; Janik VM, 2000, SCIENCE, V289, P1355, DOI 10.1126/science.289.5483.1355; Janik VM, 1998, ANIM BEHAV, V56, P829, DOI 10.1006/anbe.1998.0881; RICHARDS DG, 1984, J COMP PSYCHOL, V98, P10, DOI 10.1037/0735-7036.98.1.10; SAYIGH LS, 1990, BEHAV ECOL SOCIOBIOL, V26, P247; Snowdon C.T., 1997, SOCIAL INFLUENCES VO, DOI [10.1017/CBO9780511758843, DOI 10.1017/CBO9780511758843]; SYMMES D, 1979, ANIM BEHAV, V27, P1142, DOI 10.1016/0003-3472(79)90062-9; Tyack Peter L., 1997, Bioacoustics, V8, P21; 2000, C AN SCI COMPL INT C	9	38	41	6	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2000	289	5483					1310	1311		10.1126/science.289.5483.1310	http://dx.doi.org/10.1126/science.289.5483.1310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347RF	10979857				2022-12-28	WOS:000088942400026
J	Tanaka, Y; Guhde, G; Suter, A; Eskelinen, EL; Hartmann, D; Lullmann-Rauch, R; Janssen, PML; Blanz, J; von Figura, K; Saftig, P				Tanaka, Y; Guhde, G; Suter, A; Eskelinen, EL; Hartmann, D; Lullmann-Rauch, R; Janssen, PML; Blanz, J; von Figura, K; Saftig, P			Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice	NATURE			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; GLYCOGEN-STORAGE-DISEASE; ISOLATED RAT HEPATOCYTES; NORMAL ACID MALTASE; PROTEIN-DEGRADATION; GENE; SEQUENCE; RECEPTOR; MOUSE; CDNA	Lysosome-associated membrane protein-2 (LAMP-2) is a highly glycosylated protein and an important constituent of the lysosomal membrane(1-7). Here we show that LAMP-2 deficiency in mice increases mortality between 20 and 40 days of age. The surviving mice are fertile and have an almost normal life span. Ultrastructurally, there is extensive accumulation of autophagic vacuoles in many tissues including liver, pancreas, spleen, kidney and skeletal and heart muscle. In hepatocytes, the autophagic degradation of long-lived proteins is severely impaired. Cardiac myocytes are ultrastructurally abnormal and heart contractility is severely reduced. These findings indicate that LAMP-2 is critical for autophagy. This theory is further substantiated by the finding that human LAMP-2 deficiency(8) causing Danon's disease is associated with the accumulation of autophagic material in striated myocytes.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Univ Dundee, Dept Biol Sci, Dundee DD1 4HN, Scotland; Univ Helsinki, Inst Biotechnol, Helsinki 0001A, Finland; Univ Kiel, Inst Anat, D-24118 Kiel, Germany; Univ Gottingen, Abt Kardiol & Pneumol, D-37075 Gottingen, Germany	University of Gottingen; University of Dundee; University of Helsinki; University of Kiel; University of Gottingen	Saftig, P (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	saftig@uni-bc2.gwdg.de	Eskelinen, Eeva-Liisa/AAF-3496-2019; Saftig, Paul/A-7966-2010; Janssen, Paul ML/E-3307-2011	Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Janssen, Paul/0000-0002-9682-3014				ANDERSON RGW, 1989, METHOD CELL BIOL, V31, P463; ANDREWS FM, 1974, SOC INDIC RES, V1, P1, DOI 10.1007/BF00286419; ARSTILA AU, 1968, AM J PATHOL, V53, P687; Aumuller G, 1997, CELL TISSUE RES, V287, P335, DOI 10.1007/s004410050758; CHA Y, 1990, J BIOL CHEM, V265, P5008; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DANON MJ, 1981, NEUROLOGY, V31, P51, DOI 10.1212/WNL.31.1.51; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HENELL F, 1987, EXP MOL PATHOL, V46, P1, DOI 10.1016/0014-4800(87)90026-8; ISBRANDT D, 1994, AM J HUM GENET, V54, P454; JANSSEN PML, 1995, AM J PHYSIOL-HEART C, V269, pH676, DOI 10.1152/ajpheart.1995.269.2.H676; KONECKI DS, 1995, BIOCHEM BIOPH RES CO, V215, P757, DOI 10.1006/bbrc.1995.2528; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; MEREDITH MJ, 1988, CELL BIOL TOXICOL, V4, P405, DOI 10.1007/BF00117769; Morisawa Y, 1998, J NEUROL SCI, V160, P175, DOI 10.1016/S0022-510X(98)00242-1; MUNTONI F, 1994, NEUROMUSCULAR DISORD, V4, P233, DOI 10.1016/0960-8966(94)90024-8; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585	26	685	720	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					902	906		10.1038/35022595	http://dx.doi.org/10.1038/35022595			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972293				2022-12-28	WOS:000088903600047
J	Couper, RTL; Couper, JJ				Couper, RTL; Couper, JJ			Prader-Willi syndrome	LANCET			English	Article									Univ Adelaide, Womens & Childrens Hosp, Dept Paediat, Adelaide, SA 5006, Australia; Womens & Childrens Hosp, Dept Gastroenterol, Adelaide, SA 5006, Australia; Womens & Childrens Hosp, Dept Endocrinol & Diabet, Adelaide, SA 5006, Australia	University of Adelaide; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia	Couper, RTL (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Dept Paediat, Adelaide, SA 5006, Australia.	rcouper@medicine.adelaide.edu.au		Couper, Jennifer/0000-0003-4448-8629				Akefeldt A, 1999, J AM ACAD CHILD PSY, V38, P761, DOI 10.1097/00004583-199906000-00025; Carrel AL, 1999, J PEDIATR-US, V134, P215, DOI 10.1016/S0022-3476(99)70418-X; Couper RTL, 1999, J PAEDIATR CHILD H, V35, P331, DOI 10.1046/j.1440-1754.1999.00397.x; DOWN JL, 1990, MENTAL AFFECTIONS CH; EIHOLZER U, 2000, P 11 NOV NORD NGH S, P48; Hodapp RM, 1997, J AUTISM DEV DISORD, V27, P11, DOI 10.1023/A:1025865004299; Prader A., 1956, SCHWEIZ MED WSCHR, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24; Smith A, 1999, J PAEDIATR CHILD H, V35, P335, DOI 10.1046/j.1440-1754.1999.00396.x	8	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2000	356	9230					673	675		10.1016/S0140-6736(00)02617-9	http://dx.doi.org/10.1016/S0140-6736(00)02617-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968453				2022-12-28	WOS:000088884100041
J	Gu, M; Cooper, JM; Butler, P; Walker, AP; Mistry, PK; Dooley, JS; Schapira, AHV				Gu, M; Cooper, JM; Butler, P; Walker, AP; Mistry, PK; Dooley, JS; Schapira, AHV			Oxidative-phosphorylation defects in liver of patients with Wilson's disease	LANCET			English	Article							EVANS CINNAMON RATS; LEC RAT; HEREDITARY HEPATITIS; MITOCHONDRIAL-DNA; COPPER OVERLOAD; HEPATOCYTES; PROTEIN; MODEL; EXPRESSION; DEFICIENCY	Background Wilson's disease (WD) is caused by mutations in a P-type ATPase and is associated with copper deposition in liver and brain. The WD protein is present in the trans-Golgi network and may also be imported into mitochondria. The WD protein functions as a P-type copper transporting ATPase in the Golgi but any action in mitochondria is at present unknown. Methods We studied mitochondrial function and aconitase activity in WD liver tissue and compared the results with those in a series of healthy controls and patients without WD. Findings There was evidence of severe mitochondrial dysfunction in the livers of patients with WD. Enzyme activities were decreased as follows: complex I by 62%, complex II+III by 52%, complex IV by 33%, and aconitase by 71%. These defects did not seem to be secondary to penicillamine use, cholestasis, or poor hepatocellular synthetic function, Interpretation The results show that there is a defect of energy metabolism in WD. The pattern of enzyme defects suggests that free-radical formation and oxidative damage, probably mediated via mitochondrial copper accumulation, are important in WD pathogenesis, These results provide a rationale for a study of the use of antioxidants in WD.	UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England; Inst Neurol, London WC1, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Schapira, AHV (corresponding author), UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, Rowland Hill St, London NW3 2PF, England.	schapira@rfc.ucl.ac.uk	Schapira, Anthony H V/A-1245-2010; Cooper, J Mark/D-5826-2013; Walker, Ann P/C-1628-2008; Cooper, Jonathan/GLS-9195-2022	Schapira, Anthony H V/0000-0002-3018-3966; Cooper, J Mark/0000-0002-3007-3054; Cooper, Jonathan/0000-0002-2358-1050				BODNAR AG, 1993, AM J HUM GENET, V53, P663; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; GOLDFISCHER S, 1968, AM J PATHOL, V53, P883; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; GROSS JB, 1989, J CLIN INVEST, V83, P30, DOI 10.1172/JCI113873; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; KENNEY S, 2000, WILSON DIS MUTATION; Klein D, 1998, EUR J CLIN INVEST, V28, P302; KOWDLEY KV, 1994, DIGEST DIS SCI, V39, P2416, DOI 10.1007/BF02087659; KRAHENBUHL S, 1994, HEPATOLOGY, V19, P471, DOI 10.1016/0270-9139(94)90027-2; LI Y, 1991, J CLIN INVEST, V87, P1858, DOI 10.1172/JCI115208; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; Mansouri A, 1997, GASTROENTEROLOGY, V113, P599, DOI 10.1053/gast.1997.v113.pm9247482; MCKIM JM, 1994, GASTROENTEROLOGY, V106, pA941; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; MURATA Y, 1995, BIOCHEM BIOPH RES CO, V209, P349, DOI 10.1006/bbrc.1995.1510; Nagano K, 1998, HEPATOLOGY, V27, P799, DOI 10.1002/hep.510270323; NETTER P, 1987, CLIN PHARMACOKINET, V13, P317, DOI 10.2165/00003088-198713050-00003; OGIHARA H, 1995, PEDIATR RES, V37, P219, DOI 10.1203/00006450-199502000-00016; OWEN CA, 1997, MAYO CLIN P, V52, P73; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHENKER S, 1966, GUT, V7, P409, DOI 10.1136/gut.7.4.409; SCHILSKY ML, 1994, AM J PHYSIOL, V266, pG907, DOI 10.1152/ajpgi.1994.266.5.G907; SOKOL RJ, 1993, GASTROENTEROLOGY, V105, P178, DOI 10.1016/0016-5085(93)90024-7; SOKOL RJ, 1994, GASTROENTEROLOGY, V107, P1788, DOI 10.1016/0016-5085(94)90822-2; SOKOL RJ, 1990, GASTROENTEROLOGY, V99, P1061, DOI 10.1016/0016-5085(90)90627-D; STERNLIE.I, 1968, GASTROENTEROLOGY, V55, P354; Sternlieb I, 1995, HEPATOLOGY, V22, P1782, DOI 10.1002/hep.1840220626; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; TERADA K, 1995, BBA-MOL BASIS DIS, V1270, P58, DOI 10.1016/0925-4439(94)00072-X; THOMAS GR, 1995, NAT GENET, V9, P451, DOI 10.1038/ng0495-451e; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YAMAZAKI K, 1993, LAB ANIM SCI, V43, P61	39	85	95	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					469	474		10.1016/S0140-6736(00)02556-3	http://dx.doi.org/10.1016/S0140-6736(00)02556-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981891				2022-12-28	WOS:000088657700013
J	Watt, G; Kantipong, P; de Souza, M; Chanbancherd, P; Jongsakul, K; Ruangweerayud, R; Loomis-Price, LD; Polonis, V; Myint, KS; Birx, DL; Brown, AE; Krishna, S				Watt, G; Kantipong, P; de Souza, M; Chanbancherd, P; Jongsakul, K; Ruangweerayud, R; Loomis-Price, LD; Polonis, V; Myint, KS; Birx, DL; Brown, AE; Krishna, S			HIV-1 suppression during acute scrub-typhus infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NECROSIS-FACTOR-ALPHA; TYPE-1; LOAD; DIAGNOSIS; IMPACT	Background In HIV-1-infected individuals, viral load has been reported to rise transiently if an acute infection with another organism occurs. Our study was prompted by the unexpected finding that HIV-1 copy number fell during an acute infection with Orientia tsutsugamushi, the causative agent of scrub typhus. Methods Serial HIV-1 viral load determinations were made in ten Thai adults with scrub typhus, who were not receiving antiretroviral therapy, and in five HIV-1-infected patients who had other infections (four malaria, one leptospirosis), during and after acute infections. Sera from HIV-1-infected patients with scrub typhus and from mice immunised with O tsutsugamushi were examined for HIV-1-suppressive activity. Findings Median viral load 3 days after admission was significantly lower in the scrub-typhus group than in patients with other infections (193% vs 376% of day 28 values, p=0.03). In four O tsutsugamushi-infected patients HIV-1 RNA copy number fell by three-fold or more compared with day 28 values, and HIV-1 copy numbers were below the assay threshold in two patients with scrub typhus, Five of seven HIV-1 isolates from non-typhus patients with CD4 lymphocytes less than 200 cells/mu L were syncytia-inducing variants, whereas all ten isolates from O tsutsugamushi-infected individuals matched by CD4-cell count were non-syncytia inducing (p=0.03). Sera from an HIV-1-negative patient with scrub typhus bad potent HIV-1-suppressive activity in vitro, Sera from typhus-infected mice inhibited HIV-1 syncytia formation and bound by immunofluorescence to HIV-1-infected lymphocytes. Interpretation HIV-1-suppressive factors are produced during some scrub-typhus infection and should be investigated further in the search for novel strategies for the treatment and prevention of AIDS.	Armed Forces Res Inst Med Sci, USAMC, Retrovirol Dept, Bangkok 10400, Thailand; Armed Forces Res Inst Med Sci, USAMC, Dept Virol, Bangkok 10400, Thailand; Chiangrai Reg Hosp, Chiangrai, Thailand; Army Inst Pathol, Bangkok, Thailand; Maesod Hosp, Tak Prov, Thailand; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA; Univ London St Georges Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); St Georges University London	Watt, G (corresponding author), AFRIMS, Dept Retrovirol, HIV Interact Sect, APO, AP 96546 USA.		Myint, Khin/HHS-2027-2022	Myint, Khin/0000-0002-2087-7331; Krishna, Sanjeev/0000-0003-0066-0634				ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; BLOOM BR, 1998, SCIENCE, V268, P516; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; Carpenter C, 1998, ANN INTERN MED, V128, P1057, DOI 10.7326/0003-4819-128-12_Part_2-199806151-00002; Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447; *DIV AIDS, 1997, NIH PUBL; Garcia F, 1998, J ACQ IMMUN DEF SYND, V18, P398, DOI 10.1097/00042560-199808010-00019; Kantipong P, 1996, CLIN INFECT DIS, V23, P1168, DOI 10.1093/clinids/23.5.1168; Karp CL, 1999, CLIN INFECT DIS, V28, P947, DOI 10.1086/514745; McGuire W, 1996, T ROY SOC TROP MED H, V90, P10, DOI 10.1016/S0035-9203(96)90461-7; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; Newman GW, 1999, CLIN INFECT DIS, V28, P514, DOI 10.1086/515166; OAKS EV, 1989, INFECT IMMUN, V57, P3116, DOI 10.1128/IAI.57.10.3116-3122.1989; Ortigao-deo-Sampaio MB, 1998, AIDS, V12, pF145, DOI 10.1097/00002030-199814000-00001; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Sulkowski MS, 1998, J INFECT DIS, V178, P1642, DOI 10.1086/314491; Watt G, 1996, LANCET, V348, P86, DOI 10.1016/S0140-6736(96)02501-9; Watt G, 1998, J INFECT DIS, V177, P800, DOI 10.1086/517813; Winslow WE, 1997, J CLIN MICROBIOL, V35, P1938, DOI 10.1128/JCM.35.8.1938-1942.1997; Xiao LH, 1998, J INFECT DIS, V177, P437, DOI 10.1086/514212; ZollaPazner S, 1997, J INFECT DIS, V175, P764, DOI 10.1086/513969	23	59	61	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					475	479		10.1016/S0140-6736(00)02557-5	http://dx.doi.org/10.1016/S0140-6736(00)02557-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981892				2022-12-28	WOS:000088657700014
J	Nohturfft, A; Yabe, D; Goldstein, JL; Brown, MS; Espenshade, PJ				Nohturfft, A; Yabe, D; Goldstein, JL; Brown, MS; Espenshade, PJ			Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes	CELL			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; BOUND TRANSCRIPTION FACTOR; LOW-DENSITY LIPOPROTEIN; ENDOPLASMIC-RETICULUM; COMPETITIVE INHIBITOR; HUMAN FIBROBLASTS; CELLS; PATHWAY; TRANSPORT	SREBPs exit the ER in a complex with SCAP. Together, they move to the Golgi where SREBP is cleaved, releasing a fragment that activates genes encoding lipid biosynthetic enzymes. Sterols block ER exit, preventing cleavage, decreasing transcription, and achieving feedback control of lipid synthesis. Here, we report an in vitro system to measure incorporation of SCAP into ER vesicles. When membranes were isolated from sterol-depleted cells, SCAP entered vesicles in a reaction requiring nucleoside triphosphates and cytosol. SCAP budding was diminished in membranes from sterol-treated cells. Kinetics of induction of budding in vitro matched kinetics of ER exit in living cells expressing GFP-SCAP. These data localize the sterol-regulated step to budding of SCAP from ER and provide a system for biochemical dissection.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	jgolds@mednet.swmed.edu; mbrow1@mednet.swmed.edu	Yabe, Daisuke/J-6682-2014	Yabe, Daisuke/0000-0002-5334-7687; Nohturfft, Axel/0000-0001-9484-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, F32HL009993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-09993, HL-20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Klumperman J, 1998, J CELL SCI, V111, P3411; KRIEGER M, 1978, P NATL ACAD SCI USA, V75, P5052, DOI 10.1073/pnas.75.10.5052; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	37	263	271	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					315	323		10.1016/S0092-8674(00)00037-4	http://dx.doi.org/10.1016/S0092-8674(00)00037-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975522	Bronze			2022-12-28	WOS:000088625600007
J	Vaughan, CJ; Delanty, N				Vaughan, CJ; Delanty, N			Hypertensive emergencies	LANCET			English	Review							POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; OCCIPITAL-PARIETAL ENCEPHALOPATHY; HIGH BLOOD-PRESSURE; ENDOTHELIAL-CELLS; MALIGNANT HYPERTENSION; SODIUM-NITROPRUSSIDE; SMOOTH-MUSCLE; MANAGEMENT; FENOLDOPAM; CRISES	A hypertensive emergency is a situation in which uncontrolled hypertension is associated with acute end-organ damage. Most patients presenting with hypertensive emergency have chronic hypertension, although the disorder can present in previously normotensive individuals, particularly when associated with preeclampsia or acute glomerulonephritis. The pathophysiological mechanisms causing acute hypertensive endothelial failure are complex and incompletely understood but probably involve disturbances of the renin-angiotensin-aldosterone system, loss of endogenous vasodilator mechanisms, upregulation of proinflammatory mediators including vascular cell adhesion molecules, and release of local vasoconstrictors such as endothelin 1. Magnetic resonance imaging has demonstrated a characteristic hypertensive posterior leucoencephalopathy syndrome predominantly causing oedema of the white matter of the parietal and occipital lobes; this syndrome is potentially reversible with appropriate prompt treatment. Generally, the therapeutic approach is dictated by the particular presentation and end-organ complications. Parenteral therapy is generally preferred, and strategies include use of sodium nitroprusside, beta-blockers, labetelol, or calcium-channel antagonists, magnesium for preeclampsia and eclampsia; and short-term parenteral anticonvulsants for seizures associated with encephalopathy. Novel therapies include the peripheral dopamine-receptor agonist, fenoldapam, and may include endothelin-1 antagonists.	Royal Coll Surgeons Ireland, Dept Clin Neurol Sci, Dublin 9, Ireland; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Med,Div Cardiol, New York, NY USA; Beaumont Hosp, Div Neurol, Dublin 9, Ireland	Royal College of Surgeons - Ireland; Cornell University; NewYork-Presbyterian Hospital	Delanty, N (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Neurol Sci, Dublin 9, Ireland.	norman.delanty@eircom.net	Delanty, Norman/F-8756-2011	Delaney, Norman/0000-0002-3953-9842				[Anonymous], 1997, ARCH INTERN MED, V157, P2413; Bakshi R, 1999, NEUROLOGY, V52, P1285, DOI 10.1212/WNL.52.6.1285; Baptista MV, 1998, LANCET, V351, P414, DOI 10.1016/S0140-6736(97)10180-5; BEAUSANGLINDER M, 1981, ACTA PHYSIOL SCAND, V111, P193, DOI 10.1111/j.1748-1716.1981.tb06724.x; BENNETT NM, 1988, AM J PUBLIC HEALTH, V78, P636, DOI 10.2105/AJPH.78.6.636; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; Chalmers J, 1999, J HYPERTENS, V17, P151; Cooper R, 1997, AM J HYPERTENS, V10, P804, DOI 10.1016/S0895-7061(97)00211-2; COTTRELL JE, 1978, J NEUROSURG, V48, P329, DOI 10.3171/jns.1978.48.3.0329; Delanty N, 1997, NEUROLOGY, V49, P686, DOI 10.1212/WNL.49.3.686; Delanty N, 1998, LANCET, V352, P383, DOI 10.1016/S0140-6736(98)02158-8; Feske SK, 1997, J NEUROIMAGING, V7, P247, DOI 10.1111/jon199774247; FINNERTY FA, 1972, AM J MED, V52, P672, DOI 10.1016/0002-9343(72)90057-5; Frank Y, 1998, NEUROLOGY, V51, P915, DOI 10.1212/WNL.51.3.915; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; Gleeson JG, 1998, J CHILD NEUROL, V13, P336, DOI 10.1177/088307389801300706; GROSSMAN E, 1995, ARCH INTERN MED, V155, P450, DOI 10.1001/archinte.155.5.450; He J, 1997, MED CLIN N AM, V81, P1077, DOI 10.1016/S0025-7125(05)70568-X; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; HIRSCHL MM, 1995, ARCH INTERN MED, V155, P2217, DOI 10.1001/archinte.155.20.2217; HOUSTON MC, 1989, PROG CARDIOVASC DIS, V32, P99, DOI 10.1016/0033-0620(89)90022-4; Ito Y, 1997, NEUROLOGY, V49, P1174, DOI 10.1212/WNL.49.4.1174; Ito Y, 1998, AM J NEURORADIOL, V19, P415; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; MACARTHUR H, 1994, BIOCHEM BIOPH RES CO, V200, P395, DOI 10.1006/bbrc.1994.1462; Mancia G, 1997, LANCET, V349, P454, DOI 10.1016/S0140-6736(96)07099-7; Manfredi M, 1997, ACTA NEUROL SCAND, V96, P277; Meissner I, 1999, HYPERTENSION, V34, P466, DOI 10.1161/01.HYP.34.3.466; Montgomery HE, 1998, J HYPERTENS, V16, P635, DOI 10.1097/00004872-199816050-00011; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Muller DN, 2000, HYPERTENSION, V35, P193, DOI 10.1161/01.HYP.35.1.193; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Okada M, 1998, ARTERIOSCL THROM VAS, V18, P894, DOI 10.1161/01.ATV.18.6.894; Oparil S, 1999, AM J HYPERTENS, V12, P653, DOI 10.1016/S0895-7061(99)00059-X; ORTH H, 1975, NEW ENGL J MED, V292, P1133; Pavlakis SG, 1997, PEDIATR NEUROL, V16, P145, DOI 10.1016/S0887-8994(96)00292-5; PILMER BL, 1993, J CLIN PHARMACOL, V33, P549, DOI 10.1002/j.1552-4604.1993.tb04702.x; Pretre R, 1997, LANCET, V349, P1461, DOI 10.1016/S0140-6736(96)09372-5; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Schwartz RB, 1998, AM J NEURORADIOL, V19, P859; SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P379, DOI 10.2214/ajr.159.2.1632361; SHUSTERMAN NH, 1993, AM J MED, V95, P161, DOI 10.1016/0002-9343(93)90256-O; Torocsik HV, 1999, NEUROLOGY, V52, P1497, DOI 10.1212/WNL.52.7.1497; TOUYZ RM, 1995, J HYPERTENS, V13, P867, DOI 10.1097/00004872-199508000-00007; Verhaar MC, 1998, J HYPERTENS, V16, P45, DOI 10.1097/00004872-199816010-00008; Wang MC, 1999, NEUROSURGERY, V44, P1325, DOI 10.1097/00006123-199906000-00096; WILSON DJ, 1983, AM J MED, V75, P95, DOI 10.1016/0002-9343(83)90141-9; Wung BS, 1996, AM J PHYSIOL-HEART C, V270, pH1462, DOI 10.1152/ajpheart.1996.270.4.H1462	52	339	354	0	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					411	417		10.1016/S0140-6736(00)02539-3	http://dx.doi.org/10.1016/S0140-6736(00)02539-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972386				2022-12-28	WOS:000088486000036
J	Ellenberg, SS; Temple, R				Ellenberg, SS; Temple, R			Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MEDICATION-FREE RESEARCH; METASTATIC COLORECTAL-CANCER; ACUTE ISCHEMIC STROKE; CLINICAL RESEARCH; PERINATAL TRANSMISSION; FLUOROURACIL FAILURE; DEVELOPING-COUNTRIES; RANDOMIZED TRIAL; ETHICAL DILEMMAS	Placebo controls are commonly used in clinical trials of investigational treatments because they have important advantages. In recent years, some have criticized the use of placebo-controlled trials when effective alternative therapy exists, regardless of the expected effect of the therapy. In part 1 of this paper, ethical arguments are addressed and the interpretive problems inherent in the use of active-control equivalence trials to establish efficacy of a new treatment are clarified. However, uncertainties may complicate decisions about appropriate use of placebo controls in some situations. Part 2 discusses more fully the ethical considerations for using placebo controls in particular medical settings. The value and relevance of placebo-controlled trials of new agents in situations in which proven effective therapy is available are also explored.	US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA; US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20852 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Ellenberg, SS (corresponding author), US FDA, Ctr Biol Evaluat & Res, 1401 Rockville Pike, Rockville, MD 20852 USA.							Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], 1989, NEW ENGL J MED, V321, P406; Appelbaum Paul S, 1996, IRB, V18, P1, DOI 10.2307/3563910; Baldessarini RJ, 1999, J CLIN PSYCHIAT, V60, P117; Bath P, 1998, LANCET, V352, P1238, DOI 10.1016/S0140-6736(98)00039-7; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brody BA, 1997, CONTROL CLIN TRIALS, V18, P602, DOI 10.1016/S0197-2456(97)00006-8; Carpenter WT, 1997, ARCH GEN PSYCHIAT, V54, P401; CHRISTAKIS NA, 1991, IRB, V31, P6; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Detre T, 1996, PSYCHOPHARMACOL BULL, V32, P15; Fins JJ, 1997, ARCH GEN PSYCHIAT, V54, P415; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; Friend WC, 1996, J PSYCHIATR NEUROSCI, V21, P354; Furlan AJ, 1999, STROKE, V30, P234; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Halsey NA, 1997, BRIT MED J, V315, P965, DOI 10.1136/bmj.315.7114.965; Henn FA, 1997, ARCH GEN PSYCHIAT, V54, P412; Karim SSA, 1998, AM J PUBLIC HEALTH, V88, P564, DOI 10.2105/AJPH.88.4.564; Khan A, 2000, ARCH GEN PSYCHIAT, V57, P311, DOI 10.1001/archpsyc.57.4.311; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; Lieberman JA, 1996, PSYCHOPHARMACOL BULL, V32, P19; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MRC, 1994, LANCET, V343, P871; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI, V1; PEREZSTABLE EJ, 1995, J GEN INTERN MED, V10, P419, DOI 10.1007/BF02599912; Perry G, 1997, NEW ENGL J MED, V336, P525; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; Sherman DG, 1999, STROKE, V30, P234; Stein CM, 1999, LANCET, V353, P400, DOI 10.1016/S0140-6736(98)01373-7; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; United States Food and Drug Administration, 1999, GUID IND CLIN DEV PR; *US DEP HHS, 1993, AHCPR PUBL US DEP HH, V2; *US FDA, 1999, GUID IND FDA APPR NE; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Wilfert CM, 1999, LANCET, V353, P832, DOI 10.1016/S0140-6736(98)10414-2; 1998, P ROYAL COLL PHYS ED, V28, P367	44	246	248	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					464	470		10.7326/0003-4819-133-6-200009190-00015	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	354KM	10975965				2022-12-28	WOS:000089329700009
J	Macfarlane, GJ; Hunt, IM; Silman, AJ				Macfarlane, GJ; Hunt, IM; Silman, AJ			Role of mechanical and psychosocial factors in the onset of forearm pain: prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							REPETITIVE STRAIN INJURY; UPPER-LIMB; FIBROMYALGIA; WORKERS	Objective To deter-mine the aetiology of forearm pain. In particular to determine the relative contribution of (a) psychological factors, features of somatisation, and health anxiety and behaviour, (b) work related mechanical factors, and (c) work related psychosocial factors in the onset of forearm pain. Design 2 year prospective population based cohort study, with retrospective assessment of exposures at work. Setting Altrincham, Greater Manchester. Participants 1953 individuals aged 18-65 years. Outcome measures Forearm pain of new onset. Results At follow up, 105 (8.3%) participants reported forearm pain of new onset lasting at least one day in the past month. Among these, 67% also reported shoulder pain, 65% back pain, and 45% chronic widespread pain. Increased risks of onset were associated with high levels of psychological distress (relative risk 2.4, 95% confidence interval 1.5 to 3.8), reporting at least two other somatic symptoms (1.7, 0.95 to 3.0), and high scores on the illness behaviour subscale of the illness attitude scales. The two work related mechanical exposures associated with the highest risk of forearm pain in the future were repetitive movements of the arm (4.1, 1.7 to 10) or wrists (3.4, 1.3 to 8.7), whereas the strongest work related psychosocial risk was dissatisfaction with support from colleagues or supervisors (4.7, 2.2 to 10). Conclusions Psychological distress, aspects of illness behaviour, and other somatic symptoms are important predictors of onset of forearm pain in addition to work related psychosocial and mechanical factors. Misleading terms such as "cumulative trauma disorder" or "repetitive strain injury," implying a single uniform aetiology, should be avoided.	Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Unit Chron Dis Epidemiol, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Arthrit Res Campaign Epidemiol Unit, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Unit Chron Dis Epidemiol, Manchester M13 9PT, Lancs, England.		Macfarlane, Gary J/I-9521-2014; Hunt, Isabelle/AAM-4281-2021	Macfarlane, Gary J/0000-0003-2322-3314; Hunt, Isabelle/0000-0003-4875-8593				BONGERS PM, 1993, SCAND J WORK ENV HEA, V19, P297, DOI 10.5271/sjweh.1470; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Greening J, 1998, INT ARCH OCC ENV HEA, V71, P29, DOI 10.1007/s004200050246; Harrington JM, 1998, OCCUP ENVIRON MED, V55, P264, DOI 10.1136/oem.55.4.264; HELLIWELL P, 1999, CLIN RHEUMATOLOGY RE, P311; Hunt IM, 1999, RHEUMATOLOGY, V38, P275, DOI 10.1093/rheumatology/38.3.275; Macfarlane GJ, 1999, BEST PRACT RES CL RH, V13, P403, DOI 10.1053/berh.1999.0029; OTHMER E, 1985, AM J PSYCHIAT, V142, P1146; Papageorgiou AC, 1997, SPINE, V22, P1137, DOI 10.1097/00007632-199705150-00014; Pope DP, 1997, OCCUP ENVIRON MED, V54, P316, DOI 10.1136/oem.54.5.316; Pritchard MH, 1999, RHEUMATOLOGY, V38, P636, DOI 10.1093/rheumatology/38.7.636; PUNNETT L, 1985, SCAND J WORK ENV HEA, V11, P417, DOI 10.5271/sjweh.2205; RITCHIE J, 1981, ACCESS PRIMARY HLTH; Sharma SD, 1997, BRIT MED J, V314, P118, DOI 10.1136/bmj.314.7074.118; Speckens AEM, 1996, J PSYCHOSOM RES, V40, P95, DOI 10.1016/0022-3999(95)00561-7; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203	16	145	149	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					676	679		10.1136/bmj.321.7262.676	http://dx.doi.org/10.1136/bmj.321.7262.676			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987773	Green Published, Bronze			2022-12-28	WOS:000089444100029
J	Bond, CT; Sprengel, R; Bissonnette, JM; Kaufmann, WA; Pribnow, D; Neelands, T; Storck, T; Baetscher, M; Jerecic, J; Maylie, J; Knaus, HG; Seeburg, PH; Adelman, JP				Bond, CT; Sprengel, R; Bissonnette, JM; Kaufmann, WA; Pribnow, D; Neelands, T; Storck, T; Baetscher, M; Jerecic, J; Maylie, J; Knaus, HG; Seeburg, PH; Adelman, JP			Respiration and parturition affected by conditional overexpression of the Ca2+-activated K+ channel subunit, SK3	SCIENCE			English	Article							ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; MYOTONIC-DYSTROPHY; SKELETAL-MUSCLE; GENE-EXPRESSION; EPILEPSY; MUTATION; DISEASE; BRAIN; RAT	In:excitable cells, small-conductance Ca2+-activated potassium channels (SK channels) are responsible for the slow after-hyperpolarization that often follows an action potential. Three SK channel subunits have been molecularly characterized. The SK3 gene was targeted by homologous recombination for the insertion of a gene switch that permitted experimental regulation of SK3 expression while retaining normal SK3 promoter function. An absence of SK3 did not-present overt phenotypic consequences. However, SK3 overexpression induced abnormal respiratory responses to hypoxia and compromised parturition. Both conditions were corrected by silencing the gene. The results implicate SK3 channels as potential therapeutic targets for disorders such as sleep apnea Or sudden infant death syndrome and for regulating uterine contractions during labor.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria; Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Innsbruck; Max Planck Society	Adelman, JP (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	adelman@ohsu.edu		Kaufmann, Walter Anton/0000-0001-9735-5315				ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BEHRENS MI, 1994, MUSCLE NERVE, V17, P1264, DOI 10.1002/mus.880171104; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BOND CT, UNPUB; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; Dufour P, 1997, EUR J OBSTET GYN R B, V72, P159, DOI 10.1016/S0301-2115(96)02690-5; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gozal D, 1997, AM J RESP CRIT CARE, V155, P1755, DOI 10.1164/ajrccm.155.5.9154888; Jerecic J, 1999, ANN NY ACAD SCI, V868, P27, DOI 10.1111/j.1749-6632.1999.tb11271.x; Kaufmann WA, 1998, EUR J NEUROSCI, V10, P1084, DOI 10.1046/j.1460-9568.1998.00121.x; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Mortola JP, 1996, TISSUE OXYGEN DEPRIV, P433; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; Pribnow D, 1999, MUSCLE NERVE, V22, P742, DOI 10.1002/(SICI)1097-4598(199906)22:6<742::AID-MUS11>3.0.CO;2-1; PRIBNOW D, 1999, CURR RES ION CHANNEL, V3, P221; Ramirez JM, 1996, CURR OPIN NEUROBIOL, V6, P817, DOI 10.1016/S0959-4388(96)80033-X; RENAUD JF, 1986, NATURE, V319, P678, DOI 10.1038/319678a0; Rudnik-Schoneborn S, 1998, AM J MED GENET, V80, P314, DOI 10.1002/(SICI)1096-8628(19981204)80:4<314::AID-AJMG3>3.0.CO;2-I; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; Stocker R, 1999, GLOBAL CHANGE BIOL, V5, P95, DOI 10.1046/j.1365-2486.1998.00198.x; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuberi SM, 1999, BRAIN, V122, P817, DOI 10.1093/brain/122.5.817	28	134	138	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1942	1946		10.1126/science.289.5486.1942	http://dx.doi.org/10.1126/science.289.5486.1942			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988076				2022-12-28	WOS:000089355800048
J	Dinarello, CA				Dinarello, CA			The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dinarello, CA (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave, Denver, CO 80262 USA.		Dinarello, Charles/C-8524-2013					Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Cohen S, 1999, ARTHRITIS RHEUM, V42, pS273; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303	5	281	293	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					732	734		10.1056/NEJM200009073431011	http://dx.doi.org/10.1056/NEJM200009073431011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974140				2022-12-28	WOS:000089100500011
J	Kameyama, K; Kishi, Y; Yoshimura, M; Kanzawa, N; Sameshima, M; Tsuchiya, T				Kameyama, K; Kishi, Y; Yoshimura, M; Kanzawa, N; Sameshima, M; Tsuchiya, T			Tyrosine phosphorylation in plant bending - Puckering in a ticklish plant is controlled by dephosphorylation of its actin.	NATURE			English	Article									Sophia Univ, Fac Sci & Technol, Dept Chem, Chiyoda Ku, Tokyo 1028554, Japan; Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1710021, Japan	Sophia University; Tokyo Metropolitan Institute of Medical Science	Kameyama, K (corresponding author), Sophia Univ, Fac Sci & Technol, Dept Chem, Chiyoda Ku, 7-1 Kioicho, Tokyo 1028554, Japan.			Kanzawa, Nobuyuki/0000-0002-8703-6828				Barizza E, 1999, FEBS LETT, V447, P191, DOI 10.1016/S0014-5793(99)00272-0; BOYLE W J, 1992, Current Opinion in Oncology, V4, P156, DOI 10.1097/00001622-199202000-00021; DATTA M, 1957, NATURE, V179, P253, DOI 10.1038/179253a0; Eun SO, 1997, PLANT PHYSIOL, V115, P1491, DOI 10.1104/pp.115.4.1491; FLEURATLESSARD P, 1988, J EXP BOT, V39, P209, DOI 10.1093/jxb/39.2.209; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; Kishi Y, 1998, J CELL SCI, V111, P2923; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAMIYA T, 1988, J BIOCHEM-TOKYO, V104, P5, DOI 10.1093/oxfordjournals.jbchem.a122421; TORIYAMA H, 1971, CYTOLOGIA, V36, P359, DOI 10.1508/cytologia.36.359	10	100	107	2	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					37	37		10.1038/35024149	http://dx.doi.org/10.1038/35024149			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993062				2022-12-28	WOS:000089124000030
J	Lavender, KL; Davis, RE; Owens, WB				Lavender, KL; Davis, RE; Owens, WB			Mid-depth recirculation observed in the interior Labrador and Irminger seas by direct velocity measurements	NATURE			English	Article							EASTERN NORTH-ATLANTIC; WATER; CIRCULATION	The Labrador Sea is one of the sites where convection exports surface water to the deep ocean in winter as part of the thermohaline circulation. Labrador Sea water is characteristically cold and fresh, and it can be traced at intermediate depths (500-2,000 m) across the North Atlantic Ocean, to the south and to the east of the Labrador Sea(1-3). Widespread observations of the ocean currents that lead to this distribution of Labrador Sea water have, however, been difficult and therefore scarce. We have used more than 200 subsurface floats to measure directly basin-wide horizontal velocities at various depths in the Labrador and Irminger seas. We observe unanticipated recirculations of the mid-depth (similar to 700 m) cyclonic boundary currents in both basins, leading to an anticyclonic flow in the interior of the Labrador basin. About 40% of the floats from the region of deep convection left the basin within one year and were rapidly transported in the anticyclonic flow to the Irminger basin, and also eastwards into the subpolar gyre. Surprisingly, the float tracks did not clearly depict the deep western boundary current, which is the expected main pathway of Labrador Sea water in the thermohaline circulation. Rather, the flow along the boundary near Flemish Cap is dominated by eddies that transport water offshore. Our detailed observations of the velocity structure with a high data coverage suggest that we may have to revise our picture of the formation and spreading of Labrador Sea water, and future studies with similar instrumentation will allow new insights on the intermediate depth ocean circulation.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Woods Hole Oceanographic Institution	Lavender, KL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	klavender@ucsd.edu		Law, Kara/0000-0002-5298-6751; Davis, Russ/0000-0003-1903-6313				BRYDEN HL, 1993, GEOPH MONOG SERIES, V75, P65; CARR ME, UNPUB J GEOPHYS RES; CLARKE RA, 1983, J PHYS OCEANOGR, V13, P1764, DOI 10.1175/1520-0485(1983)013<1764:TFOLSW>2.0.CO;2; CLARKE RA, 1984, RAPP PV REUN CONS IN, V185, P120; CUNNINGHAM SA, 1995, J PHYS OCEANOGR, V25, P649, DOI 10.1175/1520-0485(1995)025<0649:LSWITE>2.0.CO;2; DAVIS RE, 1992, J ATMOS OCEAN TECH, V9, P264, DOI 10.1175/1520-0426(1992)009<0264:TALCE>2.0.CO;2; DAVIS RE, UNPUB J ATMOS OCEANI; Dickson B, 1997, NATURE, V386, P649, DOI 10.1038/386649a0; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; LAZIER JRN, 1993, J PHYS OCEANOGR, V23, P659, DOI 10.1175/1520-0485(1993)023<0659:AVVITL>2.0.CO;2; LAZIER JRN, 1973, DEEP-SEA RES, V20, P341, DOI 10.1016/0011-7471(73)90058-2; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; Levitus S., 1994, WORLD OCEAN ATLAS 19, V3; Lozier MS, 1997, SCIENCE, V277, P361, DOI 10.1126/science.277.5324.361; Marshall J, 1998, B AM METEOROL SOC, V79, P2033, DOI 10.1175/1520-0477(1998)079<2033:TLSDCE>2.0.CO;2; Min D. H., 1999, THESIS U CALIFORNIA; Paillet J, 1998, J GEOPHYS RES-OCEANS, V103, P10223, DOI 10.1029/98JC00262; Pickart RS, 1996, J GEOPHYS RES-OCEANS, V101, P20711, DOI 10.1029/96JC01453; Pickart RS, 1997, DEEP-SEA RES PT I, V44, P1025, DOI 10.1016/S0967-0637(96)00122-7; Sy A, 1997, NATURE, V386, P675, DOI 10.1038/386675a0; TALLEY LD, 1982, J PHYS OCEANOGR, V12, P1189, DOI 10.1175/1520-0485(1982)012<1189:DACOLS>2.0.CO;2	21	242	244	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					66	69		10.1038/35024048	http://dx.doi.org/10.1038/35024048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993072				2022-12-28	WOS:000089124000041
J	Proctor, RN				Proctor, RN			Expert witnesses take the stand - Historians of science can play an important role in US public health litigation.	NATURE			English	Editorial Material									Penn State Univ, Dept Hist, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Proctor, RN (corresponding author), Penn State Univ, Dept Hist, University Pk, PA 16802 USA.								0	8	8	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					15	16		10.1038/35024208	http://dx.doi.org/10.1038/35024208			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993051				2022-12-28	WOS:000089124000016
J	Stith, JE				Stith, JE			When I was your age - The more things change ...	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					23	23		10.1038/35024172	http://dx.doi.org/10.1038/35024172			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993053	Bronze			2022-12-28	WOS:000089124000021
J	Bergen, SS				Bergen, SS			Underrepresented minorities in medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SCHOOL-OF-MEDICINE; AFFIRMATIVE-ACTION; DIVERSITY; STUDENTS; PROGRAM		Univ Med & Dent New Jersey, Hastings Ctr, Newark, NJ 07107 USA; Hastings Ctr, Garrison, NY USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bergen, SS (corresponding author), Univ Med & Dent New Jersey, Hastings Ctr, 65 Bergen St,Room 1419, Newark, NJ 07107 USA.							Barzansky B, 2000, JAMA-J AM MED ASSOC, V284, P1114, DOI 10.1001/jama.284.9.1114; Cantor JC, 1998, JAMA-J AM MED ASSOC, V280, P772, DOI 10.1001/jama.280.9.772; Cantor JC, 1996, INQUIRY-J HEALTH CAR, V33, P167; Carlisle DM, 1998, AM J PUBLIC HEALTH, V88, P1314, DOI 10.2105/AJPH.88.9.1314; Cohen JJ, 1997, ACAD MED, V72, P103, DOI 10.1097/00001888-199702000-00010; Davidson RC, 1997, JAMA-J AM MED ASSOC, V278, P1153, DOI 10.1001/jama.278.14.1153; Fang D, 2000, JAMA-J AM MED ASSOC, V284, P1085, DOI 10.1001/jama.284.9.1085; Girotti JA, 1999, ACAD MED, V74, P370, DOI 10.1097/00001888-199904000-00027; Johnson JC, 1999, ACAD MED, V74, P376, DOI 10.1097/00001888-199904000-00029; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; Kondo DG, 2000, JAMA-J AM MED ASSOC, V284, P1111, DOI 10.1001/jama.284.9.1111; LUDMERER KM, 1999, TIME TO HEAL, P249; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; Palepu A, 2000, ACAD MED, V75, P157, DOI 10.1097/00001888-200002000-00014; PETERSDORF RG, 1992, ACAD MED, V67, P73, DOI 10.1097/00001888-199202000-00003; Strayhorn G, 2000, ACAD MED, V75, P355, DOI 10.1097/00001888-200004000-00015	17	15	15	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1138	1139		10.1001/jama.284.9.1138	http://dx.doi.org/10.1001/jama.284.9.1138			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	349GK	10974696				2022-12-28	WOS:000089037200017
J	Teitelbaum, SL				Teitelbaum, SL			Bone resorption by osteoclasts	SCIENCE			English	Review							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; HUMAN OSTEOBLASTIC CELLS; OSTEOPROTEGERIN LIGAND; PARATHYROID-HORMONE; AVIAN OSTEOCLASTS; GENE-EXPRESSION; KEY REGULATOR; STROMAL CELLS; FACTOR-ALPHA	Osteoporosis, a disease endemic in Western society, typically reflects an imbalance in skeletal turnover so that bone resorption exceeds bone formation. Bone resorption is the unique function of the osteoclast, and anti-osteoporosis therapy to date has targeted this cell. The osteoclast is a specialized macrophage polykaryon whose differentiation is principally regulated by macrophage colony-stimulating factor, RANK ligand, and osteoprotegerin. Reflecting integrin-mediated signals, the osteoclast develops a specialized cytoskeleton that permits it to establish an isolated microenvironment between itself and bone, wherein matrix degradation occurs by a process involving proton transport. Osteopetrotic mutants have provided a wealth of information about the genes that regulate the differentiation of osteoclasts and their capacity to resorb bone.	Washington Univ, Sch Med, Dept Pathol, Barnes Jewish Hosp N, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)	Teitelbaum, SL (corresponding author), Washington Univ, Sch Med, Dept Pathol, Barnes Jewish Hosp N, Mail Stop 90-31-649,216 S Kingshighway, St Louis, MO 63110 USA.	teitelbs@medicine.wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679				Abu-Amer Y, 1999, J BONE MINER RES, V14, P1855, DOI 10.1359/jbmr.1999.14.11.1855; AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; ABUAMER Y, IN PRESS J BIOL CHEM; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; David JP, 1999, J BONE MINER RES, V14, pS149; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FULLER K, 1994, J BONE MINER RES, V9, P17; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002-9440(10)65301-1; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stenbeck G, 2000, J CELL SCI, V113, P1577; Sunyer T, 1999, J CLIN INVEST, V103, P1409, DOI 10.1172/JCI4682; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VAANANEN HK, 1995, J CELL SCI, V108, P2729; WALKER DG, 1973, SCIENCE, V180, P875, DOI 10.1126/science.180.4088.875; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	56	2778	2956	32	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1504	1508		10.1126/science.289.5484.1504	http://dx.doi.org/10.1126/science.289.5484.1504			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968780				2022-12-28	WOS:000089071700036
J	Lloyd, S				Lloyd, S			Ultimate physical limits to computation	NATURE			English	Review							QUANTUM-MECHANICAL COMPUTERS; BLACK-HOLE; INFORMATION-TRANSFER; TURING-MACHINES; MINIMUM ENERGY; LOGIC GATE; 2ND LAW; UNIVERSAL; ENTROPY; SYSTEMS	Computers are physical systems: the laws of physics dictate what they can and cannot do. In particular, the speed with which a physical device can process information is limited by its energy and the amount of information that it can process is limited by the number of degrees of freedom it possesses. Here I explore the physical limits of computation as determined by the speed of light c, the quantum scale (h) over bar and the gravitational constant G. As an example, I put quantitative bounds to the computational power of an 'ultimate laptop' with a mass of one kilogram confined to a volume of one litre.	MIT, Dept Mech Engn, Darbeloff Lab Informat Syst & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lloyd, S (corresponding author), MIT, Dept Mech Engn, Darbeloff Lab Informat Syst & Technol, 3-160, Cambridge, MA 02139 USA.	slloyd@mit.edu						Abrams DS, 1998, PHYS REV LETT, V81, P3992, DOI 10.1103/PhysRevLett.81.3992; AHARONOV Y, 1961, PHYS REV, V122, P1649, DOI 10.1103/PhysRev.122.1649; AHARONOV Y, 1964, PHYS REV B, V134, P1417, DOI 10.1103/PhysRev.134.B1417; ANANDAN J, 1990, PHYS REV LETT, V65, P1697, DOI 10.1103/PhysRevLett.65.1697; Ballentine A.P., 1995, AM J PHYS, V63, P285; BARENCO A, 1995, PHYS REV A, V52, P3457, DOI 10.1103/PhysRevA.52.3457; BEKENSTEIN JD, 1981, PHYS REV D, V23, P287, DOI 10.1103/PhysRevD.23.287; BEKENSTEIN JD, 1981, PHYS REV LETT, V46, P623, DOI 10.1103/PhysRevLett.46.623; BEKENSTEIN JD, 1984, PHYS REV D, V30, P1669, DOI 10.1103/PhysRevD.30.1669; BENIOFF P, 1982, PHYS REV LETT, V48, P1581, DOI 10.1103/PhysRevLett.48.1581; BENIOFF P, 1980, J STAT PHYS, V22, P563, DOI 10.1007/BF01011339; BENNETT CH, 1987, SCI AM, V257, P108, DOI 10.1038/scientificamerican1187-108; BENNETT CH, 1982, INT J THEOR PHYS, V21, P905, DOI 10.1007/BF02084158; BENNETT CH, 1973, IBM J RES DEV, V17, P525, DOI 10.1147/rd.176.0525; BREMERMANN H. J., 1967, BIOL PROBLEMS HLTH, V4, P15; BREMERMANN HJ, 1982, INT J THEOR PHYS, V21, P203, DOI 10.1007/BF01857726; Bremermann HJ, 1962, SELF ORG SYSTEMS, P93; BRILLOUIN I, 1953, SCI INFORMATION THEO; Chuang IL, 1998, NATURE, V393, P143, DOI 10.1038/30181; Chuang IL, 1998, PHYS REV LETT, V80, P3408, DOI 10.1103/PhysRevLett.80.3408; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; COLEMAN S, 1991, PHYS REV LETT, V67, P1975, DOI 10.1103/PhysRevLett.67.1975; CORY DG, 1996, PHYSCOMP96, P00087; Das SR, 1996, NUCL PHYS B, V478, P561, DOI 10.1016/0550-3213(96)00453-1; DEUTSCH D, 1995, P R SOC-MATH PHYS SC, V449, P669, DOI 10.1098/rspa.1995.0065; DEUTSCH D, 1989, P ROY SOC LOND A MAT, V425, P73, DOI 10.1098/rspa.1989.0099; DEUTSCH D, 1985, P ROY SOC LOND A MAT, V400, P97, DOI 10.1098/rspa.1985.0070; DIVINCENZO DP, 1995, PHYS REV A, V51, P1015, DOI 10.1103/PhysRevA.51.1015; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; Feynman R. P., 1985, OPT NEWS, V11, P11, DOI 10.1364/ON.11.2.000011; FEYNMAN RP, 1982, INT J THEOR PHYS, V21, P467, DOI 10.1007/BF02650179; FIOLA TM, 1994, PHYS REV D, V50, P3987, DOI 10.1103/PhysRevD.50.3987; FREDKIN E, 1982, INT J THEOR PHYS, V21, P219, DOI 10.1007/BF01857727; Gershenfeld NA, 1997, SCIENCE, V275, P350, DOI 10.1126/science.275.5298.350; Grover L. K., 1996, Proceedings of the Twenty-Eighth Annual ACM Symposium on the Theory of Computing, P212, DOI 10.1145/237814.237866; Jones JA, 1998, NATURE, V393, P344, DOI 10.1038/30687; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; KEYES RW, 1970, IBM J RES DEV, V14, P152, DOI 10.1147/rd.142.0152; Laflamme R, 1996, PHYS REV LETT, V77, P198, DOI 10.1103/PhysRevLett.77.198; LANDAUER R, 1991, PHYS TODAY, V44, P23, DOI 10.1063/1.881299; LANDAUER R, 1961, IBM J RES DEV, V5, P183, DOI 10.1147/rd.53.0183; LANDAUER R, 1988, NATURE, V335, P779, DOI 10.1038/335779a0; Landauer R, 1996, PHYS LETT A, V217, P188, DOI 10.1016/0375-9601(96)00453-7; LEBEDEV DS, 1966, INFORM CONTROL, V9, P1, DOI 10.1016/S0019-9958(66)90074-X; LECERF Y, 1963, CR HEBD ACAD SCI, V257, P2597; Leff H., 1990, MAXWELLS DEMON ENTRO; Levitin LB, 1998, PHYSICA D, V120, P162, DOI 10.1016/S0167-2789(98)00051-7; LEVITIN LB, 1982, INT J THEOR PHYS, V21, P299, DOI 10.1007/BF01857732; LEVITIN LB, 1970, P 3 INT S RAD EL 3, P1; LIKHAREV KK, 1982, INT J THEOR PHYS, V21, P311, DOI 10.1007/BF01857733; LLOYD S, 1988, ANN PHYS-NEW YORK, V188, P186, DOI 10.1016/0003-4916(88)90094-2; Lloyd S, 1997, PHYS REV A, V56, P3374, DOI 10.1103/PhysRevA.56.3374; LLOYD S, 1989, PHYS REV A, V39, P5378, DOI 10.1103/PhysRevA.39.5378; Lloyd S, 1996, SCIENCE, V273, P1073, DOI 10.1126/science.273.5278.1073; LLOYD S, 1995, SCI AM, V273, P140, DOI 10.1038/scientificamerican1095-140; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; LLOYD S, 1995, PHYS REV LETT, V75, P346, DOI 10.1103/PhysRevLett.75.346; Lloyd S, 1999, PHYS REV LETT, V82, P1784, DOI 10.1103/PhysRevLett.82.1784; LLOYD S, 1993, PHYS REV LETT, V71, P943, DOI 10.1103/PhysRevLett.71.943; LLOYD S, 1994, J MOD OPTIC, V41, P2503, DOI 10.1080/09500349414552341; Margolus N, 1998, PHYSICA D, V120, P188, DOI 10.1016/S0167-2789(98)00054-2; MARGOLUS N, 1996, P 4 WORKSH PHYS COMP; Margolus N., 1986, ANN NEW YORK ACAD SC, V480, P487; MARGOLUS N, 1991, SANTA FE I SERIES, V8, P273; Maxwell J. C., 1871, THEORY HEAT; Merkle R. C., 1993, Nanotechnology, V4, P21, DOI 10.1088/0957-4484/4/1/002; Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; NOVIKOV ID, 1986, BLACK HOLES; PAGE DN, 1976, PHYS REV D, V13, P198, DOI 10.1103/PhysRevD.13.198; Pagels Heinz, 1982, COSMIC CODE QUANTUM; PELLIZZARI T, 1995, PHYS REV LETT, V75, P3788, DOI 10.1103/PhysRevLett.75.3788; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; Seitz C.L., 1985, P 1985 CHAP HILL C V; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; SLEATOR T, 1995, PHYS REV LETT, V74, P4087, DOI 10.1103/PhysRevLett.74.4087; SMOLUCHOWSKI F, 1914, VORTRAGE KINETISCHE; Steane AM, 1996, PHYS REV LETT, V77, P793, DOI 10.1103/PhysRevLett.77.793; SUSSKIND L, 1994, PHYS REV D, V50, P2700, DOI 10.1103/PhysRevD.50.2700; Szilard L, 1929, Z PHYS, V53, P840, DOI 10.1007/BF01341281; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; VONNEUMANN J, 1966, THEOR SELF REPROD AU, V3; YOUNIS SG, 1993, P 1993 S INT SYST SE; Zalka C, 1998, P ROY SOC A-MATH PHY, V454, P313, DOI 10.1098/rspa.1998.0162; Zeldovich Y.B., 1971, RELATIVISTIC ASTROPH; ZUREK WH, 1989, NATURE, V341, P119, DOI 10.1038/341119a0; ZUREK WH, 1984, PHYS REV LETT, V53, P391, DOI 10.1103/PhysRevLett.53.391; [No title captured]	96	572	580	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					1047	1054		10.1038/35023282	http://dx.doi.org/10.1038/35023282			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984064	Green Submitted			2022-12-28	WOS:000089020200057
J	Wachtershauser, G				Wachtershauser, G			Life as we don't know it	SCIENCE			English	Editorial Material							AMINO-ACIDS				Wachtershauser, G (corresponding author), Tal 29, D-80331 Munich, Germany.							Cody GD, 2000, SCIENCE, V289, P1337, DOI 10.1126/science.289.5483.1337; Fry I., 2000, EMERGENCE LIFE EARTH; HAFENBRADL D, 1995, TETRAHEDRON LETT, V36, P5179; Heinen W, 1996, ORIGINS LIFE EVOL B, V26, P131, DOI 10.1007/BF01809852; Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X	8	132	137	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2000	289	5483					1307	1308		10.1126/science.289.5483.1307	http://dx.doi.org/10.1126/science.289.5483.1307			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347RF	10979855				2022-12-28	WOS:000088942400024
J	Franklin, CE; Axelsson, M				Franklin, CE; Axelsson, M			An actively controlled heart valve	NATURE			English	Article							ALLIGATOR HEART; DYNAMICS		Univ Queensland, Dept Zool & Entomol, Brisbane, Qld 4072, Australia; Univ Gothenburg, Dept Zoophysiol, S-40530 Gothenburg, Sweden	University of Queensland; University of Gothenburg	Franklin, CE (corresponding author), Univ Queensland, Dept Zool & Entomol, Brisbane, Qld 4072, Australia.	cfranklin@zen.uq.edu.au	Franklin, Craig/G-7343-2012; Axelsson, Michael/D-1412-2009	Franklin, Craig/0000-0003-1315-3797; Axelsson, Michael/0000-0002-7839-3233				AXELSSON M, 1989, AM J PHYSIOL, V256, pR875, DOI 10.1152/ajpregu.1989.256.4.R875; Axelsson M, 1996, J EXP BIOL, V199, P359; FRANKLIN CE, 1994, J EXP BIOL, V186, P269; GREENFIELD LAZAR J., 1961, JOUR SURG RES, V1, P97, DOI 10.1016/S0022-4804(61)80003-6; GRIGG GC, 1987, J COMP PHYSIOL B, V157, P381, DOI 10.1007/BF00693365; JONES DR, 1993, J EXP BIOL, V176, P247; MALVIN GM, 1995, AM J PHYSIOL-REG I, V269, pR1133, DOI 10.1152/ajpregu.1995.269.5.R1133; SHELTON G, 1991, J EXP BIOL, V158, P539; VANMIEROP LHS, 1985, CARDIOVASCULAR SHUNT; WEBB GJW, 1979, J MORPHOL, V161, P221, DOI 10.1002/jmor.1051610209; WHITE FN, 1969, COPEIA, P567; WHITE FN, 1968, AM ZOOL, V8, P211	12	30	30	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					847	848		10.1038/35022652	http://dx.doi.org/10.1038/35022652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972278				2022-12-28	WOS:000088903600031
J	Taylor, WR				Taylor, WR			A deeply knotted protein structure and how it might fold	NATURE			English	Article								The search for knots in protein has uncovered little that would cause Alexander the Great to reach for his sword. Excluding knots formed by post-translational crosslinking, the few proteins considered to be knotted form simple trefoil knots with one end of the chain extending through a loop by only a few residues(1,2), ten in the 'best' example(3). A knot in an open chain (as distinct from a closed circle) is not rigorously defined and many weak protein knots disappear if the structure is viewed from a different angle. Here I describe a computer algorithm to detect knots in open chains that is not sensitive to viewpoint and that can define the region of the chain giving rise to the knot. It characterizes knots in proteins by the number of residues that must be removed from each end to abolish the knot. I applied this algorithm to the protein structure database and discovered a deep, figure-of-eight knot in the plant protein acetohydroxy acid isomeroreductase(4). I propose a protein folding pathway that may explain how such a knot is formed.	Natl Inst Med Res, Div Math Biol, London NW7 1AA, England	MRC National Institute for Medical Research	Taylor, WR (corresponding author), Natl Inst Med Res, Div Math Biol, Mill Hill, London NW7 1AA, England.							BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Biou V, 1997, EMBO J, V16, P3405, DOI 10.1093/emboj/16.12.3405; HERING J, 1995, CURR OPIN STRUC BIOL, V7, P416; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MANSFIELD ML, 1994, NAT STRUCT BIOL, V1, P213, DOI 10.1038/nsb0494-213; MANSFIELD ML, 1997, NAT STRUCT BIOL, V4, P116; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Takusagawa F, 1996, J AM CHEM SOC, V118, P8945; Taylor WR, 1997, J MOL BIOL, V269, P902, DOI 10.1006/jmbi.1997.1008; Taylor WR, 1999, PROTEIN SCI, V8, P654	11	376	380	0	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					916	919		10.1038/35022623	http://dx.doi.org/10.1038/35022623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972297				2022-12-28	WOS:000088903600051
J	Higenbottam, T; Siddons, T; Demoncheaux, E				Higenbottam, T; Siddons, T; Demoncheaux, E			A therapeutic role for chronic inhaled nitric oxide?	LANCET			English	Editorial Material							PRIMARY PULMONARY-HYPERTENSION; OXYGEN-THERAPY; DISEASE; PROSTACYCLIN; DELIVERY; GAS		Univ Sheffield, Sch Med, CSUHT, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Higenbottam, T (corresponding author), Univ Sheffield, Sch Med, CSUHT, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England.							Ashutosh K, 2000, THORAX, V55, P109, DOI 10.1136/thorax.55.2.109; Barbera JA, 1996, LANCET, V347, P436, DOI 10.1016/S0140-6736(96)90011-2; Barst RJ, 1997, HEART, V77, P299, DOI 10.1136/hrt.77.4.299; BISHOP JM, 1984, B EUR PHYSIOPATH RES, V20, P495; Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545; Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; Cremona G, 1997, J APPL PHYSIOL, V82, P23, DOI 10.1152/jappl.1997.82.1.23; Cuthbertson BH, 1997, INTENS CARE MED, V23, P1212, DOI 10.1007/s001340050488; Dellinger RP, 1999, INTENS CARE MED, V25, P881, DOI 10.1007/s001340050973; Demoncheaux EAG, 1996, J PHYSIOL-LONDON, V491P, pP101; FLENLEY DC, 1981, LANCET, V1, P681; Higenbottam T, 1999, LANCET, V353, P338, DOI 10.1016/S0140-6736(98)00330-4; Katayama Y, 1998, CIRCULATION, V98, P2429, DOI 10.1161/01.CIR.98.22.2429; Katayama Y, 1997, THORAX, V52, P120, DOI 10.1136/thx.52.2.120; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; OSWALDMAMMOSSER M, 1995, CHEST, V107, P1193, DOI 10.1378/chest.107.5.1193; SIDDONS T, 2000, AM REV RESP CRIT CAR, V3, pA848; Sitbon O, 1998, EUR RESPIR J, V12, P265, DOI 10.1183/09031936.98.12020265; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29	19	10	11	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					446	447		10.1016/S0140-6736(00)02548-4	http://dx.doi.org/10.1016/S0140-6736(00)02548-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981884				2022-12-28	WOS:000088657700005
J	Josefson, D				Josefson, D			FDA declines to lift ban on homosexual men as blood donors	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					722	722		10.1136/bmj.321.7263.722	http://dx.doi.org/10.1136/bmj.321.7263.722			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999890	Green Published			2022-12-28	WOS:000089546600008
J	Eisenberg, MS				Eisenberg, MS			Is it time for over-the-counter defibrillators?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATIC EXTERNAL DEFIBRILLATOR; HOSPITAL CARDIAC-ARREST; VENTRICULAR-FIBRILLATION; SURVIVAL; CPR; RESUSCITATION; PROFESSIONALS; INSTRUCTION; COMMUNITY		Univ Washington, Med Ctr, Dept Med, Div Emergency Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eisenberg, MS (corresponding author), Univ Washington, Med Ctr, Dept Med, Div Emergency Med, Box 356123, Seattle, WA 98195 USA.							Atkins DL, 1998, PEDIATRICS, V101, P393, DOI 10.1542/peds.101.3.393; BANDINI F, 1997, G ITAL CARDIOL, V11, P1121; Becker L, 1999, Prehosp Emerg Care, V3, P353, DOI 10.1080/10903129908958968; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Braslow A, 1997, RESUSCITATION, V34, P207, DOI 10.1016/S0300-9572(97)01096-4; CHADDA KD, 1987, AM J CARDIOL, V60, P732, DOI 10.1016/0002-9149(87)90396-1; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG M, 1995, ANN EMERG MED, V25, P198, DOI 10.1016/S0196-0644(95)70324-1; EISENBERG MS, 1989, AM J CARDIOL, V63, P443, DOI 10.1016/0002-9149(89)90316-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; Hossack KF, 1982, J CARDIAC REHABIL, V2, P402; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Stolberg S G, 2000, N Y Times Web, pA15; Todd KH, 1998, ANN EMERG MED, V31, P364, DOI 10.1016/S0196-0644(98)70348-8; WEAVER WD, 1990, PROGR CLIN PACING 19, P47; WEINSTEIN MC, 1995, VALUING HLTH CARE CO, P77, DOI DOI 10.1017/CBO9780511625817.005; 2000, EM TODAY        0614, P1	22	21	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1435	1438		10.1001/jama.284.11.1435	http://dx.doi.org/10.1001/jama.284.11.1435			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989409				2022-12-28	WOS:000089242500041
J	Campbell, M; Fitzpatrick, R; Haines, A; Kinmonth, AL; Sandercock, P; Spiegelhalter, D; Tyrer, P				Campbell, M; Fitzpatrick, R; Haines, A; Kinmonth, AL; Sandercock, P; Spiegelhalter, D; Tyrer, P			Framework for design and evaluation of complex interventions to improve health	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; SERVICES; CARE		Univ Oxford, Dept Publ Hlth & Primary Care, Inst Hlth Sci, Oxford OX3 7LF, England; Med Res Council Canada, Off President, Ottawa, ON K1 OW9, Canada; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Inst Publ Hlth, Dept Publ Hlth & Primary Care, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England; Western Gen Hosp NHS Trust, Dept Clin Neurosci, Neurosci Trials Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ London Imperial Coll Sci Technol & Med, Dept Publ Mental Hlth, London W2 1PD, England	University of Oxford; University of London; University College London; UCL Medical School; University of Cambridge; University of Edinburgh; MRC Biostatistics Unit; University of Cambridge; Imperial College London	Fitzpatrick, R (corresponding author), Univ Oxford, Dept Publ Hlth & Primary Care, Inst Hlth Sci, Oxford OX3 7LF, England.	raymond.fitzpatrick@nuffield.ox.ac.uk	sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135; Haines, Andy/0000-0002-8053-4605				Bradley F, 1999, BMJ-BRIT MED J, V318, P711; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Buchwald H, 1997, CONTROL CLIN TRIALS, V18, P478, DOI 10.1016/S0197-2456(96)00114-6; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Friedli K, 1998, INT REV PSYCHIATR, V10, P123, DOI 10.1080/09540269874907; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; HAINES A, 1995, BRIT MED J, V310, P815, DOI 10.1136/bmj.310.6983.815; Haynes B, 1998, BMJ-BRIT MED J, V317, P273, DOI 10.1136/bmj.317.7153.273; MANNHEIM L, 1999, CONTROLLED CLIN TRIA, V19, P149; Shepperd S, 1998, J PUBLIC HEALTH MED, V20, P344, DOI 10.1093/oxfordjournals.pubmed.a024778; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Ukoumunne OC, 1999, HLTH TECHNOLOGY ASSE, V3, piii, DOI DOI 10.3310/HTA3050; 1979, COLLINS ENGLISH DICT	14	2102	2122	2	145	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					694	696		10.1136/bmj.321.7262.694	http://dx.doi.org/10.1136/bmj.321.7262.694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987780	Green Published			2022-12-28	WOS:000089444100034
J	Lee, CT; Yin, QZ; Rudnick, RL; Chesley, JT; Jacobsen, SB				Lee, CT; Yin, QZ; Rudnick, RL; Chesley, JT; Jacobsen, SB			Osmium isotopic evidence for mesozoic removal of lithospheric mantle beneath the Sierra Nevada, California	SCIENCE			English	Article							WESTERN UNITED-STATES; CONVECTIVE INSTABILITY; CONTINENTAL-CRUST; SUBDUCTION ZONES; OXIDATION-STATE; TRACE-ELEMENT; HIGH-PRESSURE; XENOLITHS; SYSTEMATICS; BATHOLITH	Thermobarometric and Os isotopic data for peridotite xenolith:; from Late Miocene and younger Lavas in the Sierra Nevada reveal that the lithospheric mantle is vertically stratified: the shallowest portions (<45 to 60 kilometers) are cold (670 degrees to 740 degrees C) and show evidence for heating and yield Proterozoic Os model ages, whereas the deeper portions (45 to 100 kilometers) yield Phanerozoic Os model ages and show evidence for extensive cooling from temperatures >1100 degrees C to 750 degrees C. Because a variety of isotopic evidence suggests that the Sierran batholith formed on preexisting Proterozoic Lithosphere, most of:the original Lithospheric mantle appears to have been removed before the Late! Miocene, leaving only a sliver of ancient mantle beneath the crust.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Arizona, Dept Geol Sci, Tucson, AZ 85712 USA	Harvard University; University of Arizona	Lee, CT (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.		Yin, Qing-Zhu/B-8198-2009; Jacobsen, Stein/B-1759-2013; Lee, Cin-Ty/A-5469-2008; Lee, Cin-Ty/AAV-8155-2021; Jacobsen, Stein/ABA-1063-2021; Rudnick, Roberta Lyn/J-2398-2013	Yin, Qing-Zhu/0000-0002-4445-5096; Lee, Cin-Ty/0000-0002-3586-0110; Jacobsen, Stein/0000-0003-2164-0720; Rudnick, Roberta Lyn/0000-0003-1559-7463				BALLHAUS C, 1991, CONTRIB MINERAL PETR, V107, P27, DOI 10.1007/BF00311183; BEARD BL, 1995, J GEOPHYS RES-SOL EA, V100, P4169, DOI 10.1029/94JB02883; BIRD P, 1988, SCIENCE, V239, P1501, DOI 10.1126/science.239.4847.1501; BIRD P, 1979, J GEOPHYS RES, V84, P7561, DOI 10.1029/JB084iB13p07561; Brandon AD, 1996, GEOCHIM COSMOCHIM AC, V60, P1739, DOI 10.1016/0016-7037(96)00056-7; Brandon AD, 1996, SCIENCE, V272, P861, DOI 10.1126/science.272.5263.861; Chesley JT, 1999, GEOCHIM COSMOCHIM AC, V63, P1203, DOI 10.1016/S0016-7037(99)00004-6; Conrad CP, 1997, GEOPHYS J INT, V129, P95, DOI 10.1111/j.1365-246X.1997.tb00939.x; DEPAOLO DJ, 1980, SCIENCE, V209, P684, DOI 10.1126/science.209.4457.684; Dickinson W.R., 1978, LARAMIDE FOLDING ASS, V151, P355, DOI DOI 10.1130/MEM151-P355; DODGE FCW, 1988, GEOL SOC AM BULL, V100, P938, DOI 10.1130/0016-7606(1988)100<0938:FOTMAC>2.3.CO;2; Dodson A, 1998, GEOCHIM COSMOCHIM AC, V62, P3775, DOI 10.1016/S0016-7037(98)00267-1; DOMENICK MA, 1983, GEOL SOC AM BULL, V94, P713, DOI 10.1130/0016-7606(1983)94<713:NASISO>2.0.CO;2; Ducea M, 1998, EARTH PLANET SC LETT, V156, P101, DOI 10.1016/S0012-821X(98)00021-1; Ducea MN, 1996, J GEOPHYS RES-SOL EA, V101, P8229, DOI 10.1029/95JB03452; Ducea MN, 1998, CONTRIB MINERAL PETR, V133, P169, DOI 10.1007/s004100050445; Girnis AV, 1999, EUR J MINERAL, V11, P619; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; Griffin WL, 1996, CAN MINERAL, V34, P1179; Handler MR, 1997, EARTH PLANET SC LETT, V151, P61, DOI 10.1016/S0012-821X(97)00118-0; Hart S.R., 1996, GEOPHYS MONOGR SER, V95, P123; HOUSEMAN GA, 1981, J GEOPHYS RES, V86, P6115, DOI 10.1029/JB086iB07p06115; KAY RW, 1993, TECTONOPHYSICS, V219, P177, DOI 10.1016/0040-1951(93)90295-U; KISTLER RW, 1973, GEOL SOC AM BULL, V84, P3489, DOI 10.1130/0016-7606(1973)84<3489:VISRKN>2.0.CO;2; Lachenbruch A.H., 1977, EARTHS CRUST, V20, P626; Lee C., UNPUB; Liu M, 1998, GEOLOGY, V26, P299, DOI 10.1130/0091-7613(1998)026<0299:SNUADL>2.3.CO;2; LIVACCARI RF, 1993, GEOLOGY, V21, P719, DOI 10.1130/0091-7613(1993)021<0719:IEFPOC>2.3.CO;2; MCKENZIE D, 1983, NATURE, V301, P229, DOI 10.1038/301229a0; Meisel T, 1996, NATURE, V383, P517, DOI 10.1038/383517a0; MENZIES MA, 1983, NATURE, V303, P205, DOI 10.1038/303205a0; MUKHOPADHYAY B, 1994, J PETROL, V35, P1417, DOI 10.1093/petrology/35.5.1417; REISBERG L, 1995, NATURE, V376, P159, DOI 10.1038/376159a0; RUDNICK RL, 1995, NATURE, V378, P571, DOI 10.1038/378571a0; Ruppert S, 1998, TECTONOPHYSICS, V286, P237, DOI 10.1016/S0040-1951(97)00268-0; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; Snow JE, 1995, EARTH PLANET SC LETT, V136, P723, DOI 10.1016/0012-821X(95)00165-9; STEWART JH, 1972, GEOL SOC AM BULL, V83, P1345, DOI 10.1130/0016-7606(1972)83[1345:IDITCG]2.0.CO;2; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8; WERNICKE B, 1988, GEOL SOC AM BULL, V100, P1738, DOI 10.1130/0016-7606(1988)100<1738:BARETA>2.3.CO;2; Wernicke B, 1996, SCIENCE, V271, P190, DOI 10.1126/science.271.5246.190; YIN QZ, 1999, LPI CONTRIB, V29, P335; ZANDT G, 1993, SCIENCE, V261, P460, DOI 10.1126/science.261.5120.460	44	110	119	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1912	1916		10.1126/science.289.5486.1912	http://dx.doi.org/10.1126/science.289.5486.1912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988067				2022-12-28	WOS:000089355800039
J	Hilditch, K				Hilditch, K			My Addison's disease	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	6	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					645	645		10.1136/bmj.321.7261.645	http://dx.doi.org/10.1136/bmj.321.7261.645			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977856	Green Published			2022-12-28	WOS:000089243200065
J	Mankodi, A; Logigian, E; Callahan, L; McClain, C; White, R; Henderson, D; Krym, M; Thornton, CA				Mankodi, A; Logigian, E; Callahan, L; McClain, C; White, R; Henderson, D; Krym, M; Thornton, CA			Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat	SCIENCE			English	Article							TRINUCLEOTIDE REPEAT; BINDING PROTEIN; REDUCES EXPRESSION; MOLECULAR-BASIS; ACTIN GENE; CTG REPEAT; EXPANSION; MUSCLE; RNA; TRANSCRIPTS	Myotonic dystrophy (DM), the most common form of muscular dystrophy in adult humans, results from expansion of a CTC repeat in the 3' untranslated region of the DMPK gene. The mutant DMPK messenger RNA (mRNA) contains an expanded CUG repeat and is retained in the nucleus. We have expressed an untranslated CUG repeat in an unrelated mRNA in transgenic mice. Mice that expressed expanded CUG repeats developed myotonia and myopathy, whereas mice expressing a nonexpanded repeat did not, Thus, transcripts with expanded CUG repeats are sufficient to generate a DM phenotype. This result supports a role for RNA gain of function in disease pathogenesis.	Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Thornton, CA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Neurol, Box 673,601 Elmwood Ave, Rochester, NY 14642 USA.			Mankodi, Ami/0000-0002-5131-7767; WHITE, ROBERT J/0000-0002-4289-1046				ARNACK JD, 1999, HUM MOL GENET, V8, P1975; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DUBOWITZ V, 1996, MUSCLE BIOPSY PRACTI; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HARDEMAN E, COMMUNICATION; Harper P.S., 1989, MYOTONIC DYSTROPHY; HUDECKI MS, 1990, ADV EXP MED BIOL, V280, P251; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Michalowski S, 1999, NUCLEIC ACIDS RES, V27, P3534, DOI 10.1093/nar/27.17.3534; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; REININGHAUS J, 1988, MUSCLE NERVE, V11, P433, DOI 10.1002/mus.880110504; Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; THORNTON CA, 1994, ANN NEUROL, V35, P104, DOI 10.1002/ana.410350116; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TOHGI H, 1994, MUSCLE NERVE, V17, P1037, DOI 10.1002/mus.880170911; VASSILOPOULOS D, 1980, EUR NEUROL, V19, P237, DOI 10.1159/000115152; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89	30	517	543	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1769	1772		10.1126/science.289.5485.1769	http://dx.doi.org/10.1126/science.289.5485.1769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976074				2022-12-28	WOS:000089195200052
J	van der Laan, LJW; Lockey, C; Griffeth, BC; Frasier, FS; Wilson, CA; Onions, DE; Hering, BJ; Long, ZF; Otto, E; Torbett, BE; Salomon, DR				van der Laan, LJW; Lockey, C; Griffeth, BC; Frasier, FS; Wilson, CA; Onions, DE; Hering, BJ; Long, ZF; Otto, E; Torbett, BE; Salomon, DR			Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice	NATURE			English	Article							HUMAN-CELLS; ENGRAFTMENT; PIGS	Animal donors such as pigs could provide an alternative source of organs for transplantation. However, the promise of xenotransplantation is offset by the possible public health risk of a cross-species infection(1,2). All pigs contain several copies of porcine endogenous retroviruses (PERV)(3,4), and at least three variants of PERV can infect human cell lines in vitro in co-culture, infectivity and pseudotyping experiments(3,5-7). Thus, if xenotransplantation of pig tissues results in PERV viral replication, there is a risk of spreading and adaptation of this retrovirus to the human host. C-type retroviruses related to PERV are associated with malignancies of haematopoietic lineage cells in their natural hosts(8). Here we show that pig pancreatic islets produce PERV and can infect human cells in culture. After transplantation into NOD/SCID (non-obese diabetic, severe combined immunodeficiency) mice, we detect ongoing viral expression and several tissue compartments become infected. This is the first evidence that PERV is transcriptionally active and infectious cross-species in vivo after transplantation of pig tissues. These results show that a concern for PERV infection risk associated with pig islet xenotransplantation in immunosuppressed human patients may be justified.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Genet Therapy Inc, Gaithersburg, MD 20878 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Q One Biotech Ltd, Glasgow G20 OXA, Lanark, Scotland; Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA	Scripps Research Institute; Novartis; US Food & Drug Administration (FDA); University of Glasgow; University of Minnesota System; University of Minnesota Twin Cities	Salomon, DR (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Salomon, Daniel/E-9380-2012; van der Laan, Luc/M-5495-2019	van der Laan, Luc/0000-0002-0651-5334				Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; BEATTIE GM, 1994, TRANSPLANT P, V26, P3299; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; Crisa L, 1999, BLOOD, V94, P3928, DOI 10.1182/blood.V94.11.3928.423k02_3928_3940; Heneine W, 1998, LANCET, V352, P1478; HESSELTON RM, 1995, J INFECT DIS, V172, P974, DOI 10.1093/infdis/172.4.974; LAMONT C, 1991, J VIROL, V65, P4619, DOI 10.1128/JVI.65.9.4619-4628.1991; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LEVY JA, 1973, SCIENCE, V182, P1151, DOI 10.1126/science.182.4117.1151; Liu X, 1997, TRANSPL P, V29, P768, DOI 10.1016/S0041-1345(96)00476-9; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Sandrin MS, 1999, CURR OPIN IMMUNOL, V11, P527, DOI 10.1016/S0952-7915(99)00011-4; Stoye JP, 1997, NATURE, V386, P126, DOI 10.1038/386126b0; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; TOTH SR, 1986, VET PATHOL, V23, P462, DOI 10.1177/030098588602300417; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Wilson CA, 2000, J VIROL, V74, P49, DOI 10.1128/JVI.74.1.49-56.2000; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998	22	292	304	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					90	94		10.1038/35024089	http://dx.doi.org/10.1038/35024089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993079				2022-12-28	WOS:000089124000048
J	Smith, LW				Smith, LW			After hours	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1067	1067		10.1001/jama.284.9.1067	http://dx.doi.org/10.1001/jama.284.9.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974679				2022-12-28	WOS:000089037200001
J	Yao, DC; Wright, SM				Yao, DC; Wright, SM			National survey of internal medicine residency program directors regarding problem residents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBSTANCE-ABUSE; PHYSICIANS; STRESS; IMPAIRMENT; DISCRIMINATION; DEPRESSION	Context Internal medicine residency training is demanding and residents can experience a wide variety of professional and personal difficulties. A problem resident is defined by the American Board of Internal Medicine as "a trainee who demonstrates a significant enough problem that requires intervention by someone of authority." Data are sparse regarding identification and management of such residents. Objective To gain more understanding of the prevalence, identification, management, and prevention of problem residents within US internal medicine residency programs. Design, Setting, and Participants Mailed survey of all 404 internal medicine residency program directors in the United States in October 1999, of whom 298 (74%) responded. Main Outcome Measures Prevalence of problem residents; type of problems encountered; factors associated with identification and management of problem residents. Results The mean point prevalence of problem residents during academic year 1998-1999 was 6.9% (SD, 5.7%; range, 0%-39%), and 94% of programs had problem residents. The most frequently reported difficulties of problem residents were insufficient medical knowledge (48%), poor clinical judgment (44%), and inefficient use of time (44%). Stressors and depression were the most frequently identified underlying problems (42% and 24%, respectively). The most frequent processes by which problem residents were discovered included direct observation (82%) and critical incidents (59%). Chief residents and attending physicians most frequently identified problem residents (84% and 76%, respectively); problem residents rarely identified themselves(2%). Many program directors believed that residents who are from an underrepresented minority, are international medical graduates, or are older than 35 years are at increased risk of being identified as a problem resident (P<.05). Program directors believed that frequent feedback sessions (65%) and an assigned mentor for structured supervision (53%) were the most helpful interventions. Conclusion Nearly all internal medicine residency programs in this sample had problem residents, whose presenting characteristics and underlying issues were diverse and complex.	Johns Hopkins Bayview Med Ctr, Div Gen Internal Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Yao, DC (corresponding author), Univ Calif San Francisco, Med Ctr, Med Educ Program, 445 S Cedar Ave, Fresno, CA 93702 USA.							AACH RD, 1992, ANN INTERN MED, V116, P245, DOI 10.7326/0003-4819-116-3-245; *AM BOARD INT MED, 1992, PROBL RES VID; *AM BOARD INT MED, 1999, MAT ASS PROGR DIR IN; *AM MED ASS, 2000, GRAD MED ED DIR; *AM MED ASS COUNC, 1973, JAMA-J AM MED ASSOC, V223, P684; American Board of Internal Medicine, 1995, PROJ PROF; Balon R, 1997, AM J PSYCHIAT, V154, P1608, DOI 10.1176/ajp.154.11.1608; Benzer David G., 1993, Journal of the American Osteopathic Association, V93, P217; BOOTE RM, 1999, SOC GEN INT MED NAT; BUTTERFIELD PS, 1988, ARCH INTERN MED, V148, P1428, DOI 10.1001/archinte.148.6.1428; Ford C V, 1983, Psychiatr Med, V1, P143; Gordon M J, 1993, Fam Med, V25, P637; HERRINGTON RE, 1979, WISC MED J, V78, P21; HSU K, 1987, AM J PSYCHIAT, V144, P1561; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; HURWITZ TA, 1987, CAN J PSYCHIAT, V32, P165, DOI 10.1177/070674378703200301; JEX SM, 1992, INT J ADDICT, V27, P979, DOI 10.3109/10826089209065588; LANDAU C, 1986, J MED EDUC, V61, P654; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MCNAMARA RM, 1994, ANN EMERG MED, V23, P1072, DOI 10.1016/S0196-0644(94)70106-7; NESBITT D, 1988, ANN INTERN MED, V109, P154, DOI 10.7326/0003-4819-109-2-154; OConnor PG, 1997, MED CLIN N AM, V81, P1037, DOI 10.1016/S0025-7125(05)70562-9; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; REUBEN DB, 1985, ARCH INTERN MED, V145, P286, DOI 10.1001/archinte.145.2.286; REUBEN DB, 1990, JAMA-J AM MED ASSOC, V263, P958, DOI 10.1001/jama.263.7.958; Samkoff J S, 1989, Pa Med, V92, P40; Shapiro J, 1987, Fam Med, V19, P368; SMITH JW, 1986, JAMA-J AM MED ASSOC, V255, P1155, DOI 10.1001/jama.255.9.1155; *STAT CORP, 1999, STATA 6 0 COMP PROGR; STEINZOR RI, 1993, URBAN LAWYER, V25, P627; VALKO RJ, 1975, DIS NERV SYST, V36, P26; vanIneveld CHM, 1996, J GEN INTERN MED, V11, P401, DOI 10.1007/BF02600186	32	121	123	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1099	1104		10.1001/jama.284.9.1099	http://dx.doi.org/10.1001/jama.284.9.1099			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974688	Bronze			2022-12-28	WOS:000089037200009
J	Repa, JJ; Turley, SD; Lobaccaro, JMA; Medina, J; Li, L; Lustig, K; Shan, B; Heyman, RA; Dietschy, JM; Mangelsdorf, DJ				Repa, JJ; Turley, SD; Lobaccaro, JMA; Medina, J; Li, L; Lustig, K; Shan, B; Heyman, RA; Dietschy, JM; Mangelsdorf, DJ			Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers	SCIENCE			English	Article							BINDING CASSETTE TRANSPORTER-1; BILE-ACID METABOLISM; TANGIER-DISEASE; NUCLEAR RECEPTOR; MICE; GENE; IDENTIFICATION; DEFICIENCY; MUTATIONS; MEMBRANE	Several nuclear hormone receptors involved in lipid metabolism form obligate heterodimers with retinoid X receptors (RXRs) and are activated by RXR agonists such as rexinoids. Animals treated with rexinoids exhibited marked changes in cholesterol balance, including inhibition of cholesterol absorption and repressed bile acid synthesis. Studies with receptor-selective agonists revealed that oxysterol receptors (LXRs) and the bile acid receptor (FXR) are the RXR heterodimeric partners that mediate these effects by regulating expression of the reverse cholesterol transporter, ABC1, and the rate-limiting enzyme of bile acid synthesis, CYP7A1, respectively. Thus, these RXR heterodimers serve as key regulators of cholesterol homeostasis by governing reverse cholesterol transport from peripheral tissues, bile acid synthesis in Liver, and cholesterol absorption in intestine.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Tularik, S San Francisco, CA 94080 USA; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Ligand Pharmaceuticals	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Lobaccaro, Jean-Marc A./U-1928-2019; Lobaccaro, Jean-Marc/Q-3926-2019; Eckhardt, Erik/G-1567-2010	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Repa, Joyce/0000-0001-5740-1954	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL 09610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTIE AD, UNPUB; Auwerx J, 1999, CELL, V97, P161; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Carter CP, 1997, J NUTR, V127, P1344, DOI 10.1093/jn/127.7.1344; CASTILLOOLIVARE.A, 2000, J BIOL CHEM, V275, P17793; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COSTET P, IN PRESS J BIOL CHEM; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Gottardis MM, 1996, CANCER RES, V56, P5566; Homan R, 1997, CURR PHARM DESIGN, V3, P29; IKEDA I, 1988, J LIPID RES, V29, P1583; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; LOBACARRO JMA, UNPUB; LU TT, IN PRESS MOL CELL; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MIETTINEN TA, 1989, AM J CLIN NUTR, V49, P629, DOI 10.1093/ajcn/49.4.629; Mukherjee R, 1998, ARTERIOSCL THROM VAS, V18, P272, DOI 10.1161/01.ATV.18.2.272; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; REPA JJ, UNPUB; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; SCHMITZ G, 1990, EUR HEART J, V11, P197, DOI 10.1093/eurheartj/11.suppl_E.197; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; THURNHOFER H, 1990, BIOCHEMISTRY-US, V29, P2142, DOI 10.1021/bi00460a026; Turley SD, 1999, EUR HEART J SUPPL, V1, pS29; van Heek M, 2000, BRIT J PHARMACOL, V129, P1748, DOI 10.1038/sj.bjp.0703235; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2	48	1100	1152	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1524	1529		10.1126/science.289.5484.1524	http://dx.doi.org/10.1126/science.289.5484.1524			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968783				2022-12-28	WOS:000089071700039
J	Schneider, W; Veldman, A; Beyer, PA; Heller, K				Schneider, W; Veldman, A; Beyer, PA; Heller, K			A breathless toddler	LANCET			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA		Johann Wolfgang Geothe Univ Hosp, Dept Paediat, Div Neonatol, D-60596 Frankfurt, Germany; Johann Wolfgang Geothe Univ Hosp, Dept Paediat Surg, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Veldman, A (corresponding author), Johann Wolfgang Geothe Univ Hosp, Dept Paediat, Div Neonatol, D-60596 Frankfurt, Germany.							Numanoglu A, 1997, S AFR J SURG, V35, P74; WEBER TR, 1991, AM J SURG, V162, P643, DOI 10.1016/0002-9610(91)90127-Y; WOODWARD GA, 1996, PEDIAT NEONATAL TRAN, P39	3	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					480	480		10.1016/S0140-6736(00)02558-7	http://dx.doi.org/10.1016/S0140-6736(00)02558-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981893				2022-12-28	WOS:000088657700015
J	Bath, P; Bath, F; Rashid, P; Weaver, C				Bath, P; Bath, F; Rashid, P; Weaver, C			Acute ischaemic stroke - Large trial of effect of reducing blood pressure in acute stroke is being set up	BRITISH MEDICAL JOURNAL			English	Letter							ISCHEMIC STROKE		Univ Nottingham, Div Stroke Med, Nottingham NG5 1PB, England	University of Nottingham	Bath, P (corresponding author), Univ Nottingham, Div Stroke Med, City Hosp Campus, Nottingham NG5 1PB, England.		Bath-Hextall, Fiona/B-8722-2008; Bath, Philip/F-9020-2011	Bath-Hextall, Fiona/0000-0001-6583-029X; Bath, Philip/0000-0003-2734-5132				*BLOOD PRESS AC ST, 1999, COCHRANE LIB; Butterworth RJ, 1998, CEREBROVASC DIS, V8, P158, DOI 10.1159/000015842; Dyker AG, 1997, STROKE, V28, P580, DOI 10.1161/01.STR.28.3.580; Gubitz G, 2000, BMJ-BRIT MED J, V320, P692, DOI 10.1136/bmj.320.7236.692	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	2000	321	7256					300	300						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341ZA	10979697				2022-12-28	WOS:000088619800043
J	Robertson, GP; Paul, EA; Harwood, RR				Robertson, GP; Paul, EA; Harwood, RR			Greenhouse gases in intensive agriculture: Contributions of individual gases to the radiative forcing of the atmosphere	SCIENCE			English	Article							CARBON; BUDGET	Agriculture plays a major role in the global fluxes of the greenhouse gases carbon dioxide, nitrous oxide, and methane. From 1991 to 1999, we measured gas fluxes and other sources of global warming potential (GWP) in cropped and nearby unmanaged ecosystems. Net GWP (grams of carbon dioxide equivalents per square meter per year) ranged from 110 in our conventional tillage systems to -211 in early successional communities. None of the annual cropping systems provided net mitigation, although soil carbon accumulation in no-till systems came closest to mitigating all other sources of GWP. In all but one ecosystem, nitrous oxide production was the single greatest source of GWP. In the Late successional system, GWP was neutral because of significant methane oxidation. These results suggest additional opportunities for Lessening the GWP of agronomic systems.	Michigan State Univ, Dept Crop & Soil Sci, Hickory Corners, MI 49060 USA; Michigan State Univ, WK Kellogg Biol Stn, Hickory Corners, MI 49060 USA; Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Robertson, GP (corresponding author), Michigan State Univ, Dept Crop & Soil Sci, Hickory Corners, MI 49060 USA.	robertson@kbs.msu.edu	Robertson, G Philip/H-3885-2011	Robertson, G Philip/0000-0001-9771-9895				[Anonymous], 1997, REV 1996 IPCC GUID N; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Drinkwater LE, 1998, NATURE, V396, P262, DOI 10.1038/24376; FRANZLUEBBERS AJ, IN PRESS ADV SOIL SC; Groffman P.M., 1999, STANDARD SOIL METHOD, P272; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Lal R., 1999, POTENTIAL US CROPLAN; Livingston G., 1995, BIOGENIC TRACE GASES, P14; MARLAND G, 1999, TRENDS COMPENDIUM DA; Matson PA, 1998, SCIENCE, V280, P112, DOI 10.1126/science.280.5360.112; Mosier A, 1998, NUTR CYCL AGROECOSYS, V52, P225, DOI 10.1023/A:1009740530221; MOSIER A, 1991, NATURE, V350, P330, DOI 10.1038/350330a0; Paul E.A., 1997, SOIL ORGANIC MATTER; Paustian K, 1995, SOIL MANAGEMENT GREE, P69; Prather M, 1995, CLIMATE CHANGE 1994, P73; Robertson G. Philip, 1997, P347; Schlesinger WH, 1999, SCIENCE, V284, P2095, DOI 10.1126/science.284.5423.2095; SMITH KA, 1994, ENVIR SCI R, V48, P179; *USDA, 1997, AGR RES ENV IND 1996	19	944	1004	18	535	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1922	1925		10.1126/science.289.5486.1922	http://dx.doi.org/10.1126/science.289.5486.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988070	Green Submitted			2022-12-28	WOS:000089355800042
J	Schuh, S; Reisman, J; Alshehri, M; Dupuis, A; Corey, M; Arseneault, R; Alothman, G; Tennis, O; Canny, G				Schuh, S; Reisman, J; Alshehri, M; Dupuis, A; Corey, M; Arseneault, R; Alothman, G; Tennis, O; Canny, G			A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMERGENCY ROOM TREATMENT; PITUITARY-ADRENAL AXIS; BECLOMETHASONE DIPROPIONATE; SHORT-TERM; CONTROLLED TRIAL; SHORT COURSES; PROPIONATE; STEROIDS; METHYLPREDNISOLONE; BUDESONIDE	Background Inhaled corticosteroids are effective in the treatment of children with asthma. It is uncertain how inhaled corticosteroids compare with oral corticosteroids in the management of severe acute disease. Methods We performed a double-blind, randomized trial involving 100 children five years of age or older who had severe acute asthma ( indicated by a forced expiratory volume in one second [FEV1] that was less than 60 percent of the predicted value) and in whom the results could be evaluated. All were treated with an aggressive bronchodilator regimen and received one dose of either 2 mg of inhaled fluticasone through a metered-dose inhaler with a spacer or 2 mg of oral prednisone per kilogram of body weight. They were assessed hourly for up to four hours. Results The mean (+/- SD) base-line FEV1 as a percentage of the predicted value was 46.3 +/- 12.5 in the fluticasone group (51 subjects) and 43.9 +/- 9. 9 in the prednisone group (49 subjects). The FEV1 increased by a mean of 9.4 +/- 12.5 percentage points in the fluticasone group and by 18.9 +/- 9.8 percentage points in the prednisone group four hours after therapy (P< 0.001). None of the children in the prednisone group had a reduction in FEV1 as a percentage of the predicted value from base line to four hours, as compared with 25 percent of those in the fluticasone group (P< 0.001). Sixteen (31 percent) of the children treated with fluticasone were hospitalized, as compared with five (10 percent) of those treated with prednisone (P=0.01). Conclusions Children with severe acute asthma should be treated with oral prednisone and not with inhaled fluticasone or a similar inhaled corticosteroid. (N Engl J Med 2000; 343: 689-94.) (C) 2000, Massachusetts Medical Society.	Hosp Sick Children, Dept Paediat, Div Emergency Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Paediat, Div Resp Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Paediat, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Schuh, S (corresponding author), Hosp Sick Children, Div Paediat Emergency Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BARNES NC, 1993, EUR RESPIR J, V6, P877; Bootsma GP, 1996, AM J RESP CRIT CARE, V153, P924, DOI 10.1164/ajrccm.153.3.8630574; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; CONNETT GJ, 1994, ARCH DIS CHILD, V70, P170, DOI 10.1136/adc.70.3.170; DESHPANDE A, 1986, BRIT MED J, V293, P169, DOI 10.1136/bmj.293.6540.169; Diggle PJ, 1995, J AM STAT ASSOC; DOLAN LM, 1987, J ALLERGY CLIN IMMUN, V80, P81, DOI 10.1016/S0091-6749(87)80195-1; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FULLER R, 1995, RESP MED, V89, P3, DOI 10.1016/0954-6111(95)90259-7; Gibbons J.D., 1985, NONPARAMETRIC STAT I, DOI 10.2307/2531272; HARDING SM, 1990, RESP MED, V84, pA25; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; *INT AG RES CANC, 1980, IARC SCI PUBL, V32; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; LANGDON CG, 1994, BR J CLIN RES, V5, P73; Levy ML, 1996, THORAX, V51, P1087, DOI 10.1136/thx.51.11.1087; Lin RY, 1999, ANN EMERG MED, V33, P487, DOI 10.1016/S0196-0644(99)70334-3; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; Little RC, 1996, SAS SYSTEM MIXED MOD; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; MILLERLARSSON A, 1990, AGENTS ACTIONS, V29, P127, DOI 10.1007/BF01964740; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; RODRIGO C, 1994, RESP MED, V88, P755, DOI 10.1016/S0954-6111(05)80198-2; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698, DOI 10.1164/ajrccm.157.3.9704022; SCARFONE RJ, 1995, ANN EMERG MED, V26, P480, DOI 10.1016/S0196-0644(95)70118-4; SCARFONE RJ, 1993, PEDIATRICS, V92, P513; SCHNEIDER SM, 1988, J ASTHMA, V25, P189, DOI 10.3109/02770908809071365; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; SCHUH S, 1989, PEDIATRICS, V83, P513; SHAPIRO GG, 1983, PEDIATRICS, V71, P510; STEIN LM, 1990, ANN INTERN MED, V112, P822, DOI 10.7326/0003-4819-112-11-822; WENG TR, 1969, AM REV RESPIR DIS, V99, P879; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; Youngchiayaud P., 1996, European Respiratory Journal Supplement, V9, p53S; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5	40	124	133	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					689	694		10.1056/NEJM200009073431003	http://dx.doi.org/10.1056/NEJM200009073431003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974132				2022-12-28	WOS:000089100500003
J	Neish, AS; Gewirtz, AT; Zeng, H; Young, AN; Hobert, ME; Karmali, V; Rao, AS; Madara, JL				Neish, AS; Gewirtz, AT; Zeng, H; Young, AN; Hobert, ME; Karmali, V; Rao, AS; Madara, JL			Prokaryotic regulation of epithelial responses by inhibition of I kappa B-alpha ubiquitination	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; BETA-CATENIN; PROTEASOME PATHWAY; NEUTROPHILS; ATTACHMENT; ACTIVATION; BACTERIAL; SECRETION; CELLS; TRCP	Epithelia of the vertebrate intestinal tract characteristically maintain an inflammatory hyporesponsiveness toward the lumenal prokaryotic microflora. We report the identification of enteric organisms (nonvirulent Salmonella strains) whose direct interaction with model human epithelia attenuate synthesis of inflammatory effector molecules elicited by diverse proinflammatory stimuli. This immunosuppressive effect involves inhibition of the inhibitor kappa B/nuclear factor kappa B (I kappa B/NF-kappa B) pathway by blockade of I kappa B-alpha degradation, which prevents subsequent nuclear translocation of active NF-kappa B dimer, Although phosphorylation of I kappa B-alpha occurs, subsequent polyubiquitination necessary for regulated I kappa B-alpha degradation is completely abrogated. These data suggest that prokaryotic determinants could be responsible for the unique tolerance of the gastrointestinal mucosa to proinflammatory stimuli.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Unit, Atlanta, GA 30322 USA	Emory University	Neish, AS (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Unit, Atlanta, GA 30322 USA.	aneish@emory.edu	Neish, Andrew/B-3895-2009		NIDDK NIH HHS [DK-35932, DK09800, DK-47662] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035932, F32DK009800, R01DK047662, R01DK035932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Elewaut D, 1999, J IMMUNOL, V163, P1457; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hobbie S, 1997, J IMMUNOL, V159, P5550; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; MADARA JL, 1990, AM J PATHOL, V137, P1273; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; MCCORMICK BA, 1995, INFECT IMMUN, V63, P2302, DOI 10.1128/IAI.63.6.2302-2309.1995; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NELSH A, UNPUB; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Thurberg BL, 1998, CURR OPIN LIPIDOL, V9, P387, DOI 10.1097/00041433-199810000-00002; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	24	687	750	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1560	1563		10.1126/science.289.5484.1560	http://dx.doi.org/10.1126/science.289.5484.1560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968793				2022-12-28	WOS:000089071700049
J	Johnson, RE; Washington, MT; Haracska, L; Prakash, S; Prakash, L				Johnson, RE; Washington, MT; Haracska, L; Prakash, S; Prakash, L			Eukaryotic polymerases iota and zeta act sequentially to bypass DNA lesions	NATURE			English	Article							THYMINE-THYMINE DIMER; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; REPLICATION FIDELITY; ESCHERICHIA-COLI; YEAST; ETA; PHOTOPRODUCT; EXTENSION; KINETICS	DNA lesions can often block DNA replication, so cells possess specialized low-fidelity, and often error-prone, DNA polymerases that can bypass such lesions and promote replication of damaged DNA(1). The Saccharomyces cerevisiae RAD30 and human hRAD30A encode Pol eta, which bypasses a cis-syn thymine-thymine dimer efficiently and accurately(2-7). Here we show that a related human gene, hRAD30B(8), encodes the DNA polymerase Pol iota, which misincorporates deoxynucleotides at a high rate. To bypass damage, Pol iota specifically incorporates deoxynucleotides opposite highly distorting or non-instructional DNA lesions. This action is combined with that of DNA polymerase Pol zeta, which is essential for damage-induced mutagenesis, to complete the lesion bypass. Pol zeta is very inefficient in inserting deoxynucleotides opposite DNA lesions, but readily extends from such deoxynucleotides once they have been inserted. Thus, in a new model for mutagenic bypass of DNA lesions in eukaryotes, the two DNA polymerases act sequentially: Pol iota incorporates deoxynucleotides opposite DNA lesions, and Pol zeta functions as a mispair extender.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Washington, Todd/0000-0001-8680-2992; Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; Creighton S, 1995, METHOD ENZYMOL, V262, P232; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KIM WC, 1995, ORGAN SCI, V6, P44, DOI 10.1287/orsc.6.1.44; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	21	559	569	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1015	1019		10.1038/35023030	http://dx.doi.org/10.1038/35023030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984059				2022-12-28	WOS:000089020200051
J	Wilkinson, DM				Wilkinson, DM			Let's get the right man in the right job	NATURE			English	Letter									Liverpool John Moores Univ, Liverpool L3 3AF, Merseyside, England	Liverpool John Moores University	Wilkinson, DM (corresponding author), Liverpool John Moores Univ, Byrom St, Liverpool L3 3AF, Merseyside, England.							Gillon J, 2000, NATURE, V406, P685, DOI 10.1038/35021165; Medawar P., 1982, PLUTOS REPUBLIC; Wilkinson DM, 1999, OIKOS, V84, P533, DOI 10.2307/3546433	3	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					933	933		10.1038/35023190	http://dx.doi.org/10.1038/35023190			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984028	Bronze			2022-12-28	WOS:000089020200013
J	Frenking, G				Frenking, G			Chemistry - Another noble gas conquered	NATURE			English	Editorial Material									Univ Marburg, Fachbereich Chem, D-35039 Marburg, Germany	Philipps University Marburg	Frenking, G (corresponding author), Univ Marburg, Fachbereich Chem, Hans Meerwein Str, D-35039 Marburg, Germany.	frenking@chemie.uni-marburg.de						BARTLETT N, 1962, P CHEM SOC LONDON, P218; FRENKING G, 1990, STRUCT BOND, V73, P17; FRENKING G, 1989, J AM CHEM SOC, V111, P31, DOI 10.1021/ja00183a005; Khriachtchev L, 2000, NATURE, V406, P874, DOI 10.1038/35022551; LASZLO P, 1988, ANGEW CHEM INT EDIT, V27, P479, DOI 10.1002/anie.198804791; Pauling L, 1933, J AM CHEM SOC, V55, P1895, DOI 10.1021/ja01332a016; Wong MW, 2000, J AM CHEM SOC, V122, P6289, DOI 10.1021/ja9938175	7	28	28	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					836	837		10.1038/35022678	http://dx.doi.org/10.1038/35022678			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972271				2022-12-28	WOS:000088903600021
J	Tatsuo, H; Ono, N; Tanaka, K; Yanagi, Y				Tatsuo, H; Ono, N; Tanaka, K; Yanagi, Y			SLAM (CDw150) is a cellular receptor for measles virus	NATURE			English	Article							DIFFERENTIAL DOWN-REGULATION; ACTIVATION MOLECULE SLAM; HUMAN B-LYMPHOCYTES; WILD-TYPE; CD46; PROTEIN; HEMAGGLUTININ; PROLIFERATION; GLYCOPROTEIN; STRAINS	Measles virus continues to be a major killer of children, claiming roughly one million lives a year(1). Measles virus infection causes profound immunosuppression, which makes measles patients susceptible to secondary infections accounting for high morbidity and mortality(2). The Edmonston strain of measles virus, and vaccine strains derived from it, use as a cellular receptor human CD46 (refs 3, 4), which is expressed on all nucleated cells; however, most clinical isolates of measles virus cannot use CD46 as a receptor(5). Here we show that human SLAM (signalling lymphocyte-activation molecule; also known as CDw150), a recently discovered membrane glycoprotein expressed on some T and B cells(6), is a cellular receptor for measles virus, including the Edmonston strain. Transfection with a human SLAM complementary DNA enables non-susceptible cell lines to bind measles virus, support measles virus replication and develop cytopathic effects. The distribution of SLAM on various cell lines is consistent with their susceptibility to clinical isolates of measles virus. The identification of SLAM as a receptor for measles virus opens the way to a better understanding of the pathogenesis of measles virus infection, especially the immunosuppression induced by measles virus.	Kyushu Univ, Fac Med, Dept Virol, Fukuoka 8128582, Japan	Kyushu University	Yanagi, Y (corresponding author), Kyushu Univ, Fac Med, Dept Virol, Fukuoka 8128582, Japan.			ONO, NOBUYUKI/0000-0003-0709-4858; Yanagi, Yusuke/0000-0001-7815-1667				Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Buckland R, 1997, VIRUS RES, V48, P1, DOI 10.1016/S0168-1702(96)01421-9; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; Hsu EC, 1998, J VIROL, V72, P2905, DOI 10.1128/JVI.72.4.2905-2916.1998; HUBER M, 1991, VIROLOGY, V185, P299, DOI 10.1016/0042-6822(91)90777-9; Kobune F, 1996, LAB ANIM SCI, V46, P315; KOBUNE F, 1990, J VIROL, V64, P700, DOI 10.1128/JVI.64.2.700-705.1990; Lecouturier V, 1996, J VIROL, V70, P4200, DOI 10.1128/JVI.70.7.4200-4204.1996; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; Manchester M, 2000, J VIROL, V74, P3967, DOI 10.1128/JVI.74.9.3967-3974.2000; McChesney MB, 1997, VIROLOGY, V233, P74, DOI 10.1006/viro.1997.8576; MCFARLIN DE, 1980, J GEN VIROL, V48, P425, DOI 10.1099/0022-1317-48-2-425; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oldstone M.B.A., 1998, VIRUSES PLAGUES HIST; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; SCHNEIDERSCHAULIES J, 1995, J VIROL, V69, P7257, DOI 10.1128/JVI.69.11.7257-7259.1995; SCHNEIDERSCHAULIES J, 1995, P NATL ACAD SCI USA, V92, P3943, DOI 10.1073/pnas.92.9.3943; SIDORENKO SP, 1993, J IMMUNOL, V151, P4614; Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764; Tanaka K, 1998, ARCH VIROL, V143, P213, DOI 10.1007/s007050050281; Tatsuo H, 2000, J VIROL, V74, P4139, DOI 10.1128/JVI.74.9.4139-4145.2000; YANAGI Y, 1992, VIROLOGY, V187, P280, DOI 10.1016/0042-6822(92)90316-H	30	811	849	0	42	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					893	897		10.1038/35022579	http://dx.doi.org/10.1038/35022579			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972291				2022-12-28	WOS:000088903600045
J	de Gelder, B				de Gelder, B			Neuroscience - More to seeing than meets the eye	SCIENCE			English	Editorial Material									Tilburg Univ, Cognit Neurosci Lab, NL-5000 LE Tilburg, Netherlands; Catholic Univ Louvain, Fac Med, Neurophysiol Lab, B-1200 Brussels, Belgium	Tilburg University; Universite Catholique Louvain	de Gelder, B (corresponding author), Tilburg Univ, Cognit Neurosci Lab, NL-5000 LE Tilburg, Netherlands.	b.degelder@kub.nl						Bertelson P, 1998, PSYCHON B REV, V5, P482, DOI 10.3758/BF03208826; BERTELSON P, 2000, PERCEPT PSYCHOPHYS, V29, P57; Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; de Gelder B, 1999, NEUROSCI LETT, V260, P133, DOI 10.1016/S0304-3940(98)00963-X; Driver J, 1998, TRENDS COGN SCI, V2, P254, DOI 10.1016/S1364-6613(98)01188-7; KAWASHIMA R, 1995, P NATL ACAD SCI USA, V92, P5969, DOI 10.1073/pnas.92.13.5969; Macaluso E, 2000, SCIENCE, V289, P1206, DOI 10.1126/science.289.5482.1206; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; VROOMEN J, 2000, JEP HPP, V26, P2030	10	21	21	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2000	289	5482					1148	1149						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346JE	10970228				2022-12-28	WOS:000088866600024
J	Lifson, AR				Lifson, AR			Mycobacterium tuberculosis infection in travellers: tuberculosis comes home	LANCET			English	Editorial Material									Univ Minnesota, Dept Med, Div Infect Dis, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Lifson, AR (corresponding author), Univ Minnesota, Dept Med, Div Infect Dis, MMC 250, Minneapolis, MN 55455 USA.							[Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; BREWER TF, 1995, CLIN INFECT DIS, V20, P136, DOI 10.1093/clinids/20.1.136; Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376, DOI 10.1164/ajrccm.161.4.16141; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fiorentino R, 2000, LANCET, V356, P434, DOI 10.1016/S0140-6736(05)73585-6; *MN DEP HLTH, 2000, DIS CONTROL NEWSLETT, V28, P1; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301	8	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					442	443		10.1016/S0140-6736(00)02545-9	http://dx.doi.org/10.1016/S0140-6736(00)02545-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981881				2022-12-28	WOS:000088657700002
J	Magrisso, RM				Magrisso, RM			Three lessons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1351	1352		10.1001/jama.284.11.1351	http://dx.doi.org/10.1001/jama.284.11.1351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989373				2022-12-28	WOS:000089242500001
J	Allison, JJ; Kiefe, CI; Weissman, NW; Person, SD; Rousculp, M; Canto, JG; Bae, S; Williams, OD; Farmer, R; Centor, RM				Allison, JJ; Kiefe, CI; Weissman, NW; Person, SD; Rousculp, M; Canto, JG; Bae, S; Williams, OD; Farmer, R; Centor, RM			Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; SEVERITY-ADJUSTED MORTALITY; HEALTH-CARE; NONTEACHING HOSPITALS; RAPID CHANGES; DRUG-THERAPY; CENTERS; SYSTEM; COSTS	Context Issues of cost and quality are gaining importance in the delivery of medical care, and whether quality of care is better in teaching vs nonteaching hospitals is an essential question in this current national debate. Objective To examine the association of hospital teaching status with quality of care and mortality for fee-for-service Medicare patients with acute myocardial infarction (AMI). Design, setting, and Patients Analysis of Cooperative Cardiovascular Project data for 114411 Medicare patients from 4361 hospitals (22 354 patients from 439 major teaching hospitals, 22 493 patients from 455 minor teaching hospitals, and 69 564 patients from 3467 nonteaching hospitals) who had AMI between February 1994 and July 1995. Main Outcome Measures Administration of reperfusion therapy on admission, aspirin during hospitalization, and beta-blockers and angiotensin-converting enzyme inhibitors at discharge for patients meeting strict inclusion criteria; mortality at 30, 60, and 90 days and 2 years after admission. Results Among major teaching, minor teaching, and nonteaching hospitals, respectively, administration rates for aspirin were 91.2%, 86.4%, and 81.4% (P<.001); for angiotensin-converting enzyme inhibitors, 63.7%, 60.0%, and 58.0% (P<.001); for P-blockers, 48.8%, 40.3%, and 36.4% (P<.001); and for reperfusion therapy, 55.5%, 58.9%, and 55.2% (P = .29). Differences in unadjusted 30-day, 60-day, 90-day, and 2-year mortality among hospitals were significant at P<.001 for all time periods, with a gradient of increasing mortality from major teaching to minor teaching to nonteaching hospitals. Mortality differences were attenuated by adjustment for patient characteristics and were almost eliminated by additional adjustment for receipt of therapy. Conclusions In this study of elderly patients with AMI, admission to a teaching hospital was associated with better quality of care based on 3 of 4 quality indicators and lower mortality.	Univ Alabama Birmingham, Ctr Outcomes & Effectiveness Res & Educ, Div Gen Internal Med,Dept Med, Dept Hlth Serv Adm,Sch Related Hlth Profess, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Outcomes & Effectiveness Res & Educ, Sch Related Hlth Profess,Div Prevent Med, Dept Med,Dept Hlth Serv Adm, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Outcomes & Effectiveness Res & Educ, Sch Related Hlth Profess,Div Cardiovasc Med, Dept Med,Dept Hlth Serv Adm, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Pittman Gen Clin Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Lister Hill Ctr Hlth Policy, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL USA; Alabama Qual Assurance Fdn, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Allison, JJ (corresponding author), Univ Alabama Birmingham, Ctr Outcomes & Effectiveness Res & Educ, Div Gen Internal Med,Dept Med, Dept Hlth Serv Adm,Sch Related Hlth Profess, 1530 3rd Ave S,MEB 621, Birmingham, AL 35294 USA.	jallison@uab.edu		Allison, Jeroan/0000-0003-4472-2112; bae, sejong/0000-0001-9982-3223	AHRQ HHS [HS08843, HS09446] Funding Source: Medline; NCRR NIH HHS [RR00032] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008843, U18HS009446] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALHAIDER AS, 1991, HEALTH SERV RES, V26, P303; Allison J J, 2000, Jt Comm J Qual Improv, V26, P115; Ayanian JZ, 1998, HEALTH AFFAIR, V17, P194, DOI 10.1377/hlthaff.17.6.194; BALLARD DJ, 1994, HEALTH SERV RES, V28, P771; Bernard AM, 1996, ACAD MED, V71, P262, DOI 10.1097/00001888-199603000-00019; CENTOR RM, 1991, MED DECIS MAKING, V11, P102, DOI 10.1177/0272989X9101100205; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Chen J, 1999, HEALTH AFFAIR, V18, P53, DOI 10.1377/hlthaff.18.4.53; CLOUGH JD, 1993, CLEV CLIN J MED, V60, P449, DOI 10.3949/ccjm.60.6.449; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; Covinsky KE, 1997, J GEN INTERN MED, V12, P203, DOI 10.1007/s11606-006-5041-5; Donabedian A., 1980, EXPLORATIONS QUALITY; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; Espehaug B, 1999, ACTA ORTHOP SCAND, V70, P12, DOI 10.3109/17453679909000949; Fogelman AM, 1996, ACAD MED, V71, P1168, DOI 10.1097/00001888-199611000-00015; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; Greer J, 1992, Health Care Financ Rev Annu Suppl, P199; Hamilton L. C., 1992, REGRESSION GRAPHICS; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; *HEALTHC INF, 1996, AM HOSP ASS GUID HLT; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; Kolb D. A., 1991, ORG BEHAV EXPERIENTI; KRALEWSKI JE, 1995, ACAD MED, V70, P867, DOI 10.1097/00001888-199510000-00008; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; KUHN EM, 1991, MED CARE, V29, P1028, DOI 10.1097/00005650-199110000-00008; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; Magnusen K. O., 1977, ORG DESIGN DEV BEHAV; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; McArthur JH, 1997, JAMA-J AM MED ASSOC, V277, P985, DOI 10.1001/jama.277.12.985; Mechanic R, 1998, JAMA-J AM MED ASSOC, V280, P1015, DOI 10.1001/jama.280.11.1015; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Newhouse J P, 1989, Health Care Financ Rev, V11, P33; Pan CX, 1999, J AM GERIATR SOC, V47, P730, DOI 10.1111/j.1532-5415.1999.tb01599.x; QUAM L, 1993, MED CARE, V31, P498, DOI 10.1097/00005650-199306000-00003; Rosborough TK, 1998, BRIT MED J, V316, P1107, DOI 10.1136/bmj.316.7138.1107; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; Schlesinger M, 1997, HEALTH SERV RES, V32, P561; Scholer SJ, 1996, ARCH PEDIAT ADOL MED, V150, P1154, DOI 10.1001/archpedi.1996.02170360044006; Shortell, 1996, REMAKING HLTH CARE A; SHORTELL SM, 1995, HEALTH SERV RES, V30, P377; Taylor DH, 1999, NEW ENGL J MED, V340, P293, DOI 10.1056/NEJM199901283400408; UDVARHELYI IS, 1990, AM J PUBLIC HEALTH, V80, P1095, DOI 10.2105/AJPH.80.9.1095; *US DEP HHS, 1997, INT CLASS DIS CLIN M; Wells RD, 1998, ACAD MED, V73, P192, DOI 10.1097/00001888-199802000-00019; Wyatt SM, 1997, ACAD MED, V72, P922; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009	63	246	247	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1256	1262		10.1001/jama.284.10.1256	http://dx.doi.org/10.1001/jama.284.10.1256			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	350WL	10979112	Bronze, Green Published			2022-12-28	WOS:000089124600032
J	Wise, RP; Salive, ME; Braun, MM; Mootrey, GT; Seward, JF; Rider, LG; Krause, PR				Wise, RP; Salive, ME; Braun, MM; Mootrey, GT; Seward, JF; Rider, LG; Krause, PR			Postlicensure safety surveillance for varicella vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORTING-SYSTEM VAERS; POLYMERASE CHAIN-REACTION; PERIPHERAL FACIAL PALSY; ZOSTER VIRUS; HEALTHY-CHILDREN; FOLLOW-UP; THROMBOCYTOPENIA; IMMUNIZATION; CHICKENPOX; EFFICACY	Context Since its licensure in 1995, the extensive use of varicella vaccine and close surveillance of the associated anecdotal reports of suspected adverse effects provide the opportunity to detect potential risks not observed before licensure because of the relatively small sample size and other limitations of clinical trials. Objectives To detect potential hazards, including rare events, associated with varicella vaccine, and to assess case reports for clinical and epidemiological implications. Design and Setting Postlicensure case-series study of suspected vaccine adverse events reported to the US Vaccine Adverse Event Reporting System (VAERS) from March 17, 1995, through July 25, 1998. Main Outcome Measures Numbers of reported adverse events, proportions, and reporting rates (reports per 100 000 doses distributed). Results VAERS received 6574 case reports of adverse events in recipients of varicella vaccine, a rate of 67.5 reports per 100 000 doses sold. Approximately 4% of reports described serious adverse events, including 14 deaths. The most frequently reported adverse events were rashes, possible vaccine failures, and injection site reactions. Misinterpretation of varicella serology after vaccination appeared to account for 17% of reports of possible vaccine failures. Among 251 patients with herpes tester, 14 had the vaccine strain of varicella tester virus (VZV), while 12 had the wild-type virus. None of 30 anaphylaxis cases was fatal, An immunodeficient patient with pneumonia had the vaccine strain of VZV in a lung biopsy, Pregnant women occasionally received varicella vaccine through confusion with varicella tester immunoglobulin. Although the role of varicella vaccine remained unproven in most serious adverse event reports, there were a few positive rechallenge reports and consistency of many cases with syndromes recognized as complications of natural varicella. Conclusion Most of the reported adverse events associated with varicella vaccine are minor, and serious risks appear to be rare. We could not confirm a vaccine etiology for most of the reported serious events; several will require further study to clarify whether varicella vaccine plays a role. Education is needed to ensure appropriate use of varicella serologic assays and to eliminate confusion between varicella vaccine and varicella zoster immunoglobulin.	US FDA, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Rockville, MD 20857 USA; US FDA, Off Therapeut Res & Review & DNA Viruses, Div Monoclonal Antibodies, Labs Mol & Dev Immunol, Rockville, MD 20857 USA; US FDA, Off Vaccines Res & Review, Rockville, MD 20857 USA; Ctr Dis Control & Prevent, Branch Vaccine Safety & Dev, Div Epidemiol & Surveillance, Natl Immunizat Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Branch Child Vaccine Preventable Dis, Div Epidemiol & Surveillance, Natl Immunizat Program, Atlanta, GA USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Wise, RP (corresponding author), 1401 rockville Pike,FDA CBER HFM-225, Rockville, MD 20852 USA.		Rider, Lisa G/C-7083-2018	Rider, Lisa G/0000-0002-6912-2458; Krause, Philip/0000-0002-1045-7536				[Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P365; ARBETER AM, 1984, AM J DIS CHILD, V138, P434, DOI 10.1001/archpedi.1984.02140430012004; Arvin AM, 1996, ANNU REV MICROBIOL, V50, P59, DOI 10.1146/annurev.micro.50.1.59; ASANO Y, 1976, LANCET, V1, P965; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; Black S, 1999, PEDIATR INFECT DIS J, V18, P1041, DOI 10.1097/00006454-199912000-00003; Braun MM, 1997, J PEDIATR-US, V131, P529, DOI 10.1016/S0022-3476(97)70056-8; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; CHEN RT, 2000, PHARMACOEPIDEMIOLOGY; COPLAN P, 1998, PHARMACOEPIDEMIOL S2, V7, pS90; *DEP HLTH HUM SERV, 1997, 94 DEP HLTH HUM SERV; ELLENBERG SE, 1997, PUBLIC HLTH REP, V112, P9; ENDERS G, 1994, LANCET, V343, P1548, DOI 10.1016/S0140-6736(94)92943-2; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FEUSNER JH, 1979, AM J HEMATOL, V7, P255, DOI 10.1002/ajh.2830070308; *FOOD DRUG ADM, 1995, COSTART COD SYMB THE; Furuta Y, 1997, J MED VIROL, V52, P316, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;316::AID-JMV13&gt;3.0.CO;2-G; Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; HENG MCY, 1985, BRIT J DERMATOL, V112, P235, DOI 10.1111/j.1365-2133.1985.tb00089.x; Hosseinipour MC, 1998, SOUTHERN MED J, V91, P1070, DOI 10.1097/00007611-199811000-00018; Intussusception among recipients of rotavirus vaccine-United States, 1999, MMWR MORB MORTAL WKL, V48, P577; Izurieta HS, 1997, JAMA-J AM MED ASSOC, V278, P1495, DOI 10.1001/jama.278.18.1495; JOHNSON CE, 1988, PEDIATRICS, V81, P512; KAHANE S, 1981, CLIN EXP IMMUNOL, V44, P49; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KleinschmidtDeMasters BK, 1996, HUM PATHOL, V27, P927, DOI 10.1016/S0046-8177(96)90220-8; Kohl S, 1999, PEDIATR INFECT DIS J, V18, P1112, DOI 10.1097/00006454-199912000-00023; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LARUSSA P, 1992, J VIROL, V66, P1016, DOI 10.1128/JVI.66.2.1016-1020.1992; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; LAWRENCE R, 1988, NEW ENGL J MED, V318, P543, DOI 10.1056/NEJM198803033180904; Lee MS, 1998, OPHTHALMOLOGY, V105, P467, DOI 10.1016/S0161-6420(98)93029-9; Mayer JLR, 1996, PEDIATR RES, V40, P615, DOI 10.1203/00006450-199610000-00017; *MED EC CO, 1999, PHYSICIANS DESK REFE, P1908; *MERCK RES LAB, 1999, PREGN REG VAR 3 ANN; MILLER DH, 1986, J NEUROL, V233, P182, DOI 10.1007/BF00314431; MORGAN M, 1995, J INFECTION, V30, P29, DOI 10.1016/S0163-4453(95)92769-7; PETER G, 1999, MMWR-MORBID MORTAL W, V48, P1; ROBILLARD RB, 1986, OTOLARYNG HEAD NECK, V95, P292, DOI 10.1177/01945998860953P105; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8; Salzman MB, 1997, J PEDIATR-US, V131, P151, DOI 10.1016/S0022-3476(97)70140-9; Sebire G, 1999, ANN NEUROL, V45, P679, DOI 10.1002/1531-8249(199905)45:5<679::AID-ANA22>3.0.CO;2-E; SHAPIRO E, 1998, 36 ANN M INF DIS SOC; Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2; STEIDMAN DS, 1996, BRIT MED J, V313, P701; STROM BL, 1994, PHARMACOEPIDEMIOLOGY, P431; TABONY L, 1998, 36 ANN M INF DIS SOC; TAUB JW, 1995, AM J HEMATOL, V48, P104, DOI 10.1002/ajh.2830480207; TOVI F, 1980, ISRAEL J MED SCI, V16, P576; Varicella-related deaths among adults-United States 1997, 1997, MMWR MORB MORTAL WKL, V46, P409; WATSON BM, 1993, PEDIATRICS, V91, P17; WEBER RE, 1984, MOL PHYSIOL, V6, P1; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WEIBEL RE, 1985, JAMA-J AM MED ASSOC, V254, P2435, DOI 10.1001/jama.254.17.2435; WINIARSKI J, 1990, ARCH DIS CHILD, V65, P137, DOI 10.1136/adc.65.1.137; Wise RP, 1997, JAMA-J AM MED ASSOC, V278, P1176, DOI 10.1001/jama.278.14.1176; WISE RP, 1996, PRINCIPLES DRUG DEV; Wright JF, 1996, BRIT J HAEMATOL, V95, P145, DOI 10.1046/j.1365-2141.1996.d01-1872.x; 1999, MMWR MORB MORTAL WKL, V48, P55; 1999, MMWR MORB MORTAL WKL, V48, P829; 1996, MMWR MORB MORTAL WKL, V45, P1017; 1996, MMWR MORB MORTAL WKL, V45, P12; 1996, MMWR MORB MORTAL WKL, V45, P239; 1997, MMWR MORB MORTAL WKL, V46, P657; 1999, MMWR MORB MORTAL WKL, V48, P1; 1996, MMWR MORB MORTAL WKL, V45, P18	69	146	150	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1271	1279		10.1001/jama.284.10.1271	http://dx.doi.org/10.1001/jama.284.10.1271			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979114	Bronze			2022-12-28	WOS:000089124600034
J	Parkin, A				Parkin, A			Computers in clinical practice: applying experience from child psychiatry	BRITISH MEDICAL JOURNAL			English	Article							INTERVIEW; INTERVENTION; ADOLESCENTS; SYMPTOMS; SUPPORT; SERVICE; SYSTEM; ADHD		Greenwood Inst Child Hlth, Leicester LE3 0QU, Leics, England	University of Leicester	Parkin, A (corresponding author), Greenwood Inst Child Hlth, Westcotes House, Leicester LE3 0QU, Leics, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS G, 1995, PSYCHOL MED, V25, P443, DOI 10.1017/S0033291700033365; Barker J, 1995, J DIVORCE REMARRIAGE, V23, P197, DOI 10.1300/J087v23n03_13; CALAM R, 2000, J C HILD PSYCHOL, V5, P329; CARR AC, 1983, PSYCHOL MED, V13, P151, DOI 10.1017/S0033291700050157; COIERA E, 1995, BRIT MED J, V310, P1381, DOI 10.1136/bmj.310.6991.1381; Creveling CC, 1998, ARCH CLIN NEUROPSYCH, V13, P69; Cromby JJ, 1996, J INTELL DISABIL RES, V40, P489, DOI 10.1046/j.1365-2788.1996.805805.x; De Dombal F T, 1972, Br J Med Educ, V6, P238; Dunham PJ, 1998, AM J COMMUN PSYCHOL, V26, P281, DOI 10.1023/A:1022132720104; El-Sayed E, 1999, ACTA PAEDIATR, V88, P1262, DOI 10.1080/080352599750030400; ERDMAN HP, 1985, J CONSULT CLIN PSYCH, V53, P760, DOI 10.1037/0022-006X.53.6.760; GONZALEZ GM, 1993, BEHAV RES METH INSTR, V25, P301, DOI 10.3758/BF03204514; GORDON M, 1986, PSYCHOPHARMACOL BULL, V22, P288; GREIST JH, 1973, AM J PSYCHIAT, V130, P1327, DOI 10.1176/ajp.130.12.1327; GREIST JH, 1973, ARCH GEN PSYCHIAT, V29, P247; HARPER GW, 1992, J CHILD PSYCHOL PSYC, V33, P1365, DOI 10.1111/j.1469-7610.1992.tb00956.x; Jones A, 1996, COMPUT EDUC, V26, P81, DOI 10.1016/0360-1315(95)00088-7; JONES S, 1994, MY LIFE WORDS PICTUR; LEVENSON RL, 1989, AM J ORTHOPSYCHIAT, V59, P619, DOI 10.1037/h0099025; LEVITON A, 1984, HEADACHE, V24, P182, DOI 10.1111/j.1526-4610.1984.hed2404182.x; MATARAZZO JD, 1983, SC, V221, P233; MILLSTEIN SG, 1983, J PEDIATR-US, V103, P815, DOI 10.1016/S0022-3476(83)80493-4; MOORE NC, 1984, J CLIN PSYCHOL, V40, P875, DOI 10.1002/1097-4679(198405)40:3<875::AID-JCLP2270400343>3.0.CO;2-6; Patton GC, 1999, SOC PSYCH PSYCH EPID, V34, P166, DOI 10.1007/s001270050129; RICHARDS JS, 1983, J PERS ASSESS, V47, P167, DOI 10.1207/s15327752jpa4702_10; Riva G, 1999, J BEHAV THER EXP PSY, V30, P221, DOI 10.1016/S0005-7916(99)00018-X; Romer D, 1997, J SEX RES, V34, P3, DOI 10.1080/00224499709551859; RUBENZER S, 1992, J CLIN PSYCHOL, V48, P817, DOI 10.1002/1097-4679(199211)48:6<817::AID-JCLP2270480617>3.0.CO;2-5; SAWYER M, 1990, BRIT J PSYCHIAT, V157, P675, DOI 10.1192/bjp.157.5.675; SAWYER MG, 1991, J AM ACAD CHILD PSY, V30, P674, DOI 10.1097/00004583-199107000-00022; SAWYER MG, 1992, AUST NZ J PSYCHIAT, V26, P223, DOI 10.3109/00048679209072031; Schery T, 1997, BRIT J EDUC TECHNOL, V28, P271, DOI 10.1111/1467-8535.00034; SCHWARTZ MD, 1990, COMPUTER APPL PSYCHI, P11; Simmons E M Jr, 1971, Hospitals, V45, P56; SIMOLA SK, 1992, J PERS ASSESS, V58, P287, DOI 10.1207/s15327752jpa5802_8; SKINNER HA, 1983, J CONSULT CLIN PSYCH, V51, P267, DOI 10.1037/0022-006X.51.2.267; SLACK WV, 1984, MD COMPUT, V1, P2; Slate SE, 1998, BEHAV MODIF, V22, P415, DOI 10.1177/01454455980223012; STEIN SJ, 1987, APPL PSYCHOL-INT REV, V36, P343, DOI 10.1111/j.1464-0597.1987.tb01196.x; Supple AJ, 1999, J RES ADOLESCENCE, V9, P467, DOI 10.1207/s15327795jra0904_5; Swettenham J, 1996, J CHILD PSYCHOL PSYC, V37, P157, DOI 10.1111/j.1469-7610.1996.tb01387.x; WATTS K, 1982, INT J MAN MACH STUD, V17, P331, DOI 10.1016/S0020-7373(82)80035-7; Weiss, 1983, NEW HORIZONS TESTING, P237; WEISS DJ, 1985, J CONSULT CLIN PSYCH, V53, P774, DOI 10.1037/0022-006X.53.6.774; WEIZENBAUM J, 1966, COMMUN ACM, V9, P36, DOI 10.1145/357980.357991; WETZLER S, 1990, COMPUTER APPL PSYCHI, P43; ZACHARY RA, 1984, USING COMPUTERS CLIN, P151	47	17	17	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					615	+		10.1136/bmj.321.7261.615	http://dx.doi.org/10.1136/bmj.321.7261.615			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	352WW	10977843	Green Published, Bronze			2022-12-28	WOS:000089243200024
J	Siegel-Itzkovich, J				Siegel-Itzkovich, J			Israeli doctors angry at change to complaints' procedures	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					588	588						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977824				2022-12-28	WOS:000089243200009
J	Abbott, A				Abbott, A			CERN considers chasing up hints of Higgs boson	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					8	8		10.1038/35024249	http://dx.doi.org/10.1038/35024249			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993047	Bronze			2022-12-28	WOS:000089124000012
J	Gupta, M; Zare, RN				Gupta, M; Zare, RN			Chemical physics - Spinning molecules to bits	NATURE			English	Editorial Material									Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Gupta, M (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253				Karczmarek J, 1999, PHYS REV LETT, V82, P3420, DOI 10.1103/PhysRevLett.82.3420; Villeneuve DM, 2000, PHYS REV LETT, V85, P542, DOI 10.1103/PhysRevLett.85.542; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875	3	2	2	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					33	34		10.1038/35024192	http://dx.doi.org/10.1038/35024192			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993059				2022-12-28	WOS:000089124000027
J	Jarrold, MF				Jarrold, MF			Chemistry - The smallest fullerene	NATURE			English	Editorial Material							CARBON		Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Jarrold, MF (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.		Jarrold, Martin F/B-2354-2018					FOWLER PW, 1986, CHEM PHYS LETT, V131, P444, DOI 10.1016/0009-2614(86)80563-2; Goroff NS, 1996, ACCOUNTS CHEM RES, V29, P77, DOI 10.1021/ar950162d; GROSSMAN JC, 1995, PHYS REV LETT, V75, P3870, DOI 10.1103/PhysRevLett.75.3870; OBRIEN SC, 1988, J CHEM PHYS, V88, P220, DOI 10.1063/1.454640; Ott AK, 1998, J CHEM PHYS, V109, P9652, DOI 10.1063/1.477632; Prinzbach H, 2000, NATURE, V407, P60, DOI 10.1038/35024037; VON HELDEN G, 1993, CHEM PHYS LETT, V204, P15, DOI 10.1016/0009-2614(93)85599-J	7	48	48	0	23	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					26	27		10.1038/35024178	http://dx.doi.org/10.1038/35024178			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993055				2022-12-28	WOS:000089124000023
J	Tegze, M; Faigel, G; Marchesini, S; Belakhovsky, M; Ulrich, O				Tegze, M; Faigel, G; Marchesini, S; Belakhovsky, M; Ulrich, O			Structure resolution - Imaging light atoms by X-ray holography	NATURE			English	Article							IMAGES		Res Inst Solid State Phys & Opt, H-1525 Budapest, Hungary; CEA Grenoble, Dept Rech Fondamentale Mat Condensee, Serv Phys Mat & Microstruct, F-38054 Grenoble, France	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Wigner Research Centre for Physics; CEA	Tegze, M (corresponding author), Res Inst Solid State Phys & Opt, POB 49, H-1525 Budapest, Hungary.		Marchesini, Stefano/A-6795-2009; Marchesini, Stefano/GYR-1409-2022	Marchesini, Stefano/0000-0002-6798-2913; 				BARTON JJ, 1991, PHYS REV LETT, V67, P3106, DOI 10.1103/PhysRevLett.67.3106; Faigel G, 1999, REP PROG PHYS, V62, P355, DOI 10.1088/0034-4885/62/3/002; Gog T, 1996, PHYS REV LETT, V76, P3132, DOI 10.1103/PhysRevLett.76.3132; LEN PM, 1994, PHYS REV B, V50, P11275, DOI 10.1103/PhysRevB.50.11275; Szoke A., 1986, AIP Conference Proceedings, P361, DOI 10.1063/1.35963; TEGZE M, 1991, EUROPHYS LETT, V16, P41, DOI 10.1209/0295-5075/16/1/008; Tegze M, 1999, PHYS REV LETT, V82, P4847, DOI 10.1103/PhysRevLett.82.4847; Tegze M, 1996, NATURE, V380, P49, DOI 10.1038/380049a0	8	70	71	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					38	38		10.1038/35024153	http://dx.doi.org/10.1038/35024153			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993063				2022-12-28	WOS:000089124000031
J	Holy, TE; Dulac, C; Meister, M				Holy, TE; Dulac, C; Meister, M			Responses of vomeronasal neurons to natural stimuli	SCIENCE			English	Article							PUTATIVE PHEROMONE RECEPTORS; MULTIGENE FAMILY; SENSORY NEURONS; TRANSDUCTION; CELLS; ADAPTATION; MAMMALS; ORGAN; ACTIVATION; PATHWAY	The vomeronasal organ (VNO) of mammals plays an essential role in the detection of pheromones, We obtained simultaneous recordings of action potentials from Large subsets of VNO neurons. These cells responded to components of urine by increasing their firing rate. This chemosensory activation required phospholipase C function. Unlike most other sensory neurons, VNO neurons did not adapt under prolonged stimulus exposure, The full time course of the VNO spiking response is captured by a simple quantitative model of ligand binding. Many individual VNO neurons were strongly selective for either male or female mouse urine, with the effective concentrations differing as much as a thousandfold. These results establish a framework for understanding sensory coding in the vomeronasal system.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Holy, TE (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			Dulac, Catherine/0000-0001-5024-5418; Meister, Markus/0000-0003-2136-6506				Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Berghard A, 1996, J NEUROSCI, V16, P909; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Doving KB, 1998, J EXP BIOL, V201, P2913; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Inamura I, 1999, J PHYSIOL-LONDON, V517, P731, DOI 10.1111/j.1469-7793.1999.0731s.x; Inamura K, 1997, NEUROSCI LETT, V233, P129, DOI 10.1016/S0304-3940(97)00655-1; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liman ER, 1996, J NEUROSCI, V16, P4625; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McClintic J., 1978, PHYSL HUMAN BODY; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEREDITH M, 1994, PHYSIOL BEHAV, V56, P345, DOI 10.1016/0031-9384(94)90205-4; Moss RL, 1998, CHEM SENSES, V23, P483, DOI 10.1093/chemse/23.4.483; Moss RL, 1997, J NEUROPHYSIOL, V77, P2856, DOI 10.1152/jn.1997.77.5.2856; Reisert J, 1999, J PHYSIOL-LONDON, V519, P801, DOI 10.1111/j.1469-7793.1999.0801n.x; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Torre V, 1995, J NEUROSCI, V15, P7757; WYSOCKI CJ, 1991, J STEROID BIOCHEM, V39, P661, DOI 10.1016/0960-0760(91)90265-7	25	204	209	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1569	1572		10.1126/science.289.5484.1569	http://dx.doi.org/10.1126/science.289.5484.1569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968796				2022-12-28	WOS:000089071700052
J	Rodan, GA; Martin, TJ				Rodan, GA; Martin, TJ			Therapeutic approaches to bone diseases	SCIENCE			English	Review							SUPPORT OSTEOCLAST FORMATION; HORMONE-RELATED PROTEIN; RESORPTION IN-VITRO; BREAST-CANCER CELLS; PARATHYROID-HORMONE; POSTMENOPAUSAL WOMEN; CALCITONIN RECEPTOR; RANDOMIZED TRIAL; MINERAL DENSITY; ALPHA(V)BETA(3) INTEGRIN	The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture, A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far Less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.	Merck Res Labs, West Point, PA 19486 USA; St Vincents Inst Med Res, Melbourne, Vic 3065, Australia	Merck & Company; St. Vincent's Institute of Medical Research	Rodan, GA (corresponding author), Merck Res Labs, West Point, PA 19486 USA.	gideon_rodan@merck.com						Athanasou NA, 1999, HISTOL HISTOPATHOL, V14, P635, DOI 10.14670/HH-14.635; AZRIA M, 1995, CALCIFIED TISSUE INT, V57, P405, DOI 10.1007/BF00301940; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; Bossard MJ, 1999, BIOCHEMISTRY-US, V38, P15893, DOI 10.1021/bi991193+; Capparelli C, 2000, CANCER RES, V60, P783; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; Cooper Cyrus, 1996, P419; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Cummings SR, 2000, JAMA-J AM MED ASSOC, V283, P3255, DOI 10.1001/jama.283.24.3255; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Dunstan CR, 2000, ENDOCRINOLOGIST, V10, P18, DOI 10.1097/00019616-200010010-00005; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Farina C, 1999, DRUG DISCOV TODAY, V4, P163, DOI 10.1016/S1359-6446(99)01321-5; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; FRATZL P, 1994, J BONE MINER RES, V9, P1541; Frost HM, 1998, AM J HUM BIOL, V10, P599, DOI 10.1002/(SICI)1520-6300(1998)10:5<599::AID-AJHB6>3.0.CO;2-9; Giguere Y, 2000, CLIN GENET, V57, P161, DOI 10.1034/j.1399-0004.2000.570301.x; Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Harada S I, 1995, Connect Tissue Res, V31, P279, DOI 10.3109/03008209509010823; Hiraga T, 1998, EUR J CANCER, V34, P230, DOI 10.1016/S0959-8049(97)10131-9; Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999; Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333; Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALU DN, 1990, MECH AGEING DEV, V56, P49, DOI 10.1016/0047-6374(90)90114-U; KING KL, 1994, J BONE MINER RES, V9, P381; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kotake S, 1996, J BONE MINER RES, V11, P88; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurihara N, 2000, J CLIN INVEST, V105, P607, DOI 10.1172/JCI8489; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Liberman UA, 1996, NEW ENGL J MED, V334, P734; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARTIN TJ, 1998, METABOLIC BONE DIS C, P95; Masarachia P, 1998, ENDOCRINOLOGY, V139, P1401, DOI 10.1210/en.139.3.1401; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; MESSER HH, 1974, P SOC EXP BIOL MED, V146, P643; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; MILLS BG, 1984, CLIN ORTHOP RELAT R, P303; MOSEKILDE L, 1995, BONE, V16, P223, DOI 10.1016/8756-3282(94)00033-V; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; MUNDY GR, 2000, HDB EXP PHARM, V107, P641; NEER RM, 2000, EMDO 2000; Nemeth EF, 1999, TRENDS ENDOCRIN MET, V10, P66, DOI 10.1016/S1043-2760(98)00119-2; Nguyen TV, 2000, J BONE MINER RES, V15, P392, DOI 10.1359/jbmr.2000.15.3.392; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; RAISZ LG, 1972, EXCERPTA MED INT C S, V243, P446; RAKOPOULOS M, 1995, BONE, V17, P447, DOI 10.1016/8756-3282(95)00280-8; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RODAN GA, 2000, SKELETAL GROWTH FACT; Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8; Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T; Sato M, 1999, J MED CHEM, V42, P1, DOI 10.1021/jm980344o; Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo-16-5-547; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHBY J, 1990, CANCER RES, V50, P7710; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tashjian A H Jr, 1978, Recent Prog Horm Res, V34, P285; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; VIOLETTE SM, 2000, P NATL ACAD SCI USA, V97, P9373; Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145; Wada S, 1996, ENDOCRINOLOGY, V137, P312, DOI 10.1210/en.137.1.312; WADA S, 1994, J BONE MINER RES, V9, P1705; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Yamamoto M, 1998, ENDOCRINOLOGY, V139, P1411, DOI 10.1210/en.139.3.1411; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 1998, EUR J CANCER, V34, P240, DOI 10.1016/S0959-8049(97)10132-0	101	1360	1490	7	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1508	1514		10.1126/science.289.5484.1508	http://dx.doi.org/10.1126/science.289.5484.1508			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968781				2022-12-28	WOS:000089071700037
J	Loder, N				Loder, N			Cambridge seeks 1.6 pound million to buy Newton's papers	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					924	924		10.1038/35023304	http://dx.doi.org/10.1038/35023304			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984021	Bronze			2022-12-28	WOS:000089020200005
J	Waldvogel, D; van Gelderen, P; Muellbacher, W; Ziemann, U; Immisch, I; Hallett, M				Waldvogel, D; van Gelderen, P; Muellbacher, W; Ziemann, U; Immisch, I; Hallett, M			The relative metabolic demand of inhibition and excitation	NATURE			English	Article							CEREBRAL BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; PRESUPPLEMENTARY MOTOR AREA; FINGER MOVEMENTS; NORMAL VALUES; STIMULATION; BRAIN; CORTEX; ACTIVATION; CELLS	By using the (C-14)2-deoxyglucose method(1), inhibition has been shown to be a metabolically active process at the level of the synapse(2,3). This is supported by recent results from magnetic resonance spectroscopy that related the changes in neuroenergetics occurring with functional activation to neurotransmitter cycling(4). However, inhibitory synapses are less numerous and strategically better located than excitatory synapses, indicating that inhibition may be more efficient, and therefore less energy-consuming, than excitation. Here we test this hypothesis using event-related functional magnetic resonance imaging in volunteers whose motor cortex was inhibited during the no-go condition of a go/no-go task, as demonstrated by transcranial magnetic stimulation. Unlike excitation, inhibition evoked no measurable change in the blood-oxygenation-level-dependent signal in the motor cortex, indicating that inhibition is less metabolically demanding. Therefore, the 'activation' seen in functional imaging studies probably results from excitation rather than inhibition.	NINDS, Human Motor Control Sect, NIH, Bethesda, MD 20892 USA; NINDS, In Vivo NMR Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Hallett, M (corresponding author), NINDS, Human Motor Control Sect, NIH, Bldg 10,10 Ctr Dr, Bethesda, MD 20892 USA.		van Gelderen, Peter/U-4535-2019; Ziemann, Ulf/AAY-9125-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002669, Z01NS002669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN RF, 1984, J NEUROSCI, V4, P251; BEAULIEU C, 1985, J COMP NEUROL, V231, P180, DOI 10.1002/cne.902310206; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; DEFELIPE J, 1992, PROG NEUROBIOL, V39, P563, DOI 10.1016/0301-0082(92)90015-7; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; FAIREN JD, 1984, CEREB CORTEX, P201; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HALLETT M, 1975, J NEUROL NEUROSUR PS, V38, P1154, DOI 10.1136/jnnp.38.12.1154; Humberstone M, 1997, ANN NEUROL, V42, P632, DOI 10.1002/ana.410420414; Koos T, 1999, NAT NEUROSCI, V2, P467, DOI 10.1038/8138; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Leocani L, 2000, BRAIN, V123, P1161, DOI 10.1093/brain/123.6.1161; Mima T, 1999, BRAIN, V122, P1989, DOI 10.1093/brain/122.10.1989; NUDO RJ, 1986, J COMP NEUROL, V245, P553, DOI 10.1002/cne.902450410; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Peters A., 1991, FINE STRUCTURE NERVO; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; RAICHLE ME, 1981, FED PROC, V40, P2331; Raichle ME, 1998, P NATL ACAD SCI USA, V95, P765, DOI 10.1073/pnas.95.3.765; Rees G, 1997, NEUROIMAGE, V6, P270, DOI 10.1006/nimg.1997.0300; Rosler KM, 1999, NEUROREPORT, V10, P579; Rothman DL, 1999, PHILOS T R SOC B, V354, P1165, DOI 10.1098/rstb.1999.0472; Shima K, 1996, P NATL ACAD SCI USA, V93, P8694, DOI 10.1073/pnas.93.16.8694; Silva AC, 1999, J CEREBR BLOOD F MET, V19, P871, DOI 10.1097/00004647-199908000-00006; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; THAVENAZ P, 1995, P IEEE INT C IM PROC, V3, P228; VANGELDEREN P, 1995, P NATL ACAD SCI USA, V92, P6906, DOI 10.1073/pnas.92.15.6906; Weeks RA, 1999, EXP BRAIN RES, V128, P291, DOI 10.1007/s002210050849; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	30	221	223	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					995	998		10.1038/35023171	http://dx.doi.org/10.1038/35023171			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984053				2022-12-28	WOS:000089020200045
J	Schneggenburger, R; Neher, E				Schneggenburger, R; Neher, E			Intracellular calcium dependence of transmitter release rates at a fast central synapse	NATURE			English	Article							BOVINE CHROMAFFIN CELLS; NEUROTRANSMITTER RELEASE; FLASH-PHOTOLYSIS; CA2+ BINDING; TIME-COURSE; CAGED CA2+; CHELATORS; CNS; DESENSITIZATION; RECEPTORS	Calcium-triggered fusion of synaptic vesicles and neurotransmitter release are fundamental signalling steps in the central nervous system. It is generally assumed that fast transmitter release is triggered by elevations in intracellular calcium concentration ([Ca2+](i)) to at least 100 mu M near the sites of vesicle fusion(1-5). For synapses in the central nervous system, however, there are no experimental estimates of this local [Ca2+](i) signal. Here we show, by using calcium ion uncaging in the large synaptic terminals of the calyx of Held, that step-like elevations to only 10 mu M [Ca2+](i) induce fast transmitter release, which depletes around 80% of a pool of available vesicles in less than 3 ms. Kinetic analysis of transmitter release rates after [Ca2+](i) steps revealed the rate constants for calcium binding and vesicle fusion. These show that transient (around 0.5 ms) local elevations of [Ca2+](i) to peak values as low as 25 mu M can account for transmitter release during single presynaptic action potentials. The calcium sensors for vesicle fusion are far from saturation at normal release probability. This non-saturation, and the high intracellular calcium cooperativity in triggering vesicle fusion, make fast synaptic transmission very sensitive to modulation by changes in local [Ca2+](i).	Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany	Max Planck Society	Schneggenburger, R (corresponding author), Max Planck Inst Biophys Chem, Abt Membranbiophys, Fassberg 11, D-37077 Gottingen, Germany.	rschneg@gwdg.de	Neher, Erwin/A-2109-2013					ADLER EM, 1991, J NEUROSCI, V11, P1496; BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; DIAMOND JS, 1995, NEURON, V15, P1097, DOI 10.1016/0896-6273(95)90098-5; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; Lagnado L, 1996, NEURON, V17, P957, DOI 10.1016/S0896-6273(00)80226-3; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Naraghi M, 1998, BIOPHYS J, V75, P1635, DOI 10.1016/S0006-3495(98)77606-4; Ohana O, 1998, J PHYSIOL-LONDON, V513, P135, DOI 10.1111/j.1469-7793.1998.135by.x; ROBERTS WM, 1994, J NEUROSCI, V14, P3246; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; Traynelis SF, 1998, J NEUROSCI METH, V86, P25, DOI 10.1016/S0165-0270(98)00140-X; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VANDERKLOOT W, 1988, J PHYSIOL-LONDON, V402, P595, DOI 10.1113/jphysiol.1988.sp017224; Wu LG, 1999, NEURON, V23, P821, DOI 10.1016/S0896-6273(01)80039-8; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; Xu-Friedman MA, 1999, BIOPHYS J, V76, P2029, DOI 10.1016/S0006-3495(99)77360-1; YAMADA KA, 1993, J NEUROSCI, V13, P3904; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	31	541	547	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					889	893		10.1038/35022702	http://dx.doi.org/10.1038/35022702			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972290	Green Published			2022-12-28	WOS:000088903600044
J	Zheng, LL; Sekerkova, G; Vranich, K; Tilney, LG; Mugnaini, E; Bartles, JR				Zheng, LL; Sekerkova, G; Vranich, K; Tilney, LG; Mugnaini, E; Bartles, JR			The deaf jerker mouse has a mutation in the gene encoding the espin actin-bundling proteins of hair cell stereocilia and lacks espins	CELL			English	Article							INNER-EAR; UNCONVENTIONAL MYOSIN; INSITU HYBRIDIZATION; LOCALIZATION; TRANSDUCTION; IDENTIFICATION; COCHLEA; MUTANT; CHICK; MICE	The espins are actin-bundling proteins of brush border microvilli and Sertoli cell-spermatid junctions. We have determined that espins are also present in hair cell stereocilia and have uncovered a connection between the espin gene and jerker, a recessive mutation that causes hair cell degeneration, deafness, and vestibular dysfunction. The espin gene maps to the same region of mouse chromosome 4 as jerker. The tissues of jerker mice do not accumulate espin proteins but contain normal levels of espin mRNAs. The espin gene of jerker mice has a frameshift mutation that affects the espin C-terminal actin-bundling module. These data suggest that jerker mice are, in effect, espin null and that the jerker phenotype results from a mutation in the espin gene.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Northwestern University; Northwestern University; University of Pennsylvania	Bartles, JR (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	j-bartles@northwestern.edu		Bartles, James/0000-0002-7056-3875	NICHD NIH HHS [HD01210, HD35280, K02 HD001210-04] Funding Source: Medline; NIDCD NIH HHS [DC04314, R01 DC004314-01, R01 DC004314] Funding Source: Medline; NIGMS NIH HHS [R37 GM052857, R37 GM052857-23] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001210, R01HD035280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004314] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANNIKO M, 1989, ARCH OTO-RHINO-LARYN, V246, P43, DOI 10.1007/BF00454133; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bartles JR, 2000, CURR OPIN CELL BIOL, V12, P72, DOI 10.1016/S0955-0674(99)00059-9; Bartles JR, 1996, J CELL SCI, V109, P1229; Bartles JR, 1998, J CELL BIOL, V143, P107, DOI 10.1083/jcb.143.1.107; Chen B, 1999, MOL BIOL CELL, V10, P4327, DOI 10.1091/mbc.10.12.4327; Denk W, 1995, NEURON, V15, P1311, DOI 10.1016/0896-6273(95)90010-1; DEOL MS, 1954, J GENET, V52, P562, DOI 10.1007/BF02985081; Eatock RA, 1998, OTOLARYNG HEAD NECK, V119, P172, DOI 10.1016/S0194-5998(98)70052-X; EHRET G, 1977, J ACOUST SOC AM, V62, P143, DOI 10.1121/1.381496; FLOCK A, 1982, HEARING RES, V7, P75, DOI 10.1016/0378-5955(82)90082-X; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gruneberg H, 1941, P NATL ACAD SCI USA, V27, P562, DOI 10.1073/pnas.27.12.562; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; KALTENBACH JA, 1994, J COMP NEUROL, V350, P187, DOI 10.1002/cne.903500204; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIM DJ, 1986, HEARING RES, V22, P117, DOI 10.1016/0378-5955(86)90089-4; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; Lumpkin EA, 1998, J NEUROSCI, V18, P6300; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; OHMORI H, 1988, J PHYSIOL-LONDON, V399, P115; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Probst FJ, 1999, HEARING RES, V130, P1, DOI 10.1016/S0378-5955(98)00231-7; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROBERTS WM, 1988, ANNU REV CELL BIOL, V4, P63, DOI 10.1146/annurev.cb.04.110188.000431; SJOSTROM B, 1992, ACTA OTO-LARYNGOL, P141; SJOSTROM B, 1990, EUR ARCH OTO-RHINO-L, V247, P51; SJOSTROM B, 1990, ACTA OTO-LARYNGOL, V109, P353, DOI 10.3109/00016489009125155; SJOSTROM B, 1992, ORL J OTO-RHINO-LARY, V54, P220; SOBIN A, 1983, ACTA OTO-LARYNGOL, V96, P407, DOI 10.3109/00016488309132726; Steel KP, 1995, ANNU REV GENET, V29, P675; Steel KP, 1997, ANN OTO RHINOL LARYN, V106, P59; STEEL KP, 1983, BEHAV NEUROSCI, V97, P381, DOI 10.1037/0735-7044.97.3.381; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; TILNEY MS, 1989, J CELL BIOL, V109, P1711, DOI 10.1083/jcb.109.4.1711; Truett GE, 1996, MAMM GENOME, V7, P356, DOI 10.1007/s003359900103	40	208	215	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					377	385		10.1016/S0092-8674(00)00042-8	http://dx.doi.org/10.1016/S0092-8674(00)00042-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975527	Green Accepted, Bronze			2022-12-28	WOS:000088625600012
J	Stebbing, J; Copson, E; Al-Nasiri, N; Giu, GPH				Stebbing, J; Copson, E; Al-Nasiri, N; Giu, GPH			A pregnant breast lump	LANCET			English	Article							LYMPHATIC FILARIASIS		Royal Marsden Hosp, Acad Dept Med, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Stebbing, J (corresponding author), Royal Marsden Hosp, Acad Dept Med, London SW3 6JJ, England.			Stebbing, Justin/0000-0002-1117-6947				Burri H, 1996, T ROY SOC TROP MED H, V90, P671, DOI 10.1016/S0035-9203(96)90428-9; Cunningham NM, 1997, AM FAM PHYSICIAN, V55, P1199; Kapila K, 1996, ACTA CYTOL, V40, P653, DOI 10.1159/000333934; Kazura JW, 1997, J INFECT DIS, V176, P242, DOI 10.1086/514030; NICHOLAS L, 1997, B I PASTEUR, V95, P237	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					396	396		10.1016/S0140-6736(00)02532-0	http://dx.doi.org/10.1016/S0140-6736(00)02532-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972373				2022-12-28	WOS:000088486000013
J	Vernino, S; Low, PA; Fealey, RD; Stewart, JD; Farrugia, G; Lennon, VA				Vernino, S; Low, PA; Fealey, RD; Stewart, JD; Farrugia, G; Lennon, VA			Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYASTHENIA-GRAVIS; TACHYCARDIA SYNDROME; NERVOUS-SYSTEM; ANTIBODIES; THYMOMA; PSEUDOOBSTRUCTION; DYSAUTONOMIA; RECOVERY; DISEASE	Background: Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy. Methods: We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors. Results: Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy. Conclusions: Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy. (N Engl J Med 2000;343:847-55.) (C) 2000, Massachusetts Medical Society.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; McGill Univ, Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, Montreal, PQ, Canada	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; McGill University	Vernino, S (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	verns@mayo.edu	Vernino, Steven/AAD-5181-2020	Vernino, Steven/0000-0001-7799-8495				Anderson NE, 1996, NEUROLOGY, V47, P985, DOI 10.1212/WNL.47.4.985; BESINGER UA, 1983, NEUROLOGY, V33, P1316, DOI 10.1212/WNL.33.10.1316; Bohnen Nicolaas I., 1997, Neurology, V48, pA131; Bradbury S, 1925, AM HEART J, V1, P73, DOI 10.1016/S0002-8703(25)90007-5; CAMILLERI M, 1990, DIGEST DIS SCI, V35, P609, DOI 10.1007/BF01540409; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; FEALEY RD, 1989, MAYO CLIN PROC, V64, P617, DOI 10.1016/S0025-6196(12)65338-5; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; GRIESMANN GE, 1997, MANUAL CLIN LAB IMMU, P983; Hart IK, 1997, ANN NEUROL, V41, P238, DOI 10.1002/ana.410410215; HOWARD FM, 1987, ANN NY ACAD SCI, V505, P526, DOI 10.1111/j.1749-6632.1987.tb51321.x; KHURANA RK, 1997, CLIN AUTONOMIC DISOR, P545; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LENNON VA, 1991, GASTROENTEROLOGY, V100, P137, DOI 10.1016/0016-5085(91)90593-A; LENNON VA, 1996, TXB AUTOANTIBODIES, P139; Lennon Vanda A., 1997, Neurology, V48, pS23; Low PA, 1997, MUSCLE NERVE, V20, P1561, DOI 10.1002/(SICI)1097-4598(199712)20:12<1561::AID-MUS11>3.0.CO;2-3; LOW PA, 1993, J CLIN NEUROPHYSIOL, V10, P14, DOI 10.1097/00004691-199301000-00003; LOW PA, 1993, MAYO CLIN PROC, V68, P748, DOI 10.1016/S0025-6196(12)60631-4; LOW PA, 1997, CLIN AUTONOMIC DISOR, P463; Lucchinetti CF, 1998, NEUROLOGY, V50, P652, DOI 10.1212/WNL.50.3.652; RUST G, 1994, EUR J NEUROSCI, V6, P478, DOI 10.1111/j.1460-9568.1994.tb00290.x; Sandroni P, 1999, MAYO CLIN PROC, V74, P1106, DOI 10.4065/74.11.1106; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132; SHY GM, 1960, ARCH NEUROL-CHICAGO, V2, P511, DOI 10.1001/archneur.1960.03840110025004; SKOK VI, 1987, J AUTONOM NERV SYST, V21, P91, DOI 10.1016/0165-1838(87)90012-9; Smit AAJ, 1997, MAYO CLIN PROC, V72, P333, DOI 10.4065/72.4.333; SUAREZ GA, 1994, NEUROLOGY, V44, P1675, DOI 10.1212/WNL.44.9.1675; TABBAA MA, 1986, ARCH NEUROL-CHICAGO, V43, P955, DOI 10.1001/archneur.1986.00520090079023; Venkataraman S, 1998, NEUROLOGY, V51, P1764, DOI 10.1212/WNL.51.6.1764; Vernino S, 1998, NEUROLOGY, V50, P1806, DOI 10.1212/WNL.50.6.1806; Vernino S, 2000, ANN NEUROL, V47, P297, DOI 10.1002/1531-8249(200003)47:3<297::AID-ANA4>3.3.CO;2-W; Vernino S, 1999, NEUROLOGY, V53, P1233, DOI 10.1212/WNL.53.6.1233; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; YOUNG RR, 1975, BRAIN, V98, P613, DOI 10.1093/brain/98.4.613; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311	36	445	453	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					847	855		10.1056/NEJM200009213431204	http://dx.doi.org/10.1056/NEJM200009213431204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995864				2022-12-28	WOS:000089355600004
J	Nishime, EO; Cole, CR; Blackstone, EH; Pashkow, FJ; Lauer, MS				Nishime, EO; Cole, CR; Blackstone, EH; Pashkow, FJ; Lauer, MS			Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; MEDICALLY TREATED PATIENTS; CHRONOTROPIC INCOMPETENCE; PROGNOSTIC INFORMATION; MYOCARDIAL-INFARCTION; VITAL STATUS; DEATH; ASSOCIATION; SURVIVAL	Context Both attenuated heart rate recovery following exercise and the Duke tread mill exercise score have been demonstrated to be independent predictors of mortality, belt their prognostic value relative to each other has not been studied. Objective To assess the associations among abnormal heart rate recovery, treadmill exercise score, and death in patients referred specifically for exercise electrocardiography. Design and Setting Prospective cohort study conducted in an academic medical center between September 1990 and December 1997, with a median follow-up of 5.2 years. Patients A total of 9454 consecutive patients (mean [SD] age, 53 [11] years; 78% male) who underwent symptom-limited exercise electrocardiographic testing. Exclusion criteria included age younger than 30 years, history of heart failure or valvular disease, pacemaker implantation, and uninterpretable electrocardiograms. Main Outcome Measures All-cause mortality, as predicted by abnormal heart rate recovery, defined as failure of heart rate to decrease by more than 12/min during the first minute after peak exercise, and by treadmill exercise score, defined as (exercise time) - (5 x maximum ST-segment deviation) - (4 x treadmill angina index). Results Three hundred twelve deaths occurred in the cohort. Abnormal heart rate recovery and intermediate- or high-risk treadmill exercise score were present in 20% (n =1852) and 21% (n =1996) of patients. respectively. in univariate analyses, death was predicted by both abnormal heart rate recovery (8% vs 2% in patients with normal heart rate recovery; hazard ratio [HR], 4.16; 95% confidence interval [CI], 3.33-5.19; chi(2)=158; P<.001) and intermediate- or high-risk treadmill exercise score (8% vs 2% in patients with low-risk scores; HR, 4.28; 95% CI, 3.43-5.35; chi(2)=164; P<.001). After adjusting for age, sex, standard cardiovascular risk factors, medication use, and other potential confounders, abnormal heart rate recovery remained predictive of death (among the 8549 patients not taking p-blockers, adjusted HR, 2.13; 95% CI, 1.63-2.78; P<.001), as did intermediate- or high-risk treadmill exercise score (adjusted HR, 1.49, 95% CI, 2.15-1.92; P=.002). There was no interaction between these 2 predictors. Conclusions in this cohort of patients referred specifically for exercise electrocardiography, both abnormal heart rate recovery and treadmill exercise score were independent predictors of mortality. Heart rate recovery appears to provide additional prognostic information to the established treadmill exercise score and should be considered for routine incorporation into exercise test interpretation.	Cleveland Clin Fdn, Dept Cardiol, Clin Res & Exercise Lab, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Clin Res & Exercise Lab, Desk F25, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				ARAI Y, 1989, AM J PHYSIOL, V256, pH132, DOI 10.1152/ajpheart.1989.256.1.H132; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; Chen SC, 1999, ADV POLYM TECH, V18, P1, DOI 10.1002/(SICI)1098-2329(199921)18:1<1::AID-ADV1>3.0.CO;2-0; Cole CR, 2000, ANN INTERN MED, V132, P552, DOI 10.7326/0003-4819-132-7-200004040-00007; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HUBBARD BL, 1992, ARCH INTERN MED, V152, P309, DOI 10.1001/archinte.152.2.309; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kwok JMF, 1999, JAMA-J AM MED ASSOC, V282, P1047, DOI 10.1001/jama.282.11.1047; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; Lauer MS, 1997, CIRCULATION, V96, P897; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lauer MS, 1996, CIRCULATION, V93, P1520, DOI 10.1161/01.CIR.93.8.1520; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; Lauer MS, 1998, LANCET, V351, P615, DOI 10.1016/S0140-6736(97)07062-1; Lauer MS, 1998, J AM COLL CARDIOL, V32, P1280, DOI 10.1016/S0735-1097(98)00377-5; LUWAERT RJ, 1988, EUR HEART J, V9, P418, DOI 10.1093/oxfordjournals.eurheartj.a062519; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MORROW K, 1993, ANN INTERN MED, V118, P689, DOI 10.7326/0003-4819-118-9-199305010-00005; Newman TB, 1997, J AM MED INFORM ASSN, V4, P233, DOI 10.1136/jamia.1997.0040233; Pilote L, 1998, AM J CARDIOL, V81, P219, DOI 10.1016/S0002-9149(97)00871-0; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837	33	493	524	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1392	1398		10.1001/jama.284.11.1392	http://dx.doi.org/10.1001/jama.284.11.1392			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989401	Bronze			2022-12-28	WOS:000089242500033
J	Moayyedi, P; Soo, S; Deeks, J; Forman, D; Mason, J; Innes, M; Delaney, BN				Moayyedi, P; Soo, S; Deeks, J; Forman, D; Mason, J; Innes, M; Delaney, BN		Dyspepsia Rev Grp	Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia	BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; NONULCER DYSPEPSIA; FUNCTIONAL DYSPEPSIA; DOUBLE-BLIND; DUODENAL-ULCER; BENEFIT; INFECTION; SYMPTOMS; METAANALYSIS; CIMETIDINE	Objectives To evaluate efficacy and cost effectiveness of Helicobacter pylori eradication treatment in patients with non-ulcer dyspepsia infected with H pylori. Design Systematic review of randomised controlled trials comparing H pylori eradication with placebo or another drug treatment Results were incorporated into a Markov model comparing health service costs and benefits of H pylori eradication with antacid treatment over one year. Data sources Six electronic databases were searched for randomised controlled trials from January 1966 to May 2000. Experts in the field, pharmaceutical companies, and journals were contacted for information on any unpublished trials. Trial reports were reviewed according to predefined eligibility and quality criteria. Main outcome measures Relative risk reduction for remaining dyspeptic symptoms (the same or worse) at 3-12 months. Cost per dyspepsia-free month estimated from Markov model based on estimated relative risk reduction. Results Twelve trials were included in the systematic review, nine of which evaluated dyspepsia at 3-12 months in 2541 patients. H pylori eradication treatment was significantly superior to placebo in treating non-ulcer dyspepsia (relative risk reduction 9% (95% confidence interval 4% to 14%)), one case of dyspepsia being cured for every 15 people treated. H pylori eradication cost pound 56 per dyspepsia-free month during first year after treatment Conclusion H pylori eradication may he cost effective treatment for non-ulcer dyspepsia in infected patients but further evidence is needed on decision makers' willingness to pay for relief of dyspepsia.	Univ Birmingham, Sch Med, Dept Gen Practice, Birmingham B15 2TT, W Midlands, England; Gen Infirm, Ctr Digest Dis, Gastroenterol Unit, Leeds LS1 3EX, W Yorkshire, England; Imperial Canc Res Fund, NHS Ctr Stat Med, Inst Hlth Sci, Systemat Review Dev Programme, Oxford OX3 7LF, England; Univ Leeds, Cochrane Upper Gastrointestinal & Pancreat Dis Gr, Leeds LS2 9LN, W Yorkshire, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Birmingham; Leeds General Infirmary; University of Leeds; University of Oxford; University of Leeds; University of York - UK	Delaney, BN (corresponding author), Univ Birmingham, Sch Med, Dept Gen Practice, Birmingham B15 2TT, W Midlands, England.		Mason, James M/D-9904-2011; Delaney, Brendan C/C-5578-2008; Deeks, Jon/AAV-5745-2020; Moayyedi, Paul/M-6178-2014	Mason, James M/0000-0001-9210-4082; Deeks, Jon/0000-0002-8850-1971; Moayyedi, Paul/0000-0002-3616-9292; Delaney, Brendan/0000-0002-3518-0131				Axon A, 1997, BRIT MED J, V314, P1430, DOI 10.1136/bmj.314.7092.1430; BATE CM, 1992, BR J MED EC, V2, P5; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; British Medical Association Royal Pharmaceutical Society of Great Britain, 1999, BRIT NATL FORMULARY; COLINJONES DG, 1988, LANCET, V1, P576; Danesh J, 2000, LANCET, V355, P766, DOI 10.1016/S0140-6736(00)90005-9; DELANEY BC, 1999, GUT, V45, pA87; des Varannes SB, 2000, GASTROENTEROLOGY, V118, pA468, DOI 10.1016/S0016-5085(00)83986-4; Dhali GK, 1999, J GASTROEN HEPATOL, V14, P523, DOI 10.1046/j.1440-1746.1999.01909.x; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Froehlich F, 2000, GASTROENTEROLOGY, V118, pA469, DOI 10.1016/S0016-5085(00)83994-3; GIBINSKI K, 1983, J CLIN GASTROENTEROL, V5, P299; Gray AM, 1999, HLTH TECHNOL ASSESS, V3; Greenberg PD, 1999, ARCH INTERN MED, V159, P2283, DOI 10.1001/archinte.159.19.2283; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; ISENBERG JI, 1983, NEW ENGL J MED, V308, P1319, DOI 10.1056/NEJM198306023082203; Jaakkimainen RL, 1999, BMJ-BRIT MED J, V319, P1040, DOI 10.1136/bmj.319.7216.1040; Koelz HR, 1998, GASTROENTEROLOGY, V114, pA182, DOI 10.1016/S0016-5085(98)80741-5; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; Laine L, 2000, GASTROENTEROLOGY, V118, pA440, DOI 10.1016/S0016-5085(00)83874-3; Malfertheiner P, 2000, GASTROENTEROLOGY, V118, pA440, DOI 10.1016/S0016-5085(00)83873-1; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; McColl KEL, 1999, BRIT MED J, V319, P451, DOI 10.1136/bmj.319.7207.451; Miwa H, 2000, ALIMENT PHARM THERAP, V14, P317; Moayyedi P, 1998, BRIT MED BULL, V54, P243; Netten A, 1998, UNIT COSTS HLTH SOCI; NYREN O, 1986, NEW ENGL J MED, V314, P339, DOI 10.1056/NEJM198602063140603; Sheu BS, 1996, AM J GASTROENTEROL, V91, P441; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; Talley NJ, 1999, NEW ENGL J MED, V341, P1106, DOI 10.1056/NEJM199910073411502; Talley NJ, 1997, GASTROENTEROLOGY, V113, pS67, DOI 10.1016/S0016-5085(97)80016-9; TALLEY NJ, 1998, DIGESTION, V59, P7; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660	38	257	276	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					659	664		10.1136/bmj.321.7262.659	http://dx.doi.org/10.1136/bmj.321.7262.659			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987767	Bronze, Green Published			2022-12-28	WOS:000089444100020
J	Allen, P				Allen, P			Accountability for clinical governance: developing collective responsibility for quality in primary care	BRITISH MEDICAL JOURNAL			English	Article							MODEL		Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Allen, P (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.			Allen, Pauline/0000-0001-5598-1684				Baker R, 1999, BRIT MED J, V318, P779, DOI 10.1136/bmj.318.7186.779; Beecham L, 2000, BRIT MED J, V320, P401; *CASTL HLTH CTR, 1994, ANN REP 1993 94; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Goodwin N, 2000, DYNAMICS PRIMARY CAR; HUNTINGTON J, 2000, IN PRESS BMJ, V321; *LEAT D, 1988, VOL ORG ACC; LONGLEY D, 1992, PUBLIC LAW HLTH SERV; Malcolm L, 1999, BRIT MED J, V319, P1340, DOI 10.1136/bmj.319.7221.1340; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; *NHS EX, 1998, NEW NHS MOD DEP NAT; *NHS EX, 1998, 1998139 NHSE HSC; PUGNER K, 1998, BR J HLTH CARE MANAG, V4, P4; Rosen R, 2000, BRIT MED J, V321, P551, DOI 10.1136/bmj.321.7260.551; *ROYAL COLL GEN PR, 1999, GOOD MED PRACT GEN P; *SECR STAT HLTH, 1999, SUPP DOCT PROT PAT C; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917	17	24	24	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					608	611		10.1136/bmj.321.7261.608	http://dx.doi.org/10.1136/bmj.321.7261.608			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977839	Bronze, Green Published			2022-12-28	WOS:000089243200022
J	Cherry, M				Cherry, M			Construction starts on largest telescope in the south	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					4	4		10.1038/35024226	http://dx.doi.org/10.1038/35024226			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993039	Bronze			2022-12-28	WOS:000089124000004
J	DiRita, VJ				DiRita, VJ			Genomics - Genomics happens	SCIENCE			English	Editorial Material							VIBRIO-CHOLERAE GENOME; PATHOGENICITY ISLAND; GENE-CLUSTER; EL-TOR; IDENTIFICATION; EPIDEMIC; BACTERIA; STRAINS; PILUS; TOXIN		Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	DiRita, VJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.							Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; BIK EM, 1995, EMBO J, V14, P209, DOI 10.1002/j.1460-2075.1995.tb06993.x; Champion GA, 1997, MOL MICROBIOL, V23, P323, DOI 10.1046/j.1365-2958.1997.2191585.x; Fullner KJ, 1999, INFECT IMMUN, V67, P1393, DOI 10.1128/IAI.67.3.1393-1404.1999; FULLNER KJ, 2000, GEN M AM SOC MICR LO; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Lin W, 1999, P NATL ACAD SCI USA, V96, P1071, DOI 10.1073/pnas.96.3.1071; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; Marsh JW, 1998, MOL MICROBIOL, V29, P1481, DOI 10.1046/j.1365-2958.1998.01031.x; Mazel D, 1998, SCIENCE, V280, P605, DOI 10.1126/science.280.5363.605; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Watnick PI, 1999, J BACTERIOL, V181, P3606, DOI 10.1128/JB.181.11.3606-3609.1999	19	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1488	1489		10.1126/science.289.5484.1488	http://dx.doi.org/10.1126/science.289.5484.1488			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10991736				2022-12-28	WOS:000089071700031
J	Munker, C; Weyer, S; Mezger, K; Rehkamper, M; Wombacher, F; Bischoff, A				Munker, C; Weyer, S; Mezger, K; Rehkamper, M; Wombacher, F; Bischoff, A			Nb-92-Zr-92 and the early differentiation history of planetary bodies	SCIENCE			English	Article							EARLY ARCHEAN CRUST; ISOTOPE EVIDENCE; SOLAR-SYSTEM; EVOLUTION; MANTLE; METEORITE; ZIRCONS; GNEISS; CONSTRAINTS; KOMATIITES	The niobium-92-zirconium-92 (Nb-92-Zr-92) extinct radioactive decay system (half-life of about 36 million years) can place new time constraints on early differentiation processes in the silicate portion of planets and meteorites. Zirconium isotope data show that Earth and the oldest Lunar rust have the same relative abundances of Zr-92 as chondrites. Zr-92 deficits in calcium-aluminum-rich inclusions from the Allende meteorite constrain the minimum value for the initial Nb-92/Nb-93 ratio of the solar system to 0.001. The absence of Zr-92 anomalies in terrestrial and lunar samples indicates that large silicate reservoirs on Earth and the moon (such as a magma ocean residue, a depleted mantle, or a crust) formed more than 50 million years after the oldest meteorites formed.	Univ Munster, Inst Mineral, Zent Lab Geochronol, D-48149 Munster, Germany; Univ Munster, Inst Planetol, D-48149 Munster, Germany	University of Munster; University of Munster	Munker, C (corresponding author), Univ Munster, Inst Mineral, Zent Lab Geochronol, Corrensstr 24, D-48149 Munster, Germany.	muenker@nwz.uni-muenster.de	Wombacher, Frank/L-9552-2019; Mezger, Klaus/D-9502-2011; Munker, Carsten/O-7606-2015; Weyer, Stefan/AAA-8827-2020	Wombacher, Frank/0000-0002-0755-8918; Mezger, Klaus/0000-0002-2443-8539; Munker, Carsten/0000-0001-6406-559X				Amelin Y, 1999, NATURE, V399, P252, DOI 10.1038/20426; APT KE, 1974, GEOCHIM COSMOCHIM AC, V38, P1485, DOI 10.1016/0016-7037(74)90100-8; BISCHOFF A, 1987, GEOCHIM COSMOCHIM AC, V51, P2733, DOI 10.1016/0016-7037(87)90153-0; Bischoff A, 1998, METEORIT PLANET SCI, V33, P1243, DOI 10.1111/j.1945-5100.1998.tb01309.x; Bischoff A., 1987, LUNAR PLANET SCI, V18, P81; BISCHOFF A, 1992, LUNAR PLANET SCI, V23, P107; Blichert-Toft J, 1999, EARTH PLANET SC LETT, V171, P439, DOI 10.1016/S0012-821X(99)00151-X; BOWRING SA, 1989, NATURE, V340, P222, DOI 10.1038/340222a0; CARLSON RW, 1988, EARTH PLANET SC LETT, V90, P119, DOI 10.1016/0012-821X(88)90095-7; FROUDE DO, 1983, NATURE, V304, P616, DOI 10.1038/304616a0; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Goldstein S. L., 1992, EOS T AM GEOPHYS UN, V73, P323; GOLDSTEIN SL, 1984, EARTH PLANET SC LETT, V70, P221, DOI 10.1016/0012-821X(84)90007-4; GOPEL C, 1991, METEORITICS, V26, P338; Grossman JN, 1998, METEORIT PLANET SCI, V33, pA221, DOI 10.1111/j.1945-5100.1998.tb01336.x; Halliday AN, 1999, GEOCHIM COSMOCHIM AC, V63, P4157, DOI 10.1016/S0016-7037(99)00315-4; Harper CL, 1996, ASTROPHYS J, V466, P437, DOI 10.1086/177523; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; JOCHUM KP, 1986, GEOCHIM COSMOCHIM AC, V50, P1173, DOI 10.1016/0016-7037(86)90400-X; Kato T, 1996, PHYS EARTH PLANET IN, V96, P201, DOI 10.1016/0031-9201(96)03151-2; Kinny PD, 1996, PRECAMBRIAN RES, V78, P165, DOI 10.1016/0301-9268(95)00076-3; KINNY PD, 1986, EARTH PLANET SC LETT, V79, P337, DOI 10.1016/0012-821X(86)90190-1; KORNACKI AS, 1986, EARTH PLANET SC LETT, V79, P217, DOI 10.1016/0012-821X(86)90180-9; KRONER A, 1989, TECTONOPHYSICS, V161, P271, DOI 10.1016/0040-1951(89)90159-5; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; LOPEZMARTINEZ M, 1992, PRECAMBRIAN RES, V57, P91, DOI 10.1016/0301-9268(92)90095-6; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; MAAS R, 1991, GEOCHIM COSMOCHIM AC, V55, P1915, DOI 10.1016/0016-7037(91)90033-2; MAKINO T, 1977, GEOCHIM COSMOCHIM AC, V41, P1521, DOI 10.1016/0016-7037(77)90256-3; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; MINSTER JF, 1982, GEOCHIM COSMOCHIM AC, V46, P565, DOI 10.1016/0016-7037(82)90159-4; NETHAWAY DR, 1978, PHYS REV C, V17, P1409, DOI 10.1103/PhysRevC.17.1409; NOMURA M, 1983, INT J MASS SPECTROM, V50, P219, DOI 10.1016/0020-7381(83)80011-4; Sahoo SK, 1997, CHEM GEOL, V141, P117, DOI 10.1016/S0009-2541(97)00024-7; Shukolyukov A, 2000, LECT NOTES EARTH SCI, V91, P99; SNYDER GA, 1992, GEOCHIM COSMOCHIM AC, V56, P3809, DOI 10.1016/0016-7037(92)90172-F; Stewart B, 1996, EARTH PLANET SC LETT, V143, P1, DOI 10.1016/0012-821X(96)00124-0; Takeda H, 2000, GEOCHIM COSMOCHIM AC, V64, P1311, DOI 10.1016/S0016-7037(99)00434-2; TAYLOR SR, 1995, REV GEOPHYS, V33, P241, DOI 10.1029/95RG00262; Tredoux M, 1999, GEOLOGY, V27, P923, DOI 10.1130/0091-7613(1999)027<0923:URATCO>2.3.CO;2; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; Yin QZ, 2000, ASTROPHYS J, V536, pL49, DOI 10.1086/312718; Zipfel J, 1998, METEORIT PLANET SCI, V33, pA171	44	49	49	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1538	1542		10.1126/science.289.5484.1538	http://dx.doi.org/10.1126/science.289.5484.1538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968787				2022-12-28	WOS:000089071700043
J	Orwoll, E; Ettinger, M; Weiss, S; Miller, P; Kendler, D; Graham, J; Adami, S; Weber, K; Lorenc, R; Pietschmann, P; Vandormael, K; Lombardi, A; Adachi, JD; Bell, N; Body, JJ; Castro, A; Daifotis, A; Felsenberg, D; Gilchrist, N; Hoffman, A; Maricic, M; Rizzoli, R; Silverman, S; Valeriano, J				Orwoll, E; Ettinger, M; Weiss, S; Miller, P; Kendler, D; Graham, J; Adami, S; Weber, K; Lorenc, R; Pietschmann, P; Vandormael, K; Lombardi, A; Adachi, JD; Bell, N; Body, JJ; Castro, A; Daifotis, A; Felsenberg, D; Gilchrist, N; Hoffman, A; Maricic, M; Rizzoli, R; Silverman, S; Valeriano, J			Alendronate for the treatment of osteoporosis in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; VERTEBRAL FRACTURES; POSTMENOPAUSAL OSTEOPOROSIS; RANDOMIZED TRIAL; WOMEN; PREVENTION; THERAPY; RISK; PREVALENCE	Background Despite its association with disability, death, and increased medical costs, osteoporosis in men has been relatively neglected as a subject of study. There have been no large, controlled trials of treatment in men. Methods In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men ( age, 31 to 87 years; mean, 63) with osteoporosis. Approximately one third had low serum free testosterone concentrations at base line; the rest had normal concentrations. Men with other secondary causes of osteoporosis were excluded. All the men received calcium and vitamin D supplements. The main outcome measures were the percent changes in lumbar-spine, hip, and total-body bone mineral density. Results The men who received alendronate had a mean (+/- SE) increase in bone mineral density of 7.1 +/- 0.3 percent at the lumbar spine, 2.5 +/- 0.4 percent at the femoral neck, and 2.0 +/- 0.2 percent for the total body ( P<0.001 for all comparisons with base line). In contrast, men who received placebo had an increase in lumbar-spine bone mineral density of 1.8 +/- 0.5 percent (P<0.001 for the comparison with base line) and no significant changes in femoral-neck or total-body bone mineral density. The increase in bone mineral density in the alendronate group was greater than that in the placebo group at all measurement sites (P<0.001). The incidence of vertebral fractures was lower in the alendronate group than in the placebo group (0.8 percent vs. 7.1 percent, P=0.02). Men in the placebo group had a 2.4-mm decrease in height, as compared with a decrease of 0.6 mm in the alendronate group (P=0.02). Alendronate was generally well tolerated. Conclusions In men with osteoporosis, alendronate significantly increases spine, hip, and total-body bone mineral density and helps prevent vertebral fractures and decreases in height. (N Engl J Med 2000; 343:604-10.) (C) 2000, Massachusetts Medical Society.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Clin Res Ctr S Florida, Stuart, FL USA; San Diego Endocrine & Med Clin, San Diego, CA USA; Colorado Ctr Bone Res, Lakewood, CO USA; Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada; Ashford Specialist Ctr, Ashford, Australia; Univ Verona, I-37100 Verona, Italy; Graz Univ, Graz, Austria; Childrens Mem Inst, Warsaw, Poland; Univ Vienna, Vienna, Austria; Merck, Brussels, Belgium; Merck, Rahway, NJ USA	Oregon Health & Science University; Colorado Center For Bone Research; University of British Columbia; University of Verona; University of Graz; Children's Memorial Health Institute; University of Vienna; Merck & Company; Merck & Company	Orwoll, E (corresponding author), Oregon Hlth & Sci Univ, CR113,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Body, Jean-Jacques/G-9785-2015	Orwoll, Eric/0000-0002-8520-7355				Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; BARRETTCONNOR E, 1995, AM J MED, V98, pS3, DOI 10.1016/S0002-9343(05)80037-3; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BONE H, 1999, END SOC 81 ANN M JUN; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Eastell R, 1998, QJM-INT J MED, V91, P71, DOI 10.1093/qjmed/91.2.71; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Genant HK, 1997, J RHEUMATOL, V24, P1212; GENANT HK, 1994, J BONE MINER RES, V9, P1503; GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009-9236(95)90245-7; GLUER CC, 1993, OSTEOPOROSIS INT, V3, P227, DOI 10.1007/BF01623825; Herrala J, 1998, BONE, V22, P577, DOI 10.1016/S8756-3282(98)00051-9; Hochberg MC, 1999, ARTHRITIS RHEUM-US, V42, P1246, DOI 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; ONeill TW, 1996, J BONE MINER RES, V11, P1010; ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87; Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171; Reid D, 1999, J BONE MINER RES, V14, pS209; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RIGGS BL, 1993, NEW ENGL J MED, V328, P66; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SIRIS E, 1995, J BONE MINER RES, V10, pS299; SMITHBINDMAN R, 1991, J BONE MINER RES, V6, P25	25	638	673	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	2000	343	9					604	610		10.1056/NEJM200008313430902	http://dx.doi.org/10.1056/NEJM200008313430902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	348RE	10979796	Bronze			2022-12-28	WOS:000088999600002
J	de la Rubia, TD; Zbib, HM; Khraishi, TA; Wirth, BD; Victoria, M; Caturla, MJ				de la Rubia, TD; Zbib, HM; Khraishi, TA; Wirth, BD; Victoria, M; Caturla, MJ			Multiscale modelling of plastic flow localization in irradiated materials	NATURE			English	Article							ENERGY DISPLACEMENT CASCADES; MOLECULAR-DYNAMICS; COMPUTER-SIMULATION; INTERSTITIAL LOOPS; DEFECT PRODUCTION; SINGLE-CRYSTALS; METALS; DAMAGE; MICROSTRUCTURE; DISLOCATIONS	The irradiation of metals by energetic particles causes significant degradation of the mechanical properties(1,2), most notably an increased yield stress and decreased ductility, often accompanied by plastic flow localization. Such effects limit the lifetime of pressure vessels in nuclear power plants(3), and constrain the choice of materials for fusion-based alternative energy sources(4). Although these phenomena have been known for many years(1), the underlying fundamental mechanisms and their relation to the irradiation field have not been clearly demonstrated. Here we use three-dimensional multiscale simulations of irradiated metals to reveal the mechanisms underlying plastic flow localization in defect-free channels. We observe dislocation pinning by irradiation-induced clusters of defects, subsequent unpinning as defects are absorbed by the dislocations, and cross-slip of the latter as the stress is increased. The width of the plastic flow channels is limited by the interaction among opposing dislocation dipole segments and the remaining defect clusters.	Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Washington State Univ, Sch Mech & Mat Engn, Pullman, WA 99164 USA; EPFL, CRPP, CH-5232 Villigen, Switzerland	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Washington State University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	de la Rubia, TD (corresponding author), Lawrence Livermore Natl Lab, 7000 E Ave,L-353, Livermore, CA 94550 USA.	delarubia@llnl.gov	Caturla, Maria J/D-6241-2012; Wirth, Brian/O-4878-2015; Khraishi, Tariq/AGR-5867-2022	Caturla, Maria J/0000-0002-4809-6553; Wirth, Brian/0000-0002-0395-0285; Khraishi, Tariq/0000-0002-8423-2946				Averback RS, 1998, SOLID STATE PHYS, V51, P281; Baluc N, 1999, MATER RES SOC SYMP P, V540, P555; Baluc N, 1999, MATER RES SOC SYMP P, V540, P539, DOI 10.1557/PROC-540-539; Bement A. L., 1970, P 2 INT C STRENGTH M, V2, P693; Bloom EE, 1998, J NUCL MATER, V258, P7, DOI 10.1016/S0022-3115(98)00352-3; Caturla MJ, 2000, J NUCL MATER, V276, P13, DOI 10.1016/S0022-3115(99)00220-2; Dai Y, 1997, MATER RES SOC SYMP P, V439, P319, DOI 10.1557/PROC-439-319; DELARUBIA TD, 1991, PHYS REV LETT, V66, P2766, DOI 10.1103/PhysRevLett.66.2766; EYRE BL, 1965, PHILOS MAG, V12, P261, DOI 10.1080/14786436508218869; FOREMAN AJE, 1992, PHILOS MAG A, V66, P671, DOI 10.1080/01418619208201584; Friedel J., 1964, DISLOCATIONS; Ghoniem NM, 2000, J NUCL MATER, V276, P166, DOI 10.1016/S0022-3115(99)00176-2; HEINISCH HL, 1990, RADIAT EFF DEFECT S, V113, P53, DOI 10.1080/10420159008213055; Khraishi TA, 2000, PHIL MAG LETT, V80, P95, DOI 10.1080/095008300176353; KHRAISHI TA, UNPUB ACTA METALL MA; Odette GR, 1998, RADIAT EFF DEFECT S, V144, P189, DOI 10.1080/10420159808229676; Osetsky YN, 1999, PHIL MAG LETT, V79, P273, DOI 10.1080/095008399177345; Rhee M, 1998, MODEL SIMUL MATER SC, V6, P467, DOI 10.1088/0965-0393/6/4/012; RHEE M, UNPUB PHYS REV LETT; Rodney D, 1999, PHYS REV LETT, V82, P3272, DOI 10.1103/PhysRevLett.82.3272; SINGH BN, 1993, J NUCL MATER, V206, P212, DOI 10.1016/0022-3115(93)90125-I; Singh BN, 1997, J NUCL MATER, V249, P103, DOI 10.1016/S0022-3115(97)00231-6; Soneda N, 1998, PHILOS MAG A, V78, P995, DOI 10.1080/01418619808239970; Trinkaus H, 1997, J NUCL MATER, V251, P172, DOI 10.1016/S0022-3115(97)00246-8; Victoria M, 2000, J NUCL MATER, V276, P114, DOI 10.1016/S0022-3115(99)00203-2; Wirth BD, 1997, J NUCL MATER, V244, P185, DOI 10.1016/S0022-3115(96)00736-2; WIRTH BD, IN PRESS J NUCL MAT; Zbib HM, 1998, INT J MECH SCI, V40, P113, DOI 10.1016/S0020-7403(97)00043-X; Zbib HM, 2000, J NUCL MATER, V276, P154, DOI 10.1016/S0022-3115(99)00175-0	29	262	264	7	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					871	874						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972284				2022-12-28	WOS:000088903600038
J	Garde, E; Mortensen, EL; Krabbe, K; Rostrup, E; Larsson, HBW				Garde, E; Mortensen, EL; Krabbe, K; Rostrup, E; Larsson, HBW			Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study	LANCET			English	Article							ALZHEIMERS-DISEASE; FOLLOW-UP; CARDIOVASCULAR HEALTH; COGNITIVE FUNCTION; LESIONS; MRI; DEMENTIA; IMPAIRMENT; LEUKOARAIOSIS; ASSOCIATION	Background While-matter hyperintensities are commonly found on magnetic resonance imaging (MRI) of elderly people with or without dementia. Studies of the relation between severity of white-matter hyperintensities and cognitive impairment have had conflicting results. We undertook a longitudinal study of age-related decline in intellectual function and MRI at age 80 years. Methods From a cohort of 698 people born in 1914 and living in seven municipalities in Denmark, 68 healthy non-demented individuals had been tested with the Wechsler adult intelligence scale (WAIS) at ages 50, 60, and 70, and they agreed to further WAIS testing at age 80, and cerebral MRI at age 80-82 (mean age 82.3 years). We scored separately the numbers of periventricular and deep white-matter hyperintensities. Findings Scores for periventricular hyperintensities in this sample included all possible degrees of severity, but no participant scored more than 75% of maximum for deep white-matter hyperintensities. Neither type was related to the WAIS IQs of the 80-year assessment, but both were significantly associated with decline in performance IQ from age 50 to age 80 years (bivariate correlation coefficients 0.32, p=0.0087, and 0.28, p=0.0227, respectively). An analysis based on two WAIS subtests showed that the association between white-matter hyperintensities and cognitive impairment was significant only for cognitive decline in the decade 70-80 years. Interpretation Both periventricular and deep white-matter hyperintensities are related to decline in intelligence but, in healthy octogenarians, the cumulative effect of these features alone explains only a small part of the large differences among individuals in age-related decline in intelligence, Interpretation of the presence and severity of white-matter hyperintensities in a diagnostic context must be done cautiously.	Copenhagen Univ Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Inst Publ Hlth, Dept Hlth Psychol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Garde, E (corresponding author), Copenhagen Univ Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark.		Rostrup, Egill/D-8622-2017	Rostrup, Egill/0000-0001-5015-5244; Mortensen, Erik Lykke/0000-0002-6985-451X; Dichgans, Martin/0000-0002-0654-387X; Garde, Ellen/0000-0002-9906-6880				ALMKVIST O, 1992, ARCH NEUROL-CHICAGO, V49, P626, DOI 10.1001/archneur.1992.00530300062011; AUSTROM MG, 1990, J AM GERIATR SOC, V38, P1133, DOI 10.1111/j.1532-5415.1990.tb01377.x; Barber R, 1999, J NEUROL NEUROSUR PS, V67, P66, DOI 10.1136/jnnp.67.1.66; Bowie P, 1999, LANCET, V354, P1527, DOI 10.1016/S0140-6736(99)03486-8; BRACCO L, 1993, J NEUROL SCI, V120, P131, DOI 10.1016/0022-510X(93)90263-X; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; CHRISTIANSEN P, 1994, ACTA RADIOL, V35, P117; de Leeuw FE, 1999, ANN NEUROL, V46, P827, DOI 10.1002/1531-8249(199912)46:6<827::AID-ANA4>3.0.CO;2-H; Hagerup L, 1968, Ugeskr Laeger, V130, P1145; HESS G, 1974, WAIS ANVENDT PA 698; JUNQUE C, 1990, ARCH NEUROL-CHICAGO, V47, P151, DOI 10.1001/archneur.1990.00530020047013; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; LEYS D, 1990, ARCH NEUROL-CHICAGO, V47, P524, DOI 10.1001/archneur.1990.00530050040010; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; Mantyla R, 1997, STROKE, V28, P1614, DOI 10.1161/01.STR.28.8.1614; MOODY DM, 1995, RADIOLOGY, V194, P469, DOI 10.1148/radiology.194.2.7824728; MORTENSEN EL, 1993, DEV NEUROPSYCHOL, V9, P115, DOI 10.1080/87565649109540548; OBrien JT, 1997, INT J GERIATR PSYCH, V12, P369; Sabri O, 1999, STROKE, V30, P556, DOI 10.1161/01.STR.30.3.556; Salthouse TA, 1991, THEORETICAL PERSPECT; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; SCHELTENS P, 1995, NEUROLOGY, V45, P883, DOI 10.1212/WNL.45.5.883; Schmidt R, 1999, NEUROLOGY, V53, P132, DOI 10.1212/WNL.53.1.132; SIEGLER IC, 1979, J GERONTOL, V34, P242, DOI 10.1093/geronj/34.2.242; Tanabe JL, 1997, AM J NEURORADIOL, V18, P115; THOMSEN KK, 1995, AM J GERIATR CARDIOL, V3, P31; TUPLER LA, 1992, ARCH NEUROL-CHICAGO, V49, P1248, DOI 10.1001/archneur.1992.00530360046016; vanSwieten JC, 1996, J NEUROL, V243, P196; Wahlund LO, 1996, MAGN RESON IMAGING, V14, P601, DOI 10.1016/0730-725X(96)00098-7; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P1458, DOI 10.1136/jnnp.57.12.1458; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171	33	217	225	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					628	634		10.1016/S0140-6736(00)02604-0	http://dx.doi.org/10.1016/S0140-6736(00)02604-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968435				2022-12-28	WOS:000088884100010
J	Lassen, AT; Pedersen, FM; Bytzer, P; de Muckadell, OBS				Lassen, AT; Pedersen, FM; Bytzer, P; de Muckadell, OBS			Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial	LANCET			English	Article							PEPTIC-ULCER DISEASE; NONULCER DYSPEPSIA; BREATH TEST; INFECTION; GASTROSCOPY; STRATEGIES; SYMPTOMS; THERAPY	Background Strategies based on screening for Helicobacter pylori to manage dyspeptic patients in primary care have been proposed, but the clinical consequences are unclear. We did a randomised trial to assess the efficacy and safety of a test-and-eradicate strategy compared with prompt endoscopy in the management of patients with dyspepsia. Methods 500 patients presenting in primary care with dyspepsia (greater than or equal to 2 weeks of epigastric pain, no alarm symptoms) were assigned H pylori testing plus eradication therapy or endoscopy. Symptoms, quality of life, patients' satisfaction, and use of resources were recorded during 1 year of follow-up. Findings 250 patients were assigned lest-and-eradicate, and 250 prompt endoscopy. The median age was 45 years and 28% were H pylori infected. 1 year follow-up was completed by 447 patients. We found no differences in symptoms between the two groups (median registered days without dyspeptic symptoms=0.63 [IQR 0.27-0.81] in the test-and-eradicate group vs 0.67 [0.36-0.86] in the prompt endoscopy group; mean difference 0.04 [95% CI -0.01-0.10], p=0.12). Nor did we find any difference in quality of life or numbers of sick-leave days, Visits to general practitioners, or hospital admissions. In the test-and-eradicate group, 27 (12%) of the patients were dissatisfied with management, compared with eight (4%) in the endoscopy group (p=0.013). After 1 year, the use of endoscopies in the test-and-eradicate group was 0.40 times (95% CI 0.31-0.51) the use in the endoscopy group, the use of H pylori tests increased by a factor of 8.1 (5.7-13.1), the use of eradication treatments increased by a factor of 1.5 (0.9-2.7), and the use of proton-pump inhibitors was 0.89 (0.59-1.33) times the use in the endoscopy group. 43 (91% [80-98%]) of 47 peptic-ulcer patients would have been identified by endoscopy or treated by eradication therapy. Interpretation A H pylori test-and-eradicate strategy is as efficient and safe as prompt endoscopy for management of dyspeptic patients in primary care, although fewer patients are satisfied with their treatment.	Odense Univ Hosp, Dept Med Gastroenterol S, DK-5000 Odense C, Denmark; Glostrup Univ Hosp, Dept Med Gastroenterol F, Glostrup, Denmark	University of Southern Denmark; Odense University Hospital; University of Copenhagen	Lassen, AT (corresponding author), Odense Univ Hosp, Dept Med Gastroenterol S, DK-5000 Odense C, Denmark.		Lassen, Annmarie/AAA-5816-2019	Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329; Lassen, Annmarie/0000-0003-4942-6152				AGREUS L, 1995, SCAND J GASTROENTERO, V30, P752, DOI 10.3109/00365529509096323; [Anonymous], 1998, Gastroenterology, V114, P579; Asante MA, 1998, EUR J GASTROEN HEPAT, V10, P983, DOI 10.1097/00042737-199812000-00001; AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; *BRIT SOC GASTR, 1996, DYSP MAN GUID; Bytzer P, 1996, GASTROENTEROLOGY, V110, P302, DOI 10.1053/gast.1996.v110.agast960302; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; Bytzer P, 1999, ITAL J GASTROENTEROL, V31, P749; Ciociola AA, 1999, AM J GASTROENTEROL, V94, P1834, DOI 10.1111/j.1572-0241.1999.01214.x; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; Ebell MH, 1997, J FAM PRACTICE, V44, P545; FENDRICK AM, 1995, ANN INTERN MED, V123, P260, DOI 10.7326/0003-4819-123-4-199508150-00003; Fraser AG, 1998, NEW ZEAL MED J, V111, P11; GOULSTON KJ, 1991, MED J AUSTRALIA, V155, P20, DOI 10.5694/j.1326-5377.1991.tb116372.x; Heaney A, 1999, GUT, V45, P186, DOI 10.1136/gut.45.2.186; HEATLEY RV, 1987, LANCET, V2, P779; Heikkinen M, 1997, AM J GASTROENTEROL, V92, P2225; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Jones R, 1999, INT J CLIN PRACT, V53, P413; Malfertheiner P, 1997, GUT, V41, P8; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; McColl KEL, 1997, GUT, V40, P302, DOI 10.1136/gut.40.3.302; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; Silverstein MD, 1996, GASTROENTEROLOGY, V110, P72, DOI 10.1053/gast.1996.v110.pm8536890; Slade PE, 1999, EUR J GASTROEN HEPAT, V11, P857, DOI 10.1097/00042737-199908000-00008; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6	30	164	169	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					455	460		10.1016/S0140-6736(00)02553-8	http://dx.doi.org/10.1016/S0140-6736(00)02553-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981888				2022-12-28	WOS:000088657700010
J	Mease, PJ; Goffe, BS; Metz, J; VanderStoep, A; Finck, B; Burge, DJ				Mease, PJ; Goffe, BS; Metz, J; VanderStoep, A; Finck, B; Burge, DJ			Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial	LANCET			English	Article							NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; PLACEBO; METHOTREXATE; CYCLOSPORINE; SULFASALAZINE; MORTALITY; THERAPY	Background Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which tumour necrosis factor, a proinflammatory cytokine, is present in increased concentrations in joints and in the shin. Therefore, psoriatic arthritis and psoriasis may be appropriate therapeutic targets for etanercept. Methods This randomised, double-blind, placebo-controlled, 12 week study assessed the efficacy and safely of etanercept (25 mg twice-weekly subcutaneous injections) br placebo in 60 patients with psoriatic arthritis and psoriasis. Psoriatic arthritis endpoints included the proportion of patients who met the Psoriatic Arthritis Response Criteria (PsARC) and who met the American College of Rheumatology preliminary criteria for improvement (ACR20). Psoriasis endpoints included improvement in the psoriasis area and severity index (PASI) and improvement in prospectively-identified individual target lesions. Findings in this 12 week study, 26 (87%) of etanercept treated patients met the PsARC, compared with seven (23%) of placebo-controlled patients. The ARC20 was achieved by 22 (73%) of etanercept-treated patients compared with four (13%) of placebo-treated patients. Of the 19 patients in each treatment group who could be assessed for psoriasis (greater than or equal to 3% body surface area), five (26%) of etanercept-treated patients achieved a 75% improvement in the PASI, compared with none of the placebo-treated patients (p=0.015). The median PASI improvement was 46% in etanercept-treated patients versus 9% in placebo-treated patients; similarly, median target lesion improvements were 50% and 0, respectively. Etanercept was well tolerated. Interpretation Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.	Minor & James Med, Seattle, WA 98104 USA		Mease, PJ (corresponding author), Minor & James Med, 515 Minor Ave,Suite 300, Seattle, WA 98104 USA.	pmease@u.washington.edu						ALONSO JCT, 1991, BRIT J RHEUMATOL, V30, P245; BLACK RL, 1964, JAMA-J AM MED ASSOC, V189, P743; Clegg DO, 1996, ARTHRITIS RHEUM, V39, P2013, DOI 10.1002/art.1780391210; Cuellar ML, 1997, RHEUM DIS CLIN N AM, V23, P797, DOI 10.1016/S0889-857X(05)70361-6; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; ESPINOZA LR, 1994, RHEUMATOLOGY, V3; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; FARR M, 1990, BRIT J RHEUMATOL, V29, P46; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Gladman DD, 1998, ARTHRITIS RHEUM-US, V41, P1103, DOI 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N; GLADMAN DD, 1987, Q J MED, V62, P127; GREAVES MW, 1995, NEW ENGL J MED, V332, P581, DOI 10.1056/NEJM199503023320907; GUBNER R, 1951, AM J MED SCI, V221, P176, DOI 10.1097/00000441-195102000-00009; Jones G, 1997, BRIT J RHEUMATOL, V36, P95; Lebwohl M, 1998, J AM ACAD DERMATOL, V39, P464, DOI 10.1016/S0190-9622(98)70325-1; MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049-0172(73)90035-8; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; OBRIEN WM, 1962, ARTHRITIS RHEUM, V5, P312; PALIT J, 1990, BRIT J RHEUMATOL, V29, P280; Partsch G, 1998, J RHEUMATOL, V25, P105; Partsch G, 1997, J RHEUMATOL, V24, P518; PIORO MH, 1995, RHEUM DIS CLIN N AM, V21, P129; Ritchlin C, 1998, J RHEUMATOL, V25, P1544; Roenigk HH, 1998, J AM ACAD DERMATOL, V38, P478, DOI 10.1016/S0190-9622(98)70508-0; Spadaro A, 1997, CLIN EXP RHEUMATOL, V15, P609; STEM RS, 1987, TXB GEN MED, P6; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WILLKENS RF, 1984, ARTHRITIS RHEUM-US, V27, P376, DOI 10.1002/art.1780270403; Wong K, 1997, ARTHRITIS RHEUM-US, V40, P1868, DOI 10.1002/art.1780401021	30	1134	1178	0	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					385	390		10.1016/S0140-6736(00)02530-7	http://dx.doi.org/10.1016/S0140-6736(00)02530-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972371				2022-12-28	WOS:000088486000011
J	Payne, D				Payne, D			Relatives underestimate patients' desire for truth	BRITISH MEDICAL JOURNAL			English	News Item																		OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 2000, IRISH MED J, V93, P104	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					658	658						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987766				2022-12-28	WOS:000089444100019
J	Torgerson, DJ; Campbell, MK				Torgerson, DJ; Campbell, MK			Economics notes - Cost effectiveness calculations and sample size	BRITISH MEDICAL JOURNAL			English	Article							ENDOMETRIAL LASER-ABLATION; HYSTERECTOMY; MENORRHAGIA; RESECTION; TRIALS		Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland	University of York - UK; University of Aberdeen	Torgerson, DJ (corresponding author), Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019; Campbell, Marion/ABB-7063-2020	Torgerson, David/0000-0002-1667-4275; 				Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Cameron IM, 1996, EUR J OBSTET GYN R B, V70, P87, DOI 10.1016/S0301-2115(96)02558-4; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P787, DOI 10.1016/0895-4356(94)90176-7; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; TORGERSON DJ, 1995, QJM-MON J ASSOC PHYS, V88, P517	7	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					697	697		10.1136/bmj.321.7262.697	http://dx.doi.org/10.1136/bmj.321.7262.697			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987781	Green Published			2022-12-28	WOS:000089444100035
J	Mouillet-Richard, S; Ermonval, M; Chebassier, C; Laplanche, JL; Lehmann, S; Launay, JM; Kellermann, O				Mouillet-Richard, S; Ermonval, M; Chebassier, C; Laplanche, JL; Lehmann, S; Launay, JM; Kellermann, O			Signal transduction through prion protein	SCIENCE			English	Article							EXPRESSION; MOLECULES; KINASES; CELLS	The cellular prion protein PrPc is a glycosylphosphaltidylinositol-anchored cell-surface protein whose biological function is unclear: We used the murine 1C11 neuronal differentiation model to search for PrPc-dependent signal transduction through antibody-mediated cross-linking. A caveolin-1-dependent coupling of PrPc to the tyrosine kinase Fyn was observed. Clathrin might also contribute to this coupling. The ability of the 1C11 cell line to trigger PrPc-dependent Fyn activation was restricted to its fully differentiated serotonergic or noradrenergic progenies. Moreover, the signaling activity of PrPc occurred mainly at neurites. Thus, PrPc may be a signal transduction protein.	Inst Pasteur, CNRS, F-75724 Paris 15, France; Hop Lariboisiere, Serv Biochim, CR Claude Bernard, F-75009 Paris, France; IGH, CNRS, UPR 1142, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mouillet-Richard, S (corresponding author), Inst Pasteur, CNRS, F-75724 Paris 15, France.		Lehmann, Sylvain/P-1301-2017; LAPLANCHE, Jean-Louis/S-8707-2016; Mouillet, Sophie/E-4960-2017	Lehmann, Sylvain/0000-0001-6117-562X; Mouillet, Sophie/0000-0002-8950-1949; Ermonval, Myriam/0000-0002-9685-9826; Lafay-Chebassier, Claire/0000-0001-8970-5514; LAPLANCHE, Jean-Louis/0000-0003-2836-2903				Brockes JP, 1999, CURR OPIN NEUROBIOL, V9, P571, DOI 10.1016/S0959-4388(99)00016-1; Gainer AL, 1996, TRANSPLANTATION, V61, P1567, DOI 10.1097/00007890-199606150-00003; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Mouillet-Richard S, 1999, MICROBES INFECT, V1, P969, DOI 10.1016/S1286-4579(99)80514-0; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Nishida N., UNPUB; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raeber AJ, 1998, BRAIN PATHOL, V8, P715, DOI 10.1111/j.1750-3639.1998.tb00197.x; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	17	658	673	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1925	1928		10.1126/science.289.5486.1925	http://dx.doi.org/10.1126/science.289.5486.1925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988071				2022-12-28	WOS:000089355800043
J	Keller, C; Langston, C				Keller, C; Langston, C			Childhood idiopathic pulmonary hemosiderosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Keller, C (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.			Keller, Charles/0000-0003-2505-7487					0	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					781	781		10.1056/NEJM200009143431105	http://dx.doi.org/10.1056/NEJM200009143431105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984566				2022-12-28	WOS:000089221300005
J	Vestergaard, P; Mollerup, CL; Frokjaer, VB; Christiansen, P; Blichert-Toft, M; Mosekilde, L				Vestergaard, P; Mollerup, CL; Frokjaer, VB; Christiansen, P; Blichert-Toft, M; Mosekilde, L			Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism	BRITISH MEDICAL JOURNAL			English	Article							BONE-MINERAL DENSITY; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; FOLLOW-UP; PARATHYROIDECTOMY	Objectives To study whether fracture risk before and after surgery was increased in patients with primary hyperparathyroidism. Design Cohort study. Setting, Three Danish university hospitals. Participants 674 consecutive patients with primary hyperparathyroidism (median age 61, range 13-89 years) operated on during the period 1 January 1979 to 31 December 1997; 2021 age and sex matched controls from national patient register. Main outcome measure Fractures. Results The cases had an increased relative rate of fractures compared with the controls before surgery (1.8, 95% confidence interval 1.3 to 2.3) but not after surgery (1.0, 0.8 to 1.3). The risk of fracture was increased for the vertebrae (3.5, 1.3 to 9.7), the distal part of time lower leg and ankles (2.3, 1.2 to 4.3), and the non-distal part of the forearm (4.0, 1.5 to 10.6) before surgery but not after. The increase in risk of fracture began about 10-years before surgery. Risk peaked 5-6 years before surgery and remained raised, although at a lower level, in the five years immediately before surgery. A small increase in risk of fracture of the distal forearm emerged more than 10 years after surgery (2.9, 1.3 to 6.7). Conclusions Risk of fracture is increased up to 10 years before surgery in patients with primary hyperparathyroidism. The risk learns to normal after surgery.	Aarhus Univ Hosp, Aarhus Kommune Hosp, Dept Endocrinol & Metab, DK-8000 Aarhus, Denmark; Rigshosp, Dept Endocrine Surg, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Surg, Aarhus, Denmark	Aarhus University; Rigshospitalet; University of Copenhagen; Aarhus University	Vestergaard, P (corresponding author), Aarhus Kommune Hosp, Osteoporosis Clin, Hansens Gade 2, DK-8000 Aarhus C, Denmark.		Christiansen, Peer/B-7402-2015; Frøkjær, Vibe Gedsø/N-8955-2019	Christiansen, Peer/0000-0003-2748-9240; Frøkjær, Vibe Gedsø/0000-0002-9321-2365				Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Christiansen P, 1999, BONE, V25, P237, DOI 10.1016/S8756-3282(99)00150-7; Christiansen P, 1999, BONE, V25, P589, DOI 10.1016/S8756-3282(99)00207-0; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Elvius M, 1995, EUR J SURG, V161, P863; KENNY AM, 1995, SURGERY, V118, P109, DOI 10.1016/S0039-6060(05)80017-0; Khosla S, 1999, J BONE MINER RES, V14, P1700, DOI 10.1359/jbmr.1999.14.10.1700; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; LARSSON K, 1993, J INTERN MED, V234, P585, DOI 10.1111/j.1365-2796.1993.tb01017.x; LARSSON K, 1989, ACTA ORTHOP SCAND, V60, P268, DOI 10.3109/17453678909149275; LEPPLA DC, 1982, INVEST RADIOL, V17, P604, DOI 10.1097/00004424-198211000-00013; MARTIN P, 1990, ARCH INTERN MED, V150, P1495, DOI 10.1001/archinte.150.7.1495; MELLEMGAARD A, 1997, 19975 NAT BOARD HLTH, P1; MELTON LJ, 1992, ARCH INTERN MED, V152, P2269, DOI 10.1001/archinte.152.11.2269; PEACOCK M, 1984, OSTEOPOROSIS, P463; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; Silverberg SJ, 1999, NEW ENGL J MED, V341, P1249, DOI 10.1056/NEJM199910213411701; WILSON RJ, 1988, ANN INTERN MED, V109, P959, DOI 10.7326/0003-4819-109-12-959; WISHART J, 1990, ARCH INTERN MED, V150, P1329, DOI 10.1001/archinte.150.6.1329	20	209	214	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					598	602		10.1136/bmj.321.7261.598	http://dx.doi.org/10.1136/bmj.321.7261.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977834	Bronze, Green Published			2022-12-28	WOS:000089243200018
J	Fang, D; Moy, E; Colburn, L; Hurley, J				Fang, D; Moy, E; Colburn, L; Hurley, J			Racial and ethnic disparities in faculty promotion in academic medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINORITY FACULTY; WOMEN; RANK; MEN	Context Previous studies have suggested that minority medical school faculty are at a disadvantage in promotion opportunities compared with white faculty. Objective To compare promotion rates of minority and white medical school faculty in the United States. Design and Setting Analysis of data from the Association of American Medical Colleges' Faculty Roster System, the official data system for tracking US medical school faculty. Participants A total of 50 145 full-time US medical school faculty who became assistant professors or associate professors between 1980 and 1989. Faculty of historically black and Puerto Rican medical schools were excluded. Main Outcome Measures Attainment of associate or full professorship among assistant professors and full professorship among associate professors by 1997, among white, Asian or Pacific Islander (API), underrepresented minority (URM; including black, Mexican American, Puerto Rican, Native American, and Native Alaskan), and other Hispanic faculty. Results By 1997, 46% of white assistant professors (13479/28953) had been promoted, whereas 37% of API (1123/2997; P<001), 30% of URM (311/1053, P<.001), and 43% of other Hispanic assistant professors (256/598, P=.07) had been promoted. Similarly, by 1997, 50% of white associate professors (7234/14559) had been promoted, whereas 44% of API (629/1419; P<.001), 36% of URM (101/280; P<.001), and 43% of other Hispanic (122/286; P=.02) associate professors had been promoted. Racial/ethnic disparities in promotion were evident among tenure and nontenure faculty and among faculty who received and did not receive National Institutes of Health research awards. After adjusting for-cohort, sex, tenure status, degree, department, medical school type, and receipt of NIH awards, URM faculty remained less likely to be promoted compared with white faculty (relative risk [RR], 0.68 [99% confidence interval {CI}, 0.59-0.77] for assistant professors and 0.81 [99% CI, 0.65-0.99] for associate professors). API assistant professors also were less likely to be promoted (RR, 0.91 [99% CI, 0.84-0.98]), whereas API associate professors and other Hispanic assistant and associate professors were promoted at comparable rates. Conclusion Our data indicate that minority faculty are promoted at lower rates compared with white faculty.	Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Moy, E (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20037 USA.							Benz EJ, 1998, AM J MED, V105, P459; BICKEL J, 1991, ACAD MED, V66, P497, DOI 10.1097/00001888-199108000-00025; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; Cohen JJ, 1998, JAMA-J AM MED ASSOC, V280, P821, DOI 10.1001/jama.280.9.821; *DIV COMM MIN PROG, 1998, MIN STUD MED ED FACT, V11; *FAC ROST SYST, 1997, US MED SCH FAC 1997; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Nonnemaker L, 2000, NEW ENGL J MED, V342, P399, DOI 10.1056/NEJM200002103420606; Palepu A, 1998, JAMA-J AM MED ASSOC, V280, P767, DOI 10.1001/jama.280.9.767; PETERSDORF RG, 1990, ACAD MED, V65, P663, DOI 10.1097/00001888-199011000-00001; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; WHITE LJ, 1991, ANN INTERN MED, V114, P63, DOI 10.7326/0003-4819-114-1-63; WHITING BE, 1990, ACAD MED, V65, P277, DOI 10.1097/00001888-199004000-00013; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	15	233	233	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1085	1092		10.1001/jama.284.9.1085	http://dx.doi.org/10.1001/jama.284.9.1085			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974686	Bronze			2022-12-28	WOS:000089037200007
J	Sabharwal, S; Sebastian, JL; Lanouette, M				Sabharwal, S; Sebastian, JL; Lanouette, M			An educational intervention to teach medical students about examining disabled patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Med Coll Wisconsin, Milwaukee, WI 53226 USA; Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA	Medical College of Wisconsin	Sabharwal, S (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.							Andriacchi R, 1997, AM J PHYS MED REHAB, V76, pS17; BATAVIA A, 1989, AM REHABIL, V14, P9; DEJONG G, 1989, MILBANK Q, V67, P311, DOI 10.2307/3350148; POPE MA, 1991, DISABILITY AM NATL A; Vu NV., 1994, ED RES, V23, P23; Werner P, 1997, AM J PHYS MED REHAB, V76, pS21	6	6	7	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1080	1081		10.1001/jama.284.9.1080-a	http://dx.doi.org/10.1001/jama.284.9.1080-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	349GK	10974684				2022-12-28	WOS:000089037200005
J	Doyle, Y; Bull, A				Doyle, Y; Bull, A			Role of private sector in United Kingdom healthcare system	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings & St Thomas Med Sch, London SE1 9RT, England; PPP Healthcare, Tunbridge Wells TN1 1BJ, Kent, England	University of London; King's College London	Doyle, Y (corresponding author), 21 Thorpewood Ave, London SE26 4BU, England.							Bull A, 1996, J Manag Med, V10, P4, DOI 10.1108/02689239610127761; *DEP HLTH, 1999, REG PRIV VOL CAR; Maynard A, 1997, LANCET, V349, P126, DOI 10.1016/S0140-6736(96)05153-7; MURRAY CJL, 1994, GLOBAL COMP ASSESSME, P141; Normand C, 1999, SOC SCI MED, V48, P865; Smith R, 1999, BRIT MED J, V318, P209; WILLIAMS BT, 1994, BRIT MED J, V308, P1699, DOI 10.1136/bmj.308.6945.1699; 1997, LAINGS REV PRIVATE H	8	21	21	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					563	565		10.1136/bmj.321.7260.563	http://dx.doi.org/10.1136/bmj.321.7260.563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968825	Green Published			2022-12-28	WOS:000089174100029
J	Gottlieb, S				Gottlieb, S			More "cot deaths" occur in day care than at home	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					529	529		10.1136/bmj.321.7260.529/a	http://dx.doi.org/10.1136/bmj.321.7260.529/a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968808	Green Published			2022-12-28	WOS:000089174100011
J	Sandak, R; Fiez, JA				Sandak, R; Fiez, JA			Stuttering: a view from neuroimaging	LANCET			English	Editorial Material							POSITRON EMISSION TOMOGRAPHY		Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sandak, R (corresponding author), Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA.							ANDREWS G, 1983, J SPEECH HEAR DISORD, V48, P226, DOI 10.1044/jshd.4803.226; Braun AR, 1997, BRAIN, V120, P761, DOI 10.1093/brain/120.5.761; Fox PT, 1996, NATURE, V382, P158, DOI 10.1038/382158a0; Geschwind N, 1984, CEREBRAL DOMINANCE B; Ingham RJ, 1996, J SPEECH HEAR RES, V39, P1208, DOI 10.1044/jshr.3906.1208; Lawrence M, 1998, AM FAM PHYSICIAN, V57, P2175; Packman A, 2000, DISABIL REHABIL, V22, P65, DOI 10.1080/096382800297132; Peters HFM, 2000, FOLIA PHONIATR LOGO, V52, P103, DOI 10.1159/000021518; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Salmelin R, 2000, BRAIN, V123, P1184, DOI 10.1093/brain/123.6.1184; WU JC, 1995, NEUROREPORT, V6, P501, DOI 10.1097/00001756-199502000-00024; Zanini S, 1999, PERCEPT MOTOR SKILL, V89, P1095, DOI 10.2466/PMS.89.7.1095-1109; ZEBROWSKI PM, 1995, J COMMUN DISORD, V28, P75, DOI 10.1016/0021-9924(95)00002-U	13	12	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					445	446		10.1016/S0140-6736(00)02547-2	http://dx.doi.org/10.1016/S0140-6736(00)02547-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	342QY	10981883				2022-12-28	WOS:000088657700004
J	Wu, YW; Colford, JM				Wu, YW; Colford, JM			Chorioamnionitis as a risk factor for cerebral palsy - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BIRTH-WEIGHT; CYSTIC PERIVENTRICULAR LEUKOMALACIA; NECROSIS-FACTOR-ALPHA; WHITE-MATTER LESIONS; PRETERM INFANTS; INTRAVENTRICULAR HEMORRHAGE; INTRAUTERINE INFECTION; NEUROLOGIC IMPAIRMENT; MATERNAL INFECTION; PREMATURE-INFANTS	Context Chorioamnionitis has been implicated in the pathogenesis of cerebral palsy, but most studies have not reported a significant association. Cystic periventricular leukomalacia (cPVL) is believed to be a precursor of cerebral palsy in preterm infants. Objectives To determine whether chorioamnionitis is associated with cerebral palsy or cPVL and to examine factors that may explain differences in study results. Data Sources Searches of MEDLINE (1966-1999), Index Medicus (1960-1965), Doctoral Dissertation Abstracts On-Line (1861-1999), bibliographies, and online conference proceedings (1999) were performed for English-language studies with titles or abstracts that discussed prenatal risk factors for cerebral palsy or cPVL. Study Selection Of 229 initially identified publications, meta-analyses were performed on studies that addressed the association between clinical (n=19) or histologic (n=7) chorioamnionitis and cerebral palsy or cPVL in both preterm and full-term infants. Inclusion criteria were: presence of appropriate exposure and outcome measures, case-control or cohort study design, and provision of sufficient data to calculate relative risks (RRs) or odds ratios with 95% confidence intervals (Cls). Studies evaluating risk of cerebral palsy following maternal fever, urinary tract infection, or other maternal infection were collected, but not included in the meta-analysis. Data Extraction Information from individual studies was abstracted using standardized forms by 2 independent observers blinded to authors' names, journal titles, and funding sources. Data Synthesis Using a random effects model, clinical chorioamnionitis was significantly associated with both cerebral palsy (RR, 1.9; 95% CI, 1.4-2.5) and cPVL (RR, 3.0; 95% CI, 2.2-4.0) in preterm infants. The RR of histologic chorioamnionitis and cerebral palsy was 1.6 (95% CI, 0.9-2.7) in preterm infants, and histologic chorioamnionitis was significantly associated with cPVL (RR, 2.1; 95% CI, 1.5-2.9). Among full-term infants, a positive association was found between clinical chorioamnionitis and cerebral palsy (RR, 4.7; 95% CI, 1.3-16.2). Factors explaining differences in study results included varying definitions of clinical chorioamnionitis, extent of blinding in determining exposure status, and whether individual studies adjusted for potential confounders. Conclusion Our meta-analysis indicates that chorioamnionitis is a risk factor for both cerebral palsy and cPVL.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Wu, YW (corresponding author), Univ Calif San Francisco, Dept Neurol, POB 0114, San Francisco, CA 94143 USA.			Colford, John/0000-0002-3288-6956	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001692] Funding Source: NIH RePORTER; NINDS NIH HHS [5 K12 NS01692-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Allan WC, 1997, ARCH PEDIAT ADOL MED, V151, P580, DOI 10.1001/archpedi.1997.02170430046010; ALRAJEH S, 1991, DEV MED CHILD NEUROL, V33, P1048; Baud O, 1999, NEW ENGL J MED, V341, P1190, DOI 10.1056/NEJM199910143411604; BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; Bejar R F, 1992, J Perinatol, V12, P3; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BRANDT S, 1958, Dan Med Bull, V5, P47; Cai ZW, 2000, PEDIATR RES, V47, P64, DOI 10.1203/00006450-200001000-00013; Canterino JC, 1999, OBSTET GYNECOL, V93, P396, DOI 10.1016/S0029-7844(98)00455-4; CARBINE DN, 1999, NEONATAL CNS INJURY; CHURCHILL JA, 1974, DEV MED CHILD NEUROL, V16, P143; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COOPER HM, 1994, HDB RES SYNTHESIS, P402; Dammann O, 1998, Semin Pediatr Neurol, V5, P190, DOI 10.1016/S1071-9091(98)80034-X; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; DAMMANN O, 1999, PATHOGENESIS, V1, P171; DANIEL WW, 1995, BIOSTATISTICS FDN AN, P224; Deguchi K, 1996, PEDIATR NEUROL, V14, P13, DOI 10.1016/0887-8994(95)00223-5; DEVRIES LS, 1988, AM J DIS CHILD, V142, P732, DOI 10.1001/archpedi.1988.02150070046023; Dommergues MA, 2000, ANN NEUROL, V47, P54, DOI 10.1002/1531-8249(200001)47:1<54::AID-ANA10>3.3.CO;2-P; EASTMAN NJ, 1955, AM J OBSTET GYNECOL, V69, P950, DOI 10.1016/0002-9378(55)90094-6; EVANS PR, 1948, ARCH DIS CHILD, V23, P213, DOI 10.1136/adc.23.116.213; GAFFNEY G, 1994, ARCH DIS CHILD-FETAL, V70, pF195, DOI 10.1136/fn.70.3.F195; Gray PH, 1997, AUST NZ J OBSTET GYN, V37, P161, DOI 10.1111/j.1479-828X.1997.tb02245.x; Grether J. K., 2000, American Journal of Obstetrics and Gynecology, V182, pS95; Grether JK, 1998, JAMA-J AM MED ASSOC, V279, P118; Grether JK, 1996, J PEDIATR-US, V128, P407, DOI 10.1016/S0022-3476(96)70292-5; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HERBST A, 1995, OBSTET GYNECOL, V86, P790, DOI 10.1016/0029-7844(95)00254-O; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kim JN, 1999, YONSEI MED J, V40, P363, DOI 10.3349/ymj.1999.40.4.363; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; Laisram Nonica, 1992, Indian Journal of Pediatrics, V59, P723, DOI 10.1007/BF02859408; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; Leviton A, 1999, PEDIATR RES, V46, P566, DOI 10.1203/00006450-199911000-00013; LILIENFELD AM, 1951, AM J HYG, V53, P262; Magee J. F., 1996, Modern Pathology, V9, p4P; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAYER PS, 1978, OBSTET GYNECOL, V51, P399, DOI 10.1097/00006250-197804000-00003; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Murphy DJ, 1996, ARCH DIS CHILD-FETAL, V74, pF105, DOI 10.1136/fn.74.2.F105; Murphy DJ, 1997, BMJ-BRIT MED J, V314, P404, DOI 10.1136/bmj.314.7078.404; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NEBEL W, 1962, NC MED J, V23, P229; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; Nelson KB, 1998, AM J OBSTET GYNECOL, V179, P507, DOI 10.1016/S0002-9378(98)70387-4; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; NELSON KB, 1995, PEDIATRICS, V95, P263; O'Shea TM, 1998, PAEDIATR PERINAT EP, V12, P72; O'Shea TM, 1998, AM J EPIDEMIOL, V147, P362; PALMER L, 1995, PAEDIATR PERINAT EP, V9, P171, DOI 10.1111/j.1365-3016.1995.tb00132.x; Perlman JM, 1996, PEDIATRICS, V97, P822; Perlman JM, 1997, PEDIATRICS, V99, P851, DOI 10.1542/peds.99.6.851; PETITTI DB, 2000, MONOGRAPHS EPIDEMIOL; Petridou E, 1996, SCAND J SOC MED, V24, P14, DOI 10.1177/140349489602400104; POLIVKA B, 1990, RISK FACTORS CEREBRA, P132; Polivka B J, 1997, J Obstet Gynecol Neonatal Nurs, V26, P405, DOI 10.1111/j.1552-6909.1997.tb02722.x; Redline RW, 1998, ARCH PATHOL LAB MED, V122, P1091; Roberts AK, 1999, AM J OBSTET GYNECOL, V180, P1297, DOI 10.1016/S0002-9378(99)70632-0; ROBOZ P, 1962, ARCH PEDIATR, V79, P233; ROLAND EH, 1996, ANN NEUROL, V40, P3213; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P648; Russel P., 1979, AM J DIAG GYN OBSTET, V1, P127; Spinillo A, 1998, BRIT J OBSTET GYNAEC, V105, P865, DOI 10.1111/j.1471-0528.1998.tb10231.x; Spinillo A, 1997, EARLY HUM DEV, V48, P81, DOI 10.1016/S0378-3782(96)01838-5; SWEET RL, 1995, INFECT DIS FEMALE GE, P554; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; Verma U, 1997, AM J OBSTET GYNECOL, V176, P275, DOI 10.1016/S0002-9378(97)70485-X; Volpe JJ, 1997, BRAIN DEV-JPN, V19, P519, DOI 10.1016/S0387-7604(97)00078-8; Wilson-Costello D, 1998, PEDIATRICS, V102, P315, DOI 10.1542/peds.102.2.315; Wiswell TE, 1996, PEDIATRICS, V98, P918; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; Yoon B. H., 1999, American Journal of Obstetrics and Gynecology, V180, pS2; Yoon BH, 1998, AM J OBSTET GYNECOL, V179, P1254, DOI 10.1016/S0002-9378(98)70142-5; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P797, DOI 10.1016/S0002-9378(97)70271-0; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P19, DOI 10.1016/S0002-9378(97)70432-0; Yoon BH, 1996, AM J OBSTET GYNECOL, V174, P1433, DOI 10.1016/S0002-9378(96)70585-9; Yoon BH, 1997, AM J OBSTET GYNECOL, V177, P406, DOI 10.1016/S0002-9378(97)70206-0; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	83	659	683	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1417	1424		10.1001/jama.284.11.1417	http://dx.doi.org/10.1001/jama.284.11.1417			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989405				2022-12-28	WOS:000089242500037
J	Chadwick, DW; Crook, PJ; Young, AJ; McDowell, DM; Dornan, TL; New, JP				Chadwick, DW; Crook, PJ; Young, AJ; McDowell, DM; Dornan, TL; New, JP			Using the internet to access confidential patient records: a case study	BRITISH MEDICAL JOURNAL			English	Article							NETWORKING		Hope Hosp, Dept Endocrinol & Diabet, Salford M6 8HD, Lancs, England; Univ Salford, IS Inst, Salford M5 4WT, Lancs, England	University of Salford	New, JP (corresponding author), Hope Hosp, Dept Endocrinol & Diabet, Salford M6 8HD, Lancs, England.			Chadwick, David/0000-0003-3145-055X; New, John/0000-0003-4146-025X				ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; *DEP HLTH, 1999, INF HLTH INF STRAT M; Department of Health The Caldicott Committee, 1997, REP REV PAT ID INF; Keen J, 1998, BRIT MED J, V316, P1291, DOI 10.1136/bmj.316.7140.1291; *NHS EX INF MAN GR, 1995, NHS WID NETW; Roscoe T, 1998, HLTH INFORMATION INT, V3, P2; VAUGHAN NJA, 1995, DIABETIC MED, V12, P717, DOI 10.1111/j.1464-5491.1995.tb00576.x	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					612	614		10.1136/bmj.321.7261.612	http://dx.doi.org/10.1136/bmj.321.7261.612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977842	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000089243200023
J	Rogers, AE; Addington-Hall, JM; Abery, AJ; McCoy, ASM; Bulpitt, C; Coats, AJS; Gibbs, JSR				Rogers, AE; Addington-Hall, JM; Abery, AJ; McCoy, ASM; Bulpitt, C; Coats, AJS; Gibbs, JSR			Knowledge and communication difficulties for patients with chronic heart failure: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EDUCATION; DISEASE	Objectives To explore patients' understanding of chronic heart failure; to investigate their need for information and issues concerning communication. Design Qualitative analysis of in-depth interviews by a constant comparative approach. Participants 27 patients identified by cardiology and care of the elderly physicians as having symptomatic heart failure (New York Heart Association functional class of II, III, or IV) and who had been admitted to hospital with heart failure in the past 20 months. Results Participants were aged 38-94 (mean 69 years); 20 had a New York Heart Association classification of III or IV. All had at least one concurrent illness. Participants sought information from the research interviewer about their heart failure, their prognosis, and likely manner of death. They also described several factors that could inhibit successful communication with their doctors. These included difficulties in getting to hospital appointments, confusion, short term memory loss, and the belief that doctors did not want to provide patients with too much knowledge. Conclusions Good communication requires the ability both to listen and to impart relevant information. Effective and better ways of communicating with patients with chronic heart failure need to be tested. Disease specific barriers to effective communication, such as short term memory loss, confusion, and fatigue should be addressed. Strategies to help patients ask questions, including those related to prognosis, should be developed.	Guys Kings & St Thomass Med Sch, Dept Palliat Care & Policy, London SE5 6PJ, England; St Christophers Hospice, London SE5 6PJ, England; Charing Cross Hosp, Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Cardiol, London W6 8RF, England; Hammersmith Hosp, Imperial Coll Sch Med, London W12 0NN, England; Royal Brompton Hosp, London SW3 6NP, England	University of London; King's College London; Imperial College London; Imperial College London; Royal Brompton Hospital	Rogers, AE (corresponding author), Guys Kings & St Thomass Med Sch, Dept Palliat Care & Policy, New Med Sch Bldg, London SE5 6PJ, England.	Angela.rogers@kcl.ac.uk	Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				[Anonymous], 1997, J R Coll Physicians Lond, V31, P258; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DRACUP K, 1994, JAMA-J AM MED ASSOC, V272, P1442, DOI 10.1001/jama.272.18.1442; FREEDLAND KE, 1991, J GERIATR PSYCHIAT, V24, P59; Green J, 1999, BRIT MED J, V319, P421; Koenig HG, 1998, GEN HOSP PSYCHIAT, V20, P29, DOI 10.1016/S0163-8343(98)80001-7; Lynn J, 1997, New Horiz, V5, P56; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; McCarthy M, 1997, J ROY SOC MED, V90, P128, DOI 10.1177/014107689709000304; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; Morse JM, 1999, QUAL HEALTH RES, V9, P5, DOI 10.1177/104973299129121622; PONIKOWSKI P, 1997, AM J CARDIOL, V80, P90; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Swan JW, 1997, J AM COLL CARDIOL, V30, P527, DOI 10.1016/S0735-1097(97)00185-X; Wehby D, 1999, HEART LUNG, V28, P31, DOI 10.1016/S0147-9563(99)70041-5	16	163	172	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2000	321	7261					605	607		10.1136/bmj.321.7261.605	http://dx.doi.org/10.1136/bmj.321.7261.605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	352WW	10977838	Bronze, Green Published			2022-12-28	WOS:000089243200021
J	Schnohr, P; Parner, J; Lange, P				Schnohr, P; Parner, J; Lange, P			Mortality in joggers: population based study of 4658 men	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; HEALTH		Bispebjerg Univ Hosp, Copenhagen City Heart Study, DK-2400 Copenhagen NV, Denmark; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen, Denmark; Hvidovre Univ Hosp, Dept Resp Dis, DK-2650 Hvidovre, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen	Schnohr, P (corresponding author), Bispebjerg Univ Hosp, Copenhagen City Heart Study, Bispebjerg Bakke 24, DK-2400 Copenhagen NV, Denmark.							Andersen P. K., 2012, STAT MODELS BASED CO; Appleyard M., 1989, SCAND J SOC MED, V41, P1; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402	4	32	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					602	603		10.1136/bmj.321.7261.602	http://dx.doi.org/10.1136/bmj.321.7261.602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977835	Green Published, Bronze			2022-12-28	WOS:000089243200019
J	Hone, J; Batlogg, B; Benes, Z; Johnson, AT; Fischer, JE				Hone, J; Batlogg, B; Benes, Z; Johnson, AT; Fischer, JE			Quantized phonon spectrum of single-wall carbon nanotubes	SCIENCE			English	Article							VIBRATIONAL-MODES; BUNDLES; HEAT	The electronic spectra of carbon nanotubes and other nanoscale systems are quantized because of their small radii. Similar quantization in the phonon spectra has been difficult to observe because of the far smaller energy scale. We probed this regime by measuring the temperature-dependent specific heat of purified single-wall nanotubes. The data show direct evidence of one-dimensional quantized phonon subbands. Above 4 kelvin, they are in excellent agreement with model calculations of individual nanotubes and differ markedly from the specific heat of two-dimensional graphene or three-dimensional graphite. Detailed modeling yields an energy of 4.3 millielectron volts for the Lowest quantized phonon subband and a tube-tube (or "lattice") Debye energy of 1.1 millielectron volts, implying a small intertube coupling in bundles.	Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Univ Penn, Res Struct Matter Lab, Philadelphia, PA 19104 USA; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA; Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Alcatel-Lucent; Lucent Technologies; AT&T; University of Pennsylvania	Johnson, AT (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.		Hone, James C/E-1879-2011	Hone, James C/0000-0002-8084-3301				ALEXANDER MG, 1980, PHYS REV B, V22, P4535, DOI 10.1103/PhysRevB.22.4535; Benedict LX, 1996, SOLID STATE COMMUN, V100, P177, DOI 10.1016/0038-1098(96)00386-9; Berber S, 2000, PHYS REV LETT, V84, P4613, DOI 10.1103/PhysRevLett.84.4613; Cole MW, 2000, PHYS REV LETT, V84, P3883, DOI 10.1103/PhysRevLett.84.3883; DESAI PD, 1987, INT J THERMOPHYS, V8, P763, DOI 10.1007/BF00500793; Henrard L, 2000, EUR PHYS J B, V13, P661, DOI 10.1007/s100510050083; HENRARD L, 1999, PHYS REV B, V60, P8521; HONE J, 1999, PHYS REV B, V59, P2514; JISHI RA, 1982, CARBON, V20, P127; Kahn D, 1999, PHYS REV B, V60, P6535, DOI 10.1103/PhysRevB.60.6535; Kane CL, 1998, EUROPHYS LETT, V41, P683, DOI 10.1209/epl/i1998-00214-6; KELLY MJ, 1982, J PHYS C SOLID STATE, V15, pL969, DOI 10.1088/0022-3719/15/27/005; Maarouf AA, 2000, PHYS REV B, V61, P11156, DOI 10.1103/PhysRevB.61.11156; Mizel A, 1999, PHYS REV B, V60, P3264, DOI 10.1103/PhysRevB.60.3264; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Peierls R.F., 1955, QUANTUM THEORY SOLID; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; Roukes ML, 1999, PHYSICA B, V263, P1, DOI 10.1016/S0921-4526(98)01482-3; Saito R, 1998, PHYS REV B, V57, P4145, DOI 10.1103/PhysRevB.57.4145; Schwab K, 2000, NATURE, V404, P974, DOI 10.1038/35010065; Teizer W, 1999, PHYS REV LETT, V82, P5305, DOI 10.1103/PhysRevLett.82.5305; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yao Z, 2000, PHYS REV LETT, V84, P2941, DOI 10.1103/PhysRevLett.84.2941	25	434	448	0	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1730	1733		10.1126/science.289.5485.1730	http://dx.doi.org/10.1126/science.289.5485.1730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976062	Green Submitted			2022-12-28	WOS:000089195200040
J	Showman, AP; Dowling, TE				Showman, AP; Dowling, TE			Nonlinear simulations of Jupiter's 5-micron hot spots	SCIENCE			English	Article							GALILEO PROBE; CLOUD STRUCTURE; ATMOSPHERIC COMPOSITION; WATER-VAPOR; ABUNDANCE; WAVES; SHOEMAKER-LEVY-9; DOWNDRAFTS; ORIGIN	Large-scale nonlinear simulations of Jupiter's 5-micron hot spots produce Long-lived coherent structures that cause subsidence in local regions, explaining the Low cloudiness and the dryness measured by the Galileo probe inside a hot spot. Like observed hot spots, the simulated coherent structures are equatorially confined, have periodic spacing, propagate west relative to the flow, are generally confined to one hemisphere, and have an anticyclonic gyre on their equatorward side, The southern edge of the simulated hot spots develops vertical shear of up to 70 meters per second in the eastward wind, which can explain the results of the Galileo probe Doppler wind experiment.	NASA, Ames Res Ctr, Natl Res Council, Moffett Field, CA 94035 USA; Univ Louisville, Comparat Planetol Lab, Louisville, KY 40292 USA	National Academies of Sciences, Engineering & Medicine; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Louisville	Showman, AP (corresponding author), NASA, Ames Res Ctr, Natl Res Council, Mail Stop 245-3, Moffett Field, CA 94035 USA.		Dowling, Timothy E/J-4537-2013	Dowling, Timothy E/0000-0002-7400-2274				ALLISON M, 1990, ICARUS, V83, P282, DOI 10.1016/0019-1035(90)90069-L; Atkinson DH, 1998, J GEOPHYS RES-PLANET, V103, P22911, DOI 10.1029/98JE00060; Atreya SK, 1999, PLANET SPACE SCI, V47, P1243, DOI 10.1016/S0032-0633(99)00047-1; ATREYA SK, 1997, 3 GALILEOS MAN SPACE; Baker RD, 1998, ICARUS, V136, P340, DOI 10.1006/icar.1998.6016; Beebe R.F., 1989, NASA SPEC PUBL, V494, P245; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; BJORAKER GL, 1986, ASTROPHYS J, V311, P1058, DOI 10.1086/164842; BOYD JP, 1991, ENRICO FERMI, V109, P51; CARLSON BE, 1994, J GEOPHYS RES-PLANET, V99, P14623, DOI 10.1029/94JE01222; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; Dowling TE, 1998, ICARUS, V132, P221, DOI 10.1006/icar.1998.5917; DOWLING TE, 1995, ICARUS, V117, P439, DOI 10.1006/icar.1995.1169; FLASAR FM, 1986, J ATMOS SCI, V43, P2683, DOI 10.1175/1520-0469(1986)043<2683:MWAAPO>2.0.CO;2; Folkner WM, 1998, J GEOPHYS RES-PLANET, V103, P22847, DOI 10.1029/98JE01635; Friedson A.J., 1999, B AM ASTRON SOC, V31, P1155; Guillot T, 1999, SCIENCE, V286, P72, DOI 10.1126/science.286.5437.72; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; Irwin PGJ, 1998, J GEOPHYS RES-PLANET, V103, P23001, DOI 10.1029/98JE00948; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; MAHAFFY PR, 1999, B AM ASTRON SOC, V31, P1154; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; Ortiz JL, 1998, J GEOPHYS RES-PLANET, V103, P23051, DOI 10.1029/98JE00696; Owen T, 1999, NATURE, V402, P269, DOI 10.1038/46232; OWEN TC, 1996, EOS S, V77, pS171; POLLACK JB, 1989, ORIGIN EVOLUTION PLA, P564; Roos-Serote M, 1998, J GEOPHYS RES-PLANET, V103, P23023, DOI 10.1029/98JE01049; Showman AP, 1998, ICARUS, V132, P205, DOI 10.1006/icar.1998.5898; Vasavada AR, 1998, ICARUS, V135, P265, DOI 10.1006/icar.1998.5984	30	97	98	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1737	1740						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976064				2022-12-28	WOS:000089195200042
J	Matthews, GJ; Hall, S				Matthews, GJ; Hall, S			Renal-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New York Med Coll, Valhalla, NY 10595 USA	New York Medical College	Matthews, GJ (corresponding author), New York Med Coll, Valhalla, NY 10595 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					701	701		10.1056/NEJM200009073431005	http://dx.doi.org/10.1056/NEJM200009073431005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974134				2022-12-28	WOS:000089100500005
J	Schrope, M				Schrope, M			Trouble in the greenhouse	NATURE			English	Article							ANTHROPOGENIC AEROSOLS; CLOUD ALBEDO; DROPLETS; MODEL											Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; COAKLEY JA, 1987, SCIENCE, V237, P1020, DOI 10.1126/science.237.4818.1020; Facchini MC, 1999, NATURE, V401, P257, DOI 10.1038/45758; Han QY, 1998, J CLIMATE, V11, P1516, DOI 10.1175/1520-0442(1998)011<1516:GSOTRO>2.0.CO;2; Intergovernmental Panel on Climate Change, 1999, AV GLOB ATM; Lohmann U, 1999, J GEOPHYS RES-ATMOS, V104, P9169, DOI 10.1029/1999JD900046; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rotstayn LD, 1999, J GEOPHYS RES-ATMOS, V104, P9369, DOI 10.1029/1998JD900009; Satheesh SK, 1999, J GEOPHYS RES-ATMOS, V104, P27421, DOI 10.1029/1999JD900478; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2	13	4	4	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					10	12		10.1038/35024254	http://dx.doi.org/10.1038/35024254			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993048	Bronze			2022-12-28	WOS:000089124000013
J	Tumbula, DL; Becker, HD; Chang, W; Soll, D				Tumbula, DL; Becker, HD; Chang, W; Soll, D			Domain-specific recruitment of amide amino acids for protein synthesis	NATURE			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; EVOLUTION; GENE; BIOSYNTHESIS; BACTERIA; AMIDOTRANSFERASE; TRANSLATION; RECOGNITION; ENZYME	The formation of aminoacyl-transfer RNA is a crucial step in ensuring the accuracy of protein synthesis. Despite the central importance of this process in all living organisms, it remains unknown how archaea and some bacteria synthesize Asn-tRNA and Gln-tRNA. These amide aminoacyl-tRNAs can be formed by the direct acylation of tRNA, catalysed by asparaginyl-tRNA synthetase and glutaminyl-tRNA synthetase, respectively. A separate, indirect pathway involves the formation of mis-acylated Asp-tRNA(Asn) or Glu-tRNA(Gln), and the subsequent amidation of these amino acids while they are bound to tRNA, which is catalysed by amidotransferases(1,2). Here we show that all archaea possess an archaea-specific heterodimeric amidotransferase (encoded by gatD and gatE) for Gln-tRNA formation. However, Asn-tRNA synthesis in archaea is divergent: some archaea use asparaginyl-tRNA synthetase, whereas others use a heterotrimeric amidotransferase (encoded by the gatA, gatB and gatC genes). Because bacteria primarily use transamidation(3), and the eukaryal cytoplasm uses glutaminyl-tRNA synthetase, it appears that the three domains use different mechanisms for Gln-tRNA synthesis; as such, this is the only known step in protein synthesis where all three domains have diverged. Closer inspection of the two amidotransferases reveals that each of them recruited a metabolic enzyme to aid its function; this provides direct evidence for a relationship between amino-acid metabolism and protein biosynthesis.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.			Hansen, Debra T./0000-0003-4395-8297; Becker, Hubert/0000-0002-4102-7520				BAYLEY ST, 1967, CAN J BIOCHEM, V46, P937; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Brown JR, 1999, J MOL EVOL, V49, P485, DOI 10.1007/PL00006571; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Di Giulio M, 2000, TRENDS GENET, V16, P17, DOI 10.1016/S0168-9525(99)01893-4; Fournand D, 1998, APPL ENVIRON MICROB, V64, P2844; Gagnon Y, 1996, J BIOL CHEM, V271, P14856, DOI 10.1074/jbc.271.25.14856; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Handy J, 1999, J MOL EVOL, V49, P709, DOI 10.1007/PL00006592; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1996, P NATL ACAD SCI USA, V93, P6953, DOI 10.1073/pnas.93.14.6953; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; Kim SI, 1997, J BACTERIOL, V179, P5625, DOI 10.1128/jb.179.17.5625-5627.1997; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; Nabholz CE, 1997, P NATL ACAD SCI USA, V94, P7903, DOI 10.1073/pnas.94.15.7903; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Siatecka M, 1998, EUR J BIOCHEM, V256, P80, DOI 10.1046/j.1432-1327.1998.2560080.x; Sissler M, 1999, P NATL ACAD SCI USA, V96, P8985, DOI 10.1073/pnas.96.16.8985; Soll D., 1974, ENZYMES, V10, P489; SPRING KJ, 1986, J BACTERIOL, V166, P135, DOI 10.1128/jb.166.1.135-142.1986; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Weiner AM, 1999, CURR BIOL, V9, pR842, DOI 10.1016/S0960-9822(00)80041-X; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf YI, 1999, GENOME RES, V9, P689; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909	30	133	139	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					106	110		10.1038/35024120	http://dx.doi.org/10.1038/35024120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993083				2022-12-28	WOS:000089124000052
J	Krakower, JY; Coble, TY; Williams, DJ; Jones, RF				Krakower, JY; Coble, TY; Williams, DJ; Jones, RF			Review of US medical school finances, 1998-1999	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Based on data from the Annual Medical School Questionnaire of the Liaison Committee on Medical Education, to which 100% of the 125 accredited allopathic US medical schools responded, we found that revenue supporting programs and activities of the 125 accredited medical schools in the United States totaled $39761 million in 1998-1999, Three sources accounted for 79.3% of total revenues: practice plans ($13 724 million; 34.5%), grants and contracts ($11982 million; 30.1%), and hospital support ($5814 million; 14.6%), In the aggregate, total revenues increased by 7.4% between 1997-1998 and 1998-1999, a consequence at least in part due to a 2.9% increase in the number of full-time faculty, The largest increase in dollar amount came from grants and contracts ($1101 million; 10.2% increase), Revenue increases were not evenly distributed across the schools, Increases of 10% or more in key revenue sources-practice plans and hospital support-were reported by approximately one fourth of all schools, Another one fourth reported decreases in these same sources.	Assoc Amer Med Coll, Inst Data Syst, Sect Inst & Fac Studies, Washington, DC 20037 USA	Association of American Medical Colleges	Krakower, JY (corresponding author), Assoc Amer Med Coll, Inst Data Syst, Sect Inst & Fac Studies, 2450 N St NW, Washington, DC 20037 USA.							Krakower JY, 1999, JAMA-J AM MED ASSOC, V282, P847, DOI 10.1001/jama.282.9.847; *US BUR LAB STAT, 1999, CPI DET REP	2	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1127	1129		10.1001/jama.284.9.1127	http://dx.doi.org/10.1001/jama.284.9.1127			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974693				2022-12-28	WOS:000089037200014
J	Humbles, AA; Lu, B; Nilsson, CA; Lilly, C; Israel, E; Fujiwara, Y; Gerard, NP; Gerard, C				Humbles, AA; Lu, B; Nilsson, CA; Lilly, C; Israel, E; Fujiwara, Y; Gerard, NP; Gerard, C			A role for the C3a anaphylatoxin receptor in the effector phase of asthma	NATURE			English	Article							MAST-CELLS; SIGNAL-TRANSDUCTION; C5A RECEPTOR; MOUSE; EOSINOPHILS; NEUTROPHILS; COMPLEMENT; EXPRESSION; RESPONSES; PATHWAY	Asthma is a chronic inflammatory disease of the airways and lung mucosa with a strong correlation to atopy and acquired (IgE) immunity(1). However, many features of bronchial asthma, such as smooth muscle contraction, mucus secretion and recruitment of inflammatory cells, are consistent with the actions of complement anaphylatoxins, in particular C3a and C5a(2). Complement activation forms a central core of innate immune defence against mucosal bacteria, viruses, fungi, helminths and other pathogens. As a system of 'pattern-recognition molecules', foreign surface antigens and immune complexes lead to a proteolytic cascade culminating in a lytic membrane attack(2,3). The anaphylatoxins C3a and C5a are liberated as activation byproducts and are potent pro-inflammatory mediators that bind to specific cell surface receptors and cause leukocyte activation, smooth muscle contraction and vascular permeability(2). Here we show that in a murine model of allergic airway disease, genetic deletion of the C3a receptor protects against the changes in lung physiology seen after allergen challenge. Furthermore, human asthmatics develop significant levels of ligand C3a following intra-pulmonary deposition of allergen, but not saline. We propose that, in addition to acquired immune responses, the innate immune system and complement (C3a in particular) are involved in the pathogenesis of asthma.	Harvard Univ, Childrens Hosp, Sch Med, Ina Sue Perlmutter Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div Hematol & Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Gerard, C (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Ina Sue Perlmutter Lab, Boston, MA 02115 USA.	gerard_c@gonzo.tch.harvard.edu						[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BARNES PJ, 1997, ASTHMA, P1051; BHATIA M, UNPUB AM J PHYSL; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chao TH, 1999, J BIOL CHEM, V274, P9721, DOI 10.1074/jbc.274.14.9721; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Drazen JM, 1999, P ASSOC AM PHYSICIAN, V111, P547, DOI 10.1046/j.1525-1381.1999.t01-1-99242.x; Fischer MB, 1996, J IMMUNOL, V157, P549; GERARD NP, 1997, ASTHMA, P639; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Hsu MH, 1997, IMMUNOGENETICS, V47, P64, DOI 10.1007/s002510050327; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nilsson G, 1996, J IMMUNOL, V157, P1693; ONODERA H, 1997, ARERUGI, V41, P1567; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SCHWARTZ RS, 1991, J INVASIVE CARDIOL, V3, P3; SMITH JK, 1990, ANN ALLERGY, V65, P304; STIMLER NP, 1983, PLATELET ACTIVATING, P195; STIMLERGERARD NP, 1987, J IMMUNOL, V138, P1908; Tornetta MA, 1997, J IMMUNOL, V158, P5277	27	287	309	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					998	1001		10.1038/35023175	http://dx.doi.org/10.1038/35023175			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984054				2022-12-28	WOS:000089020200046
J	[Anonymous]				[Anonymous]			Tea but no cake	NATURE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					921	921						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984017				2022-12-28	WOS:000089020200001
J	Blasius, B; Stone, L				Blasius, B; Stone, L			Ecology - Nonlinearity and the Moran effect	NATURE			English	Article							DYNAMICS; SHEEP		Tel Aviv Univ, Dept Zool, Porter Super Ctr Ecol & Environm Studies, IL-69978 Tel Aviv, Israel	Tel Aviv University	Blasius, B (corresponding author), Tel Aviv Univ, Dept Zool, Porter Super Ctr Ecol & Environm Studies, Ramat Aviv, IL-69978 Tel Aviv, Israel.		Blasius, Bernd/AAH-1897-2019; Blasius, Bernd/GLU-4137-2022	Blasius, Bernd/0000-0002-6558-1462; Stone, Lewi/0000-0002-6465-579X				Blasius B, 1999, NATURE, V399, P354, DOI 10.1038/20676; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; Hudson PJ, 1999, TRENDS ECOL EVOL, V14, P1, DOI 10.1016/S0169-5347(98)01498-0; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; Stenseth NC, 1998, NATURE, V394, P620, DOI 10.1038/29177	5	38	39	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					846	847		10.1038/35022646	http://dx.doi.org/10.1038/35022646			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972277				2022-12-28	WOS:000088903600029
J	Imbach, P; Kuhne, T				Imbach, P; Kuhne, T			Sequelae of treatment of ITP with anti-D (Rh-o) immunoglobulin	LANCET			English	Editorial Material							IMMUNE THROMBOCYTOPENIC PURPURA		Childrens Univ Hosp UKBB, Dept Pediat Oncol Hematol, CH-4005 Basel, Switzerland		Imbach, P (corresponding author), Childrens Univ Hosp UKBB, Dept Pediat Oncol Hematol, CH-4005 Basel, Switzerland.		Kuehne, Thomas/I-6143-2019	Kuehne, Thomas/0000-0002-7387-7028				BLANCHETTE V, 1994, LANCET, V344, P703, DOI 10.1016/S0140-6736(94)92205-5; Gaines AR, 2000, BLOOD, V95, P2523, DOI 10.1182/blood.V95.8.2523.008k13_2523_2529; Imbach Paul A., 1997, Current Opinion in Pediatrics, V9, P35, DOI 10.1097/00008480-199702000-00009; SALAMA A, 1986, AM J HEMATOL, V22, P241, DOI 10.1002/ajh.2830220304; Tarantino MD, 1999, J PEDIATR-US, V134, P21, DOI 10.1016/S0022-3476(99)70367-7	5	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					447	448		10.1016/S0140-6736(00)02549-6	http://dx.doi.org/10.1016/S0140-6736(00)02549-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981885				2022-12-28	WOS:000088657700006
J	Fitzpatrick, JM				Fitzpatrick, JM			Will laser replace TURP for the treatment of benign prostatic hyperplasia?	LANCET			English	Editorial Material							TRANSURETHRAL RESECTION; PROSTATECTOMY; ABLATION; MORTALITY		Mater Misericordiae Hosp, Dublin 7, Ireland; Univ Coll Dublin, Dublin 7, Ireland	Mater Misericordiae University Hospital; University College Dublin; University College Dublin	Fitzpatrick, JM (corresponding author), Mater Misericordiae Hosp, Dublin 7, Ireland.							ANSON K, 1995, UROLOGY, V46, P305, DOI 10.1016/S0090-4295(99)80211-8; COWLES RS, 1995, UROLOGY, V46, P155, DOI 10.1016/S0090-4295(99)80185-X; Gilling PJ, 1999, J UROLOGY, V162, P1640, DOI 10.1016/S0022-5347(05)68186-4; Keoghane SR, 2000, BJU INT, V85, P74, DOI 10.1046/j.1464-410x.2000.00407.x; McAllister WJ, 2000, BJU INT, V85, P437, DOI 10.1046/j.1464-410x.2000.00439.x; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NARAYAN P, 1995, J UROLOGY, V154, P2083, DOI 10.1016/S0022-5347(01)66701-6; Neal DE, 1997, BRIT J UROL, V79, P69; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SEAGROATT V, 1995, LANCET, V346, P1521, DOI 10.1016/S0140-6736(95)92052-8	10	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					357	358		10.1016/S0140-6736(00)02524-1	http://dx.doi.org/10.1016/S0140-6736(00)02524-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972365				2022-12-28	WOS:000088486000005
J	Wynia, MK; Cummins, DS; VanGeest, JB; Wilson, IB				Wynia, MK; Cummins, DS; VanGeest, JB; Wilson, IB			Should physicians manipulate reimbursement rules to benefit patients? Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA; New England Med Ctr, Div Clin Care Res, Boston, MA 02111 USA	American Medical Association; Tufts Medical Center	Wynia, MK (corresponding author), Amer Med Assoc, Inst Eth, 515 N State St, Chicago, IL 60610 USA.		Wynia, Matthew/T-2210-2019; Wilson, Ira/F-9190-2016	Wilson, Ira/0000-0002-0246-738X				Illingworth P, 2000, J MED PHILOS, V25, P62, DOI 10.1076/0360-5310(200002)25:1;1-V;FT062; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; Rosenbaum S, 1999, NEW ENGL J MED, V340, P229, DOI 10.1056/NEJM199901213400312	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1382	1383						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989398				2022-12-28	WOS:000089242500028
J	Grabar, S; Le Moing, V; Goujard, C; Leport, C; Kazatchkine, MD; Costagliola, D; Weiss, L				Grabar, S; Le Moing, V; Goujard, C; Leport, C; Kazatchkine, MD; Costagliola, D; Weiss, L			Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							RNA LEVELS; LYMPHOCYTE COUNTS; VIRAL-LOAD; PLASMA; VIRUS; SUPPRESSION; MORTALITY; RECOVERY; FAILURE; DISEASE	Background: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not known. Objective: To study the relation between clinical outcome of HIV-infected patients receiving highly active antiretroviral therapy (HAART) and early immunologic and virologic responses to such therapy, Design: Prospective cohort study. Setting: 68 hospitals in France. Patients: 2236 protease inhibitor-naive patients. Intervention: Initiation of HAART with one protease inhibitor and two nucleoside analogues between July 1996 and March 1997. Measurements: Immunologic and virologic response at 6 months. Multivariate Cox models were used to assess the relation between these responses and progression to a new AIDS-defining event or death. Results: On the basis of 6-month immunologic and virologic responses, patients were classified into four groups: complete response (47.5%), complete nonresponse (16.2%), immunologic response only (19.0%), and virologic response only (17.3%). After month 6 and within a median of 18 months, 69 patients died and 123 experienced a new AIDS-defining event. After adjustment, complete nonresponders and those with only a virologic response had significantly higher risks for clinical progression at 6 months (relative risk, 3.38 [95% CI, 2.28 to 5.02] and 1.98 [CI, 1.26 to 3.10], respectively) than complete responders. The difference between complete responders and those with only an immunologic response at 6 months was weaker and nonsignificant (relative risk, 1.55 [CI, 0.96 to 2.50]). Conclusions: Immunologic response after 6 months of HAART indicates a favorable clinical outcome in HIV-infected patients regardless of virologic response. This suggests that both immunologic and virologic markers should be used in clinical practice to evaluate treatment response.	Hop Bichat Claude Bernard, INSERM, F-75877 Paris 18, France; Hop Broussais, F-75674 Paris, France; Hop Bicetre, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Grabar, S (corresponding author), Univ Paris 06, INSERM, SC4, 27 Rue Chaligny, F-75571 Paris 12, France.		Costagliola, Dominique/H-5849-2011; Grabar, Sophie/AAM-9857-2020; WEISS, Laurence/B-1373-2012	Costagliola, Dominique/0000-0003-0765-0869; Le Moing, Vincent/0000-0002-9529-2792				Belec L, 2000, J INFECT DIS, V181, P1808, DOI 10.1086/315429; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; DEEKS S, 1999, 6 C RETR OPP INF CHI, P205; Eastman PS, 1998, J VIROL, V72, P5154, DOI 10.1128/JVI.72.6.5154-5164.1998; FAYE A, 1999, 6 C RETR OPP INF CHI, P130; Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009; GRABAR S, 1992, MMWR-MORBID MORTAL W, V41, P1; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; KATLAMA C, 1999, 7 EUR C CLIN ASP TRE; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KAUFMANN D, 1999, 6 C RETR OPP INF CHI, P130; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Le Moing V, 2000, J ACQ IMMUN DEF SYND, V24, P82; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; Levitz SM, 1998, NEW ENGL J MED, V338, P1074, DOI 10.1056/NEJM199804093381517; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Masur H, 1999, ANN INTERN MED, V131, P873, DOI 10.7326/0003-4819-131-11-199912070-00022; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MONTFORTE AD, 1999, AIDS, V13, P1669; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; Sloand EM, 1999, BLOOD, V94, P1021, DOI 10.1182/blood.V94.3.1021.415k29_1021_1027; STODDART C, 1999, 6 C RETR OPP INF CHI, P67; WEISS L, 1999, 4 EUR C AIDS RES TEM, P66	33	325	331	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					401	410		10.7326/0003-4819-133-6-200009190-00007	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975957				2022-12-28	WOS:000089329700001
J	Geim, AK; Dubonos, SV; Grigorieva, IV; Novoselov, KS; Peeters, FM; Schweigert, VA				Geim, AK; Dubonos, SV; Grigorieva, IV; Novoselov, KS; Peeters, FM; Schweigert, VA			Non-quantized penetration of magnetic field in the vortex state of superconductors	NATURE			English	Article								As first pointed out by Bardeen and Ginzburg in the early sixties(1,2), the amount of magnetic flux carried by vortices in superconducting materials depends on their distance from the sample edge, and can be smaller than one flux quantum, phi(0) = h/2e (where h is Planck's constant and e is the electronic charge). In bulk superconductors, this reduction of flux becomes negligible at submicrometre distances from the edge, but in thin films the effect may survive much farther into the material(3,4). But the effect has not been observed experimentally, and it is often assumed that magnetic field enters type II superconductors in units of f0. Here we measure the amount of flux introduced by individual vortices in a superconducting film, finding that the flux always differs substantially from f0. We have observed vortices that carry as little as 0.001 phi(0), as well as 'negative vortices', whose penetration leads to the expulsion of magnetic field. We distinguish two phenomena responsible for non-quantized flux penetration: the finite-size effect(1-4) and a nonlinear screening of the magnetic field due to the presence of a surface barrier. The latter effect has not been considered previously, but is likely to cause non-quantized penetration in most cases.	Catholic Univ Nijmegen, NL-6525 ED Nijmegen, Netherlands; Univ Manchester, Dept Phys, Manchester M13 9PL, Lancs, England; Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia; Univ Instelling Antwerp, Dept Phys, B-2610 Wilrijk, Belgium; Russian Acad Sci, Inst Theoret & Appl Mech, Novosibirsk 630090, Russia	Radboud University Nijmegen; University of Manchester; Russian Academy of Sciences; University of Antwerp; Russian Academy of Sciences; Khristianovich Institute of Theoretical & Applied Mechanics SB RAS	Geim, AK (corresponding author), Catholic Univ Nijmegen, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		Geim, Andre K/J-7888-2012; Novoselov, Kostya S/G-9581-2014	Geim, Andre K/0000-0003-2861-8331; Novoselov, Kostya S/0000-0003-4972-5371; hai yan, he/0000-0003-0366-6185				BARDEEN J, 1961, PHYS REV LETT, V7, P162, DOI 10.1103/PhysRevLett.7.162; FETTER AL, 1980, PHYS REV B, V22, P1200, DOI 10.1103/PhysRevB.22.1200; Fuchs DT, 1998, NATURE, V391, P373, DOI 10.1038/34879; Geim AK, 2000, PHYS REV LETT, V85, P1528, DOI 10.1103/PhysRevLett.85.1528; Geim AK, 1998, NATURE, V396, P144, DOI 10.1038/24110; Geim AK, 1997, APPL PHYS LETT, V71, P2379, DOI 10.1063/1.120034; GINZBURG VL, 1962, SOV PHYS JETP-USSR, V15, P207; KOGAN VG, 1994, PHYS REV B, V49, P15874, DOI 10.1103/PhysRevB.49.15874; Palacios JJ, 2000, PHYS REV LETT, V84, P1796, DOI 10.1103/PhysRevLett.84.1796; SCHWEIGERT VA, 1999, PHYS REV LETT, V83, P2049; WHITE WR, 1993, PHYS REV LETT, V70, P670, DOI 10.1103/PhysRevLett.70.670	11	154	155	2	51	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					55	57		10.1038/35024025	http://dx.doi.org/10.1038/35024025			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993068	Green Submitted			2022-12-28	WOS:000089124000037
J	Rhein, M				Rhein, M			Oceanography - Drifters reveal deep circulation	NATURE			English	Editorial Material							LABRADOR SEA-WATER		Univ Bremen, Abt Ozeanog, Inst Umweltphys, D-28359 Bremen, Germany	University of Bremen	Rhein, M (corresponding author), Univ Bremen, Abt Ozeanog, Inst Umweltphys, Kufsteiner Str, D-28359 Bremen, Germany.		Rhein, Monika/P-1969-2016	Rhein, Monika/0000-0003-1496-2828				Curry RG, 1998, NATURE, V391, P575, DOI 10.1038/35356; Dickson B, 1997, NATURE, V386, P649, DOI 10.1038/386649a0; Lavender KL, 2000, NATURE, V407, P66, DOI 10.1038/35024048; Molinari RL, 1998, GEOPHYS RES LETT, V25, P2249, DOI 10.1029/98GL01853; Sy A, 1997, NATURE, V386, P675, DOI 10.1038/386675a0; TALLEY LD, 1982, J PHYS OCEANOGR, V12, P1189, DOI 10.1175/1520-0485(1982)012<1189:DACOLS>2.0.CO;2; Wunsch C, 2000, NATURE, V405, P743, DOI 10.1038/35015639	7	8	8	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					30	31		10.1038/35024186	http://dx.doi.org/10.1038/35024186			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993057				2022-12-28	WOS:000089124000025
J	Seeber, L; Armbruster, JG				Seeber, L; Armbruster, JG			Earthquakes as beacons of stress change	NATURE			English	Article							SOUTHERN-CALIFORNIA; STATIC STRESS; 1992 LANDERS; LOMA-PRIETA; AFTERSHOCKS; SEQUENCE	Aftershocks occurring on faults in the far-field of a large earthquake rupture can generally be accounted for by changes in static stress on these faults caused by the rupture(1,2). This implies that faults interact, and that the timing of an earthquake can be affected by previous nearby ruptures(3-6). Here we explore the potential of small earthquakes to act as 'beacons' for the mechanical state of the crust. We investigate the static-stress changes resulting from the 1992 Landers earthquake in southern California which occurred in an area of high seismic activity stemming from many faults. We first gauge the response of the regional seismicity to the Landers event with a new technique, and then apply the same method to the inverse problem of determining the slip distribution on the main rupture from the seismicity. Assuming justifiable parameters, we derive credible matches to slip profiles obtained directly from the Landers mainshock(7,8). Our results provide a way to monitor mechanical conditions in the upper crust, and to investigate processes leading to fault failure.	Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Seeber, L (corresponding author), Lamont Doherty Earth Observ, Palisades, NY 10964 USA.							Deng JS, 1999, GEOPHYS RES LETT, V26, P3209, DOI 10.1029/1999GL010496; Deng JS, 1997, J GEOPHYS RES-SOL EA, V102, P9859, DOI 10.1029/96JB03897; Dieterich JH, 1996, P NATL ACAD SCI USA, V93, P3787, DOI 10.1073/pnas.93.9.3787; Erickson L., 1986, THESIS STANFORD U; Gross S, 1998, J GEOPHYS RES-SOL EA, V103, P4915, DOI 10.1029/97JB03010; Hardebeck JL, 1998, J GEOPHYS RES-SOL EA, V103, P24427, DOI 10.1029/98JB00573; HARRIS RA, 1992, NATURE, V360, P251, DOI 10.1038/360251a0; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24439, DOI 10.1029/98JB00793; HUDNUT KW, 1989, GEOPHYS RES LETT, V16, P199, DOI 10.1029/GL016i002p00199; HUDNUT KW, 1994, B SEISMOL SOC AM, V84, P625; JAUME SC, 1992, SCIENCE, V258, P1325, DOI 10.1126/science.258.5086.1325; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; MENKE W, 1989, GEOPHYSICAL DATA ANA, P53; REASENBERG PA, 1992, SCIENCE, V255, P1687, DOI 10.1126/science.255.5052.1687; SCHOLZ C, 1990, MECH EARTHQUAKES FAU, P53; SEEBER L, 1995, J GEOPHYS RES-SOL EA, V100, P8285, DOI 10.1029/94JB02939; STEIN RS, 1983, J GEOPHYS RES, V88, P6477, DOI 10.1029/JB088iB08p06477; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668	20	47	61	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					69	72		10.1038/35024055	http://dx.doi.org/10.1038/35024055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993073				2022-12-28	WOS:000089124000042
J	Shigenobu, S; Watanabe, H; Hattori, M; Sakaki, Y; Ishikawa, H				Shigenobu, S; Watanabe, H; Hattori, M; Sakaki, Y; Ishikawa, H			Genome sequence of the endocellular bacterial symbiont of aphids Buchnera sp APS	NATURE			English	Article							PROTEIN-SECRETION SYSTEM; ENDOSYMBIOTIC BACTERIA; ACYRTHOSIPHON-PISUM; GENES	Almost all aphid species (Homoptera, Insecta) have 60-80 huge cells called bacteriocytes, within which are round-shaped bacteria that are designated Buchnera(1). These bacteria are maternally transmitted to eggs and embryos through host generations, and the mutualism between the host and the bacteria is so obligate that neither can reproduce independently(2). Buchnera is a close relative of Escherichia coli(3), but it contains more than 100 genomic copies per cell(4), and its genome size is only a seventh of that of E. coli(5). Here we report the complete genome sequence of Buchnera sp. strain APS, which is composed of one 640,681-base-pair chromosome and two small plasmids. There are genes for the biosyntheses of amino acids essential for the hosts in the genome, but those for non-essential amino acids are missing, indicating complementarity and syntrophy between the host and the symbiont. In addition, Buchnera lacks genes for the biosynthesis of cell-surface components, including lipopolysaccharides and phospholipids, regulator genes and genes involved in defence of the cell. These results indicate that Buchnera is completely symbiotic and viable only in its limited niche, the bacteriocyte.	RIKEN, Genome Sci Ctr, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo; University of Tokyo	Sakaki, Y (corresponding author), RIKEN, Genome Sci Ctr, Kitasato 1-15-1, Sagamihara, Kanagawa 2288555, Japan.	sakai@ims.u-tokyo.ac.jp; iskw@biol.s.u-tokyo.ac.jp	Shigenobu, Shuji/B-6239-2011; Hattori, Masahira/C-6958-2016; Hattori, Masahira/AAD-3785-2019	Shigenobu, Shuji/0000-0003-4640-2323; Hattori, Masahira/0000-0001-9467-0344; 				BAUMANN P, 2000, PROKARYOTES; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Charles H, 1999, J MOL EVOL, V48, P142, DOI 10.1007/PL00006452; DOUGLAS AE, 1988, INSECT BIOCHEM, V18, P599, DOI 10.1016/0020-1790(88)90012-1; Douglas AE, 1998, ANNU REV ENTOMOL, V43, P17, DOI 10.1146/annurev.ento.43.1.17; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; HOUK EJ, 1980, ANNU REV ENTOMOL, V25, P161, DOI 10.1146/annurev.en.25.010180.001113; Komaki K, 1999, J MOL EVOL, V48, P717, DOI 10.1007/PL00006516; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Marais A, 1996, J BACTERIOL, V178, P7003, DOI 10.1128/jb.178.23.7003-7009.1996; MITTLER TE, 1971, J NUTR, V101, P1023, DOI 10.1093/jn/101.8.1023; MORAN NA, 1993, P ROY SOC B-BIOL SCI, V253, P167, DOI 10.1098/rspb.1993.0098; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; MUNSON MA, 1991, INT J SYST BACTERIOL, V41, P566, DOI 10.1099/00207713-41-4-566; Nakabachi A, 1999, J INSECT PHYSIOL, V45, P1, DOI 10.1016/S0022-1910(98)00104-8; Nogueira T, 2000, CURR OPIN MICROBIOL, V3, P154, DOI 10.1016/S1369-5274(00)00068-0; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SASAKI T, 1995, J INSECT PHYSIOL, V41, P41, DOI 10.1016/0022-1910(94)00080-Z; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tomii K, 1998, GENOME RES, V8, P1048, DOI 10.1101/gr.8.10.1048; vanHam RCHJ, 1997, J BACTERIOL, V179, P4768, DOI 10.1128/jb.179.15.4768-4777.1997; Watanabe H, 1997, J MOL EVOL, V44, pS57, DOI 10.1007/PL00000052; WHITEHEAD LF, 1993, J GEN MICROBIOL, V139, P821, DOI 10.1099/00221287-139-4-821; Yada T, 1996, DNA Res, V3, P355, DOI 10.1093/dnares/3.6.355; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456; [No title captured]	30	973	1587	4	169	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					81	86		10.1038/35024074	http://dx.doi.org/10.1038/35024074			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993077	Bronze			2022-12-28	WOS:000089124000046
J	Miles, EW; Davies, DR				Miles, EW; Davies, DR			Protein evolution - On the ancestry of barrels	SCIENCE			English	Editorial Material							TRYPTOPHAN SYNTHASE; SEQUENCE-ANALYSIS		NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Miles, EW (corresponding author), NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK034002, ZIHDK034002, Z01DK024140, Z01DK034002] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; FANI R, 1994, J MOL EVOL, V38, P489, DOI 10.1007/BF00178849; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; MILES EW, 1982, BIOCHEMISTRY-US, V21, P2586, DOI 10.1021/bi00540a002; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Thoma R, 1998, EXTREMOPHILES, V2, P379, DOI 10.1007/s007920050082; Thornton JM, 1999, J MOL BIOL, V293, P333, DOI 10.1006/jmbi.1999.3054; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	12	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1490	1490		10.1126/science.289.5484.1490	http://dx.doi.org/10.1126/science.289.5484.1490			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10991737				2022-12-28	WOS:000089071700032
J	Lipson, H; Pollack, JB				Lipson, H; Pollack, JB			Automatic design and manufacture of robotic lifeforms	NATURE			English	Article							EVOLUTION	Biological life is in control of its own means of reproduction, which generally involves complex, autocatalysing chemical reactions. But this autonomy of design and manufacture has not yet been realized artificially(1). Robots are still laboriously designed and constructed by teams of human engineers, usually at considerable expense. Few robots are available because these costs must be absorbed through mass production, which is justified only for toys, weapons and industrial systems such as automatic teller machines. Here we report the results of a combined computational and experimental approach in which simple electromechanical systems are evolved through simulations from basic building blocks (bars, actuators and artificial neurons); the 'fittest' machines (defined by their locomotive ability) are then fabricated robotically using rapid manufacturing technology. We thus achieve autonomy of design and construction using evolution in a 'limited universe' physical simulation(2,3) coupled to automatic fabrication.	Brandeis Univ, Volen Ctr Complex Syst, Dept Comp Sci, Waltham, MA 02454 USA	Brandeis University	Lipson, H (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Dept Comp Sci, Waltham, MA 02454 USA.							Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Beer R. D., 1990, INTELLIGENCE ADAPTIV; Bentley P.J., 1999, EVOLUTIONARY DESIGN; Chellapilla K, 1999, P IEEE, V87, P1471, DOI 10.1109/5.784222; FLOREANO D, 1994, ANIMALS ANIMATS, V3, P421; Fogel L. J., 1966, ARTIF INTELL; Funes P, 1998, ARTIF LIFE, V4, P337, DOI 10.1162/106454698568639; GRUAU F, 1997, P 4 EUR C ART LIF; HOLLAND J, 1975, ADAPTATION NATURAL A; HUSBANDS P, 1998, EVOLUTIONARY ROBOTIC; JOY B, 2000, WIRED, V8, P238; Kochan A, 1997, RAPID PROTOTYPING J, V3, P150, DOI 10.1108/13552549710191863; KOMOSINSKI M, 1999, 5 EUR C ART LIF ECAL, P261; Koza JR, 1992, GENETIC PROGRAMMING; Langton C, 1989, ARTIFICIAL LIFE; Leger C., 1999, AUTOMATED SYNTHESIS; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; LUND H, 1996, P IEEE 3 INT C EV CO, P384; Mahfoud S. W.., 1995, NICHING METHODS GENE; Moravec H., 1999, ROBOT MERE MACHINE T; Nolfi S, 1997, ROBOT AUTON SYST, V22, P187, DOI 10.1016/S0921-8890(97)00038-9; Pollack JB, 1998, MACH LEARN, V32, P225, DOI 10.1023/A:1007417214905; Rechenberg I., 1973, EVOLUTIONSSTRATEGIE; SIMS K, 1994, ARTIF LIFE, V4, P28; SMITH JM, 1992, NATURE, V355, P772; SWINSON M, 1998, BAA9909 DARPA; Thompson A., 1997, EVOLUTIONARY ROBOTIC, P101; WATSON RA, 1999, 99 C EV COMP, P335; Ziemelis K, 1998, NATURE, V393, P619, DOI 10.1038/31333; [No title captured]	30	504	518	11	107	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					974	978		10.1038/35023115	http://dx.doi.org/10.1038/35023115			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984047				2022-12-28	WOS:000089020200039
J	Yin, HW; Pruyne, D; Huffaker, TC; Bretscher, A				Yin, HW; Pruyne, D; Huffaker, TC; Bretscher, A			Myosin V orientates the mitotic spindle in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MICROTUBULE ORIENTATION; ASTRAL MICROTUBULES; POLARIZED DELIVERY; BUDDING YEAST; ACTIN; LOCALIZATION; KINESIN; PROTEIN; GROWTH	Coordination of spindle orientation with the axis of cell division is an essential process in all eukaryotes. In addition to ensuring accurate chromosomal segregation, proper spindle orientation also establishes differential cell fates and proper morphogenesis(1). In both animal and yeast cells, this process is dependent on cytoplasmic microtubules interacting with the cortical actin-based cytoskeleton(2-5), although the motive force was unknown. Here we show that yeast Myo2, a myosin V that translocates along polarized actin cables into the bud(6), orientates the spindle early in the cell cycle by binding and polarizing the microtubule-associated protein Kar9 (refs 7-9). The tail domain of Myo2 that binds Kar9 also interacts with secretory vesicles(12) and vacuolar elements(13), making it a pivotal component of yeast cell polarization.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Huffaker, TC (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Biotechnol Bldg, Ithaca, NY 14853 USA.			Huffaker, Tim/0000-0003-0916-0441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040479] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Beningo KA, 2000, MOL BIOL CELL, V11, P691, DOI 10.1091/mbc.11.2.691; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; Chen XYP, 1998, J CELL BIOL, V141, P1169, DOI 10.1083/jcb.141.5.1169; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Heil-Chapdelaine RA, 1999, J CELL BIOL, V144, P809, DOI 10.1083/jcb.144.5.809; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Theesfeld CL, 1999, J CELL BIOL, V146, P1019, DOI 10.1083/jcb.146.5.1019; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495	30	251	255	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1013	1015		10.1038/35023024	http://dx.doi.org/10.1038/35023024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984058				2022-12-28	WOS:000089020200050
J	Garrett, WS; Chen, LM; Kroschewski, R; Ebersold, M; Turley, S; Trombetta, S; Galan, JE; Mellman, I				Garrett, WS; Chen, LM; Kroschewski, R; Ebersold, M; Turley, S; Trombetta, S; Galan, JE; Mellman, I			Developmental control of endocytosis in dendritic cells by Cdc42	CELL			English	Article							GTP-BINDING PROTEIN; SALMONELLA-TYPHIMURIUM; RHO-GTPASES; NUCLEAR RESPONSES; SECRETION SYSTEM; EPITHELIAL-CELLS; HOST-CELLS; MEMBRANE; COMPLEX; ANTIGEN	Dendritic cells (DCs) developmentally regulate antigen uptake by controlling their endocytic capacity. Immature DCs actively internalize antigen. However, mature DCs are poorly endocytic, functioning instead to present antigens to T cells. We have found that endocytic downregulation reflects a decrease in endocytic activity controlled by Rho family GTPases, especially Cdc42. Blocking Cdc42 function by Toxin B treatment or injection of dominant-negative inhibitors of Cdc42 abrogates endocytosis in immature DCs. In mature DCs, injection of constitutively active Cdc42 or microbial delivery of a Cdc42 nucleotide exchange factor reactivates endocytosis. DCs regulate endogenous levels of Cdc42-GTP with activated Cdc42 detectable only in immature cells. We conclude that DCs developmentally regulate endocytosis at least in part by controlling levels of activated Cdc42.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, New Haven, CT 06520 USA; Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT 06520 USA	Yale University; Yale University; Ludwig Institute for Cancer Research; Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	ira.mellman@yale.edu	Mellman, Ira/ABG-5896-2020	Garrett, Wendy/0000-0002-5092-0150; Kroschewski, Ruth/0000-0002-6032-2568	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034098, R01AI034098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46128] Funding Source: Medline; NIAID NIH HHS [AI-34098] Funding Source: Medline; NIGMS NIH HHS [GM-29765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Driessen C, 1999, J CELL BIOL, V147, P775, DOI 10.1083/jcb.147.4.775; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1992, J BACTERIOL, V174, P4338; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Li GP, 1997, J BIOL CHEM, V272, P10337; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; PYPAERT M, 1992, METHOD ENZYMOL, V219, P212; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; West MA, 1999, EUR J IMMUNOL, V29, P3450, DOI 10.1002/(SICI)1521-4141(199911)29:11<3450::AID-IMMU3450>3.0.CO;2-A; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1	47	344	349	3	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					325	334		10.1016/S0092-8674(00)00038-6	http://dx.doi.org/10.1016/S0092-8674(00)00038-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975523	Bronze			2022-12-28	WOS:000088625600008
J	Zoo, YM; Stoeckli, E; Chen, H; Tessier-Lavigne, M				Zoo, YM; Stoeckli, E; Chen, H; Tessier-Lavigne, M			Squeezing axons out of the gray matter: A role for slit and semaphorin proteins from midline and ventral spinal cord	CELL			English	Article							OLFACTORY-BULB AXONS; GROWTH CONE GUIDANCE; COMMISSURAL NEURONS; FLOOR-PLATE; INTERMEDIATE TARGET; NERVOUS-SYSTEM; CNS MIDLINE; ROOF PLATE; FAMILY; CHEMOATTRACTANT	Commissural axons cross the nervous system midline and then turn to grow alongside it, neither recrossing nor projecting back into ventral regions. In Drosophila, the midline repellent Slit prevents recrossing: axons cross once because they are initially unresponsive to Slit, becoming responsive only upon crossing. We show that commissural axons in mammals similarly acquire responsiveness to a midline repellent activity upon crossing. Remarkably, they also become responsive to a repellent activity from ventral spinal cord, helping explain why they never reenter that region. Several Slit and Semaphorin proteins, expressed in midline and/or ventral tissues, mimic these repellent activities, and midline guidance defects are observed in mice lacking neuropilin-2, a Semaphorin receptor. Thus, Slit and Semaphorin repellents from midline and nonmidline tissues may help prevent crossing axons from reentering gray matter, squeezing them into surrounding fiber tracts.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Basel, Dept Integrat Biol, CH-4051 Basel, Switzerland	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Basel	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.	marctl@itsa.ucsf.edu		Stoeckli, Esther/0000-0002-8485-0648	NINDS NIH HHS [F32 NS010273] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010273] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cajal SR., 1893, CELLULE, V9, P119; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Christensen CRL, 1998, CANCER RES, V58, P1238; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; de Castro F, 1999, J NEUROSCI, V19, P4428; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Imondi R, 2000, DEVELOPMENT, V127, P1397; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Richards LJ, 1997, J NEUROSCI, V17, P2445; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; SILOSSANTIAGO I, 1992, J COMP NEUROL, V325, P514, DOI 10.1002/cne.903250405; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Wang H, 1999, NATURE, V401, P765, DOI 10.1038/44521; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7	46	289	293	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					363	375		10.1016/S0092-8674(00)00041-6	http://dx.doi.org/10.1016/S0092-8674(00)00041-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975526	Bronze, Green Accepted			2022-12-28	WOS:000088625600011
J	Olin, JW				Olin, JW			Current concepts: Thromboangiitis obliterans (Buerger's disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOKING; MANIFESTATIONS; EXPERIENCE; OCCLUSION; THERAPY; WOMEN		Heart & Vasc Inst New Jersey, Morristown, NJ 07960 USA		Olin, JW (corresponding author), Heart & Vasc Inst New Jersey, 111 Madison Ave, Morristown, NJ 07960 USA.	olinjwl@aol.com						ADAR R, 1983, NEW ENGL J MED, V308, P1113, DOI 10.1056/NEJM198305123081901; Allen EV, 1929, AM J MED SCI, V178, P237, DOI 10.1097/00000441-192908000-00009; Beshev L, 1998, EUR J VASC ENDOVASC, V16, P456; Buerger L, 1908, AM J MED SCI, V136, P567, DOI 10.1097/00000441-190810000-00011; CABEZASMOYA R, 1970, ARCH SURG-CHICAGO, V101, P632; Cachovan M, 1988, THROMBOANGIITIS OBLI, P31; CORELLI F, 1973, J CARDIOVASC SURG, V14, P28; DEITCH EA, 1981, AM SURGEON, V47, P326; DIBLE JH, 1966, PATHOLOGY LIMB ISCHA, P79; Donatelli F, 1997, J THORAC CARDIOV SUR, V113, P800, DOI 10.1016/S0022-5223(97)70243-5; Eichhorn J, 1998, AM J MED SCI, V315, P17, DOI 10.1097/00000441-199801000-00004; FIELDING JE, 1988, NEW ENGL J MED, V319, P1452, DOI 10.1056/NEJM198812013192205; FIESSINGER JN, 1990, LANCET, V335, P555, DOI 10.1016/0140-6736(90)90346-7; GIFFORD RW, 1951, P STAFF M MAYO CLIN, V26, P241; GROVE WJ, 1992, ANN ROY COLL SURG, V74, P115; Harten P, 1996, ANGIOLOGY, V47, P419, DOI 10.1177/000331979604700415; Hooten WM, 1998, MAYO CLIN PROC, V73, P529, DOI 10.4065/73.6.529; HUSSEIN EA, 1993, INT SURG, V78, P54; INADA K, 1974, ARCH SURG-CHICAGO, V108, P663; ISHIKAWA K, 1976, ANN REPORT BUERGERS, P3; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; JOYCE JW, 1990, RHEUM DIS CLIN N AM, V16, P463; Kobayashi M, 1999, J VASC SURG, V29, P451, DOI 10.1016/S0741-5214(99)70273-9; Kubota Y, 1997, CARDIOVASC INTER RAD, V20, P380, DOI 10.1007/s002709900172; LAMBETH JT, 1970, AMER J ROENTGENOL RA, V109, P553, DOI 10.2214/ajr.109.3.553; Lau H, 1997, AUST NZ J SURG, V67, P264, DOI 10.1111/j.1445-2197.1997.tb01960.x; LEU HJ, 1975, PATHOL MICROBIOL, V43, P151, DOI 10.1159/000162812; LEU HJ, 1985, SCHWEIZ MED WSCHR, V115, P1080; LIE JT, 1990, RHEUM DIS CLIN N AM, V16, P269; Lie JT, 1998, INT J CARDIOL, V66, pS249, DOI 10.1016/S0167-5273(98)00176-4; LIE JT, 1987, MEDICINE, V66, P65, DOI 10.1097/00005792-198701000-00002; LIE JT, 1988, PATHOL ANNU, V23, P257; LIE JT, 1989, ACTA PATHOL JAPON, V39, P153; LIE JT, 1988, ARTHRITIS RHEUM, V31, P812, DOI 10.1002/art.1780310620; Makita S, 1996, CIRCULATION, V94, P211; Matsushita M, 1998, SURGERY, V124, P498, DOI 10.1016/S0039-6060(98)70095-9; MATSUSHITA M, 1991, J VASC SURG, V14, P53; MCKUSICK VA, 1962, JAMA-J AM MED ASSOC, V181, P5, DOI 10.1001/jama.1962.03050270007002; MCKUSICK VA, 1962, B JOHNS HOPKINS HOSP, V110, P145; Michail PO, 1998, EUR J VASC ENDOVASC, V16, P445, DOI 10.1016/S1078-5884(98)80016-6; Mills J L, 1993, Semin Vasc Surg, V6, P14; Mills J L, 1991, Ann Vasc Surg, V5, P570, DOI 10.1007/BF02015288; MILLS JL, 1987, AM J SURG, V154, P123, DOI 10.1016/0002-9610(87)90301-1; Olin Jeffrey W., 1994, Current Opinion in Rheumatology, V6, P44, DOI 10.1097/00002281-199401000-00008; OLIN JW, 1990, CIRCULATION, V82, P3; OLIN JW, 1992, CURRENT MANAGEMENT H, P265; Olin JW, 2000, VASCULAR SURG, P350; Olin JW, 1996, VASC MED, P1033; Papa MZ, 1996, EUR J VASC ENDOVASC, V11, P335, DOI 10.1016/S1078-5884(96)80081-5; PAPA MZ, 1992, PERSPECT VASC SURG, V5, P1, DOI DOI 10.1177/153100359200500102; ROSEN N, 1985, ARCH PATHOL LAB MED, V109, P962; Sasajima T, 1997, EUR J VASC ENDOVASC, V13, P186, DOI 10.1016/S1078-5884(97)80017-2; Sasaki S, 1999, AM J SURG, V177, P316, DOI 10.1016/S0002-9610(99)00046-X; Sayin A, 1993, Cardiovasc Surg, V1, P377; Shionoya S, 1998, INT J CARDIOL, V66, pS243, DOI 10.1016/S0167-5273(98)00175-2; SHIONOYA S, 1983, WORLD J SURG, V7, P544, DOI 10.1007/BF01655948; SHIONOYA S, 1978, J CARDIOVASC SURG, V19, P69; SHIONOYA S, 1989, VASCULAR SURG, P207; Shionoya Shigehiko, 1995, P657; Singh I, 1996, AUST NZ J SURG, V66, P372, DOI 10.1111/j.1445-2197.1996.tb01214.x; Swigris JJ, 1999, J VASC SURG, V29, P928, DOI 10.1016/S0741-5214(99)70221-1; SZILAGYI DE, 1964, ARCH SURG-CHICAGO, V88, P824, DOI 10.1001/archsurg.1964.01310230100021; Talwar S, 1998, AUST NZ J SURG, V68, P38, DOI 10.1111/j.1445-2197.1998.tb04634.x; Verstraete M, 1998, EUR J VASC ENDOVASC, V15, P300; Von Winiwarter F, 1879, ARCH KLIN CHIR, V23, P202; WILLIAMS G, 1969, J CLIN PATHOL, V22, P573, DOI 10.1136/jcp.22.5.573	66	323	347	4	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					864	869		10.1056/NEJM200009213431207	http://dx.doi.org/10.1056/NEJM200009213431207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995867				2022-12-28	WOS:000089355600007
J	Stevinson, C; Pittler, MH; Ernst, E				Stevinson, C; Pittler, MH; Ernst, E			Garlic for treating hypercholesterolemia - A meta-analysis of randomized clinical trials	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-LIPIDS; ALLIUM-SATIVUM; TOTAL CHOLESTEROL; PLASMA-LIPIDS; SERUM-LIPIDS; METAANALYSIS; BIAS; LIPOPROTEINS; QUALITY	Purpose: To investigate the effect of garlic on total cholesterol level in persons with elevated levels by conducting a metaanalysis of randomized, double-blind, placebo-controlled trials. Data Sources: Systematic literature searches were conducted on the MEDLINE, EMBASE, BIOSIS, Cochrane Library, AMED, and CISCOM databases. Manufacturers of commercial garlic preparations and experts in the field were asked about published or unpublished trials. Study Selection: Selected trials were required to state that they were randomized, double-blind, and placebo-controlled; use garlic monopreparations; include persons with mean total cholesterol levels of at least 5.17 mmol/L (200 mg/dL); and report total cholesterol level as an end point There were no language restrictions. Data Extraction: Two reviewers, blinded to key identifiers of each paper, independently extracted data in a standardized manner and assessed methodologic quality by using the Jadad scale. Discrepancies were settled through discussion. Data Synthesis: In the 13 trials included in the meta-analysis, garlic reduced total cholesterol level from baseline significantly more than placebo (P < 0.01); the weighted mean difference was -0.41 mmol/L (95% CI, -0.66 to -0.15 mmol/L) (-15.7 mg/dL [CI, -25.6 to -5.7 mg/dL]). Six diet-controlled trials with the highest scores for methodologic quality revealed a nonsignificant difference between garlic and placebo groups; the weighted mean difference was -0.11 mmol/L(CI, -0.30 to 0.08 mmol/L) (-4.3 mg/dL ICI, -11.7 to 3.1 mg/dL]). Conclusions: The available data suggest that garlic is superior to placebo in reducing total cholesterol levels. However, the size of the effect is modest, and the robustness of the effect is debatable. The use of garlic for hypercholesterolemia is therefore of questionable value.	Univ Exeter, Dept Complementary Med, Exeter EX2 4NT, Devon, England	University of Exeter	Ernst, E (corresponding author), Univ Exeter, Dept Complementary Med, 25 Victoria Pk Rd, Exeter EX2 4NT, Devon, England.	E.Ernst@exeter.ac.uk						Adler AJ, 1997, AM J CLIN NUTR, V65, P445, DOI 10.1093/ajcn/65.2.445; Auer W, 1990, Br J Clin Pract Suppl, V69, P3; BARRIE SA, 1987, J ORTHOMOL MED, V2, P15; Berthold HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/jama.279.23.1900; BHUSHAN S, 1979, Indian Journal of Physiology and Pharmacology, V23, P211; BIMMERMANN A, 1988, THERAPIEWOCHE, V38, P3885; BORDIA A, 1975, ATHEROSCLEROSIS, V21, P15, DOI 10.1016/0021-9150(75)90091-X; Bordia A, 1998, PROSTAG LEUKOTR ESS, V58, P257, DOI 10.1016/S0952-3278(98)90034-5; BORDIA A, 1981, AM J CLIN NUTR, V34, P2100, DOI 10.1093/ajcn/34.10.2100; Bordia A, 1982, Indian Heart J, V34, P86; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; ERNST E, 1987, PHARMATHERAPEUTICA, V5, P83; ERNST E, 1986, COMPTES RENDUS THERA, V4, P4; ERNST E, 1986, ARZTLICHE PRAXIS, V51, P3; Gadkari J V, 1991, J Postgrad Med, V37, P128; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HOLZGARTNER H, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1473; Isaacsohn JL, 1998, ARCH INTERN MED, V158, P1189, DOI 10.1001/archinte.158.11.1189; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JAIN AK, 1993, AM J MED, V94, P632, DOI 10.1016/0002-9343(93)90216-C; Kandziora J., 1988, ARZTL FORSCH, V35, P3; KIESEWETTER H, 1991, INT J CLIN PHARM TH, V29, P151; Kiesewetter H, 1990, Br J Clin Pract Suppl, V69, P24; Koscielny J, 1999, ATHEROSCLEROSIS, V144, P237, DOI 10.1016/S0021-9150(99)00060-X; Lash JP, 1998, TRANSPLANT P, V30, P189, DOI 10.1016/S0041-1345(97)01227-X; LAU BHS, 1987, NUTR RES, V7, P139, DOI 10.1016/S0271-5317(87)80026-X; LAWSON LD, 1998, Q REV NAT MED    FAL, P187; LEWIS B, 1987, EUR HEART J, V8, P77; LULEY C, 1986, ARZNEIMITTEL-FORSCH, V36-1, P766; Lutomski J, 1984, Z PHYTOTHER, V5, P938; MADER FH, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1111; McCrindle BW, 1998, ARCH PEDIAT ADOL MED, V152, P1089; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MULROW CD, 1997, CONDUCT SYSTEMATIC R; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; Nieminen P, 1999, LANCET, V353, P1592, DOI 10.1016/S0140-6736(99)00415-8; PHELPS S, 1993, LIPIDS, V28, P475, DOI 10.1007/BF02535949; Pittler MH, 2000, J CLIN EPIDEMIOL, V53, P485, DOI 10.1016/S0895-4356(99)00220-6; PLENGVIDHYA C, 1988, Journal of the Medical Association of Thailand, V71, P248; PYORALA K, 1994, EUR HEART J, V15, P1300; REUTER HD, 1996, GARLIC SCI THERAPEUT; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; ROTZSCH W, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1223; SANTOS OSD, 1993, BR J CLIN RES, V4, P27; Saradeth T, 1994, Phytomedicine, V1, P183, DOI 10.1016/S0944-7113(11)80062-0; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz V, 1998, RATIONAL PHYTOTHERAP; SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; Steiner M, 1998, J CARDIOVASC PHARM, V31, P904, DOI 10.1097/00005344-199806000-00014; Steiner M, 1996, AM J CLIN NUTR, V64, P866, DOI 10.1093/ajcn/64.6.866; STEVINSON C, 2000, FOCUS ALTERNATIVE CO, V5, P23; SUCUR M, 1980, Diabetologia Croatica, V9, P323; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; Vorberg G, 1990, Br J Clin Pract Suppl, V69, P7; WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009; Zimmermann W, 1990, Br J Clin Pract Suppl, V69, P20	64	210	218	2	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					420	429		10.7326/0003-4819-133-6-200009190-00009	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975959				2022-12-28	WOS:000089329700003
J	Donini-Lenhoff, FG; Hedrick, HL				Donini-Lenhoff, FG; Hedrick, HL			Growth of specialization in graduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The growth of specialization in graduate medical education (CME) and physician practice continues at a rapid rate, generating increasing national attention, Although the major educational, accrediting, and certifying bodies have mechanisms for approving new areas of study and practice, the results of their efforts have not been consistently congruent. This article presents information about GME since the beginnings of its standardization and accreditation in the early 20th century, its growth during and following World War II, and the variations among accredited specialties and subspecialties, certificates, and self-designated practice areas that have resulted from this long period of unstructured growth.	Amer Med Assoc, Med Educ Prod, Chicago, IL 60610 USA	American Medical Association	Donini-Lenhoff, FG (corresponding author), Amer Med Assoc, Med Educ Prod, 515 N State St, Chicago, IL 60610 USA.							*ACCR COUNC GRAD M, 2000, ACGME M FEBR 14; *AM BOARD MED SPEC, 2000, ANN REP REF HDB, P98; *AM MED ASS, 2000, GRAD MED ED DIR 2000; *AM MED ASS, 1980, P AM MED ASS HOUS DE, P72; *AM MED ASS WEB SI, 2000, PHYS PRACT ARR; [Anonymous], 1927, JAMA-J AM MED ASSOC, V88, P829; CAMPION FD, 1984, AMA US HLTH POLICY, P32; *CIT COMM GRAD MED, 1966, GRAD ED PHYS, P15; *COUNC MED ED HOSP, 1943, CONS LIST APPR INT 1; *COUNC MED SPEC SO, 1998, BAL GEN SPEC AM MED; DEITRICK JE, 1953, MED SCH US MIDC, P276; Ginzberg E, 1999, ACAD MED, V74, P522, DOI 10.1097/00001888-199905000-00018; *GRAD MED ED ADV C, 2000, GRAD MED ED ADV COMM, pB4; Grumbach K, 1999, NEW ENGL J MED, V341, P2008, DOI 10.1056/NEJM199912233412611; Howell JD, 1999, ACAD MED, V74, P521; LUDMERER KM, 1999, TIME HEAL AM MED ED, P83; MARTINI CJM, 1992, JAMA-J AM MED ASSOC, V268, P1097, DOI 10.1001/jama.268.9.1097; PETERSDORF RG, 1993, TAKING CHARGE GRADUA, P187; STEVENS R, 1998, AM MED PUBL INT, P395; SWANSON AG, 1993, TAK CHARG GRAD MED E, P57; 1925, JAMA, V85, P595; 1950, JAMA, V144, P115; 1940, JAMA, V115, P699; 1921, JAMA, V77, P538; 1927, JAMA, V89, P625; 1924, JAMA, V83, P518; 1933, JAMA, V101, P714	27	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1284	1289		10.1001/jama.284.10.1284	http://dx.doi.org/10.1001/jama.284.10.1284			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979116				2022-12-28	WOS:000089124600036
J	Silverstein, FE; Faich, G; Goldstein, JL; Simon, LS; Pincus, T; Whelton, A; Makuch, R; Eisen, G; Agarwal, NM; Stenson, WF; Burr, AM; Zhao, WW; Kent, JD; Lefkowith, JB; Verburg, KM; Geis, GS				Silverstein, FE; Faich, G; Goldstein, JL; Simon, LS; Pincus, T; Whelton, A; Makuch, R; Eisen, G; Agarwal, NM; Stenson, WF; Burr, AM; Zhao, WW; Kent, JD; Lefkowith, JB; Verburg, KM; Geis, GS			Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEPTIC-ULCER DISEASE; ANTIINFLAMMATORY DRUGS; SELECTIVE-INHIBITION; ELDERLY PERSONS; DOUBLE-BLIND; RISK; COMPLICATIONS; ASPIRIN; CYCLOOXYGENASE; METAANALYSIS	Context Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1. Whether COX-2-specific inhibitors are associated with fewer clinical GI toxic effects is unknown. Objective To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs. Design The Celecoxib Long-term Arthritis Safety Study (CLASS), a double-blind, randomized controlled trial conducted from September 1998 to March 2000. Setting Three hundred eighty-six clinical sites in the United States and Canada. Participants A total of 8059 patients (greater than or equal to 18 years old) with osteoarthritis (OA) or rheumatoid arthritis (RA) were enrolled in the study, and 7968 received at least 1 dose of study drug. A total of 4573 patients (57%) received treatment for 6 months. Interventions Patients were randomly assigned to receive celecoxib, 400 mg twice per day (2 and 4 times the maximum RA and OA dosages, respectively; n = 3987); ibuprofen, 800 mg 3 times per day (n = 1985); or diclofenac, 75 mg twice per day (n = 1996). Aspirin use for cardiovascular prophylaxis (less than or equal to 325 mg/d) was permitted. Main Outcome Measures Incidence of prospectively defined symptomatic upper GI ulcers and ulcer complications (bleeding, perforation, and obstruction) and other adverse effects during the 6-month treatment period. Results For all patients, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 0.76% vs 1.45% (P = .09) and 2.08% vs 3.54% (P = .02), respectively. For patients not taking aspirin, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 0.44% vs 1.27% (P = .04) and 1.40% vs 2.91% (P = .02). For patients taking aspirin, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 2.01% vs 2.12% (P = .92) and 4.70% vs 6.00% (P = .49). Fewer celecoxib-treated patients than NSAID-treated patients experienced chronic GI blood loss, GI intolerance, hepatotoxicity, or renal toxicity. No difference was noted in the incidence of cardiovascular events between celecoxib and NSAIDs, irrespective of aspirin use. Conclusions In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages. The decrease in upper GI toxicity was strongest among patients not taking aspirin concomitantly.	Pharmacia Clin Res & Dev, Skokie, IL 60077 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Pharmaceut Safety Assessments Inc, Narberth, PA USA; Univ Illinois, Coll Med, Dept Med, Sect Digest & Liver Dis, Chicago, IL USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Rheumatol & Metab Bone Dis, Boston, MA USA; Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Gastroenterol, Nashville, TN 37212 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Yale Univ, Dept Biostat, New Haven, CT USA; Duke Univ, Div Gastroenterol, Durham, NC USA; Washington Univ, Div Gastroenterol, St Louis, MO USA	Pfizer; University of Washington; University of Washington Seattle; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Vanderbilt University; Vanderbilt University; Johns Hopkins University; Yale University; Duke University; Washington University (WUSTL)	Lefkowith, JB (corresponding author), Pharmacia Clin Res & Dev, 4901 Searle Pkwy,Bldg A3E, Skokie, IL 60077 USA.	James.B.Lefkowith@monasanto.com						*AM COLL RHEUM, 1997, AM COLL RHEUM CLIN G; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P74; Crofford LJ, 2000, ARTHRITIS RHEUM-US, V43, P4, DOI 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Goldstein JL, 2000, AM J GASTROENTEROL, V95, P1681; Goldstein JL, 1999, GASTROENTEROLOGY, V116, pA174; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003; HALLAS J, 1995, SCAND J GASTROENTERO, V30, P438, DOI 10.3109/00365529509093304; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Kelly JP, 1996, LANCET, V348, P1413, DOI 10.1016/S0140-6736(96)01254-8; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LANZA LL, 1995, ARCH INTERN MED, V155, P1371, DOI 10.1001/archinte.155.13.1371; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacDonald TM, 1997, BMJ-BRIT MED J, V315, P1333, DOI 10.1136/bmj.315.7119.1333; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; PAULUS HE, 1988, ARTHRITIS RHEUM, V31, P1450, DOI 10.1002/art.1780311118; PAULUS HE, 1997, PRIMER RHEUMATIC DIS, P422; Pincus T, 2000, J RHEUMATOL, V27, P1020; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Rodriguez LAG, 1998, ARCH INTERN MED, V158, P33, DOI 10.1001/archinte.158.1.33; *SCOTTL, 1997, SCOTTL PHYS DRUG DIA; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Singh G, 1998, J RHEUMATOL, V25, P8; SINGH G, 2000, AM J THER, V7, P121; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; STALNIKOWICZDARVASI R, 1995, J CLIN GASTROENTEROL, V21, P13; VERBURG KM, IN PRESS AM J THER; WELL J, 1995, BRIT MED J, V310, P827; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/s0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8]; Wolfe F, 2000, ARTHRITIS RHEUM-US, V43, P378, DOI 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	39	2384	2500	10	206	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1247	1255		10.1001/jama.284.10.1247	http://dx.doi.org/10.1001/jama.284.10.1247			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979111	Bronze			2022-12-28	WOS:000089124600031
J	Kling, J				Kling, J			The flaw is human - The end of the Human Genome Reclamation Project	NATURE			English	Article																			0	2	2	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					941	941		10.1038/35023065	http://dx.doi.org/10.1038/35023065			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984031	Bronze			2022-12-28	WOS:000089020200022
J	Krieger, MJB; Billeter, JB; Keller, L				Krieger, MJB; Billeter, JB; Keller, L			Ant-like task allocation and recruitment in cooperative robots	NATURE			English	Article							INSECT SOCIETIES; HONEY-BEE; COLONIES; SIZE; DIVISION; LABOR	One of the greatest challenges in robotics is to create machines that are able to interact with unpredictable environments in real time. A possible solution may be to use swarms of robots behaving in a self-organized manner, similar to workers in an ant colony(1-5). Efficient mechanisms of division of labour, in particular series-parallel operation and transfer of information among group members(6), are key components of the tremendous ecological success of ants(7,8). Here we show that the general principles regulating division of labour in ant colonies indeed allow the design of flexible, robust and effective robotic systems. Groups of robots using ant-inspired algorithms of decentralized control techniques foraged more efficiently and maintained higher levels of group energy than single robots. But the benefits of group living decreased in larger groups, most probably because of interference during foraging. Intriguingly, a similar relationship between group size and efficiency has been documented in social insects(9-11). Moreover, when food items were clustered, groups where robots could recruit other robots in an ant-like manner were more efficient than groups without information transfer, suggesting that group dynamics of swarms of robots may follow rules similar to those governing social insects.	Univ Lausanne, Inst Ecol, BB, CH-1015 Lausanne, Switzerland; Swiss Fed Inst Technol, Lab Microinformat, CH-1015 Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Keller, L (corresponding author), Univ Lausanne, Inst Ecol, BB, CH-1015 Lausanne, Switzerland.	Laurent.Keller@ie-zea.unil.ch	keller, laurent/AAI-7175-2020	keller, laurent/0000-0002-5046-9953				Anderson C, 1999, AM NAT, V154, P521, DOI 10.1086/303255; [Anonymous], 1971, INSECT SOC; Beckers R., 1994, P 4 INT WORKSH SYNTH, P181; BONABEAU E, 1996, P ROY SOC LOND B BIO, V265, P327; Bonabeau E DdRDF, 1999, SWARM INTELLIGENCE N; Cao YU, 1997, AUTON ROBOT, V4, P7, DOI 10.1023/A:1008855018923; DENEUBOURG JL, 1990, P 1 INT C SIM AD BEH, P181; DETRAIN C, 1999, INFORMATION PROCESSI, P537; GORDON DM, 1993, ANIM BEHAV, V45, P1083, DOI 10.1006/anbe.1993.1134; HOLLDOBLER B, 1974, J COMP PHYSIOL, V90, P105, DOI 10.1007/BF00694481; Holldobler B., 1990, pi; Jeanne RL, 1996, BEHAV ECOL, V7, P43, DOI 10.1093/beheco/7.1.43; Kube C. Ronald, 1993, Adaptive Behavior, V2, P189, DOI 10.1177/105971239300200204; MOGLICH M, 1974, SCIENCE, V186, P1046, DOI 10.1126/science.186.4168.1046; Mondada Francesco, 1994, P 3 INT S EXPT ROBOT, P501; Oster G.F., 1978, Monographs in Population Biology, pi; Pacala SW, 1996, EVOL ECOL, V10, P127, DOI 10.1007/BF01241782; Robinson GE, 1997, BIOESSAYS, V19, P1099, DOI 10.1002/bies.950191209; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; ROBINSON GE, 1987, J COMP PHYSIOL A, V160, P613, DOI 10.1007/BF00611934; Seeley T., 1995, WISDOM HIVE SOCIAL P; Seeley TD, 1997, AM NAT, V150, pS22, DOI 10.1086/286048; Sokal R.R., 2012, BIOMETRY; SUNDSTROM L, 1995, AM NAT, V146, P182, DOI 10.1086/285794; TSCHINKEL WR, 1993, ECOL MONOGR, V63, P425, DOI 10.2307/2937154; Wilson E.O, 1990, SUCCESS DOMINANCE EC	26	215	220	9	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					992	995		10.1038/35023164	http://dx.doi.org/10.1038/35023164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984052	Green Published			2022-12-28	WOS:000089020200044
J	Bonesteel, N				Bonesteel, N			Quantum Hall effect - Composite fermions pair up	NATURE			English	Editorial Material							LANDAU-LEVEL; STATES		Florida State Univ, Dept Phys, Tallahassee, FL 32310 USA; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Bonesteel, N (corresponding author), Florida State Univ, Dept Phys, Tallahassee, FL 32310 USA.							COOPER LN, 1956, PHYS REV, V104, P1189, DOI 10.1103/PhysRev.104.1189; GREITER M, 1992, NUCL PHYS B, V374, P567, DOI 10.1016/0550-3213(92)90401-V; HALPERIN BI, 1993, PHYS REV B, V47, P7312, DOI 10.1103/PhysRevB.47.7312; JAIN JK, 1989, PHYS REV LETT, V63, P199, DOI 10.1103/PhysRevLett.63.199; MOORE G, 1991, NUCL PHYS B, V360, P362, DOI 10.1016/0550-3213(91)90407-O; Morf RH, 1998, PHYS REV LETT, V80, P1505, DOI 10.1103/PhysRevLett.80.1505; Pan W, 1999, PHYS REV LETT, V83, P3530, DOI 10.1103/PhysRevLett.83.3530; Rezayi EH, 2000, PHYS REV LETT, V84, P4685, DOI 10.1103/PhysRevLett.84.4685; Scarola VW, 2000, NATURE, V406, P863, DOI 10.1038/35022524; Willett RL, 1997, ADV PHYS, V46, P447, DOI 10.1080/00018739700101528; WILLETT RL, 1987, PHYS REV LETT, V59, P3846	11	0	0	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					840	841		10.1038/35022689	http://dx.doi.org/10.1038/35022689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972273				2022-12-28	WOS:000088903600024
J	Demakis, JG; Beauchamp, C; Cull, WL; Denwood, R; Eisen, SA; Lofgren, R; Nichol, K; Woolliscroft, J; Henderson, WG				Demakis, JG; Beauchamp, C; Cull, WL; Denwood, R; Eisen, SA; Lofgren, R; Nichol, K; Woolliscroft, J; Henderson, WG		Dept Vet Affairs Computer Rem	Improving residents' compliance with standards of ambulatory care - Results from the VA cooperative study on computerized reminders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTIVE CARE; CONTROLLED TRIAL; PHYSICIAN PERFORMANCE; INFLUENZA VACCINATION; PATIENT REMINDERS; BLOOD-PRESSURE; PROTOCOL; FEEDBACK; RESPOND; WORK	Context Computerized systems to remind physicians to provide appropriate care have not been widely evaluated in large numbers of patients in multiple clinical settings. Objective To examine whether a computerized reminder system operating in multiple Veterans Affairs (VA) ambulatory care clinics improves resident physician compliance with standards of ambulatory care. Design, Setting, and Participants A total of 275 resident physicians at 12 VA medical centers were randomly assigned in firms or half-day clinic blocks to either a reminder group (n=132) or a control group (n=143), During a 17-month study period (January 31, 1995-June 30, 1996), the residents cared for 12989 unique patients for whom at least 1 of the studied standards of care (SOC) was applicable. Main Outcome Measures Compliance with 13 SOC, tracked using hospital databases and encounter forms completed by residents, compared between residents in the reminder group vs those in the control group. Results Measuring compliance as the proportion of patients in compliance with all applicable SOC by their last visit during the study period, the reminder group had statistically significantly higher rates of compliance than the control group for all standards combined (58.8% vs 53.5%; odds ratio [OR], 1.24; 95% confidence interval [CI], 1.08-1.42; P=.002) and for 5 of the 13 standards examined individually. Measuring compliance as the proportion of all visits for which care was indicated in which residents provided proper care, the reminder group also had statistically significantly higher rates of compliance than the control group for all standards combined (17.9% vs 12.2%; OR, 1.57; 95% CI, 1.45-1.71; P<.001) and for 9 of the 13 standards examined individually. The benefit of reminders, however, declined throughout the course of the study, even though the reminders remained active. Conclusions Our data indicate that reminder systems installed at multiple sites can improve residents' compliance to multiple SOC. The benefits of such systems, however, appear to deteriorate over time. Future research needs to explore methods to better sustain the benefits of reminders.	VA Hlth Serv Res & Dev Serv, Washington, DC USA; Durham VAMC, Dept Ambulatory Care, Durham, NC USA; Hines VA Cooperat Studies Program Coordinating Ct, Hines, IL USA; St Louis VAMC, Dept Rheumatol, St Louis, MO USA; Med Coll Wisconsin, Dept Gen Internal Med, Milwaukee, WI 53226 USA; Minneapolis VAMC, Dept Internal Med, Minneapolis, MN USA; Univ Michigan, Dept Gen Med, Ann Arbor, MI 48109 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Michigan System; University of Michigan	Henderson, WG (corresponding author), Edward Hines Vet Adm Hosp, 151K,POB 5000, Hines, IL 60141 USA.			Eisen, Seth/0000-0001-7746-6624				BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BARNETT GO, 1978, MED CARE, V16, P1962; BECKER DM, 1989, AM J PREV MED, V5, P353, DOI 10.1016/S0749-3797(18)31056-0; Davis D, 1998, INT J PSYCHIAT MED, V28, P21, DOI 10.2190/UA3R-JX9W-MHR5-RC81; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; LANDIS S, 1992, NC MED J, V53, P578; LIPSITZ SR, 1994, BIOMETRICS, V50, P270, DOI 10.2307/2533218; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Sicotte C, 1996, J BEHAV MED, V19, P367, DOI 10.1007/BF01904763; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; Wensing M, 1994, Int J Qual Health Care, V6, P115	26	157	159	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1411	1416		10.1001/jama.284.11.1411	http://dx.doi.org/10.1001/jama.284.11.1411			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989404	Bronze			2022-12-28	WOS:000089242500036
J	DeSimone, JA; Pomerantz, RJ; Babinchak, TJ				DeSimone, JA; Pomerantz, RJ; Babinchak, TJ			Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEASE-INHIBITOR THERAPY; MYCOBACTERIUM-AVIUM COMPLEX; HIV-INFECTED PATIENTS; IMMUNE RESTORATION SYNDROME; CYTOMEGALOVIRUS RETINITIS; AIDS PATIENTS; HERPES-ZOSTER	Purpose: To review reported inflammatory reactions occurring after initiation of highly active antiretroviral therapy (HAART) in persons infected with HIV-1 and to explore the mechanisms leading to these reactions. Data Sources: MEDLINE search of biomedical literature reporting inflammatory reactions after HAART. Bibliographies of retrieved reports were also reviewed. Study Selection: Articles describing patients infected with HIV-1 who had immunologic and virologic responses to HAART and subsequently developed inflammatory reactions. Data Extraction: Data on the immune status, clinical characteristics, and therapeutic management of patients who were seropositive for HIV-1 and had inflammatory reactions after HAART. Data Synthesis: Inflammatory reactions involving opportunistic infections, AIDS-associated malignant conditions, and other non-infectious diseases have recently been described in patients infected with HIV-1. These conditions often appeared shortly after the introduction of HAART and were associated with pronounced reductions in plasma HIV-1 viral load and increases in CD4(+) T-lymphocyte counts. Clinical presentation was often atypical of that in patients with untreated HIV-1 infection, probably because of restored immunity. Most cases improved despite continuation of HAART, although some patients required anti-inflammatory drugs or specific antimicrobial agents. Conclusions: Clinicians caring for patients who are infected with HIV-1 and receiving HAART must be aware of this new and diverse clinical syndrome. As more HAART recipients are studied. new presentations will probably be observed.	Thomas Jefferson Univ, Dept Med, Div Infect Dis, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Dept Med, Div Infect Dis, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.	roger.j.pomerantz@mail.tju.edu						ABEL S, 2000, 13 INT AIDS C DURB S; AFGHANI B, 1994, CLIN INFECT DIS, V19, P1092, DOI 10.1093/clinids/19.6.1092; Aldeen T, 1998, AIDS, V12, P1719; Arribas JR, 1998, AIDS, V12, P1722; BARBARO DJ, 1989, REV INFECT DIS, V11, P625; Behrens G, 1998, LANCET, V351, P1057, DOI 10.1016/S0140-6736(05)79022-X; BERGER BB, 1979, AM J OPHTHALMOL, V88, P1020, DOI 10.1016/0002-9394(79)90409-4; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BOTTARO E, 1997, 3 ARG C AIDS MAR PLA; Bouscarat F, 2000, AIDS, V14, P617, DOI 10.1097/00002030-200003310-00019; Boyraz-Ikiz HD, 1999, AIDS, V13, P867, DOI 10.1097/00002030-199905070-00022; Brau N, 1997, LANCET, V349, P924, DOI 10.1016/S0140-6736(05)62700-6; CA DS, 2000, 13 INT AIDS C DURB S; Cabie A, 1998, EUR J CLIN MICROBIOL, V17, P812, DOI 10.1007/s100960050196; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9; CARTER EJ, 1994, CHEST, V106, P1896, DOI 10.1378/chest.106.6.1896; Chien JW, 1998, CHEST, V114, P933, DOI 10.1378/chest.114.3.933; Cinti SK, 2000, CLIN INFECT DIS, V30, P511, DOI 10.1086/313705; Collazos J, 1999, AIDS, V13, P1426, DOI 10.1097/00002030-199907300-00032; COLOMBERO D, 2000, 13 INT AIDS C DURB S; Cribier B, 1996, RES VIROLOGY, V147, P263, DOI 10.1016/0923-2516(96)82284-9; Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636; Davaro R E, 1999, AIDS Read, V9, P167; Deayton JR, 2000, AIDS, V14, P1163, DOI 10.1097/00002030-200006160-00013; del Giudice P, 1999, ARCH DERMATOL, V135, P1129, DOI 10.1001/archderm.135.9.1129; Di Perri G, 1998, LANCET, V351, P1056, DOI 10.1016/S0140-6736(98)26014-4; Dworkin MS, 1998, ARCH INTERN MED, V158, P1828, DOI 10.1001/archinte.158.16.1828; EGBERT PR, 1980, ANN INTERN MED, V93, P664, DOI 10.7326/0003-4819-93-5-664; Foudraine NA, 1999, AIDS, V13, P177, DOI 10.1097/00002030-199902040-00005; French M, 1998, LANCET, V351, P1056, DOI 10.1016/S0140-6736(05)79021-8; FRENCH MAH, 1992, AIDS, V6, P1293, DOI 10.1097/00002030-199211000-00009; Furrer H, 1999, AM J MED, V106, P371, DOI 10.1016/S0002-9343(99)00015-7; GELBER RH, 1995, BENNETTS PRINCIPLES, P2243; Gilquin J, 1998, LANCET, V352, P1907, DOI 10.1016/S0140-6736(05)60398-4; Gilquin J, 1997, AIDS, V11, P1659; GLESBY MJ, 1995, CLIN INFECT DIS, V21, P370, DOI 10.1093/clinids/21.2.370; Harindra V, 1998, LANCET, V351, P1058, DOI 10.1016/S0140-6736(05)79023-1; HAVLIR D, 1999, 6 C RETR OPP INF 31; HILL AR, 1994, CLIN INFECT DIS, V19, P774, DOI 10.1093/clinids/19.4.774; HOLLENDER E, 2000, P 7 C RETR OPP INF 3; JABS D, 2000, P 7 C RETR OPP INF 3; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; John M, 1998, AIDS, V12, P2289, DOI 10.1097/00002030-199817000-00010; John M, 1998, MED J AUSTRALIA, V169, P473, DOI 10.5694/j.1326-5377.1998.tb123372.x; JUBAULT V, 2000, P 7 C RETR OPP INF 3; KAPLAN M, 1998, 5 C RETR OPP INF 1 5; Karavellas MP, 1999, J INFECT DIS, V179, P697, DOI 10.1086/314639; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Kotecha N, 1998, AM J MED, V105, P541, DOI 10.1016/S0002-9343(98)00321-0; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; MAJE J, 1999, INF DIS SOC AM 37 AN; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Mastroianni CM, 1998, AIDS, V12, P1939; Matsuda J, 1997, LANCET, V350, P364, DOI 10.1016/S0140-6736(05)63416-2; Mayo J, 1998, AIDS, V12, P1720; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Mirmirani P, 1999, J AM ACAD DERMATOL, V41, P285, DOI 10.1016/S0190-9622(99)70364-6; Monsuez JJ, 1998, ARTHRITIS RHEUM, V41, P740, DOI 10.1002/1529-0131(199804)41:4&lt;740::AID-ART25&gt;3.0.CO;2-M; Naccache JM, 1999, AM J RESP CRIT CARE, V159, P2009, DOI 10.1164/ajrccm.159.6.9807152; Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001; Nigro L, 1999, ITAL J GASTROENTEROL, V31, P85; PACKER SJ, 1988, ANN INTERN MED, V109, P389, DOI 10.7326/0003-4819-109-5-389; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; Phillips P, 1999, J ACQ IMMUN DEF SYND, V20, P122, DOI 10.1097/00042560-199902010-00003; PHILLIPS P, 2000, P 7 C RETR OPP INF 3; PIALOUX G, 1998, 12 WORLD AIDS C 28 J; Puoti M, 2000, J INFECT DIS, V181, P2033, DOI 10.1086/315529; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; Ragni MV, 1999, J INFECT DIS, V180, P2027, DOI 10.1086/315143; RAO GP, 1995, J NEUROSURG, V83, P359, DOI 10.3171/jns.1995.83.2.0359; Rockstroh JK, 1998, AIDS, V12, pS42; ROONEY JJ, 1976, AM J MED, V60, P517, DOI 10.1016/0002-9343(76)90718-X; Rosenfeld C R, 1999, AIDS Read, V9, P393; ROZENBAUM R, 1994, CLIN INFECT DIS, V18, P369, DOI 10.1093/clinids/18.3.369; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Schwietert S, 1999, DEUT MED WOCHENSCHR, V124, P45, DOI 10.1055/s-2007-1024241; Sharp MJ, 1998, PEDIATR INFECT DIS J, V17, P660, DOI 10.1097/00006454-199807000-00021; Velasco M, 1999, NEW ENGL J MED, V340, P1765, DOI 10.1056/NEJM199906033402215; Vento S, 1996, LANCET, V347, P92, DOI 10.1016/S0140-6736(96)90212-3; Vento S, 1998, AIDS, V12, P116; Vento S, 1998, LANCET, V351, P1058, DOI 10.1016/S0140-6736(05)79024-3; Weir A, 1997, AIDS, V11, P1895, DOI 10.1097/00002030-199715000-00022; Woods ML, 1998, AIDS, V12, P1491, DOI 10.1097/00002030-199812000-00011; Yoo L, 1996, J IMMUNOL, V157, P1313; YOUNG LS, 1986, REV INFECT DIS, V8, P1024; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2; Zhang TT, 1997, INFECT IMMUN, V65, P3594, DOI 10.1128/IAI.65.9.3594-3599.1997; Zietz C, 1999, NEW ENGL J MED, V340, P1923, DOI 10.1056/NEJM199906173402415; Zylberberg H, 1998, CLIN INFECT DIS, V26, P1104, DOI 10.1086/520281; Zylberberg H, 1998, CLIN INFECT DIS, V27, P1255, DOI 10.1086/514987	94	276	287	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					447	454		10.7326/0003-4819-133-6-200009190-00013	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975963				2022-12-28	WOS:000089329700007
J	Sharma, R				Sharma, R			Time expired materials "contributed to 26 deaths"	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					590	590						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977829				2022-12-28	WOS:000089243200013
J	MacBeath, G; Schreiber, SL				MacBeath, G; Schreiber, SL			Printing proteins as microarrays for high-throughput function determination	SCIENCE			English	Article							RECEPTOR; CLONING; KINASE; ACTIVATION; DOMAIN; GENES	Systematic efforts are currently under way to construct defined sets of cloned genes for high-throughput expression and purification of recombinant proteins. To facilitate subsequent studies of protein function, we have developed miniaturized assays that accommodate extremely Low sample volumes and enable the rapid, simultaneous processing of thousands of proteins. A high-precision robot designed to manufacture complementary DNA microarrays was used to spot proteins onto chemically derivatized glass slides at extremely high spatial densities. The proteins attached covalently to the slide surface yet retained their ability to interact specifically with other proteins, or with small molecules, in solution. Three applications for protein microarrays were demonstrated: screening for protein-protein interactions, identifying the substrates of protein kinases, and identifying the protein targets of small molecules.	Harvard Univ, Ctr Genome Res, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Biol Chem, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	MacBeath, G (corresponding author), Harvard Univ, Ctr Genome Res, 16 Divin Ave, Cambridge, MA 02138 USA.							Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BJORCK L, 1984, J IMMUNOL, V133, P969; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Tanaka H, 1999, MOL PHARMACOL, V55, P356, DOI 10.1124/mol.55.2.356; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	21	2293	2745	11	467	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1760	1763						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976071				2022-12-28	WOS:000089195200049
J	Nowak, MA; Page, KM; Sigmund, K				Nowak, MA; Page, KM; Sigmund, K			Fairness versus reason in the Ultimatum Game	SCIENCE			English	Article							EVOLUTION; COOPERATION; RECIPROCITY; BEHAVIOR	In the Ultimatum Came, two players are offered a chance to win a certain sum of money. ALL they must do is divide it. The proposer suggests how to split the sum. The responder can accept or reject the deal. If the deal is rejected, neither player gets anything. The rational solution, suggested by game theory, is for the proposer to offer the smallest possible share and for the responder to accept it. If humans play the game, however, the most frequent outcome is a fair share. In this paper, we develop an evolutionary approach to the Ultimatum Came. We show that fairness will evolve if the proposer can obtain some information on what deals the responder has accepted in the past. Hence, the evolution of fairness, similarly to the evolution of cooperation, is Linked to reputation.	Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA; Univ Vienna, Inst Math, A-1090 Vienna, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	Institute for Advanced Study - USA; University of Vienna; International Institute for Applied Systems Analysis (IIASA)	Nowak, MA (corresponding author), Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA.	nowak@ias.edu	Nowak, Martin A/A-6977-2008					BANERJEE A, 1995, LEARNING RATIONALITY; Bethwaite J, 1996, J ECON PSYCHOL, V17, P259, DOI 10.1016/0167-4870(96)00006-2; BINMORE K, 1985, AM ECON REV, V75, P1178; Binmore K., 1992, FUN GAMES TEXT GAME; Bolton GE, 2000, AM ECON REV, V90, P166, DOI 10.1257/aer.90.1.166; BOLTON GE, 1995, GAME ECON BEHAV, V10, P95, DOI 10.1006/game.1995.1026; Ellingsen T, 1997, Q J ECON, V112, P581, DOI 10.1162/003355397555299; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; FEHR E, 1999, HOMO RECIPROCANS HUM; Frank R. H., 1988, PASSIONS REASON; GALE J, 1995, GAME ECON BEHAV, V8, P56, DOI 10.1016/S0899-8256(05)80017-X; GUTH W, 1982, J ECON BEHAV ORGAN, V3, P367, DOI 10.1016/0167-2681(82)90011-7; GUTH W, 1990, J ECON PSYCHOL, V11, P417, DOI 10.1016/0167-4870(90)90021-Z; Hofbauer J, 1998, VIEN CIR INST YEARBK, V5, P245; Hofbauer J, 1998, EVOLUTIONARY GAMES P; Huck S, 1999, GAME ECON BEHAV, V28, P13, DOI 10.1006/game.1998.0691; KAHNEMAN D, 1986, J BUS, V59, pS285, DOI 10.1086/296367; KANDORI M, 1993, ECONOMETRICA, V61, P29, DOI 10.2307/2951777; KIRCHSTEIGER G, 1994, J ECON BEHAV ORGAN, V25, P373, DOI 10.1016/0167-2681(94)90106-6; Lotem A, 1999, NATURE, V400, P226, DOI 10.1038/22247; Maynard Smith J., 1982, pi; Nowak MA, 1998, J THEOR BIOL, V194, P561, DOI 10.1006/jtbi.1998.0775; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Roth A.E., 1995, HDB EXPT EC; ROTH AE, 1991, AM ECON REV, V81, P1068; RUBINSTEIN A, 1982, ECONOMETRICA, V50, P97, DOI 10.2307/1912531; Schelling Thomas C., 1960, STRATEGY CONFLICT; THALER RH, 1988, J ECON PERSPECT, V2, P195, DOI 10.1257/jep.2.4.195; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; YOUNG HP, 1993, J ECON THEORY, V59, P145, DOI 10.1006/jeth.1993.1009; YOUNG HP, 1993, ECONOMETRICA, V61, P57, DOI 10.2307/2951778; Zahavi A, 1996, HANDICAP PRINCIPLE	32	481	490	7	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2000	289	5485					1773	1775		10.1126/science.289.5485.1773	http://dx.doi.org/10.1126/science.289.5485.1773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	352BT	10976075	Green Submitted			2022-12-28	WOS:000089195200053
J	Xiong, J; Fischer, WM; Inoue, K; Nakahara, M; Bauer, CE				Xiong, J; Fischer, WM; Inoue, K; Nakahara, M; Bauer, CE			Molecular evidence for the early evolution of photosynthesis	SCIENCE			English	Article							REACTION CENTERS; MG-CHELATASE; CHL-D; PROTEINS; SUBUNIT; PROKARYOTES; TOBACCO; ORIGIN; TREE; RNA	The origin and evolution of photosynthesis have Long remained enigmatic due to a Lack of sequence information of photosynthesis genes across the entire photosynthetic domain. To probe early evolutionary history of photosynthesis, we obtained new sequence information of a number of photosynthesis genes from the green sulfur bacterium Chlorobium tepidum and the green nonsulfur bacterium Chloroflexus aurantiacus. A total of 31 open reading frames that encode enzymes involved in bacteriochlorophyll/porphyrin biosynthesis, carotenoid biosynthesis, and photosynthetic electron transfer were identified in about 100 kilobase pairs of genomic sequence. Phylogenetic analyses of multiple magnesium-tetrapyrrole biosynthesis genes using a combination of distance, maximum parsimony, and maximum likelihood methods indicate that heliobacteria are closest to the Last common ancestor of all oxygenic photosynthetic Lineages and that green sulfur bacteria and green nonsulfur bacteria are each other's closest relatives. Parsimony and distance analyses further identify purple bacteria as the earliest emerging photosynthetic Lineage. These results challenge previous conclusions based on 16S ribosomal RNA and Hsp60/Hsp70 analyses that green nonsulfur bacteria or heliobacteria are the earliest phototrophs. The overall consensus of our phylogenetic analysis, that bacteriochlorophyll biosynthesis evolved before chlorophyll biosynthesis, also argues against the long-held Granick hypothesis.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Kanagawa Univ, Dept Biol Sci, Kanagawa 2591293, Japan	Indiana University System; Indiana University Bloomington; Kanagawa University	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	cbauer@bio.indiana.edu	Fischer, Will/AAD-2807-2019	Fischer, Will/0000-0003-4579-4062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053940] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040941, R01 GM053940, GM53940] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEER-ROMERO P, 1988, FEMS Microbiology Letters, V49, P451, DOI 10.1016/0378-1097(88)90341-2; BLANKENSHIP RE, 1994, ANTON LEEUW INT J G, V65, P311, DOI 10.1007/BF00872216; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P91, DOI 10.1007/BF00039173; BURKE DH, 1993, P NATL ACAD SCI USA, V90, P7134, DOI 10.1073/pnas.90.15.7134; Chaw SM, 2000, P NATL ACAD SCI USA, V97, P4086, DOI 10.1073/pnas.97.8.4086; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fujita Y, 2000, J BIOL CHEM, V275, P23583, DOI 10.1074/jbc.M002904200; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; Grafe S, 1999, P NATL ACAD SCI USA, V96, P1941, DOI 10.1073/pnas.96.5.1941; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GRNAICK S, 1965, EVOLVING GENES PROTE, P67; Gupta RS, 1999, MOL MICROBIOL, V32, P893, DOI 10.1046/j.1365-2958.1999.01417.x; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; NEEFS JM, 1993, NUCLEIC ACIDS RES, V21, P3025, DOI 10.1093/nar/21.13.3025; NITSCHKE W, 1997, PHOTOSYNTHESIS COMPR, P285; OCHMAN H, 1988, GENETICS, V120, P621; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OLSON JM, 1987, INT REV CYTOL, V108, P209, DOI 10.1016/S0074-7696(08)61439-4; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; POSPIECH A, 1995, TRENDS GENET, V11, P217, DOI 10.1016/S0168-9525(00)89052-6; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; Van de Peer Y, 1997, J MOL EVOL, V45, P619, DOI 10.1007/PL00006266; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; XIONG J, UNPUB; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	35	351	401	4	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2000	289	5485					1724	1730		10.1126/science.289.5485.1724	http://dx.doi.org/10.1126/science.289.5485.1724			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976061				2022-12-28	WOS:000089195200039
J	Brott, T; Bogousslavsky, J				Brott, T; Bogousslavsky, J			Drug therapy - Treatment of acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; AMERICAN-HEART-ASSOCIATION; EARLY INTRAVENOUS THROMBOLYSIS; RANDOMIZED CONTROLLED TRIAL; HEALTH-CARE PROFESSIONALS; CAROTID TERRITORY STROKE; ACUTE HEMISPHERIC STROKE; PERFUSION-WEIGHTED MRI; SPECIAL WRITING GROUP		Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; CHU Vaudois, Dept Neurol, CH-1011 Lausanne, Switzerland	Mayo Clinic; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Brott, T (corresponding author), Mayo Clin, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	brott.thomas@mayo.edu			NINDS NIH HHS [2RO1 NS3067806 EDC-2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030678] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; Adams HP, 1999, NEUROLOGY, V53, P122, DOI 10.1212/WNL.53.1.122; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; ADAMS HP, 1998, CEREBROVASC DIS, P1430; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 1999, STROKE, V30, P1604, DOI 10.1161/01.STR.30.8.1604; *AM HEART ASS, 1997, HEART STROK STAT UPD; [Anonymous], 1998, JAMA, V279, P1265; Asplund K, 1996, CEREBROVASC DIS, V6, P3, DOI 10.1159/000107983; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; Atkinson RP, 1998, CEREBROVASC DIS, V8, P23, DOI 10.1159/000047500; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BARNWELL SL, 1994, AM J NEURORADIOL, V15, P1817; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; Becker KJ, 1996, AM J NEURORADIOL, V17, P255; Bednar MM, 1999, STROKE, V30, P887, DOI 10.1161/01.STR.30.4.887; Bendszus M, 1998, NEURORADIOLOGY, V40, P54, DOI 10.1007/s002340050540; BLAKELEY DD, 1995, ANN INTERN MED, V122, P360, DOI 10.7326/0003-4819-122-5-199503010-00007; BOCK RW, 1996, SURG CEREBROVASCULAR, P48; Bogousslavsky J, 1997, CEREBROVASC DIS, V7, P113; Bogousslavsky J, 1998, CEREBROVASC DIS, V8, P59; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; BRATINA P, 1995, STROKE, V26, P409, DOI 10.1161/01.STR.26.3.409; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brott T, 1998, STROKE, V29, P1504, DOI 10.1161/01.STR.29.8.1504; Brott T, 1997, STROKE, V28, P1530, DOI 10.1161/01.STR.28.8.1530; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; BROTT T, 1991, THROMBOLYTIC THERAPY, P196; Buchan AM, 2000, NEUROLOGY, V54, P679, DOI 10.1212/WNL.54.3.679; CANDELISE L, 1995, LANCET, V346, P1509; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chamorro A, 1999, ARCH NEUROL-CHICAGO, V56, P1098, DOI 10.1001/archneur.56.9.1098; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Cross DT, 1997, AM J NEURORADIOL, V18, P1221; Culebras A, 1997, STROKE, V28, P1480, DOI 10.1161/01.STR.28.7.1480; Darby DG, 1999, STROKE, V30, P2043, DOI 10.1161/01.STR.30.10.2043; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; Devuyst G, 1999, CURR OPIN NEUROL, V12, P73, DOI 10.1097/00019052-199902000-00012; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; DUVUYST G, 1997, ACUTE STOKE TREATMEN, P65; EINHAUPL KM, 1991, LANCET, V338, P597, DOI 10.1016/0140-6736(91)90607-Q; Elmstahl S, 1999, DYSPHAGIA, V14, P61, DOI 10.1007/PL00009588; Endo S, 1998, AM J NEURORADIOL, V19, P1169; EZURA M, 1992, SURG NEUROL, V38, P353, DOI 10.1016/0090-3019(92)90021-E; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; Firlik AD, 1998, J NEUROSURG, V89, P243, DOI 10.3171/jns.1998.89.2.0243; Fisher M, 1998, JAMA-J AM MED ASSOC, V279, P1298, DOI 10.1001/jama.279.16.1298; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Grau AJ, 1999, ARCH NEUROL-CHICAGO, V56, P1159, DOI 10.1001/archneur.56.9.1159; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; GRESHAM GE, 1995, CLIN PRACTICE GUIDEL, V16; GRESHAM GE, 1998, STROKE PATHOPHYSIOLO, P1389; Grond M, 1998, STROKE, V29, P1544, DOI 10.1161/01.STR.29.8.1544; Grond M, 1998, ARCH NEUROL-CHICAGO, V55, P466, DOI 10.1001/archneur.55.4.466; Grotta J, 1997, NEW ENGL J MED, V337, P1310; Grotta JC, 1998, STROKE, V29, P429, DOI 10.1161/01.STR.29.2.429; GUBITZ G, 1999, COCHRANE REV, V2; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Heiss WD, 1999, STROKE, V30, P1486, DOI 10.1161/01.STR.30.7.1486; Higashida R T, 1994, J Endovasc Surg, V1, P4; Hommel M, 1996, NEW ENGL J MED, V335, P145; HOMMEL M, 1998, CEREBROVASC DIS, V8, pA64; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; Jahan R, 1999, AM J NEURORADIOL, V20, P1291; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; KOROGI Y, 1994, RADIOLOGY, V193, P187, DOI 10.1148/radiology.193.1.8090890; KOTHARI R, 1995, STROKE, V26, P937, DOI 10.1161/01.STR.26.6.937; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; KRIEGER D, 1992, J NEUROL, V239, P183, DOI 10.1007/BF00839136; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Lansberg MG, 1999, STROKE, V30, P678, DOI 10.1161/01.STR.30.3.678; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; Mann G, 1999, STROKE, V30, P744, DOI 10.1161/01.STR.30.4.744; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; Marks MP, 1999, NEUROLOGY, V52, P1792, DOI 10.1212/WNL.52.9.1792; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayo NE, 2000, STROKE, V31, P1016, DOI 10.1161/01.STR.31.5.1016; MCDOWELL FH, 1993, J STROKE CEREBROVASC, V3, P133; McNamara RL, 1997, ANN INTERN MED, V127, P775, DOI 10.7326/0003-4819-127-9-199711010-00001; Mitchell PJ, 1997, CEREBROVASC DIS, V7, P94, DOI 10.1159/000108174; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Pathansali R, 1998, J HUM HYPERTENS, V12, P73, DOI 10.1038/sj.jhh.1000569; PELZ DM, 1986, RADIOLOGY, V160, P369, DOI 10.1148/radiology.160.2.3726115; *PER CENTR NERV SY, 1996, PER CENTR NERV SYST; Pohjasvaara T, 1998, STROKE, V29, P75, DOI 10.1161/01.STR.29.1.75; Porteous G H, 1999, Prehosp Emerg Care, V3, P211; POWERS WJ, 1993, NEUROLOGY, V43, P461, DOI 10.1212/WNL.43.3_Part_1.461; Reith J, 1997, STROKE, V28, P1585, DOI 10.1161/01.STR.28.8.1585; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; ROPPER AH, 1988, NEUROLOGICAL NEUROSU, P23; Rosenblum WI, 1997, J NEUROTRAUM, V14, P313, DOI 10.1089/neu.1997.14.313; Sandercock P, 1997, LANCET, V349, P1569; SASAKI O, 1995, NEUROSURGERY, V36, P246, DOI 10.1227/00006123-199502000-00002; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; SHERMAN DG, 1996, SURG CEREBROVASCULAR, P43; Stegmayr B, 1999, STROKE, V30, P709, DOI 10.1161/01.STR.30.4.709; Strobel CJ, 1999, ENVIRON MONIT ASSESS, V56, P1, DOI 10.1023/A:1005911822444; Suarez JI, 1999, STROKE, V30, P2094, DOI 10.1161/01.STR.30.10.2094; *SUBC ADV CARD LIF, 1997, ADV CARDIAC LIFE SUP; Tanne D, 1999, NEUROLOGY, V53, P424, DOI 10.1212/WNL.53.2.424; Thorvaldsen P, 1997, STROKE, V28, P500, DOI 10.1161/01.STR.28.3.500; TOMSICK T, 1992, AM J NEURORADIOL, V13, P257; Toni D, 2000, NEUROLOGY, V54, P684, DOI 10.1212/WNL.54.3.684; Trouillas P, 1996, STROKE, V27, P882, DOI 10.1161/01.STR.27.5.882; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; Ueda T, 1999, STROKE, V30, P2360, DOI 10.1161/01.STR.30.11.2360; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; Wang DZ, 2000, STROKE, V31, P77, DOI 10.1161/01.STR.31.1.77; Wildermuth S, 1998, STROKE, V29, P935, DOI 10.1161/01.STR.29.5.935; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; Zivin JA, 1998, NEUROLOGY, V50, P599, DOI 10.1212/WNL.50.3.599	143	230	262	5	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					710	722		10.1056/NEJM200009073431007	http://dx.doi.org/10.1056/NEJM200009073431007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974136				2022-12-28	WOS:000089100500007
J	Merz, AJ; So, M; Sheetz, MP				Merz, AJ; So, M; Sheetz, MP			Pilus retraction powers bacterial twitching motility	NATURE			English	Article							NEISSERIA-GONORRHOEAE; EPITHELIAL-CELLS; IV PILI; ESCHERICHIA-COLI; PROTEIN; GENE; TRANSFORMATION; RESOLUTION; BIOGENESIS; VIRULENCE	Twitching and social gliding motility allow many Gram negative bacteria to crawl along surfaces, and are implicated in a wide range of biological functions(1). Type IV pili (Tfp) are required for twitching and social gliding, but the mechanism by which these filaments promote motility has remained enigmatic(1-4). Here we use laser tweezers(5) to show that Tfp forcefully retract. Neisseria gonorrhoeae cells that produce Tfp actively crawl on a glass surface and form adherent microcolonies. When laser tweezers are used to place and hold cells near a microcolony, retractile forces pull the cells toward the microcolony. In quantitative experiments, the Tfp of immobilized bacteria bind to latex beads and retract, pulling beads from the tweezers at forces that can exceed 80 pN. Episodes of retraction terminate with release or breakage of the Tfp tether. Both motility and retraction mediated by Tfp occur at about 1 mu m s(-1) and require protein synthesis and function of the PilT protein. Our experiments establish that Tfp filaments retract, generate substantial force and directly mediate cell movement.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27705 USA	Oregon Health & Science University; Duke University	Sheetz, MP (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.		So, Magdalene/ABB-8918-2020	So, Magdalene/0000-0001-8301-0674				Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; BRADLEY DE, 1972, BIOCHEM BIOPH RES CO, V47, P142, DOI 10.1016/S0006-291X(72)80021-4; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; BROSSAY L, 1994, INFECT IMMUN, V62, P2302, DOI 10.1128/IAI.62.6.2302-2308.1994; Comolli JC, 1999, INFECT IMMUN, V67, P3625, DOI 10.1128/IAI.67.7.3625-3630.1999; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; DUPUY B, 1991, J BACTERIOL, V173, P7589, DOI 10.1128/jb.173.23.7589-7598.1991; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Krause S, 2000, P NATL ACAD SCI USA, V97, P3067, DOI 10.1073/pnas.050578697; Mahadevan L, 2000, SCIENCE, V288, P95, DOI 10.1126/science.288.5463.95; Merz AJ, 1999, MOL MICROBIOL, V32, P1316, DOI 10.1046/j.1365-2958.1999.01459.x; NOVOTNY CP, 1974, J BACTERIOL, V117, P1306, DOI 10.1128/JB.117.3.1306-1311.1974; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Pujol C, 1999, P NATL ACAD SCI USA, V96, P4017, DOI 10.1073/pnas.96.7.4017; SEIFERT HS, 1988, NATURE, V336, P392, DOI 10.1038/336392a0; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; SHEETZ MP, 1997, LASER TWEEZERS CELL; SWANSON J, 1978, INFECT IMMUN, V19, P320, DOI 10.1128/IAI.19.1.320-331.1978; Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V; Wolfgang M, 1998, P NATL ACAD SCI USA, V95, P14973, DOI 10.1073/pnas.95.25.14973; Wolfgang M, 1998, MOL MICROBIOL, V29, P321, DOI 10.1046/j.1365-2958.1998.00935.x; Yoshida T, 1999, J BACTERIOL, V181, P2038, DOI 10.1128/JB.181.7.2038-2043.1999	30	596	607	1	72	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					98	102		10.1038/35024105	http://dx.doi.org/10.1038/35024105			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993081				2022-12-28	WOS:000089124000050
J	Kondo, DG; Judd, VE				Kondo, DG; Judd, VE			Demographic characteristics of US medical school admission committees	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFIRMATIVE-ACTION; MINORITY-STUDENTS; DIVERSITY	Context Although concerns continue to be raised about the diversity of the US physician workforce, there has never been a nationwide survey of both the sex and underrepresented minority (URM) composition of medical school admission committees. Objective To document US medical school admission committee membership in several demographic domains, including sex and URM (African American, Mexican American, mainland Puerto Rican, Native American, Native Hawaiian, and Native Alaskan) status. Design Mailed survey. Setting and Participants Deans or directors of admission at 85 US medical schools that were members of the Association of American Medical Colleges (response rate, 70%). Main Outcome Measures Prevalence of 1999-2000 school-year committee members in demographic categories, such as sex, URM status, physician or medical student status; compensation status. Results The overall ratio of men to women on admission committees was 1.77 to 1, On average, 16% of committee members were from URM groups. Physicians with URM status comprised 8% of committee membership; 51% of committees had 1 or 0 URM physicians. Seventy-four percent of committees had at least 1 medical student; medical students comprised 15% of total membership. Ninety-one percent of committees operated on a volunteer basis. Conclusion Although representation of women and persons with URM status on medical school admission committees has improved since 1972, URM membership, in particular, remains low.	Menninger Clin, Karl Menninger Sch Psychiat & Mental Hlth Sci, Topeka, KS 66601 USA; Univ Utah, Sch Med, Dept Pediat, Div Pediat Cardiol, Salt Lake City, UT USA; Univ Utah, Sch Med, Sch Admiss & Divers & Community Outreach, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kondo, DG (corresponding author), Menninger Clin, Karl Menninger Sch Psychiat & Mental Hlth Sci, POB 829, Topeka, KS 66601 USA.			Kondo, Douglas/0000-0003-2066-777X				ARNOLD DM, 1984, J MED EDUC, V59, P131; Barzansky B, 1999, JAMA-J AM MED ASSOC, V282, P840, DOI 10.1001/jama.282.9.840; Burrow GN, 1998, ACAD MED, V73, P1052, DOI 10.1097/00001888-199810000-00010; Carlisle DM, 1998, AM J PUBLIC HEALTH, V88, P1314, DOI 10.2105/AJPH.88.9.1314; Clawson DK, 1999, CLIN ORTHOP RELAT R, P34; Cohen JJ, 1997, ACAD MED, V72, P103, DOI 10.1097/00001888-199702000-00010; DeVille K, 1999, MT SINAI J MED, V66, P247; GEE HH, 1957, J MED EDUC, V32, P863; Gingrich D, 1999, Acad Med, V74, pS49; Juster F, 1999, Acad Med, V74, pS45, DOI 10.1097/00001888-199901000-00030; Nickens HW, 1996, JAMA-J AM MED ASSOC, V275, P572, DOI 10.1001/jama.275.7.572; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; OETGEN WJ, 1972, J MED EDUC, V47, P966; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Tekian A, 1998, ACAD MED, V73, P986, DOI 10.1097/00001888-199809000-00019; Thomson WA, 1999, ACAD MED, V74, P312, DOI 10.1097/00001888-199904000-00010	16	15	15	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1111	1113		10.1001/jama.284.9.1111	http://dx.doi.org/10.1001/jama.284.9.1111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974690				2022-12-28	WOS:000089037200011
J	Hariraj, R; Stoner, E; Jader, S; Preston, DM				Hariraj, R; Stoner, E; Jader, S; Preston, DM			Drug points - Prolonged cholestasis associated with irbesartan	BRITISH MEDICAL JOURNAL			English	Article							HEPATOTOXICITY; LOSARTAN		Royal Free Med Sch, London, England	University of London; University College London	Hariraj, R (corresponding author), Royal Free Med Sch, London, England.							Andrade RJ, 1998, ANN PHARMACOTHER, V32, P1371, DOI 10.1345/aph.18087a; BENICHOU C, 1990, J HEPATOL, V11, P272; Bosch X, 1997, JAMA-J AM MED ASSOC, V278, P1572, DOI 10.1001/jama.278.19.1572; HAGLEY MT, 1993, ANN PHARMACOTHER, V27, P228, DOI 10.1177/106002809302700220; Nygaard Birte, 1996, Blood Pressure, V5, P190, DOI 10.3109/08037059609062128	5	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					547	547		10.1136/bmj.321.7260.547	http://dx.doi.org/10.1136/bmj.321.7260.547			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968816	Green Published, Bronze			2022-12-28	WOS:000089174100021
J	May, MJ; D'Acquisto, F; Madge, LA; Glockner, J; Pober, JS; Ghosh, S				May, MJ; D'Acquisto, F; Madge, LA; Glockner, J; Pober, JS; Ghosh, S			Selective inhibition of NF-kappa B activation by a peptide that blocks the interaction of NEMO with the I kappa B kinase complex	SCIENCE			English	Article							IKK-BETA SUBUNIT; GAMMA; MICE; IDENTIFICATION; APOPTOSIS; COMPONENT; PROTEINS; SKIN	Activation of the transcription factor nuclear factor (NF)-kappa B by proinflammatory stimuli Leads to increased expression of genes involved in inflammation. Activation of NF-kappa B requires the activity of an inhibitor of kappa B (I kappa B)-kinase (IKK) complex containing two kinases (IKK alpha and IKK beta) and the regulatory protein NEMO (NF-kappa B essential modifier). An amino-terminal alpha-helical region of NEMO associated with a carboxyl-terminal segment of IKK alpha and IKK beta that we term the NEMO-binding domain (NBD), A cell-permeable NBD peptide blocked association of NEMO with the IKK complex and inhibited cytokine-induced NF-kappa B activation and NF-kappa B-dependent gene expression. The peptide also ameliorated inflammatory responses in two experimental mouse models of acute inflammation. The NBD provides a target for the development of drugs that would block proinflammatory activation of the IKK complex without inhibiting basal NF-kappa B activity.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Intdepartmental Program Vasc Biol & Transplantat, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA.	sankar.ghosh@yale.edu	D'Acquisto, Fulvio/E-7204-2018	D'Acquisto, Fulvio/0000-0002-4513-1608; May, Michael/0000-0002-2485-3716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443, R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ajuebor MN, 1998, IMMUNOLOGY, V95, P625; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CHANG J, 1987, EUR J PHARMACOL, V142, P197, DOI 10.1016/0014-2999(87)90108-7; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; GETTING SJ, BR J PHARM, V120, P1075; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; May M. M., UNPUB; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; POBER JS, 1986, J IMMUNOL, V136, P1680; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	32	588	644	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1550	1554		10.1126/science.289.5484.1550	http://dx.doi.org/10.1126/science.289.5484.1550			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968790				2022-12-28	WOS:000089071700046
J	Taipale, J; Chen, JK; Cooper, MK; Wang, BL; Mann, RK; Milenkovic, L; Scott, MP; Beachy, PA				Taipale, J; Chen, JK; Cooper, MK; Wang, BL; Mann, RK; Milenkovic, L; Scott, MP; Beachy, PA			Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine	NATURE			English	Article							BASAL-CELL CARCINOMAS; SONIC HEDGEHOG; HUMAN HOMOLOG; CUBITUS-INTERRUPTUS; PROTEIN; MICE; GENE; MEDULLOBLASTOMAS; REPRESSOR	Basal cell carcinoma, medulloblastoma, rhabdomyosarcoma and other human tumours are associated with mutations that activate the proto-oncogene Smoothened (SMO) or that inactivate the tumour suppressor Patched (PTCH). Smoothened and Patched mediate the cellular response to the Hedgehog (Hh) secreted protein signal, and oncogenic mutations affecting these proteins cause excess activity of the Hh response pathway(1,2). Here we show that the plant-derived teratogen cyclopamine, which inhibits the Hh response(3,4), is a potential 'mechanism-based' therapeutic agent for treatment of these tumours. We show that cyclopamine or synthetic derivatives with improved potency block activation of the Hh response pathway and abnormal cell growth associated with both types of oncogenic mutation. Our results also indicate that cyclopamine may act by influencing the balance between active and inactive forms of Smoothened.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.		Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Lange Y, 1999, J LIPID RES, V40, P2264; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pietsch T, 1997, CANCER RES, V57, P2085; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Sasaki H, 1997, DEVELOPMENT, V124, P1313; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	29	1059	1129	1	79	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1005	1009		10.1038/35023008	http://dx.doi.org/10.1038/35023008			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984056				2022-12-28	WOS:000089020200048
J	Ashwell, M				Ashwell, M			Elsie Widdowson (1906-2000) - Obituary	NATURE			English	Biographical-Item									Ashwell Associates, Ashwell SG7 5PZ, Herts, England		Ashwell, M (corresponding author), Ashwell Associates, Ashwell St, Ashwell SG7 5PZ, Herts, England.								0	3	3	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					844	844		10.1038/35022699	http://dx.doi.org/10.1038/35022699			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972275				2022-12-28	WOS:000088903600027
J	Rochon, PA; Tu, JV; Anderson, GM; Gurwitz, JH; Clark, JP; Lau, P; Szalai, JP; Sykora, K; Naylor, CD				Rochon, PA; Tu, JV; Anderson, GM; Gurwitz, JH; Clark, JP; Lau, P; Szalai, JP; Sykora, K; Naylor, CD			Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction	LANCET			English	Article							CLINICAL-TRIALS; ELDERLY PATIENTS; DRUG-THERAPY; HIGH-RISK; MORTALITY; MORBIDITY; OUTCOMES; PROJECT	Background Many older people do not receive beta-blocker therapy after myocardial infarction or receive doses lower than those tested in trials, perhaps because physicians fear that beta-blockers may precipitate heart failure. We examined the relation between use of beta-blockers, the dose used, and hospital admission for heart failure and 1-year survival in a cohort of all older patients surviving myocardial infarction in Ontario, Canada. Methods We collected data on a cohort of 13 623 patients aged 66 years or older who were discharged from hospital after a myocardial infarction and who did not receive beta-blocker therapy or received low, standard, or high doses. We used Cox's proportional-hazards models to study the association of dose with admission for heart failure and survival with adjustment for factors including age, sex, and comorbidity. Findings Among 8232 patients with no previous history of heart failure, dispensing of beta-blocker therapy was associated with a 43% reduction in subsequent admission for heart failure (adjusted risk ratio 0.57 [95% CI 0.48-0.69]) compared with patients not dispensed this therapy. Among the 4681 patients prescribed beta-blockers, the risk of admission was greater in the high-dose than in the low-dose group (1.53 [1.01-2.31]). Among all 13 623 patients in the cohort, 2326 (17.1%) died by 1 year. Compared with those not dispensed beta-blocker therapy, the adjusted risk ratio for mortality was lower for all three doses (low 0.40 [0.34-0.47], standard 0.36 [0.31-0.42], high 0.43 [0.33-0.56]), Interpretation Compared with high-dose beta-blocker therapy, low-dose treatment is associated with a lower rate of hospital admission for heart failure and has a similar 1-year survival benefit. Our findings support the need for a randomised controlled trial comparing doses of beta-blocker therapy in elderly patients.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Sunnybrooke & Womens Coll Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; Sunnybrooke & Womens Coll Hlth Sci Ctr, Dept Publ Hlth Sci, Toronto, ON, Canada; Sunnybrooke & Womens Coll Hlth Sci Ctr, Dept Hlth Adm, Toronto, ON, Canada; Univ Toronto, Fac Med, Deans Off, Toronto, ON, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Fallon Healthcare Syst, Meyers Primary Care Inst, Worcester, MA USA; Univ Massachusetts, Sch Med, Worcester, MA 01605 USA	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Massachusetts System; University of Massachusetts Worcester	Rochon, PA (corresponding author), Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151; Clark, Jocalyn/0000-0002-8014-3989				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Barron HV, 1998, ARCH INTERN MED, V158, P449, DOI 10.1001/archinte.158.5.449; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; *CAN PHARM ASS, 1998, COMP PHARM SPEC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; Cox JL, 1997, CAN J CARDIOL, V13, P351; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FALLEN EL, 1995, CAN J CARDIOL, V11, P477; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; HJALMARSON A, 1983, CIRCULATION, V67, P26; *JOINT FORM COMM 1, 1997, BRIT NAT FORM; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lechat P, 1999, LANCET, V353, P9; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; *MED EC CO INC, 1997, PHYS DESK REF; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; ROCHON PA, 1993, ARCH INTERN MED, V153, P243, DOI 10.1001/archinte.153.2.243; Rochon PA, 1999, J AM GERIATR SOC, V47, P954, DOI 10.1111/j.1532-5415.1999.tb01290.x; Rochon PA, 1998, CAN MED ASSOC J, V159, P321; Rochon PA, 1999, CAN MED ASSOC J, V161, P1403; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; Sharpe N, 1999, LANCET, V353, P1988, DOI 10.1016/S0140-6736(99)90183-6; TU JV, 1999, CARDIOVASCULAR HLTH, P25; Tu LV, 1999, CAN MED ASSOC J, V161, P1257; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; WILCOX RG, 1980, BRIT MED J, V280, P885, DOI 10.1136/bmj.280.6218.885	33	57	59	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2000	356	9230					639	644		10.1016/S0140-6736(00)02606-4	http://dx.doi.org/10.1016/S0140-6736(00)02606-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968437				2022-12-28	WOS:000088884100012
J	Kaiser, P; Flick, K; Wittenberg, C; Reed, SI				Kaiser, P; Flick, K; Wittenberg, C; Reed, SI			Regulation of transcription by ubiquitination without proteolysis: Cdc34/SCFMet30-mediated inactivation of the transcription factor Met4	CELL			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; YEAST KINETOCHORE; PROTEIN; PROTEASOME; COMPLEXES; KINASE; LIGASE; CDC34; DEGRADATION	Polyubiquitination of proteins by Cdc34/SCF complexes targets them for degradation by the 26S proteasome. The essential F-box protein Met30 is the substrate recognition subunit of the ubiquitin ligase SCFMet30. The critical target of SCFMet30 is the transcription factor Met4, as deletion of MET4 suppresses the lethality of met30 mutants. Surprisingly, Met4 is a relatively stable protein and its abundance is not influenced by Met30. However, transcriptional repression of Met4 target genes correlates with Cdc34 /SCFMet30-dependent ubiquitination of Met4. Functionally, ubiquitinated Met4 associates with target promoters but fails to form functional transcription complexes. Our data reveal a novel proteolysis-independent function for Cdc34/SCF and indicate that ubiquitination of transcription factors can be utilized to directly regulate their activities.	Scripps Res Inst, La Jolla, CA USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, MB7, La Jolla, CA USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006, R37GM038328, R01GM043487, R01GM038328] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38328, GM46006, GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PATTON EE, 1988, YEAST GEN MOL BIOL M; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMPSON AH, 1995, CAN J PSYCHIAT, V40, P15, DOI 10.1177/070674379504000106; Verma R, 1997, METHOD ENZYMOL, V283, P366; YOON HJ, 1995, MOL CELL BIOL, V15, P4835	27	233	238	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 4	2000	102	3					303	314		10.1016/S0092-8674(00)00036-2	http://dx.doi.org/10.1016/S0092-8674(00)00036-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975521	Bronze			2022-12-28	WOS:000088625600006
J	Humphrey, JH; Rice, AL				Humphrey, JH; Rice, AL			Vitamin A supplementation of young infants	LANCET			English	Editorial Material							A SUPPLEMENTATION; MOTHERS; AGE; IMMUNIZATION; FONTANELLE; MORBIDITY; MORTALITY; TOLERANCE; VACCINES; DELIVERY		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Human Nutr, Baltimore, MD 21205 USA	Johns Hopkins University	Humphrey, JH (corresponding author), ZVITAMBO Project, 21 Van Praagh Ave, Harare, Zimbabwe.	humphrey@zvitambo.icon.co.zw						AGOESTINA T, 1994, B WORLD HEALTH ORGAN, V72, P859; BAQUI AH, 1995, ACTA PAEDIATR, V84, P863, DOI 10.1111/j.1651-2227.1995.tb13781.x; Beaton G, 1993, ACC SCN STATE ART SE; BECKER NH, 1963, AM J PATHOL, V43, P1017; CHAPPELL JE, 1985, EARLY HUM DEV, V11, P157, DOI 10.1016/0378-3782(85)90103-3; DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6; *ESGPAN COMM, 1977, ACTA PAEDIATR SC   S, V262, P8; [FAO WHO Expert Consultation], 1988, FAO FOOD NUTR SER; FOMON AJ, 1993, NUTR NORMAL INFANTS, P409; HILL A, 1981, PEDIATRICS, V68, P623; Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1; Humphrey JH, 1998, AM J CLIN NUTR, V68, P109, DOI 10.1093/ajcn/68.1.109; Iliff PJ, 1999, NUTR RES, V19, P1437, DOI 10.1016/S0271-5317(99)00101-3; MADDUX GW, 1974, J NUTR, V104, P478, DOI 10.1093/jn/104.4.478; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; OLSON JA, 1979, ARCH LATINOAM NUTR, V29, P521; OLSON JA, 1984, AM J CLIN NUTR, V39, P903, DOI 10.1093/ajcn/39.6.903; RAHMAN MM, 1995, EUR J CLIN NUTR, V49, P439; Rice AL, 1999, J NUTR, V129, P356, DOI 10.1093/jn/129.2.356; Roy SK, 1997, EUR J CLIN NUTR, V51, P302, DOI 10.1038/sj.ejcn.1600398; SHAPIRO K, 1985, J NEUROSURG, V63, P69, DOI 10.3171/jns.1985.63.1.0069; STABELL C, 1995, EUR J CLIN NUTR, V49, P73; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; Thanangkul O., 1974, JOINT WHO USAID M CO; vanDillen J, 1996, LANCET, V347, P1705, DOI 10.1016/S0140-6736(96)91541-X; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; WEST KP, 1995, AM J CLIN NUTR, V62, P143, DOI 10.1093/ajcn/62.1.143; WEST KP, 1992, B WORLD HEALTH ORGAN, V70, P733; WEST KP, 1986, VITAMIN A DEFICIENCY, P325	29	34	37	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					422	424		10.1016/S0140-6736(00)02541-1	http://dx.doi.org/10.1016/S0140-6736(00)02541-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972388				2022-12-28	WOS:000088486000038
J	Sidley, P				Sidley, P			South African leaders come under pressure to admit HIV/AIDS link	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					722	722						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999891				2022-12-28	WOS:000089546600009
J	Colven, R; Harrington, RD; Spach, DH; Cohen, CJ; Hooton, TM				Colven, R; Harrington, RD; Spach, DH; Cohen, CJ; Hooton, TM			Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS TYPE-1 INFECTION; COMBINATION THERAPY; DISCONTINUATION; VIREMIA; PLASMA; LOAD	Background: Although viral rebound follows cessation of suppressive antiretroviral therapy in chronic HIV infection, a viremic clinical syndrome has not been described. Objective: To describe a retroviral syndrome associated with cessation of effective antiretroviral therapy in chronic HIV infection. Design: Case reports. Setting: Outpatient HIV specialty clinics in Seattle, Washington, and Boston, Massachusetts. Patients: Three patients with chronic HIV infection who discontinued suppressive antiretroviral therapy. Measurements: Clinical course, plasma HIV RNA levels, and CD4 cell counts before, during, and after cessation of antiretroviral therapy. Results: Within 6 weeks after stopping antiretroviral therapy, each patient experienced a clinical illness that resembled a primary HIV syndrome. This coincided with a marked increase in HIV RNA level and, in two of three patients, a decrease in CD4 cell count. After antiretroviral therapy was restarted, each patient's symptoms rapidly resolved in association with resuppression of HIV RNA and increase in CD4 cell count or percentage. Conclusion: A retroviral rebound syndrome similar to that seen in primary HIV syndrome can occur in patients with chronic HIV infection after cessation of suppressive antiretroviral therapy.	Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; Harvard Vanguard Med Associates, Boston, MA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harvard Vanguard Medical Associates	Colven, R (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359763, Seattle, WA 98104 USA.							BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Daar ES, 1998, ANN INTERN MED, V128, P827, DOI 10.7326/0003-4819-128-10-199805150-00005; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Jubault V, 1998, AIDS, V12, P2358; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001	10	48	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					430	434		10.7326/0003-4819-133-6-200009190-00010	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975960				2022-12-28	WOS:000089329700004
J	Malkowski, MG; Ginell, SL; Smith, WL; Garavito, RM				Malkowski, MG; Ginell, SL; Smith, WL; Garavito, RM			The productive conformation of arachidonic acid bound to prostaglandin synthase	SCIENCE			English	Article							CYCLOOXYGENASE ACTIVE-SITE; ENDOPEROXIDE-H SYNTHASE-1; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN COLON-CANCER; CRYSTAL-STRUCTURE; H-2 SYNTHASE; ASPIRIN; INHIBITION; BINDING; COX-2	Prostaglandin H synthase-1 and -2 (PGHS-1 and -2) catalyze the committed step in prostaglandin synthesis and are targets for nonsteroidal anti-inflammatory drugs (NSAIDs) Like aspirin. We have determined the structure of PGHS-1 at 3 angstrom resolution with arachidonic acid (AA) bound in a chemically productive conformation. The fatty acid adopts an extended L-shaped conformation that positions the 13proS hydrogen of AA for abstraction by tyrosine-385, the Likely radical donor. A space also exists for oxygen addition on the antarafacial surface of the carbon in the 11-position (C-11). While this conformation allows endoperoxide formation between C-11 and C-9, it also implies that a subsequent conformational rearrangement must occur to allow formation of the C-8/C-12 bond and to position C-15 for attack by a second molecule of oxygen.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Michigan State University; United States Department of Energy (DOE); Argonne National Laboratory	Garavito, RM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	garavito@magaera.bch.msu.edu	Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NHLBI NIH HHS [F32 HL10170-01, R01 HL56773] Funding Source: Medline; NIGMS NIH HHS [P01 GM57323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773, F32HL010170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Garavito RM, 1996, J BIOENERG BIOMEMBR, V28, P13, DOI 10.1007/BF02150674; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; HSI LC, 1995, BIOCHEM BIOPH RES CO, V207, P652, DOI 10.1006/bbrc.1995.1237; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, ARCH BIOCHEM BIOPHYS, V380, P39, DOI 10.1006/abbi.2000.1906; Marnett LJ, 1998, CURR OPIN CHEM BIOL, V2, P482, DOI 10.1016/S1367-5931(98)80124-5; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SMITH P, 1995, INT J ENVIRON HEAL R, V5, P5; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SMITH WW, UNPUB; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	40	243	246	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2000	289	5486					1933	1937		10.1126/science.289.5486.1933	http://dx.doi.org/10.1126/science.289.5486.1933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988074				2022-12-28	WOS:000089355800046
J	Deng, MC; De Meester, JMJ; Smits, JMA; Heinecke, J; Scheld, HH				Deng, MC; De Meester, JMJ; Smits, JMA; Heinecke, J; Scheld, HH		Comp Outcome Clin Profiles Transpl	Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratifred by heart failure severity	BRITISH MEDICAL JOURNAL			English	Article							LUNG-TRANSPLANTATION; SURVIVAL BENEFIT; MORTALITY; RECIPIENTS; RISK	Objective To determine whether there is a survival benefit associated with cardiac transplantation in Germany. Design Prospective observational cohort study. Setting All 889 adult patients listed for a first heart transplant in Germany in 1997. Main outcome measure Mortality, stratified by heart failure severity. Results Within 1 year after listing, patients with a predicted high risk had the highest global death rate (51% v 32% and 29% for medium and low risk patients respectively; P < 0.0001), had the highest risk of dying on the waiting list (32% v 20% and 20%; P = 0.0003), and were more likely to receive a transplant (48% v 45% and 41%; P = 0.01). Differences between the risk groups in outcome after transplantation did not reach significance (P = 0.2). Transplantation was not associated with a reduction in mortality risk for the total cohort, but it did provide a survival benefit for the high risk group. Conclusion Cardiac transplantation in Germany is currently associated with a survival benefit only in patients with a predicted high risk of dying on the waiting list Patients with a predicted low or medium risk have no reduction in mortality risk associated with transplantation; they should be managed with organ saving approaches rather than transplantation.	Univ Munster, Dept Cardiothorac Surg, D-48129 Munster, Germany; Eurotransplant Fdn, NL-2301 CH Leiden, Netherlands; Univ Munster, Inst Biomath, D-48129 Munster, Germany	University of Munster; University of Munster	Deng, MC (corresponding author), Columbia Univ Coll Phys & Surg, Heart Failure Ctr, 630 W 168th St, New York, NY 10032 USA.							Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; BYAR DP, 1976, NEW ENGL J MED, V295, P74, DOI 10.1056/NEJM197607082950204; De Meester J, 1999, J HEART LUNG TRANSPL, V18, P563, DOI 10.1016/S1053-2498(99)00002-9; Deng MC, 2000, THORAC CARDIOV SURG, V48, P183, DOI 10.1055/s-2000-9637; Edwards EB, 1997, TRANSPL P, V29, P459, DOI 10.1016/S0041-1345(96)00201-1; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Gibbons RD, 2000, SCIENCE, V287, P237, DOI 10.1126/science.287.5451.237; Goldstein DJ, 1998, NEW ENGL J MED, V339, P1522, DOI 10.1056/NEJM199811193392107; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Hosenpud JD, 1999, J HEART LUNG TRANSPL, V18, P611, DOI 10.1016/S1053-2498(99)00037-6; Hunt SA, 1993, J AM COLL CARDIOL, V22, P1; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P319, DOI 10.1001/jama.279.4.319; Kirsch M, 1998, J HEART LUNG TRANSPL, V17, P268; Lucey M R, 1998, Transplantation, V66, P956, DOI 10.1097/00007890-199810150-00034; MCGIFFIN DC, 1998, CURR OPIN ORGAN TRAN, V3, P44; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Smits JMA, 1998, TRANSPLANTATION, V66, P1146, DOI 10.1097/00007890-199811150-00006; STEVENSON LW, 1991, J AM COLL CARDIOL, V18, P919, DOI 10.1016/0735-1097(91)90747-W; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303	20	125	132	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					540	545		10.1136/bmj.321.7260.540	http://dx.doi.org/10.1136/bmj.321.7260.540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968814	Green Published, Bronze			2022-12-28	WOS:000089174100018
J	Rosen, R				Rosen, R			Clinical governance in primary care - Improving quality in the changing world of primary care	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MODEL		Kings Fund, London W1M 0AN, England		Rosen, R (corresponding author), Kings Fund, London W1M 0AN, England.							[Anonymous], 1999, EFFECTIVE HLTH CARE, V5; *AUD COMM, 2000, PCG AG EARL PROGR PC; Baker R, 1999, BRIT MED J, V318, P779, DOI 10.1136/bmj.318.7186.779; Banta HD, 1995, HLTH CARE TECHNOLOGY; *CHIEF MED OFF, 1998, REV CONT PROF DEV GE; *DEP HLTH, 1998, 1 CLASS SERVICE; Ferriman A, 1999, BRIT MED J, V318, P1305, DOI 10.1136/bmj.318.7194.1305a; Fugelli P, 1996, BRIT MED J, V312, P456, DOI 10.1136/bmj.312.7029.456; GRAY DP, 1997, 50 RCGP; GRAY DP, 1992, PLANNING PRIMARY CAR; Greenhalgh T, 1999, QUALITY GEN PRACTICE; GROL R, 1994, FAM PRACT, V11, P460, DOI 10.1093/fampra/11.4.460; *HARR W PRIM CAR G, 1999, CLIN GOV ED TRAIN SU; Howie JGR, 1997, MEASURING QUALITY GE; *KINGS FUND HLTH Q, 1999, PRIM CAR GROUP STAND; Malcolm L, 1999, BRIT MED J, V319, P1340, DOI 10.1136/bmj.319.7221.1340; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; New B., 1999, GOOD ENOUGH SERVICE; *NHS EX, 1999, HSC1999065 NHS EX; *NW THAM REG OFF, 1993, DEV PRIM HLTH CAR DI; PUGNER K, 1998, BR J HLTH CARE MAN S, V12, P4; ROLAND M, 1998, QUALITY ASSESSMENT G; ROLAND M, 1999, CLIN GOVERNANCE PRAC; *ROYAL COLL GEN PR, 1999, CLIN GOV PRACT ADV P; *ROYAL COLL GEN PR, 1999, MEMB ASS PERF GUID N; SALTER B, 2000, REFORMING REGULATION; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; TOON P, 1994, WHAT IS GOOD GEN PRA; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; WILKIN D, 2000, NATL TRACKER SURVEY; WYE L, 2000, CLIN GOVERNANCE PRIM; [No title captured]	32	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	2000	321	7260					551	554		10.1136/bmj.321.7260.551	http://dx.doi.org/10.1136/bmj.321.7260.551			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968820	Bronze, Green Published			2022-12-28	WOS:000089174100023
J	Stevenson, D				Stevenson, D			Europa's ocean - the case strengthens	SCIENCE			English	Editorial Material							SALT		CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Stevenson, D (corresponding author), CALTECH, Div Geol & Planetary Sci, 1200 E Calif Blvd, Pasadena, CA 91125 USA.							Carlson RW, 1999, SCIENCE, V286, P97, DOI 10.1126/science.286.5437.97; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; Hoppa GV, 1999, SCIENCE, V285, P1899, DOI 10.1126/science.285.5435.1899; Kargel JS, 1998, SCIENCE, V280, P1211, DOI 10.1126/science.280.5367.1211; Kivelson MG, 2000, SCIENCE, V289, P1340, DOI 10.1126/science.289.5483.1340; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; Pappalardo RT, 1999, J GEOPHYS RES-PLANET, V104, P24015, DOI 10.1029/1998JE000628; Pappalardo RT, 1999, SCI AM, V281, P54, DOI 10.1038/scientificamerican1099-54; Showman AP, 1999, SCIENCE, V286, P77, DOI 10.1126/science.286.5437.77	10	33	33	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2000	289	5483					1305	+		10.1126/science.289.5483.1305	http://dx.doi.org/10.1126/science.289.5483.1305			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347RF	10979854				2022-12-28	WOS:000088942400023
J	Hutchings, JA				Hutchings, JA			Collapse and recovery of marine fishes	NATURE			English	Article							COD; EXTINCTION	Over-exploitation and subsequent collapse of marine fishes has focused attention on the ability of affected populations to recover to former abundance levels(1-3) and on the degree to which their persistence is threatened by extinction(4,5). Although potential for recovery has been assessed indirectly(1), actual changes in population size following long-term declines have not been examined empirically. Here I show that there is very little evidence for rapid recovery from prolonged declines, in contrast to the perception that marine fishes are highly resilient to large population reductions(6,7). With the possible exception of herring and related species that mature early in life and are fished with highly selective equipment, my analysis of 90 stocks reveals that many gadids (for example, cod, haddock) and other non-clupeids (for example, flatfishes) have experienced little, if any, recovery as much as 15 years after 45-99% reductions in reproductive biomass. Although the effects of overfishing on single species may generally be reversible(1), the actual time required for recovery appears to be considerable. To exempt marine fishes from existing criteria used to assign extinction risk(6,7) would be inconsistent with precautionary approaches to fisheries management and the conservation of marine biodiversity.	Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	Dalhousie University	Hutchings, JA (corresponding author), Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada.	jhutch@mscs.dal.ca	Hutchings, Jeffrey/ABA-1098-2020	Hutchings, Jeffrey/0000-0003-1572-5429				Alverson DL, 1994, FISH TECHNOL, DOI DOI 10.3168/JDS.S0022-0302(94)77044-2; Campbell RR, 1996, CAN FIELD NAT, V110, P454; Carlton JT, 1999, ANNU REV ECOL SYST, V30, P515, DOI 10.1146/annurev.ecolsys.30.1.515; Casey JM, 1998, SCIENCE, V281, P690, DOI 10.1126/science.281.5377.690; Cook RM, 1997, NATURE, V385, P521, DOI 10.1038/385521a0; FROESE R, 1999, FISHBASE 99; HILBORN R, 1992; Hudson E, 1996, MARINE FISH IUCN RED; Hutchings J. A., 1995, N ATLANTIC FISHERIES, P38; HUTCHINGS JA, 1994, CAN J FISH AQUAT SCI, V51, P2126, DOI 10.1139/f94-214; *INT UN CONS NAT, 1996, IUCN RED LIST THREAT; *IUCN SPEC SURV CO, 1999, IUCN RED LIST CAT; Jennings S, 1998, ADV MAR BIOL, V34, P201, DOI 10.1016/S0065-2881(08)60212-6; LANDE R, 1993, AM NAT, V142, P911, DOI 10.1086/285580; Liermann M, 1997, CAN J FISH AQUAT SCI, V54, P1976, DOI 10.1139/cjfas-54-9-1976; Musick JA, 1999, FISHERIES, V24, P6, DOI 10.1577/1548-8446(1999)024<0006:CTDERI>2.0.CO;2; Myers RA, 1996, MAR ECOL PROG SER, V138, P293, DOI 10.3354/meps138293; MYERS RA, 1995, SCIENCE, V269, P1106, DOI 10.1126/science.269.5227.1106; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Roff Derek A., 1992; Saether BE, 1998, OIKOS, V83, P403, DOI 10.2307/3546856; Shank CC, 1999, CAN FIELD NAT, V113, P318; Sinclair Alan F., 1997, P71; Smith T. D., 1994, SCALING FISHERIES SC	24	612	640	4	491	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					882	+		10.1038/35022565	http://dx.doi.org/10.1038/35022565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972288				2022-12-28	WOS:000088903600042
J	van der Kooij, FM; Kassapidou, K; Lekkerkerker, HNW				van der Kooij, FM; Kassapidou, K; Lekkerkerker, HNW			Liquid crystal phase transitions in suspensions of polydisperse plate-like particles	NATURE			English	Article							NEMATIC-ISOTROPIC TRANSITION; HARD-SPHERES; SMECTIC PHASE; MONTE-CARLO; BEHAVIOR; CRYSTALLIZATION; DISPERSIONS; SYSTEMS; RODS	Colloidal suspensions that form periodic self-assembling structures on sub-micrometre scales are of potential technological interest; for example, three-dimensional arrangements of spheres in colloidal crystals(1) might serve as photonic materials(2), intended to manipulate light. Colloidal particles with non-spherical shapes (such as rods and plates) are of particular interest because of their ability to form liquid crystals. Nematic liquid crystals possess orientational order; smectic and columnar liquid crystals additionally exhibit positional order (in one or two dimensions respectively). However, such positional ordering(3,4) may be inhibited in polydisperse colloidal suspensions. Here we describe a suspension of plate-like colloids that shows isotropic, nematic and columnar phases on increasing the particle concentration. We find that the columnar two-dimensional crystal persists for a polydispersity of up to 25%, with a cross-over to smectic-like ordering at very high particle concentrations. Our results imply that liquid crystalline order in synthetic mesoscopic materials may be easier to achieve than previously thought.	Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University	Lekkerkerker, HNW (corresponding author), Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, Padualaan 8, NL-3584 CH Utrecht, Netherlands.							BARRAT JL, 1986, J PHYS-PARIS, V47, P1547, DOI 10.1051/jphys:019860047090154700; Bates MA, 1999, J CHEM PHYS, V111, P1732, DOI 10.1063/1.479433; Bates MA, 1999, J CHEM PHYS, V110, P6553, DOI 10.1063/1.478558; Bates MA, 1998, J CHEM PHYS, V109, P6193, DOI 10.1063/1.477248; Bernal JD, 1941, J GEN PHYSIOL, V25, P111, DOI 10.1085/jgp.25.1.111; BIBETTE J, 1991, J COLLOID INTERF SCI, V147, P474, DOI 10.1016/0021-9797(91)90181-7; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; Bolhuis PG, 1996, PHYS REV E, V54, P634, DOI 10.1103/PhysRevE.54.634; Brown ABD, 1999, EUR PHYS J B, V11, P481, DOI 10.1007/s100510050959; Brown ABD, 1998, LANGMUIR, V14, P3129, DOI 10.1021/la971294d; Dogic Z, 1997, PHYS REV LETT, V78, P2417, DOI 10.1103/PhysRevLett.78.2417; FRENKEL D, 1988, NATURE, V332, P822, DOI 10.1038/332822a0; GITZEN WH, 1970, ALUMINA CERAMIC MAT, V31; GUINIER A, 1994, XRAY DIFFRACTION CRY, P169; Kofke DA, 1999, PHYS REV E, V59, P618, DOI 10.1103/PhysRevE.59.618; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; MCRAE R, 1988, J CHEM PHYS, V88, P1114, DOI 10.1063/1.454230; ONSAGER L, 1949, ANN NY ACAD SCI, V51, P627, DOI 10.1111/j.1749-6632.1949.tb27296.x; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1987, J PHYS-PARIS, V48, P709, DOI 10.1051/jphys:01987004805070900; PUSEY PN, 1991, HOUCH SESS 51 LIQ FR, pCH10; SMITH H, 1992, FEMS MICROBIOL LETT, V79, P287; van Bruggen MPB, 1999, MACROMOLECULES, V32, P2256, DOI 10.1021/ma981196e; van der Kooij FM, 2000, LANGMUIR, V16, P5317, DOI 10.1021/la991571b; van der Kooij FM, 2000, PHYS REV LETT, V84, P781, DOI 10.1103/PhysRevLett.84.781; van der Kooij FM, 1998, J PHYS CHEM B, V102, P7829, DOI 10.1021/jp981534d; VEERMAN JAC, 1992, PHYS REV A, V45, P5632, DOI 10.1103/PhysRevA.45.5632	28	363	366	6	192	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					868	871		10.1038/35022535	http://dx.doi.org/10.1038/35022535			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972283	Green Published			2022-12-28	WOS:000088903600037
J	Taton, TA; Mirkin, CA; Letsinger, RL				Taton, TA; Mirkin, CA; Letsinger, RL			Scanometric DNA array detection with nanoparticle probes	SCIENCE			English	Article							POLYNUCLEOTIDES	A method for analyzing combinatorial DNA arrays using oligonucleotide-modified gold nanoparticle probes and a conventional flatbed scanner is described here. Labeling oligonucleotide targets with nanoparticle rather than fluorophore probes substantially alters the melting profiles of the target; from an array substrate. This difference permits the discrimination of an oligonucleotide sequence from targets with single nucleotide mismatches with a selectivity that is over three times that observed for fluorophore-labeled targets. In addition, when coupled with a signal amplification method based on nanoparticle-promoted reduction of silver(I), the sensitivity of this scanometric array detection system exceeds that of the analogous fluorophore system by two orders of magnitude.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Ctr Nanofabricat & Mol Self Assembly, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.		Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057356] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57356] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Chrisey LA, 1996, NUCLEIC ACIDS RES, V24, P3031, DOI 10.1093/nar/24.15.3031; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393; Forman JE, 1998, ACS SYM SER, V682, P206; Hacker G. W., 1989, COLLOIDAL GOLD PRINC, V1; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MUCIC RC, 1999, THESIS NW U EVANSTON; SAIKI RK, 1998, MUTATION DETECTION P, pCH7; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Zehbe I, 1997, AM J PATHOL, V150, P1553	12	2180	2409	10	650	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1757	1760		10.1126/science.289.5485.1757	http://dx.doi.org/10.1126/science.289.5485.1757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976070				2022-12-28	WOS:000089195200048
J	[Anonymous]				[Anonymous]			Joys of darkness	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993036				2022-12-28	WOS:000089124000001
J	Malartre, E				Malartre, E			Words, words, words - Kissing a biotechnological blarney stone	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					833	833		10.1038/35022671	http://dx.doi.org/10.1038/35022671			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972269	Bronze			2022-12-28	WOS:000088903600019
J	Zenisek, D; Steyer, JA; Almers, W				Zenisek, D; Steyer, JA; Almers, W			Transport, capture and exocytosis of single synaptic vesicles at active zones	NATURE			English	Article							RETINAL BIPOLAR CELLS; FROG NEUROMUSCULAR-JUNCTION; LIVE CHROMAFFIN CELLS; TRANSMITTER RELEASE; SECRETORY GRANULES; CALCIUM CURRENT; HAIR-CELLS; ENDOCYTOSIS; TERMINALS; MEMBRANE	To sustain high rates of transmitter release, synaptic terminals must rapidly re-supply vesicles to release sites and prime them for exocytosis. Here we describe imaging of single synaptic vesicles near the plasma membrane of live ribbon synaptic terminals. Vesicles were captured at small, discrete active zones near the terminal surface. An electric stimulus caused them to undergo rapid exocytosis, seen as the release of a fluorescent lipid from the vesicles into the plasma membrane. Next, vesicles held in reserve about 20 nm from the plasma membrane advanced to exocytic sites, and became release-ready 250 ms later. Apparently a specific structure holds vesicles at an active zone to bring v-SNAREs and t-SNAREs, the proteins that mediate vesicle fusion, within striking distance of each other, and then allows the triggered movement of such vesicles to the plasma membrane.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Oregon Health & Science University; University of California System; University of California Berkeley	Almers, W (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	almersw@ohsu.edu	Zenisek, David/C-6555-2011					Axelrod D, 1992, TOPICS FLUORESCENCE, P289; Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; GRAY EG, 1971, BRAIN RES, V35, P1, DOI 10.1016/0006-8993(71)90591-9; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; ISSA NP, 1994, P NATL ACAD SCI USA, V91, P7578, DOI 10.1073/pnas.91.16.7578; KOBAYASHI K, 1995, J PHYSIOL-LONDON, V483, P79, DOI 10.1113/jphysiol.1995.sp020569; Lagnado L, 1996, NEURON, V17, P957, DOI 10.1016/S0896-6273(00)80226-3; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; Lenzi D, 1999, J NEUROSCI, V19, P119, DOI 10.1523/JNEUROSCI.19-01-00119.1999; LILEY AW, 1953, J NEUROPHYSIOL, V16, P509, DOI 10.1152/jn.1953.16.5.509; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Mennerick S, 1996, NEURON, V17, P1241, DOI 10.1016/S0896-6273(00)80254-8; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Neves G, 1999, J PHYSIOL-LONDON, V515, P181, DOI 10.1111/j.1469-7793.1999.181ad.x; Oheim M, 1998, EUR BIOPHYS J BIOPHY, V27, P83, DOI 10.1007/s002490050114; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; RAVIOLA E, 1975, J CELL BIOL, V65, P192, DOI 10.1083/jcb.65.1.192; Rouze NC, 1998, J NEUROSCI, V18, P8614; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; Sakaba T, 1997, NEUROSCI RES, V27, P357, DOI 10.1016/S0168-0102(97)01168-1; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Schneggenburger R, 1999, NEURON, V23, P399, DOI 10.1016/S0896-6273(00)80789-8; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Toomre D, 2000, J CELL BIOL, V149, P33, DOI 10.1083/jcb.149.1.33; von Gersdorff H, 1998, NEURON, V21, P1177, DOI 10.1016/S0896-6273(00)80634-0; vonGersdorff H, 1996, NEURON, V16, P1221, DOI 10.1016/S0896-6273(00)80148-8; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Wu LG, 1999, NEURON, V23, P821, DOI 10.1016/S0896-6273(01)80039-8; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	40	349	358	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					849	854		10.1038/35022500	http://dx.doi.org/10.1038/35022500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972279				2022-12-28	WOS:000088903600033
J	Nolo, R; Abbott, LA; Bellen, HJ				Nolo, R; Abbott, LA; Bellen, HJ			Senseless, a Zn finger transcription factor, is necessary and sufficient for sensory organ development in Drosophila	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; DEPENDENT KINASE INHIBITOR; HAIRY-WING MUTATIONS; PRONEURAL GENE; CELL FATE; NEURONAL PRECURSORS; ADULT DROSOPHILA; NEUROGENIC GENES; CUT LOCUS	The senseless (sens) gene is required for proper development of most cell types of the embryonic and adult peripheral nervous system (PNS) of Drosophila. Sens is a nuclear protein with four Zn fingers that is expressed and required in the sensory organ precursors (SOP) for proper proneural gene expression. Ectopic expression of Sens in many ectodermal cells causes induction of PNS external sensory organ formation and is able to recreate an ectopic proneural field. Hence, sens is both necessary and sufficient for PNS development. Our data indicate that proneural genes activate sens expression. Sens is then in turn required to further activate and maintain proneural gene expression. This feedback mechanism is essential for selective enhancement and maintenance of proneural gene expression in the SOPs.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Program Dev Biol, Houston, TX 77030 USA; Univ Colorado, Mol Cellular Dev Biol Dept, Boulder, CO 80309 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Colorado System; University of Colorado Boulder	Bellen, HJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.			Bellen, Hugo/0000-0001-5992-5989				ABBOTT LA, 1986, DEV BIOL, V115, P233, DOI 10.1016/0012-1606(86)90243-5; ABBOTT LA, 1990, ROUX ARCH DEV BIOL, V198, P448, DOI 10.1007/BF00399055; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; Ben-Arie N, 2000, DEVELOPMENT, V127, P1039; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BRAND M, 1993, DEVELOPMENT, V119, P1; BREWSTER R, 1995, DEVELOPMENT, V121, P2923; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; Chanut F, 1997, DEVELOPMENT, V124, P559; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; Culi J, 1998, GENE DEV, V12, P2036, DOI 10.1101/gad.12.13.2036; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hassan B, 1997, DEV GENET, V21, P117, DOI 10.1002/(SICI)1520-6408(1997)21:2<117::AID-DVG1>3.0.CO;2-A; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HUANG F, 1991, DEVELOPMENT, V111, P1087; Huang ML, 2000, NEURON, V25, P57, DOI 10.1016/S0896-6273(00)80871-5; IP YT, 1994, DEVELOPMENT, V120, P199; JACK J, 1991, DEVELOPMENT, V113, P735; Jan Yuh Nung, 1993, P1207; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JENNINGS B, 1995, DEVELOPMENT, V121, P3745; Jia YW, 1997, DEVELOPMENT, V124, P2063; Jia YW, 1996, GENETICS, V142, P141; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KRAMATSCHEK B, 1994, DEVELOPMENT, V120, P815; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Ligoxygakis P, 1999, DEVELOPMENT, V126, P2205; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Modolell J, 1997, PERSPECT DEV NEUROBI, V4, P285; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Murphy EP, 1996, GENE EXPRESSION, V5, P169; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakao K, 1996, NEURON, V16, P275, DOI 10.1016/S0896-6273(00)80046-X; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Salzberg A, 1997, GENETICS, V147, P1723; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schweisguth F, 1996, DEV GENET, V18, P28, DOI 10.1002/(SICI)1520-6408(1996)18:1&lt;28::AID-DVG4&gt;3.0.CO;2-3; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; Spradling AC, 1999, GENETICS, V153, P135; TATA F, 1993, DEVELOPMENT, P139; VAESSIN H, 1994, DEVELOPMENT, V120, P935; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; XU T, 1993, DEVELOPMENT, V117, P1223; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	74	402	406	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 4	2000	102	3					349	362		10.1016/S0092-8674(00)00040-4	http://dx.doi.org/10.1016/S0092-8674(00)00040-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975525	Bronze			2022-12-28	WOS:000088625600010
J	Cole, TJ				Cole, TJ			Commentary: Beware regression to the mean	BRITISH MEDICAL JOURNAL			English	Editorial Material									Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Cole, TJ (corresponding author), Inst Child Hlth, Dept Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 29	2000	321	7256					281	281						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341ZA	10979690				2022-12-28	WOS:000088619800030
J	Kelsen, DP				Kelsen, DP			Surrogate endpoints in assessment of new drugs in colorectal cancer	LANCET			English	Editorial Material							ADJUVANT		Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Kelsen, DP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.							DEGRAMONT A, 1998, P AN M AM SOC CLIN, V17, pA257; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Haller DG, 1998, P AN M AM SOC CLIN, V17, p256a; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; SALTZ LB, 1999, P AM SOC CLIN ONCOL, V18, pA242	6	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					353	354		10.1016/S0140-6736(00)02522-8	http://dx.doi.org/10.1016/S0140-6736(00)02522-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972363				2022-12-28	WOS:000088486000003
J	Dobson, R				Dobson, R			Scientists show that vCJD can be transmitted through blood	BRITISH MEDICAL JOURNAL			English	News Item																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					721	721		10.1136/bmj.321.7263.721	http://dx.doi.org/10.1136/bmj.321.7263.721			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999888	Green Published			2022-12-28	WOS:000089546600006
J	Yu, G; Nishimura, M; Arawaka, S; Levitan, D; Zhang, LL; Tandon, A; Song, YQ; Rogaeva, E; Chen, FS; Kawaral, T; Supala, A; Levesque, L; Yu, H; Yang, DS; Holmes, E; Millman, P; Liang, Y; Zhang, DM; Xu, DH; Sato, C; Rogaev, E; Smith, M; Janus, C; Zhang, YN; Aebersold, R; Farrer, L; Sorbi, S; Bruni, A; Fraser, P; St George-Hyslop, P				Yu, G; Nishimura, M; Arawaka, S; Levitan, D; Zhang, LL; Tandon, A; Song, YQ; Rogaeva, E; Chen, FS; Kawaral, T; Supala, A; Levesque, L; Yu, H; Yang, DS; Holmes, E; Millman, P; Liang, Y; Zhang, DM; Xu, DH; Sato, C; Rogaev, E; Smith, M; Janus, C; Zhang, YN; Aebersold, R; Farrer, L; Sorbi, S; Bruni, A; Fraser, P; St George-Hyslop, P			Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and beta APP processing	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; MISSENSE MUTATIONS; NOTCH; COMPLEX; CATENIN; COMPONENT; CLEAVAGE; RELEASE	Nicastrin, a transmembrane glycoprotein, forms high molecular weight complexes with presenilin 1 and presenilin 2. Suppression of nicastrin expression in Caenorhabditis elegans embryos induces a subset of notch/glp-1 phenotypes similar to those induced by simultaneous null mutations in both presenilin homologues of C. elegans(sel-12 and hop-1). Nicastrin also binds carboxy-terminal derivatives of beta-amyloid precursor protein (beta APP), and modulates the production of the amyloid beta-peptide (A beta) from these derivatives. Missense mutations in a conserved hydrophilic domain of nicastrin increase A beta(42) and A beta(40) peptide secretion. Deletions in this domain inhibit A beta production. Nicastrin and presenilins are therefore likely to be functional components of a multimeric complex necessary for the intramembranous proteolysis of proteins such as Notch/GLP-1 and beta APP.	Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Schering Plough Corp, Res Inst, Dept CNS & Cardiovasc Res, Kenilworth, NJ 07033 USA; Univ Washington, Seattle, WA 98195 USA; Boston Univ, Sch Med, Genet Program, Boston, MA 02118 USA; Univ Florence, Dept Neurol, I-50134 Florence, Italy; Ctr Reg Neurogenet, USL 6, I-88046 Lamezia Terme, Italy	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Merck & Company; Schering Plough Corporation; University of Washington; University of Washington Seattle; Boston University; University of Florence	St George-Hyslop, P (corresponding author), Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Ctr Res Neurodegenerat Dis, Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.		Farrer, Lindsay/AAS-1035-2020; Rogaev, Evgeny/AAN-7662-2020; Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Bruni, Amalia/K-5038-2016	St George-Hyslop, Peter/0000-0003-0796-7209; Arawaka, Shigeki/0000-0002-1505-3012; Farrer, Lindsay/0000-0001-5533-4225; Song, You-Qiang/0000-0001-9407-2256; Xu, Dazhong/0000-0001-9264-3342; Yu, Wai Haung/0000-0001-7186-6731; Bruni, Amalia/0000-0003-3471-3343				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CHEN F, IN PRESS J BIOL CHEM; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; FELDMAN RG, 1963, NEUROLOGY, V13, P811, DOI 10.1212/WNL.13.10.811; Figeys D, 1996, NAT BIOTECHNOL, V14, P1579, DOI 10.1038/nbt1196-1579; FONCIN JF, 1985, REV NEUROL, V141, P194; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Howell DC., 2013, STAT METHODS PSYCHOL, V8; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; PREISS JR, 1987, CELL, V51, P601; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; YU G, IN PRESS J BIOL CHEM; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054; Zubenko GS, 1998, GENOMICS, V50, P121, DOI 10.1006/geno.1998.5306	44	795	840	0	46	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					48	54		10.1038/35024009	http://dx.doi.org/10.1038/35024009			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993067				2022-12-28	WOS:000089124000036
J	Yedidia, MJ; Gillespie, CC; Moore, GT				Yedidia, MJ; Gillespie, CC; Moore, GT			Specific clinical competencies for managing care - Views of residency directors and managed care medical directors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; EDUCATION; STUDENTS; FACULTY	Context Although medical educators recognize the need to prepare physicians to work effectively in managed care environments, managed care is often perceived negatively by academic physicians. Curricular reform has been hampered by a failure to seek agreement about specific clinical competencies that are important to both managed care directors and medical educators. Objectives To identify specific clinical competencies in the managed care setting and to assess agreement between residency directors and managed care medical directors on the importance of these competencies. Design, Setting, and Participants Surveys (1998-1999) of a national sample of 59 residency directors involved in managed care training programs (response rate, 94%); a sample of 186 residents in these programs and 258 matched control residents (response rate, 77%); and national samples of 147 managed care organization (MCO) medical directors (response rate, 67%) and 140 primary care residency program directors in areas of high MCO penetration (response rate, 73%). Main Outcome Measures Specific clinical managed care tasks as defined by residency directors; self-reported confidence in performing these tasks by sample residents vs control residents; and importance of these tasks as rated by MCO medical directors and residency program directors. Results wenty-six specific clinical managed care tasks were identified by the residency directors, Residents who participated in managed care training were significantly more confident than their counterparts in performing 20 of the 26 tasks (P<.01 for all). Residency directors and MCO medical directors viewed 65% of these tasks as important to patient care during the next 5 years. Of the 10 tasks most highly rated by residency directors and MCO medical directors, 9 were the same, addressing time management, ethics, case management, practice guidelines, cost-effective clinical decision making, referral management, disease management, patient satisfaction, and clinical epidemiology. Conclusions Our data indicate that residency directors and managed care medical directors value mastery of many of the same specific clinical competencies in managed care. Previously documented negative attitudes toward managed care among academic physicians may obscure an underlying concordance about the skills essential to managing the health of populations.	NYU, Robert F Wagner Grad Sch Publ Serv, Ctr Hlth & Publ Serv Res, New York, NY 10003 USA; Harvard Pilgrim Hlth Ctr, Boston, MA USA	New York University; Harvard Pilgrim Health Care	Yedidia, MJ (corresponding author), NYU, Robert F Wagner Grad Sch Publ Serv, Ctr Hlth & Publ Serv Res, 726 Broadway,5th Floor, New York, NY 10003 USA.			Gillespie, Colleen/0000-0001-9096-3430				Blumenthal D, 1996, JAMA-J AM MED ASSOC, V276, P725; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; *GROUP HLTH ASS AM, 1994, PRIM CAR PHYS REC RE, P19; GUMBINER R, 1994, INQUIRY-J HEALTH CAR, V31, P330; *INT PUBL, 1998, COMP EDGE 8 1 DAT CD; JACOBS MO, 1987, J MED EDUC, V62, P725; Lane DS, 1998, AM J PREV MED, V14, P229, DOI 10.1016/S0749-3797(97)00068-8; Lurie N, 1996, ACAD MED, V71, P1044, DOI 10.1097/00001888-199610000-00009; Mainous AG, 1997, ACAD MED, V72, P385, DOI 10.1097/00001888-199705000-00019; *MAN CAR INF CTR, 1999, NAT DIR MAN CAR ORG; Meyer GS, 1997, ACAD MED, V72, P669, DOI 10.1097/00001888-199708000-00010; SCOTT CS, 1991, ACAD MED, V66, P106, DOI 10.1097/00001888-199102000-00013; Seifer SD, 1998, WESTERN J MED, V168, P400; SHINE KI, 1996, URBAN MED CTR BALANC; SHUGARS DA, 1994, HLTH AM PRACTITIONER; Simon SR, 1999, NEW ENGL J MED, V340, P928, DOI 10.1056/NEJM199903253401206	16	26	26	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1093	1098		10.1001/jama.284.9.1093	http://dx.doi.org/10.1001/jama.284.9.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974687	Bronze			2022-12-28	WOS:000089037200008
J	Beutler, E; Felitti, V; Gelbart, T; Ho, N				Beutler, E; Felitti, V; Gelbart, T; Ho, N			The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic	ANNALS OF INTERNAL MEDICINE			English	Article							INCREASED TRANSFERRIN SATURATION; VOLUNTARY BLOOD-DONORS; HEREDITARY HEMOCHROMATOSIS; S65C VARIANT; GENE; POPULATION; MUTATIONS; HOMOZYGOTES; HEMOGLOBIN; RECEPTOR	Background: The gene that causes most cases of hereditary hemochromatosis is designated HFE. Three mutations exist at this locus at a relatively high gene frequency. Objective: To determine the gene frequency of the three HFE mutations and to relate genotypes to various clinical and laboratory variables. Design: Observational study. Setting: Health appraisal clinic. Patients: 10 198 adults who registered for health appraisal and consented to DNA examination for hemochromatosis. Consenting patients were slightly older and had attained a slightly higher educational level than nonconsenting patients. Measurements: Extensive medical history and laboratory tests, including complete blood count, transferrin saturation, and other chemistries; serum ferritin levels; and HFE genotype. Results: In white participants, the gene frequencies were 0.063 for the C282Y mutation, 0.152 for the H63D mutation, and 0.016 for the S65C mutation. Gene frequencies were lower in other ethnic groups. In participants with HFE mutations, the average serum transferrin saturation and ferritin levels were slightly increased, as were mean hemoglobin levels and mean corpuscular volume. A transferrin saturation of 50% had a sensitivity of only 0.52 (95% CI, 0.345 to 0.686) and a specificity of 0.908 (CI, 0.902 to 0.914) for detection of homozygosity. A ferritin level of 200 mu g/L in women and 250 mu g/L in men had a sensitivity of 0.70 (CI, 0.540 to 0.854) and a specificity of 0.803 (CI, 0.796 to 0.811). The prevalence of iron deficiency anemia was lower in women who carried HFE mutations. Conclusions: Screening for transferrin saturation and ferritin levels does not detect all homozygotes for the major hemochromatosis mutation. Heterozygotes for HFE mutations had a lower prevalence of iron deficiency anemia.	Scripps Res Inst, La Jolla, CA 92037 USA; Kaiser Permanente, San Diego, CA USA	Scripps Research Institute; Kaiser Permanente	Beutler, E (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	beutler@scripps.edu		Gelbart, Terri/0000-0002-7863-1262	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIDDK NIH HHS [DK53505-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arya N, 1999, BLOOD CELL MOL DIS, V25, P354, DOI 10.1006/bcmd.1999.0264; Barton JC, 2000, J LAB CLIN MED, V135, P96, DOI 10.1016/S0022-2143(00)70026-6; Beutler E, 1997, AM J HUM GENET, V61, P762; Beutler E, 1999, BLOOD CELL MOL DIS, V25, P358, DOI 10.1006/bcmd.1999.0265; BEUTLER E, 1957, NEW ENGL J MED, V256, P692, DOI 10.1056/NEJM195704112561506; BEUTLER E, IN PRESS GENETIC TES; BEUTLER E, 2000, BLOOD CELLS MOL DIS; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Burke W, 1999, MOL MED TODAY, V5, P428, DOI 10.1016/S1357-4310(99)01578-6; Datz C, 1998, CLIN CHEM, V44, P2429; EDWARDS CQ, 1980, ANN INTERN MED, V93, P519, DOI 10.7326/0003-4819-93-4-519; EDWARDS CQ, 1994, ADV EXP MED BIOL, V356, P303; Edwards CQ, 1998, SEMIN HEMATOL, V35, P72; Fairbanks VF, 1998, GUT, V43, P441, DOI 10.1136/gut.43.3.441; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jezequel P, 1998, HUM GENET, V102, P332, DOI 10.1007/s004390050701; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lebron JA, 1999, J MOL BIOL, V289, P1109, DOI 10.1006/jmbi.1999.2842; McDonnell SM, 1999, AM J MED, V107, P30, DOI 10.1016/S0002-9343(99)00163-1; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; PERRY GS, 1992, J NUTR, V122, P1417, DOI 10.1093/jn/122.7.1417; Rochette J, 1999, AM J HUM GENET, V64, P1056, DOI 10.1086/302318; Rossi E, 2000, CLIN CHEM, V46, P162; Ryan E, 1998, BLOOD CELL MOL DIS, V24, P428, DOI 10.1006/bcmd.1998.0211; Somerville MJ, 1999, AM J HUM GENET, V65, P924, DOI 10.1086/302550; Spriggs EL, 1999, AM J HUM GENET, V65, pA492; Willis G, 2000, GUT, V46, P401, DOI 10.1136/gut.46.3.401; Willis G, 1999, LANCET, V354, P221, DOI 10.1016/S0140-6736(99)02195-9; Worwood M, 1998, CLIN LAB HAEMATOL, V20, P65, DOI 10.1046/j.1365-2257.1998.00028.x	33	221	223	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					329	337		10.7326/0003-4819-133-5-200009050-00008	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979877				2022-12-28	WOS:000089111900002
J	Schmid, PE; Tokeshi, M; Schmid-Araya, JM				Schmid, PE; Tokeshi, M; Schmid-Araya, JM			Relation between population density and body size in stream communities	SCIENCE			English	Article							GRAVEL STREAM; ABUNDANCE; CHIRONOMIDAE; ASSEMBLAGES; REGRESSION; SEDIMENTS; DYNAMICS; DIPTERA	The existence of a general relation between population density and body size in animal assemblages has been debated because of known biases and ambiguities in the published data and data handling. Using new comprehensive data sets from two geographically separated stream communities that encompass 448 and 260 invertebrate taxa with a wide range of body sizes, we show that an inverse proportionality between density and body size is a consistent feature in these communities. The scaling across taxa is not statistically different between the two systems, indicating a convergent pattern of communities, Variation in the regression slope among different taxonomic groups indicates that these communities are not governed universally by a single ecological or energetic rule.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Kyushu Univ, Amakusa Marine Biol Lab, Kumamoto, Japan	University of London; Queen Mary University London; Kyushu University	Schmid, PE (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	p.e.schmid@qmw.ac.uk		Schmid, Peter E./0000-0002-2510-3941				BABU GJ, 1992, COMMUN STAT SIMULAT, V21, P533, DOI 10.1080/03610919208813034; BLACKBURN TM, 1993, J ANIM ECOL, V62, P694, DOI 10.2307/5389; BLACKBURN TM, 1994, PHILOS T ROY SOC B, V343, P33, DOI 10.1098/rstb.1994.0005; Blackburn TM, 1999, OIKOS, V85, P570, DOI 10.2307/3546707; BRETSCHKO G, 1992, Regulated Rivers Research and Management, V7, P17, DOI 10.1002/rrr.3450070104; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; DUNCAN A, 1989, HYDROBIOLOGIA, V186, P11, DOI 10.1007/BF00048891; GASTON KJ, 1988, AM NAT, V132, P662, DOI 10.1086/284881; GRIFFITHS D, 1992, J ANIM ECOL, V61, P307, DOI 10.2307/5323; Griffiths D, 1998, J ANIM ECOL, V67, P795, DOI 10.1046/j.1365-2656.1998.00244.x; ISOBE T, 1990, ASTROPHYS J, V364, P104, DOI 10.1086/169390; Kleiber M., 1962, FIRE LIFE; LABARBERA M, 1989, ANNU REV ECOL SYST, V20, P97, DOI 10.1146/annurev.es.20.110189.000525; LAWTON JH, 1989, OIKOS, V55, P429, DOI 10.2307/3565606; LEICHTFRIED M, 1991, MITT OSTERR GEOL GES, V83, P229; MARQUET PA, 1990, SCIENCE, V250, P1125, DOI 10.1126/science.250.4984.1125; MARQUET PA, 1995, J ANIM ECOL, V64, P325, DOI 10.2307/5894; MORSE DR, 1985, NATURE, V314, P731, DOI 10.1038/314731a0; NEE S, 1991, NATURE, V351, P212; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SCHMID PE, 1993, FRESHWATER BIOL, V30, P239, DOI 10.1111/j.1365-2427.1993.tb00806.x; Schmid PE, 1997, FRESHWATER BIOL, V38, P67, DOI 10.1046/j.1365-2427.1997.00197.x; Schmid PE, 2000, ADV ECOL RES, V30, P339; SCHMID PE, 1999, JAHRESBER BIOL STATI, V16, P51; SCHMIDARAYA JM, 1994, LIMNOL OCEANOGR, V39, P1813, DOI 10.4319/lo.1994.39.8.1813; SCHMIDARAYA JM, 1995, JBER BIOL STN LUNZ, V15, P11; SCHONBORN W, 1977, OECOLOGIA, V27, P171, DOI 10.1007/BF00345821; TOKESHI M, 1999, SPECIES COEXISTENCE, P318	28	102	107	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1557	1560		10.1126/science.289.5484.1557	http://dx.doi.org/10.1126/science.289.5484.1557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968792				2022-12-28	WOS:000089071700048
J	Albrecht, M; Lutz, M; Spek, AL; van Koten, G				Albrecht, M; Lutz, M; Spek, AL; van Koten, G			Organoplatinum crystals for gas-triggered switches	NATURE			English	Article							SINGLE-CRYSTAL; MOLECULAR MACHINES; CARBON NANOTUBES; DIFFRACTION; HYDROGEN; METALS; MOTION	Considerable effort is being devoted to the fabrication of nanoscale devices(1). Molecular machines, motors and switches have been made, generally operating in solution(2-7), but for most device applications (such as electronics and opto-electronics), a maximal degree of order and regularity is required(8). Crystalline materials would be excellent systems for these purposes, as crystals comprise a vast number of self-assembled molecules, with a perfectly ordered three-dimensional structure(9). In non-porous crystals, however, the molecules are densely packed and any change in them (due, for example, to a reaction) is likely to destroy the crystal and its properties. Here we report the controlled and fully reversible crystalline-state reaction of gaseous SO2 with nonporous crystalline materials consisting of organoplatinum molecules. This process, including repetitive expansion-reduction sequences (on gas uptake and release) of the crystal lattice, modifies the structures of these molecules without affecting their crystallinity. The process is based on the incorporation of SO2 into the colourless crystals and its subsequent liberation from the orange adducts by reversible bond formation and cleavage(10). We therefore expect that these crystalline materials will rnd applications for gas storage devices and as opto-electronic switches(11,12).	Univ Utrecht, Debye Inst, Dept Met Mediated Synth, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res Crystal & Struct Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	van Koten, G (corresponding author), Univ Utrecht, Debye Inst, Dept Met Mediated Synth, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		van Koten, Gerard/AAN-4652-2021; albrecht, martin/B-4141-2014	van Koten, Gerard/0000-0003-3293-8370; albrecht, martin/0000-0001-7403-2329				Albrecht M, 1999, ADV MATER, V11, P171, DOI 10.1002/(SICI)1521-4095(199902)11:2<171::AID-ADMA171>3.0.CO;2-F; Albrecht M, 2000, CHEM-EUR J, V6, P1431, DOI 10.1002/(SICI)1521-3765(20000417)6:8<1431::AID-CHEM1431>3.3.CO;2-4; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; Braga D, 1998, CHEM REV, V98, P1375, DOI 10.1021/cr960091b; Buss CE, 1998, J AM CHEM SOC, V120, P7783, DOI 10.1021/ja981218c; Chen P, 1999, SCIENCE, V285, P91, DOI 10.1126/science.285.5424.91; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; DARENSBOURG MY, 1995, INORG CHEM, V34, P6287, DOI 10.1021/ic00129a013; Davies PJ, 1996, ANGEW CHEM INT EDIT, V35, P1959, DOI 10.1002/anie.199619591; Desiraju G. R., 1989, CRYSTAL ENG DESIGN O; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; DUNITZ JD, 1996, PERSPECTIVES SUPRAMO, P7; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Fabbrizzi L, 1999, ACCOUNTS CHEM RES, V32, P846, DOI 10.1021/ar990013l; Fox MA, 1999, ACCOUNTS CHEM RES, V32, P201, DOI 10.1021/ar9600953; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Kobatake S, 1999, J AM CHEM SOC, V121, P2380, DOI 10.1021/ja983717j; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Langley PJ, 1999, CHEM SOC REV, V28, P279, DOI 10.1039/a704290f; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Liu CY, 1999, ACCOUNTS CHEM RES, V32, P235, DOI 10.1021/ar980031n; Moffat K, 1998, ACTA CRYSTALLOGR A, V54, P833, DOI 10.1107/S0108767398010605; NOVAK K, 1993, ANGEW CHEM INT EDIT, V32, P1614, DOI 10.1002/anie.199316141; OHASHI Y, 1982, J AM CHEM SOC, V104, P6353, DOI 10.1021/ja00387a033; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; SCHEFFER JR, 1990, PHOTOCHEMISTRY ORG C, P185; VANKOTEN G, 1989, PURE APPL CHEM, V61, P1681, DOI 10.1351/pac198961101681	29	485	489	1	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					970	974		10.1038/35023107	http://dx.doi.org/10.1038/35023107			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984046	Green Published			2022-12-28	WOS:000089020200038
J	Stover, CK; Pham, XQ; Erwin, AL; Mizoguchi, SD; Warrener, P; Hickey, MJ; Brinkman, FSL; Hufnagle, WO; Kowalik, DJ; Lagrou, M; Garber, RL; Goltry, L; Tolentino, E; Westbrock-Wadman, S; Yuan, Y; Brody, LL; Coulter, SN; Folger, KR; Kas, A; Larbig, K; Lim, R; Smith, K; Spencer, D; Wong, GKS; Wu, Z; Paulsen, IT; Reizer, J; Saier, MH; Hancock, REW; Lory, S; Olson, MV				Stover, CK; Pham, XQ; Erwin, AL; Mizoguchi, SD; Warrener, P; Hickey, MJ; Brinkman, FSL; Hufnagle, WO; Kowalik, DJ; Lagrou, M; Garber, RL; Goltry, L; Tolentino, E; Westbrock-Wadman, S; Yuan, Y; Brody, LL; Coulter, SN; Folger, KR; Kas, A; Larbig, K; Lim, R; Smith, K; Spencer, D; Wong, GKS; Wu, Z; Paulsen, IT; Reizer, J; Saier, MH; Hancock, REW; Lory, S; Olson, MV			Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen	NATURE			English	Article							BACTERIUM MYXOCOCCUS-XANTHUS; MYCOBACTERIUM-TUBERCULOSIS; TWITCHING MOTILITY; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; CHEMOTAXIS; INFECTIONS; SECRETION; PROTEINS; GENES	Pseudomonas aeruginosa is a ubiquitous environmental bacterium that is one of the top three causes of opportunistic human infections. A major factor in its prominence as a pathogen is its intrinsic resistance to antibiotics and disinfectants. Here we report the complete sequence of P. aeruginosa strain PAO1. At 6.3 million base pairs, this is the largest bacterial genome sequenced, and the sequence provides insights into the basis of the versatility and intrinsic drug resistance of P. aeruginosa. Consistent with its larger genome size and environmental adaptability, P. aeruginosa contains the highest proportion of regulatory genes observed for a bacterial genome and a large number of genes involved in the catabolism, transport and efflux of organic compounds as well as four potential chemotaxis systems. We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances.	Univ Washington, Genome Ctr, Dept Med & Genet, Seattle, WA 98195 USA; Pathogenesis Corp, Seattle, WA 98119 USA; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Hannover Med Sch, Klin Forschergrp, D-30623 Hannover, Germany; Inst Genom Res, Rockville, MD 20850 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of British Columbia; Hannover Medical School; J. Craig Venter Institute; University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Olson, MV (corresponding author), Univ Washington, Genome Ctr, Dept Med & Genet, Box 352145, Seattle, WA 98195 USA.	mvo@u.washington.edu	WONG, Gane Ka-Shu/G-5784-2013; Brinkman, Fiona/N-3195-2013; Paulsen, Ian T/K-3832-2012; Hancock, Robert E. W./E-1145-2013	WONG, Gane Ka-Shu/0000-0001-6108-5560; Brinkman, Fiona/0000-0002-0584-4099; Paulsen, Ian T/0000-0001-9015-9418; Hancock, Robert E. W./0000-0001-5989-8503; Stover, Charles/0000-0002-7406-1696				Ahearn DG, 1999, METHOD ENZYMOL, V310, P551; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armitage JP, 1997, MICROBIOL-UK, V143, P3671, DOI 10.1099/00221287-143-12-3671; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bleves S, 1999, J BACTERIOL, V181, P4012, DOI 10.1128/JB.181.13.4012-4019.1999; BODEY GP, 1983, REV INFECT DIS, V5, P279; Brown MH, 1999, MOL MICROBIOL, V31, P394, DOI 10.1046/j.1365-2958.1999.01162.x; China B, 1999, VET RES, V30, P181; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DARZINS A, 1994, MOL MICROBIOL, V11, P137, DOI 10.1111/j.1365-2958.1994.tb00296.x; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hancock REW, 1998, NAT BIOTECHNOL, V16, P216, DOI 10.1038/nbt0398-216; Hancock REW, 1998, CLIN INFECT DIS, V27, pS93, DOI 10.1086/514909; Hardalo C, 1997, CRIT REV MICROBIOL, V23, P47, DOI 10.3109/10408419709115130; HOLLOWAY BW, 1955, J GEN MICROBIOL, V13, P572, DOI 10.1099/00221287-13-3-572; Kaneko T, 1996, DNA Res, V3, P109; KATO J, 1994, J BACTERIOL, V176, P5874, DOI 10.1128/JB.176.18.5874-5877.1994; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; MAHAN MJ, 1991, GENETICS, V129, P1021; MCBRIDE MJ, 1989, P NATL ACAD SCI USA, V86, P424, DOI 10.1073/pnas.86.2.424; MOULTON RC, 1979, J BACTERIOL, V137, P274, DOI 10.1128/JB.137.1.274-280.1979; NELSON JW, 1990, INFECT IMMUN, V58, P1489, DOI 10.1128/IAI.58.6.1489-1495.1990; Nikaido H, 1998, CLIN INFECT DIS, V27, pS32, DOI 10.1086/514920; NOEL GJ, 1994, J INFECT DIS, V169, P425, DOI 10.1093/infdis/169.2.425; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; OHGA T, 1993, FEMS MICROBIOL LETT, V113, P63; Paulsen IT, 1998, J MOL BIOL, V277, P573, DOI 10.1006/jmbi.1998.1609; Schmidt KD, 1996, J BACTERIOL, V178, P85, DOI 10.1128/jb.178.1.85-93.1996; Schmidt KD, 1998, ELECTROPHORESIS, V19, P509, DOI 10.1002/elps.1150190410; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Temple LM, 1998, BIOTECH HAN, V10, P35; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Westbrock-Wadman S, 1999, ANTIMICROB AGENTS CH, V43, P2975, DOI 10.1128/AAC.43.12.2975; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899	44	3186	4822	20	632	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					959	964		10.1038/35023079	http://dx.doi.org/10.1038/35023079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984043	Bronze			2022-12-28	WOS:000089020200035
J	Sasaki, T; Irie-Sasaki, J; Horie, Y; Bachmaier, K; Fata, JE; Li, M; Suzuki, A; Bouchard, D; Ho, A; Redston, M; Gallinger, S; Khokha, R; Mak, TW; Hawkins, PT; Stephens, L; Scherer, SW; Tsao, M; Penninger, JM				Sasaki, T; Irie-Sasaki, J; Horie, Y; Bachmaier, K; Fata, JE; Li, M; Suzuki, A; Bouchard, D; Ho, A; Redston, M; Gallinger, S; Khokha, R; Mak, TW; Hawkins, PT; Stephens, L; Scherer, SW; Tsao, M; Penninger, JM			Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)K gamma	NATURE			English	Article							PHOSPHOINOSITIDE 3-KINASE; TUMOR SUPPRESSION; COLON-CARCINOMA; CANCER; PTEN; PATHWAY; KINASE; PI3K; GENE; APC	Phosphoinositide-3-OH kinases (PI(3)Ks) constitute a family of evolutionarily conserved lipid kinases that regulate a vast array of fundamental cellular responses, including proliferation, transformation, differentiation and protection from apoptosis(1,2). PI(3)K-mediated activation of the cell survival kinase PKB/Akt, and negative regulation of PI(3)K signalling by the tumour suppressor PTEN (refs 3, 4) are key regulatory events in tumorigenesis(5-7). Thus, a model has arisen that PI(3)K gamma promote development of cancers. Here we report that genetic inactivation of the p110 gamma catalytic subunit of PI(3)K gamma (ref. 8) leads to development of invasive colorectal adenocarcinomas in mice. In humans, p110 gamma protein expression is lost in primary colorectal adenocarcinomas from patients and in colon cancer cell lines. Overexpression of wild-type or kinase-dead p110 gamma in human colon cancer cells with mutations of the tumour suppressors APC and p53, or the oncogenes beta-catenin and Ki-ras, suppressed tumorigenesis. Thus, loss of p110 gamma in mice leads to spontaneous, malignant epithelial tumours in the colorectum and p110 gamma can block the growth of human colon cancer cells.	Ontario Canc Inst, Amegen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Hosp Sick Children, Dept Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; Samuel Lunenfeld Res Inst, Ctr Canc Genet, Toronto, ON M5G 1X5, Canada; Babraham Inst, Cambridge CB2 4AT, England; Univ Toronto, Dept Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Toronto; University of Toronto	Penninger, JM (corresponding author), Ontario Canc Inst, Amegen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	Jpenning@amgen.com	Scherer, Stephen W./B-3785-2013; Penninger, Josef M/I-6860-2013; Gallinger, Steven/E-4575-2013; Bachmaier, Kurt/B-6331-2014; Suzuki, Akira/GYD-6697-2022; Bachmaier, Kurt/AHC-5491-2022; Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Scherer, Stephen W./0000-0002-8326-1999; Penninger, Josef M/0000-0002-8194-3777; Bachmaier, Kurt/0000-0002-0299-2707; Suzuki, Akira/0000-0002-5950-8808; Bachmaier, Kurt/0000-0002-0299-2707; Tsao, Ming Sound/0000-0002-9160-5405; stephens, len/0000-0002-2771-3487; Sasaki, Takehiko/0000-0003-1837-3748; Hawkins, Phillip/0000-0002-6979-0464				Bernstein HG, 1998, CELL MOL BIOL, V44, P973; BOUTRON MC, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P13, DOI 10.1097/00008469-199110002-00003; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GRODEN J, 1995, CANCER RES, V55, P1531; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; Zhou SB, 1999, NEW ENGL J MED, V341, P1144, DOI 10.1056/NEJM199910073411510	24	91	100	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					897	902		10.1038/35022585	http://dx.doi.org/10.1038/35022585			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972292				2022-12-28	WOS:000088903600046
J	Konarzewski, W				Konarzewski, W			Continuing to use APACHE II scores ensures consistency	BRITISH MEDICAL JOURNAL			English	Letter									Colchester Gen Hosp, Dept Anaesthet, Colchester CO4 5JL, Essex, England		Konarzewski, W (corresponding author), Colchester Gen Hosp, Dept Anaesthet, Colchester CO4 5JL, Essex, England.							Shann F, 2000, BRIT MED J, V320, P714, DOI 10.1136/bmj.320.7236.714	1	1	1	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	2000	321	7257					383	384						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QH	10991569				2022-12-28	WOS:000088656300053
J	Mehta, SR; Eikelboom, JW; Yusuf, S				Mehta, SR; Eikelboom, JW; Yusuf, S			Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN-ACTIVATOR; FRONT-LOADED ALTEPLASE; DOUBLE-BLIND; RECOMBINANT STAPHYLOKINASE; CORONARY THROMBOLYSIS; INTRAVENOUS UROKINASE; PATENCY TRIAL; ANISTREPLASE; STREPTOKINASE	Background Although thrombolytic therapy given by bolus injection seems to be as effective as infusion over 60-90 min, no single trial has been adequately powered to detect clinically important safety differences between the two strategies. We did a meta-analysis to find out whether bolus administration of thrombolytics is associated with an increased frequency of intracranial haemorrhage, Methods We identified randomised trials comparing bolus with infusion thrombolytic therapy by a search of electronic databases, reference lists, and conference proceedings. Odds ratios for primary intracranial haemorrhage, non-haemorrhagic stroke, mortality, and reinfarction were calculated for each trial and were combined in a fixed-effects model. Findings Seven trials, involving a total of 103 972 patients, met our inclusion criteria. Bolus treatment was associated with an increased risk of intracranial haemorrhage compared with infusion (0.8 vs 0.6%; odds ratio 1.25 [95% CI 1.08-1.45]; p=0.003). The increased risk was most striking in trials comparing bolus with infusion administration of the same agent (1.75 [1.32-2.33], p=0.0001), but was also evident in trials comparing a newer-generation bolus agent with standard infusion therapy (1.25 [1.03-1.50]; p=0.02). The rates of non-haemorrhagic stroke (0.94 [0.81-1.09]), 30-day mortality (1.01 [0.97-1.06]), or reinfarction (1.04 [0.97-1.11]) did not differ between the two strategies. Interpretation The increased risk of bolus thrombolytic treatment seems to be primarily associated with the method of administration rather than properties of the agents. Although the increased risk of intracranial haemorrhage is small, physicians should balance this risk against the putative benefits of easier administration with no difference in mortality or reinfarction.	McMaster Univ, Hamilton Hlth Sci Corp, Div Cardiol, Hamilton, ON, Canada; McMaster Univ, Hamilton Hlth Sci Corp, Populat Hlth Inst, Hamilton, ON, Canada	McMaster University; McMaster University	Yusuf, S (corresponding author), Hamilton Gen Hosp, McMaster Clin, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.csu.mcmaster.ca	Eikelboom, John/AAG-6117-2019	Eikelboom, John/0000-0003-4126-1285				ANDERSON JL, 1992, J AM COLL CARDIOL, V20, P753, DOI 10.1016/0735-1097(92)90170-R; ANDERSON JL, 1991, CIRCULATION, V83, P126, DOI 10.1161/01.CIR.83.1.126; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antman EM, 1999, CIRCULATION, V100, P498; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Bar FW, 1998, CIRCULATION, V98, P505; Bar FW, 1998, J THROMB THROMBOLYS, V6, P147, DOI 10.1023/A:1008809907268; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BASSAND JP, 1991, CIRCULATION, V84, P1107, DOI 10.1161/01.CIR.84.3.1107; Bleich SD, 1998, AM HEART J, V136, P741, DOI 10.1016/S0002-8703(98)70024-9; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Califf RM, 2000, AM HEART J, V139, pS33, DOI 10.1067/mhj.2000.104090; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; CANNON CP, 1994, J AM COLL CARDIOL, V24, P1602, DOI 10.1016/0735-1097(94)90163-5; Cannon CP, 1997, CIRCULATION, V95, P351; den Heijer P, 1998, CIRCULATION, V98, P2117, DOI 10.1161/01.CIR.98.20.2117; GEMMILL JD, 1991, BRIT HEART J, V66, P134; HOGG KJ, 1990, LANCET, V335, P254, DOI 10.1016/0140-6736(90)90069-H; HUNT D, 1992, LANCET, V339, P753; *INT JOINT EFF COM, 1995, LANCET, V346, P329; Kawai C, 1997, J AM COLL CARDIOL, V29, P1447, DOI 10.1016/S0735-1097(97)00074-0; KAWAI C, 1992, CIRCULATION S, V86, P1; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; LOPEZSENDON J, 1988, CIRCULATION S2, V78, P277; MATHEY DG, 1985, AM J CARDIOL, V55, P878, DOI 10.1016/0002-9149(85)90710-6; MONNIER P, 1987, DRUGS, V33, P175, DOI 10.2165/00003495-198700333-00029; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; PACOURET G, 1991, EUR HEART J, V12, P179, DOI 10.1093/oxfordjournals.eurheartj.a059866; Park SJ, 1998, AM J CARDIOL, V82, P811, DOI 10.1016/S0002-9149(98)00444-5; PURVIS JA, 1994, J AM COLL CARDIOL, V23, P6, DOI 10.1016/0735-1097(94)90495-2; PURVIS JA, 1991, AM J CARDIOL, V68, P1570, DOI 10.1016/0002-9149(91)90311-8; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; RELIKVANWELY L, 1991, AM J CARDIOL, V68, P296; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; Tebbe U, 1998, J AM COLL CARDIOL, V31, P487, DOI 10.1016/S0735-1097(97)00553-6; TEBBE U, 1989, AM J CARDIOL, V64, P448, DOI 10.1016/0002-9149(89)90419-0; Topol E, 1997, NEW ENGL J MED, V337, P1118; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; Vanderschueren S, 1996, THROMB HAEMOSTASIS, V76, P541; VandeWerf F, 1997, NEW ENGL J MED, V337, P1124; VOGT P, 1993, AM J CARDIOL, V71, P274, DOI 10.1016/0002-9149(93)90790-J; Weitz JI, 1999, THROMB HAEMOSTASIS, V82, P974; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	47	52	53	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					449	454		10.1016/S0140-6736(00)02552-6	http://dx.doi.org/10.1016/S0140-6736(00)02552-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981887				2022-12-28	WOS:000088657700009
J	Nance, WE; Liu, XZ; Pandya, A				Nance, WE; Liu, XZ; Pandya, A			Relation between choice of partner and high frequency of cannexin-26 deafness	LANCET			English	Article							MUTATIONS	Recessive mutations at the connexin-26 gene locus are now recognised as the cause of nearly half of all cases of genetic deafness in many populations. We suggest that this high frequency is only seen In populations with a long tradition of intermarriage among deaf people. Available data are consistent with the hypothesis that such marriages might well have contributed to the high frequency of connexin-ae deafness in the USA, and could represent a novel mechanism for maintaining specific genotypes at unexpectedly high frequencies.	Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Otolaryngol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pediat, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Nance, WE (corresponding author), Virginia Commonwealth Univ, Dept Human Genet, POB 980033, Richmond, VA 23298 USA.	nance@hsc.vcu.edu			NIDCD NIH HHS [DC-02530, DC-04293, DC-04530] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002530, R03DC004530, R01DC004293] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BELL AG, 1883, NAT ACAD SCI MEM, V2, P177; Denoyelle F, 1999, LANCET, V353, P1298, DOI 10.1016/S0140-6736(98)11071-1; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Fay E.A., 1898, MARRIAGES DEAF AM; Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52; Fuse Y, 1999, NEUROREPORT, V10, P1853, DOI 10.1097/00001756-199906230-00010; GREEN GE, 1999, JAMA-J AM MED ASSOC, V281, P193; KEISELL DP, 1997, NATURE, V387, P80; LIU XZ, 1988, CHINESE MED GENET, V5, P193; Reardon W, 1998, LANCET, V351, P383, DOI 10.1016/S0140-6736(05)78347-1; ROSE SP, 1975, THESIS INDIANA U BLO; Rose SP, 1977, CHILDHOOD DEAFNESS, P19	12	48	57	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					500	501		10.1016/S0140-6736(00)02565-4	http://dx.doi.org/10.1016/S0140-6736(00)02565-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981905				2022-12-28	WOS:000088657700036
J	Hansson, L; Hedner, T; Lund-Johansen, P; Kjeldsen, SE; Lindholm, LH; Syvertsen, JO; Lanke, J; de Faire, U; Dahlof, B; Karlberg, BE				Hansson, L; Hedner, T; Lund-Johansen, P; Kjeldsen, SE; Lindholm, LH; Syvertsen, JO; Lanke, J; de Faire, U; Dahlof, B; Karlberg, BE		NORDIL Study Grp	Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; ISOLATED SYSTOLIC HYPERTENSION; DOUBLE-BLIND; ACTIVE TREATMENT; BLOOD-PRESSURE; METAANALYSIS; REVERSAL; PLACEBO; THERAPY	Background Calcium antagonists are a first-line treatment for hypertension. The effectiveness of diltiazem, a nondihydropyridine calcium antagonist, in reducing cardiovascular morbidity or mortality is unclear. We compared the effects of diltiazem with that of diuretics, beta-blockers, or both on cardiovascular morbidity and mortality in hypertensive patients. Methods In a prospective, randomised, open, blinded endpoint study, we enrolled 10 881 patients, aged 50-74 years, at health centres in Norway and Sweden, who had diastolic blood pressure of 100 mm Hg or more. We randomly assigned patients diltiazem, or diuretics, beta-blockers, or both. The combined primary endpoint was fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death. Analysis was done by intention to treat. Findings Systolic and diastolic blood pressure were lowered effectively in the diltiazem and diuretic and beta-blocker groups (reduction 20.3/18.7 vs 23.3/18.7 mm Hg; difference in systolic reduction p<0.001). A primary endpoint occurred in 403 patients in the diltiazem group and in 400 in the diuretic and beta-blocker group (16.6 vs 16.2 events per 1000 patient-years; relative risk 1.00 [95% CI 0.87-1.15], p=0.97). Fatal and non-fatal stroke occurred in 159 patients in the diltiazem group and in 196 in the diuretic and beta-blocker group (6.4 vs 7.9 events per 1000 patient-years; 0.80 [0.65-0.99], p=0.04) and fatal and non-fatal myocardial infarction in 183 and 157 patients (7.4 vs 6.3 events per 1000 patient-years; 1.16 [0.94-1.44], p=0.17). Interpretation Diltiazem was as effective as treatment based on diuretics, beta-blockers, or both in preventing the combined primary endpoint of all stroke, myocardial infarction, and other cardiovascular death.	Univ Uppsala, Dept Publ Hlth & Social Sci, S-75125 Uppsala, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden; Haukeland Univ Hosp, Dept Cardiol, N-5021 Bergen, Norway; Ulleval Univ Hosp, Dept Cardiol, Oslo, Norway; Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden; Univ Lund, Dept Stat, Lund, Sweden; Varna Med Ctr, Moss, Norway; Karolinska Univ Hosp, Dept Med, Stockholm, Sweden; Ostra Hosp, Dept Med, S-41685 Gothenburg, Sweden; Linkoping Univ Hosp, Dept Endocrinol, S-58185 Linkoping, Sweden	Uppsala University; Sahlgrenska University Hospital; University of Bergen; Haukeland University Hospital; University of Oslo; Umea University; Lund University; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Linkoping University	Hansson, L (corresponding author), Univ Uppsala, Dept Publ Hlth & Social Sci, POB 609, S-75125 Uppsala, Sweden.							COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Grossman E, 1997, AM J CARDIOL, V80, P1453, DOI 10.1016/S0002-9149(97)00722-4; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hedner T, 1999, BLOOD PRESSURE, V8, P296, DOI 10.1080/080370599439517; JENNINGS GL, 1997, HBK HYPERT, V18, P184; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, DRUGS, V35, P1, DOI 10.2165/00003495-198800355-00002; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; LUNDJOHANSEN P, 1990, EUR HEART J, V11, P543, DOI 10.1093/oxfordjournals.eurheartj.a059748; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; Messerli FH, 2000, LANCET, V355, P863, DOI 10.1016/S0140-6736(00)00092-1; Schmieder RE, 1998, NEPHROL DIAL TRANSPL, V13, P564, DOI 10.1093/ndt/13.3.564; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; Staessen JA, 2000, EUR HEART J, V21, P2, DOI 10.1053/euhj.1999.1833; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BRIT MED J, V317, P713; The Nordic Diltiazem Study (NORDIL), 1993, BLOOD PRESSURE, V2, P312; *WHO ISH, 1989, J HYPERTENS, V7, P689	23	674	708	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					359	365		10.1016/S0140-6736(00)02526-5	http://dx.doi.org/10.1016/S0140-6736(00)02526-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972367				2022-12-28	WOS:000088486000007
J	Jouven, X; Zureik, M; Desnos, M; Courbon, D; Ducimetiere, P				Jouven, X; Zureik, M; Desnos, M; Courbon, D; Ducimetiere, P			Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; MITRAL-VALVE PROLAPSE; PROGNOSTIC-SIGNIFICANCE; HEART-DISEASE; FOLLOW-UP; HYPERTROPHIC CARDIOMYOPATHY; TREADMILL EXERCISE; HEALTHY-MEN; ARRHYTHMIAS; PREVALENCE	Background: Exercise testing is widely used in the diagnosis of coronary artery disease, but the long-term outcome for asymptomatic persons with exercise-induced premature ventricular depolarizations remains unclear. We used data from the Paris Prospective Study I to assess the long-term outcome of such persons. Methods: A total of 6101 asymptomatic French men (42 to 53 years of age) who were free of clinically detectable cardiovascular disease underwent a standardized graded exercise test between 1967 and 1972. Subjects were prospectively classified as having or not having frequent premature ventricular depolarizations (a run of two or more consecutive premature ventricular depolarizations or premature ventricular depolarizations constituting more than 10 percent of all ventricular depolarizations during any of the 30-second electrocardiographic recordings). Results: During exercise, 138 subjects had frequent premature ventricular depolarizations. After 23 years of follow-up, these subjects had a higher risk of death from cardiovascular causes than the men without frequent premature ventricular depolarizations during exercise (relative risk, 2.67; 95 percent confidence interval, 1.76 to 4.07). In a multivariate model, with adjustment for standard coronary risk factors and the presence or absence of premature ventricular depolarizations before exercise and during recovery from exercise, both exercise-induced ischemia and the occurrence of frequent premature ventricular depolarizations during exercise remained independently associated with an increased risk of death from cardiovascular causes, with similar relative risks (2.63 [95 percent confidence interval, 1.93 to 3.59] and 2.53 [95 percent confidence interval, 1.65 to 3.88], respectively). Conclusions: The occurrence of frequent premature ventricular depolarizations during exercise in asymptomatic middle-aged men is associated with a long-term increase in the risk of death from cardiovascular causes. (N Engl J Med 2000;343:826-33.) (C) 2000, Massachusetts Medical Society.	Univ Paris 05, Serv Cardiol, Hop Europeen Georges Pompidou, Fac Necker Enfants Malad, F-75015 Paris, France; Hop Paul Brousse, INSERM, U258, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jouven, X (corresponding author), Univ Paris 05, Serv Cardiol, Hop Europeen Georges Pompidou, Fac Necker Enfants Malad, 20 Rue Le Blanc, F-75015 Paris, France.	xavier.jouven@bcc.ap-hop-paris.fr	Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; CALIFF RM, 1983, J AM COLL CARDIOL, V2, P1060, DOI 10.1016/S0735-1097(83)80330-1; DIMSDALE JE, 1984, JAMA-J AM MED ASSOC, V251, P630, DOI 10.1001/jama.251.5.630; DRORY Y, 1990, AM J CARDIOL, V66, P1092, DOI 10.1016/0002-9149(90)90510-8; DUCIMETIERE P, 1980, LANCET, V1, P1346; FARIS JV, 1976, AM J CARDIOL, V37, P617, DOI 10.1016/0002-9149(76)90404-5; FILIPOVSKY J, 1992, HYPERTENSION, V20, P333, DOI 10.1161/01.HYP.20.3.333; FLEG JL, 1984, AM J CARDIOL, V54, P762, DOI 10.1016/S0002-9149(84)80204-0; Fontaine G, 1998, CIRCULATION, V97, P1532, DOI 10.1161/01.CIR.97.16.1532; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Froelicher V F Jr, 1974, Am J Cardiol, V34, P770, DOI 10.1016/0002-9149(74)90694-8; GIAGNONI E, 1983, NEW ENGL J MED, V309, P1085, DOI 10.1056/NEJM198311033091803; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GORDON DJ, 1986, CIRCULATION, V74, P252, DOI 10.1161/01.CIR.74.2.252; JANSSEN MJA, 1995, EUR HEART J, V16, P674, DOI 10.1093/oxfordjournals.eurheartj.a060972; Kuck KH, 1997, PACE, V20, P2706, DOI 10.1111/j.1540-8159.1997.tb06120.x; La Vecchia L, 1998, CLIN CARDIOL, V21, P731; MARCUS FI, 1982, CIRCULATION, V65, P384, DOI 10.1161/01.CIR.65.2.384; Maron BJ, 1997, LANCET, V350, P1330; MCHENRY PL, 1984, CIRCULATION, V70, P547, DOI 10.1161/01.CIR.70.4.547; Michaelides AP, 1999, NEW ENGL J MED, V340, P340, DOI 10.1056/NEJM199902043400502; MORROW K, 1993, ANN INTERN MED, V118, P689, DOI 10.7326/0003-4819-118-9-199305010-00005; NAIR CK, 1983, J AM COLL CARDIOL, V1, P1201, DOI 10.1016/S0735-1097(83)80130-2; Pogwizd SM, 1998, CIRCULATION, V98, P2404, DOI 10.1161/01.CIR.98.22.2404; Rywik TM, 1998, CIRCULATION, V97, P2117, DOI 10.1161/01.CIR.97.21.2117; SAMI M, 1984, AM J CARDIOL, V54, P1182, DOI 10.1016/S0002-9149(84)80064-8; Shaw LJ, 1998, CIRCULATION, V98, P1622, DOI 10.1161/01.CIR.98.16.1622; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; TOFF WD, 1988, EUR HEART J SUPPL, V9, pG119; UDALL JA, 1977, CIRCULATION, V56, P985, DOI 10.1161/01.CIR.56.6.985; VEDIN JA, 1972, AM J CARDIOL, V29, P25, DOI 10.1016/0002-9149(72)90120-8; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; *WHO, 1967, INT CLASS DIS MAN IN, V1, P3	33	162	172	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					826	833		10.1056/NEJM200009213431201	http://dx.doi.org/10.1056/NEJM200009213431201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995861				2022-12-28	WOS:000089355600001
J	Kolesnikova, OA; Entelis, NS; Mireau, H; Fox, TD; Martin, RP; Tarassov, IA				Kolesnikova, OA; Entelis, NS; Mireau, H; Fox, TD; Martin, RP; Tarassov, IA			Suppression of mutations in mitochondrial DNA by tRNAs imported from the cytoplasm	SCIENCE			English	Article							TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; TRYPANOSOMA-BRUCEI; PROTEIN; TRNA(LYS); AMINOACYLATION; IDENTITY; INVIVO; LEADER	Mitochondrial import of a cytoplasmic transfer RNA (tRNA) in yeast requires the preprotein import machinery and cytosolic factors. We investigated whether the tRNA import pathway can be used to correct respirator,, deficiencies due to mutations in the mitochondrial DNA and whether this system can be transferred into human cells. We show that cytoplasmic tRNAs with altered aminoacylation identity can be specifically targeted to the mitochondria and participate in mitochondrial translation. We also show that human mitochondria, which do not normally import tRNAs, are able to internalize yeast tRNA derivatives in vitro and that this import requires an essential yeast import factor.	Moscow MV Lomonosov State Univ, Dept Mol Biol, Moscow 119899, Russia; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Lomonosov Moscow State University; Cornell University	Tarassov, IA (corresponding author), Mecan Mol Div Cellulaire & Dev, CNRS, FRE 2168, 21 Rue Rene Descartes, F-57084 Strasbourg, France.	I.Tarassov@ibmc.u-strasbg.fr		Fox, Thomas/0000-0001-7629-3661; Mireau, Hakim/0000-0002-2299-5139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029362] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Aphasizhev R, 1997, RNA, V3, P489; BEATTIE DS, 1987, MITOCHONDRIA PRACTIC, P283; Dietrich A, 1996, PLANT J, V10, P913, DOI 10.1046/j.1365-313X.1996.10050913.x; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; Entelis NS, 1996, FEBS LETT, V384, P38, DOI 10.1016/0014-5793(96)00259-1; Entelis NS, 1998, P NATL ACAD SCI USA, V95, P2838, DOI 10.1073/pnas.95.6.2838; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; Kazakova HA, 1999, FEBS LETT, V442, P193, DOI 10.1016/S0014-5793(98)01653-6; LI K, 1994, J CELL BIOL, V124, P871, DOI 10.1083/jcb.124.6.871; Magalhaes PJ, 1998, MOL BIOL CELL, V9, P2375, DOI 10.1091/mbc.9.9.2375; MARTIN RP, 1979, BIOCHEMISTRY-US, V18, P4600, DOI 10.1021/bi00588a021; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; Mireau H, 2000, J BIOL CHEM, V275, P13291, DOI 10.1074/jbc.275.18.13291; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; Nabholz CE, 1999, MOL BIOL CELL, V10, P2547, DOI 10.1091/mbc.10.8.2547; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schneider Andre, 1994, Trends in Cell Biology, V4, P282, DOI 10.1016/0962-8924(94)90218-6; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1999, MITOCHONDRIAL DIS MO, P303; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WIESENBERGER G, 1995, MOL CELL BIOL, V15, P3291; Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253	26	119	127	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2000	289	5486					1931	1933		10.1126/science.289.5486.1931	http://dx.doi.org/10.1126/science.289.5486.1931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988073				2022-12-28	WOS:000089355800045
J	Redecker, D; Kodner, R; Graham, LE				Redecker, D; Kodner, R; Graham, LE			Glomalean fungi from the Ordovician	SCIENCE			English	Article							ARBUSCULAR MYCORRHIZAE; GEOSIPHON-PYRIFORME; LAND PLANTS; CYANOBACTERIA; ORIGIN	Fossilized fungal hyphae and spores from the Ordovician of Wisconsin (with an age of about 460 million years) strongly resemble modern arbuscular mycorrhizal fungi (Glomales, Zygomycetes), These fossils indicate that Glomales-like fungi were present at a time when the Land flora most likely only consisted of plants; on,the bryophytic Level. Thus, these fungi may have played a crucial role in facilitating the colonization of Land by plants, and the fossils support molecular estimates of fungal phylogeny that place the origin of the major groups of terrestrial fungi (Ascomycota, Basidiomycota, and Glomales) around 600 million years ago.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison	Redecker, D (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	redecker@nature.berkeley.edu						Alexopoulos C. J., 1996; Berbee ML, 2001, MYCOTA, V7, P229; DENNIS RL, 1970, MYCOLOGIA, V62, P578, DOI 10.2307/3757529; Gehrig H, 1996, J MOL EVOL, V43, P71, DOI 10.1007/BF02352301; GRAY J, 1982, GEOLOGY, V10, P197, DOI 10.1130/0091-7613(1982)10<197:CLPMFL>2.0.CO;2; HIBBETT DS, 1995, NATURE, V377, P487, DOI 10.1038/377487a0; HUFF WD, 1992, GEOLOGY, V20, P875, DOI 10.1130/0091-7613(1992)020<0875:GOVAFI>2.3.CO;2; ILLMAN WI, 1984, MYCOLOGIA, V76, P545, DOI 10.2307/3793338; MORTON JB, 1988, MYCOTAXON, V32, P267; OSBORN JM, 1995, AM J BOT, V82, P1074, DOI 10.2307/2446238; Phipps CJ, 1996, MYCOLOGIA, V88, P707, DOI 10.2307/3760964; PIROZYNSKI KA, 1975, BIOSYSTEMS, V6, P153, DOI 10.1016/0303-2647(75)90023-4; Ragan MA, 1996, P NATL ACAD SCI USA, V93, P11907, DOI 10.1073/pnas.93.21.11907; Redecker D, 2000, MOL PHYLOGENET EVOL, V14, P276, DOI 10.1006/mpev.1999.0713; REMY W, 1994, P NATL ACAD SCI USA, V91, P11841, DOI 10.1073/pnas.91.25.11841; Schussler A, 2000, MYCORRHIZA, V10, P15, DOI 10.1007/s005720050282; SCHUSSLER A, 1994, BOT ACTA, V107, P36, DOI 10.1111/j.1438-8677.1994.tb00406.x; SHERWOODPIKE MA, 1985, LETHAIA, V18, P1, DOI 10.1111/j.1502-3931.1985.tb00680.x; SIMON L, 1993, NATURE, V363, P67, DOI 10.1038/363067a0; SLOAN RE, 1987, MINNESOTA GEOLOGICAL, V35, P7; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; STAHL M, 1949, PLANTA, V37, P103, DOI 10.1007/BF01929705; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; Taylor T.N., 1996, PALYNOLOGY PRINCIPLE, P427; TAYLOR TN, 1994, NATURE, V367, P601, DOI 10.1038/367601a0; Taylor TN, 1999, NATURE, V399, P648, DOI 10.1038/21349	26	661	725	4	235	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2000	289	5486					1920	1921		10.1126/science.289.5486.1920	http://dx.doi.org/10.1126/science.289.5486.1920			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988069				2022-12-28	WOS:000089355800041
J	Guyatt, GH; Haynes, RB; Jaeschke, RZ; Cook, DJ; Green, L; Naylor, CD; Wilson, MC; Richardson, WS				Guyatt, GH; Haynes, RB; Jaeschke, RZ; Cook, DJ; Green, L; Naylor, CD; Wilson, MC; Richardson, WS		Evidence-Based Med Working Grp	Users' Guides to The Medical Literature - XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIAL; NARRATIVE BASED MEDICINE; HELP ME; DECISION-ANALYSIS; HEART-FAILURE; ARTICLE; WILL; THERAPY; RECOMMENDATIONS	This series provides clinicians with strategies and tools to interpret and integrate evidence from published research in their care of patients. The 2 key principles for applying all the articles in this series to patient care relate to the value-laden nature of clinical decisions and to the hierarchy of evidence postulated by evidence-based medicine. Clinicians need to be able to distinguish high from low quality in primary studies, systematic reviews, practice guidelines, and other integrative research focused on management recommendations. An evidence-based practitioner must also understand the patient's circumstances or predicament; identify knowledge gaps and frame questions to fill those gaps; conduct an efficient literature search; critically appraise the research evidence; and apply that evidence to patient care. However, treatment judgments often reflect clinician or societal values concerning whether intervention benefits are worth the cost. Many unanswered questions concerning how to elicit preferences and how to incorporate them in clinical encounters constitute an enormously challenging frontier for evidence-based medicine. Time limitation remains the biggest obstacle to evidence-based practice but clinicians should seek evidence from as high in the appropriate hierarchy of evidence as possible, and every clinical decision should be geared toward the particular circumstances of the patient.	McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Fac Med, Dept Med, Toronto, ON, Canada; Univ Toronto, Fac Med, Off Dean, Toronto, ON, Canada; Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC USA; Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst & Med, Dept Ambulatory Care, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst & Med, Dept Res, San Antonio, TX USA	McMaster University; McMaster University; University of Toronto; University of Toronto; University of Michigan System; University of Michigan; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Guyatt, GH (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Haynes, Robert Brian/0000-0002-1453-3196				Califf RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Greenhalgh T, 1999, BRIT MED J, V318, P48; Greenhalgh T, 1999, BMJ-BRIT MED J, V318, P323, DOI 10.1136/bmj.318.7179.323; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; GUYATT GH, 2000, BRIT MED J, V320, P945; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Haynes R B, 1996, ACP J Club, V125, pA14; Haynes R B, 1997, ACP J Club, V126, pA14; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hunt DL, 2000, JAMA-J AM MED ASSOC, V283, P1875, DOI 10.1001/jama.283.14.1875; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LARSON EB, 1993, JAMA-J AM MED ASSOC, V270, P2708, DOI 10.1001/jama.270.22.2708; Lechat P, 1999, LANCET, V353, P9; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Mahon J, 1996, BRIT MED J, V312, P1069; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Nisbett R., 1980, HUMAN INFERENCE; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	42	489	508	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1290	1296		10.1001/jama.284.10.1290	http://dx.doi.org/10.1001/jama.284.10.1290			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979117				2022-12-28	WOS:000089124600037
J	Drake, S; Taylor, S; Brown, D; Pillay, D				Drake, S; Taylor, S; Brown, D; Pillay, D			Improving the care of patients with genital herpes	BRITISH MEDICAL JOURNAL			English	Review							SIMPLEX VIRUS-INFECTION; PLACEBO-CONTROLLED TRIAL; ACYCLOVIR; TYPE-2; PREGNANCY; WOMEN; ACQUISITION; RATES		Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham B9 5SS, W Midlands, England; Cent Publ Hlth Lab, London NW9 5DF, England; Univ Birmingham, Div Immun & Infect, Antiviral Susceptibil Reference Unit, Publ Hlth Lab Serv, Birmingham B15 2TT, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham; Public Health England; University of Birmingham	Drake, S (corresponding author), Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham B9 5SS, W Midlands, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1989, J EPIDEMIOL COMMUN H, V43, P53, DOI 10.1136/jech.43.1.53; ANDRIA GM, 1999, NEW ENGL J MED, V341, P1432; BAGDADES EK, 1992, AIDS, V6, P1317, DOI 10.1097/00002030-199211000-00012; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P275, DOI 10.1111/j.1471-0528.1998.tb10086.x; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; Chakrabarti S, 2000, J INFECT DIS, V181, P2055, DOI 10.1086/315524; *CLIN EFF GROUP AS, 1999, SEX TRANSM INFECT, V75, P24; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Fox P A, 1999, HIV Med, V1, P10, DOI 10.1046/j.1468-1293.1999.00003.x; Gutierrez KM, 1999, J INFECT DIS, V180, P199, DOI 10.1086/314848; Harden EA, 2000, ANTIVIR RES, V46, pA78; JOHNSON A, 1994, SEXUAL ATTITUDES LIF, P110; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; Lalezari J, 1997, J INFECT DIS, V176, P892, DOI 10.1086/516542; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; Smith JR, 1998, BRIT J OBSTET GYNAEC, V105, P255; Taylor S, 1999, J CLIN PATHOL, V52, P1, DOI 10.1136/jcp.52.1.1; Tookey P, 1996, PAEDIATR PERINAT EP, V10, P432, DOI 10.1111/j.1365-3016.1996.tb00070.x; Vyse AJ, 2000, SEX TRANSM INFECT, V76, P183, DOI 10.1136/sti.76.3.183; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237	26	24	24	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					619	623		10.1136/bmj.321.7261.619	http://dx.doi.org/10.1136/bmj.321.7261.619			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977846	Green Published			2022-12-28	WOS:000089243200026
J	Davis, PM; Rubinstein, JL; Liu, KH; Gao, SS; Knopoff, L				Davis, PM; Rubinstein, JL; Liu, KH; Gao, SS; Knopoff, L			Northridge earthquake damage caused by geologic focusing of seismic waves	SCIENCE			English	Article							ANGELES URBAN AREA; SANTA-MONICA; GROUND-MOTION; AMPLIFICATION	Despite being Located 21 kilometers from the epicenter of the 1994 Northridge earthquake (magnitude 6.7), the city of Santa Monica experienced anomalously concentrated damage with Mercalli intensity IX, an intensity as Large as that experienced in the vicinity of the epicenter. Seismic records from aftershocks suggest that the damage resulted from the focusing of seismic waves by several underground acoustic Lenses at depths of about 3 kilometers, formed by the faults that bound the northwestern edge of the Los Angeles basin. The amplification was greatest for high-frequency waves and was Less powerful at lower frequencies, which is consistent with focusing theory and finite-difference simulations.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Kansas State Univ, Dept Geol, Manhattan, KS 66506 USA; Univ Calif Los Angeles, Dept Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Kansas State University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Davis, PM (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	pdavis@ess.ucla.edu	DAVIS, Paul/HCH-8889-2022; Gao, Stephen/F-1395-2011; Davis, Paul/E-7151-2012; Liu, Kelly H/B-7731-2019	Gao, Stephen/0000-0001-7530-7128; Liu, Kelly H/0000-0001-7691-9556; Rubinstein, Justin/0000-0003-1274-6785				AKI K, 1969, J GEOPHYS RES, V74, P615, DOI 10.1029/JB074i002p00615; Alex CM, 1998, GEOPHYS RES LETT, V25, P3441, DOI 10.1029/98GL52668; BEVINGTON PR, 1997, DATA REDUCTION ERROR; Boore DM, 1997, B SEISMOL SOC AM, V87, P327; Born M., 1980, PRINCIPLES OPTICS; Gao S, 1996, B SEISMOL SOC AM, V86, pS209; Graves RW, 1998, B SEISMOL SOC AM, V88, P1224; Harmsen SC, 1997, B SEISMOL SOC AM, V87, P866; Hartzell S, 1997, B SEISMOL SOC AM, V87, P1377; LAWSON AC, 1908, CALIFORNIA EARTHQU 1, V1, P253; LIU H, 1998, THESIS U CALIFORNIA; Marcuse D., 1982, LIGHT TRANSMISSION O; MARSHALL GA, 1994, 94442 USGS; Pratt TL, 1998, GEOPHYSICS, V63, P479, DOI 10.1190/1.1444349; TRIFUNAC MD, 1975, B SEISMOL SOC AM, V65, P581; Wright T.L., 1991, AAPG MEMOIR, V52, P35	16	66	71	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2000	289	5485					1746	1750		10.1126/science.289.5485.1746	http://dx.doi.org/10.1126/science.289.5485.1746			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976067				2022-12-28	WOS:000089195200045
J	Akoulitchev, S; Chuikov, S; Reinberg, D				Akoulitchev, S; Chuikov, S; Reinberg, D			TFIIH is negatively regulated by cdk8-containing mediator complexes	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; KINASE-ACTIVITY; PHOSPHORYLATION; CDK7; CTD; SRB; E1A; CAK	The mammalian cyclin-dependent kinase 8 (cdk8)(1) gene has been linked with a subset of acute lymphoblastic leukaemias(2), and its corresponding protein has been functionally implicated in regulation of transcription(3,4). Mammalian cdk8 and cyclin C, and their respective yeast homologues, Srb10 and Srb11, are components of the RNA polymerase II holoenzyme complex(5,6) where they function as a protein kinase that phosphorylates the carboxyterminal domain (CTD) of the largest subunit of RNA polymerase II (ref. 7). The yeast SRB10 and SRB11 genes have been implicated in the negative regulation of transcription(8). The cdk8/cyclin C protein complex is also found in a number of mammalian Mediator-like protein complexes(3,5,9-12), which repress activated transcription independently of the CTD in vitro(9,10). Here we show that cdk8/cyclin C can regulate transcription by targeting the cdk7/cyclin H subunits of the general transcription initiation factor IIH (TFIIH). cdk8 phosphorylates mammalian cyclin H in the vicinity of its functionally unique amino-terminal and carboxy-terminal alpha-helical domains(13). This phosphorylation represses both the ability of TFIIH to activate transcription and its CTD kinase activity. In addition, mimicking cdk8 phosphorylation of cyclin H in vivo has a dominant-negative effect on cell growth. Our results link the Mediator complex and the basal transcription machinery by a regulatory pathway involving two cyclin-dependent kinases. This pathway appears to be unique to higher organisms.	Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Reinberg, D (corresponding author), Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016				Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; Gould K.L., 1994, PROTEIN KINASES, P149; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HAUER CA, 1989, NUCLEIC ACIDS RES, V17, P1989, DOI 10.1093/nar/17.5.1989; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Kazmi MA, 1996, BIOTECHNIQUES, V21, P304; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rickert P, 1996, ONCOGENE, V12, P2631; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871	29	290	309	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					102	106		10.1038/35024111	http://dx.doi.org/10.1038/35024111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993082				2022-12-28	WOS:000089124000051
J	Mantovani, A				Mantovani, A			Immunology - Investigating T-cell memory	NATURE			English	Article									Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Brescia, Dept Biotechnol, Sect Gen Pathol, I-25123 Brescia, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia	Mantovani, A (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.		Mantovani, Alberto/HCI-7449-2022	Mantovani, Alberto/0000-0001-5578-236X				Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; MILLAN JL, 1995, CRIT REV CL LAB SCI, V32, P1, DOI 10.3109/10408369509084680; Rocha B, 1999, NATURE, V399, P531, DOI 10.1038/21086; TERAO M, 1987, P NATL ACAD SCI USA, V84, P7051, DOI 10.1073/pnas.84.20.7051	4	2	2	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					40	40		10.1038/35024159	http://dx.doi.org/10.1038/35024159			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993065				2022-12-28	WOS:000089124000033
J	Reilinger, RE; Ergintav, S; Burgmann, R; McClusky, S; Lenk, O; Barka, A; Gurkan, O; Hearn, L; Feigl, KL; Cakmak, R; Aktug, B; Ozener, H; Toksoz, MN				Reilinger, RE; Ergintav, S; Burgmann, R; McClusky, S; Lenk, O; Barka, A; Gurkan, O; Hearn, L; Feigl, KL; Cakmak, R; Aktug, B; Ozener, H; Toksoz, MN			Coseismic and postseismic fault slip for the 17 August 1999, M=7.5, Izmit, Turkey earthquake	SCIENCE			English	Article							NORTH-ANATOLIAN FAULT; SAN-ANDREAS FAULT; HALF-SPACE; DEFORMATION; LITHOSPHERE; SEA; LANDERS; SURFACE; CRUST; DEPTH	We use Global Positioning System (GPS) observations and elastic half-space models to estimate the distribution of coseismic and postseismic slip along the Izmit earthquake rupture. Our results indicate that Large coseismic slip (reaching 5.7 meters) is confined to the upper 10 kilometers of the crust, correlates with structurally distinct fault segments, and is relatively Low near the hypocenter, Continued surface deformation during the first 75 days after the earthquake indicates an aseismic fault slip of as much as 0.43 meters on and below the coseismic rupture. These observations are consistent with a transition from unstable (episodic Large earthquakes) to stable (fault creep) sliding at the base of the seismogenic zone.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02142 USA; TUBITAK, Marmara Res Ctr, Earth Sci Res Inst, TR-41470 Gebze, Turkey; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Gen Command Mapping, Ankara, Turkey; Tech Univ Istanbul, Eurasia Earth Sci Inst, Istanbul, Turkey; Bogazici Univ, Kandilli Observ, Istanbul, Turkey; Dept Terr & Planetary Dynam, CNRS, UMR 5562, F-31400 Toulouse, France	Massachusetts Institute of Technology (MIT); Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); University of California System; University of California Berkeley; Harita Genel Komutanligi; Ministry of Defense - Turkey; Istanbul Technical University; Bogazici University; Centre National de la Recherche Scientifique (CNRS)	Reilinger, RE (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, E34,42 Carleton St, Cambridge, MA 02142 USA.		ergintav, semih/P-9315-2015; Aktug, Bahadir/AAF-7076-2020; Ozener, Haluk/A-1860-2016; Burgmann, Roland/AAE-5138-2022; Cakmak, Rahsan/C-3113-2014; Feigl, Kurt/E-8106-2012	ergintav, semih/0000-0001-7080-183X; Ozener, Haluk/0000-0003-2531-3030; Burgmann, Roland/0000-0002-3560-044X; McClusky, Simon/0000-0003-4040-925X; Aktug, Bahadir/0000-0002-7995-4477; Feigl, Kurt/0000-0002-2059-6708				AMBRASEYS NN, 1970, TECTONOPHYSICS, V9, P143, DOI 10.1016/0040-1951(70)90014-4; AYHAN ME, 1999, 1999 INT UN GEOD GEO; Barka A., 1999, EOS, V80, pF647; BARKA AA, 1997, ACTIVE TECTONICS NW, P55; BILHAM R, UNPUB; Bourne SJ, 1998, NATURE, V391, P655, DOI 10.1038/35556; Burgmann R, 1997, J GEOPHYS RES-SOL EA, V102, P4933, DOI 10.1029/96JB03171; CHAVEZ DE, 1985, B SEISMOL SOC AM, V75, P583; Deng JS, 1998, SCIENCE, V282, P1689, DOI 10.1126/science.282.5394.1689; ELLSWORTH WL, 1990, US GEOL SURV PROF PA, V1515, P153; ERGIN M, 1999, EOS, V80, P1663; FREYMUELLER J, 1994, B SEISMOL SOC AM, V84, P646; GILBERT LE, 1994, J GEOPHYS RES-SOL EA, V99, P23975, DOI 10.1029/94JB01558; Goldstein RM, 1998, GEOPHYS RES LETT, V25, P4035, DOI 10.1029/1998GL900033; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; HEARN EH, 2000, EOS, V81, pS307; HERECE E, 1999, KOCAELI DEPREMI KIRI; Hubert-Ferrari A, 2000, NATURE, V404, P269, DOI 10.1038/35005054; Ivins ER, 2000, J GEOPHYS RES-SOL EA, V105, P3229, DOI 10.1029/1999JB900409; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; MAKRIS J, 1984, MAR GEOL, V55, P347, DOI 10.1016/0025-3227(84)90076-8; Massonnet D, 1998, REV GEOPHYS, V36, P441, DOI 10.1029/97RG03139; McClusky S, 2000, J GEOPHYS RES-SOL EA, V105, P5695, DOI 10.1029/1999JB900351; Molnar P, 1999, SCIENCE, V286, P516, DOI 10.1126/science.286.5439.516; Nalbant SS, 1998, J GEOPHYS RES-SOL EA, V103, P24469, DOI 10.1029/98JB01491; NUR A, 1974, SCIENCE, V183, P204, DOI 10.1126/science.183.4121.204; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Parsons T, 2000, SCIENCE, V288, P661, DOI 10.1126/science.288.5466.661; PINAR A, 1999, EOS, V80, pF648; Pollitz FF, 2000, J GEOPHYS RES-SOL EA, V105, P8035, DOI 10.1029/1999JB900380; POLLITZ FF, 1992, B SEISMOL SOC AM, V82, P422; SAVAGE JC, 1990, J GEOPHYS RES-SOLID, V95, P4873, DOI 10.1029/JB095iB04p04873; SCHOLZ CH, 1988, GEOL RUNDSCH, V77, P319, DOI 10.1007/BF01848693; SIBSON RH, 1986, ANNU REV EARTH PL SC, V14, P149, DOI 10.1146/annurev.ea.14.050186.001053; Stein RS, 1997, GEOPHYS J INT, V128, P594, DOI 10.1111/j.1365-246X.1997.tb05321.x; Straub C, 1997, J GEOPHYS RES-SOL EA, V102, P27587, DOI 10.1029/97JB02563; TAJIMA F, 1999, EOS, V80, pF669; THATCHER W, 1995, J GEOPHYS RES-SOL EA, V100, P3885, DOI 10.1029/94JB03064; THATCHER W, 1983, J GEOPHYS RES, V88, P5893, DOI 10.1029/JB088iB07p05893; TOKSOZ MN, 1979, PURE APPL GEOPHYS, V117, P1258, DOI 10.1007/BF00876218; TOKSOZ MN, 1999, EOS, V80, pF647; TSE ST, 1986, J GEOPHYS RES-SOLID, V91, P9452, DOI 10.1029/JB091iB09p09452; YALCIN N, 1999, 1999 INT UN GEOD GEO	43	265	275	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1519	+		10.1126/science.289.5484.1519	http://dx.doi.org/10.1126/science.289.5484.1519			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968782				2022-12-28	WOS:000089071700038
J	Nadis, S				Nadis, S			Astronomers reveal the secrets of the name game	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					819	819		10.1038/35022735	http://dx.doi.org/10.1038/35022735			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972264	Bronze			2022-12-28	WOS:000088903600011
J	Rozan, TF; Lassman, ME; Ridge, DP; Luther, GW				Rozan, TF; Lassman, ME; Ridge, DP; Luther, GW			Evidence for iron, copper and zinc complexation as multinuclear sulphide clusters in oxic rivers	NATURE			English	Article							SULFIDE COMPLEXATION; ORGANIC-MATTER; SEAWATER; PHYTOPLANKTON; VOLTAMMETRY; TOXICITY; CU2+	The availability and toxicity of trace metals in fresh water are known to be regulated by the complexation of free metal ions with dissolved organic matter(1-3). The potential role of inorganic sulphides in binding trace metals has been largely ignored because of the reduced persistence of sulphides in these oxic waters. However, nanomolar concentrations of copper and zinc sulphides have been observed in four rivers in Connecticut and Maryland(4,5). Here we report dissolved (< 0.2 mu m particle diameter) sulphide concentrations ranging up to 600 nM, with more than 90% being complexed by copper, iron and zinc. These complexes account for up to 20% of the total dissolved Fe and Zn and 45% of the total dissolved Cu. Fourier transform mass spectrometry reveals that these complexes are not simple M(HS)(+) protonated species(6,7) but are higher-order unprotonated clusters (M3S3, M4S6, M2S4), similar to those found in laboratory solutions(8-10) and bio-inorganic molecules(11). These extended structures have high stability constants(8,10) and are resistant to oxidation and dissociation(10,12), which may help control the toxicity of these and other less abundant, but more toxic, trace metals, such as silver, cadmium and mercury.	Univ Delaware, Coll Marine Studies, Lewes, DE 19958 USA; Univ Delaware, Lamont DuPont Lab, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware; University of Delaware	Rozan, TF (corresponding author), Univ Delaware, Coll Marine Studies, 700 Pilottown Rd, Lewes, DE 19958 USA.		Ridge, Douglas/A-7539-2013; Luther, George/A-6384-2008	Luther, George/0000-0002-0780-885X				Al-Farawati R, 1999, MAR CHEM, V63, P331, DOI 10.1016/S0304-4203(98)00056-5; Breault RF, 1996, ENVIRON SCI TECHNOL, V30, P3477, DOI 10.1021/es9601301; Croot PL, 1999, MAR CHEM, V67, P219, DOI 10.1016/S0304-4203(99)00054-7; DITORO DM, 1992, ENVIRON SCI TECHNOL, V26, P96, DOI 10.1021/es00025a009; DYRSSEN D, 1988, MAR CHEM, V24, P143, DOI 10.1016/0304-4203(88)90045-X; HELZ GR, 1993, GEOCHIM COSMOCHIM AC, V57, P15, DOI 10.1016/0016-7037(93)90464-8; Henneke E, 1997, GEOCHIM COSMOCHIM AC, V61, P307, DOI 10.1016/S0016-7037(96)00355-9; Kim SD, 1999, ENVIRON TOXICOL CHEM, V18, P2433, DOI 10.1002/etc.5620181108; Knauer K, 1997, J PHYCOL, V33, P596, DOI 10.1111/j.0022-3646.1997.00596.x; LUTHER GW, 1991, GEOCHIM COSMOCHIM AC, V55, P2839, DOI 10.1016/0016-7037(91)90449-F; Luther GW, 1999, GEOCHIM COSMOCHIM AC, V63, P3159, DOI 10.1016/S0016-7037(99)00243-4; Luther GW, 1996, ENVIRON SCI TECHNOL, V30, P671, DOI 10.1021/es950417i; *MICR CO, 1993, OPUS UT IS PROGR VER; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Rickard D, 1999, ESTUARIES, V22, P693, DOI 10.2307/1353056; Rozan TF, 1999, ENVIRON SCI TECHNOL, V33, P3021, DOI 10.1021/es981206r; Rozan TF, 2000, ANAL CHIM ACTA, V415, P175, DOI 10.1016/S0003-2670(00)00844-8; Rozan TF, 1999, GEOCHIM COSMOCHIM AC, V63, P3311, DOI 10.1016/S0016-7037(99)00253-7; Sunda WG, 1998, SCI TOTAL ENVIRON, V219, P165, DOI 10.1016/S0048-9697(98)00226-5; THEBERGE SM, 1999, THESIS U DELAWARE; THEBERGE SM, 1997, AQUAT GEOCHEM, V3, P1; VAZQUEZ F, 1989, GEOPHYS RES LETT, V16, P1363, DOI 10.1029/GL016i012p01363; WALSH RS, 1994, LIMNOL OCEANOGR, V39, P941, DOI 10.4319/lo.1994.39.4.0941; Xue HB, 1997, ENVIRON SCI TECHNOL, V31, P1902, DOI 10.1021/es960551i; Xue HB, 1996, AQUAT SCI, V58, P69, DOI 10.1007/BF00877641	25	175	179	2	102	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					879	882		10.1038/35022561	http://dx.doi.org/10.1038/35022561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972287				2022-12-28	WOS:000088903600041
J	Sinha, AA				Sinha, AA			How do we measure up?	LANCET			English	Editorial Material									Cornell Univ, Weill Med Coll, Dept Dermatol, New York, NY 10021 USA	Cornell University	Sinha, AA (corresponding author), Cornell Univ, Weill Med Coll, Dept Dermatol, New York, NY 10021 USA.							CAZENAVE PLA, 1852, ANN MALAD PEAU SYPH, V4, P113; Parodi A, 2000, BRIT J DERMATOL, V142, P457, DOI 10.1046/j.1365-2133.2000.03356.x; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					448	448		10.1016/S0140-6736(00)02550-2	http://dx.doi.org/10.1016/S0140-6736(00)02550-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981886				2022-12-28	WOS:000088657700007
J	Buggy, D				Buggy, D			Can anaesthetic management influence surgical-wound healing?	LANCET			English	Editorial Material							COLORECTAL-CANCER; OXYGEN-TENSION; INFECTION; RISK		Univ Leicester, Dept Anaesthesia, Leicester LE5 4PW, Leics, England; Leicester Gen Hosp, Leicester NHS Trust, Univ Hosp, Leicester LE5 4PW, Leics, England	University of Leicester; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Buggy, D (corresponding author), Univ Leicester, Dept Anaesthesia, Leicester LE5 4PW, Leics, England.			Buggy, Donal/0000-0003-3922-4397				Akca O, 1999, LANCET, V354, P41, DOI 10.1016/S0140-6736(99)00874-0; Akca O, 1999, ANESTHESIOLOGY, V91, P991, DOI 10.1097/00000542-199910000-00019; Allen DB, 1997, ARCH SURG-CHICAGO, V132, P991; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BREMMELGAARD A, 1989, J HOSP INFECT, V13, P1, DOI 10.1016/0195-6701(89)90090-X; Buggy DJ, 2000, BRIT J ANAESTH, V84, P615, DOI 10.1093/bja/84.5.615; BUSCH ORC, 1993, NEW ENGL J MED, V328, P1372, DOI 10.1056/NEJM199305133281902; Carli F, 1997, ANESTHESIOLOGY, V86, P1033, DOI 10.1097/00000542-199705000-00005; Gannong WF, 1999, REV MED PHYSL; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; JONSSON K, 1991, ANN SURG, V214, P605, DOI 10.1097/00000658-199111000-00011; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; McBride WT, 1996, ANAESTHESIA, V51, P465, DOI 10.1111/j.1365-2044.1996.tb07793.x; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; VANOSS CJ, 1980, J RETICULOENDOTH SOC, V27, P561	18	48	50	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					355	357		10.1016/S0140-6736(00)02523-X	http://dx.doi.org/10.1016/S0140-6736(00)02523-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972364				2022-12-28	WOS:000088486000004
J	Parmanum, J; Field, D; Rennie, J; Steer, P				Parmanum, J; Field, D; Rennie, J; Steer, P		Brit Assoc Perinatal Med	National census of availability of neonatal intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COTS	Objective To determine whether availability of neonatal intensive care cots is a problem in any or all parts of the United Kingdom. Design Three month census fi-om 1 April to 30 June 1999 comprising simple data sheets on transfers out of tertiary units. Setting The 37 largest high risk perinatal centres in the United Kingdom. Participants One obstetric specialist and one neonatal specialist in each centre. Main outcome measures Suboptimal care resulting directly from pressure on service-that is, transfers out of tertiary units (either in utero or after delivery) because the unit was "full" and not because the hospital was incapable of providing the care needed. Results All units provided data. The number of intensive care cots in each unit was between five and 16. During the three months 309 transfers occurred (equivalent to 1236 per year), of which 264 were in utero and 45 postnatal. Sixty five in utero transfers involved multiple births, hence the census related to 382 babies (1528 per year). There was considerable regional variation. The reason for transfer in most cases was "lack of neonatal beds". Conclusions Currently most major perinatal centres in the United Kingdom are regularly unable to meet in-house demand; this has implications for the service as a whole. The NHS has set no standards to help health authorities and primary care groups develop services relating to this specialty; such a step may well be an appropriate lever for change.	Univ Leicester, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Kings Coll Hosp London, London SE5 9RS, England; Imperial Coll Sch Med, London W2 1PG, England	University of Leicester; King's College Hospital NHS Foundation Trust; King's College Hospital; Imperial College London	Field, D (corresponding author), Univ Leicester, Dept Child Hlth, Robert Kilpatrick Clin Sci Bldg, Leicester LE2 7LX, Leics, England.	dfield@lri.org.uk						BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; *CLIN STAND ADV GR, 1993, ACC AV NEON INT CAR; *DEP EP PUBL HLTH, 1999, TRENT NEON SURV 1998; Field D, 1999, ARCH DIS CHILD-FETAL, V80, pF111, DOI 10.1136/fn.80.2.F111; FIELD DJ, 1989, BRIT MED J, V299, P1305, DOI 10.1136/bmj.299.6711.1305; MCINTOSH N, 1989, BRIT MED J, V298, P169; MCLOUGHLIN A, 1993, ARCH DIS CHILD-FETAL, V68, P597, DOI 10.1136/adc.68.5_Spec_No.597; Milligan DWA, 1997, ARCH DIS CHILD-FETAL, V76, pF197, DOI 10.1136/fn.76.3.F197; MORRIS D, 1993, ARCH DIS CHILD-FETAL, V68, P544; National Association of Health Authorities, 1993, REINV HLTH CAR NEW M; *ROYAL COLL PHYS, 1988, MED CAR NEWB ENGL WA; SIMPSON H, 1981, ARCH DIS CHILD, V56, P90, DOI 10.1136/adc.56.2.90; 1999, TIMES           0803	13	39	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2000	321	7263					727	729		10.1136/bmj.321.7263.727	http://dx.doi.org/10.1136/bmj.321.7263.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999901	Green Published, Bronze			2022-12-28	WOS:000089546600018
J	Hujoel, PP; Drangsholt, M; Spiekerman, C; DeRouen, TA				Hujoel, PP; Drangsholt, M; Spiekerman, C; DeRouen, TA			Periodontal disease and coronary heart disease risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; DENTAL DISEASE; CARDIOVASCULAR-DISEASE; INFECTION; HEALTH; ATHEROSCLEROSIS; INFORMATION; MORTALITY; PATHOGENS; INVASION	Context Research has suggested a relationship between periodontal disease and coronary heart disease (CHD), but data on the association between these 2 common conditions are inconclusive due to the possibility of confounding. Objective To evaluate the risk of CHD in persons with periodontitis, gingivitis, or no periodontal disease. Design Prospective cohort study. Setting The First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, conducted in 1982-1984, 1986, 1987, and 1992. Participants A total of 8032 dentate adults aged 25 to 74 years with no reported history of cardiovascular disease, including 1859 individuals with periodontitis, 2421 with gingivitis, and 3752 with healthy periodontal tissues. Main Outcome Measure First occurrence of death from CHD or hospitalization due to CHD, or revascularization procedures, obtained from death certificates and medical records, by baseline periodontal status. Results During follow-up, 1265 individuals had at least 1 CHD event, including CHD fatality (n=468) or at least 1 hospitalization with a diagnosis of CHD (n=1022), including coronary revascularization procedures (n=155). After adjustment for known cardiovascular risk factors, gingivitis was not associated with CHD (hazard ratio, 1.05; 95% confidence interval. 0.88-1.26), while periodontitis was associated with a nonsignificant increased risk for CHD event (hazard ratio, 1.14; 95% confidence interval, 0.96-1.36). Conclusion This study did not find convincing evidence of a causal association be tween periodontal disease and CHD risk.	Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Dent, Dept Oral Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hujoel, PP (corresponding author), Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Box 357475, Seattle, WA 98195 USA.			Hujoel, Philippe/0000-0002-4040-104X	NIDCR NIH HHS [R29-DE12190, P30-DE09743] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P30DE009743, R29DE012190] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albandar JM, 1999, J PERIODONTOL, V70, P30, DOI 10.1902/jop.1999.70.1.30; Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; Beck J D, 1998, Ann Periodontol, V3, P127, DOI 10.1902/annals.1998.3.1.127; Breslow RA, 1999, ANN EPIDEMIOL, V9, P254, DOI 10.1016/S1047-2797(98)00071-4; Christen WG, 1998, CIRCULATION, V97, P821; Danesh J, 1999, AM HEART J, V138, pS434, DOI 10.1016/S0002-8703(99)70270-X; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Deshpande RG, 1998, INFECT IMMUN, V66, P5337, DOI 10.1128/IAI.66.11.5337-5343.1998; DESTEFANO F, 1993, BRIT MED J, V306, P688, DOI 10.1136/bmj.306.6879.688; Dorn BR, 1999, INFECT IMMUN, V67, P5792, DOI 10.1128/IAI.67.11.5792-5798.1999; Graubard BL, 1999, JNCI-J NATL CANCER I, V91, P1005, DOI 10.1093/jnci/91.12.1005; Herzberg M C, 1998, Ann Periodontol, V3, P151, DOI 10.1902/annals.1998.3.1.151; Herzberg MC, 1996, J PERIODONTOL, V67, P1138, DOI 10.1902/jop.1996.67.10s.1138; Joshipura K J, 1998, Ann Periodontol, V3, P175, DOI 10.1902/annals.1998.3.1.175; Joshipura KJ, 1996, J DENT RES, V75, P1631, DOI 10.1177/00220345960750090301; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; KRONMAL RA, 1993, J ROY STAT SOC A STA, V156, P379, DOI 10.2307/2983064; KWEIDER M, 1993, SCOT MED J, V38, P73, DOI 10.1177/003693309303800304; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MACLURE M, 1990, INT J EPIDEMIOL, V19, P782, DOI 10.1093/ije/19.4.782; MATTILA KJ, 1993, EUR HEART J, V14, P51; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; Mattila KJ, 1998, CLIN INFECT DIS, V26, P719, DOI 10.1086/514570; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; Meyer DH, 1998, CURR OPIN MICROBIOL, V1, P88, DOI 10.1016/S1369-5274(98)80147-1; Morrison HI, 1999, J CARDIOVASC RISK, V6, P7; Newman HN, 1998, INT DENT J, V48, P173, DOI 10.1111/j.1875-595X.1998.tb00474.x; RUSSELL A. L., 1956, JOUR DENTAL RES, V35, P350, DOI 10.1177/00220345560350030401; Shah BV, 1997, SUDAAN USERS MANUAL; Slavkin HC, 1999, J AM DENT ASSOC, V130, P109, DOI 10.14219/jada.archive.1999.0038; Slots J, 1998, J DENT RES, V77, P1764, DOI 10.1177/00220345980770100101; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; WU T, 1999, CIRCULATION, V99, P8	34	294	302	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1406	1410		10.1001/jama.284.11.1406	http://dx.doi.org/10.1001/jama.284.11.1406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989403	Bronze			2022-12-28	WOS:000089242500035
J	Reynolds, T				Reynolds, T			The ethics of placebo-controlled trials	ANNALS OF INTERNAL MEDICINE			English	News Item																			0	10	11	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					491	492		10.7326/0003-4819-133-6-200009190-00103	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00103			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975985				2022-12-28	WOS:000089329700024
J	Blanks, RG; Moss, SM; McGahan, CE; Quinn, MJ; Babb, PJ				Blanks, RG; Moss, SM; McGahan, CE; Quinn, MJ; Babb, PJ			Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM SURVIVAL; RATES; AGE	Objective To assess the impact of the NHS breast screening programme on mortality from breast cancer in women aged 55-69 years over the period 1990-8. Design Age cohort model with data for 1971-89 used to predict mortality for 1990-8 with assumption of no major effect from screening or improvements in treatment until after 1989. Effect of screening and other factors on mortality estimated by comparing three year moving averages of observed mortality with those predicted (by five year age groups from 50-54 to 75-79), the effect of screening being restricted to certain age groups. Setting England and Wales. Subjects Women aged 40 to 79 years. Results Compared with predicted mortality in the absence of screening or other effects the total reduction in mortality from breast cancer in 1998 in women aged 55-69 was estimated as 21.3%. Direct effect of screening was estimated as 6.4% (range of estimates from 5.4-11.8%). Effect of all other factors (improved treatment with tamoxifen and chemotherapy, and earlier presentation outside the screening programme) was estimated as 14.9% (range 12.2-14.9%). Conclusions By 1998 both screening and other factors, including improvements in treatment, had resulted in substantial reductions in mortality from breast cancer. Many deaths in the 1990s will be of women diagnosed in the 1980s and early 1990s, before invitation to screening. Further major effects from screening and treatment are expected, which together with cohort effects should result in further substantial reductions in mortality from breast cancer, particularly for women aged 55-69, over die next 10 years.	Inst Canc Res, Canc Screening Evaluat Unit, Epidemiol Sect, Sutton SM2 5NG, Surrey, England; Off Natl Stat, Demog & Hlth Div, London SW1V 2QQ, England	University of London; Institute of Cancer Research - UK	Moss, SM (corresponding author), Inst Canc Res, Canc Screening Evaluat Unit, Epidemiol Sect, Sutton SM2 5NG, Surrey, England.							ABE O, 1992, LANCET, V339, P71; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; COLEMAN MP, 1999, STUDIES MED POULATIO, V61; COLEMAN MP, 1993, SCI PUBLICATIONS, V121; DAY NE, 1989, BRIT J CANCER, V59, P954, DOI 10.1038/bjc.1989.203; Department of Health, 1992, HLTH NAT STRAT HLTH; Department of Health and Welsh Office, 1995, POL FRAM COMM CANC S; DUFFY SW, 1996, LANCET, V346, P852; Forrest APM, 1986, BREAST CANC SCREENIN; LANGLANDS AO, 1979, BRIT MED J, V2, P1247, DOI 10.1136/bmj.2.6200.1247; Moss S, 1998, J EPIDEMIOL COMMUN H, V52, P111, DOI 10.1136/jech.52.2.111; *NHS BREAST SCREEN, 1999, NHS BSP 1999; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; QUINN M, 1995, BRIT MED J, V311, P1391, DOI 10.1136/bmj.311.7017.1391; Stockton D, 1997, BRIT MED J, V314, P472, DOI 10.1136/bmj.314.7079.472; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; van den Akker-van Marle E, 1999, J MED SCREEN, V6, P30, DOI 10.1136/jms.6.1.30; Young KC, 1997, BRIT J RADIOL, V70, P482, DOI 10.1259/bjr.70.833.9227229; Zahl PH, 1997, STAT MED, V16, P1435, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1435::AID-SIM570>3.0.CO;2-8	20	257	261	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					665	669		10.1136/bmj.321.7262.665	http://dx.doi.org/10.1136/bmj.321.7262.665			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987769	Green Published, Bronze			2022-12-28	WOS:000089444100021
J	Steed, JW				Steed, JW			Crystals that breathe	NATURE			English	Editorial Material									Kings Coll London, Dept Chem, London WC2R 2LS, England	University of London; King's College London	Steed, JW (corresponding author), Kings Coll London, Dept Chem, London WC2R 2LS, England.	jon.steed@kcl.ac.uk	Steed, Jonathan/A-7916-2008	Steed, Jonathan/0000-0002-7466-7794				Albrecht M, 2000, NATURE, V406, P970, DOI 10.1038/35023107; ATWOOD JL, 1996, COMPREHENSIVE SUPRAM, V7; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Steed J.W., 2022, SUPRAMOL CHEM; Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f	6	11	11	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					943	944		10.1038/35023194	http://dx.doi.org/10.1038/35023194			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984032				2022-12-28	WOS:000089020200023
J	Klingenheben, T; Zabel, M; D'Agostino, RB; Cohen, RJ; Hohnloser, SH				Klingenheben, T; Zabel, M; D'Agostino, RB; Cohen, RJ; Hohnloser, SH			Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure	LANCET			English	Article							SURVIVAL; RISK	Measurement of microvolt level T-wave alternans in the surface electrocardiogram Is a novel way to assess the risk of ventricular arrhythmias. Seven taste of arrhythmic risk, including T-wave alternans, were undertaken in 107 consecutive patients with congestive heart failure and no history of sustained ventricular arrhythmias; the patients were followed up for arrhythmic events during the next 18 months. Of the patients with events, 11 had positive and two indeterminate T-wave alternans results; there ware no arrhythmic events among patients with negative T-wave alternans results. Of the seven tests, only T-wave alternans was a significant (p=0.0036) and independent predictor of arrhythmic events.	Univ Frankfurt, D-60590 Frankfurt, Germany; Boston Univ, Boston, MA 02215 USA; MIT, Cambridge, England	Goethe University Frankfurt; Boston University	Hohnloser, SH (corresponding author), Dept Med, Div Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.							HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hohnloser SH, 1998, J CARDIOVASC ELECTR, V9, P1258, DOI 10.1111/j.1540-8167.1998.tb00101.x; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; ROSENBAUM DS, 1994, NEW ENGL J MED, V330, P235, DOI 10.1056/NEJM199401273300402	5	211	220	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					651	652		10.1016/S0140-6736(00)02609-X	http://dx.doi.org/10.1016/S0140-6736(00)02609-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968440				2022-12-28	WOS:000088884100015
J	McKee, M; Jacobson, B				McKee, M; Jacobson, B			Public health in Europe	LANCET			English	Article							CHANGING LIFE EXPECTANCY; ISCHEMIC-HEART-DISEASE; INDEPENDENT INQUIRY; INEQUALITIES; EXPERIENCE; PREVENTION; PRIORITIES; DIFFUSION; MORTALITY; FINLAND	Any attempt to describe public health in Europe faces the twin problems of defining Europe and of dealing with the diversity of health and health systems it contains. Health status varies considerably between countries. In some, health is improving, with substantial decreases In heart disease in many western and central European countries. In others, especially in the former Soviet Union, there is concern about the rapid increase in tuberculosis and AIDS. A national analysis does, however, conceal a substantial variation within countries, between regions, and between social classes. The responses to these threats to health are also diverse. A few countries have developed effective mechanisms to design and implement appropriate policies but, in many countries, the public-health community is weak. In particular, public health has largely failed in its role as an advocate of the health of the population. There are, however, many encouraging signs that this may change in the future.	Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England; E London & City Hlth Author, London, England	University of London; London School of Hygiene & Tropical Medicine; St Georges University London	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, Keppel St, London WC1E 7HT, England.	Martin.McKee@Ishtm.ac.uk	McKee, Marc D/E-2187-2011; McKee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; McKee, Martin/0000-0002-0121-9683				Acheson D, 1998, BRIT MED J, V317, P1659, DOI 10.1136/bmj.317.7173.1659; [Anonymous], 1998, INDEPENDENT INQUIRY; Ashton J, 1999, BRIT MED J, V318, P601, DOI 10.1136/bmj.318.7183.601; Ashton J, 1992, HLTH CITIES; BAGGOTT R, 1987, POLICY POLIT, V15, P137, DOI 10.1332/030557387782455182; BARDSLEY M, 1998, HLTH LONDONERS PUBLI; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; Chapman S. L. D., 1994, FIGHT PUBLIC HLTH; Chenet L, 1997, J EPIDEMIOL COMMUN H, V51, P510, DOI 10.1136/jech.51.5.510; Chenet L, 1996, J EPIDEMIOL COMMUN H, V50, P404, DOI 10.1136/jech.50.4.404; Chenet L, 1996, J PUBLIC HEALTH MED, V18, P329, DOI 10.1093/oxfordjournals.pubmed.a024514; *COMM EUR COMM, 1998, 230 COM COMM EUR COM; Costongs C, 1997, HEALTH PROMOT INT, V12, P9, DOI 10.1093/heapro/12.1.9; *COUNC EUR EMCDDA, 1997, EST PREV PROBL DRUG; DALZIEL M, IN PRESS EUR J PUBL; Davidson BL, 1998, BRIT MED J, V316, P2, DOI 10.1136/bmj.316.7124.2; DELANEY F, 1994, HLTH ED J, V53, P474; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP ED EMPL, 1998, ED ACT ZON INTRO; *DEP HLTH, 1995, EL95129CI9547 DEP HL; *DEP HLTH, 1999, 199242LAC9938 NHS EX; *DEP HLTH, 1999, CM4386; Department of Health, 1999, RED HLTH IN ACT REP; DESENCLOS JC, 1993, LANCET, V341, P1003, DOI 10.1016/0140-6736(93)91084-Y; FARMER P, 1999, GLOBAL IMPACT DRUG R; Figueras J, 1998, EUR J PUBLIC HEALTH, V8, P99, DOI 10.1093/eurpub/8.2.99; Fulop N, 1996, PUBLIC HEALTH, V110, P307, DOI 10.1016/S0033-3506(96)80095-3; Fulop N, 1999, BRIT MED J, V319, P139, DOI 10.1136/bmj.319.7203.139; Giesecke J, 1998, LANCET, V352, P1308, DOI 10.1016/S0140-6736(98)00042-7; GREEN J, 1998, EVIDENCE POLICY ACCI; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; HAYWARD A, 1998, TUBERCULOSIS CONTROL; Jacobson B, 1998, BRIT MED J, V316, P164; KUNST AE, MEASURING SOCIOECONO; LIGHT DW, 1986, AM J PUBLIC HEALTH, V76, P78, DOI 10.2105/AJPH.76.1.78; *LOND SCH HYG TROP, 2000, SCI EV ARR MAN EP EM; McKee M, 1999, BMJ-BRIT MED J, V318, P1300, DOI 10.1136/bmj.318.7194.1300; McKee M, 1996, J ROY SOC MED, V89, P424, DOI 10.1177/014107689608900803; McKee M, 1998, EUR J PUBLIC HEALTH, V8, P3, DOI 10.1093/eurpub/8.1.3; McKee M, 1996, HEALTH POLICY, V37, P117, DOI 10.1016/0168-8510(95)00829-2; MCKEE M, 1992, EUR J PUBLIC HEALTH, V2, P45; MCKEE M, 1998, REFORMING PUBLIC HLT, P135; McKee M, 1996, J EUROPEAN SOCIAL PO, V6, P263, DOI DOI 10.1177/095892879600600401; MIDDLETON J, 1991, BRIT MED J, V302, P521, DOI 10.1136/bmj.302.6775.521; Mossialos E, 1998, J Health Serv Res Policy, V3, P65; Ngongo KN, 1999, HEALTH POLICY, V48, P1, DOI 10.1016/S0168-8510(99)00029-9; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; Peto R, 1994, MORTALITY SMOKING DE; Puska P, 1998, B WORLD HEALTH ORGAN, V76, P419; Reich M, 2018, STORY MINIMALISM 1; SCHOLTEN H J, 1991, World Health Statistics Quarterly, V44, P160; *SCI GOV COUNC, 1991, SOC IN HLTH HLTH POL; ScottSamuel A, 1996, BRIT MED J, V313, P183, DOI 10.1136/bmj.313.7051.183; Smith GD, 1998, BMJ-BRIT MED J, V317, P1465, DOI 10.1136/bmj.317.7171.1465; Social Exclusion Unit, 1998, BRING BRIT TOG NAT S; Stern V., 1999, SENTENCED DIE PROBLE; Tichonova L, 1997, LANCET, V350, P210, DOI 10.1016/S0140-6736(97)01382-2; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; Weil O, 1998, EUR J PUBLIC HEALTH, V8, P256, DOI 10.1093/eurpub/8.3.256; White M., 1993, LANCET, P43, DOI [10.1016/0140-6736(93)92505-N., 10.1016/0140-6736(93)92505-N]; Whitehead M, 1998, MILBANK Q, V76, P469, DOI 10.1111/1468-0009.00099; *WHO, 1996, ALC LESS BETT; *WHO, 1990, IT CAN BE DONE SMOKE; *WHO, 1999, HLTH 21 HLTH 21 CENT; *WHO, 1985, REG OFF EUR TARG HLT; *WHO, 1999, IMPL NAT ENV HLTH AC; *WHO, 2000, HTLH ALL DAT; Zatonski WA, 1998, BMJ-BRIT MED J, V316, P1047	68	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2000	356	9230					665	670		10.1016/S0140-6736(00)02616-7	http://dx.doi.org/10.1016/S0140-6736(00)02616-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	346RD	10968451				2022-12-28	WOS:000088884100039
J	Hoyt, MA				Hoyt, MA			Exit from mitosis: Spindle pole power	CELL			English	Review							BUDDING YEAST; MITOTIC EXIT; CHECKPOINT PATHWAY; PHOSPHATASE CDC14; ANAPHASE; PHOSPHORYLATION; DAMAGE; KINASE; PDS1		Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.							Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Balasubramanian MK, 2000, J CELL SCI, V113, P1503; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bloecher A, 2000, NAT CELL BIOL, V2, P556, DOI 10.1038/35019601; Cerutti L, 2000, CURR OPIN GENET DEV, V10, P65, DOI 10.1016/S0959-437X(99)00044-1; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	19	72	72	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 4	2000	102	3					267	270		10.1016/S0092-8674(00)00031-3	http://dx.doi.org/10.1016/S0092-8674(00)00031-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975516	Bronze			2022-12-28	WOS:000088625600001
J	Brown, MJ; Palmer, CR; Castaigne, A; de Leeuw, PW; Mancia, G; Rosenthal, T; Ruilope, LM				Brown, MJ; Palmer, CR; Castaigne, A; de Leeuw, PW; Mancia, G; Rosenthal, T; Ruilope, LM			Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)	LANCET			English	Article							ISOLATED SYSTOLIC HYPERTENSION; CORONARY HEART-DISEASE; BLOOD-PRESSURE; TRIAL; RISK; POPULATIONS; GUIDELINES; MANAGEMENT; PROJECT; THERAPY	Background The efficacy of antihypertensive drugs newer than diuretics and beta-blockers has not been established. We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity in high-risk patients with hypertension. Methods We did a prospective, randomised, double-blind trial in Europe and Israel in 6321 patients aged 55-80 years with hypertension (blood pressure greater than or equal to 150/95 mm Hg, or greater than or equal to 160 mm Hg systolic). Patients had at least one additional cardiovascular risk factor. We randomly assigned patients nifedipine 30 mg in a long-acting gastrointestinal-transport-system (GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mu g plus amiloride 2.5 mg; n=3164). Dose titration was by dose doubling, and addition of atenolol 25-50 mg or enalapril 5-10 mg. The primary outcome was cardiovascular death, myocardial infarction, heart failure, or stroke. Analysis was done by intention to treat. Findings Primary outcomes occurred in 200 (6.3%) patients in the nifedipine group and in 182 (5.8%) in the co-amilozide group (18.2 vs 16.5 events per 1000 patient-years; relative risk 1.10 [95% CI 0.91-1.34], p=0.35). Overall mean blood pressure fell from 173/99 mm Hg (SD 14/8) to 138/82 mm Hg (12/7). There was an 8% excess of withdrawals from the nifedipine group because of peripheral oedema (725 vs 518, p<0.0001), but serious adverse events were more frequent in the co-amilozide group (880 vs 796, p=0.02). Deaths were mainly non-vascular (nifedipine 176 vs co-amilozide 172; p=0.81). 80% of the primary events occurred in patients receiving randomised treatment (157 nifedipine, 147 co-amilozide, difference 0.33% [-0.7 to 1.4]). Interpretation Nifedipine once daily and co-amilozide were equally effective in preventing overall cardiovascular or cerebrovascular complications. The choice of drug can be decided by tolerability and blood-pressure response rather than long-term safety or efficacy.	Univ Cambridge, Clin Pharmacol Unit, Cambridge, England; Univ Cambridge, Ctr Appl Med Stat, Cambridge, England; Univ Paris, Hop Henri Mondor, Serv Cardiol, Paris, France; Univ Maastricht, Maastricht, Netherlands; Univ Milan, Cattedra Med Interna, Milan, Italy; Tel Aviv Univ, Chaim Sheba Med Ctr, Hypertens Unit, IL-69978 Tel Aviv, Israel; Univ Madrid, Hosp 12 Octubre, Dept Nephrol, Madrid 3, Spain	University of Cambridge; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Universite Paris Cite; Maastricht University; University of Milan; Chaim Sheba Medical Center; Tel Aviv University; Hospital Universitario 12 de Octubre	Brown, MJ (corresponding author), Addenbrookes Hosp, Clin Pharmacol Unit, ACCI, Level 6,Box 110, Cambridge CB2 2QQ, England.		de Leeuw, Peter W./J-4552-2016	de Leeuw, Peter W./0000-0002-4949-5812; Ruilope, Luis M/0000-0001-6278-7951				Black HR, 1997, ARCH INTERN MED, V157, P2413; Brown MJ, 1998, J HYPERTENS, V16, P2113; Brown MJ, 2000, LANCET, V355, P653, DOI 10.1016/S0140-6736(05)72390-4; Brown MJ, 2000, HYPERTENSION, V35, P1038, DOI 10.1161/01.HYP.35.5.1038; BROWNING CR, 1996, HOLOCAUST GENOCIDE S, V10, P3, DOI 10.1093/hgs/10.1.3; Chalmers J, 1999, CLIN EXP HYPERTENS, V21, P1009; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dickerson JEC, 1999, LANCET, V353, P2008, DOI 10.1016/S0140-6736(98)07614-4; Dobson AJ, 1998, ANN MED, V30, P199, DOI 10.3109/07853899808999404; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Gueyffier F, 1999, LANCET, V353, P1795, DOI 10.1016/S0140-6736(05)75892-X; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; Neal B, 1999, CLIN EXP HYPERTENS, V21, P517, DOI 10.3109/10641969909060985; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Treasure T, 1998, BRIT MED J, V317, P362	29	886	959	1	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					366	372		10.1016/S0140-6736(00)02527-7	http://dx.doi.org/10.1016/S0140-6736(00)02527-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972368				2022-12-28	WOS:000088486000008
J	Jeffcoate, S				Jeffcoate, S			The retrieval of Ladysmith	LANCET			English	Review											Jeffcoate, S (corresponding author), 5 Elmhurst Dr, Surrey RH4 2BA, England.							Amery Leopold Stennett, 1909, TIMES HIST WAR S AFR, V6; BETT WR, 1953, ANN ROY COLL SURG, V12, P189; Burdett-Coutts William, 1900, SICK WOUNDED S AFRIC; CHURCHILL W, 1900, LONDON LADYSMITH VIA; DOYLE A. Conan, 1900, SIGN 4; Flower Newman, 1950, JUST IT HAPPENED; Ford, 1980, TRUE HIST ELEPHANT M; GANDHI MK, 1982, AUTOBIOGRAPHY STUDY; GIBBS DD, 1992, J ROY SOC MED, V85, P565; McCormac W., 1900, BMJ-BRIT MED J, V1, P1611; Pakenham T., 1992, BOER WAR; TREVES F, 1900, TALE FIELD HOSPITAL; Treves F., 1897, PRACTITIONER, V58, P619; Treves Sir Frederick, 1923, ELEPHANT MAN OTHER R; TROMBLEY S, 1989, F TREVES EXTRA ORDIN	15	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					418	421		10.1016/S0140-6736(00)02540-X	http://dx.doi.org/10.1016/S0140-6736(00)02540-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972387				2022-12-28	WOS:000088486000037
J	Levy, DJ				Levy, DJ			An aspirin tablet and a gastric ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hamot Med Ctr, Erie, PA 16550 USA		Levy, DJ (corresponding author), Hamot Med Ctr, Erie, PA 16550 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					863	863		10.1056/NEJM200009213431206	http://dx.doi.org/10.1056/NEJM200009213431206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995866				2022-12-28	WOS:000089355600006
J	Ross, EA; Szabo, NJ; Tebbett, IR				Ross, EA; Szabo, NJ; Tebbett, IR			Lead content of calcium supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DIETARY LEAD; EXPOSURE	Context Substantial quantities of lead have been reported in some over-the-counter calcium supplement preparations, including not only bonemeal and dolomite, but also over-the-counter natural and refined calcium carbonate formulations. Examination of this issue is warranted given recent increases in physician recommendations for calcium supplements for prevention and treatment of osteoporosis. Objectives To determine the lead content of calcium supplements and to quantify the lead exposure from popular brands of calcium in dosages used for childhood recommended daily allowance, osteoporosis, and phosphate binding in dialysis patients. Design and Setting Analysis of lead content in 21 formulations of nonprescription calcium carbonate (including 7 natural [ie, oyster shell] and 14 refined), 1 brand of prescription-only calcium acetate, and 1 noncalcium synthetic phosphate binder conducted in March 2000, Main Outcome Measures Lead content, assayed using electrothermal atomic absorption, expressed as micrograms of lead per 800 mg/d of elemental calcium, per 1500 mg/d of calcium, and for a range of dosages for patients with renal failure. Six mu g/d of lead was considered the absolute dietary limit, with no more than 1 mu g/d being the goal for supplements. Results Four of 7 natural products had measurable lead content, amounting to approximately 1 mu g/d for 800 mg/d of calcium, between 1 and 2 mu g/d for 1500 mg/d of calcium, and up to 10 mu g/d for renal dosages, Four of the 14 refined products had similar lead content, including up to 3 mu g/d of lead in osteoporosis calcium dosages and up to 20 mu g/d in high renal dosages, No lead was detected in the calcium acetate or polymer products. Lead was present even in some brand name products from major pharmaceutical companies not of natural oyster shell derivation. Conclusions Despite increasingly stringent limits of lead exposure, many calcium supplement formulations contain lead and thereby may pose an easily avoidable public health concern.	Univ Florida, Div Nephrol Hypertens & Transplantat, Coll Med, Gainesville, FL 32610 USA; Univ Florida, Coll Vet Med, Dept Physiol Sci, Analyt Toxicol Core Lab, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Ross, EA (corresponding author), Univ Florida, Div Nephrol Hypertens & Transplantat, Coll Med, Box 100224, Gainesville, FL 32610 USA.	Rossea@medicine.ufl.edu						Adachi JD, 1998, CALCIFIED TISSUE INT, V63, P429, DOI 10.1007/s002239900552; Bolger PM, 1996, FOOD ADDIT CONTAM A, V13, P53, DOI 10.1080/02652039609374380; BOULOS BM, 1988, AM J HYPERTENS, V1, pS137, DOI 10.1093/ajh/1.3.137S; BOURGOIN BP, 1993, AM J PUBLIC HEALTH, V83, P1155, DOI 10.2105/AJPH.83.8.1155; CARR C J, 1987, American Pharmacy, V27, P49; CARRINGTON CD, 1992, REGUL TOXICOL PHARM, V16, P265, DOI 10.1016/0273-2300(92)90006-U; Carrington CD, 1996, FOOD ADDIT CONTAM, V13, P61, DOI 10.1080/02652039609374381; D'Haese PC, 1999, CLIN CHEM, V45, P1548; Ervin R.B., 1999, VITAL HLTH STAT, V11, P1; NAVARRO JA, 1992, CLIN CHIM ACTA, V211, P133, DOI 10.1016/0009-8981(92)90189-W; ROBERTS HJ, 1983, SOUTHERN MED J, V76, P556, DOI 10.1097/00007611-198305000-00005; Sargent JD, 1999, AM J CLIN NUTR, V69, P1224; SLESINSKI MJ, 1995, J AM DIET ASSOC, V95, P921, DOI 10.1016/S0002-8223(95)00255-3; SLITONEN PH, 1994, J ASSOC OFF ANA CHEM, V77, P1299; SUITOR CW, 1990, J AM DIET ASSOC, V90, P268; *US DEP HHS AG TOX, 1999, TOX PROF LEAD; *US EPA OFF HLTH E, 1999, INT RISK INF SYST; *US FDA, 1990, HFF156 US FDA US PHS; *US FDA, 1981, LEAD BON; *US PHARM CONV INC, 2000, US PHARM NAT FORM, P277; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; WHITING SJ, 1994, NUTR REV, V52, P95, DOI 10.1111/j.1753-4887.1994.tb01396.x; 1999, CONSUMER REPORTS, V64, P9	23	44	47	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1425	1429		10.1001/jama.284.11.1425	http://dx.doi.org/10.1001/jama.284.11.1425			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989406				2022-12-28	WOS:000089242500038
J	Shackleton, NJ				Shackleton, NJ			The 100,000-year ice-age cycle identified and found to lag temperature, carbon dioxide, and orbital eccentricity	SCIENCE			English	Article							HUON PENINSULA; SEA-LEVEL; CORE; FRAMEWORK; HISTORY; CLIMATE	The deep-sea sediment oxygen isotopic composition (delta(18)O) record is dominated by a 100,000-year cyclicity that is universally interpreted as the main ice-age rhythm, Here, the ice volume component of this delta(18)O signal was extracted by using the record of delta(18)O in atmospheric oxygen trapped in Antarctic ice at Vostok, precisely orbitally tuned. The benthic marine delta(18)O record is heavily contaminated by the effect of deep-water temperature variability, but by using the Vostok record, the delta(18)O signals of ice volume, deep-water temperature, and additional processes affecting air delta(18)O (that is, a varying Dole effect) were separated. At the 100,000-year period, atmospheric carbon dioxide, Vostok air temperature, and deep-water temperature are in phase with orbital eccentricity, whereas ice volume Lags these three variables. Hence, the 100,000-year cycle does not arise from ice sheet dymamics; instead, it is probably the response of the global carbon cycle that gene rates the eccentricity signal by causing changes in atmospheric carbon dioxide concentration.	Univ Cambridge, Dept Earth Sci, Godwin Lab, Cambridge CB2 3SA, England	University of Cambridge	Shackleton, NJ (corresponding author), Univ Cambridge, Dept Earth Sci, Godwin Lab, Pembroke St, Cambridge CB2 3SA, England.							BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; BENDER M, 1994, GLOBAL BIOGEOCHEM CY, V8, P363, DOI 10.1029/94GB00724; Bender ML, 1999, GEOPH MONOG SERIES, V112, P149; BROECKER WS, 1970, REV GEOPHYS SPACE GE, V8, P169, DOI 10.1029/RG008i001p00169; Chappell J, 1996, EARTH PLANET SC LETT, V141, P227, DOI 10.1016/0012-821X(96)00062-3; CROWLEY TJ, 1983, GEOLOGY, V11, P275, DOI 10.1130/0091-7613(1983)11<275:ICIALQ>2.0.CO;2; Duplessy J.C., 1988, LECT NOTES EARTH SCI, V16, P83; Edwards RL, 1997, SCIENCE, V276, P782, DOI 10.1126/science.276.5313.782; Esat TM, 1999, SCIENCE, V283, P197, DOI 10.1126/science.283.5399.197; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; IMBRIE J, 1985, J GEOL SOC LONDON, V142, P417, DOI 10.1144/gsjgs.142.3.0417; IMBRIE J, 1980, SCIENCE, V207, P943, DOI 10.1126/science.207.4434.943; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Matthews R. K., 1973, Quaternary Research, V3, P147, DOI 10.1016/0033-5894(73)90061-6; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; MULLER RA, 1995, NATURE, V377, P107, DOI 10.1038/377107b0; NINKOVICH D, 1975, EARTH PLANET SC LETT, V27, P20, DOI 10.1016/0012-821X(75)90156-9; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; SHACKLETON N, 1967, NATURE, V215, P15, DOI 10.1038/215015a0; Shackleton N. J., 1973, Quaternary Research, V3, P39, DOI 10.1016/0033-5894(73)90052-5; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; Weertman J., 1964, J GLACIOL, V5, P145	27	692	769	7	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1897	1902		10.1126/science.289.5486.1897	http://dx.doi.org/10.1126/science.289.5486.1897			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988063				2022-12-28	WOS:000089355800035
J	McPherson, K; Steel, CM; Dixon, JM				McPherson, K; Steel, CM; Dixon, JM			ABC of breast disease: Breast cancer-epidemiology, risk factors, and genetics	BMJ-BRITISH MEDICAL JOURNAL			English	Review									London Sch Hyg & Trop Med, London WC1, England; Univ St Andrews, St Andrews, Fife, Scotland; Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of St Andrews; University of Edinburgh	McPherson, K (corresponding author), London Sch Hyg & Trop Med, London WC1, England.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BILIMORIA MM, 1995, CA-CANCER J CLIN, V45, P263, DOI 10.3322/canjclin.45.5.263; BLACK DM, 1994, EUR J CANCER, V30A, P1957, DOI 10.1016/0959-8049(94)00386-J; BRINTON LA, 1996, DIS BREAST, P159; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; DECKER D, 1993, JAMA-J AM MED ASSOC, V269, P2608; DEMICHELE A, 2000, DIS BREAST, P221; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Hill ADK, 1997, BRIT J SURG, V84, P1334; ISAACS CJD, 2000, DIS BREAST, P237; JORDAN CV, 2000, DIS BREAST, P265; JORDAN VC, 1998, BREAST CANC RES TREA, V50, P227; Powles T, 1998, LANCET, V352, P98; Veronesi U, 1998, LANCET, V352, P93; Willett WC., 2000, DIS BREAST, V2, P175	16	914	944	0	94	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2000	321	7261					624	628		10.1136/bmj.321.7261.624	http://dx.doi.org/10.1136/bmj.321.7261.624			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977847	Green Submitted, Green Published			2022-12-28	WOS:000089243200031
J	Goldstein, DS; Holmes, C; Li, ST; Bruce, S; Metman, LV; Cannon, RO				Goldstein, DS; Holmes, C; Li, ST; Bruce, S; Metman, LV; Cannon, RO			Cardiac sympathetic denervation in Parkinson disease	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIPLE SYSTEM ATROPHY; METAIODOBENZYLGUANIDINE MYOCARDIAL SCINTIGRAPHY; AUTONOMIC FAILURE; PLASMA DIHYDROXYPHENYLALANINE; HUMAN-HEART; NOREPINEPHRINE; 6-<F-18>FLUORODOPAMINE; DEGENERATION; DYSFUNCTION; DEATH	Background: In Parkinson disease, orthostatic hypotension can result from L-dopa treatment or from sympathetic neurocirculatory failure. The latter is detected by abnormal blood pressure responses to the Valsalva maneuver and can be associated with loss of functional cardiac sympathetic nerve terminals. Objective: To determine the frequency of cardiac sympathetic denervation in Parkinson disease, with or without sympathetic neurocirculatory failure, and its association with disease duration, severity, and L-dopa treatment. Design: Intergroup comparisons in resting patients. Setting: National Institutes of Health Clinical Center, Bethesda, Maryland. Patients: 29 patients with Parkinson disease (9 with sympathetic neurocirculatory failure, 10 who had stopped receiving or had never been treated with L-dopa), 24 patients with multiple-system atrophy (17 with sympathetic neurocirculatory failure, 8 receiving L-dopa), 7 patients with pure autonomic failure, 33 controls with episodic or persistent orthostatic intolerance without sympathetic neurocirculatory failure, and 19 normal volunteers. Measurements: Beat-to-beat blood pressure responses to the Valsalva maneuver, Interventricular septal 6-[F-18]fluorodopamine-derived radioactivity, cardiac extraction fraction of [H-3]norepinephrine, appearance rate of norepinephrine in coronary sinus plasma (cardiac norepinephrine spillover) and venous-arterial differences in levels of dihydroxyphenylglycol (DHPG) and endogenous L-dopa. Results: Of the 29 patients with Parkinson disease, 9 with sympathetic neurocirculatory failure and 11 without had low septal 6-[F-18]fluorodopamine-derived radioactivity (2861 +/- 453 Bq/mL per MBq/kg and 5217 +/- 525 Bq/mL per MBq/kg, respectively). All 6 patients with Parkinson disease and decreased 6-[F-18]fluorodopamine-derived radioactivity who underwent right-heart catheterization had a decreased cardiac extraction fraction of [H-3]norepinephrine and virtually no cardiac norepinephrine spillover or venous-arterial increments in plasma levels of DHPG and L-dopa. Sympathetic neurocirculatory failure and decreased 6-[F-18]fluorodopamine-derived radioactivity were unrelated to disease duration, disease severity, or L-dopa treatment. Conclusions: Many patients with Parkinson disease-including all those with sympathetic neurocirculatory failure-have evidence of cardiac sympathetic denervation. This suggests that loss of catecholamine innervation in Parkinson disease occurs in the nigrostriatal system in the brain and in the sympathetic nervous system in the heart.	NINDS, NIH, Bethesda, MD 20892 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rush University	Goldstein, DS (corresponding author), NINDS, NIH, Bldg 10,Room 6N252,10 Ctr Dr,MSC-1620, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews AM, 1996, MOL PHARMACOL, V50, P1511; Appenzeller O., 1997, AUTONOMIC NERVOUS SY; Braune S, 1998, ACTA NEUROL SCAND, V97, P307, DOI 10.1111/j.1600-0404.1998.tb05958.x; Braune S, 1999, NEUROLOGY, V53, P1020, DOI 10.1212/WNL.53.5.1020; Burke WJ, 1999, BRAIN RES, V816, P633, DOI 10.1016/S0006-8993(98)01211-6; CHIUEH CC, 1983, J PHARMACOL EXP THER, V225, P529; EISENHOFER G, 1992, CIRCULATION, V85, P1775, DOI 10.1161/01.CIR.85.5.1775; EISENHOFER G, 1989, J CLIN ENDOCR METAB, V68, P247, DOI 10.1210/jcem-68-2-247; FELTEN DL, 1992, ANN NEUROL, V32, pS133, DOI 10.1002/ana.410320723; Gilman S, 1998, CLIN AUTON RES, V8, P359, DOI 10.1007/BF02309628; GOLDSTEIN DS, 1993, J AM COLL CARDIOL, V22, P1961, DOI 10.1016/0735-1097(93)90786-Z; Goldstein DS, 1997, CLIN AUTON RES, V7, P17, DOI 10.1007/BF02267622; GOLDSTEIN DS, 1987, J CLIN ENDOCR METAB, V64, P856, DOI 10.1210/jcem-64-4-856; GOLDSTEIN DS, 1988, CIRCULATION, V78, P41, DOI 10.1161/01.CIR.78.1.41; Goldstein DS, 1997, NEW ENGL J MED, V336, P696, DOI 10.1056/NEJM199703063361004; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; HIRAYAMA M, 1995, J AUTONOM NERV SYST, V53, P230, DOI 10.1016/0165-1838(95)00002-F; HOEHN MM, 1975, ARCH NEUROL-CHICAGO, V32, P50, DOI 10.1001/archneur.1975.00490430072013; HOLMES C, 1994, J CHROMATOGR B, V653, P131, DOI 10.1016/0378-4347(93)E0430-X; HUGHES AJ, 1993, ARCH NEUROL-CHICAGO, V50, P140, DOI 10.1001/archneur.1993.00540020018011; Hutchins GD, 1997, CARDIOLOGY, V88, P106, DOI 10.1159/000177316; Kopin IJ, 1998, AM J PHYSIOL-REG I, V275, pR165, DOI 10.1152/ajpregu.1998.275.1.R165; MAGALHAES M, 1995, ACTA NEUROL SCAND, V91, P98; NETTEN PM, 1995, CLIN AUTON RES, V5, P85, DOI 10.1007/BF01827468; Niimi Y, 1999, CLIN AUTON RES, V9, P139, DOI 10.1007/BF02281627; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189; Pifl C, 1996, J PHARMACOL EXP THER, V277, P1437; Satoh A, 1999, J NUCL MED, V40, P371; Satoh A, 1997, Nihon Rinsho, V55, P202; Senard JM, 1997, J NEUROL NEUROSUR PS, V63, P584, DOI 10.1136/jnnp.63.5.584; Takatsu H, 2000, J NUCL MED, V41, P71; Yoshita M, 1997, Rinsho Shinkeigaku, V37, P476; Yoshita M, 1998, J NEUROL SCI, V155, P60, DOI 10.1016/S0022-510X(97)00278-5; YOUDIM MBH, 1993, ADV NEUROL, V60, P259	36	268	276	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					338	347		10.7326/0003-4819-133-5-200009050-00009	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979878				2022-12-28	WOS:000089111900003
J	Bourara, K; Litvak, S; Araya, A				Bourara, K; Litvak, S; Araya, A			Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; SEQUENCE; PROTEIN; TRANSLATION; MECHANISM; ADENOSINE; CLONING; SITE	RNA editing involves posttranscriptional alterations of messenger RNA (mRNA) sequences modifying the information content encoded by the genetic message. Here, it is shown that, in chronically infected H9 cells, human immunodeficiency virus-type 1 (HIV-1) mRNAs undergo guanine-to-adenine (G-to-A) and cytosine-to-uracil (C-to-U) changes. C-to-A modification in the untranslated region of exon 1 was present only in spliced HIV-1 mRNAs. The creation of stop codons in HIV-1 mRNAs may function to control the translation of viral proteins, such as viral protein R, that are involved in the regulation of HIV-1 expression and the survival of chronically infected cells.	Univ Bordeaux 2, Lab Replicat & Express Genomes Eucaryotes & Retro, CNRS, UMR 5097, F-33076 Bordeaux, France; IFR 66 Pathol Infect, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Araya, A (corresponding author), Univ Bordeaux 2, Lab Replicat & Express Genomes Eucaryotes & Retro, CNRS, UMR 5097, 146 Rue Leo Saignat, F-33076 Bordeaux, France.							ARAYA A, 1994, PHYSIOL PLANTARUM, V91, P543, DOI 10.1111/j.1399-3054.1994.tb02986.x; BLANC V, 1995, FEBS LETT, V373, P56, DOI 10.1016/0014-5793(95)00991-H; Cantor C. R., 1980, BIOPHYSICAL CHEM 1; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CATTANEO R, 1989, CELL, V56, P759, DOI 10.1016/0092-8674(89)90679-X; Coffin J, 1997, RETROVIRUSES; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; JACQUES JP, 1994, EMBO J, V13, P5496, DOI 10.1002/j.1460-2075.1994.tb06884.x; Kim T, 1996, J VIROL, V70, P7594, DOI 10.1128/JVI.70.11.7594-7602.1996; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; LITVAK S, 1996, RETROVIRAL REVERSE T; LORD RC, 1968, DEV APPL SPECTROSC, V6, P179; MARTINEZ MA, 1995, NUCLEIC ACIDS RES, V23, P2573, DOI 10.1093/nar/23.14.2573; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SAMBROOK T, 1989, MOL CLONING LAB MANU, P2; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SCHWARTZ S, 1992, MOL CELL BIOL, V12, P207, DOI 10.1128/MCB.12.1.207; SHARMEEN L, 1991, P NATL ACAD SCI USA, V88, P8096, DOI 10.1073/pnas.88.18.8096; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; ZHENG HQ, 1992, J VIROL, V66, P4693, DOI 10.1128/JVI.66.8.4693-4697.1992	27	41	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1564	1566		10.1126/science.289.5484.1564	http://dx.doi.org/10.1126/science.289.5484.1564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968794				2022-12-28	WOS:000089071700050
J	Lang, D; Thoma, R; Henn-Sax, M; Sterner, R; Wilmanns, M				Lang, D; Thoma, R; Henn-Sax, M; Sterner, R; Wilmanns, M			Structural evidence for evolution of the beta/alpha barrel scaffold by gene duplication and fusion	SCIENCE			English	Article							HISTIDINE BIOSYNTHESIS; SEQUENCE-ANALYSIS; PROTEIN FUNCTION; IDENTIFICATION; CONSERVATION; REFINEMENT; PATHWAY; PROGRAM; ENZYMES; MAPS	The atomic structures of two proteins in the histidine biosynthesis pathway consist of beta/alpha barrels with a twofold repeat pattern. It is Likely that these proteins evolved by twofold gene duplication and gene fusion from a common half-barrel ancestor. These ancestral domains are not visible as independent domains in the extant proteins but can be inferred from a combination of sequence and structural analysis. The detection of subdomain structures may be useful in efforts to search genome sequences for functionally and structurally related proteins.	DESY, EMBL, Hamburg Outstn, D-22603 Hamburg, Germany; Univ Basel, Biozentrum, Biophys Chem Abt, CH-4056 Basel, Switzerland; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Basel; University of Gottingen; University of Cologne	Wilmanns, M (corresponding author), DESY, EMBL, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.		Thomä, Reiner S./I-3719-2013	Wilmanns, Matthias/0000-0002-4643-5435; Sterner, Reinhard/0000-0001-8177-8460				Alifano P, 1996, MICROBIOL REV, V60, P44, DOI 10.1128/MMBR.60.1.44-69.1996; Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BORK P, 1995, PROTEIN SCI, V4, P268; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; FANI R, 1994, J MOL EVOL, V38, P489, DOI 10.1007/BF00178849; Gerlt JA, 1998, CURR OPIN CHEM BIOL, V2, P607, DOI 10.1016/S1367-5931(98)80091-4; Gerlt JA, 2000, NAT STRUCT BIOL, V7, P171, DOI 10.1038/73249; Hasson MS, 1998, P NATL ACAD SCI USA, V95, P10396, DOI 10.1073/pnas.95.18.10396; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOMMEL U, 1995, BIOCHEMISTRY-US, V34, P5429, DOI 10.1021/bi00016a014; HOROWITZ NH, 1945, P NATL ACAD SCI USA, V31, P153, DOI 10.1073/pnas.31.6.153; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurgens C, 2000, P NATL ACAD SCI USA, V97, P9925, DOI 10.1073/pnas.160255397; KLEM TJ, 1993, BIOCHEMISTRY-US, V32, P5177, DOI 10.1021/bi00070a029; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE E, 1997, CRYSTALLOGRAPHIC COM, P100; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Morgenstern B, 1999, MOL BIOL EVOL, V16, P1654, DOI 10.1093/oxfordjournals.molbev.a026079; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nagano N, 1999, PROTEIN SCI, V8, P2072, DOI 10.1110/ps.8.10.2072; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petsko GA, 2000, NATURE, V403, P606, DOI 10.1038/35001176; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoma R, 1998, EXTREMOPHILES, V2, P379, DOI 10.1007/s007920050082; Thoma R, 1999, FEBS LETT, V454, P1, DOI 10.1016/S0014-5793(99)00757-7; WILMANNS M, 1993, P NATL ACAD SCI USA, V90, P1379, DOI 10.1073/pnas.90.4.1379; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; YANOFSKY C, 1999, ENCY MOL BIOL, V4, P2676	38	254	260	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1546	1550		10.1126/science.289.5484.1546	http://dx.doi.org/10.1126/science.289.5484.1546			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968789				2022-12-28	WOS:000089071700045
J	Michler, P; Imamoglu, A; Mason, MD; Carson, PJ; Strouse, GF; Buratto, SK				Michler, P; Imamoglu, A; Mason, MD; Carson, PJ; Strouse, GF; Buratto, SK			Quantum correlation among photons from a single quantum dot at room temperature	NATURE			English	Article							NANOCRYSTALLITES; FLUORESCENCE	Maxwell's equations successfully describe the statistical properties(1,2) of fluorescence from an ensemble of atoms or semiconductors in one or more dimensions. But quantization of the radiation field is required to explain the correlations of light generated by a single two-level quantum emitter, such as an atom, ion or single molecule(3-6). The observation of photon antibunching in resonance fluorescence from a single atom unequivocally demonstrated the non-classical nature of radiation(3). Here we report the experimental observation of photon antibunching from an artificial system-a single cadmium selenide quantum dot at room temperature. Apart from providing direct evidence for a solid-state non-classical light source, this result proves that a single quantum dot acts like an artificial atom, with a discrete anharmonic spectrum. In contrast, we rnd the photon-emission events from a cluster of several dots to be uncorrelated.	Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Biochem & Chem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Imamoglu, A (corresponding author), Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA.			Michler, Peter/0000-0002-2949-2462				BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; DIEDRICH F, 1987, PHYS REV LETT, V58, P203, DOI 10.1103/PhysRevLett.58.203; Efros AL, 1997, PHYS REV LETT, V78, P1110, DOI 10.1103/PhysRevLett.78.1110; Empedocles S, 1999, ACCOUNTS CHEM RES, V32, P389, DOI 10.1021/ar9501939; Fleury L, 2000, PHYS REV LETT, V84, P1148, DOI 10.1103/PhysRevLett.84.1148; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Klimov VI, 1998, PHYS REV LETT, V80, P4028, DOI 10.1103/PhysRevLett.80.4028; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; Walls D. F., 1994, QUANTUM OPT	14	805	828	3	246	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					968	970		10.1038/35023100	http://dx.doi.org/10.1038/35023100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984045				2022-12-28	WOS:000089020200037
J	Peercy, PS				Peercy, PS			The drive to miniaturization	NATURE			English	Editorial Material								Following the introduction of silicon-based integrated circuitry over three decades ago, the integration density of such circuits has doubled every 12 to 18 months: this observation is known as Moore's law. For this historical trend to continue, significant challenges need to be overcome in several key technological areas. But for many of these challenges, there are at present no known solutions.	Univ Wisconsin, Coll Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Peercy, PS (corresponding author), Univ Wisconsin, Coll Engn, Madison, WI 53706 USA.							DENNARD RH, 1974, IEEE J SOLID-ST CIRC, VSC 9, P256, DOI 10.1109/JSSC.1974.1050511; Fischetti MV, 2000, APPL PHYS LETT, V76, P2277, DOI 10.1063/1.126320; Moore G. E., 1965, ELECTRONICS, V38, P1, DOI DOI 10.1109/JPROC.1998.658762	3	342	348	5	90	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1023	1026		10.1038/35023223	http://dx.doi.org/10.1038/35023223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984060				2022-12-28	WOS:000089020200053
J	Buyse, M; Thirion, P; Carlson, RW; Burzykowski, T; Molenberghs, G; Piedbois, P				Buyse, M; Thirion, P; Carlson, RW; Burzykowski, T; Molenberghs, G; Piedbois, P		Meta-Analysis Grp Canc	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis	LANCET			English	Article							POSTOPERATIVE ADJUVANT THERAPY; CLINICAL-TRIALS; COLON-CANCER; END-POINTS; FLUOROURACIL; LEUCOVORIN; SURROGATE; APPROVAL; DRUGS	Background Treatment of advanced colorectal cancer has progressed substantially. However, improvements in response rates have not always translated into significant survival benefits. Doubts have therefore been raised about the usefulness of tumour response as a clinical endpoint. Methods This meta-analysis was done on individual data from 3791 patients enrolled in 25 randomised trials of first-line treatment with standard bolus intravenous fluoropyrimidines versus experimental treatments (fluorouracil plus leucovorin, fluorouracil plus methotrexate, fluorouracil continuous infusion, or hepatic-arterial infusion of floxuridine), Analyses were by intention to treat. Findings Compared with bolus fluoropyrimidines, experimental fluoropyrimidines led to significantly higher tumour response rates (454 responses among 2031 patients vs 209 among 1760; odds ratio 0.48 [95% CI 0.40-0.57], p<0.0001) and better survival (1808 deaths among 2031 vs 1580 among 1760; hazard ratio 0.90 [0.84-0.97], p=0.003). The survival benefits could be explained by the higher tumour response rates. However, a treatment that lowered the odds of failure to respond by 50% would be expected to decrease the odds of death by only 6%. In addition, less than half of the variability of the survival benefits in the 25 trials could be explained by the variability of the response benefits in these trials. Interpretation These analyses confirm that an increase in tumour response rate translates into an increase in overall survival for patients with advanced colorectal cancer. However, in the context of individual trials, knowledge that a treatment has benefits on tumour response does not allow accurate prediction of the ultimate benefit on survival.	Int Inst Drug Dev, B-1050 Brussels, Belgium; Limburgs Univ Ctr, Diepenbeek, Belgium; Hop Henri Mondor, Dept Oncol, F-94010 Creteil, France; Stanford Univ, Med Ctr, Div Med Oncol, Stanford, CA 94305 USA; Inst Oncol, Warsaw, Poland	International Drug Development Institute; Hasselt University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Stanford University; Maria Sklodowska-Curie National Research Institute of Oncology	Buyse, M (corresponding author), Int Inst Drug Dev, 430 Ave Louise B14, B-1050 Brussels, Belgium.	mbuyse@id2.be	Carlson, Robert/AAQ-8098-2020; Burzykowski, Tomasz/T-2222-2018	Burzykowski, Tomasz/0000-0003-3378-975X; Buyse, Marc/0000-0002-4559-0994				ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BURZYKOWSKI T, 1999, P BIOPH SECT AM STAT, P40; Buyse M, 1996, J NATL CANCER I, V88, P252; Buyse M, 1996, STAT MED, V15, P2797, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V; Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853; Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49; Cocchetto DM, 1998, DRUG INF J, V32, P27, DOI 10.1177/009286159803200105; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; Food and Drug Administration, 1996, REINV REG CANC DRUGS; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GRAF W, 1994, BRIT J CANCER, V70, P559, DOI 10.1038/bjc.1994.345; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; LABIANCA R, 1995, LANCET, V345, P939; LAVIN P, 1980, CANCER, V46, P1536, DOI 10.1002/1097-0142(19801001)46:7<1536::AID-CNCR2820460707>3.0.CO;2-K; Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.3.CO;2-T; MOLENBERGHS G, IN PRESS STAT MED; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Organization W.H, 1979, WHO HDB REP RES CANC; OYE RK, 1984, JAMA-J AM MED ASSOC, V252, P2722, DOI 10.1001/jama.252.19.2722; PIEDBOIS P, 1994, J CLIN ONCOL, V12, P960; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; WEISS GB, 1983, CONTROL CLIN TRIALS, V4, P43, DOI 10.1016/S0197-2456(83)80011-7; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; Wolmark N, 1998, J CLIN ONCOL, V16, P301	27	330	338	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					373	378		10.1016/S0140-6736(00)02528-9	http://dx.doi.org/10.1016/S0140-6736(00)02528-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972369				2022-12-28	WOS:000088486000009
J	Rotig, A; Appelkvist, EL; Geromel, V; Chretien, D; Kadhom, N; Edery, P; Lebideau, M; Dallner, G; Munnich, A; Ernster, L; Rustin, P				Rotig, A; Appelkvist, EL; Geromel, V; Chretien, D; Kadhom, N; Edery, P; Lebideau, M; Dallner, G; Munnich, A; Ernster, L; Rustin, P			Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q(10) deficiency	LANCET			English	Article							MITOCHONDRIAL ENCEPHALOMYOPATHY; ISOPRENOID BIOSYNTHESIS; TRANS-PRENYLTRANSFERASE; DIAGNOSIS	Background The respiratory-chain deficiencies are a broad group of largely untreatable diseases, Among them, coenzyme Q(10) (ubiquinone) deficiency constitutes a subclass that deserves early and accurate diagnosis. Methods We assessed respiratory-chain function in two siblings with severe encephalomyopathy and renal failure. We used high-performance liquid chromatography analyses, combined with radiolabelling experiments, to quantify cellular coenzyme Q(10) content. Clinical follow-up and detailed biochemical investigations of respiratory chain activity were carried out over the 3 years of oral quinone administration, Findings Deficiency of coenzyme Q(10)-dependent respiratory-chain activities was identified in muscle biopsy, circulating lymphocytes, and cultured skin fibroblasts, Undetectable coenzyme Q(10) and results of radiolabelling experiments in cultured fibroblasts supported the diagnosis of widespread coenzyme Q(10) deficiency. Stimulation of respiration and fibroblast enzyme activities by exogenous quinones in vitro prompted us to treat the patients with oral ubidecarenone (5 mg/kg daily), which resulted in a substantial improvement of their condition over 3 years of therapy. Interpretation Particular attention should be paid to multiple quinone-responsive respiratory-chain enzyme deficiency because this rare disorder can be successfully treated by oral ubidecarenone.	Hop Necker Enfants Malad, INSERM, U393, Unite Rech Handicaps Genet Enfant, F-75743 Paris 15, France; Hop Necker Enfants Malad, Serv Genet, F-75743 Paris, France; Ctr Hosp Reg, Serv Pediat, Nantes, France; Karolinska Inst, Clin Res Ctr, Huddinge, Sweden; Stockholm Univ, Dept Biochem, S-10691 Stockholm, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois; Nantes Universite; CHU de Nantes; Karolinska Institutet; Stockholm University	Rustin, P (corresponding author), Hop Necker Enfants Malad, INSERM, U393, Unite Rech Handicaps Genet Enfant, F-75743 Paris 15, France.		Edery, Patrick/B-6407-2012; Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703				Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9; BOURGERON T, 1993, NEUROMUSCULAR DISORD, V3, P605, DOI 10.1016/0960-8966(93)90124-3; Chretien D, 1998, BIOCHEM J, V329, P249, DOI 10.1042/bj3290249; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; HOFFMANN GF, 1992, J INHERIT METAB DIS, V15, P738, DOI 10.1007/BF01800016; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; RUSTIN P, 1991, BIOCHEM J, V274, P249, DOI 10.1042/bj2740249; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V; Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238; TANAKA K, 1980, CLIN CHEM, V26, P1847; TECLEBRHAN H, 1993, J BIOL CHEM, V268, P23081; Tzagoloff A., 1983, MITOCHONDRIA; Vassault A., 1991, TECHNIQUES DIAGNOSTI, P285	18	287	298	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					391	395		10.1016/S0140-6736(00)02531-9	http://dx.doi.org/10.1016/S0140-6736(00)02531-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972372				2022-12-28	WOS:000088486000012
J	Gaeta, G; De Michele, M; Cuomo, S; Guarini, P; Foglia, MC; Bond, MG; Trevisan, M				Gaeta, G; De Michele, M; Cuomo, S; Guarini, P; Foglia, MC; Bond, MG; Trevisan, M			Arterial abnormalities in the offspring of patients with premature myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; INTIMA-MEDIA THICKNESS; OXIDE SYNTHASE GENE; RISK-FACTORS; PARENTAL HISTORY; FAMILY HISTORY; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; NITRIC-OXIDE; DEPENDENT DILATATION	Background: The offspring of patients with premature coronary disease may be at increased risk for atherosclerosis. We undertook a study to determine whether changes in brachial-artery reactivity and the thickness of the carotid intima and media, two markers of early atherosclerosis, are present in adolescents and young adults with a parental history of premature myocardial infarction. Methods: We enrolled 40 healthy young people whose parents had had premature myocardial infarction (48 percent male; mean [+/-SD] age, 19.0+/-5.2 years) and 40 control subjects who were matched with the first group according to age and sex. All the subjects underwent high-resolution B-mode ultrasound examinations for the measurement of the brachial-artery vasodilatory response after arterial occlusion (i.e., reactive hyperemia) and the intima-media thickness of the distal common carotid arteries. Results: As compared with the control subjects, the offspring of patients with premature myocardial infarction had lower flow-mediated reactivity of the brachial arteries (5.7+/-5.0 percent, vs. 10.2+/-6.6 percent in the control subjects; P=0.001) and greater mean intima-media thickness of the common carotid artery (0.49+/-0.08 mm, vs. 0.44+/-0.07 mm in the control subjects; P=0.004). In the subjects with a parental history of premature myocardial infarction, an inverse association was found between brachial-artery reactivity and carotid intima-media thickness (r=-0.46, P=0.003). In a conditional logistic-regression analysis, both brachial-artery reactivity and carotid intima-media thickness were significantly and independently correlated with a parental history of premature myocardial infarction. Conclusions: Structural and functional changes are present at an early age in the arteries of persons with a parental history of premature myocardial infarction. (N Engl J Med 2000;343:840-6.) (C) 2000, Massachusetts Medical Society.	Wake Forest Univ, Bowman Gray Sch Med, Div Vasc Ultrasound Res, Winston Salem, NC 27157 USA; A Cardarelli Hosp, Div Cardiol, Naples, Italy; A Cardarelli Hosp, Clin Anal Lab, Naples, Italy; Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy; S Maria di Lorcto Hosp, Div Cardiol, Naples, Italy; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA	Wake Forest University; Wake Forest Baptist Medical Center; Antonio Cardarelli Hospital; Antonio Cardarelli Hospital; University of Naples Federico II; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Bond, MG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Div Vasc Ultrasound Res, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Tanaka, Gohichi/A-1684-2010	Crisanti, Andrea/0000-0002-2406-4426; trevisan, maurizio/0000-0001-5479-0050				BAO WH, 1995, CIRCULATION, V91, P365, DOI 10.1161/01.CIR.91.2.365; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P1468, DOI 10.1016/0735-1097(94)90141-4; Clarkson P, 1997, CIRCULATION, V96, P3378; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; De Bacquer D, 1999, J AM COLL CARDIOL, V33, P1491, DOI 10.1016/S0735-1097(99)00067-4; Enderle MD, 1998, HEART, V80, P349, DOI 10.1136/hrt.80.4.349; FREEDMAN DS, 1986, NEW ENGL J MED, V315, P721, DOI 10.1056/NEJM198609183151202; Friedlander Y, 1998, CIRCULATION, V97, P155, DOI 10.1161/01.CIR.97.2.155; Ghiadoni L, 1998, HYPERTENSION, V32, P25, DOI 10.1161/01.HYP.32.1.25; Greenlund KJ, 1999, CIRCULATION, V99, P2144, DOI 10.1161/01.CIR.99.16.2144; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; Jousilahti P, 1996, J CLIN EPIDEMIOL, V49, P497, DOI 10.1016/0895-4356(95)00581-1; KAPRIO J, 1993, CIRCULATION, V87, P1960, DOI 10.1161/01.CIR.87.6.1960; Nakayama M, 1999, CIRCULATION, V99, P2864, DOI 10.1161/01.CIR.99.22.2864; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; Neunteufl T, 1997, ATHEROSCLEROSIS, V129, P111, DOI 10.1016/S0021-9150(96)06018-2; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PHILLIPS RL, 1974, AM J EPIDEMIOL, V100, P87, DOI 10.1093/oxfordjournals.aje.a112021; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; RILEY WA, 1986, ARTERIOSCLEROSIS, V6, P378, DOI 10.1161/01.ATV.6.4.378; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SRINIVASAN SR, 1991, CIRCULATION, V84, P160, DOI 10.1161/01.CIR.84.1.160; Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41; Wood D, 1998, EUR HEART J, V19, P1434; Yataco AR, 1999, AM J CARDIOL, V83, P754, DOI 10.1016/S0002-9149(98)00984-9; Zannad F, 1998, HUM GENET, V103, P183, DOI 10.1007/s004390050804; Zureik M, 1999, ARTERIOSCL THROM VAS, V19, P366, DOI 10.1161/01.ATV.19.2.366	32	135	142	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					840	846		10.1056/NEJM200009213431203	http://dx.doi.org/10.1056/NEJM200009213431203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995863	Bronze			2022-12-28	WOS:000089355600003
J	Temple, R; Ellenberg, SS				Temple, R; Ellenberg, SS			Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; EQUIVALENCE; ORTHODOXY; MYTHS	In recent years, several authors have argued that placebo-controlled trials are invariably unethical when known effective therapy is available for the condition being studied, regardless of the condition or the consequences of deferring treatment. Some have also disputed the Value of placebo-controlled trials in such a setting, asserting that the comparison of new treatment with old treatment is sufficient to establish efficacy and is all that should be of interest. This article considers the ethical concerns about use of placebo controls and describes the limited ability of active-control equivalence (also known as noninferiority) trials to establish efficacy of new therapies in many medical contexts. The authors conclude that placebo-controlled trials are not uniformly unethical when known effective therapies are available; rather. their acceptability is determined by whether the patient will be harmed by deferral of therapy. If patients are not harmed, such trials can ethically be carried out. Furthermore, active-control trials, although valuable, informative, and appropriate in many circumstances, often cannot provide reliable evidence of the effectiveness of a new therapy.	US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, Ctr Drug Evaluat & Res, 5600 Fishers Lane,HFD-101-WOC II-6014, Rockville, MD 20857 USA.							AGOSTINI A, 1995, LANCET, V310, P170; *AM MED ASS COUNC, 1996, 2A1996 AM MED ASS CO; AMERY W, 1975, J CLIN PHARMACOL, V15, P674, DOI 10.1002/j.1552-4604.1975.tb05919.x; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; DOLLERY CT, 1979, EUR J CLIN PHARMACOL, V15, P219, DOI 10.1007/BF00618508; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; FLEMING TR, 1987, CANCER TREAT REP, V71, P1061; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; FRESTON JW, 1986, AM J GASTROENTEROL, V81, P307; GROF P, 1993, WHO EXPERT SERIES BI, V2, P28; HENRY D, 1995, BMJ-BRIT MED J, V310, P1279, DOI 10.1136/bmj.310.6990.1279; *INT C HARM, 1999, FED REGISTER, V64, P51767; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; LASAGNA L, 1979, EUR J CLIN PHARMACOL, V15, P373, DOI 10.1007/BF00561733; Laska Eugene M., 1994, P29; LEBER PD, 1989, EPILEPSIA, V30, pS57, DOI 10.1111/j.1528-1157.1989.tb05816.x; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; MAKUCH R, 1989, J CLIN EPIDEMIOL, V42, P503, DOI 10.1016/0895-4356(89)90146-7; MAX MB, 1994, CLIN PHARMACOL THER, V56, P237, DOI 10.1038/clpt.1994.130; MODELL W, 1958, JAMA-J AM MED ASSOC, V167, P2190, DOI 10.1001/jama.1958.72990350005006; PLEDGER G, 1990, STAT ISSUES DRUG RES, P226; PRIEN RF, 1988, PSYCHOPHARMACOL BULL, V24, P4; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SACHAR DB, 1984, AM J GASTROENTEROL, V79, P913; SMITH JL, 1989, AM J GASTROENTEROL, V84, P469; SRAMEK JJ, 1995, NEW ENGL J MED, V332, P62; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; TEMPLE R, 1983, P AM STAT ASS, P1; TEMPLE RJ, 1994, COMMUN STAT THEORY, V23, P499, DOI 10.1080/03610929408831269; Temple Robert, 1996, Account Res, V4, P267, DOI 10.1080/08989629608573887; Tramer MR, 1998, BMJ-BRIT MED J, V317, P875, DOI 10.1136/bmj.317.7162.875; US Department of Health and Human Services. Food and Drug Administration, 1988, GUID FORM CONT CLIN; *WORLD MED ASS, 1985, SUMM HIST WORLD MED; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	40	584	598	1	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					455	463		10.7326/0003-4819-133-6-200009190-00014	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00014			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975964				2022-12-28	WOS:000089329700008
J	Vickers, A				Vickers, A			Recent advances - Complementary medicine	BRITISH MEDICAL JOURNAL			English	Review							CONTROLLED TRIALS; ACUPUNCTURE; ABC; HEALTH; BACK		Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Vickers, A (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.			Vickers, Andrew/0000-0003-1525-6503				[Anonymous], 1998, COMPLEMENT THER MED, V6, P211; Bhattacharya B, 2000, J Altern Complement Med, V6, P77, DOI 10.1089/acm.2000.6.77; *BRIT MED ASS BOAR, 2000, AC EFF SAF PRACT; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654; FRASER J, 1993, J ADV NURS, V18, P238, DOI 10.1046/j.1365-2648.1993.18020238.x; Grossman SA, 1999, ONCOLOGY-NY, V13, P33; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Haynes RB, 1999, BRIT MED J, V319, P1632; Inglis B., 1965, FRINGE MED; Koch ME, 1998, ANESTHESIOLOGY, V89, P300, DOI 10.1097/00000542-199808000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; LINDE K, 2000, COCHRANE LIB; Melchart D, 1999, CEPHALALGIA, V19, P779, DOI 10.1046/j.1468-2982.1999.1909779.x; Moerman D E, 2000, Adv Mind Body Med, V16, P33; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richards K C, 1998, Am J Crit Care, V7, P288; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Schrader E, 2000, INT CLIN PSYCHOPHARM, V15, P61, DOI 10.1097/00004850-200015020-00001; SMITH WP, 1995, J CLIN PSYCHOL, V51, P269; Vickers A, 1999, BRIT MED J, V319, P1176, DOI 10.1136/bmj.319.7218.1176; Vickers A, 1999, Complement Ther Med, V7, P3, DOI 10.1016/S0965-2299(99)80053-3; Vickers A. J., 1998, Complementary Therapies in Medicine, V6, P185, DOI 10.1016/S0965-2299(98)80026-5; Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602; VINCENT CA, 1989, CLIN J PAIN, V5, P305, DOI 10.1097/00002508-198912000-00006; WHITE AR, 2000, COCHRANE LIB; WILT T, 2000, COCHRANE LIB; Winter M J, 1994, J Post Anesth Nurs, V9, P340; WOOD C, 1993, J ROY SOC MED, V86, P254; Zollman C, 1999, BRIT MED J, V319, P693, DOI 10.1136/bmj.319.7211.693; Zollman C, 1999, BRIT MED J, V319, P901, DOI 10.1136/bmj.319.7214.901; 1980, BMJ, V280, P1; 1999, BMJ, V319, pR2	36	69	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					683	686		10.1136/bmj.321.7262.683	http://dx.doi.org/10.1136/bmj.321.7262.683			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987776	Green Published			2022-12-28	WOS:000089444100031
J	AbdAlla, S; Lother, H; Quitterer, U				AbdAlla, S; Lother, H; Quitterer, U			AT(1)-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration	NATURE			English	Article							BRADYKININ B2 RECEPTOR; B-2 RECEPTOR; INTERNALIZATION; OVEREXPRESSION; DIMERIZATION; MECHANISMS; TERMINUS; BINDING; SYSTEM	The vasopressor angiotensin II regulates vascular contractility and blood pressure through binding to type 1 angiotensin II receptors (AT(1); refs 1, 2). Bradykinin, a vasodepressor, is a functional antagonist of angiotensin II (ref. 3). The two hormone systems are interconnected by the angiotensin-converting enzyme, which releases angiotensin II from its precursor and inactivates the vasodepressor bradykinin(4). Here we show that the AT(1) receptor and the bradykinin (B-2) receptor also communicate directly with each other. They form stable heterodimers, causing increased activation of G alpha(q) and G alpha(i) proteins, the two major signalling proteins triggered by AT(1). Furthermore, the endocytotic pathway of both receptors changed with heterodimerization. This is the first example of signal enhancement triggered by heterodimerization of two different vasoactive hormone receptors.	Inst Pharmakol, D-97078 Wurzburg, Germany; Heinrich Pette Inst, D-20251 Hamburg, Germany; Genet Engn & Biotechnol Res Inst, Alexandria, Egypt	University of Wurzburg; Heinrich Pette Institute	Quitterer, U (corresponding author), Inst Pharmakol, Versbacher Str 9, D-97078 Wurzburg, Germany.	toph029@rzbox.uni-wuerzburg.de						AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 1996, J BIOL CHEM, V271, P27382, DOI 10.1074/jbc.271.44.27382; BASCANDS JL, 1994, AM J PHYSIOL-RENAL, V267, pF871, DOI 10.1152/ajprenal.1994.267.5.F871; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; MACEWAN DJ, 1995, MOL PHARMACOL, V48, P316; Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885; Mastro R, 1999, ANAL BIOCHEM, V273, P313, DOI 10.1006/abio.1999.4224; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; PARRATT JR, 1994, TRENDS PHARMACOL SCI, V15, P19, DOI 10.1016/0165-6147(94)90129-5; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Tsuchida S, 1999, KIDNEY INT, V56, P509, DOI 10.1046/j.1523-1755.1999.00574.x; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhuo JL, 1998, KIDNEY INT, V54, pS22, DOI 10.1046/j.1523-1755.1998.06705.x	28	389	408	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					94	98		10.1038/35024095	http://dx.doi.org/10.1038/35024095			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993080				2022-12-28	WOS:000089124000049
J	Woelk, H				Woelk, H		Remotiv Imipramine Study Grp	Comparison of St John's wort and imipramine for treating depression: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODERATE DEPRESSION; CLINICAL-TRIALS; EXTRACT; MULTICENTER; PLACEBO; LI-160	Objectives To compare the efficacy and tolerability of Hypericum perforatum (St John's wort extract) with imipramine in patients with mild to moderate depression. Design Randomised, multicentre, double blind, parallel group trial. Setting 40 outpatient clinics in Germany. Participants 324 outpatients with mild to moderate depression. Intervention 75 mg imipramine twice daily or 250 mg hypericum extract ZE 117 twice daily for 6 weeks. Main outcome measures Hamilton depression rating scale, clinical global impression scale, and patient's global impression scale. Results Among the 157 participants taking hypericum mean scores on the Hamilton depression scale decreased from 22.4 at baseline to 12.00 at end point; among the 167 participants taking imipramine they fell from 22.1 to 12.75. Mean clinical global impression scores at end point were 2.22 out of 7 for the hypericum group and 2.42 for the imipramine group. On the 7 point self assessments of global improvement completed by participants (score of 1 indicating "very much improved" and 7 indicating "very much deteriorated") mean scores were 2.44 in the hypericum group and 2.60 in the imipramine group. None of the differences between treatment groups were significant However, the mean score on the anxiety-somatisation subscale of the Hamilton scale (3.79 in the hypericum group and 4.26 in the imipramine group) indicated a significant advantage for hypericum relative to imipramine. Mean scores on the 5 point scale used by participants to assess tolerability (score of 1 indicating excellent tolerability and 5 indicating very poor tolerability) were better for hypericum (1.67) than imipramine (2.35). Adverse events occurred in 62/157 (39%) participants taking hypericum and in 105/167 (63%) taking imipramine. 4 (3%) participants taking hypericum withdraw because of adverse events compared with 26 (16%) taking imipramine. Conclusions This Hypericum perforatum extract is therapeutically equivalent to imipramine in treating mild to moderate depression, but patients tolerate hypericum better.	Univ Giessen, Akad Lehrkrankenhaus, Klin Psychiat & Psychotherapie, D-35394 Giessen, Germany	Justus Liebig University Giessen	Woelk, H (corresponding author), Univ Giessen, Akad Lehrkrankenhaus, Klin Psychiat & Psychotherapie, Licher Str 106, D-35394 Giessen, Germany.							ANGST J, 1989, PHARMACOPSYCHIATRY, V22, P3, DOI 10.1055/s-2007-1014568; *COMM PROP MED PRO, 1997, NOT GUID GOOD CLIN P; Commission Nationale de Pharmacopee France [French Pharmacopoeia Commission], 1982, PHARM FRANC; DeSmet PAGM, 1996, BMJ-BRIT MED J, V313, P241, DOI 10.1136/bmj.313.7052.241; Ernst E, 1995, Fortschr Med, V113, P354; *EUR UN, 1996, GOOD CLIN PRACT CLIN, V3, P115; FERNIE WT, 1997, HERBAL SIMPLES; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HANSGEN KD, 1998, J GERIAT PSYCHIAT S1, V7; HARRER G, 1994, J GERIAT PSYCHIAT S1, V7; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; *KOMM DTSCH ARZN C, 1986, JOH HYP HERB; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Nebel A, 1999, ANN PHARMACOTHER, V33, P502, DOI 10.1345/aph.18252; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; PICKERING C, 1979, CHRONOLOGICAL HIST P; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; PRATT A, 1953, WILD FLOWERS; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Schrader E, 1998, HUM PSYCHOPHARM CLIN, V13, P163, DOI 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.3.CO;2-9; Vorbach E U, 1994, J Geriatr Psychiatry Neurol, V7 Suppl 1, pS19, DOI 10.1177/089198879400700107; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; Witte B, 1995, Fortschr Med, V113, P404	27	182	189	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					536	539		10.1136/bmj.321.7260.536	http://dx.doi.org/10.1136/bmj.321.7260.536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968813	Bronze, Green Published			2022-12-28	WOS:000089174100017
J	Kingon, AI; Maria, JP; Streiffer, SK				Kingon, AI; Maria, JP; Streiffer, SK			Alternative dielectrics to silicon dioxide for memory and logic devices	NATURE			English	Review							BA0.7SR0.3TIO3 THIN-FILMS; CHEMICAL-VAPOR-DEPOSITION; OXIDES; RELAXATION; CERAMICS	The silicon-based microelectronics industry is rapidly approaching a point where device fabrication can no longer be simply scaled to progressively smaller sizes. Technological decisions must now be made that will substantially alter the directions along which silicon devices continue to develop. One such challenge is the need for higher permittivity dielectrics to replace silicon dioxide, the properties of which have hitherto been instrumental to the industry's success. Considerable efforts have already been made to develop replacement dielectrics for dynamic random-access memories. These developments serve to illustrate the magnitude of the now urgent problem of identifying alternatives to silicon dioxide for the gate dielectric in logic devices, such as the ubiquitous field-effect transistor.	N Carolina State Univ, Dept Mat Sci & Engn, Raleigh, NC 27695 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA	University of North Carolina; North Carolina State University; United States Department of Energy (DOE); Argonne National Laboratory	Kingon, AI (corresponding author), N Carolina State Univ, Dept Mat Sci & Engn, Raleigh, NC 27695 USA.	angus_kingon@ncsu.edu	Streiffer, Stephen K/A-1756-2009; Kingon, Angus/AAE-5842-2021					Alers GB, 1998, APPL PHYS LETT, V73, P1517, DOI 10.1063/1.122191; Baniecki JD, 1998, APPL PHYS LETT, V72, P498, DOI 10.1063/1.120796; Basceri C, 1997, J APPL PHYS, V82, P2497, DOI 10.1063/1.366062; BASCERI C, 1997, THESIS N CAROLINA ST; Bilodeau SM, 1997, SOLID STATE TECHNOL, V40, P235; BUSKIRK P, 1998, INTEGR FERROELECTR, V21, P273; Campbell SA, 1997, IEEE T ELECTRON DEV, V44, P104, DOI 10.1109/16.554800; CHENG YC, 1973, J APPL PHYS, V44, P923, DOI 10.1063/1.1662292; Copel M, 2000, APPL PHYS LETT, V76, P436, DOI 10.1063/1.125779; Eisenbeiser K, 2000, APPL PHYS LETT, V76, P1324, DOI 10.1063/1.126023; Fazan P. C., 1994, Integrated Ferroelectrics, V4, P247, DOI 10.1080/10584589408017028; FAZAN PC, 1992, IEEE ELECTR DEVICE L, V13, P86, DOI 10.1109/55.144967; Grossmann M, 1998, INTEGR FERROELECTR, V22, P603; Gusev EP, 2000, APPL PHYS LETT, V76, P176, DOI 10.1063/1.125694; Hergenrother J. M., 1999, International Electron Devices Meeting 1999. Technical Digest (Cat. No.99CH36318), P75, DOI 10.1109/IEDM.1999.823850; Hilton AD, 1996, J PHYS D APPL PHYS, V29, P1321, DOI 10.1088/0022-3727/29/5/028; Hirose M, 2000, SEMICOND SCI TECH, V15, P485, DOI 10.1088/0268-1242/15/5/308; HORIKAWA T, 1995, JPN J APPL PHYS 1, V34, P5478, DOI 10.1143/JJAP.34.5478; Hubbard KJ, 1996, J MATER RES, V11, P2757, DOI 10.1557/JMR.1996.0350; IWLK GD, 2000, J APPL PHYS, V87, P484; Kingon AI, 1996, MRS BULL, V21, P46, DOI 10.1557/S0883769400035910; Kotecki DE, 1999, IBM J RES DEV, V43, P367, DOI 10.1147/rd.433.0367; Kotecki DE, 1997, INTEGR FERROELECTR, V16, P1, DOI 10.1080/10584589708013025; LASH SE, 1999, THESIS N CAROLINA ST; Lo SH, 1997, IEEE ELECTR DEVICE L, V18, P209, DOI 10.1109/55.568766; Luan H. F., 1999, International Electron Devices Meeting 1999. Technical Digest (Cat. No.99CH36318), P141, DOI 10.1109/IEDM.1999.823865; MATSUBARA S, 1990, MATER RES SOC SYMP P, V200, P243, DOI 10.1557/PROC-200-243; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; Moore G. E., 1965, IEDM, V38, P11; Muller DA, 1999, NATURE, V399, P758, DOI 10.1038/21602; SCHLOM DG, IN PRESS APPL PHYS A; Semiconductor Industry Association, 1999, INT TECHN ROADM SEM; SHANNON RD, 1993, J APPL PHYS, V73, P348, DOI 10.1063/1.353856; Streiffer SK, 1999, J APPL PHYS, V86, P4565, DOI 10.1063/1.371404; Summerfelt Sr, 1997, ELECTR MAT SCI TECHN, V3, P1; Wilk GD, 1999, APPL PHYS LETT, V74, P2854, DOI 10.1063/1.124036; Wu EY, 2000, SEMICOND SCI TECH, V15, P425, DOI 10.1088/0268-1242/15/5/301	37	1100	1151	14	214	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					1032	1038		10.1038/35023243	http://dx.doi.org/10.1038/35023243			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984062				2022-12-28	WOS:000089020200055
J	Rosin-Arbesfeld, R; Townsley, F; Bienz, M				Rosin-Arbesfeld, R; Townsley, F; Bienz, M			The APC tumour suppressor has a nuclear export function	NATURE			English	Article							POLYPOSIS-COLI PROTEIN; BETA-CATENIN; ADENOMATOUS POLYPOSIS; SOMATIC MUTATION; SIGNAL; CRM1; GENE; ASSOCIATION; ACTIVATION; GSK3-BETA	The adenomatous polpyposis coli (APC) protein is mutated in most colorectal tumours(1). Nearly all APC mutations are truncations, and many of these terminate in the mutation cluster region located halfway through the protein(2-4). In cancer cells expressing mutant APC, beta-catenin is stabilized(5,6) and translocates into the nucleus to act as a transcriptional co-activator of T-cell factor(7). During normal development, APC also promotes the destabilization of beta-catenin and Drosophila Armadillo(8-11). It does so by binding to the Axin complex which earmarks beta-catenin/Armadillo for degradation by the proteasome pathway(12). APC has a regulatory role in this process(13,14), which is poorly understood. Here we show that APC contains highly conserved nuclear export signals 3' adjacent to the mutation cluster region that enable it to exit from the nucleus. This ability is lost in APC mutant cancer cells, and we provide evidence that beta-catenin accumulates in the nucleus as a result. Thus, the ability of APC to exit from the nucleus appears to be critical for its tumour suppressor function.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hamada F, 1999, GENES CELLS, V4, P465, DOI 10.1046/j.1365-2443.1999.00272.x; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lal G, 2000, SEMIN SURG ONCOL, V18, P314; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Lantz VA, 1999, MECH DEVELOP, V85, P111, DOI 10.1016/S0925-4773(99)00096-9; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; MIYAKI M, 1994, CANCER RES, V54, P3011; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, CANCER RES, V57, P4624; Shih IM, 2000, CANCER RES, V60, P1671; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064	30	283	289	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					1009	1012		10.1038/35023016	http://dx.doi.org/10.1038/35023016			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984057				2022-12-28	WOS:000089020200049
J	Webster, GJM; Hallett, R; Whalley, SA; Meltzer, M; Balogun, K; Brown, D; Farrington, CP; Sharma, S; Hamilton, G; Farrow, SC; Ramsay, ME; Teo, CG; Dusheiko, GM				Webster, GJM; Hallett, R; Whalley, SA; Meltzer, M; Balogun, K; Brown, D; Farrington, CP; Sharma, S; Hamilton, G; Farrow, SC; Ramsay, ME; Teo, CG; Dusheiko, GM			Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; HEALTH-CARE; C VIRUS; TRANSMISSION; MEDICINE; ENGLAND; WALES; DNA	Background Unregulated skin-piercing procedures potentially facilitate the transmission of bloodborne pathogens. In February, 1998, a patient who had recently received autohaemotherapy at an alternative medicine clinic in the UK was diagnosed with acute hepatitis B. The autohaemotherapy procedure involved the drawing of 1 mL of the patient's blood, mixing with saline, and reinjection of the autologous blood mixture. We investigated the extent of hepatitis B virus (HBV) infection in patients and staff of the clinic. Methods Patients who had attended the clinic between January, 1997, and February, 1998, were tested for serological markers of HBV, and for HBV DNA by PCR. HBV DNA was sequenced to assess the relatedness of the virus identified in the cases. We analysed the number and dates of visits with regard to HBV status. Findings Serum samples were received from 352 patients and four staff members. Serological evidence of exposure to HBV was found in 57 (16%). Of the 33 patients and staff who were positive for hepatitis B surface antigen, 30 (91%) showed complete nucleotide identity in the DNA segments derived from the surface and core genes. Five patients with linked infection had markers of chronic hepatitis B, and one of these was regarded as the likely source of the outbreak. The attack rate was associated with the number of visits (p<0.0001) and the week of visit (p=0.011). Contaminated saline in a repeatedly used bottle was the probable vehicle of transmission. Interpretation We have described a large community-based outbreak of hepatitis B due to transmission by a single HBV variant. Our findings emphasise the continuing risk of transmission of bloodborne viruses in all health-care settings where skin-piercing procedures are used.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Hepatol, London NW3 2PF, England; Publ Hlth Lab Serv, Hepatitis & Retrovirus Lab, London, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Barnet Hlth Author, London, England	University of London; University College London; UCL Medical School; Public Health England; Public Health England	Dusheiko, GM (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Hepatol, Royal Free Campus, London NW3 2PF, England.	g.dusheiko@rfc.ucl.ac.uk	Dusheiko, Geoffrey M/C-7677-2010; Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640; Farrington, Conor Patrick/0000-0002-7148-2612				ALTER MJ, 1983, ANN INTERN MED, V99, P33; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Balogun MA, 1999, EPIDEMIOL INFECT, V122, P125, DOI 10.1017/S0950268898001733; Bocci V, 1998, PERSPECT BIOL MED, V42, P131; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BOXALL EH, 1978, J MED VIROL, V2, P377, DOI 10.1002/jmv.1890020411; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; *CDCP, 1996, 56 CDCP, P36; Daschner FD, 1997, EUR J CLIN MICROBIOL, V16, P620, DOI 10.1007/BF02447930; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Gabriel C, 1996, LANCET, V347, P541, DOI 10.1016/S0140-6736(96)91171-X; Harris KA, 1999, J MED VIROL, V58, P127, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt;127::AID-JMV5&gt;3.0.CO;2-K; Heptonstall J, 1997, NEW ENGL J MED, V336, P178, DOI 10.1056/NEJM199701163360304; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; LIMENTANI AE, 1979, LANCET, V2, P86; NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341; Olwin J H, 1997, J Altern Complement Med, V3, P155, DOI 10.1089/acm.1997.3.155; PETROSILLO N, 1995, J HOSP INFECT, V30, P273, DOI 10.1016/0195-6701(95)90262-7; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; STRYKER WS, 1986, J FAM PRACTICE, V22, P155; TEDDER RS, 1995, LANCET, V346, P137, DOI 10.1016/S0140-6736(95)91207-X; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; *UK HLTH DEP, 1996, IMM INF DIS 1996; *UK HLTH DEP, 1993, PROT HLTH CAR WORK P; YUSOF JHM, 1994, J INFECT DIS, V169, P62, DOI 10.1093/infdis/169.1.62	27	37	38	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2000	356	9227					379	384		10.1016/S0140-6736(00)02529-0	http://dx.doi.org/10.1016/S0140-6736(00)02529-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972370				2022-12-28	WOS:000088486000010
J	West, R				West, R			Adjustment for potential confounders may have been taken too far - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	West, R (corresponding author), Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales.							BARKER DJP, 1989, LANCET, V2, P577; CHALMERS I., 1978, Hlth Trends, V10, P24; D'Arcy Hart P, 1939, TUBERCULOSIS SOCIAL; Rothman K, 1986, MODERN EPIDEMIOLOGY; WEST R R, 1988, International Journal of Epidemiology, V17, P392, DOI 10.1093/ije/17.2.392	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 22	2000	321	7255					213	213						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338XG	10979671				2022-12-28	WOS:000088448100022
J	Payne, DNR; Lincoln, C; Bush, A				Payne, DNR; Lincoln, C; Bush, A			Lesson of the week - Right sided aortic arch in children with persistent respiratory symptoms	BRITISH MEDICAL JOURNAL			English	Review									Royal Brompton & Harefield NHS Trust, Dept Paediat Resp Med, London SW3 6NP, England; Royal Brompton & Harefield NHS Trust, Dept Cardiothorac Surg, London SW3 6NP, England	Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Bush, A (corresponding author), Royal Brompton & Harefield NHS Trust, Dept Paediat Resp Med, London SW3 6NP, England.							Balfour-Lynn I, 1999, ARCH DIS CHILD, V80, P201, DOI 10.1136/adc.80.2.201; FELSON B, 1963, RADIOLOGY, V81, P745, DOI 10.1148/81.5.745; FONTANA RS, 1962, CONGENITAL CARDIAC D; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; STEWART JR, 1966, AMER J ROENTGENOL RA, V97, P377, DOI 10.2214/ajr.97.2.377; West JB, 1995, RESP PHYSL ESSENTIAL	6	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					687	688		10.1136/bmj.321.7262.687	http://dx.doi.org/10.1136/bmj.321.7262.687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987777	Green Published			2022-12-28	WOS:000089444100032
J	Schindler, T; Bornmann, W; Pellicena, P; Miller, WT; Clarkson, B; Kuriyan, J				Schindler, T; Bornmann, W; Pellicena, P; Miller, WT; Clarkson, B; Kuriyan, J			Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase	SCIENCE			English	Article							CRYSTAL-STRUCTURE; C-ABL; INSULIN-RECEPTOR; COMPLEX; DOMAIN; SPECIFICITY; GROWTH	The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous Leukemia (CML), A small-molecule inhibitor of Abl (STI-571) is effective in the treatment of CML. We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571. Critic:al to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally Located "activation Loop" is not phosphorylated. The conformation of this Loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases, These results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029362] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BRASHER B, UNPUB; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchdunger E., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P559; BUCHDUNGER E, 1998, 89 ANN M AM ASS CANC; DOREY K, UNPUB; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p368A; DRUKER BJ, 1999, 41 ANN M AM SOC HEM; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zimmermann J, 1997, BIOORG MED CHEM LETT, V7, P187, DOI 10.1016/S0960-894X(96)00601-4	31	1492	1629	2	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1938	1942		10.1126/science.289.5486.1938	http://dx.doi.org/10.1126/science.289.5486.1938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988075				2022-12-28	WOS:000089355800047
J	Morrell, CJ; Spiby, H; Walters, S; Morgan, A				Morrell, CJ; Spiby, H; Walters, S; Morgan, A			Costs and effectiveness of community postnatal support workers: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL SUPPORT; HOME VISITATION; DEPRESSION	Objectives To establish the relative cost effectiveness of postnatal support in the community in addition to the usual care provided lay community midwives. Design Randomised controlled trial with six month follow up. Setting Recruitment in a university teaching hospital and care provided in women's homes. Participants 623 postnatal women allocated at random to intervention (311) or control (312) group. Intervention Up to 10 home visits in the first postnatal month of up to three hours duration by a community postnatal support worker. Main outcome measure General health status as measured by the SF-36 and risk of postnatal depression. Breast feeding rates, satisfaction with care, use of services, and personal costs. Results At six weeks there was no significant improvement in health status among the women in the intervention group. At six weeks the mean total NHS costs were pound 635 for the intervention group and pound 456 for the control group (P = 0.001). At six months figures were pound 815 and pound 639 (P = 0.001). There were no differences between the groups in use of social services or personal costs. The women in the intervention group were very satisfied with the support worker visits. Conclusions There was no health benefit of additional home visits by community postnatal support workers compared with traditional community midwifery visiting as measured by the SF-36. There were no savings to the NHS over six months after the introduction of the community postnatal support worker service.	Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Sch Hlth & Related Res, Sheffield Hlth Econ Grp, Sheffield S1 4DA, S Yorkshire, England	University of Sheffield; Northern General Hospital; University of Sheffield	Morrell, CJ (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Med Care Res Unit, Sheffield S1 4DA, S Yorkshire, England.			Walters, Stephen/0000-0001-9000-8126				[Anonymous], 1997, UNIT COSTS HLTH SOCI; [Anonymous], 1995, BR J MIDWIFE; Audit Commission, 1997, 1 CLASS DEL IMPR MAT; BRAZIER E, 1992, BRIT MED J, V306, P1407; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; Cohen S, 1985, SOCIAL SUPPORT HLTH; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Dennis M, 1997, BRIT MED J, V314, P1071, DOI 10.1136/bmj.314.7087.1071; Drummond MF, 2015, METHODS EC EVALUATIO; Efron B., 1994, MONOGRAPHS STAT APPL; ELBOURNE D, 1989, EFFECTIVE CARE PREGN, P221; Glazener CM, 1993, CONT REV OBSTET GYNA, V5, P130; Houston M J, 1981, Health Bull (Edinb), V39, P166; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; KUMAR R, 1995, BR J MIDWIFERY, V3, P314; MATICH JR, 1992, SOC SCI MED, V34, P919; MONTGOMERY E, 1994, MIDWIFERY, V5, P9; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; OAKLEY H, 1996, J REPROD INFANT PSYC, V14, P7; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; RAY KL, 2000, COCHRANE LIB; SPIBY H, 1999, RCM MIDWIVES J, V2, P20; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	24	144	146	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					593	598		10.1136/bmj.321.7261.593	http://dx.doi.org/10.1136/bmj.321.7261.593			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	352WW	10977833	Green Published, Bronze			2022-12-28	WOS:000089243200017
J	Pimenta, J; Catchpole, M; Gray, M; Hopwood, J; Randall, S				Pimenta, J; Catchpole, M; Gray, M; Hopwood, J; Randall, S			Evidence based health policy report - Screening for genital chlamydial infection	BRITISH MEDICAL JOURNAL			English	Article							TRACHOMATIS		Publ Hlth Lab Serv, London NW9 5EQ, England; Inst Hlth Sci, Natl Screening Comm, Oxford OX3 7LF, England; St Catherines Hosp, Evidence Based Practice Ctr, Birkenhead L42 0LQ, Merseyside, England; St Marys Hosp, Ella Gordon Unit, Portsmouth PO3 6AD, Hants, England	Public Health England; University of Oxford; University of Liverpool	Pimenta, J (corresponding author), Publ Hlth Lab Serv, London NW9 5EQ, England.							ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; Boag F, 1998, BMJ-BRIT MED J, V316, P1474, DOI 10.1136/bmj.316.7143.1474; Chief Medical Officers Expert Advisory Group, 1998, MAIN REP CMOS EXP AD; *DEP HLTH, 1999, 1 EV GOV STRAT SEX H; *DEP HLTH, 1999, SEX HLTH STRAT PROF; Duncan B, 1999, BRIT MED J, V318, P931, DOI 10.1136/bmj.318.7188.931; HERRMANN BF, 1991, SEX TRANSM DIS, V18, P233, DOI 10.1097/00007435-199110000-00007; Johnson AM, 1994, SEXUAL ATTITUDES LIF; LAMAGNI T, 1999, COMMUN DIS REP S, V8, pS1; Macleod J, 1999, BRIT MED J, V319, P188, DOI 10.1136/bmj.319.7203.188b; *NAT OP POLLS SOC, 1999, JN430458 NOP SOC POL; *NAT SCREEN COMM, 1998, 1 HLTH DEP UK NAT SC; Nicoll A, 1999, BRIT MED J, V318, P1321, DOI 10.1136/bmj.318.7194.1321; RENTON A, 1994, NEED ASSESSMENT HLTH; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; TURNER H, 1998, MAIN REPORT CMOS EXP, pCH11; van den Hoek J A, 1999, Ned Tijdschr Geneeskd, V143, P668; YORKE JA, 1978, SEX TRANSM DIS, V5, P51, DOI 10.1097/00007435-197804000-00003	18	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					629	631		10.1136/bmj.321.7261.629	http://dx.doi.org/10.1136/bmj.321.7261.629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977848	Green Published			2022-12-28	WOS:000089243200032
J	Liu, ZY; Zhang, XX; Mao, YW; Zhu, YY; Yang, ZY; Chan, CT; Sheng, P				Liu, ZY; Zhang, XX; Mao, YW; Zhu, YY; Yang, ZY; Chan, CT; Sheng, P			Locally resonant sonic materials	SCIENCE			English	Article							BAND-STRUCTURE; COMPOSITES	We have fabricated sonic crystals, based on the idea of Localized resonant structures, that exhibit spectral gaps with a Lattice constant two orders of magnitude smaller than the relevant wavelength. Disordered composites made from such localized resonant structures behave as a material with effective negative elastic constants and a total wave reflector within certain tunable sonic frequency ranges. A 2-centimeter slab of this composite material is shown to break the conventional mass-density Law of sound transmission by one or more orders of magnitude at 400 hertz.	Hong Kong Univ Sci & Technol, Dept Phys, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Sheng, P (corresponding author), Hong Kong Univ Sci & Technol, Dept Phys, Kowloon, Hong Kong, Peoples R China.		Sheng, Ping/I-3733-2013; Zhang, xixiang/D-7046-2011	Sheng, Ping/0000-0001-9000-6366; Zhang, xixiang/0000-0002-3478-6414; Yang, Zhi Yu/0000-0003-3405-3015; Chan, Che Ting/0000-0002-9335-8110				Bousse L., 1996, Technical Digest. Solid-State Sensor and Actuator Workshop, P272; Brekhovskikh L. M., 1980, WAVES LAYERED MEDIA; Jackson J., 1975, CLASSICAL ELECTRODYN; JOANNOPOULOUS JD, 1995, PHOTONIC CRYSTALS; KAFESAKI M, 1995, PHYS REV B, V52, P13317, DOI 10.1103/PhysRevB.52.13317; Kafesaki M, 1999, PHYS REV B, V60, P11993, DOI 10.1103/PhysRevB.60.11993; KAFESAKI M, 1995, SOLID STATE COMMUN, V96, P285, DOI 10.1016/0038-1098(95)00444-0; KUSHWAHA MS, 1993, PHYS REV LETT, V71, P2022, DOI 10.1103/PhysRevLett.71.2022; Liu ZY, 2000, PHYS REV B, V62, P2446, DOI 10.1103/PhysRevB.62.2446; MARTINEZSALA R, 1995, NATURE, V378, P241, DOI 10.1038/378241a0; Psarobas IE, 2000, PHYS REV B, V62, P278, DOI 10.1103/PhysRevB.62.278	11	3349	3578	178	1113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1734	1736		10.1126/science.289.5485.1734	http://dx.doi.org/10.1126/science.289.5485.1734			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976063				2022-12-28	WOS:000089195200041
J	Foca, M; Jakob, K; Whittier, S; Della Latta, P; Factor, S; Rubenstein, D; Saiman, L				Foca, M; Jakob, K; Whittier, S; Della Latta, P; Factor, S; Rubenstein, D; Saiman, L			Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NOSOCOMIAL INFECTIONS; EPIDEMIOLOGY; RESERVOIRS; PERSONNEL; INFANTS; HANDS	Background Nosocomial infections due to Pseudomonas aeruginosa have been well described, but the environmental reservoir of the organism varies. We conducted an epidemiologic and molecular investigation of endemic P. aeruginosa infection among infants in a neonatal intensive care unit that was associated with carriage of the organisms on the hands of health care workers. Methods In August 1998, colonization or infection with P. aeruginosa was identified in six infants. Surveillance cultures for P. aeruginosa were obtained from the other 27 infants in the unit, and possible environmental reservoirs were also assessed. The hands of health care workers were inspected and cultured, and risk factors for P. aeruginosa colonization were evaluated. Isolates were analyzed for clonality by pulsed-field gel electrophoresis. Results Surveillance cultures showed that three additional infants were colonized with P. aeruginosa. Cultures of environmental specimens were negative, but cultures of the hands of 10 of 165 health care workers (6 percent) were positive for P. aeruginosa. Increasing age (P=0.05) and a history of the use of artificial fingernails or nail wraps (P=0.03) were both risk factors for colonization of the hands. From January 1997 to August 1998, 49 infants were infected or colonized with P. aeruginosa. Pulsed-field gel electrophoresis demonstrated that 17 of these infants and 1 health care worker who had onychomycosis had the same clone. Infants who were exposed to this health care worker in August 1998 were at greater risk of having this clone than infants who were not exposed to this health care worker (odds ratio, 41.2; 95 percent confidence interval, 1.8 to 940.0; P=0.006). Conclusions An increased rate of infection and colonization with P. aeruginosa among infants in neonatal intensive care units should be investigated by assessing potential reservoirs, including environmental sources as well as patients and health care workers. (N Engl J Med 2000; 343: 695-700.) (C) 2000, Massachusetts Medical Society.	New York Presbyterian Hosp, Dept Pediat, Div Infect Dis, New York, NY 10021 USA; New York Presbyterian Hosp, Dept Pediat, Div Neonatol, New York, NY USA; New York Presbyterian Hosp, Dept Hosp Epidemiol, New York, NY USA; New York Presbyterian Hosp, Dept Pathol, New York, NY USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA	NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Foca, M (corresponding author), New York Presbyterian Hosp, Dept Pediat, Div Infect Dis, New York, NY 10021 USA.		Factor, Stephanie H/C-7182-2009	Factor, Stephanie H/0000-0003-0125-8639				ADAMS BG, 1982, J HYG-CAMBRIDGE, V89, P33, DOI 10.1017/S0022172400070510; ADAMS BG, 1992, J HYG LOND, V89, P23; ASAY LD, 1960, NEW ENGL J MED, V262, P1062, DOI 10.1056/NEJM196005262622104; BROWN DG, 1977, J PEDIATR-US, V90, P453, DOI 10.1016/S0022-3476(77)80715-4; Cordero L, 1999, INFECT CONT HOSP EP, V20, P242, DOI 10.1086/501619; FIERER J, 1967, NEW ENGL J MED, V276, P991, DOI 10.1056/NEJM196705042761801; Gaynes RP, 1996, PEDIATRICS, V98, P357; GRUNDMANN H, 1993, J INFECT DIS, V168, P943, DOI 10.1093/infdis/168.4.943; GUPTA AK, 1993, J TROP PEDIATRICS, V39, P32, DOI 10.1093/tropej/39.1.32; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P47; JELLARD CH, 1967, J HYG-CAMB, V65, P219, DOI 10.1017/S0022172400045708; Knights H T, 1968, N Z Med J, V67, P617; KNITTLE MA, 1975, J PEDIATR-US, V86, P433, DOI 10.1016/S0022-3476(75)80980-2; Larson EL, 1998, AM J INFECT CONTROL, V26, P513, DOI 10.1016/S0196-6553(98)70025-2; LEIGH L, 1995, PEDIATR INFECT DIS J, V14, P367, DOI 10.1097/00006454-199505000-00006; Moolenaar RL, 2000, INFECT CONT HOSP EP, V21, P80, DOI 10.1086/501739; POTTINGER J, 1989, AM J INFECT CONTROL, V17, P340, DOI 10.1016/0196-6553(89)90003-5; Shah SS, 1998, PEDIATR INFECT DIS J, V17, P97, DOI 10.1097/00006454-199802000-00004; Speijer H, 1999, J CLIN MICROBIOL, V37, P3654, DOI 10.1128/JCM.37.11.3654-3661.1999; Talon D, 1996, J HOSP INFECT, V32, P135, DOI 10.1016/S0195-6701(96)90055-9; USOWICZ AG, 1988, EARLY HUM DEV, V16, P27, DOI 10.1016/0378-3782(88)90084-9; WIDMER AF, 1993, CLIN INFECT DIS, V16, P372, DOI 10.1093/clind/16.3.372	22	139	148	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					695	700		10.1056/NEJM200009073431004	http://dx.doi.org/10.1056/NEJM200009073431004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974133				2022-12-28	WOS:000089100500004
J	Shifren, JL; Braunstein, GD; Simon, JA; Casson, PR; Buster, JE; Redmond, GP; Burki, RE; Ginsburg, ES; Rosen, RC; Leiblum, SR; Caramelli, KE; Mazer, NA; Jones, KP; Daugherty, CA				Shifren, JL; Braunstein, GD; Simon, JA; Casson, PR; Buster, JE; Redmond, GP; Burki, RE; Ginsburg, ES; Rosen, RC; Leiblum, SR; Caramelli, KE; Mazer, NA; Jones, KP; Daugherty, CA			Transdermal testosterone treatment in women with impaired sexual function after oophorectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; MENOPAUSAL WOMEN; ANDROGEN; LIFE	Background The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause. Methods Seventy-five women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day orally) and, in random order, placebo, 150 mu g of testosterone, and 300 mu g of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone. Results The mean (+/- SD) serum free testosterone concentration increased from 1.2 +/- 0.8 pg per milliliter (4.2 +/- 2.8 pmol per liter) during placebo treatment to 3.9 +/- 2.4 pg per milliliter (13.5 +/- 8.3 pmol per liter) and 5.9 +/- 4.8 pg per milliliter (20.5 +/- 16.6 pmol per liter) during treatment with 150 and 300 mu g of testosterone per day respectively (normal range, 1.3 to 6.8 pg per milliliter [4.5 to 23.6 pmol per liter]). Despite an appreciable placebo response, the higher testosterone dose resulted in further increases in scores for frequency of sexual activity and pleasure orgasm in the Brief Index of Sexual Functioning for Women (P = 0.03 for both comparisons with placebo). At the higher dose, the percentages of women who had sexual fantasies masturbated, or engaged in sexual intercourse at least once a week increased two to three times from base line. The positive-well-being, depressed-mood, and composite scores of the Psychological General Well-Being Index also improved at the higher dose (P = 0.04, P = 0.03, and P = 0.04, respectively, for the comparison with placebo), but the scores on the telephone-based diary did not increase significantly. Conclusions In women who have undergone oophorectomy and hysterectomy transdermal testosterone improves sexual function and psychological well-being. (N Engl J Med 2000; 343: 682-8.) (C) 2000, Massachusetts Medical Society.	Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Dept Obstet & Gynecol, Boston, MA 02114 USA; Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; Womens Hlth Res Ctr, Laurel, MD USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Fdn Dev Endocrinol, Cleveland, OH USA; Brigham & Womens Hosp, Ctr Reprod Med, Boston, MA 02115 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA; Watson Labs, Dept Clin Res, Salt Lake City, UT USA; Univ Utah, Med Ctr, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA; Abesta Corp, Salt Lake City, UT USA	Harvard University; Massachusetts General Hospital; Cedars Sinai Medical Center; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Utah System of Higher Education; University of Utah	Shifren, JL (corresponding author), Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Dept Obstet & Gynecol, VBK-113, Boston, MA 02114 USA.		Mazer, Norman A/HGU-8266-2022					ABRAMOVITCH RA, 1974, J ORG CHEM, V39, P340, DOI 10.1021/jo00917a013; Baird D T, 1969, Recent Prog Horm Res, V25, P611; BIRD CE, 1972, J CLIN ENDOCR METAB, V34, P467, DOI 10.1210/jcem-34-3-467; Chow S, 1992, DESIGN ANAL BIOAVAIL; DAVIS S, 1996, MATURITAS, V21, P227; Dupuy H.J., 1984, ASSESSMENT QUALITY L, P170; GEOLA FL, 1980, J CLIN ENDOCR METAB, V51, P620, DOI 10.1210/jcem-51-3-620; HUGHES CL, 1991, GYNECOL ONCOL, V40, P42, DOI 10.1016/0090-8258(91)90083-H; JUDD H L, 1976, Clinical Obstetrics and Gynecology, V19, P775, DOI 10.1097/00003081-197612000-00005; LORENZO EM, 1970, J CLIN ENDOCR METAB, V31, P556, DOI 10.1210/jcem-31-5-556; Mazer NA, 2000, J CONTROL RELEASE, V65, P303, DOI 10.1016/S0168-3659(99)00252-7; Mazer NA, 2000, MENOPAUSE, V7, P350, DOI 10.1097/00042192-200007050-00009; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; Miller K, 1998, J CLIN ENDOCR METAB, V83, P2717, DOI 10.1210/jc.83.8.2717; MISHELL DR, 1989, AM J OBSTET GYNECOL, V161, P1825, DOI 10.1016/S0002-9378(89)80001-8; Morrison DM, 1999, J SEX RES, V36, P76, DOI 10.1080/00224499909551970; NATHORSTBOOS J, 1993, J PSYCHOSOM OBST GYN, V14, P283; NATHORSTBOOS J, 1992, GYNECOL OBSTET INVES, V34, P97, DOI 10.1159/000292735; PALATSI R, 1984, ACTA DERM-VENEREOL, V64, P517; SHERWIN BB, 1985, PSYCHOSOM MED, V47, P339, DOI 10.1097/00006842-198507000-00004; SHERWIN BB, 1987, PSYCHOSOM MED, V49, P397, DOI 10.1097/00006842-198707000-00009; Shifren JL, 1998, MENOPAUSE, V5, P189; SOUTHREN AL, 1968, J CLIN ENDOCR METAB, V28, P1105, DOI 10.1210/jcem-28-8-1105; TAYLOR JF, 1994, ARCH SEX BEHAV, V23, P627, DOI 10.1007/BF01541816; WIKLUND I, 1992, MATURITAS, V14, P225, DOI 10.1016/0378-5122(92)90117-M	25	627	656	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					682	688		10.1056/NEJM200009073431002	http://dx.doi.org/10.1056/NEJM200009073431002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	350KU	10974131	Bronze			2022-12-28	WOS:000089100500002
J	Mao, L; Begum, D; Chuang, HW; Budiman, MA; Szymkowiak, EJ; Irish, EE; Wing, RA				Mao, L; Begum, D; Chuang, HW; Budiman, MA; Szymkowiak, EJ; Irish, EE; Wing, RA			JOINTLESS is a MADS-box gene controlling tomato flower abscission zone development	NATURE			English	Article							MAP-BASED CLONING; TRANSCRIPTION FACTORS; MODEL SYSTEM; CROP PLANTS; ANTIRRHINUM; ARABIDOPSIS; HOMOLOGY	Abscission is a universal and dynamic process in plants whereby organs such as leaves, flowers and fruit are shed, both during normal development, and in response to tissue damage and stress(1). Shedding occurs by separation of cells in anatomically distinct regions of the plant, called abscission zones (AZs). During abscission, the plant hormone ethylene stimulates cells to produce enzymes that degrade the middle lamella between cells in the AZ. The physiology and regulation of abscission at fully developed AZs is well known(2,3), but the molecular biology underlying their development is not. Here we report the first isolation of a gene directly involved in the development of a functional plant AZ. Tomato plants with the jointless mutation(4) fail to develop AZs on their pedicels and so abscission of flowers or fruit does not occur normally. We identify JOINTLESS as a new MADS-box gene in a distinct phylogenetic clade separate from those functioning in floral organs. We propose that a deletion in JOINTLESS accounts for the failure of activation of pedicel AZ development in jointless tomato plants.	Clemson Univ, Genome Inst, Clemson, SC 29634 USA; Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	Clemson University; University of Iowa	Wing, RA (corresponding author), Clemson Univ, Genome Inst, 100 Jordan Hall, Clemson, SC 29634 USA.		Wing, Rod A/Z-2885-2019; Irish, Erin/C-7331-2016	Wing, Rod A/0000-0001-6633-6226; Irish, Erin/0000-0003-4244-7938				Addicott F.T, 1982, ABSCISSION; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTHONY RG, 1995, PLANT PHYSIOL, V108, P441, DOI 10.1104/pp.108.1.441; Bernatzky R., 1986, PLANT MOL BIOL REP, V4, P37, DOI [10.1007/BF02672487, DOI 10.1007/BF02672487]; Bleecker AB, 1997, PLANT CELL, V9, P1169, DOI 10.1105/tpc.9.7.1169; Budiman MA, 2000, GENOME RES, V10, P129; BUTLER L, 1936, J HERED, V37, P25; Carmona MJ, 1998, PLANTA, V207, P181, DOI 10.1007/s004250050471; GUO Q, 1998, DEVELOPMENT, V125, P509; Jinn TL, 2000, GENE DEV, V14, P108; Kang HG, 1997, MOL CELLS, V7, P559; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; Petersen M, 1996, PLANT MOL BIOL, V31, P517, DOI 10.1007/BF00042225; PNUELI L, 1994, PLANT CELL, V6, P163, DOI 10.1105/tpc.6.2.163; Pnueli L, 1998, DEVELOPMENT, V125, P1979; PNUELI L, 1991, PLANT J, V1, P255, DOI 10.1111/j.1365-313X.1991.00255.x; RICK CM, 1988, ANNU REV GENET, V22, P281, DOI 10.1146/annurev.ge.22.120188.001433; RICK CM, 1955, AM SOC HORT SCI, V66, P354; Riechmann JL, 1997, BIOL CHEM, V378, P1079; ROBERTS JA, 1984, PLANTA, V160, P159, DOI 10.1007/BF00392864; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Szymkowiak EJ, 1999, PLANT CELL, V11, P159, DOI 10.1105/tpc.11.2.159; WING RA, 1994, MOL GEN GENET, V242, P681, DOI 10.1007/BF00283423; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; ZHANG HB, 1994, MOL GEN GENET, V244, P613, DOI 10.1007/BF00282751	26	231	264	6	78	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					910	913		10.1038/35022611	http://dx.doi.org/10.1038/35022611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972295				2022-12-28	WOS:000088903600049
J	Bolli, GB; Owens, DR				Bolli, GB; Owens, DR			Insulin glargine	LANCET			English	Editorial Material							DIABETES-MELLITUS; NPH INSULIN; I-RECEPTOR; ANALOG		Univ Perugia, Dept Internal Med, I-06126 Perugia, Italy; Cardiff Univ, Diabet Res Unit, Cardiff CF4 4XN, S Glam, Wales	University of Perugia; Cardiff University	Bolli, GB (corresponding author), Univ Perugia, Dept Internal Med, I-06126 Perugia, Italy.							Berti L, 1998, HORM METAB RES, V30, P123, DOI 10.1055/s-2007-978849; Bolli GB, 1999, DIABETOLOGIA, V42, P1151, DOI 10.1007/s001250051286; Bolli GB, 1999, J PEDIATR ENDOCR MET, V12, P737; Heinemann L, 2000, DIABETES CARE, V23, P644, DOI 10.2337/diacare.23.5.644; Jehle PM, 1999, LANCET, V354, P1604, DOI 10.1016/S0140-6736(98)12459-5; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; Lepore M, 1999, DIABETES, V48, pA97; OWENS DR, 1999, DIABETES CURRENT PER; PICKUP JC, 1978, BRIT MED J, V1, P204, DOI 10.1136/bmj.1.6107.204; Pieber T, 1998, DIABETES, V47, pA62; Ratner RE, 2000, DIABETES CARE, V23, P639, DOI 10.2337/diacare.23.5.639; Slieker LJ, 1997, DIABETOLOGIA, V40, pS54, DOI 10.1007/s001250051402; Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963; Yki-Jarvinen H, 2000, DIABETES, V49, pA130	14	145	149	2	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					443	445		10.1016/S0140-6736(00)02546-0	http://dx.doi.org/10.1016/S0140-6736(00)02546-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981882				2022-12-28	WOS:000088657700003
J	O'Donoghue, GM; Nikolopoulos, TP; Archbold, SM				O'Donoghue, GM; Nikolopoulos, TP; Archbold, SM			Determinants of speech perception in children after cochlear implantation	LANCET			English	Article							SKILLS	Background Cochlear implants provide access to the speech signal in those profoundly deaf children who derive no material benefit from acoustic hearing aids. Speech perception after implantation can vary widely-we have analysed the contribution of several factors. Methods We examined 40 children with mean age at implantation of 52 months who were either born deaf or became deaf before 3 years. All patients received the same multichannel implant system and were followed up for 5 years. We used connected discourse tracking (CDT) as the measure of speech perception. The effect of five potential predictors (age at implantation, number of inserted electrodes, origin of deafness, mode of communication, and socioeconomic group) on speech perception was analysed. Findings The mean number of words per minute perceived increased from 0 before implantation to 44.8 (SD 24.3) 5 years after implantation. Repeated-measures ANOVA showed that children significantly progressed over time (p=0.001). Age at implantation was a significant covariate (p=0.01) and mode of communication was a significant between-individuals factor (p=0.04). Interpretation Young age at intervention and oral communication mode are the most important known determinants of later speech perception in young children after cochlear implantation. Early identification of candidate children necessitates implementation of universal neonatal screening programmes for hearing impairment.	Univ Nottingham Hosp, Dept Otolaryngol, Nottingham Paediat Cochlear Implant Program, Nottingham NG7 2UH, England	University of Nottingham	O'Donoghue, GM (corresponding author), Univ Nottingham Hosp, Dept Otolaryngol, Nottingham Paediat Cochlear Implant Program, Nottingham NG7 2UH, England.							DEFILIPPO CL, 1978, J ACOUST SOC AM, V63, P1186, DOI 10.1121/1.381827; *GOV STAT SERV, 1991, STAND OCC CLASS, V3, P38; LANE H, 1995, AM J OTOL, V16, P393; Miyamoto R. T., 1995, Annals of Otology Rhinology and Laryngology, V104, P334; Mondain M, 1997, ARCH OTOLARYNGOL, V123, P181; Nikolopoulos TP, 1998, HOSP MED, V59, P46; O'Donoghue G M, 1998, Acta Otorhinolaryngol Belg, V52, P111; O'Donoghue GM, 1998, AM J OTOL, V19, P762; Plant G, 1998, EAR HEARING, V19, P394, DOI 10.1097/00003446-199810000-00006; SHEA JJ, 1994, AM J OTOL, V15, P66; SUMMERFIELD AQ, 1997, AM J OTOL, V18, P166; TYEMURRAY N, 1988, J SPEECH HEAR DISORD, V53, P226, DOI 10.1044/jshd.5303.226; TYEMURRAY N, 1995, J ACOUST SOC AM, V98, P2454, DOI 10.1121/1.413278; TYLER RS, 1993, COCHLEAR IMPLANTS AU, P191; Waltzman SB, 1997, AM J OTOL, V18, P342	15	150	152	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					466	468		10.1016/S0140-6736(00)02555-1	http://dx.doi.org/10.1016/S0140-6736(00)02555-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981890				2022-12-28	WOS:000088657700012
J	Welsh, J				Welsh, J			Health workers at risk	LANCET			English	Editorial Material									Amnesty Int, Int Secretariat, Med Programme, London WC1X 0DW, England		Welsh, J (corresponding author), Amnesty Int, Int Secretariat, Med Programme, London WC1X 0DW, England.							*DEC GEN WORLD MED, 1983, FERN VOLT; Physicians for Human Rights, 1996, TORT TURK ITS UNW AC; REYES H, 1996, MEDISCH CONTACT, V45, P1456	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					503	503		10.1016/S0140-6736(05)74170-2	http://dx.doi.org/10.1016/S0140-6736(05)74170-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981907				2022-12-28	WOS:000088657700038
J	Lei, M; Lu, WG; Meng, WY; Parrini, MC; Eck, MJ; Mayer, BJ; Harrison, SC				Lei, M; Lu, WG; Meng, WY; Parrini, MC; Eck, MJ; Mayer, BJ; Harrison, SC			Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch	CELL			English	Article							P21-ACTIVATED PROTEIN-KINASE; ALDRICH-SYNDROME PROTEIN; HEAVY-CHAIN KINASE; ADAPTER PROTEIN; MEMBRANE LOCALIZATION; CRYSTAL-STRUCTURE; TYROSINE KINASE; ALPHA-PAK; MYOSIN-I; CDC42	The p21-activated kinases (PAKs), stimulated by binding with GTP-liganded forms of Cdc42 or Pac, modulate cytoskeletal actin assembly and activate MAP-kinase pathways. The 2.3 Angstrom resolution crystal structure of a complex between the N-terminal autoregulatory fragment and the C-terminal kinase domain of PAK1 shows that GTPase binding will trigger a series of conformational changes, beginning with disruption of a PAK1 dimer and ending with rearrangement of the kinase active site into a catalytically competent state. An inhibitory switch (IS) domain, which overlaps the GTPase binding region of PAK1, positions a polypeptide segment across the kinase cleft. GTPase binding will refold part of the IS domain and unfold the rest. A related switch has been seen in the Wiskott-Aldrich syndrome protein (WASP).	Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Harrison, SC (corresponding author), Childrens Hosp, Mol Med Lab, 320 Longwood Ave, Boston, MA 02115 USA.	harrison@xtal2000.harvard.edu	Parrini, Maria Carla/J-5390-2016	Parrini, Maria Carla/0000-0002-7082-9792	NCI NIH HHS [1R01 CA2258-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Gizachew D, 2000, BIOCHEMISTRY-US, V39, P3963, DOI 10.1021/bi992646d; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1989, CRYSTALLOGRAPHIC COM; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Tu H, 1999, MOL CELL BIOL, V19, P602; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	57	416	424	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					387	397		10.1016/S0092-8674(00)00043-X	http://dx.doi.org/10.1016/S0092-8674(00)00043-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975528	Bronze			2022-12-28	WOS:000088625600013
J	Srivatsa, S; Amjadi, HR				Srivatsa, S; Amjadi, HR			Generalist and cardiologist care for congestive heart failure	ANNALS OF INTERNAL MEDICINE			English	Letter							MANAGEMENT		Covenant Med Ctr, Waterloo, IA 50702 USA		Srivatsa, S (corresponding author), Covenant Med Ctr, Waterloo, IA 50702 USA.							Auerbach AD, 2000, ANN INTERN MED, V132, P191, DOI 10.7326/0003-4819-132-3-200002010-00004; Edep ME, 1997, J AM COLL CARDIOL, V30, P518, DOI 10.1016/S0735-1097(97)00176-9; Fonarow GC, 1997, J AM COLL CARDIOL, V30, P725, DOI 10.1016/S0735-1097(97)00208-8; Morris DL, 2000, ANN INTERN MED, V132, P238, DOI 10.7326/0003-4819-132-3-200002010-00011; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					481	482		10.7326/0003-4819-133-6-200009190-00021	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975971				2022-12-28	WOS:000089329700013
J	[Anonymous]				[Anonymous]			Indian doctors not accountable, says consumer report	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2000	321	7261					588	588						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977823	Green Published			2022-12-28	WOS:000089243200008
J	Magnuson, JJ; Robertson, DM; Benson, BJ; Wynne, RH; Livingstone, DM; Arai, T; Assel, RA; Barry, RG; Card, V; Kuusisto, E; Granin, NG; Prowse, TD; Stewart, KM; Vuglinski, VS				Magnuson, JJ; Robertson, DM; Benson, BJ; Wynne, RH; Livingstone, DM; Arai, T; Assel, RA; Barry, RG; Card, V; Kuusisto, E; Granin, NG; Prowse, TD; Stewart, KM; Vuglinski, VS			Historical trends in lake and river ice cover in the Northern Hemisphere	SCIENCE			English	Article							LAURENTIAN SHIELD; AIR TEMPERATURES; BREAK-UP; RECORDS; DATES; MODEL	Freeze and breakup dates of ice on Lakes and rivers provide consistent evidence of Later freezing and earlier breakup around the Northern Hemisphere from 1846 to 1995, Over these 150 years, changes in freeze dates averaged 5.8 days per 100 years Later, and changes in breakup dates averaged 6.5 days per 100 years earlier; these translate to increasing air temperatures of about 1.2 degrees C per 100 years. Interannual variability in both freeze and breakup dates has increased since 1950. A few Longer time series reveal reduced ice cover (a warming trend) beginning as early as the 16th century, with increasing rates of change after about 1850.	Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA; US Geol Survey, Div Water Resources, Middleton, WI 53562 USA; Virginia Polytech Inst & State Univ, Dept Forestry, Blacksburg, VA 24061 USA; Swiss Fed Inst Environm Sci & Technol, Dept Environm Phys, CH-8600 Dubendorf, Switzerland; Rissho Univ, Dept Geog, Shinjuku Ku, Tokyo 141, Japan; NOAA, Great Lakes Ecosyst Res Lab, Ann Arbor, MI 48105 USA; Univ Colorado, World Data Ctr Glaciol, Boulder, CO 80309 USA; Metropolitan State Univ, Coll Arts & Sci, St Paul, MN 55106 USA; Finnish Environm Inst, FIN-00251 Helsinki, Finland; Limnol Inst, Irkutsk 664033, Russia; Environm Canada, Natl Water Res Inst, Saskatoon, SK S7N 3H5, Canada; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; State Hydrol Inst, St Petersburg 199053, Russia	University of Wisconsin System; University of Wisconsin Madison; United States Department of the Interior; United States Geological Survey; Virginia Polytechnic Institute & State University; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; Minnesota State Colleges & Universities; Metropolitan State University; Finnish Environment Institute; Irkutsk Science Centre of the Russian Academy of Sciences; Russian Academy of Sciences; Limnological Institute SB RAS; Environment & Climate Change Canada; National Water Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Magnuson, JJ (corresponding author), Univ Wisconsin, Ctr Limnol, Madison, WI 53706 USA.		Robertson, Dale/O-1913-2018; Wynne, Randolph H/A-8966-2009; Granin, Nikolay/J-4801-2018	Robertson, Dale/0000-0001-6799-0596; Wynne, Randolph H/0000-0003-3649-835X; Barry, Roger/0000-0001-9239-0859				Anderson WL, 1996, LIMNOL OCEANOGR, V41, P815, DOI 10.4319/lo.1996.41.5.0815; ARAI T, IN PRESS VERH INT VE; Arakawa H., 1954, CIGAKU ZASHI, V63, P193; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Assel RA, 1998, ICE IN SURFACE WATERS, VOL 1, P147; ASSEL RA, 1995, LIMNOL OCEANOGR, V40, P165, DOI 10.4319/lo.1995.40.1.0165; BELTAOS S, 2000, CONTRIBUTIONS IHP V, P22; BENSON BJ, IN PRESS VERH INT VE; Gray D. M., 1993, HDB HYDROLOGY; Kiefer F., 1972, NATURKUNDE BODENSEES; KOBAYASHI T, 1996, COMMUNICATION; KRATZ TK, IN PRESS VERH INT VE; KUUSISTO E, 1993, SNOW WATCH 92 DETECT, P57; KUUSISTO E, IN PRESS VERH INT VE; Livingstone DM, 1997, CLIMATIC CHANGE, V37, P407, DOI 10.1023/A:1005371925924; Magnuson J. J., 1997, FRESHWATER ECOSYSTEM, P7; MAGNUSON JJ, IN PRESS VERH INT VE; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; PALECKI MA, 1986, J CLIM APPL METEOROL, V25, P893, DOI 10.1175/1520-0450(1986)025<0893:FUABUO>2.0.CO;2; PROWSE TD, 1993, NORD HYDROL, V24, P169; RANNIE WF, 1983, CLIMATIC CHANGE, V5, P283, DOI 10.1007/BF02423523; ROBERTSON DM, 1992, CLIMATIC CHANGE, V21, P407, DOI 10.1007/BF00141379; ROBERTSON DM, 1989, THESIS U WISCONSINMA; SIMOJOKI H, 1940, ANN ACAD SCI FENN A, V52, P1; Smith LC, 2000, PHYS GEOGR, V21, P46, DOI 10.1080/02723646.2000.10642698; Soldatova I. I., 1993, RUSSIAN METEOROLOGY, V9, P70; Tanaka M., 1982, Weather, V37, P252, DOI 10.1002/j.1477-8696.1982.tb03626.x; Timmermann A, 1999, NATURE, V398, P694, DOI 10.1038/19505; Tramoni F., 1985, Z GLETSCHERKUNDE GLA, V21, P43; Vavrus SJ, 1996, LIMNOL OCEANOGR, V41, P822, DOI 10.4319/lo.1996.41.5.0822; Wynne RH, 1996, LIMNOL OCEANOGR, V41, P832, DOI 10.4319/lo.1996.41.5.0832; Wynne RH, 1998, PHOTOGRAMM ENG REM S, V64, P607; WYNNE RH, IN PRESS VERH INT VE	33	874	922	8	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 8	2000	289	5485					1743	1746		10.1126/science.289.5485.1743	http://dx.doi.org/10.1126/science.289.5485.1743			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976066				2022-12-28	WOS:000089195200044
J	Kouwenhoven, L				Kouwenhoven, L			Nanotechnology - Bouncing a C-60 ball	NATURE			English	Editorial Material									Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, ERATO Mesoscop Correlat Project, NL-2600 GA Delft, Netherlands	Delft University of Technology; Delft University of Technology	Kouwenhoven, L (corresponding author), Delft Univ Technol, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.							Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Gorelik LY, 1998, PHYS REV LETT, V80, P4526, DOI 10.1103/PhysRevLett.80.4526; Keller MW, 1999, SCIENCE, V285, P1706, DOI 10.1126/science.285.5434.1706; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Schwab K, 2000, NATURE, V404, P974, DOI 10.1038/35010065	5	7	7	1	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					35	36		10.1038/35024197	http://dx.doi.org/10.1038/35024197			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993061				2022-12-28	WOS:000089124000029
J	Sharp, DJ; Rogers, GC; Scholey, JM				Sharp, DJ; Rogers, GC; Scholey, JM			Microtubule motors in mitosis	NATURE			English	Review							KINESIN-LIKE PROTEIN; CENTROMERE-ASSOCIATED KINESIN; CROSS-LINKS MICROTUBULES; MITOTIC SPINDLE; CENP-E; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DYNEIN; ANTIPARALLEL MICROTUBULES; CHROMOSOME SEGREGATION; ASPERGILLUS-NIDULANS	The mitotic spindle uses microtubule-based motor proteins to assemble itself and to segregate sister chromatids. It is becoming clear that motors invoke several distinct mechanisms to generate the forces that drive mitosis. Moreover, in carrying out its function, the spindle appears to pass through a series of transient steady-state structures, each established by a delicate balance of forces generated by multiple complementary and antagonistic motors. Transitions from one steady state to the next can occur when a change in the activity of a subset of mitotic motors tips the balance.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Scholey, JM (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	jmscholey@ucdavis.edu						Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Bowman AB, 1999, J CELL BIOL, V146, P165; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COLE DG, 1994, J BIOL CHEM, V269, P22913; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Follette PJ, 1997, CURR OPIN GENET DEV, V7, P17, DOI 10.1016/S0959-437X(97)80104-9; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Gordon DM, 1999, J BIOL CHEM, V274, P28779, DOI 10.1074/jbc.274.40.28779; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P259, DOI 10.1085/jgp.50.6.259; Karabay A, 1999, BIOCHEMISTRY-US, V38, P1838, DOI 10.1021/bi981850i; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; KURIYAMA R, 1994, J CELL SCI, V107, P3485; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee S, 1999, MOL BIOL CELL, V10, P771, DOI 10.1091/mbc.10.3.771; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD KL, 1979, J CELL BIOL, V83, P443, DOI 10.1083/jcb.83.2.443; MCINTOSH JR, 1989, SCI AM, V261, P48, DOI 10.1038/scientificamerican1089-48; MCINTOSH JR, 1969, NATURE, V224, P659, DOI 10.1038/224659a0; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MELUH PB, CELL, V61, P548; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; Mountain V, 1999, J CELL BIOL, V147, P351, DOI 10.1083/jcb.147.2.351; Narasimhulu SB, 1998, PLANT CELL, V10, P957, DOI 10.1105/tpc.10.6.957; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pidoux AL, 1996, MOL BIOL CELL, V7, P1639, DOI 10.1091/mbc.7.10.1639; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Ruden DM, 1997, DEV BIOL, V191, P284, DOI 10.1006/dbio.1997.8726; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Sharp DJ, 2000, BBA-MOL CELL RES, V1496, P128, DOI 10.1016/S0167-4889(00)00014-8; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Tokai N, 1996, EMBO J, V15, P457, DOI 10.1002/j.1460-2075.1996.tb00378.x; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WANG SZ, 1995, J CELL BIOL, V128, P761, DOI 10.1083/jcb.128.5.761; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	79	459	470	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					41	47		10.1038/35024000	http://dx.doi.org/10.1038/35024000			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993066				2022-12-28	WOS:000089124000035
J	Sullivan, RM; Landers, M; Yeaman, B; Wilson, DA				Sullivan, RM; Landers, M; Yeaman, B; Wilson, DA			Neurophysiology - Good memories of bad events in infancy	NATURE			English	Article									Univ Oklahoma, Dept Zool, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Sullivan, RM (corresponding author), Univ Oklahoma, Dept Zool, Norman, OK 73019 USA.			Wilson, Donald/0000-0001-8918-2151; Sullivan, Regina Marie/0000-0002-2406-8857	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033402] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD033402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amaral DG, 1992, AMYGDALA NEUROBIOLOG, P465; Bowlby J, 1969, ATTACHMENT, V1; CAMP LL, 1989, DEV PSYCHOBIOL, V22, P25; CHAMBERS KC, 1990, ANNU REV NEUROSCI, V13, P373, DOI 10.1146/annurev.ne.13.030190.002105; DAVIS M, 1992, P255; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; HAROUTUNIAN V, 1979, SCIENCE, V205, P927, DOI 10.1126/science.472715; Hunt PS, 1997, LEARN MOTIV, P53; KUCHARSKI D, 1984, DEV PSYCHOBIOL, V17, P465, DOI 10.1002/dev.420170505; WILSON DA, 1994, BEHAV NEURAL BIOL, V61, P1, DOI 10.1016/S0163-1047(05)80039-1	10	239	239	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					38	39		10.1038/35024156	http://dx.doi.org/10.1038/35024156			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993064	Green Accepted			2022-12-28	WOS:000089124000032
J	Solin, SA; Thio, T; Hines, DR; Heremans, JJ				Solin, SA; Thio, T; Hines, DR; Heremans, JJ			Enhanced room-temperature geometric magnetoresistance in inhomogeneous narrow-gap semiconductors	SCIENCE			English	Article							GIANT MAGNETORESISTANCE	A symmetric van der Pauw disk of homogeneous nonmagnetic indium antimonide with an embedded concentric gold inhomogeneity is found to exhibit room-temperature geometric magnetoresistance as high as 100, 9100, and 750,000 percent at magnetic fields of 0.05, 0.25, and 4.0 teslas, respectively. For inhomogeneities of sufficiently Large diameter relative to that of the surrounding disk, the resistance is field-independent up to an onset field above which it increases rapidly. These results can be understood in terms of the field-dependent deflection of current around the inhomogeneity.	NEC Res Inst, Princeton, NJ 08540 USA; Ohio Univ, Dept Phys & Astron, Athens, OH 45701 USA	NEC Corporation; University System of Ohio; Ohio University	Solin, SA (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.							Brug JA, 1996, MRS BULL, V21, P23, DOI 10.1557/S0883769400036320; EGELHOFF WF, 1995, J APPL PHYS, V78, P273, DOI 10.1063/1.360692; Heremans JP, 1997, MATER RES SOC SYMP P, V475, P63, DOI 10.1557/PROC-475-63; HERRING C, 1960, J APPL PHYS, V31, P1939, DOI 10.1063/1.1735477; JIN S, 1994, J APPL PHYS, V76, P6929, DOI 10.1063/1.358119; KUZE N, 1997, 3 5S REV, V10, P28; Levy PM, 1994, SOLID STATE PHYS, V47, P367, DOI 10.1016/S0081-1947(08)60642-6; Neal Bertram H., 1994, THEORY MAGNETIC RECO; O'Grady K, 1998, J MAGN MAGN MATER, V177, P886, DOI 10.1016/S0304-8853(97)01048-2; PARKER SD, 1989, SEMICOND SCI TECH, V4, P663, DOI 10.1088/0268-1242/4/8/010; PARKINS SPS, 1999, B AM PHYS SOC, V44, P1555; Popovic R., 1991, HALL EFFECT DEVICES; RAO CNR, 1998, COLOSSAL MAGNETORESI; Shik A.Y., 1995, ELECT PROPERTIES INH, Vfirst; Solin SA, 1996, APPL PHYS LETT, V69, P4105, DOI 10.1063/1.117833; SOLIN SA, UNPUB; Thio T, 1998, APPL PHYS LETT, V72, P3497, DOI 10.1063/1.121639; Thio T, 1998, PHYS REV B, V57, P12239, DOI 10.1103/PhysRevB.57.12239; WEISS H, 1963, Z PHYS, V176, P399, DOI 10.1007/BF01375169; WIEDER HH, 1971, HALL GENERATORS MAGN; WOLFE CM, 1972, J ELECTROCHEM SOC, V119, P250, DOI 10.1149/1.2404170; ZAWADZKI W, 1974, ADV PHYS, V23, P435, DOI 10.1080/00018737400101371	22	298	315	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1530	1532		10.1126/science.289.5484.1530	http://dx.doi.org/10.1126/science.289.5484.1530			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968784				2022-12-28	WOS:000089071700040
J	Devoret, MH; Schoelkopf, RJ				Devoret, MH; Schoelkopf, RJ			Amplifying quantum signals with the single-electron transistor	NATURE			English	Review							SMALL TUNNEL-JUNCTIONS; CHARGE SENSITIVITY; ROOM-TEMPERATURE; NOISE; COMPUTATION; PHOTON; CONDUCTANCE; AMPLIFIER; BOX	Transistors have continuously reduced in size and increased in switching speed since their invention in 1947. The exponential pace of transistor evolution has led to a revolution in information acquisition, processing and communication technologies. And reigning over most digital applications is a single device structure - the field-effect transistor (FET). But as device dimensions approach the nanometre scale, quantum effects become increasingly important for device operation, and conceptually new transistor structures may need to be adopted. A notable example of such a structure is the single-electron transistor, or SET1-4. Although it is unlikely that SETs will replace FETs in conventional electronics, they should prove useful in ultra-low-noise analog applications. Moreover, because it is not affected by the same technological limitations as the FET, the SET can approach closely the quantum limit of sensitivity. It might also be a useful read-out device for a solid-state quantum computer.	Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; CEA Saclay, Serv Phys Etat Condense, F-91191 Gif Sur Yvette, France	Yale University; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Devoret, MH (corresponding author), Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA.		Schoelkopf, Robert J/J-8178-2012					Andre MO, 1999, APPL PHYS LETT, V75, P698, DOI 10.1063/1.124486; AVERIN DV, 1986, J LOW TEMP PHYS, V62, P345, DOI 10.1007/BF00683469; Averin DV, 1998, SOLID STATE COMMUN, V105, P659, DOI 10.1016/S0038-1098(97)10001-1; Bocko MF, 1997, IEEE T APPL SUPERCON, V7, P3638, DOI 10.1109/77.622206; Bouchiat V, 1998, PHYS SCRIPTA, VT76, P165, DOI 10.1238/Physica.Topical.076a00165; Braginsky V. B., 1992, QUANTUM MEASUREMENT; CAVES CM, 1982, PHYS REV D, V26, P1817, DOI 10.1103/PhysRevD.26.1817; CAVES CM, 1980, REV MOD PHYS, V52, P341, DOI 10.1103/RevModPhys.52.341; DEVORET MH, 1992, NATO ADV SCI I B-PHY, V294, P1; FULTON TA, 1987, PHYS REV LETT, V59, P109, DOI 10.1103/PhysRevLett.59.109; GRABERT H, 1994, PHYS REV B, V50, P17364, DOI 10.1103/PhysRevB.50.17364; Gurvitz SA, 1997, PHYS REV B, V56, P15215, DOI 10.1103/PhysRevB.56.15215; Kane BE, 1998, NATURE, V393, P133, DOI 10.1038/30156; Keller MW, 1999, SCIENCE, V285, P1706, DOI 10.1126/science.285.5434.1706; Komiyama S, 2000, NATURE, V403, P405, DOI 10.1038/35000166; Korotkov AN, 1999, APPL PHYS LETT, V74, P4052, DOI 10.1063/1.123258; KOROTKOV AN, 1992, SPRIN S ELE, V31, P45; KOROTKOV AN, 2000, CONDMAT0003225; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613; MAR DJ, 1994, APPL PHYS LETT, V64, P631, DOI 10.1063/1.111072; Mather JC, 1999, NATURE, V401, P654, DOI 10.1038/44301; MEARS CA, 1990, APPL PHYS LETT, V57, P2487, DOI 10.1063/1.104111; MEIRAV U, 1990, PHYS REV LETT, V65, P771, DOI 10.1103/PhysRevLett.65.771; MONROE C, 1995, PHYS REV LETT, V75, P4011, DOI 10.1103/PhysRevLett.75.4011; Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036; MOVSHOVICH R, 1990, PHYS REV LETT, V65, P1419, DOI 10.1103/PhysRevLett.65.1419; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Naveh Y, 2000, IEEE ELECTR DEVICE L, V21, P242, DOI 10.1109/55.841309; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; Pashkin YA, 2000, APPL PHYS LETT, V76, P2256, DOI 10.1063/1.126313; Pospieszalski M. W., 1998, Proceedings of 2nd ESA Workshop on Millimetre Wave Technology and Applications: Antennas, Circuits and Systems (WPP-149), P221; Schoelkopf RJ, 1999, IEEE T APPL SUPERCON, V9, P2935, DOI 10.1109/77.783645; Schoelkopf RJ, 1998, SCIENCE, V280, P1238, DOI 10.1126/science.280.5367.1238; SCHOELLER H, 1994, PHYS REV B, V50, P18436, DOI 10.1103/PhysRevB.50.18436; Shirakashi J, 1998, APPL PHYS LETT, V72, P1893, DOI 10.1063/1.121218; Shnirman A, 1998, PHYS REV B, V57, P15400, DOI 10.1103/PhysRevB.57.15400; Steane A, 1998, REP PROG PHYS, V61, P117, DOI 10.1088/0034-4885/61/2/002; TURCHETTE QA, 1995, PHYS REV LETT, V75, P4710, DOI 10.1103/PhysRevLett.75.4710; Wolf H, 1997, IEEE T INSTRUM MEAS, V46, P303, DOI 10.1109/19.571840; Zhuang L, 1998, APPL PHYS LETT, V72, P1205, DOI 10.1063/1.121014; Zorin AB, 1996, PHYS REV LETT, V76, P4408, DOI 10.1103/PhysRevLett.76.4408	42	339	346	2	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					1039	1046		10.1038/35023253	http://dx.doi.org/10.1038/35023253			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984063				2022-12-28	WOS:000089020200056
J	Nishino, I; Fu, J; Tanji, K; Yamada, T; Shimojo, S; Koori, T; Mora, M; Riggs, JE; Oh, SJ; Koga, Y; Sue, CM; Yamamoto, A; Murakami, N; Shanske, S; Byrne, E; Bonilla, E; Nonaka, I; DiMauro, S; Hirano, M				Nishino, I; Fu, J; Tanji, K; Yamada, T; Shimojo, S; Koori, T; Mora, M; Riggs, JE; Oh, SJ; Koga, Y; Sue, CM; Yamamoto, A; Murakami, N; Shanske, S; Byrne, E; Bonilla, E; Nonaka, I; DiMauro, S; Hirano, M			Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)	NATURE			English	Article							LYSOSOMAL GLYCOGEN-STORAGE; NORMAL ACID MALTASE; CELL-SURFACE EXPRESSION; MEMBRANE ATTACK COMPLEX; MENTAL-RETARDATION; GENE; GLYCOPROTEINS; FORM	"Lysosomal glycogen storage disease with normal acid maltase'', which was originally described by Danon et al.(1), is characterized clinically by cardiomyopathy, myopathy and variable mental retardation. The pathological hallmark of the disease is intracytoplasmic vacuoles containing autophagic material and glycogen in skeletal and cardiac muscle cells. Sarcolemmal proteins and basal lamina are associated with the vacuolar membranes(2,3). Here we report ten unrelated patients, including one of the patients from the original case report(1), who have primary deficiencies of LAMP-2, a principal lysosomal membrane protein. From these results and the finding that LAMP-2-deficient mice manifest a similar vacuolar cardioskeletal myopathy, we conclude that primary LAMP-2 deficiency is the cause of Danon disease(4). To our knowledge this is the first example of human cardiopathymyopathy that is caused by mutations in a lysosomal structural protein rather than an enzymatic protein.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo 1878502, Japan; Kyushu Univ, Dept Neurol, Higashi Ku, Fukuoka 8128582, Japan; St Marianna Univ, Sch Med, Dept Internal Med, Miyamae Ku, Kawasaki, Kanagawa 2168512, Japan; Yokohama Rosai Hosp, Dept Pediat, Kouhoku Ku, Kanagawa 2220036, Japan; Natl Neurol Inst C Besta, Dept Neuromuscular Dis, I-20133 Milan, Italy; W Virginia Univ, Dept Neurol, Morgantown, WV 26506 USA; Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Kurume Univ, Dept Pediat & Child Hlth, Fukuoka 8300011, Japan; St Vincents Hosp, Dept Clin Neurosci, Fitzroy, Vic 3065, Australia	Columbia University; Columbia University; National Center for Neurology & Psychiatry - Japan; Kyushu University; Saint Marianna University; Yokohama Rosai Hospital; IRCCS Istituto Neurologico Besta; West Virginia University; University of Alabama System; University of Alabama Birmingham; Kurume University; St Vincent's Hospital Melbourne	Nishino, I (corresponding author), Columbia Univ, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.		Nishino, Ichizo/G-2676-2010; Fu, Jin/A-3510-2012; Mora, Marina/J-2883-2018	Nishino, Ichizo/0000-0001-9452-112X; Mora, Marina/0000-0002-5765-2320; Hirano, Michio/0000-0002-7070-7402; Koga, Yasutoshi/0000-0002-6664-1295				Auranen M, 2000, ANN NEUROL, V47, P666, DOI 10.1002/1531-8249(200005)47:5<666::AID-ANA19>3.3.CO;2-E; BYRNE E, 1986, BRAIN, V109, P523, DOI 10.1093/brain/109.3.523; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; DANON MJ, 1981, NEUROLOGY, V31, P51, DOI 10.1212/WNL.31.1.51; DWORZAK F, 1994, NEUROMUSCULAR DISORD, V4, P243, DOI 10.1016/0960-8966(94)90025-6; Fukuda M, 1994, Subcell Biochem, V22, P199; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; Itoh Masahiro, 1993, No To Hattatsu, V25, P459; KANNAN K, 1995, EUR J HAEMATOL, V55, P145; Katsumi Y, 1996, J NEUROL SCI, V140, P46, DOI 10.1016/0022-510X(96)00077-9; Katsumi Y, 1994, Rinsho Shinkeigaku, V34, P827; KONECKI DS, 1995, BIOCHEM BIOPH RES CO, V215, P757, DOI 10.1006/bbrc.1995.2528; Lewin B, 1997, GENES; Louboutin JP, 1997, ANN NEUROL, V41, P117, DOI 10.1002/ana.410410121; Louboutin JP, 1996, MUSCLE NERVE, V19, P1144, DOI 10.1002/(SICI)1097-4598(199609)19:9<1144::AID-MUS10>3.0.CO;2-V; Matsumoto S, 1999, Rinsho Shinkeigaku, V39, P717; MATTEI MG, 1990, J BIOL CHEM, V265, P7548; Morisawa Y, 1998, J NEUROL SCI, V160, P175, DOI 10.1016/S0022-510X(98)00242-1; MUNTONI F, 1994, NEUROMUSCULAR DISORD, V4, P233, DOI 10.1016/0960-8966(94)90024-8; MURAKAMI N, 1995, NEUROMUSCULAR DISORD, V5, P149, DOI 10.1016/0960-8966(94)00046-C; RIGGS JE, 1983, NEUROLOGY, V33, P873, DOI 10.1212/WNL.33.7.873; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; Verloes A, 1997, AM J MED GENET, V72, P135, DOI 10.1002/(SICI)1096-8628(19971017)72:2<135::AID-AJMG3>3.0.CO;2-U; VILLANOVA M, 1995, ANN NEUROL, V37, P637, DOI 10.1002/ana.410370514; Villard L, 2000, EUR J HUM GENET, V8, P125, DOI 10.1038/sj.ejhg.5200432	29	593	629	2	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					906	910		10.1038/35022604	http://dx.doi.org/10.1038/35022604			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972294				2022-12-28	WOS:000088903600048
J	Scarola, VW; Park, K; Jain, JK				Scarola, VW; Park, K; Jain, JK			Cooper instability of composite fermions	NATURE			English	Article							FILLED LANDAU-LEVEL; QUANTUM HALL; MONOPOLE HARMONICS; STATES; QUANTIZATION	When confined to two dimensions and exposed to a strong magnetic field, electrons screen the Coulomb interaction in a topological fashion; they capture an even number of quantum vortices and transform into particles called 'composite fermions' (refs 1-3). The fractional quantum Hall effect(4) occurs in such a system when the ratio (or 'filling factor', nu) of the number of electrons and the degeneracy of their spin-split energy states (the Landau levels) takes on particular values. The Landau level filling nu = 1/2 corresponds to a metallic state in which the composite fermions form a gapless Fermi sea(5-8). But for nu = 5/2, a fractional quantum Hall effect is observed instead(9,10); this unexpected result is the subject of considerable debate and controversy(11). Here we investigate the difference between these states by considering the theoretical problem of two composite fermions on top of a fully polarized Fermi sea of composite fermions. We find that they undergo Cooper pairing to form a p-wave bound state at nu = 5/2, but not at nu = 1/2. In effect, the repulsive Coulomb interaction between electrons is overscreened in the nu = 5/2 state by the formation of composite fermions, resulting in a weak, attractive interaction.	Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Jain, JK (corresponding author), Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA.		Scarola, Vito/AAG-7503-2019; Scarola, Vito/G-5412-2012	Scarola, Vito/0000-0002-8653-2723; Scarola, Vito/0000-0002-8653-2723				Bonesteel NE, 1999, PHYS REV LETT, V82, P984, DOI 10.1103/PhysRevLett.82.984; Eisenstein J. P., 1997, PERSPECTIVES QUANTUM, P37; FANG FF, 1966, PHYS REV LETT, V16, P797, DOI 10.1103/PhysRevLett.16.797; GOLDMAN VJ, 1994, PHYS REV LETT, V72, P2065, DOI 10.1103/PhysRevLett.72.2065; GREITER M, 1992, NUCL PHYS B, V374, P567, DOI 10.1016/0550-3213(92)90401-V; HALDANE FDM, 1983, PHYS REV LETT, V51, P605, DOI 10.1103/PhysRevLett.51.605; HALPERIN BI, 1993, PHYS REV B, V47, P7312, DOI 10.1103/PhysRevB.47.7312; Heinonen O., 1998, COMPOSITE FERMIONS; JAIN JK, 1989, PHYS REV LETT, V63, P199, DOI 10.1103/PhysRevLett.63.199; Jain JK, 1997, INT J MOD PHYS B, V11, P2621, DOI 10.1142/S0217979297001301; Kamilla RK, 1997, PHYS REV B, V55, P13417, DOI 10.1103/PhysRevB.55.R13417; KANG W, 1993, PHYS REV LETT, V71, P3850, DOI 10.1103/PhysRevLett.71.3850; MOORE G, 1991, NUCL PHYS B, V360, P362, DOI 10.1016/0550-3213(91)90407-O; Morf RH, 1998, PHYS REV LETT, V80, P1505, DOI 10.1103/PhysRevLett.80.1505; Pan W, 1999, PHYS REV LETT, V83, P3530, DOI 10.1103/PhysRevLett.83.3530; Park K, 1998, PHYS REV B, V58, P10167, DOI 10.1103/PhysRevB.58.R10167; Park K, 1999, PHYS REV LETT, V83, P5543, DOI 10.1103/PhysRevLett.83.5543; REZAYI EH, 1999, CONDMAT9906137; Sarma Sankar Das, 1997, PERSPECTIVES QUANTUM; WILLETT RL, 1993, PHYS REV LETT, V71, P3846, DOI 10.1103/PhysRevLett.71.3846; WILLETT RL, 1987, PHYS REV LETT, V59, P1779; Wojs A, 1999, SOLID STATE COMMUN, V110, P45, DOI 10.1016/S0038-1098(99)00004-6; WU TT, 1976, NUCL PHYS B, V107, P365, DOI 10.1016/0550-3213(76)90143-7; WU XG, 1995, PHYS REV B, V51, P1752, DOI 10.1103/PhysRevB.51.1752; ZHANG FC, 1986, PHYS REV B, V33, P2903, DOI 10.1103/PhysRevB.33.2903	27	81	81	0	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					863	865		10.1038/35022524	http://dx.doi.org/10.1038/35022524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972281	Green Submitted			2022-12-28	WOS:000088903600035
J	Weijer, C; Emanuel, EJ				Weijer, C; Emanuel, EJ			Ethics - Protecting communities in biomedical research	SCIENCE			English	Article							GUIDELINES		Dalhousie Univ, Dept Bioeth, Halifax, NS B3H 4H7, Canada; NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	Dalhousie University; National Institutes of Health (NIH) - USA	Weijer, C (corresponding author), Dalhousie Univ, Dept Bioeth, Halifax, NS B3H 4H7, Canada.	charles.weijer@dal.ca	Weijer, Charles/ABC-5433-2020	Weijer, Charles/0000-0002-5510-1074				[Anonymous], 1979, BELM REP; *AUSTR NAT HLTH ME, 1991, GUID ETH MATT AB TOR; *CAN TRIC WORK GRO, 1996, COD COND RES INV HUM; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lehrman S, 1997, NATURE, V389, P322, DOI 10.1038/38579; Levine Carol, 1991, IRB, V13, P1; LEVINE ROBERT J., 1988, ETHICS REGULATION CL, V2nd; Macaulay AC, 1998, CAN J PUBLIC HEALTH, V89, P105, DOI 10.1007/BF03404399; *MRC CAN NAT SCI E, 1998, TRIC POL STAT ETH CO; Nathan DG, 1999, LANCET, V353, P771, DOI 10.1016/S0140-6736(99)00072-0; Rawls J., 1971, THEORY JUSTICE; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Walzer M., 1983, SPHERES JUSTICE; Weijer C, 1999, NAT GENET, V23, P275, DOI 10.1038/15455; Weijer C, 1999, CAMB Q HEALTHC ETHIC, V8, P501, DOI 10.1017/S0963180199004120; Weijer Charles, 1999, Account Res, V7, P21, DOI 10.1080/08989629908573940	17	183	185	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 18	2000	289	5482					1142	1144		10.1126/science.289.5482.1142	http://dx.doi.org/10.1126/science.289.5482.1142			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	346JE	10970227				2022-12-28	WOS:000088866600020
J	Chirac, P; von Schoen-Angerer, T; Kasper, T; Ford, N				Chirac, P; von Schoen-Angerer, T; Kasper, T; Ford, N			AIDS: patent rights versus patient's rights	LANCET			English	Editorial Material									Med Sans Frontieres, F-75554 Paris 11, France	Doctors Without Borders	Chirac, P (corresponding author), Med Sans Frontieres, 8 rue St Sabin, F-75554 Paris 11, France.			von Schoen-Angerer, Tido/0000-0003-3601-7480				Ainsworth M, 2000, LANCET, V356, P55, DOI 10.1016/S0140-6736(00)02440-5; Kaitin KI, 2000, DRUG INF J, V34, P1; MITSUYA H, 1989, NY TIMES        0928; Palella FJ, 1999, NEW ENGL J MED, V279, P853; Zwi K, 2000, BRIT MED J, V320, P1551, DOI 10.1136/bmj.320.7249.1551	5	12	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 5	2000	356	9228					502	502		10.1016/S0140-6736(00)02566-6	http://dx.doi.org/10.1016/S0140-6736(00)02566-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342QY	10981906				2022-12-28	WOS:000088657700037
J	McMichael, AJ; Beaglehole, R				McMichael, AJ; Beaglehole, R			The changing global context of public health	LANCET			English	Article							EPIDEMIOLOGY; GLOBALIZATION; MORTALITY; DISEASE	Future health prospects depend increasingly on globalisation processes and on the impact of global environmental change. Economic globalisation-entailing deregulated trade and investment-is a mixed blessing for health. Economic growth and the dissemination of technologies have widely enhanced life expectancy. However, aspects of globalisation are jeopardising health by eroding social and environmental conditions, exacerbating the rich-poor gap, and disseminating consumerism. Global environmental changes reflect the growth of populations and the intensity of economic activity. These changes include altered composition of the atmosphere, land degradation, depletion of terrestrial aquifers and ocean fisheries, and loss of biodiversity. This weakening of life-supporting systems poses health risks. Contemporary public health must therefore encompass the interrelated tasks of reducing social and health inequalities and achieving health-sustaining environments.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; Univ Auckland, Fac Med & Hlth Sci, Dept Community Hlth, Auckland 1, New Zealand	University of London; London School of Hygiene & Tropical Medicine; University of Auckland	McMichael, AJ (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	t.mcmichael@LSHTM.ac.uk						Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1997, LANCET, V350, P229; [Anonymous], 1999, WORLD HLTH REPORT 19; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Bijlmakers L. A., 1998, 105 NORD AFR I; Capra F., 1996, WEB LIFE; *CLIM CHANG IMP RE, 1996, POT EFF CLIM CHANG U; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; Dixon J., 1998, PROTECTING OUR PLANE; Epstein P, 1998, LANCET, V351, P577, DOI 10.1016/S0140-6736(05)78570-6; *FAO, 1995, STAT WORLD FISH 1995; Gray J., 1998, FALSE DAWN DELUSIONS; Hoogvelt Ankie, 1997, GLOBALIZATION POSTCO; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; Kinnon CM, 1998, WORLD HEALTH FORUM, V19, P397; Koopman JS, 1996, AM J PUBLIC HEALTH, V86, P630, DOI 10.2105/AJPH.86.5.630; LAST JM, 1992, PUBLIC HLTH PREVENTI, P677; LEE K, IN PRESS SOC SCI MED; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; LEON DA, IN PRESS POVERTY INE; Levy Barry S, 1997, WAR PUBLIC HLTH; Loh J., 1998, LIVING PLANET REPORT; LOOMIS D, 1990, INT J EPIDEMIOL, V19, P1, DOI 10.1093/ije/19.1.1; MARTENS WJM, IN PRESS GLOBAL ENV; McMichael A J, 1993, PLANETARY OVERLOAD G; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; McMichael AJ, 1999, BMJ-BRIT MED J, V319, P977, DOI 10.1136/bmj.319.7215.977; McMichael AJ, 1997, BMJ-BRIT MED J, V315, P805, DOI 10.1136/bmj.315.7111.805; McMichael AJ, 1999, AM J EPIDEMIOL, V149, P887; McMichael P., 1996, DEV SOCIAL CHANGE; Myers N., 1995, ENV EXODUS EMERGENT; MYERS N, 1997, NATUES SERVICES SOC; Navarro V, 1998, AM J PUBLIC HEALTH, V88, P742, DOI 10.2105/AJPH.88.5.742; Parry M, 1999, GLOBAL ENVIRON CHANG, V9, pS51, DOI 10.1016/S0959-3780(99)00018-7; Pearce N, 1996, AM J PUBLIC HEALTH, V86, P678, DOI 10.2105/AJPH.86.5.678; PIMENTEL D, 1995, SCIENCE, V267, P1117, DOI 10.1126/science.267.5201.1117; POWLES J, 1992, SOC SCI MED, V35, P377, DOI 10.1016/0277-9536(92)90330-S; *RED CROSS, 1999, WORLD DIS REP 1998; SHERRY P, 1997, DIET NUTR CHRONIC DI; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; Stephens C, 1999, EUR J PUBLIC HEALTH, V9, P3, DOI 10.1093/eurpub/9.1.3; *UK MET OFF, 1998, CLIM CHANG ITS IMP; *UN ENV PROG, 1998, ENV EFF OZ DEPL 1998; *UN ENV PROGR, 1999, GLOB ENV OUTL 2000; UNDP,, 1990, HUMAN DEV REPORT 199; WATSON P, 1995, SOC SCI MED, V41, P923, DOI 10.1016/0277-9536(94)00405-I; Watts S. J., 1997, EPIDEMICS HIST DIS P; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; Wilson E. O., 1998, CONSILIENCE UNITY KN; World Bank, 1997, STAT CHANG WORLD WOR; *WORLD RES I, 1998, WORLD RES 1998 1999; Yach D, 1998, AM J PUBLIC HEALTH, V88, P735, DOI 10.2105/AJPH.88.5.735; Yach D, 1998, AM J PUBLIC HEALTH, V88, P738, DOI 10.2105/AJPH.88.5.738	54	133	137	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2000	356	9228					495	499		10.1016/S0140-6736(00)02564-2	http://dx.doi.org/10.1016/S0140-6736(00)02564-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	342QY	10981904				2022-12-28	WOS:000088657700035
J	Adachi, M; Takayanagi, R; Tomura, A; Imasaki, K; Kato, S; Goto, K; Yanase, T; Ikuyama, S; Nawata, H				Adachi, M; Takayanagi, R; Tomura, A; Imasaki, K; Kato, S; Goto, K; Yanase, T; Ikuyama, S; Nawata, H			Androgen-insensitivity syndrome as a possible coactivator disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE-BINDING DOMAIN; NUCLEAR RECEPTOR COACTIVATORS; HUMAN GLUCOCORTICOID RECEPTOR; STEROID-BINDING; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; ACID; PROTEIN; CELLS; LEADS		Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Tokyo, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan	Kyushu University; Japan Science & Technology Agency (JST); University of Tokyo	Nawata, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.							Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; IMASAKI K, 1995, ENDOCR J, V42, P643, DOI 10.1507/endocrj.42.643; IMASAKI K, 1994, EUR J ENDOCRINOL, V130, P569, DOI 10.1530/eje.0.1300569; Imasaki K, 1996, MOL CELL ENDOCRINOL, V120, P15, DOI 10.1016/0303-7207(96)03812-9; IMASAKI K, 1996, CLIN PEDIAT ENDOCRIN, V5, P1; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Mu YM, 1998, CLIN ENDOCRINOL, V49, P301, DOI 10.1046/j.1365-2265.1998.00520.x; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NAKAO R, 1993, J CLIN ENDOCR METAB, V77, P103, DOI 10.1210/jcem.77.1.8325932; Nawata H, 1996, HORM RES, V46, P15, DOI 10.1159/000185173; QUIGLEY CA, 1995, ENDOCR REV, V16, P546; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269	35	118	120	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	2000	343	12					856	862		10.1056/NEJM200009213431205	http://dx.doi.org/10.1056/NEJM200009213431205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354XB	10995865				2022-12-28	WOS:000089355600005
J	Brown, J; Kellermann, AL				Brown, J; Kellermann, AL			The shocking truth about automated external defibrillators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; EMERGENCY MEDICAL TECHNICIANS; VENTRICULAR-FIBRILLATION; RAPID DEFIBRILLATION; FOLLOW-UP; SURVIVAL; RESUSCITATION; SERVICES; SYSTEM; POLICE		Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA	Emory University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kellermann, AL (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.	AKELL01@sph.emory.edu						AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BECK CS, 1947, JAMA-J AM MED ASSOC, V135, P985, DOI 10.1001/jama.1947.62890150005007a; COBB LA, 1975, CIRCULATION, V52, P223; CUMMINS O, 1997, ADV CARDIAC LIFE SUP, P1; CUMMINS RO, 1984, LANCET, V2, P318; EISENBERG MS, 1989, AM J CARDIOL, V63, P443, DOI 10.1016/0002-9149(89)90316-0; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; Gentile D, 1988, J Tenn Med Assoc, V81, P144; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Gundry JW, 1999, CIRCULATION, V100, P1703, DOI 10.1161/01.CIR.100.16.1703; HALLSTROM AP, 2000, CRISP CURRENT AWARD; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kloeck W, 1997, CIRCULATION, V95, P2183, DOI 10.1161/01.CIR.95.8.2183; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Lui JCZ, 1999, RESUSCITATION, V41, P113, DOI 10.1016/S0300-9572(99)00058-1; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; *OFF INF PUBL AFF, 1997, CPSC WARNS SMOK DET; ORNATO JP, 1984, ANN EMERG MED, V13, P1096, DOI 10.1016/S0196-0644(84)80331-5; Riegel B, 1998, Am J Crit Care, V7, P402; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Sweeney TA, 1998, ANN EMERG MED, V31, P234, DOI 10.1016/S0196-0644(98)70313-0; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; 1998, NY TIMES        1126, pA22; 2000, EM TODAY        0614, P1	31	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1438	1441		10.1001/jama.284.11.1438	http://dx.doi.org/10.1001/jama.284.11.1438			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989410				2022-12-28	WOS:000089242500042
J	Kane, B				Kane, B			HIV vaccines: Inch by inch	ANNALS OF INTERNAL MEDICINE			English	News Item																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					489	490		10.7326/0003-4819-133-6-200009190-00102	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975984				2022-12-28	WOS:000089329700023
J	Blamey, RW; Wilson, ARM; Patnick, J				Blamey, RW; Wilson, ARM; Patnick, J			ABC of breast diseases - Screening for breast cancer	BRITISH MEDICAL JOURNAL			English	Review							MAMMOGRAPHY		City Hosp Nottingham, Nottingham, England; NHS Breast Screening Programme, Sheffield, S Yorkshire, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Blamey, RW (corresponding author), City Hosp Nottingham, Nottingham, England.							BLAMEY RW, 1999, NEW ENGL J MED, V8, P215; KERTILOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PAGE DL, 1992, BREAST, V1, P3; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189	5	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					689	693		10.1136/bmj.321.7262.689	http://dx.doi.org/10.1136/bmj.321.7262.689			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987778	Green Published			2022-12-28	WOS:000089444100033
J	Deakin, CD; Low, JL				Deakin, CD; Low, JL			Accuracy of the advanced trauma life support guidelines for predicting systolic blood pressure using carotid, femoral and radial pulses: observational study	BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp NHS Trust, Shackleton Dept Anaesthet, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp NHS Trust, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England		Deakin, CD (corresponding author), Southampton Gen Hosp NHS Trust, Shackleton Dept Anaesthet, Southampton SO16 6YD, Hants, England.							Collicott, 1985, ADV TRAUMA LIFE SUPP; POULTON TJ, 1988, ANN EMERG MED, V17, P107, DOI 10.1016/S0196-0644(88)80538-9	2	86	89	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					673	674		10.1136/bmj.321.7262.673	http://dx.doi.org/10.1136/bmj.321.7262.673			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987771	Bronze, Green Published			2022-12-28	WOS:000089444100024
J	Domeier, ME; Morse, DP; Knight, SW; Portereiko, M; Bass, BL; Mango, SE				Domeier, ME; Morse, DP; Knight, SW; Portereiko, M; Bass, BL; Mango, SE			A link between RNA interference and nonsense-mediated decay in Caenorhabditis elegans	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; GENETIC INTERFERENCE; PROTEIN; SURVEILLANCE; IDENTITY; HOMOLOG; PHA-4	Double-stranded RNA (dsRNA) inhibits expression of homologous genes by a process' involving messenger RNA degradation. To gain insight into the mechanism of degradation, we examined how RNA interference is affected by mutations in the smg genes, which are required for nonsense-mediated decay. For three of six smg genes tested, mutations resulted in animals that were initially silenced by dsRNA but then recovered; wild-type animals remained silenced. The Levels of target messenger RNAs were restored during recovery, and RNA editing and degradation of the dsRNA were identical to those of the wild type. We suggest that persistence of RNA interference relies on a subset of smg genes.	Univ Utah, Huntsman Canc Inst Ctr Children, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Mango, SE (corresponding author), Univ Utah, Huntsman Canc Inst Ctr Children, Salt Lake City, UT 84112 USA.			Mango, Susan/0000-0002-2146-3237	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA42014] Funding Source: Medline; PHS HHS [42014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON PW, COMMUNICATION; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRENNER S, 1974, GENETICS, V77, P71; Cali BM, 1999, GENETICS, V151, P605; Cali BM, 1998, MOL GEN GENET, V260, P176, DOI 10.1007/s004380050883; CZAPLINSKI K, 1995, RNA, V1, P610; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; HODGKIN J, 1989, GENETICS, V123, P301; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; KALTENBACH L, UNPUB; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Korf I, 1998, DEVELOPMENT, V125, P2469; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MANGO SE, 1994, DEVELOPMENT, V120, P3019; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Morrison M, 1997, P NATL ACAD SCI USA, V94, P9782, DOI 10.1073/pnas.94.18.9782; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Page MF, 1999, MOL CELL BIOL, V19, P5943; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; PULAK RA, 1988, MOL CELL BIOL, V8, P3748, DOI 10.1128/MCB.8.9.3748; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	32	122	154	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1928	1930		10.1126/science.289.5486.1928	http://dx.doi.org/10.1126/science.289.5486.1928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988072				2022-12-28	WOS:000089355800044
J	Galuske, RAW; Schlote, W; Bratzke, H; Singer, W				Galuske, RAW; Schlote, W; Bratzke, H; Singer, W			Interhemispheric asymmetries of the modular structure in human temporal cortex	SCIENCE			English	Article							CAT VISUAL-CORTEX; INTRINSIC CONNECTIONS; HUMAN-BRAIN; SPEECH; ORGANIZATION; SPECIFICITY; ANATOMY; REGION; AREAS	Language-relevant processing of auditory signals is Lateralized and involve the posterior part of Brodmann area 22. We found that the functional Lateralization in this area was accompanied by interhemispheric differences in the organization of the intrinsic: microcircuitry. Neuronal tract tracing revealed a modular network of long-range intrinsic connections Linking regularly spaced clusters of neurons. Although the cluster diameter was similar in both hemispheres, their spacing was about 20 percent Larger in the Left hemisphere. Assuming similar relations between functional and anatomical architecture as in visual cortex, the present data suggest that more functionally distinct columnar systems are included per surface unit in the Left than in the right area 22.	Max Planck Inst Brain Res, Dept Neurophysiol, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Edinger Inst, Neurol Inst, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Inst Forens Med, D-60596 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt	Galuske, RAW (corresponding author), Max Planck Inst Brain Res, Dept Neurophysiol, Deutschordenstr 46, D-60528 Frankfurt, Germany.	galuske@mpih-frankfurt.mpg.de	Singer, Wolf/D-6874-2012					AMIR Y, 1993, J COMP NEUROL, V334, P19, DOI 10.1002/cne.903340103; Baynes K, 1990, J Cogn Neurosci, V2, P159, DOI 10.1162/jocn.1990.2.3.159; Belin P, 1998, J NEUROSCI, V18, P6388; Belin P, 1998, J COGNITIVE NEUROSCI, V10, P536, DOI 10.1162/089892998562834; Binder JR, 1997, J NEUROSCI, V17, P353, DOI 10.1523/JNEUROSCI.17-01-00353.1997; Brodmann K, 1909, VERGLEICHENDE LOKALI; BURKHALTER A, 1993, J NEUROSCI, V13, P1916, DOI 10.1523/jneurosci.13-05-01916.1993; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; Fiez JA, 1996, CEREB CORTEX, V6, P1, DOI 10.1093/cercor/6.1.1; GALABURDA AM, 1978, ARCH NEUROL-CHICAGO, V35, P812, DOI 10.1001/archneur.1978.00500360036007; Galuske RAW, 1996, CEREB CORTEX, V6, P417, DOI 10.1093/cercor/6.3.417; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; Hutsler JJ, 1996, CEREB CORTEX, V6, P260, DOI 10.1093/cercor/6.2.260; KISVARDAY ZF, 1992, NEUROSCIENCE, V46, P275, DOI 10.1016/0306-4522(92)90050-C; LOFTUS WC, 1993, CEREB CORTEX, V3, P348; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, ANNU REV PSYCHOL, V45, P333, DOI 10.1146/annurev.psych.45.1.333; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; Schmidt KE, 1997, J NEUROSCI, V17, P5480; SCHWARTZ J, 1980, SCIENCE, V207, P1380, DOI 10.1126/science.7355297; SELDON HL, 1981, BRAIN RES, V229, P277, DOI 10.1016/0006-8993(81)90994-X; SMITH A, 1975, NEUROLOGY, V25, P813, DOI 10.1212/WNL.25.9.813; TSO DY, 1986, J NEUROSCI, V6, P1160; von Economo C, 1925, CYTOARCHITEKTONIK HI; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/jneurosci.14-04-01908.1994	29	189	193	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2000	289	5486					1946	1949		10.1126/science.289.5486.1946	http://dx.doi.org/10.1126/science.289.5486.1946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988077				2022-12-28	WOS:000089355800049
J	Depuyt, A; Carty, E; Mason, I; Durcan, C; Epstein, O				Depuyt, A; Carty, E; Mason, I; Durcan, C; Epstein, O			CyberTranscriber - the virtual medical secretary on your desk	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Free Hosp, Ctr Gastroenterol, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Depuyt, A (corresponding author), Royal Free Hosp, Ctr Gastroenterol, Pond St, London NW3 2QG, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					618	618		10.1136/bmj.321.7261.618	http://dx.doi.org/10.1136/bmj.321.7261.618			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977844	Green Published, Bronze			2022-12-28	WOS:000089243200025
J	Rogers, DJ; Randolph, SE				Rogers, DJ; Randolph, SE			The global spread of malaria in a future, warmer world	SCIENCE			English	Article							CLIMATE-CHANGE; SENSITIVITY; DISEASES; DENGUE; IMPACT; RISK	The frequent warnings that global climate change will allow falciparum malaria to spread into northern Latitudes, including Europe and Large parts of the United States, are based on biological transmission models driven principally by temperature. These models were assessed for their value in predicting present, and therefore future, malaria distribution. In an alternative statistical approach, the recorded present-day global distribution of falciparum malaria was used to establish the current multivariate climatic constraints. These results were applied to future climate scenarios to predict future distributions, which showed remarkably few changes, even under the most extreme scenarios.	Univ Oxford, Dept Zool, Trypanosomiasis & Land Use Africa Res Grp, Oxford OX1 3PS, England; Univ Oxford, Dept Zool, Oxford Tick Res Grp, Oxford OX1 3PS, England	University of Oxford; University of Oxford	Rogers, DJ (corresponding author), Univ Oxford, Dept Zool, Trypanosomiasis & Land Use Africa Res Grp, S Parks Rd, Oxford OX1 3PS, England.	david.rogers@zoology.ox.ac.uk	Randolph, Sarah/AAR-9346-2021					ANDERSON R M, 1991; Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241; HAINES A, 1999, CLIMATE CHANGE HUMAN; HULME M, 1998, CLIMATE CHANGE SCENA; Johns TC, 1997, CLIM DYNAM, V13, P103, DOI 10.1007/s003820050155; Lindsay SW, 1998, B WORLD HEALTH ORGAN, V76, P33; MA ZK, 1995, PHOTOGRAMM ENG REM S, V61, P435; Martens P, 1999, GLOBAL ENVIRON CHANG, V9, pS89, DOI 10.1016/S0959-3780(99)00020-5; Martens P, 1998, HLTH CLIMATE CHANGE; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; Martens WJM, 1997, CLIMATIC CHANGE, V35, P145, DOI 10.1023/A:1005365413932; MARTENS WJM, 1995, GLOBAL ENVIRON CHANG, V5, P195, DOI 10.1016/0959-3780(95)00051-O; MARTENS WJM, 1994, 461502003 DUTCH NAT; MARTIN PH, 1995, AMBIO, V24, P200; Matsuoka Y, 1994, J GLOBAL ENV ENG, V1, P1; McMichael AJ, 1998, BRIT MED BULL, V54, P475; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; Patz JA, 1998, ENVIRON HEALTH PERSP, V106, P147, DOI 10.1289/ehp.98106147; Patz JA, 1999, CURR OPIN MICROBIOL, V2, P445, DOI 10.1016/S1369-5274(99)80078-2; REEVES WC, 1994, J MED ENTOMOL, V31, P323, DOI 10.1093/jmedent/31.3.323; Rogers DJ, 1996, ANN TROP MED PARASIT, V90, P225, DOI 10.1080/00034983.1996.11813049; Schwartlander B, 1997, LANCET, V350, P141, DOI 10.1016/S0140-6736(05)61844-2; Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2; SNOW RW, 1999, WORLD HLTH REPORT 19; Taubes G, 1997, SCIENCE, V278, P1004, DOI 10.1126/science.278.5340.1004; *WHO, 1989, 89967 WHOVBC; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P285	27	384	402	0	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 8	2000	289	5485					1763	1766		10.1126/science.289.5485.1763	http://dx.doi.org/10.1126/science.289.5485.1763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352BT	10976072				2022-12-28	WOS:000089195200050
J	Eichler, R; Bruchle, W; Dressler, R; Dullmann, CE; Eichler, B; Gaggeler, HW; Gregorich, KE; Hoffman, DC; Hubener, S; Jost, DT; Kirbach, UW; Laue, CA; Lavanchy, VM; Nitsche, H; Patin, JB; Piguet, D; Schadel, M; Shaughnessy, DA; Strellis, DA; Taut, S; Tobler, L; Tsyganov, YS; Turler, A; Vahle, A; Wilk, PA; Yakushev, AB				Eichler, R; Bruchle, W; Dressler, R; Dullmann, CE; Eichler, B; Gaggeler, HW; Gregorich, KE; Hoffman, DC; Hubener, S; Jost, DT; Kirbach, UW; Laue, CA; Lavanchy, VM; Nitsche, H; Patin, JB; Piguet, D; Schadel, M; Shaughnessy, DA; Strellis, DA; Taut, S; Tobler, L; Tsyganov, YS; Turler, A; Vahle, A; Wilk, PA; Yakushev, AB			Chemical characterization of bohrium (element 107)	NATURE			English	Article							SUPERHEAVY NUCLEI; SEABORGIUM; IDENTIFICATION; CHEMISTRY; ISOTOPES; RHENIUM; SEARCH	The arrangement of the chemical elements in the periodic table highlights resemblances in chemical properties, which reflect the elements' electronic structure. For the heaviest elements, however, deviations in the periodicity of chemical properties are expected(1-3): electrons in orbitals with a high probability density near the nucleus are accelerated by the large nuclear charges to relativistic velocities, which increase their binding energies and cause orbital contraction. This leads to more efficient screening of the nuclear charge and corresponding destabilization of the outer d and f orbitals: it is these changes that can give rise to unexpected chemical properties. The synthesis of increasingly heavy elements(4-6), now including that of elements 114, 116 and 118, allows the investigation of this effect, provided sufficiently long-lived isotopes for chemical characterization are available(7). In the case of elements 104 and 105, for example, relativistic effects interrupt characteristic trends in the chemical properties of the elements constituting the corresponding columns of the periodic table(8), whereas element 106 behaves in accordance with the expected periodicity(9-12). Here we report the chemical separation and characterization of six atoms of element 107 (bohrium, Bh), in the form of its oxychloride. We find that this compound is less volatile than the oxychlorides of the lighter elements of group VII, thus confirming relativistic calculations(13) that predict the behaviour of bohrium, like that of element 106, to coincide with that expected on the basis of its position in the periodic table.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Paul Scherrer Inst, Lab Radio & Umweltchem, CH-5232 Villigen, Switzerland; Gesell Schwerionenforsch GmbH, D-64291 Darmstadt, Germany; Tech Univ Dresden, Inst Analyt Chem, D-01062 Dresden, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Nucl Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Rossendorf Inc, Forschungszentrum Rossendorf EV, Inst Radiochem, D-01314 Dresden, Germany; Joint Inst Nucl Res, Flerov Lab Nucl React, Dubna 141980, Russia	University of Bern; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Helmholtz Association; Technische Universitat Dresden; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Joint Institute for Nuclear Research - Russia	Gaggeler, HW (corresponding author), Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland.		Wilk, Philip A/B-5954-2008; Düllmann, Christoph E/L-3401-2017; Türler, Andreas/D-3913-2014; Eichler, Robert/G-5130-2011	Düllmann, Christoph E/0000-0002-1194-0423; Türler, Andreas/0000-0002-4274-1056; Eichler, Robert/0000-0002-6690-7284; Shaughnessy, Dawn/0000-0001-6589-1447				DROBOT DV, 1972, ZH NEORG KHIM+, V17, P1762; DROBOT DV, 1972, RUSS J INORG CHEM, V17, P914; Eichler B, 1999, J PHYS CHEM A, V103, P9296, DOI 10.1021/jp9917751; Eichler R, 2000, RADIOCHIM ACTA, V88, P87, DOI 10.1524/ract.2000.88.2.087; Eichler R, 1999, RADIOCHIM ACTA, V87, P151; Feller J, 1998, Z NATURFORSCH B, V53, P184, DOI 10.1515/znb-1998-0210; Gaggeler H.W., 1997, P RA WELCH FDN 41 C, P43; GAGGELER HW, 1991, NUCL INSTRUM METH A, V309, P201, DOI 10.1016/0168-9002(91)90103-W; GIBSON JK, 1991, J FLUORINE CHEM, V55, P299, DOI 10.1016/S0022-1139(00)82358-1; GUEST A, 1972, CAN J CHEMISTRY, V50, P1807, DOI 10.1139/v72-290; HOFMANN S, 1995, Z PHYS A-HADRON NUCL, V350, P281, DOI 10.1007/BF01291182; KRATZ JV, 1999, HEAVY ELEMENTS RELAT, P129; Lougheed R, 1997, NATURE, V388, P21, DOI 10.1038/40272; MUNZENBERG G, 1981, Z PHYS A-HADRON NUCL, V300, P107, DOI 10.1007/BF01412623; Ninov V, 1999, PHYS REV LETT, V83, P1104, DOI 10.1103/PhysRevLett.83.1104; Oganessian YT, 1999, PHYS REV LETT, V83, P3154, DOI 10.1103/PhysRevLett.83.3154; Oganessian YT, 1999, NATURE, V400, P242, DOI 10.1038/22281; Pershina V, 2000, J CHEM PHYS, V113, P1441, DOI 10.1063/1.481961; Pershina VG, 1996, CHEM REV, V96, P1977, DOI 10.1021/cr941182g; PYYKKO P, 1988, CHEM REV, V88, P563, DOI 10.1021/cr00085a006; RINKE K, 1967, J LESS-COMMON MET, V12, P497, DOI 10.1016/0022-5088(67)90022-7; Schadel M, 1997, NATURE, V388, P55, DOI 10.1038/40375; SCHADEL M, 1995, RADIOCHIM ACTA, V68, P7; Schwerdtfeger P, 1998, ENCY COMPUTATIONAL C, V4, P2480; Turler A, 1999, ANGEW CHEM INT EDIT, V38, P2212, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2212::AID-ANIE2212>3.0.CO;2-6; WILK PA, IN PRESS PHYS REV LE; ZVARA I, 1984, SOV RADIOCHEM+, V26, P72; Zvara I, 1998, RADIOCHIM ACTA, V81, P179; ZVARA I, 1984, RADIOKHIMIYA, V26, P76; Zvara I., 1985, RADIOCHIM ACTA, V38, P95, DOI DOI 10.1524/RACT.1985.38.2.95	30	95	99	1	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					63	65		10.1038/35024044	http://dx.doi.org/10.1038/35024044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993071				2022-12-28	WOS:000089124000040
J	Maienschein, J				Maienschein, J			Old wine in new bottles - An agenda for biology that's in its second century - and still going strong.	NATURE			English	Editorial Material									Arizona State Univ, Dept Philosophy, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Maienschein, J (corresponding author), Arizona State Univ, Dept Philosophy, Tempe, AZ 85287 USA.								0	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					21	21		10.1038/35024170	http://dx.doi.org/10.1038/35024170			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993052	Bronze			2022-12-28	WOS:000089124000020
J	Marlar, RA; Leonard, BL; Billman, BR; Lambert, PM; Marlar, JE				Marlar, RA; Leonard, BL; Billman, BR; Lambert, PM; Marlar, JE			Biochemical evidence of cannibalism at a prehistoric Puebloan site in southwestern Colorado	NATURE			English	Article								The existence of cannibalism is one of the most controversial issues in the archaeology of the American Southwest. Disarticulated, cut-marked and heat-altered human remains from nonburial contexts at prehistoric Puebloan (Anasazi) archaeological sites in the Four Corners region of the American Southwest have been interpreted by some scholars as evidence of cannibalism(1). Osteological studies indicate that many of the disarticulated bodies found at these sites were processed in a manner consistent with food preparation(2). Opponents of this interpretation point out that non-cannibalistic practices such as secondary interment, corpse mutilation and ritualized witch executions might account for the assemblages(3-7). Osteological evidence alone does not document the actual ingestion of human flesh. Here we show consumption of human flesh did occur as demonstrated in preserved human waste containing identifiable human tissue remains from a site with osteological evidence of cannibalism.	Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Colorado Archaeol Soc, Denver, CO 80250 USA; Soil Syst Inc, Phoenix, AZ 85004 USA; Univ N Carolina, Dept Anthropol, Chapel Hill, NC 27599 USA; Utah State Univ, Dept Sociol Social Work & Anthropol, Logan, UT 84322 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of North Carolina; University of North Carolina Chapel Hill; Utah System of Higher Education; Utah State University	Marlar, RA (corresponding author), Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA.	marlarr@den-res.org	Lambert, Patricia/E-8570-2010	Billman, Brian/0000-0002-7818-7878				[Anonymous], 1992, DIET DEMOGRAPHY DIS; BAKER S, 1990, THESIS B YOUNG U PRO; Billman BR, 2000, AM ANTIQUITY, V65, P145, DOI 10.2307/2694812; BILLMAN BR, IN PRESS SOIL SYSTEM, V22; BROWN P, 1983, ETHNOGRAPHY CANNIBAL; BULLOCK PY, 1991, KIVA, V57, P5; CHAGNON NA, 1998, YANONAMO; Darling JA, 1998, AM ANTHROPOL, V100, P732; Dongoske KE, 2000, AM ANTIQUITY, V65, P179, DOI 10.2307/2694813; GRAYSON DK, 1990, J ANTHROPOL RES, V46, P223, DOI 10.1086/jar.46.3.3630425; HAMMOND W, 1998, PRELIMINARY REPORT 1, P22; Keenleyside A, 1997, ARCTIC, V50, P36; Lambert PM, 2000, AM ANTIQUITY, V65, P397, DOI 10.2307/2694066; Lambert PM, 2000, INT J OSTEOARCHAEOL, V10, P49, DOI 10.1002/(SICI)1099-1212(200001/02)10:1<49::AID-OA504>3.0.CO;2-B; LAMBERT PM, 1999, SOIL SYSTEMS PUBLICA, V22, pCH6; LEONARD BL, IN PRESS SOIL SYSTEM, V22, pCH3; MINNIS PE, 1989, AM ANTIQUITY, V54, P543, DOI 10.2307/280782; NEWMAN ME, IN PRESS SOIL SYSTEM, V22; REINHARD KJ, IN PRESS SOIL SYSTEM, V22; Turner C.G., 1999, MAN CORN CANNIBALISM; VINTON SD, 1997, THESIS U NEBRASKA; WHITE TIM, 1992, 5MTUMR2346 PRINC U; [No title captured]	23	77	78	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					74	78		10.1038/35024064	http://dx.doi.org/10.1038/35024064			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	350WE	10993075				2022-12-28	WOS:000089124000044
J	Prinzbach, H; Weller, A; Landenberger, P; Wahl, F; Worth, J; Scott, LT; Gelmont, M; Olevano, D; von Issendorff, B				Prinzbach, H; Weller, A; Landenberger, P; Wahl, F; Worth, J; Scott, LT; Gelmont, M; Olevano, D; von Issendorff, B			Gas-phase production and photoelectron spectroscopy of the smallest fullerene, C-20	NATURE			English	Article							CARBON CLUSTERS; PAGODANE ROUTE; DODECAHEDRANES; RINGS; C-36; CHAINS; IONS	Fullerenes are graphitic cage structures incorporating exactly twelve pentagons(1). The smallest possible fullerene is thus C-20, which consists solely of pentagons. But the extreme curvature and reactivity of this structure have led to doubts about its existence and stability. Although theoretical calculations have identified, besides this cage, a bowl and a monocyclic ring isomer as low-energy members of the C-20 cluster family(2), only ring isomers of C-20 have been observed(3-6) so far. Here we show that the cage-structured fullerene C-20 can be produced from its perhydrogenated form (dodecahedrane C20H20) by replacing the hydrogen atoms bwith relatively weakly bound bromine atoms, followed by gasphase debromination. For comparison we have also produced the bowl isomer of C-20 using the same procedure. We characterize the generated C-20 clusters using mass-selective anion photoelectron spectroscopy; the observed electron affinities and vibrational structures of these two C-20 isomers differ significantly from each other, as well as from those of the known monocyclic isomer. We expect that these unique C-20 species will serve as a benchmark test for further theoretical studies.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Univ Freiburg, Fak Phys, D-79104 Freiburg, Germany	University of Freiburg; Boston College; University of Freiburg	Prinzbach, H (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany.		Scott, Lawrence T./G-5020-2018; von Issendorff, Bernd/B-1941-2015	Scott, Lawrence T./0000-0003-3496-8506; von Issendorff, Bernd/0000-0002-4358-4494				BECKHAUS HD, 1995, J AM CHEM SOC, V117, P8885, DOI 10.1021/ja00139a036; Bertau M, 1997, TETRAHEDRON, V53, P10029, DOI 10.1016/S0040-4020(97)00345-1; CIOSLOWSKY J, 1995, J AM CHEM SOC, V17, P10381; Duskesas G, 1997, THEOR CHEM ACC, V97, P110, DOI 10.1007/s002140050243; Fowler PW, 1999, CHEM PHYS LETT, V300, P369, DOI 10.1016/S0009-2614(98)01385-2; Galli G, 1998, PHYS REV B, V57, P1860, DOI 10.1103/PhysRevB.57.1860; HABERLAND H, 1991, REV SCI INSTRUM, V62, P2621, DOI 10.1063/1.1142241; HANDSCHUH H, 1995, PHYS REV LETT, V74, P1095, DOI 10.1103/PhysRevLett.74.1095; Heilbronner E., 1993, REFLECTIONS SYMMETRY; Koshio A, 2000, J AM CHEM SOC, V122, P398, DOI 10.1021/ja9934347; KROTO HW, 1987, NATURE, V329, P529, DOI 10.1038/329529a0; KROTO HW, 1994, INT J MASS SPECTROM, V138, P1, DOI 10.1016/0168-1176(94)04062-1; MCEWEN AB, 1986, J ORG CHEM, V51, P4357, DOI 10.1021/jo00373a006; Melder JP, 1996, RES CHEM INTERMEDIAT, V22, P667, DOI 10.1163/156856796X00142; Piskoti C, 1998, NATURE, V393, P771, DOI 10.1038/31668; PRINZBACH H, 1994, ANGEW CHEM INT EDIT, V33, P2239, DOI 10.1002/anie.199422391; Scott LT, 1997, J AM CHEM SOC, V119, P10963, DOI 10.1021/ja972019g; Van Orden A, 1998, CHEM REV, V98, P2313, DOI 10.1021/cr970086n; VON HELDEN G, 1993, CHEM PHYS LETT, V204, P15, DOI 10.1016/0009-2614(93)85599-J; VON HELDEN G, 1993, NATURE, V363, P60, DOI 10.1038/363060a0; WAHL F, 1993, ANGEW CHEM INT EDIT, V32, P1722, DOI 10.1002/anie.199317221; Wakabayashi T, 1997, J CHEM PHYS, V107, P4783, DOI 10.1063/1.474841; YANG S, 1988, CHEM PHYS LETT, V144, P431, DOI 10.1016/0009-2614(88)87291-9	23	655	682	7	137	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					60	63		10.1038/35024037	http://dx.doi.org/10.1038/35024037			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993070				2022-12-28	WOS:000089124000039
J	Brotherton, SE; Simon, FA; Tomany, SC				Brotherton, SE; Simon, FA; Tomany, SC			US graduate medical education, 1999-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This report examines data collected through the American Medical Association Annual Survey of Graduate Medical Education Programs for 1999-2000 and compares these data with similar data collected during the past several years. The number of resident physicians enrolled during 1999-2000 was 606 more than during the previous year; graduates of US osteopathic medical schools (USDOs) had the greatest proportional increase (5.2%), The number of physicians entering graduate medical education (GME) for the first time in 1999-2000 (n = 22 320) also increased, with the number of USDOs increasing the most, by 14.5%, followed by international medical graduates (IMGs) at 6.5%, Between academic years 1998-1999 and 1999-2000, the number of physicians with prior US GME occupying first-year positions for which prior GME was not required (GY1 positions) increased by more than 300 (12%), Compared with graduates of US allopathic and osteopathic medical schools (USMGs), IMGs were more likely to seek additional training after graduating from a program. However, this was not true of IMGs who were US citizens or who had been naturalized or had permanent residency status. For the second year in a row, the number of white graduates of US allopathic medical schools (USMDs) entering GME has declined (2.0%), while the number of Hispanic GY1 USMDs has increased by 10.5%. The number of Asian CY1 USMDs increased steadily (11.0%) but the number of blacks decreased by 7.1% from 1998-1999, Growth continues, both in numbers and in heterogeneity of physicians in training, and must be considered in the future development of policy to guide US GME.	Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA; Univ Wisconsin, Dept Ophthalmol, Madison, WI USA	American Medical Association; University of Wisconsin System; University of Wisconsin Madison	Simon, FA (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60610 USA.	frank_simon@ama-assn.org						*ASS AM MED COLL, 2000, AAMC DAT BOOK STAT I; *COUNC GRAD MED ED, 1999, COGME PHYS WORKF POL; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; *COUNC GRAD MED ED, 1996, PAT CAR PHYS SUPPL R; DeVille K, 1999, AM J PUBLIC HEALTH, V89, P1256, DOI 10.2105/AJPH.89.8.1256; Dunn MR, 1997, JAMA-J AM MED ASSOC, V278, P750, DOI 10.1001/jama.278.9.750; Dunn MR, 1998, JAMA-J AM MED ASSOC, V280, P809, DOI 10.1001/jama.280.9.809; *MED PAYM ADV COMM, 1999, RETH MED PAYM POL GR; Miller RS, 1999, JAMA-J AM MED ASSOC, V282, P855, DOI 10.1001/jama.282.9.855; MITKA M, 1997, AM MED NEWS     0120, P1; Pardes H, 2000, JAMA-J AM MED ASSOC, V283, P2427, DOI 10.1001/jama.283.18.2427; Salsberg E, 2000, JAMA-J AM MED ASSOC, V283, P1749, DOI 10.1001/jama.283.13.1749	12	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1121	1126		10.1001/jama.284.9.1121	http://dx.doi.org/10.1001/jama.284.9.1121			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974692				2022-12-28	WOS:000089037200013
J	Clark, RT				Clark, RT			Baby Jose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Clark, RT (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Fost N, 1999, JAMA-J AM MED ASSOC, V281, P2041, DOI 10.1001/jama.281.21.2041; Kuhse H, 1986, J Med Humanit Bioeth, V7, P79, DOI 10.1007/BF01117900	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1144	1145		10.1001/jama.284.9.1144	http://dx.doi.org/10.1001/jama.284.9.1144			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974699				2022-12-28	WOS:000089037200020
J	Collins, MM; MacDonald, R; Wilt, TJ				Collins, MM; MacDonald, R; Wilt, TJ			Diagnosis and treatment of chronic abacterial prostatitis: A systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC IDIOPATHIC PROSTATITIS; NON-BACTERIAL PROSTATITIS; PELVIC PAIN SYNDROME; NONBACTERIAL PROSTATITIS; DOUBLE-BLIND; ULTRASONOGRAPHIC FINDINGS; PHYSICIAN VISITS; NATIONAL SURVEY; SYMPTOM INDEX; YOUNGER MEN	Purpose: The optimal management of chronic abacterial prostatitis is not known. A systematic review of the literature was done to answer the following questions: Are there accurate, reliable tests to diagnose chronic abacterial prostatitis? Are there effective therapies for it? Data Sources: Studies were identified by searching MEDLINE (1966 to 1999), the Cochrane Library, and bibliographies of identified articles and reviews and by contacting an expert. Study Selection: Diagnostic test articles were included if they reported on controlled studies; treatment articles were included if they reported on randomized or controlled trials. No language restrictions were applied. Data Extraction: For each selected article, two investigators independently extracted key data on study design, patient characteristics, diagnostic test or treatment characteristics, and outcomes. Data Synthesis: 19 diagnostic test articles and 14 treatment trials met the inclusion criteria. The disparity among studies in design, interventions, and other factors precluded quantitative analysis or pooling of the findings. Diagnostic test articles included 1384 men (mean age, 33 to 67 years) and evaluated infection; inflammation, immunology, and biochemistry; psychological factors; and ultrasonography. Treatment trials included 570 men (mean age, 38 to 45 years) and evaluated medications used to treat benign prostatic hyperplasia, anti-inflammatory drugs, antibiotics, thermotherapy, and miscellaneous medications. No trial was done in the United States. Conclusions: There is no gold-standard diagnostic test for chronic abacterial prostatitis, and the methodologic quality of available studies of diagnostic tests is low. The few treatment trials are methodologically weak and involved small samples. The routine use of antibiotics acid alpha-blockers to treat chronic abacterial prostatitis is not supported by the existing evidence.	Massachusetts Gen Hosp, Boston, MA 02114 USA; Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res 1110, Vet Affairs Coordinating Ctr Cochrane Review Grp, Minneapolis, MN 55417 USA; Minneapolis Vet Affairs Ctr Chron Dis Outcomes Re, Minneapolis, MN USA	Harvard University; Massachusetts General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Wilt, TJ (corresponding author), Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res 1110, Vet Affairs Coordinating Ctr Cochrane Review Grp, 1 Vet Dr, Minneapolis, MN 55417 USA.	tim.wilt@med.va.gov			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053736, U01DK053736] Funding Source: NIH RePORTER; AHRQ HHS [HS 08397] Funding Source: Medline; NIDDK NIH HHS [DK53736] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELATIF OMA, 1991, HUM PATHOL, V22, P41, DOI 10.1016/0046-8177(91)90059-X; Alexander RB, 1996, UROLOGY, V48, P568, DOI 10.1016/S0090-4295(96)00234-8; Alexander RB, 1997, UROLOGY, V50, P893, DOI 10.1016/S0090-4295(97)00456-1; Alexander RB, 1998, UROLOGY, V52, P744, DOI 10.1016/S0090-4295(98)00390-2; ANDERSON RU, 1979, J UROLOGY, V121, P292, DOI 10.1016/S0022-5347(17)56758-0; Aus G, 1996, BRIT J UROL, V77, P851, DOI 10.1046/j.1464-410X.1996.01014.x; Baert L, 1974, Curr Med Res Opin, V2, P631; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Bennett Betsy D., 1993, P399; Berger RE, 1997, J UROLOGY, V157, P863, DOI 10.1016/S0022-5347(01)65066-3; BERGER RE, 1989, J UROLOGY, V141, P328, DOI 10.1016/S0022-5347(17)40757-9; Berghuis JP, 1996, J PSYCHOSOM RES, V41, P313, DOI 10.1016/S0022-3999(96)00157-2; Collins MM, 1998, UROLOGY, V52, P422; Collins MM, 1999, UROLOGY, V53, P921; Collins MM, 2000, UROLOGY, V55, P403, DOI 10.1016/S0090-4295(99)00536-1; Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X; COLLINS MM, 2000, COCHRANE DATABASE SY, V2; DELAROSETTE JJMCH, 1995, EUR UROL, V27, P47; DELAROSETTE JJMCH, 1992, EUR UROL, V22, P14; DELAROSETTE JJMCH, 1992, EUR UROL, V22, P222; DELAROSETTE JJMCH, 1993, UROLOGY, V42, P654, DOI 10.1016/0090-4295(93)90529-J; DELAROSETTE JJMCH, 1993, UROLOGY, V41, P301, DOI 10.1016/0090-4295(93)90584-W; DELAROSETTE JJMCH, 1992, UROL INT, V48, P323; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DOBLE A, 1991, UROLOGY, V38, P247, DOI 10.1016/S0090-4295(91)80355-B; DOBLE A, 1989, UROL CLIN N AM, V16, P763; Domingue G J Sr, 1998, Curr Opin Urol, V8, P45, DOI 10.1097/00042307-199801000-00009; Drabick JJ, 1997, MIL MED, V162, P380, DOI 10.1093/milmed/162.6.380; DRACH GW, 1978, J UROLOGY, V120, P266, DOI 10.1016/S0022-5347(17)57135-9; EGAN KJ, 1994, CLIN J PAIN, V10, P218, DOI 10.1097/00002508-199409000-00008; FOWLER J, 1996, ADULT PED UROLOGY, V2, P1715; Johansen TEB, 1998, EUR UROL, V34, P457; KELTIKANGASJARVINEN L, 1989, EUR UROL, V16, P181; Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236; Krieger JN, 1996, UROLOGY, V48, P715, DOI 10.1016/S0090-4295(96)00421-9; Krieger JN, 1996, J CLIN MICROBIOL, V34, P3120, DOI 10.1128/JCM.34.12.3120-3128.1996; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; Leskinen M, 1999, UROLOGY, V53, P502, DOI 10.1016/S0090-4295(98)00540-8; Letzel, 1983, THERAPIEWOCHE, V33, P4694, DOI [10.1002/central/CN-00175452/full, DOI 10.1002/CENTRAL/CN-00175452/FULL]; Lipsky BA, 1999, AM J MED, V106, P327, DOI 10.1016/S0002-9343(99)00017-0; Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X; LOWENTRITT JE, 1995, J UROLOGY, V154, P1378, DOI 10.1016/S0022-5347(01)66870-8; MARMAR JL, 1980, UROLOGY, V16, P261, DOI 10.1016/0090-4295(80)90038-2; MartinezGarcia F, 1996, J UROLOGY, V156, P340, DOI 10.1097/00005392-199608000-00003; MEARES EM, 1973, JAMA-J AM MED ASSOC, V224, P1372, DOI 10.1001/jama.224.10.1372; MEARES EM, 1968, INVEST UROL, V5, P492; MEARES EM, 1991, MED CLIN N AM, V75, P405, DOI 10.1016/S0025-7125(16)30462-X; MEARES EM, 1998, CAMPBELLS UROLOGY, V1, P615; MONTORSI F, 1993, PROSTATE, V22, P139, DOI 10.1002/pros.2990220206; Moon T D, 1998, Curr Opin Urol, V8, P39, DOI 10.1097/00042307-199801000-00008; Moon TD, 1997, UROLOGY, V50, P543, DOI 10.1016/S0090-4295(97)00308-7; Moon TD, 1997, UROLOGY, V50, P700, DOI 10.1016/S0090-4295(97)00336-1; Muraro G. B., 1995, Archivio di Medicina Interna, V47, P73; NADLER R, 1998, J UROLOGY, pA271; Nickel J C, 1997, Tech Urol, V3, P38; Nickel JC, 1996, LANCET, V347, P1711; Nickel JC, 1996, J UROLOGY, V155, P1950, DOI 10.1016/S0022-5347(01)66056-7; Nickel JC, 1998, UROLOGY, V52, P797, DOI 10.1016/S0090-4295(98)00297-0; Nickel JC, 1998, UROL CLIN N AM, V25, P677, DOI 10.1016/S0094-0143(05)70056-2; Nickel JC, 1998, UROLOGY, V51, P362; NICKEL JC, 1992, J UROLOGY, V147, P398, DOI 10.1016/S0022-5347(17)37247-6; Okada S, 1985, Hinyokika Kiyo, V31, P179; OSBORN DE, 1981, BRIT J UROL, V53, P621, DOI 10.1111/j.1464-410X.1981.tb03275.x; Pansadoro V, 1996, EUR UROL, V30, P24; Persson BE, 1996, J UROLOGY, V155, P961, DOI 10.1016/S0022-5347(01)66358-4; Persson BE, 1996, J UROLOGY, V155, P958, DOI 10.1016/S0022-5347(01)66357-2; PFAU A, 1986, UROL CLIN N AM, V13, P695; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Roberts RO, 1998, UROLOGY, V51, P578, DOI 10.1016/S0090-4295(98)00034-X; Roberts RO, 1997, UROLOGY, V49, P809, DOI 10.1016/S0090-4295(97)00235-5; Sagliaschi G, 1987, Recenti Prog Med, V78, P264; Sauvain JL, 1997, J RADIOL, V78, P491; Schaeffer Anthony J., 1993, P414; Shah Tariq K., 1993, Journal of Urology, V149, p405A; SHORTLIFFE LMD, 1986, MEDICINE, V65, P399, DOI 10.1097/00005792-198611000-00005; SHORTLIFFE LMD, 1992, J UROLOGY, V148, P1461; Shoskes DA, 1999, UROLOGY, V54, P960, DOI 10.1016/S0090-4295(99)00358-1; SIMMONS PD, 1985, BRIT J UROL, V57, P43, DOI 10.1111/j.1464-410X.1985.tb08982.x; Stamey T, 1980, PATHOGENESIS TREATME, P342; STERN J, 1999, CLIN EVIDENCE, V2, P311; STROHMAIER WL, 1988, HELV CHIR ACTA, V55, P301; TaylorRobinson D, 1996, CLIN INFECT DIS, V23, P671, DOI 10.1093/clinids/23.4.671; Tchetgen MBN, 1997, UROL CLIN N AM, V24, P283, DOI 10.1016/S0094-0143(05)70374-8; Thin RN, 1997, INT J STD AIDS, V8, P475; VASSILY O, 1999, J UROL S, V16, pA33; WEDREN H, 1987, SCAND J UROL NEPHROL, V21, P81, DOI 10.3109/00365598709180298; Wenninger K, 1996, J UROLOGY, V155, P965, DOI 10.1016/S0022-5347(01)66359-6; WISHNOW KI, 1982, J UROLOGY, V127, P689, DOI 10.1016/S0022-5347(17)53998-1; Zaichick V. Ye, 1996, International Urology and Nephrology, V28, P687, DOI 10.1007/BF02552165	89	101	111	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					367	381		10.7326/0003-4819-133-5-200009050-00013	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00013			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979882				2022-12-28	WOS:000089111900007
J	Oechel, WC; Vourlitis, GL; Hastings, SJ; Zulueta, RC; Hinzman, L; Kane, D				Oechel, WC; Vourlitis, GL; Hastings, SJ; Zulueta, RC; Hinzman, L; Kane, D			Acclimation of ecosystem CO2 exchange in the Alaskan Arctic in response to decadal climate warming	NATURE			English	Article							TUNDRA ECOSYSTEMS; ATMOSPHERIC CO2; TUSSOCK TUNDRA; CARBON STORAGE; ENERGY FLUXES; NET CO2; GROWTH; SYSTEM; SOILS	Long-term sequestration of carbon in Alaskan Arctic tundra ecosystems was reversed by warming and drying of the climate in the early 1980s, resulting in substantial losses of terrestrial carbon(1,2). But recent measurements suggest that continued warming and drying has resulted in diminished CO2 efflux, and in some cases, summer CO2 sink activity(3,4). Here we compile summer CO2 flux data for two Arctic ecosystems from 1960 to the end of 1998. The results show that a return to summer sink activity has come during the warmest and driest period observed over the past four decades, and indicates a previously undemonstrated capacity for ecosystems to metabolically adjust to long-term (decadal or longer) changes in climate. The mechanisms involved are likely to include changes in nutrient cycling, physiological acclimation, and population and community reorganization. Nevertheless, despite the observed acclimation, the Arctic ecosystems studied are still annual net sources of CO2 to the atmosphere of at least 40 g C m(-2) yr(-1), due to winter release of CO2, implying that further climate change may still exacerbate CO2 emissions from Arctic ecosystems.	San Diego State Univ, Dept Biol, Global Change Res Grp, San Diego, CA 92182 USA; Calif State Univ, Program Biomed Sci, San Marcos, CA 92096 USA; Univ Alaska, Inst Water Resources, Fairbanks, AK 99706 USA	California State University System; San Diego State University; California State University System; California State University San Marcos; University of Alaska System; University of Alaska Fairbanks	Oechel, WC (corresponding author), San Diego State Univ, Dept Biol, Global Change Res Grp, San Diego, CA 92182 USA.		Oechel, Walter/M-1347-2019; Oechel, Walter C/F-9361-2010	Oechel, Walter C/0000-0002-3504-026X				BILLINGS WD, 1982, OECOLOGIA, V52, P7; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; CHAPIN FS, 1995, ECOLOGY, V76, P694, DOI 10.2307/1939337; CHAPIN FS, 1985, ECOLOGY, V66, P564, DOI 10.2307/1940405; Christensen TR, 1999, APPL SOIL ECOL, V11, P127, DOI 10.1016/S0929-1393(98)00146-2; COYNE PI, 1975, J APPL ECOL, V12, P587, DOI 10.2307/2402176; GRULKE NE, 1990, OECOLOGIA, V83, P485, DOI 10.1007/BF00317199; JOHNSON PL, 1970, ECOLOGY, V51, P73, DOI 10.2307/1933600; McGuire AD, 1992, GLOBAL BIOGEOCHEM CY, V6, P101, DOI 10.1029/92GB00219; McKane RB, 1997, ECOLOGY, V78, P1188, DOI 10.1890/0012-9658(1997)078[1188:RAAOHC]2.0.CO;2; MILLER PC, 1983, SIMULATION, V40, P119, DOI 10.1177/003754978304000402; MOREHEAD DL, 1993, ARCTIC ALPINE RES, V25, P403; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; OBERBAUER SF, 1989, HOLARCTIC ECOL, V12, P312; Oechel WC, 1998, J GEOPHYS RES-ATMOS, V103, P28993, DOI 10.1029/1998JD200015; Oechel WC, 1998, GLOB CHANGE BIOL, V4, P77, DOI 10.1046/j.1365-2486.1998.00110.x; OECHEL WC, 1993, NATURE, V361, P520, DOI 10.1038/361520a0; Oechel WC, 1997, GLOBAL BIOGEOCHEM CY, V11, P163, DOI 10.1029/96GB03035; OECHEL WC, 1994, TRENDS ECOL EVOL, V9, P324, DOI 10.1016/0169-5347(94)90152-X; OECHEL WC, 1995, ECOL APPL, V5, P846, DOI 10.2307/1941992; OECHEL WC, 1995, ADV SOIL SCI SOILS G, P117; Rastetter E. B., 1997, GLOBAL CHANGE ARCTIC, P437; SMITH TM, 1993, NATURE, V361, P523, DOI 10.1038/361523a0; THORNTHWAITE CJ, 1948, GEOGR REV, V38, P1; TIESZEN LL, 1975, PHOTOSYNTHETICA, V9, P376; Vourlitis GL, 1999, ECOLOGY, V80, P686, DOI 10.1890/0012-9658(1999)080[0686:ECMOCA]2.0.CO;2; Vourlitis GL, 1997, J ECOL, V85, P575, DOI 10.2307/2960529; Vourlitis GL, 2000, ECOL APPL, V10, P60, DOI 10.1890/1051-0761(2000)010[0060:PMFSPM]2.0.CO;2; VOURLITIS GL, 1993, FUNCT ECOL, V7, P369, DOI 10.2307/2390217; Waelbroeck C, 1997, GEOPHYS RES LETT, V24, P229, DOI 10.1029/97GL00071; Zimov SA, 1996, CLIMATIC CHANGE, V33, P111, DOI 10.1007/BF00140516	31	445	517	8	162	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					978	981		10.1038/35023137	http://dx.doi.org/10.1038/35023137			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984048				2022-12-28	WOS:000089020200040
J	Endow, SA; Higuchi, H				Endow, SA; Higuchi, H			A mutant of the motor protein kinesin that moves in both directions on microtubules	NATURE			English	Article							IN-VITRO MOTILITY; CRYSTAL-STRUCTURE; NCD; MOLECULES; BINDING	Molecular motors move directionally to either the plus or the minus end of microtubules or actin filaments. Kinesin moves towards microtubule plus ends, whereas the kinesin-related Ncd motor moves to the minus ends. The 'neck'-the region between the stalk and motor domain-is required for Ncd to move to microtubule minus ends(1,2), but the mechanism underlying directional motor movement is not understood. Here we show that a single amino-acid change in the Ncd neck causes the motor to reverse directions and move with wild-type velocities towards the plus or minus end; thus, the neck is functional but directionality is defective. Mutation of a motor-core residue that touches the neck residue in crystal structures(2,3) also results in movement in both directions, indicating that directed movement to the minus end requires interactions of the neck and motor core. Low-density laser-trap assays show that a conformational change or working stroke of the Ncd motor is directional and biased towards the minus end, whereas that of the neck mutant occurs in either direction. We conclude that the directional bias of the working stroke is dependent on neck/motor core interactions. Absence of these interactions removes directional constraints and permits movement in either direction.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Tohoku Univ, Dept Met, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Sendai, Miyagi 9808579, Japan	Duke University; Tohoku University; Tohoku University	Endow, SA (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.	endow@duke.edu		Endow, Sharyn A./0000-0002-0907-8889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHANDRA R, 1993, METHOD CELL BIOL, V39, P115, DOI 10.1016/S0091-679X(08)60165-X; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; Endow SA, 1999, NAT CELL BIOL, V1, pE163, DOI 10.1038/14113; ENDOW SA, 1999, GUIDEBOOK CYTOSKELET, P403; HATSUMI M, 1992, J CELL SCI, V103, P1013; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOYT MA, 1993, GENETICS, V135, P35; Iwatani S, 1999, BIOCHEMISTRY-US, V38, P10318, DOI 10.1021/bi9904095; Kozielski F, 1999, STRUCTURE, V7, P1407, DOI 10.1016/S0969-2126(00)80030-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835	18	146	148	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					913	916		10.1038/35022617	http://dx.doi.org/10.1038/35022617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972296				2022-12-28	WOS:000088903600050
J	De Souza, CPC; Osmani, AH; Wu, LP; Spotts, JL; Osmani, SA				De Souza, CPC; Osmani, AH; Wu, LP; Spotts, JL; Osmani, SA			Mitotic histone H3 phosphorylation by the NIMA kinase in Aspergillus nidulans	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; CELL-CYCLE REGULATORS; CHROMOSOME CONDENSATION; PROTEIN-KINASE; CHROMATIN CONDENSATION; 13S CONDENSIN; FISSION YEAST; SUBSTRATE-SPECIFICITY; OKADAIC ACID; MURINE NEK3	Phosphorylation of histone H3 serine 10 correlates with chromosome condensation and is required for normal chromosome segregation in Tetrahymena. This phosphorylation is dependent upon activation of the NIMA kinase in Aspergillus nidulans. NIMA expression also induces Ser-10 phosphorylation inappropriately in S phase-arrested cells and in the absence of NIMXcdc2 activity. At mitosis, NIMA becomes enriched on chromatin and subsequently localizes to the mitotic spindle and spindle pole bodies. The chromatin-like localization of NIMA early in mitosis is tightly correlated with histone H3 phosphorylation. Finally, NIMA can phosphorylate histone H3 Ser-10 in vitro, suggesting that NIMA is a mitotic histone H3 kinase, perhaps helping to explain how NIMA promotes chromatin condensation in A. nidulans and when expressed in other eukaryotes.	Geisinger Med Clin, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA	Geisinger Medical Center	Osmani, SA (corresponding author), Geisinger Med Clin, Weis Ctr Res, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.	sosmani@geisinger.edu	Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42564] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hayashi K, 1999, BIOCHEM BIOPH RES CO, V264, P449, DOI 10.1006/bbrc.1999.1536; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; Krien MJE, 1998, J CELL SCI, V111, P967; Kurasawa Y, 1999, ONCOGENE, V18, P5131, DOI 10.1038/sj.onc.1203133; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; Murray AW, 1998, SCIENCE, V282, P425, DOI 10.1126/science.282.5388.425; OAKLEY BR, 1993, CELL CYCLE PRACTICAL, P127; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OCONNELL MJ, 1992, EMBO J, V11, P2139, DOI 10.1002/j.1460-2075.1992.tb05273.x; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1994, J CELL SCI, V107, P1519; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; Rhee K, 1997, DEVELOPMENT, V124, P2167; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Van Hooser A, 1998, J CELL SCI, V111, P3497; Wang SL, 1998, BIOCHEM J, V334, P197, DOI 10.1042/bj3340197; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wu L, 1998, J CELL BIOL, V141, P1575, DOI 10.1083/jcb.141.7.1575; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	66	125	129	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 4	2000	102	3					293	302		10.1016/S0092-8674(00)00035-0	http://dx.doi.org/10.1016/S0092-8674(00)00035-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975520	Bronze			2022-12-28	WOS:000088625600005
J	Josefson, D				Josefson, D			HRT may protect against peripheral vascular disease	BRITISH MEDICAL JOURNAL			English	News Item																		Westendorp ICD, 2000, ARCH INTERN MED, V160, P2498, DOI 10.1001/archinte.160.16.2498	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					723	723						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999894				2022-12-28	WOS:000089546600011
J	Strachan, DP; Moran, SE; McInneny, K; Smalls, M				Strachan, DP; Moran, SE; McInneny, K; Smalls, M			Reduced risk of hospital admission for childhood asthma among Scottish twins: record linkage study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	A recent study of Swedish army conscripts found a reduced prevalence of asthma and allergic rhinitis among twins.' We analysed routine data on hospital admissions in Scotland to compare risks of asthma and other respiratory complaints among twins and singletons.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland	St Georges University London; NHS National Services Scotland	Strachan, DP (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Braback L, 1998, CLIN EXP ALLERGY, V28, P936; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235	5	18	19	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	2000	321	7263					732	733		10.1136/bmj.321.7263.732	http://dx.doi.org/10.1136/bmj.321.7263.732			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999904	Green Published, Bronze			2022-12-28	WOS:000089546600021
J	Eckenrode, J; Ganzel, B; Henderson, CR; Smith, E; Olds, DL; Powers, J; Cole, R; Kitzman, H; Sidora, K				Eckenrode, J; Ganzel, B; Henderson, CR; Smith, E; Olds, DL; Powers, J; Cole, R; Kitzman, H; Sidora, K			Preventing child abuse and neglect with a program of nurse home visitation - The limiting effects of domestic violence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							15-YEAR FOLLOW-UP; RANDOMIZED TRIAL; PREGNANT-WOMEN; LIFE-COURSE; CONFLICT	Context Home visitation to families with young children has been promoted as an effective way to prevent child maltreatment, but few studies have examined the conditions under which such programs meet this goal. Objective To investigate whether the presence of domestic violence limits the effects of nurse home visitation interventions in reducing substantiated reports of child abuse and neglect. Design Fifteen-year follow-up study of a randomized trial. Setting Semirural community in upstate New York. Participants Of 400 socially disadvantaged pregnant women with no previous live births enrolled consecutively between April 1978 and September 1980, 324 mothers and their children participated in the follow-up study. Interventions Families were randomly assigned to receive routine perinatal care (control group; n=184 participated in follow-up), routine care plus nurse home visits during pregnancy only (n =100), or routine care plus nurse home visits during pregnancy and through the child's second birthday (n =116). Main Outcome Measures Number of substantiated reports over the entire 15-year period involving the study child as subject regardless of the identity of the perpetrator or involving the mother as perpetrator regardless of the identity of the child abstracted from state records and analyzed by treatment group and level of domestic violence in the home as measured by the Conflict Tactics Scale. Results Families receiving home visitation during pregnancy and infancy had significantly fewer child maltreatment reports involving the mother as perpetrator (P=.01) or the study child as subject (P=.04) than families not receiving home visitation, The number of maltreatment reports for mothers who received home visitation during pregnancy only was not different from the control group. For mothers who received visits through the child's second birthday, the treatment effect decreased as the level of domestic violence increased. Of women who reported 28 or fewer incidents of domestic violence (79% of sample), home-visited mothers had significantly fewer child maltreatment reports during the 15-year period than mothers not receiving the longer-term intervention (P =.01). However, this intervention did not significantly reduce child maltreatment among mothers reporting more than 28 incidents of domestic violence (21% of sample). Conclusions The presence of domestic violence may limit the effectiveness of interventions to reduce incidence of child abuse and neglect.	Cornell Univ, Family Life Dev Ctr, Ithaca, NY 14853 USA; Cornell Univ, Dept Human Dev, Ithaca, NY 14853 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Rochester, Dept Psychiat, Rochester, NY USA; Univ Rochester, Sch Nursing, Rochester, NY USA	Cornell University; Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Rochester; University of Rochester	Eckenrode, J (corresponding author), Cornell Univ, Family Life Dev Ctr, MVR Hall, Ithaca, NY 14853 USA.		Smith, Elliott G./A-8167-2012	Smith, Elliott G./0000-0002-3432-093X; Kitzman, Harriet/0000-0001-9470-7979	NCI NIH HHS [90-CA-1631] Funding Source: Medline; NIMH NIH HHS [R01-MH49381, 1-K05-MH01382-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049381, K05MH001382] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Appel AE, 1998, J FAM PSYCHOL, V12, P578, DOI 10.1037/0893-3200.12.4.578; Brown CH, 1999, AM J COMMUN PSYCHOL, V27, P673, DOI 10.1023/A:1022142021441; Cummings EM, 1998, CHILDREN EXPOSED TO MARITAL VIOLENCE, P55, DOI 10.1037/10257-002; Daro DA, 1999, FUTURE CHILD, V9, P152, DOI 10.2307/1602726; Duggan AK, 1999, FUTURE CHILD, V9, P66, DOI 10.2307/1602722; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Gomby DS, 1999, FUTURE CHILD, V9, P4, DOI 10.2307/1602719; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; HUGHES HM, 1988, AM J ORTHOPSYCHIAT, V58, P77, DOI 10.1111/j.1939-0025.1988.tb01568.x; Johnson P.O., 1936, STAT RES MEMOIRS, V1, P57; Long JS, 1997, REGRESSION MODELS CA; Magdol L, 1997, J CONSULT CLIN PSYCH, V65, P68, DOI 10.1037/0022-006X.65.1.68; MARGOLIN G, 1909, MARGOLIN G, P57; Markman H., 1994, FIGHTING YOUR MARRIA; MARKMAN HJ, 1993, J CONSULT CLIN PSYCH, V61, P70, DOI 10.1037/0022-006X.61.1.70; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; McFarlane J, 1998, J Obstet Gynecol Neonatal Nurs, V27, P64, DOI 10.1111/j.1552-6909.1998.tb02592.x; MILLER RG, 1966, SIMULTANEOUS STAT IN; OLDS D, 1995, PEDIATRICS, V95, P365; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; OLDS DL, 1988, AM J PUBLIC HEALTH, V78, P1436, DOI 10.2105/AJPH.78.11.1436; OLDS DL, 1994, PEDIATRICS, V93, P89; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; OLDS DL, 1993, FUTURE CHILD, V3, P51; Parker B, 1999, RES NURS HEALTH, V22, P59; POTTHOFF RF, 1964, PSYCHOMETRIKA, V29, P241, DOI 10.1007/BF02289721; SEDLAK A, 1996, 3 NAT INC STUD CHILD; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; Tjaden Patricia., 1998, PREVALENCE INCIDENCE; U.S. Advisory Board on Child Abuse and Neglect, 1991, CREAT CAR COMM BLUEP	36	248	248	2	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1385	1391		10.1001/jama.284.11.1385	http://dx.doi.org/10.1001/jama.284.11.1385			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	352WN	10989400	Bronze			2022-12-28	WOS:000089242500032
J	Fairgrieve, SD; Jackson, M; Jonas, P; Walshaw, D; White, K; Montgomery, TL; Burn, J; Lynch, SA				Fairgrieve, SD; Jackson, M; Jonas, P; Walshaw, D; White, K; Montgomery, TL; Burn, J; Lynch, SA			Population based, prospective study of the care of women with epilepsy in pregnancy	BRITISH MEDICAL JOURNAL			English	Article									Royal Victoria Infirm, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Fairgrieve, SD (corresponding author), Royal Victoria Infirm, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.			Burn, John/0000-0002-9823-2322; Lynch, Sally Ann/0000-0003-3540-1333	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		O'Donoghue, 1997, ADULTS POORLY CONTRO; *REG MAT SURV OFF, 1991, NO REG CONG ABN SURV; *REG MAT SURV OFF, 1995, NO PER MORT SURV ANN; Ridsdale L, 1997, BRIT MED J, V314, P120, DOI 10.1136/bmj.314.7074.120; Wiebe S, 2000, BMJ-BRIT MED J, V320, P3, DOI 10.1136/bmj.320.7226.3	5	116	116	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					674	675		10.1136/bmj.321.7262.674	http://dx.doi.org/10.1136/bmj.321.7262.674			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987772	Bronze, Green Published			2022-12-28	WOS:000089444100025
J	Sumpio, BE				Sumpio, BE			Foot ulcers	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIABETIC FOOT; ULCERATION; NEUROPATHY; RISK; OSTEOMYELITIS; AMPUTATION; GANGRENE; MELLITUS; PATIENT; BYPASS		Yale Univ, Sch Med, Dept Vasc Surg, New Haven, CT 06510 USA	Yale University	Sumpio, BE (corresponding author), Yale Univ, Sch Med, Dept Vasc Surg, 333 Cedar St, New Haven, CT 06510 USA.	bauer.sumpio@yale.edu						AbouZamzam AM, 1996, ARCH SURG-CHICAGO, V131, P894; *AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS54; [Anonymous], 1999, Adv Wound Care, V12, P155; Armstrong D G, 1996, J Foot Ankle Surg, V35, P585; Barrow J., 1992, FOOT, V1, P195; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; Berceli SA, 1999, J VASC SURG, V30, P499, DOI 10.1016/S0741-5214(99)70077-7; BERGSTROM N, 1994, AHCPR PUBLICATION, P1; BIRKE JA, 1986, LEPROSY REV, V57, P261; BOULTON AJM, 1984, DIABETES CARE, V7, P42, DOI 10.2337/diacare.7.1.42; BOULTON AJM, 1983, DIABETES CARE, V6, P26, DOI 10.2337/diacare.6.1.26; Boulton AJM., 1992, FOOT, V2, P67, DOI DOI 10.1016/0958-2592(92)90020-P]; Catanzariti A R, 1995, J Foot Ankle Surg, V34, P23; CAVANAGH P R, 1991, Diabetologia, V34, pA39; *DEP HLTH HUM SERV, 1998, NAT DIAB FACT SHEET; EHRLICH K, 1993, INFECT MED, V10, P21; FRYKBERG R, 1994, MED SURG MANAGEMENT, P394; Frykberg RG, 1997, J AM PODIAT MED ASSN, V87, P305, DOI 10.7547/87507315-87-7-305; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; Habershaw G., 1995, MANAGEMENT DIABETIC, P53; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Kamal K, 1996, J AM COLL SURGEONS, V183, P271; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; KLENERMAN L, 1991, FOOT ITS DISORDERS, P27; KNOX R, 2000, INT J ANGIOL, V1, P1; KUMAR S, 1991, DIABETES RES CLIN PR, V13, P63, DOI 10.1016/0168-8227(91)90034-B; Laing P, 1998, AM J SURG, V176, p11S, DOI 10.1016/S0002-9610(98)00182-2; Lavery LA, 1998, ARCH INTERN MED, V158, P157, DOI 10.1001/archinte.158.2.157; LEVIN ME, 1995, DIABETES CARE, V18, P1383, DOI 10.2337/diacare.18.10.1383; LOGERFO FW, 1992, ARCH SURG-CHICAGO, V127, P617; MCNEELY MJ, 1995, DIABETES CARE, V18, P216, DOI 10.2337/diacare.18.2.216; NAWOCZENSKI DA, 1988, J AM PODIAT MED ASSN, V78, P455, DOI 10.7547/87507315-78-9-455; OBRIEN IAD, 1988, NEW ENGL J MED, V318, P1619; Reiber GE, 1998, AM J SURG, V176, p5S, DOI 10.1016/S0002-9610(98)00181-0; Simeone LR, 1997, J AM PODIAT MED ASSN, V87, P313, DOI 10.7547/87507315-87-7-313; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; VEITH FJ, 1986, J VASC SURG, V3, P104; Veves A., 1991, FOOT, V2, P89, DOI [DOI 10.1016/0958-2592(91)90036-B, 10.1016/0958-2592(91)90036-B]; Yeager RA, 1998, AM J SURG, V175, P388, DOI 10.1016/S0002-9610(98)00045-2; [No title captured]	41	109	127	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					787	793		10.1056/NEJM200009143431107	http://dx.doi.org/10.1056/NEJM200009143431107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984568				2022-12-28	WOS:000089221300007
J	Lurie, JD; Gerber, PD; Sox, HC				Lurie, JD; Gerber, PD; Sox, HC			A pain in the back	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dartmouth Med Sch, Dept Med, Hanover, NH USA	Dartmouth College	Lurie, JD (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Spine Ctr, SPORT, 1 Med Ctr Dr, Lebanon, NH 03756 USA.				NIAMS NIH HHS [AR4544401] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR045444] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14, P1; BODEN D, 1995, ESSENTIALS SPINE, P97; Carragee EJ, 1997, J BONE JOINT SURG AM, V79A, P874, DOI 10.2106/00004623-199706000-00011; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; Sapico F L, 1990, Infect Dis Clin North Am, V4, P539; SOX HC, 1986, ANN INTERN MED, V104, P515, DOI 10.7326/0003-4819-104-4-515; WIPF JE, 1995, MED CLIN N AM, V79, P231, DOI 10.1016/S0025-7125(16)30065-7	10	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					723	726		10.1056/NEJM200009073431008	http://dx.doi.org/10.1056/NEJM200009073431008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974137				2022-12-28	WOS:000089100500008
J	Polejaeva, IA; Chen, SH; Vaught, TD; Page, RL; Mullins, J; Ball, S; Dai, YF; Boone, J; Walker, S; Ayares, DL; Colman, A; Campbell, KHS				Polejaeva, IA; Chen, SH; Vaught, TD; Page, RL; Mullins, J; Ball, S; Dai, YF; Boone, J; Walker, S; Ayares, DL; Colman, A; Campbell, KHS			Cloned pigs produced by nuclear transfer from adult somatic cells	NATURE			English	Article							EMBRYOS; OOCYTES; FETAL; MICE; TRANSPLANTATION; LINE	Since the first report of live mammals produced by nuclear transfer from a cultured differentiated cell population in 1995 (ref. 1), successful development has been obtained in sheep(2,3), cattle(4), mice(5) and goats(6) using a variety of somatic cell types as nuclear donors. The methodology used for embryo reconstruction in each of these species is essentially similar: diploid donor nuclei have been transplanted into enucleated MII oocytes that are activated on, or after transfer. In sheep(2) and goat(6) preactivated oocytes have also proved successful as cytoplast recipients. The reconstructed embryos are then cultured and selected embryos transferred to surrogate recipients for development to term. In pigs, nuclear transfer has been significantly less successful; a single piglet was reported after transfer of a blastomere nucleus from a four-cell embryo to an enucleated oocyte(7); however, no live offspring were obtained in studies using somatic cells such as diploid or mitotic fetal fibroblasts as nuclear donors(8,9). The development of embryos reconstructed by nuclear transfer is dependent upon a range of factors. Here we investigate some of these factors and report the successful production of cloned piglets from a cultured adult somatic cell population using a new nuclear transfer procedure.	PPL Therapeut Inc, Blacksburg, VA 24060 USA; PPL Therapeut Inc, Roslin EH25 9PP, Midlothian, Scotland		Polejaeva, IA (corresponding author), PPL Therapeut Inc, 1700 Kraft Dr, Blacksburg, VA 24060 USA.	ipolejaeva@ppl-therapeutics.com	Polejaeva, Irina/G-4881-2012	Polejaeva, Irina/0000-0002-0858-5889				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CANSECO RS, 1994, TRANSGENIC RES, V3, P20, DOI 10.1007/BF01976023; CHRISTENSON RK, 1971, J ANIM SCI, V32, P282; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Colman A, 1999, Cloning, V1, P185; Kwon OY, 1996, P NATL ACAD SCI USA, V93, P13010, DOI 10.1073/pnas.93.23.13010; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; MCGRATH J, 1983, J EXP ZOOL, V228, P355, DOI 10.1002/jez.1402280218; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; Ouhibi N, 1996, REPROD NUTR DEV, V36, P661; PETTERS RM, 1993, J REPROD FERTIL, P61; Platt JL, 1996, CURR OPIN IMMUNOL, V8, P721, DOI 10.1016/S0952-7915(96)80091-4; POLGE C, 1966, J REPROD FERTIL, V12, P395, DOI 10.1530/jrf.0.0120395; PRATHER RS, 1991, MOL REPROD DEV, V28, P405, DOI 10.1002/mrd.1080280413; PRATHER RS, 1989, BIOL REPROD, V41, P414, DOI 10.1095/biolreprod41.3.414; Tao T, 1999, ANIM REPROD SCI, V56, P133, DOI 10.1016/S0378-4320(99)00037-8; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	22	905	1127	2	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					86	90		10.1038/35024082	http://dx.doi.org/10.1038/35024082			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993078				2022-12-28	WOS:000089124000047
J	Roditi, HA; Fisher, NS; Sanudo-Wilhelmy, SA				Roditi, HA; Fisher, NS; Sanudo-Wilhelmy, SA			Uptake of dissolved organic carbon and trace elements by zebra mussels	NATURE			English	Article							WATER HUDSON RIVER; DREISSENA-POLYMORPHA; AMINO-ACIDS; FOOD; BIOACCUMULATION; INVASION; COLLOIDS; RELEASE; METALS; MATTER	Zebra mussels (Dreissena polymorpha) are widespread and abundant in major freshwater ecosystems in North America, even though the phytoplankton food resources in some of these systems seem to be too low to sustain them(1,2). Because phytoplankton biomass is greatly depleted in ecosystems with large D. polymorpha populations(3,4) and bacteria do not seem to be an important food source for this species(5), exploitation of alternative carbon sources may explain the unexpected success of D. polymorpha in such environments. Here we examine the possibility that absorption of dissolved organic carbon (DOC) from water(6-9) could provide a nutritional supplement to zebra mussels. We find that mussels absorb C-14-labelled DOC produced by cultured diatoms with an efficiency of 0.23%; this indicates that DOC in natural waters could contribute up to 50% of the carbon demand of zebra mussels. We also find that zebra mussels absorb some dissolved metals that have been complexed by the DOM; although absorption of dissolved selenium was unaffected by DOC, absorption of dissolved cadmium, silver and mercury by the mussels increased 32-, 8.7- and 3.6-fold, respectively, in the presence of high-molecular-weight DOC.	SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fisher, NS (corresponding author), SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA.	nfisher@notes.cc.sunysb.edu						ARMSTRONG FA, 1966, NATURE, V211, P481, DOI 10.1038/211481a0; Campbell P.G.C., 1995, METAL SPECIATION BIO, P45; Caraco NF, 1997, ECOLOGY, V78, P588, DOI 10.1890/0012-9658(1997)078[0588:ZMIIAL]2.0.CO;2; Carvalho RA, 1999, LIMNOL OCEANOGR, V44, P403, DOI 10.4319/lo.1999.44.2.0403; Ciborowski JJH, 1997, J N AM BENTHOL SOC, V16, P771, DOI 10.2307/1468170; CUTTER GA, 1992, MAR CHEM, V40, P65, DOI 10.1016/0304-4203(92)90048-F; DECHO AW, 1990, OCEANOGR MAR BIOL, V28, P73; Fahnenstiel GL, 1995, J GREAT LAKES RES, V21, P435, DOI 10.1016/S0380-1330(95)71057-7; FERGUSON JC, 1982, BIOL BULL, V162, P1, DOI 10.2307/1540965; Findlay S, 1998, MICROBIAL ECOL, V36, P131, DOI 10.1007/s002489900100; Findlay S, 1996, ESTUARIES, V19, P866, DOI 10.2307/1352303; Fisher NS, 1996, ENVIRON SCI TECHNOL, V30, P3232, DOI 10.1021/es960009u; HEDGES JI, 1994, LIMNOL OCEANOGR, V39, P743, DOI 10.4319/lo.1994.39.4.0743; HOWARTH RW, 1992, BIOGEOCHEMISTRY, V16, P83; KEPKAY PE, 1994, MAR ECOL PROG SER, V109, P293, DOI 10.3354/meps109293; KOUCH J, 1996, ENVIRON INT, V22, P585; KRYGER J, 1988, OECOLOGIA, V77, P34, DOI 10.1007/BF00380921; LEE BG, 1992, LIMNOL OCEANOGR, V37, P1345; Madon SP, 1998, CAN J FISH AQUAT SCI, V55, P401, DOI 10.1139/cjfas-55-2-401; Nichols S. Jerrine, 1993, P733; Roditi HA, 1999, LIMNOL OCEANOGR, V44, P1730, DOI 10.4319/lo.1999.44.7.1730; Santschi P.H., 1999, BIOGEOCHEMISTRY GULF, P347; SANUDOWILHELMY SA, 1996, EOS, V77, pF200; STEPHENS GC, 1964, BIOL BULL, V126, P150, DOI 10.2307/1539425; Strayer DL, 1996, CAN J FISH AQUAT SCI, V53, P1143, DOI 10.1139/cjfas-53-5-1143; WALZ N, 1978, Archiv fuer Hydrobiologie Supplement, V55, P121; Wang WX, 1996, MAR ECOL PROG SER, V140, P91, DOI 10.3354/meps140091; Wotton RS, 1996, J N AM BENTHOL SOC, V15, P127, DOI 10.2307/1467438; WRIGHT SH, 1989, ANNU REV PHYSIOL, V51, P585, DOI 10.1146/annurev.ph.51.030189.003101; WRIGHT SH, 1984, J COMP PHYSIOL, V154, P249, DOI 10.1007/BF02464404	30	126	131	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 7	2000	407	6800					78	80		10.1038/35024069	http://dx.doi.org/10.1038/35024069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993076				2022-12-28	WOS:000089124000045
J	West, DC; Pomeroy, JR; Park, JK; Gerstenberger, EA; Sandoval, J				West, DC; Pomeroy, JR; Park, JK; Gerstenberger, EA; Sandoval, J			Critical thinking in graduate medical education - A role for concept mapping assessment?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Joint Meeting of the Pediatric-Academic-Societies	MAY   16, 2000	BOSTON, MASSACHUSETTS	Pediat Acad Soc			CONCEPT MAPS; SCIENCE; KNOWLEDGE; VALIDITY; TOOL	Context Tools to assess the evolving conceptual framework of physicians-in-training are limited, despite their critical importance to physicians' evolving clinical expertise. Concept mapping assessment (CMA) enables teachers to view students' organization of their knowledge at various points in training. Objective To assess whether CMA reflects expected differences and changes in the conceptual framework of resident physicians, whether concept maps can be scored reliably, and how well CMA scores relate to the results of standard in-training examination. Design, Setting, and Participants A group of 21 resident physicians (9 first-year and 12 second- and third-year residents) from a university-based pediatric training program underwent concept map training, drew a preinstruction concept map about seizures, completed an education course on seizures, and then drew a postinstruction map. Maps were scored independently by 3 raters using a standardized method. The study was conducted in May and June 1999. Main Outcome Measures Preinstruction map total scores and subscores in 4 categories compared with postinstruction map scores; map scores of second- and third-year residents compared with first-year residents; and interrater correlation of map scores. Results Total CMA scores increased after instruction from a mean (SD) preinstruction map score of 429 (119) to a mean postinstruction map score of 516 (196) (P=.03). Second- and third-year residents scored significantly higher than first year residents before instruction (mean [SD] score of 472 [116] vs 371 [102], respectively; P=.04), but not after instruction (mean [SD] scores, 561 [203] vs 456 [179], respectively; P=.16). Second- and third-year residents had greater preinstruction map complexity as measured by cross-link score (P=.01) than first-year residents. The CMA score had a weak to no correlation with the American Board of Pediatrics In-training Examination score (r=0.10-0.54). Interrater correlation of map scoring ranged from weak to moderate for the preinstruction map (r=0.51-0.69) and moderate to strong for the postinstruction map (r=0.74-0.88). Conclusions Our data provide preliminary evidence that concept mapping assessment reflects expected differences and change in the conceptual framework of resident physicians. Concept mapping assessment and standardized testing may measure different cognitive domains.	Univ Calif Davis, Sch Educ, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Div Educ, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	West, DC (corresponding author), Univ Calif Davis, Sch Educ, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.		West, Daniel/AAW-3111-2020	West, Daniel/0000-0002-0909-4213				ARNAUDIN MW, 1984, J COLL SCI TEACH, V14, P117; AUSUBEL D. P., 1978, ED PSYCHOL COGNITIVE, V2; AUSUBEL D. P, 1963, PSYCHOL MEANINGFUL V; BARLAVIE BZ, 1988, DISS ABSTR INT A, V48, P2590; BEYERBACH BA, 1986, DISS ABSTR INT A, V46, P2622; BODNER GM, 1986, J CHEM EDUC, V63, P873, DOI 10.1021/ed063p873; Chastonay P, 1999, TEACH LEARN MED, V11, P21, DOI 10.1207/S15328015TLM1101_6; Coleman EB, 1998, J LEARN SCI, V7, P387, DOI 10.1207/s15327809jls0703&4_5; EDMONDSON KM, 1994, ACAD MED, V69, P108, DOI 10.1097/00001888-199402000-00004; Edmondson KM, 1998, TEACH LEARN MED, V10, P21, DOI 10.1207/S15328015TLM1001_5; Gertzog, 1982, SCI EDUC, V66, P211, DOI DOI 10.1002/SCE.3730660207; GLASER R, 1989, ANNU REV PSYCHOL, V40, P631, DOI 10.1146/annurev.ps.40.020189.003215; Gowin D.B., 1984, LEARNING LEARN, DOI [10.1017/CBO9781139173469, DOI 10.1017/CBO9781139173469]; HEINZEFRY JA, 1990, SCI EDUC, V74, P461, DOI 10.1002/sce.3730740406; Lahtinen V, 1997, BRIT J EDUC PSYCHOL, V67, P13, DOI 10.1111/j.2044-8279.1997.tb01223.x; MARKHAM KM, 1994, J RES SCI TEACH, V31, P91, DOI 10.1002/tea.3660310109; Markow PG, 1998, J RES SCI TEACH, V35, P1015, DOI 10.1002/(SICI)1098-2736(199811)35:9<1015::AID-TEA4>3.0.CO;2-G; McClure JR, 1999, J RES SCI TEACH, V36, P475, DOI 10.1002/(SICI)1098-2736(199904)36:4<475::AID-TEA5>3.0.CO;2-O; McGaghie WC, 1996, ACAD MED, V71, pS13, DOI 10.1097/00001888-199601000-00029; NOVAK J. D., 1972, INDIVIDUALIZED SCI L, P14; Novak J. D., 1983, SCI EDUC, V67, P625, DOI DOI 10.1002/SCE.3730670511; Novak J. D., 1995, LEARNING SCI SCH RES, P229; NOVAK JD, 1991, AM EDUC RES J, V28, P117, DOI 10.3102/00028312028001117; NOVAK JD, 1990, J RES SCI TEACH, V27, P937, DOI 10.1002/tea.3660271003; NOVAK JD, 1981, AM BIOL TEACH, V43, P13; Piaget J, 1959, LANGUAGE THOUGHT CHI; Regis A, 1996, J CHEM EDUC, V73, P1084, DOI 10.1021/ed073p1084; ROYER JM, 1993, REV EDUC RES, V63, P201, DOI 10.2307/1170473; RuizPrimo MA, 1996, J RES SCI TEACH, V33, P569, DOI 10.1002/(SICI)1098-2736(199608)33:6<569::AID-TEA1>3.0.CO;2-M; STUART HA, 1985, EUR J SCI EDUC, V7, P73, DOI 10.1080/0140528850070108; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405; VONGLASERFELD E, 1992, PRACTICE CONSTRUCTIV; Wandersee J., 1998, TEACHING SCI UNDERST, P281	33	115	119	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1105	1110		10.1001/jama.284.9.1105	http://dx.doi.org/10.1001/jama.284.9.1105			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	349GK	10974689	Bronze			2022-12-28	WOS:000089037200010
J	Anzueto, A; Angel, L				Anzueto, A; Angel, L			Update in pulmonary disease	ANNALS OF INTERNAL MEDICINE			English	Review									Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; S Texas Vet Affairs Hlth Care Syst, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Anzueto, A (corresponding author), Vet Affairs Med Ctr, 111E,7400 Merton Minter Blvd, San Antonio, TX 78284 USA.			Angel, Luis/0000-0002-5045-9712				Adams SG, 2000, CHEST, V117, P1345, DOI 10.1378/chest.117.5.1345; Bartlett JG, 2000, ANN INTERN MED, V133, P285, DOI 10.7326/0003-4819-133-4-200008150-00013	2	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					360	366		10.7326/0003-4819-133-5-200009050-00012	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979881				2022-12-28	WOS:000089111900006
J	Gray, J; Majeed, A; Kerry, S; Rowlands, G				Gray, J; Majeed, A; Kerry, S; Rowlands, G			Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To identify patients with ischaemic heart disease by using a practice computer and to estimate the work required to do so. Design Cross sectional study. Data from the notes and from the computer records of 1680 patients were used to build a database. This was used to compare different methods of identifying patients with ischaemic heart disease. Setting 11 general practices in the Battersea primary care group in south London. Subjects 1 in 40 random sample of patients aged 45 or older. Main outcome measures Numbers of patients identified with ischaemic heart disease. Results The combination of the Read code for ischaemic heart disease (G3) and a prescription for a nitrate had a 73% sensitivity and a yield (100/positive predictive value) of one case of ischaemic heart disease for every 1.2 sets of notes reviewed. By searching the records of patients also receiving aspirin, atenolol, digoxin, or a statin, the sensitivity was increased to 96% but the yield fell to one in three. Conclusion Although commonly used to identify cases, a computer search for G3 code or nitrate missed almost 30% of patients with ischaemic heart disease. A substantially higher percentage of patients can be identified by adding other drugs to the search strategy.	Lavender Hill Grp Practice, Battersea Res Grp, London SW11 5TU, England; UCL, Sch Publ Policy, London WC1H 9EZ, England; St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England	University of London; University College London; St Georges University London	Gray, J (corresponding author), Lavender Hill Grp Practice, Battersea Res Grp, London SW11 5TU, England.	jgray@drs.desk.sthames.nhs.uk	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Majeed, Azeem/0000-0002-2357-9858				*4S STUDY GROUP, 1994, LANCET, V344, P383; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; CALMAN K, 1998, STATE PUBLIC HLTH 19; *DEP HLTH, 2000, NAT SERV FRAM COR HE; McCallum AK, 1997, BRIT J GEN PRACT, V47, P417; MOHER M, IN PRESS BR J GEN PR; MOSER K, 1999, HLTH STAT Q, V2, P28; *NHS CTR REV DISS, 1995, EFFECTIVENESS MATTER, V1; *STAT CORP, 1999, STAT STAT SOFTW REL; Thiru K, 1999, J PUBLIC HEALTH MED, V21, P179, DOI 10.1093/pubmed/21.2.179	10	49	49	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2000	321	7260					548	550		10.1136/bmj.321.7260.548	http://dx.doi.org/10.1136/bmj.321.7260.548			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351TK	10968818	Green Published			2022-12-28	WOS:000089174100022
J	Pasquale, E				Pasquale, E			Turning attraction into repulsion	SCIENCE			English	Editorial Material							NEURAL DEVELOPMENT; TYROSINE KINASE; EPH RECEPTORS; PROTEIN; LIGAND; EPHRIN-A5		Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, E (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CAGAN RL, 1992, CELL, V69, P393, DOI 10.1016/0092-8674(92)90442-F; Davenport RW, 1998, J NEUROSCI, V18, P975; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Lai KO, 1999, FEBS LETT, V458, P265, DOI 10.1016/S0014-5793(99)01159-X; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Schlondorff J, 1999, J CELL SCI, V112, P3603; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251	16	7	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2000	289	5483					1308	1310		10.1126/science.289.5483.1308	http://dx.doi.org/10.1126/science.289.5483.1308			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347RF	10979856				2022-12-28	WOS:000088942400025
J	Shanahan, F				Shanahan, F			Therapeutic manipulation of gut flora	SCIENCE			English	Editorial Material							CROHNS-DISEASE; INTERLEUKIN-10; MICE		Cork Univ Hosp, Dept Med, Cork, Ireland	University College Cork	Shanahan, F (corresponding author), Cork Univ Hosp, Dept Med, Cork, Ireland.		Shanahan, Fergus/ABF-2390-2020	Shanahan, Fergus/0000-0003-0467-0936				Campieri M, 1999, GASTROENTEROLOGY, V116, P1246, DOI 10.1016/S0016-5085(99)70029-6; COLLINS JK, 1999, GASTROENTEROLOGY, V116, pG2981; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; Dugas B, 1999, IMMUNOL TODAY, V20, P387, DOI 10.1016/S0167-5699(99)01448-6; Sartor RB, 1997, INFLAMM BOWEL DIS, V3, P230, DOI 10.1002/ibd.3780030309; Shanahan F, 2000, INFLAMM BOWEL DIS, V6, P107, DOI 10.1097/00054725-200005000-00007; Shanahan F, 2000, AM J PHYSIOL-GASTR L, V278, pG191, DOI 10.1152/ajpgi.2000.278.2.G191; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454	10	73	79	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 25	2000	289	5483					1311	1312		10.1126/science.289.5483.1311	http://dx.doi.org/10.1126/science.289.5483.1311			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347RF	10979858				2022-12-28	WOS:000088942400027
J	Flower, R				Flower, R			The man who knew doses - John Gaddum did much to define what it means to be a pharmacologist.	NATURE			English	Editorial Material									Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Flower, R (corresponding author), Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.								0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					831	831		10.1038/35022668	http://dx.doi.org/10.1038/35022668			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972268				2022-12-28	WOS:000088903600018
J	Adam, R; Cailliez, V; Majno, P; Karam, V; McMaster, P; Calne, RY; O'Grady, J; Pichlmayr, R; Neuhaus, P; Otte, JB; Hoeckerstedt, K; Bismuth, H				Adam, R; Cailliez, V; Majno, P; Karam, V; McMaster, P; Calne, RY; O'Grady, J; Pichlmayr, R; Neuhaus, P; Otte, JB; Hoeckerstedt, K; Bismuth, H			Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study	LANCET			English	Article							EXTENDED COLD ISCHEMIA; GRAFT; SPLIT; EXPERIENCE; DONORS	Background No model exists for liver transplantation to estimate the mortality risk in a given patient, and no standard by which to assess performance in different centres. We investigated the intrinsic mortality risk in the absence of known mortality risk factors, Methods We identified mortality risk factors and risk ratios quantified in data from the European Liver Transplant Registry (22 089 patients at 102 centres in 18 countries) registered from 1988 to 1997. To develop a model of the intrinsic risk and the risk ratios for specific factors, univariate and multivariate analyses were done separately for the overall population, for adults, and for children younger than 15 years, and the number of deaths were estimated, We validated the model by comparing mortality in patients without risk factors with the model-adjusted mortality in patients with risk factors. Findings Overall 5-year and 8-year actuarial survival was 66% (95% CI 65-66) and 61% (60-62). 65% of deaths occurred within 6 months, Retransplantation, transplantation for cancer, acute liver failure, fewer than 20 split-liver grafts per year, and a centre workload of fewer than 25 transplants per year were the main risk factors of 12 identified factors, 1-year and 5-year death rates among adults with no risk factors were similar to model estimates (15 [13-16] vs 14% [13-15], and 22 (20-24) vs 23% [21-24]). Corresponding data for paediatric transplants were 9% (7-12) compared with 11% (9-12) and 13% (10-17) compared with 14% (11-16). The reduction of mortality risk in high-volume centres was even greater in patients without risk factors (48 vs 23%, p<0.001). Interpretation The normalised intrinsic mortality risk can be combined with the relative risk ratios of known risk factors to better estimate the mortality risk of a given procedure in a given patient. Centres can assess performance by removing potential bias of donor and recipient selection.	Hop Paul Brousse, ELTR Coordinating Ctr, F-94804 Villejuif, France; Hop Univ, Geneva, Switzerland; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Addenbrookes Hosp, Cambridge, England; Kings Coll Hosp London, London, England; Hannover Med Sch, Hannover, Germany; Free Univ Berlin, Berlin, Germany; Clin Univ St Luc, Brussels, Belgium; Helsinki Univ Hosp, FIN-00170 Helsinki, Finland; Ctr Hepato Billiaire, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; University of Geneva; University of Birmingham; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; King's College Hospital NHS Foundation Trust; King's College Hospital; Hannover Medical School; Free University of Berlin; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Adam, R (corresponding author), Hop Paul Brousse, Ctr Hepatobiliaire, F-94804 Villejuif, France.	rene.adam@pbr.ap-hop-paris.fr		Karam, Vincent/0000-0002-7391-0190				ADAM R, 1992, LANCET, V340, P1373, DOI 10.1016/0140-6736(92)92559-X; ADAM R, 1995, TRANSPLANT P, V27, P1181; Azoulay D, 1996, ANN SURG, V224, P737, DOI 10.1097/00000658-199612000-00009; Belle S H, 1995, Liver Transpl Surg, V1, P347, DOI 10.1002/lt.500010602; BELLE SH, 1993, PITT UNOS LIVER TRAN; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; BISMUTH H, 1995, ANN SURG, V222, P109, DOI 10.1097/00000658-199508000-00002; BISMUTH H, 1995, PRESSE MED, V24, P1106; CLAVIEN PA, 1994, ANN SURG, V220, P109, DOI 10.1097/00000658-199408000-00002; *CONS C IND LIV TR, 1994, HEPATOLOGY, V20, P63; Emre S, 1996, TRANSPLANTATION, V62, P62, DOI 10.1097/00007890-199607150-00013; *EUR LIV TRANSPL R, 1998, DAT AN 05 1968 06 19; GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S; *INT FIG ORG DON T, 1998, ORGAN TISSUE, V1, P5; KALAYOGLU M, 1988, LANCET, V1, P617; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Lin HM, 1998, JAMA-J AM MED ASSOC, V280, P1153, DOI 10.1001/jama.280.13.1153; Marino IR, 1998, LIVER TRANSPLANT SUR, V4, pS115; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328; PICHLMAYR R, 1994, HEPATOLOGY, V20, pS33, DOI 10.1016/0270-9139(94)90271-2; Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019	22	213	218	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 19	2000	356	9230					621	627		10.1016/S0140-6736(00)02603-9	http://dx.doi.org/10.1016/S0140-6736(00)02603-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968434				2022-12-28	WOS:000088884100009
J	Brenner, C; Kroemer, G				Brenner, C; Kroemer, G			Apoptosis - Mitochondria - the death signal integrators	SCIENCE			English	Editorial Material							NUR77		Inst Gustave Roussy, Natl League Canc, Apoptosis Canc & Immun Lab, CNRS,UMR 1599, F-94805 Villejuif, France; Univ Technol Compiegne, CNRS, UMR6022, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Brenner, C (corresponding author), Inst Gustave Roussy, Natl League Canc, Apoptosis Canc & Immun Lab, CNRS,UMR 1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790	14	308	349	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2000	289	5482					1150	1151		10.1126/science.289.5482.1150	http://dx.doi.org/10.1126/science.289.5482.1150			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346JE	10970229				2022-12-28	WOS:000088866600026
J	Kazazian, HH				Kazazian, HH			Genetics - L1 retrotransposons shape the mammalian genome	SCIENCE			English	Editorial Material							ELEMENTS; INACTIVATION; TELOMERASE; SEQUENCE		Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Kazazian, HH (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.							Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eickbush TH, 1997, SCIENCE, V277, P911, DOI 10.1126/science.277.5328.911; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Marahrens Y, 1999, GENE DEV, V13, P2624, DOI 10.1101/gad.13.20.2624; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; *U PENN DEP GEN, RETR INS HUM GEN	19	128	129	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 18	2000	289	5482					1152	1153		10.1126/science.289.5482.1152	http://dx.doi.org/10.1126/science.289.5482.1152			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346JE	10970230				2022-12-28	WOS:000088866600027
J	Hawthorne, G; Irgens, LM; Lie, RT				Hawthorne, G; Irgens, LM; Lie, RT			RETRACTED: Outcome of pregnancy in diabetic women in northeast England and in Norway, 1994-7 (Retracted Article. See vol 327, pg 905, 2003)	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Retracted Publication								In northeast England, perinatal mortality is five times higher and congenital malformation is four times higher for pregnancies in diabetic women than for those in women who do not have diabetes.' The same is true in other regions in the United Kingdom,(2 3) but this is not the case in Norway.(4) Why is the outcome of pregnancy in diabetic women better in Norway? Does Norway use the same definitions and record the same outcome data as the United Kingdom? If the data are standardised will these differences disappear! If not, what is causing the difference in the outcome of pregnancy in diabetic women? The methodology for data collection needs to be standardised between the two countries to determine whether differences in outcome are real before looking for explanations in the healthcare systems of the two countries. We compare the outcome of pregnancy in women with diabetes based on prospective population data collected in Norway and northeast England.	No Diabet Pregnancy Survey, Reg Matern Survey Off, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Hauletend Hosp, Med Birth Registry Norway, N-5021 Bergen, Norway	Newcastle University - UK; University of Bergen; Haukeland University Hospital	Hawthorne, G (corresponding author), No Diabet Pregnancy Survey, Reg Matern Survey Off, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	gillian.hawthorne@nth.northy.nhs.uk						Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Diabetes care and research in Europe, 1990, DIABETIC MED, V7, P360; HADDEN DR, 1998, DIABETIC MED S1, V15, pS16; HAWTHORNE G, 1994, BRIT MED J, V315, P279; Hellesen Harald Bjarne, 1996, Tidsskrift for den Norske Laegeforening, V116, P3465	5	26	28	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2000	321	7263					730	731		10.1136/bmj.321.7263.730	http://dx.doi.org/10.1136/bmj.321.7263.730			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FE	10999902	Bronze, Green Published			2022-12-28	WOS:000089546600019
J	Van Overmeire, B; Smets, K; Lecoutere, D; Van de Broek, H; Weyler, J; De Groote, K; Langhendries, JP				Van Overmeire, B; Smets, K; Lecoutere, D; Van de Broek, H; Weyler, J; De Groote, K; Langhendries, JP			A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CEREBRAL BLOOD-FLOW; PRETERM INFANTS; REGIONAL CIRCULATION; PREMATURE-INFANTS; NEWBORN PIGLETS; HEMODYNAMICS; PROSTANOIDS; PREVENTION; HEMORRHAGE	Background Indomethacin is the conventional treatment for patent ductus arteriosus in preterm infants. However, its use is associated with various side effects In a prospective study, we compared ibuprofen and indomethacin with regard to efficacy and safety for the early treatment of patent ductus arteriosus in preterm infants. Methods We studied 148 infants (gestational age, 24 to 32 weeks) who had the respiratory distress syndrome and an echocardiographically confirmed ductus arteriosus. The infants were at five neonatal intensive care centers to receive three intravenous doses of either cin (0.2 mg per kilogram of body weight, given at 12-hour intervals) or ibuprofen (a first dose of 10 mg per kilogram, followed at 24-hour intervals by two doses of 5 mg per kilogram each), starting on the third of life. The rate of ductal closure, the need for additional treatment, side effects, complications, and the infants clinical course were recorded. Results The rate of ductal closure was similar with the two treatments: ductal closure occurred in 49 of infants given indomethacin (66 percent), and in 52 of 74 given ibuprofen (70 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 117; P=0.41). The numbers of infants who needed a second pharmacologic treatment or surgical ductal ligation did not differ significantly between the two groups. Oliguria occurred in 5 infants treated with ibuprofen and in 14 treated with indomethacin ( P=0.03). There were no significant differences with respect to other side effects or complications. Conclusions Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is less likely to induce oliguria. (N Engl J Med 2000; 343: 674-81.) (C) 2000, Massachusetts Medical Society.	Univ Antwerp Hosp, Dept Pediat, Div Neonatol, B-2650 Edegem, Belgium; Ghent Univ Hosp, Dept Pediat, Div Neonatol, Ghent, Belgium; St Jan Ziekenhuis, Neonatal Intens Care Unit, Brugge, Belgium; Queen Paola Childrens Hosp, Neonatal Intens Care Unit, Antwerp, Belgium; Univ Antwerp, Dept Epidemiol & Community Med, Antwerp, Belgium; St Vincents Clin, Neonatal Intens Care Unit, Rocourt, Belgium	University of Antwerp; Ghent University; Ghent University Hospital; University of Antwerp	Van Overmeire, B (corresponding author), Univ Antwerp Hosp, Dept Pediat, Div Neonatol, Wilrijkstr 10, B-2650 Edegem, Belgium.	bart.van.overmeire@uza.uia.ac.be	Weyler, Joost JJ/O-8594-2016	Weyler, Joost JJ/0000-0001-7271-5492				Aranda JV, 1997, ACTA PAEDIATR, V86, P289, DOI 10.1111/j.1651-2227.1997.tb08892.x; BALCOM RJ, 1993, PEDIATRICS, V91, P540; BETKERUR MV, 1981, PEDIATRICS, V68, P99; CHEMTOB S, 1993, PEDIATR RES, V33, P336; CHEMTOB S, 1991, PEDIATR RES, V30, P106, DOI 10.1203/00006450-199107000-00021; CHEMTOB S, 1990, STROKE, V21, P777, DOI 10.1161/01.STR.21.5.777; COCEANI F, 1979, CAN J PHYSIOL PHARM, V57, P825, DOI 10.1139/y79-126; COTTON RB, 1978, J PEDIATR-US, V93, P647, DOI 10.1016/S0022-3476(78)80910-X; Couser RJ, 1996, J PEDIATR-US, V128, P631, DOI 10.1016/S0022-3476(96)80127-2; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; FEIGEN LP, 1981, J PHARMACOL EXP THER, V219, P679; GERSONY WM, 1993, J PEDIAT, V102, P895; GROSFELD JL, 1983, J PEDIATR SURG, V18, P738, DOI 10.1016/S0022-3468(83)80015-3; KLIEGMAN RM, 1984, NEW ENGL J MED, V310, P1093, DOI 10.1056/NEJM198404263101707; Lagercrantz H, 1997, ACTA PAEDIATR, V86, P11; MAHONY L, 1982, NEW ENGL J MED, V306, P506, DOI 10.1056/NEJM198203043060903; MALCOLM DD, 1993, J APPL PHYSIOL, V74, P1672, DOI 10.1152/jappl.1993.74.4.1672; MCCORMICK DC, 1993, PEDIATR RES, V33, P603, DOI 10.1203/00006450-199306000-00015; Mosca F, 1997, J PEDIATR-US, V131, P549, DOI 10.1016/S0022-3476(97)70060-X; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PATEL J, 1995, LANCET, V346, P255, DOI 10.1016/S0140-6736(95)91304-1; Pezzati M, 1999, J PEDIATR-US, V135, P733, DOI 10.1016/S0022-3476(99)70093-4; Ramanathan Rangasamy, 1997, Pediatric Research, V41, p171A; RENNIE JM, 1986, ARCH DIS CHILD, V61, P233, DOI 10.1136/adc.61.3.233; SHANKARAN S, 1982, J PEDIATR-US, V100, P469, DOI 10.1016/S0022-3476(82)80462-9; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Speziale MV, 1999, BIOL NEONATE, V76, P242, DOI 10.1159/000014165; Van Overmeire B, 1999, PEDIATR RES, V45, p230A, DOI 10.1203/00006450-199904020-01369; VANBEL F, 1991, J PEDIATR-US, V118, P621, DOI 10.1016/S0022-3476(05)83391-8; Vane JR, 1997, ADV EXP MED BIOL, V433, P131; VANOVERMEIRE B, 1995, PEDIATR RES, V38, P886; VanOvermeire B, 1997, ARCH DIS CHILD-FETAL, V76, pF179, DOI 10.1136/fn.76.3.F179; Varvarigou A, 1996, JAMA-J AM MED ASSOC, V275, P539, DOI 10.1001/jama.275.7.539	34	269	278	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					674	681		10.1056/NEJM200009073431001	http://dx.doi.org/10.1056/NEJM200009073431001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974130				2022-12-28	WOS:000089100500001
J	Gilbert, K; Larocque, BJ; Patrick, LT				Gilbert, K; Larocque, BJ; Patrick, LT			Prospective evaluation of cardiac risk indices for patients undergoing noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Article							SURGICAL-PROCEDURES; PREDICTION	Background: Prediction of perioperative cardiac complications is important in the medical management of patients undergoing noncardiac surgery. Several indices have been developed to aid prediction, but their performance has not been systematically compared. Objective: To compare four existing methods for predicting perioperative cardiac risk. Design: Prospective cohort study. Setting: Two teaching hospitals in London, Ontario, Canada. Patients: 2035 patients referred for medical consultation before elective or urgent noncardiac surgery. Measurements: Myocardial infarction, unstable angina, acute pulmonary edema, or death. The indices were compared by examining the areas under their respective receiver-operating characteristic (ROC) curves. Results: Cardiac complications occurred in 6.4% of patients. The area under the ROC curve was 0.625 (95% CI, 0.575 to 0.676) for the American Society of Anesthesiologists index, 0.642 (CI, 0.588 to 0.695) for the Goldman index. 0.601 (CI, 0.544 to 0.657) for the modified Detsky index, and 0.654 (0.601 to 0.708) for the Canadian Cardiovascular Society index. These values did not significantly differ. Conclusions: Existing indices for prediction of cardiac complications perform better than chance, but no index is significantly superior. There is room for improvement in our ability to predict such complications.	Univ Western Ontario, St Josephs Hlth Ctr, Dept Med, London, ON N6A 4V2, Canada	Western University (University of Western Ontario)	Gilbert, K (corresponding author), Univ Western Ontario, St Josephs Hlth Ctr, Dept Med, 268 Grosvenor St,Room E209, London, ON N6A 4V2, Canada.	kgilbert@julian.uwo.ca		Gilbert, Kenneth/0000-0003-0024-9941				ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; LEWIN I, 1971, ANN SURG, V174, P217, DOI 10.1097/00000658-197108000-00008; MICHEL LA, 1990, J THORAC CARDIOV SUR, V100, P595; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; ZELDIN RA, 1984, CAN J SURG, V27, P402	12	96	100	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2000	133	5					356	359		10.7326/0003-4819-133-5-200009050-00011	http://dx.doi.org/10.7326/0003-4819-133-5-200009050-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350QD	10979880				2022-12-28	WOS:000089111900005
J	Liu, XH; Lin, JJ; Harich, S; Schatz, GC; Yang, XM				Liu, XH; Lin, JJ; Harich, S; Schatz, GC; Yang, XM			A quantum state-resolved insertion reaction: O(D-1)+H-2(J=O) -> OH((2)Pi, v, N)+H(S-2)	SCIENCE			English	Article							DIFFERENTIAL CROSS-SECTIONS; REACTION DYNAMICS; MOLECULAR-BEAM; SCATTERING; PRODUCT; PHOTODISSOCIATION; O((1)D)+HD; NM	The O(D-1) + H-2 --> OH + H reaction, which proceeds mainly as an insertion reaction at a collisional energy of 1.3 kilocalories per mole, has been investigated with the high-resolution H atom Rydberg "tagging" time-of-flight technique and the quasiclassical trajectory (QCT) method. Quantum state-resolved differential cross sections were measured for this prototype reaction. Different rotationally-vibrationally excited OH products have markedly different angular distributions, whereas the total reaction products are roughly forward and backward symmetric. Theoretical results obtained from QCT calculations indicate that this reaction is dominated by the insertion mechanism, with a small contribution from the collinear abstraction mechanism through quantum tunneling.	Acad Sinica, Inst Atom & Mol Sci, Taipei, Taiwan; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan	Academia Sinica - Taiwan; Northwestern University; National Tsing Hua University	Yang, XM (corresponding author), Acad Sinica, Inst Atom & Mol Sci, Taipei, Taiwan.	xmyang@poliams.sinica.edu.tw	Schatz, George C./ABF-1341-2020; Lin, Jim/F-7916-2012; Yang, Xueming/C-8764-2013	Lin, Jim/0000-0002-8308-2552; 				Ahmed M, 1999, CHEM PHYS LETT, V301, P372, DOI 10.1016/S0009-2614(99)00048-2; Alagia M, 1998, J CHEM PHYS, V108, P6698, DOI 10.1063/1.476085; ANDERSON JG, 1987, ANNU REV PHYS CHEM, V38, P489, DOI 10.1146/annurev.physchem.38.1.489; Baer M, 1999, J CHEM PHYS, V110, P10231, DOI 10.1063/1.478955; Casavecchia P, 2000, REP PROG PHYS, V63, P355, DOI 10.1088/0034-4885/63/3/203; CHE DC, 1995, J CHEM PHYS, V103, P5164, DOI 10.1063/1.470606; Davidson ER, 1998, FARADAY DISCUSS, V110, P207; Dixon-Lewis G., 1977, COMPREHENSIVE CHEM K, V17, P1; DOUGLAS BE, 1983, CONCEPTS MODELS INOR, P461; Drukker K, 1999, J CHEM PHYS, V111, P2451, DOI 10.1063/1.479522; Faubel M, 1998, J PHYS CHEM A, V102, P8695, DOI 10.1021/jp982488k; FAUBEL M, 1995, CHEM PHYS LETT, V232, P197, DOI 10.1016/0009-2614(94)01337-U; Gray Seymour, COMMUNICATION; Gray SK, 1999, J PHYS CHEM A, V103, P9448, DOI 10.1021/jp991601j; Hsu YT, 1999, J CHEM PHYS, V111, P7921, DOI 10.1063/1.480127; Hsu YT, 1997, J CHEM PHYS, V107, P1664, DOI 10.1063/1.474518; Hsu YT, 1997, J CHEM PHYS, V107, P2351, DOI 10.1063/1.474579; Hsu YT, 1999, J CHEM PHYS, V111, P7931, DOI 10.1063/1.480128; Hwang DW, 1999, J CHEM PHYS, V110, P4119, DOI 10.1063/1.478293; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; MARANGOS JP, 1990, J OPT SOC AM B, V7, P1254, DOI 10.1364/JOSAB.7.001254; NEUMARK DM, 1985, J CHEM PHYS, V82, P3045, DOI 10.1063/1.448254; NEUMARK DM, 1985, J CHEM PHYS, V82, P3067, DOI 10.1063/1.448255; Peng T, 1996, CHEM PHYS LETT, V248, P37, DOI 10.1016/0009-2614(95)01285-0; Schatz GC, 1997, FARADAY DISCUSS, V108, P357, DOI 10.1039/a705888h; Schnieder L, 1997, J CHEM PHYS, V107, P6175, DOI 10.1063/1.474283; SCHNIEDER L, 1995, SCIENCE, V269, P207, DOI 10.1126/science.269.5221.207; SCHNIEDER L, 1990, J CHEM PHYS, V92, P7027, DOI 10.1063/1.458243; TERNAY AL, 1976, CONT ORGANIC CHEM, P257	29	124	128	4	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1536	1538		10.1126/science.289.5484.1536	http://dx.doi.org/10.1126/science.289.5484.1536			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968786				2022-12-28	WOS:000089071700042
J	McConnell, JR; Arthern, RJ; Mosley-Thompson, E; Davis, CH; Bales, RC; Thomas, R; Burkhart, JF; Kyne, JD				McConnell, JR; Arthern, RJ; Mosley-Thompson, E; Davis, CH; Bales, RC; Thomas, R; Burkhart, JF; Kyne, JD			Changes in Greenland ice sheet elevation attributed primarily to snow accumulation variability	NATURE			English	Article							FIRN DENSIFICATION	The response of grounded ice sheets to a changing climate critically influences possible future changes in sea level. Recent satellite surveys over southern Greenland show little overall elevation change at higher elevations, but large spatial variability(1-3). Using satellite studies alone, it is not possible to determine the geophysical processes responsible for the observed elevation changes and to decide if recent rates of change exceed the natural variability. Here we derive changes in ice-sheet elevation in southern Greenland, for the years 1978-88, using a physically based model of firn densification(4) and records of annual snow accumulation reconstructed from 12 ice cores at high elevation. Our patterns of accumulation-driven elevation change agree closely with contemporaneous satellite measurements of ice-sheet elevation change, and we therefore attribute the changes observed in 1978-88 to variability in snow accumulation. Similar analyses of longer ice-core records show that in this decade the Greenland ice sheet exhibited typical variability at high elevations, well within the long-term natural variability. Our results indicate that a better understanding of ice-sheet mass changes will require long-term measurements of both surface elevation and snow accumulation.	Univ & Community Coll Syst Nevada, Desert Res Inst, Reno, NV 89512 USA; Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Geog, Columbus, OH 43210 USA; Univ Missouri, Dept Elect Engn, Columbia, MO 65211 USA; Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA; NASA, Wallops Flight Facil, EG&G Serv, Wallops Isl, VA 23337 USA; Univ Nebraska, Snow & Ice Res Grp, Lincoln, NE 68583 USA	Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; University of Washington; University of Washington Seattle; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Missouri System; University of Missouri Columbia; University of Arizona; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Nebraska System; University of Nebraska Lincoln	McConnell, JR (corresponding author), Univ & Community Coll Syst Nevada, Desert Res Inst, Reno, NV 89512 USA.	jmcconn@dri.edu	Burkhart, John/B-7095-2008; Burkhart, John/AAB-4744-2021; Mosley-Thompson, Ellen S/Z-2100-2018	Burkhart, John/0000-0002-5587-1693; Burkhart, John/0000-0002-5587-1693; 				ALLEY RB, 1987, J PHYS-PARIS, V48, P249, DOI 10.1051/jphyscol:1987135; ANKLIN M, 1994, TELLUS B, V46, P294, DOI 10.1034/j.1600-0889.1994.t01-3-00005.x; Anklin M, 1998, J GEOPHYS RES-ATMOS, V103, P28775, DOI 10.1029/98JD02718; Arthern RJ, 1998, CLIMATIC CHANGE, V40, P605, DOI 10.1023/A:1005320713306; CLAUSEN HB, 1988, ANN GLACIOLOGY, V0010; Davis CH, 2000, IEEE T GEOSCI REMOTE, V38, P1367, DOI 10.1109/36.843031; Davis CH, 1996, IEEE T GEOSCI REMOTE, V34, P1066, DOI 10.1109/36.536522; Davis CH, 1998, SCIENCE, V279, P2086, DOI 10.1126/science.279.5359.2086; Fisher D. A., 1985, ANN GLACIOL, V7, P76, DOI DOI 10.1017/S0260305500005942; Krabill W, 1999, SCIENCE, V283, P1522, DOI 10.1126/science.283.5407.1522; MAENO N, 1983, J PHYS CHEM-US, V87, P4103, DOI 10.1021/j100244a023; McConnell JR, 2000, J GEOPHYS RES-ATMOS, V105, P4039, DOI 10.1029/1999JD901049; Ohmura A., 1987, Z GLETSCHERKD GLAZIA, V23, P1; SIGG A, 1991, NATURE, V351, P557, DOI 10.1038/351557a0; THOMAS R, UNPUB POLAR GEOGR; VANDERVEEN CJ, 1993, CLIMATIC CHANGE, V23, P383, DOI 10.1007/BF01091624; ZWALLY HJ, 1998, SCIENCE, V281, P1251	17	62	63	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2000	406	6798					877	879		10.1038/35022555	http://dx.doi.org/10.1038/35022555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972286				2022-12-28	WOS:000088903600040
J	DeParle, NA				DeParle, NA			Medicare & you 2001	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US Hlth Care Financing Adm, Baltimore, MD 21207 USA		DeParle, NA (corresponding author), US Hlth Care Financing Adm, Baltimore, MD 21207 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1372	1372		10.1001/jama.284.11.1372	http://dx.doi.org/10.1001/jama.284.11.1372			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989384				2022-12-28	WOS:000089242500009
J	Gronbaek, M; Becker, U; Johansen, D; Gottschau, A; Schnohr, P; Hein, HO; Jensen, G; Sorensen, TIA				Gronbaek, M; Becker, U; Johansen, D; Gottschau, A; Schnohr, P; Hein, HO; Jensen, G; Sorensen, TIA			Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer	ANNALS OF INTERNAL MEDICINE			English	Article							DENSITY-LIPOPROTEIN; FRENCH PARADOX; 7 COUNTRIES; DANISH MEN; RED WINE; RISK; CONSUMPTION; WOMEN; DIET; BEER	Background: Although the J-shaped relation between alcohol intake and mortality has been reproduced in many large cohort studies, the question of whether the effects of beer, wine, and spirits differ remains controversial. Objective: To examine the relation between intake of different types of alcohol and death from all causes, coronary heart disease, and cancer. Design: Pooled cohort studies in which intake of beer, wine, and spirits; smoking status; educational level; physical activity; and body mass index were assessed at baseline. Setting: Copenhagen, Denmark. Participants: 13 064 men and 11 459 women 20 to 98 years of age. Measurements: Number of deaths and time to death from all causes, coronary heart disease, and cancer during follow-up. Results: During 257 859 person-years of follow-up, 4833 participants died. J-shaped relations were found between total alcohol intake and mortality at various levels of wine intake. Compared with nondrinken, light drinkers who avoided wine had a relative risk for death from all causes of 0.90 (95% CI, 0.82 to 0.99) and those who drank wine had a relative risk of 0.66 (CI, 0.55 to 0.77). Heavy drinkers who avoided wine were at higher risk for death from all causes than were heavy drinkers who included wine in their alcohol intake. Wine drinkers had significantly lower mortality from both coronary heart disease and cancer than did non-wine drinkers (P = 0.007 and P = 0.004, respectively). Conclusion: Wine intake may have a beneficial effect on all-cause mortality that is additive to that of alcohol. This effect may be attributable to a reduction in death from both coronary heart disease and cancer.	Copenhagen Univ Hosp, Hvidovre Hosp, Inst Prevent Med,Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Gronbaek, M (corresponding author), Kommune Hosp Copenhagen, Inst Prevent Med, DK-1399 Copenhagen, Denmark.		Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474				APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; Gronbaek M, 2000, EUR J CLIN NUTR, V54, P174, DOI 10.1038/sj.ejcn.1600919; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEITMANN BL, 1993, INT J OBESITY, V17, P329; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; Mabeck C E, 1980, Ugeskr Laeger, V142, P257; McCullagh P., 1989, GEN LINEAR MODELS, V(2nd), DOI [10.1007/978-1-4899-3242-6, https://doi.org/10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RIMM EB, 1995, AM J CLIN NUTR, V61, p1378S, DOI 10.1093/ajcn/61.6.1378S; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; RUF JC, 1995, ARTERIOSCL THROM VAS, V15, P140, DOI 10.1161/01.ATV.15.1.140; *SAS I, 1993, SAS STAT SOFTW GENMO; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; WILSON V, 1995, BRIT MED J, V311, P1166, DOI 10.1136/bmj.311.7013.1166b; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18	41	362	377	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					411	419		10.7326/0003-4819-133-6-200009190-00008	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975958				2022-12-28	WOS:000089329700002
J	Kilby, JM; Goepfert, PA; Miller, AP; Gnann, JW; Sillers, M; Saag, MS; Bucy, RP				Kilby, JM; Goepfert, PA; Miller, AP; Gnann, JW; Sillers, M; Saag, MS; Bucy, RP			Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFLUENZA VACCINATION; DISCONTINUATION; REPLICATION; PLASMA; BLOOD	Background: Clinical and virologic consequences of temporary interruption of HIV therapy are incompletely understood. Objective: To describe a febrile illness that was consistent with the acute HIV syndrome and occurred after interruption of antiretroviral therapy. Design: Case report. Setting: University clinic. Patient: HIV-infected man. Measurements: Plasma viral load, lymphocyte subsets, diagnostic evaluation (including cultures and serologic tests), and analysis of lymph node tissue. Results: The patient began antiretroviral therapy 3 months after initial HIV exposure and had sustained viral suppression, except during a brief scheduled treatment interruption. One hundred sixty-nine days after resuming therapy, the patient discontinued it again immediately following an influenza vaccination. Eleven days later, he presented with a febrile mononucleosis-like syndrome associated with dramatic shifts in plasma HIV RNA level (<50 to >1 000 000 copies/mU and CD4 cell count (0.743 x 10(9) cells/L to 0.086 x 10(9) cells/L). Evaluation for alternative causes of fever was unrevealing. Symptoms resolved rapidly with resumption of HIV therapy. Conclusion: Therapeutic interruption may be associated with profound viral rebound and recurrence of the acute HIV syndrome.	Univ Alabama Birmingham, Clin 1917, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Kilby, JM (corresponding author), Univ Alabama Birmingham, Clin 1917, 908 20th St S, Birmingham, AL 35294 USA.			Kilby, J. Michael/0000-0003-3222-1003	NCRR NIH HHS [MO1 RR00032] Funding Source: Medline; NIAID NIH HHS [U01 AI 41530] Funding Source: Medline; PHS HHS [R01 A144672] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041530] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; Bucy RP, 1999, J CLIN INVEST, V103, P1391, DOI 10.1172/JCI5863; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Daar ES, 1998, ANN INTERN MED, V128, P827, DOI 10.7326/0003-4819-128-10-199805150-00005; Gunthard HF, 2000, J INFECT DIS, V181, P522, DOI 10.1086/315260; Lisziewicz J, 1998, LANCET, V352, P199, DOI 10.1016/S0140-6736(98)24029-3; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; OBRIEN WA, 1995, BLOOD, V86, P1082; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Saag MS, 1999, NAT MED, V5, P609, DOI 10.1038/9452; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006	14	50	53	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2000	133	6					435	438		10.7326/0003-4819-133-6-200009190-00011	http://dx.doi.org/10.7326/0003-4819-133-6-200009190-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354KM	10975961				2022-12-28	WOS:000089329700005
J	Huntington, J; Gillam, SP; Rosen, R				Huntington, J; Gillam, SP; Rosen, R			Clinical governance in primary care - Organisational development for clinical governance	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Huntington, J (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.							BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; GROL R, 1994, FAM PRACT, V11, P460, DOI 10.1093/fampra/11.4.460; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	7	20	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	2000	321	7262					679	682		10.1136/bmj.321.7262.679	http://dx.doi.org/10.1136/bmj.321.7262.679			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356LE	10987774	Green Published, Bronze			2022-12-28	WOS:000089444100030
J	Beja, O; Aravind, L; Koonin, EV; Suzuki, MT; Hadd, A; Nguyen, LP; Jovanovich, S; Gates, CM; Feldman, RA; Spudich, JL; Spudich, EN; DeLong, EF				Beja, O; Aravind, L; Koonin, EV; Suzuki, MT; Hadd, A; Nguyen, LP; Jovanovich, S; Gates, CM; Feldman, RA; Spudich, JL; Spudich, EN; DeLong, EF			Bacterial rhodopsin: Evidence for a new type of phototrophy in the sea	SCIENCE			English	Article							16S RIBOSOMAL-RNA; ESCHERICHIA-COLI; PROTON RELEASE; PHYLOGENETIC DIVERSITY; MEMBRANE-VESICLES; BINDING-PROTEIN; BACTERIORHODOPSIN; TRANSDUCER; GENE; ARCHAEAL	Extremely halophilic archaea contain retinal-binding integral membrane proteins called bacteriorhodopsins that function as Light-driven proton pumps. So far, bacteriorhodopsins capable of generating a chemiosmotic membrane potential in response to Light have been demonstrated only in halophilic archaea. We describe here a type of rhodopsin derived from bacteria that was discovered through genomic analyses of naturally occuring marine bacterioplankton. The bacterial rhodopsin was encoded in the genome of an uncultivated gamma-proteobacterium and shared highest amino acid sequence similarity with archaeal rhodopsins. The protein was functionally expressed in Escherichia coli and bound retinal to form an active, Light-driven proton pump. The new rhodopsin exhibited a photochemical reaction cycle with intermediates and kinetics characteristic of archaeal proton-pumping rhodopsins. Our results demonstrate that archaeal-like rhodopsins are broadly distributed among different taxa, including members of the domain Bacteria. Our data also indicate that a previously unsuspected mode of bacterially mediated Light-driven energy generation may commonly occur in oceanic surface waters worldwide.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Amersham Pharmacia Biotech, Mol Dynam, Sunnyvale, CA 94086 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	Monterey Bay Aquarium Research Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Pfizer; University of Texas System	DeLong, EF (corresponding author), Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.		Suzuki, Marcelino/D-3329-2009	Suzuki, Marcelino/0000-0003-3868-6362; Aravind, L/0000-0003-0771-253X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01775-02S1] Funding Source: Medline; NIGMS NIH HHS [R01GM27750] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acinas SG, 1999, APPL ENVIRON MICROB, V65, P514; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BEJA O, IN PRESS ENV MICROBI; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Eilers H, 2000, APPL ENVIRON MICROB, V66, P3044, DOI 10.1128/AEM.66.7.3044-3051.2000; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heberle J, 2000, BBA-BIOENERGETICS, V1458, P135, DOI 10.1016/S0005-2728(00)00064-5; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KEUNEN JG, 1991, PROKARYOTES, P2638; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Mukohata Y, 1999, J BIOCHEM-TOKYO, V125, P649, DOI 10.1093/oxfordjournals.jbchem.a022332; MULLINS TD, 1995, LIMNOL OCEANOGR, V40, P148, DOI 10.4319/lo.1995.40.1.0148; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; Rappe MS, 1997, LIMNOL OCEANOGR, V42, P811, DOI 10.4319/lo.1997.42.5.0811; ROBERTSON DE, 1980, BIOCHEMISTRY-US, V19, P5692, DOI 10.1021/bi00566a005; Sasaki J, 1998, BIOPHYS J, V75, P2435, DOI 10.1016/S0006-3495(98)77687-8; SCHMIDT TM, 1991, J BACTERIOL, V173, P4371, DOI 10.1128/JB.173.14.4371-4378.1991; SEIDEL R, 1995, P NATL ACAD SCI USA, V92, P3036, DOI 10.1073/pnas.92.7.3036; Shimono K, 1997, FEBS LETT, V420, P54, DOI 10.1016/S0014-5793(97)01487-7; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; STOECKENIUS W, 1979, BIOCHIM BIOPHYS ACTA, V505, P215, DOI 10.1016/0304-4173(79)90006-5; SUZUKI M, UNPUB; Suzuki MT, 1997, APPL ENVIRON MICROB, V63, P983, DOI 10.1128/AEM.63.3.983-989.1997; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915	39	1055	1125	11	240	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1902	1906		10.1126/science.289.5486.1902	http://dx.doi.org/10.1126/science.289.5486.1902			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	10988064				2022-12-28	WOS:000089355800036
J	Childs, R; Chernoff, A; Contentin, N; Bahceci, E; Schrump, D; Leitman, S; Read, EJ; Tisdale, J; Dunbar, C; Linehan, WM; Young, NS; Barrett, AJ; Clave, E; Epperson, D; Mayo, V				Childs, R; Chernoff, A; Contentin, N; Bahceci, E; Schrump, D; Leitman, S; Read, EJ; Tisdale, J; Dunbar, C; Linehan, WM; Young, NS; Barrett, AJ; Clave, E; Epperson, D; Mayo, V			Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; GRAFT-VERSUS-LEUKEMIA; MYELOABLATIVE THERAPY; BREAST-CANCER; HOST DISEASE; TUMOR; INTERLEUKIN-2; CHEMOTHERAPY; CHIMERISM; ENGRAFTMENT	Background: Since allogeneic stem-cell transplantation can induce curative graft-versus-leukemia reactions in patients with hematologic cancers, we sought to induce analogous graft-versus-tumor effects in patients with metastatic renal-cell carcinoma by means of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Methods: Nineteen consecutive patients with refractory metastatic renal-cell carcinoma who had suitable donors received a preparative regimen of cyclophosphamide and fludarabine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identical sibling or a sibling with a mismatch of a single HLA antigen. Cyclosporine, used to prevent graft-versus-host disease, was withdrawn early in patients with mixed T-cell chimerism or disease progression. Patients with no response received up to three infusions of donor lymphocytes. Results: At the time of the last follow-up, 9 of the 19 patients were alive 287 to 831 days after transplantation (median follow-up, 402 days). Two had died of transplantation-related causes, and eight from progressive disease. In 10 patients (53 percent) metastatic disease regressed; 3 had a complete response, and 7 had a partial response. The patients who had a complete response remained in remission 27, 25, and 16 months after transplantation. Regression of metastases was delayed, occurring a median of 129 days after transplantation, and often followed the withdrawal of cyclosporine and the establishment of complete donor-T-cell chimerism. These results are consistent with a graft-versus-tumor effect. Conclusions: Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy. (N Engl J Med 2000;343:750-8.) (C) 2000, Massachusetts Medical Society.	NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; NCI, Div Clin Sci, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Div Clin Sci, Surg Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Warren Grant Magnuson Clin Ctr, Dept Transfus Med, NIH, Bethesda, MD 20892 USA; NIDDKD, Mol & Clin Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Childs, R (corresponding author), NHLBI, Hematol Branch, NIH, 10-7C103,10 Ctr Dr,MSC 1652, Bethesda, MD 20892 USA.		Clave, Emmanuel/ABD-8112-2020	Clave, Emmanuel/0000-0001-8217-5039; Dunbar, Cynthia/0000-0002-7645-838X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002342, Z01HL002342] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Childs R, 1999, BRIT J HAEMATOL, V107, P396, DOI 10.1046/j.1365-2141.1999.01706.x; Childs R, 1999, BLOOD, V94, P3234, DOI 10.1182/blood.V94.9.3234.421k16_3234_3241; Childs RW, 1999, J CLIN ONCOL, V17, P2044, DOI 10.1200/JCO.1999.17.7.2044; Dazzi F, 2000, BLOOD, V95, P67, DOI 10.1182/blood.V95.1.67.001k07_67_71; DROZ JP, 1988, SEMIN SURG ONCOL, V4, P97; Dumas F, 1999, INT J CANCER, V80, P799, DOI 10.1002/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.3.CO;2-L; Eibl B, 1996, BLOOD, V88, P1501, DOI 10.1182/blood.V88.4.1501.bloodjournal8841501; FAIRLAMB DJ, 1981, CANCER, V47, P2102, DOI 10.1002/1097-0142(19810415)47:8<2102::AID-CNCR2820470833>3.0.CO;2-K; Figlin RA, 1997, J UROLOGY, V158, P740, DOI 10.1016/S0022-5347(01)64304-0; Giralt S, 1997, BLOOD, V89, P4531, DOI 10.1182/blood.V89.12.4531; Khouri IF, 1998, J CLIN ONCOL, V16, P2817, DOI 10.1200/JCO.1998.16.8.2817; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; MACKINNON S, 1992, BLOOD, V80, P3235; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; QUESADA JR, 1983, CANCER RES, V43, P940; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; Rowlings PA, 1997, BRIT J HAEMATOL, V97, P855, DOI 10.1046/j.1365-2141.1997.1112925.x; SHEVRIN DH, 1989, INVEST NEW DRUG, V7, P251; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; SLAVIN S, 1988, BLOOD S, V72, pA407; Sykes M, 1999, LANCET, V353, P1755, DOI 10.1016/S0140-6736(98)11135-2; Ueno NT, 1998, J CLIN ONCOL, V16, P986, DOI 10.1200/JCO.1998.16.3.986; Van den Eynde B, 1999, J EXP MED, V190, P1793, DOI 10.1084/jem.190.12.1793; vanBesien KW, 1997, BONE MARROW TRANSPL, V19, P977, DOI 10.1038/sj.bmt.1700781; Verdonck LF, 1996, LANCET, V347, P800, DOI 10.1016/S0140-6736(96)90871-5; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Yagoda A, 1989, Semin Urol, V7, P199	29	778	837	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					750	758		10.1056/NEJM200009143431101	http://dx.doi.org/10.1056/NEJM200009143431101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984562				2022-12-28	WOS:000089221300001
J	Sutter, RW; Suleiman, AJM; Malankar, P; Al-Khusaiby, S; Mehta, F; Clements, GB; Pallansch, MA; Robertson, SE				Sutter, RW; Suleiman, AJM; Malankar, P; Al-Khusaiby, S; Mehta, F; Clements, GB; Pallansch, MA; Robertson, SE			Trial of a supplemental dose of four poliovirus vaccines	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARALYTIC POLIOMYELITIS; POTENCY; IMMUNOGENICITY; POLIOVACCINE; IMMUNIZATION; VACCINATION; ASSOCIATION; POPULATION; TROPICS; OMAN	Background: The immunogenicity of oral poliovirus vaccine (OPV), particularly the type 3 component, is lower in infants in most developing countries than in infants in industrialized countries. We conducted a multicenter trial in Oman to evaluate the response to a supplemental dose of four poliovirus vaccine formulations. Methods: At nine months of age, infants were randomly assigned to receive inactivated-poliovirus vaccine (IPV), administered subcutaneously; trivalent OPV manufactured in the United States or in Europe; or monovalent type 3 OPV. Serum samples were collected at enrollment and 7 and 30 days later. All of the infants had previously received five doses of OPV. Results: We enrolled 1025 infants; 785 (76.6 percent) met all the study requirements. At enrollment, 96.8 percent of the infants were seropositive for poliovirus type 1, 98.0 percent for type 2, and 88.0 percent for type 3. At 30 days there were no significant increases in type 3 seroprevalence or in the median antibody titer in the groups of infants who received OPV. Among the recipients of IPV, type 3 seroprevalence increased from 87.8 percent at enrollment to 97.1 percent at 30 days (P<0.001), and the median antibody titer increased from 1:228 to 1:1448 or higher (P<0.001). The rapid initial increase in the antibody titer suggests a secondary immune response. Conclusions: A supplemental dose of IPV has excellent immunogenicity and leads to increases in the titer of antibodies against type 3 poliovirus, whereas supplemental doses of the oral vaccines do not have these effects. (N Engl J Med 2000;343:767-73.) (C) 2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Informat Serv, Natl Immunizat Program E34, Atlanta, GA 30333 USA; Minist Hlth, Muscat, Oman; WHO, Dept Vaccines & Biol, Glasgow, Lanark, Scotland; Royal Hosp, Muscat, Oman; Ruchill Hosp, Glasgow, Lanark, Scotland	Centers for Disease Control & Prevention - USA; World Health Organization; The Royal Hospital, Sultanate of Oman	Sutter, RW (corresponding author), Ctr Dis Control & Prevent, Informat Serv, Natl Immunizat Program E34, 1600 Clifton Rd, Atlanta, GA 30333 USA.	rws4@cdc.gov						ALBRECHT P, 1983, J BIOL STAND, V11, P91, DOI 10.1016/S0092-1157(83)80031-6; BERNKOPF H, 1957, AM J TROP MED HYG, V6, P697, DOI 10.4269/ajtmh.1957.6.697; CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19, DOI 10.1093/tropej/35.1.19; CIRNE MD, 1995, J INFECT DIS, V171, P1097, DOI 10.1093/infdis/171.5.1097; COX HR, 1959, SCI PUBL PAN AM HLTH, V44, P229; DOMOK I, 1974, B WORLD HEALTH ORGAN, V51, P333; GHENDON YZ, 1961, ACTA VIROL, V5, P265; GLEZEN WP, 1966, AM J EPIDEMIOL, V83, P224, DOI 10.1093/oxfordjournals.aje.a120578; Greenwood BM, 1997, J INFECT DIS, V175, pS215; HORWITZ A, 1961, POLIOMYELITIS, P221; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; John T J, 1972, Indian Pediatr, V9, P252; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; KOK PW, 1992, B WORLD HEALTH ORGAN, V70, P93; KURNOSOVA LM, 1960, LIVE VACCINE POLIOMY; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; *MIN HLTH, 1995, 1990 1995 COMM HLTH, V4, P1; MINOR P, 1990, BIOLOGICALS, V18, P243, DOI 10.1016/1045-1056(90)90013-P; Modlin JF, 1997, J INFECT DIS, V175, pS228, DOI 10.1093/infdis/175.Supplement_1.S228; MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B; Myaux JA, 1996, PEDIATR INFECT DIS J, V15, P204, DOI 10.1097/00006454-199603000-00006; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; PAL SR, 1966, INDIAN J MED RES, V54, P507; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PATRIARCA PA, 1993, MEASLES POLIOMYELITI, P303; PLOTKIN SA, 1999, VACCINES, P345; Posey DL, 1997, J INFECT DIS, V175, pS258, DOI 10.1093/infdis/175.Supplement_1.S258; ROBERTSON H. E., 1962, CANADIAN JOUR PUBL HEALTH, V53, P179; ROBERTSON SE, 1994, B WORLD HEALTH ORGAN, V72, P907; Sabin AB, 1999, B WORLD HEALTH ORGAN, V77, P196; SALK J, 1982, ANN CLIN RES, V14, P204; *SAS I, 1989, SAS STAT US GUID VER, V1; SCHOUB BD, 1988, J INFECT DIS, V157, P836, DOI 10.1093/infdis/157.4.836; SUTTER RW, 1993, INT J EPIDEMIOL, V22, P936, DOI 10.1093/ije/22.5.936; Sutter RW, 1997, J INFECT DIS, V175, pS235, DOI 10.1093/infdis/175.Supplement_1.S235; SWARTZ TA, 1972, J HYG-CAMBRIDGE, V70, P719, DOI 10.1017/S0022172400022567; VERLINDE JD, 1959, 1 INT C LIV POL VACC, P355; VOROSHILOVA MK, 1961, POLIOMYELITIS, P296; *WHO, 1997, WHOEPILHIS9701; *WHO EPI CDS POLIO, 1990, WHOEPICDSPOLIO901; World Health Organization, 1996, WHOEPIGEN9503REV1; World Health Organization, 1997, WHOVSQ9704; 1999, MMWR MORB MORTAL WKL, V48, P416	44	53	55	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2000	343	11					767	773		10.1056/NEJM200009143431103	http://dx.doi.org/10.1056/NEJM200009143431103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352LZ	10984564				2022-12-28	WOS:000089221300003
J	Elam, MB; Hunninghake, DB; Davis, KB; Garg, R; Johnson, C; Egan, D; Kostis, JB; Sheps, DS; Brinton, EA				Elam, MB; Hunninghake, DB; Davis, KB; Garg, R; Johnson, C; Egan, D; Kostis, JB; Sheps, DS; Brinton, EA		ADMIT Investigators	Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease - The ADMIT Study: A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; NICOTINIC-ACID; CHOLESTEROL; THERAPY; HYPERTRIGLYCERIDEMIA; ATHEROSCLEROSIS; DYSLIPIDEMIA; GEMFIBROZIL; MECHANISM; MELLITUS	Context Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. Objective To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. Design and Setting Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. Participants A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. Interventions After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). Main Outcome Measures Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use: compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. Results Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C, Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P = .04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3 % (P = .04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. Conclusions Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.	Univ Tennessee, Div Clin Pharmacol, Hlth Sci Ctr, Memphis, TN 38163 USA; Memphis Vet Affairs Med Ctr, Memphis, TN USA; Univ Minnesota, Minneapolis, MN USA; Univ Washington, Seattle, WA 98195 USA; Axio Res Corp, Seattle, WA USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Robert Wood Johnson Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA; Univ N Carolina, Chapel Hill, NC USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Wake Forest University; Wake Forest Baptist Medical Center	Elam, MB (corresponding author), Univ Tennessee, Div Clin Pharmacol, Hlth Sci Ctr, 874 union Ave, Memphis, TN 38163 USA.				NCRR NIH HHS [MO1-RROO21] Funding Source: Medline; NHLBI NIH HHS [HC-25110-6, N0I-HC-35124] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025110, N01HC035124] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; Alvarsson M, 1996, SCAND J CLIN LAB INV, V56, P563, DOI 10.3109/00365519609088812; Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Egan DA, 1999, AM J CARDIOL, V83, P569, DOI 10.1016/S0002-9149(98)00915-1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1990, JAMA-J AM MED ASSOC, V264, P723, DOI 10.1001/jama.264.6.723; GARG A, 1989, DIABETES, V38, P364, DOI 10.2337/diabetes.38.3.364; GARG A, 1992, DIABETES, V41, P111, DOI 10.2337/diab.41.2.S111; GAUT ZN, 1971, METABOLISM, V20, P1031, DOI 10.1016/0026-0495(71)90026-6; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; GRAY DR, 1994, ANN INTERN MED, V121, P252, DOI 10.7326/0003-4819-121-4-199408150-00003; GRUNDY SM, 1981, J LIPID RES, V22, P24; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; GURIAN H, 1959, AM J MED SCI, V237, P12, DOI 10.1097/00000441-195901000-00003; Haffner SM, 1998, DIABETES CARE, V21, P160, DOI 10.2337/diacare.21.1.160; ILLINGWOUTH DR, 1994, ARCH INTERN MED, V154, P1586, DOI 10.1001/archinte.154.14.1586; Jin FY, 1997, ARTERIOSCL THROM VAS, V17, P2020, DOI 10.1161/01.ATV.17.10.2020; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; MIETTINEN TA, 1969, ACTA MED SCAND, V186, P247; MOLNAR GD, 1964, METABOLISM, V13, P181, DOI 10.1016/0026-0495(64)90131-3; OKI JC, 1995, PHARMACOTHERAPY, V15, P317; PARSONS WB, 1961, ARCH INTERN MED, V107, P653, DOI 10.1001/archinte.1961.03620050019003; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; TORNVALL P, 1991, J INTERN MED, V230, P415, DOI 10.1111/j.1365-2796.1991.tb00466.x	32	355	426	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1263	1270		10.1001/jama.284.10.1263	http://dx.doi.org/10.1001/jama.284.10.1263			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979113				2022-12-28	WOS:000089124600033
J	Bosch, X				Bosch, X			Patients' group to publish names of negligent doctors	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	2000	321	7261					587	587						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WW	10977822				2022-12-28	WOS:000089243200007
J	Klein, J; Sato, A				Klein, J; Sato, A			Advances in immunology - The HLA system - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL RECEPTOR; HISTOCOMPATIBILITY ANTIGEN; 3-DIMENSIONAL STRUCTURE; MHC RESTRICTION; CLASS-II; PEPTIDE; COMPLEX; REPERTOIRE; SELECTION; CD4		Max Planck Inst Biol, Immungenet Abt, D-72076 Tubingen, Germany	Max Planck Society	Klein, J (corresponding author), Max Planck Inst Biol, Immungenet Abt, Corrensstr 42, D-72076 Tubingen, Germany.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Forbes SA, 1999, IMMUNOGENETICS, V50, P152, DOI 10.1007/s002510050591; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garboczi DN, 1999, IMMUNITY, V10, P1, DOI 10.1016/S1074-7613(00)80001-1; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; Klein J, 1998, SCAND J IMMUNOL, V47, P199; KLEIN J, 1986, NATURAL HIST MAJOR H; KLEIN J, 1998, IMMUNOLOGY; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MOSS PAH, 1992, ANNU REV IMMUNOL, V10, P71, DOI 10.1146/annurev.iy.10.040192.000443; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Parham P, 1999, IMMUNOL REV, V172; RAMMENSEE HG, 1997, MHC LIGANDS PEPTIDE; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; Tanaka K, 1998, IMMUNOL REV, V163, P161; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104	24	489	506	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 7	2000	343	10					702	709		10.1056/NEJM200009073431006	http://dx.doi.org/10.1056/NEJM200009073431006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350KU	10974135				2022-12-28	WOS:000089100500006
J	Ducy, P; Schinke, T; Karsenty, G				Ducy, P; Schinke, T; Karsenty, G			The osteoblast: A sophisticated fibroblast under central surveillance	SCIENCE			English	Review							BONE-FORMATION; CLEIDOCRANIAL DYSPLASIA; TARGETED DISRUPTION; INDIAN HEDGEHOG; NERVOUS-SYSTEM; GENE; MICE; DIFFERENTIATION; DROSOPHILA; CBFA1	The study of the biology of osteoblasts, or bone-forming cells, illustrates how mammalian genetics has profoundly modified our understanding of cell differentiation and physiologic processes. Indeed, genetic-based studies over the past 5 years have revealed how osteoblast differentiation is controlled through growth and transcription factors. Likewise, the recent identification, using mutant mouse models, of a central component in the regulation of bone formation expands our understanding of the control of bone remodeling. This regulatory Loop, which involves the hormone Leptin, may help to explain the protective effect of obesity on bone mass in humans. In addition, it provides a novel physiologic concept that may shed Light on the etiology of osteoporosis and help to identify new therapeutic targets.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu						Acampora D, 1999, DEVELOPMENT, V126, P3795; AMLING M, UNPUB; Chorev Michael, 1996, P305; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DAVIDSON DR, 1991, SEM DEV BIOL, V2, P405; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Horton William A., 1993, P73; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanzler B, 1998, DEVELOPMENT, V125, P2587; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Mundy G. R., 1996, P301; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; PIERRE JM, 2000, SKELETAL GROWTH FACT, P179; Potts J. T., 1998, METABOLIC BONE DIS C, P52; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TREMOLLIERES FA, 1993, J CLIN ENDOCR METAB, V77, P683, DOI 10.1210/jc.77.3.683; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Westvik J, 1996, ACTA PAEDIATR, V85, P44, DOI 10.1111/j.1651-2227.1996.tb14265.x	48	808	872	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 1	2000	289	5484					1501	1504		10.1126/science.289.5484.1501	http://dx.doi.org/10.1126/science.289.5484.1501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968779				2022-12-28	WOS:000089071700035
J	Grebenev, S; Sartakov, B; Toennies, JP; Vilesov, AF				Grebenev, S; Sartakov, B; Toennies, JP; Vilesov, AF			Evidence for superfluidity in para-hydrogen clusters inside helium-4 droplets at 0.15 kelvin	SCIENCE			English	Article							INTEGRAL MONTE-CARLO; MOLECULAR-HYDROGEN; LIQUID-HELIUM; SPECTROSCOPY; GLASS; HE-4; H-2	A linear carbonyl sulfide (OCS) molecule surrounded by 14 to 16 para-hydrogen (pH(2)) molecules, or similar numbers of ortha-deuterium (oD(2)) molecules, within large helium-4 (He-4) droplets and inside mixed He-4/He-3 droplets was investigated by infrared spectroscopy. In the pure He-4 droplets (0.38 kelvin), both systems exhibited spectral features that indicate the excitation of angular momentum around the OCS axis. In the colder He-4/He-3 droplets (0.15 kelvin), these features remained in the oD(2) cluster spectra but disappeared in the pH(2) spectra, indicating that the angular momentum is no Longer excited. These results are consistent with the onset of superfluidity, thereby providing the first evidence for superfluidity in a Liquid other then helium.	Max Planck Inst Stromungsforsch, D-37073 Gottingen, Germany; Russian Acad Sci, Inst Gen Phys, Moscow 117942, Russia	Max Planck Society; Russian Academy of Sciences; Prokhorov General Physics Institute of the Russian Academy of Sciences	Toennies, JP (corresponding author), Max Planck Inst Stromungsforsch, Bunsenstr 10, D-37073 Gottingen, Germany.		Sartakov, Boris/K-7324-2018; Sartakov, Boris/M-4873-2019	Sartakov, Boris/0000-0001-9498-7587				BREWER DF, 1995, J LOW TEMP PHYS, V101, P317, DOI 10.1007/BF00754595; CEPERLEY DM, COMMUNICATION; CHAKRAVARTY C, 1995, MOL PHYS, V84, P845, DOI 10.1080/00268979500100601; Cheng E, 1996, J CHEM PHYS, V104, P2669, DOI 10.1063/1.470989; Cheng E, 1996, J CHEM PHYS, V104, P3155, DOI 10.1063/1.471081; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; FEYNMAN RP, 1953, PHYS REV, V91, P1301, DOI 10.1103/PhysRev.91.1301; GINZBURG VL, 1972, JETP LETT-USSR, V15, P242; Gordillo MC, 1999, PHYS REV B, V60, P6790, DOI 10.1103/PhysRevB.60.6790; Grebenev S, 2000, J CHEM PHYS, V112, P4485, DOI 10.1063/1.481011; Grebenev S, 1998, SCIENCE, V279, P2083, DOI 10.1126/science.279.5359.2083; Harms J, 1999, J CHEM PHYS, V110, P5124, DOI 10.1063/1.479110; Hartmann M, 1996, SCIENCE, V272, P1631, DOI 10.1126/science.272.5268.1631; HERZBERG G, 1945, INFRARED RAMAN SPECT, P400; Higgins KR, COMMUNICATION; Kinugawa K, 1997, J CHEM PHYS, V106, P1154, DOI 10.1063/1.473211; London F, 1938, NATURE, V141, P643, DOI 10.1038/141643a0; LUI FC, 1995, PHYS REV B, V51, P2848; MARIS HJ, 1983, J LOW TEMP PHYS, V51, P471, DOI 10.1007/BF00683224; MCMAHON MA, 1994, CHEM PHYS, V182, P119, DOI 10.1016/0301-0104(94)00041-7; NOZIERES P, 1990, THEORY QUANTUM LIQUI, V2; Pi M, 1999, PHYS REV LETT, V82, P3093, DOI 10.1103/PhysRevLett.82.3093; SCHARF D, 1992, J CHEM PHYS, V97, P3590, DOI 10.1063/1.462994; SCHARF D, 1992, CHEM PHYS LETT, V197, P231, DOI 10.1016/0009-2614(92)85760-8; Schindler M, 1996, PHYS REV B, V53, P11451, DOI 10.1103/PhysRevB.53.11451; SINDZINGRE P, 1991, PHYS REV LETT, V67, P1871, DOI 10.1103/PhysRevLett.67.1871; Toennies JP, 1998, ANNU REV PHYS CHEM, V49, P1, DOI 10.1146/annurev.physchem.49.1.1; WIECHERT H, 1991, PHYSICA B, V169, P144, DOI 10.1016/0921-4526(91)90221-Y	28	210	212	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1532	1535		10.1126/science.289.5484.1532	http://dx.doi.org/10.1126/science.289.5484.1532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968785				2022-12-28	WOS:000089071700041
J	Kato, M; Mizuno, K; Crozier, A; Fujimura, T; Ashihara, H				Kato, M; Mizuno, K; Crozier, A; Fujimura, T; Ashihara, H			Plant biotechnology - Caffeine synthase gene from tea leaves	NATURE			Unspecified	Article							BLOOD-PRESSURE; COFFEE; CORONARY; DISEASE; GREEN; RISK		Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Univ Tsukuba, Inst Agr & Forest Engn, Tsukuba, Ibaraki 3058572, Japan; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Plant Prod & Human Nutr Grp, Glasgow G12 8QQ, Lanark, Scotland	Ochanomizu University; University of Tsukuba; University of Glasgow	Kato, M (corresponding author), Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan.	a.crozier@bio.gla.ac.uk	Crozier, Alan/H-6642-2017	Crozier, Alan/0000-0001-7581-6782				Ashihara H, 1999, ADV BOT RES, V30, P117; CHOU TM, 1994, COMP BIOCHEM PHYS C, V109, P173, DOI 10.1016/0742-8413(94)00048-F; Fujiki H, 1999, J CANCER RES CLIN, V125, P589, DOI 10.1007/s004320050321; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; James JE, 1997, LANCET, V349, P279, DOI 10.1016/S0140-6736(96)04253-5; Kato M, 1999, PLANT PHYSIOL, V120, P579, DOI 10.1104/pp.120.2.579; Lane JD, 1998, PSYCHOSOM MED, V60, P327, DOI 10.1097/00006842-199805000-00019; Leenen R, 2000, EUR J CLIN NUTR, V54, P87, DOI 10.1038/sj.ejcn.1600900; MAZZAFERA P, 1991, PHYTOCHEMISTRY, V30, P3913, DOI 10.1016/0031-9422(91)83433-L; Nurminen ML, 1999, EUR J CLIN NUTR, V53, P831, DOI 10.1038/sj.ejcn.1600899; Ross JR, 1999, ARCH BIOCHEM BIOPHYS, V367, P9, DOI 10.1006/abbi.1999.1255; STENSVOLD I, 1992, PREV MED, V21, P546, DOI 10.1016/0091-7435(92)90062-M; Vinson JA, 1998, FEBS LETT, V433, P44, DOI 10.1016/S0014-5793(98)00880-1	13	137	169	1	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2000	406	6799					956	957		10.1038/35023072	http://dx.doi.org/10.1038/35023072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984041	Green Accepted			2022-12-28	WOS:000089020200032
J	Waltereit, P; Brandt, O; Trampert, A; Grahn, HT; Menniger, J; Ramsteiner, M; Reiche, M; Ploog, KH				Waltereit, P; Brandt, O; Trampert, A; Grahn, HT; Menniger, J; Ramsteiner, M; Reiche, M; Ploog, KH			Nitride semiconductors free of electrostatic fields for efficient white light-emitting diodes	NATURE			English	Article							MOLECULAR-BEAM EPITAXY; QUANTUM-WELLS; MACROSCOPIC POLARIZATION; GAN; GROWTH; BLUE	Compact solid-state lamps based on light-emitting diodes (LEDs)(1,2) are of current technological interest as an alternative to conventional light bulbs. The brightest LEDs available so far emit red light and exhibit higher luminous efficiency than fluorescent lamps. If this luminous efficiency could be transferred to white LEDs, power consumption would be dramatically reduced, with great economic and ecological consequences. But the luminous efficiency of existing white LEDs is still very low, owing to the presence of electrostatic fields within the active layers(3). These fields are generated by the spontaneous and piezoelectric polarization along the [0001] axis of hexagonal group-III nitrides-the commonly used materials for light generation(4-6). Unfortunately, as this crystallographic orientation corresponds to the natural growth direction of these materials deposited on currently available substrates(7). Here we demonstrate that the epitaxial growth of GaN/(Al,Ga)N on tetragonal LiAlO(2) in a non-polar direction allows the fabrication of structures free of electrostatic fields, resulting in an improved quantum efficiency. We expect that this approach will pave the way towards highly efficient white LEDs.	Paul Drude Inst Festkorperelekt, D-10117 Berlin, Germany	Paul Drude Institute for Solid State Electronics	Waltereit, P (corresponding author), Paul Drude Inst Festkorperelekt, Hausvogteipl 5-7, D-10117 Berlin, Germany.	walter@pdi-berlin.de	Brandt, Oliver/A-9438-2014; Trampert, Achim/AAH-5229-2020; Grahn, Holger T/P-8953-2016	Brandt, Oliver/0000-0002-9503-5729; 				Bernardini F, 1998, PHYS REV B, V57, pR9427, DOI 10.1103/PhysRevB.57.R9427; Bernardini F, 1997, PHYS REV B, V56, P10024, DOI 10.1103/PhysRevB.56.R10024; Bogner G., 1999, Compound Semiconductor, V5, p28, 30; Brandt O, 1999, APPL PHYS LETT, V75, P4019, DOI 10.1063/1.125524; Brandt O, 1998, S SEMI SCI, V6, P417; Deguchi T, 1999, JPN J APPL PHYS 2, V38, pL914, DOI 10.1143/JJAP.38.L914; Della Sala F, 1999, APPL PHYS LETT, V74, P2002, DOI 10.1063/1.123727; Fiorentini V, 1999, PHYS REV B, V60, P8849, DOI 10.1103/PhysRevB.60.8849; Fricke J, 1999, APPL PHYS LETT, V74, P3471, DOI 10.1063/1.124131; Hellman ES, 1997, MRS INTERNET J N S R, V2, pU32; Iwata K, 1997, JPN J APPL PHYS 2, V36, pL661, DOI 10.1143/JJAP.36.L661; Jiang HT, 1999, IEEE J QUANTUM ELECT, V35, P1483, DOI 10.1109/3.792574; Langer R, 1999, APPL PHYS LETT, V74, P3827, DOI 10.1063/1.124193; LUDWIG W, 1978, FESXTKORPERPHYSIK; MAREZIO M, 1965, ACTA CRYSTALLOGR, V19, P396, DOI 10.1107/S0365110X65003511; MORKOC H, 1995, SCIENCE, V267, P51, DOI 10.1126/science.267.5194.51; Mukai T, 1998, J CRYST GROWTH, V189, P778, DOI 10.1016/S0022-0248(98)00292-9; NISHIDA T, 1999, COMPOUND SEMICOND, V5, P12; Northrup JE, 1996, PHYS REV B, V53, P10477, DOI 10.1103/PhysRevB.53.R10477; Ponce FA, 1997, NATURE, V386, P351, DOI 10.1038/386351a0; SCHNITZER I, 1993, APPL PHYS LETT, V63, P2174, DOI 10.1063/1.110575; Thamm A, 2000, PHYS REV B, V61, P16025, DOI 10.1103/PhysRevB.61.16025; Waltereit P, 1999, APPL PHYS LETT, V74, P3660, DOI 10.1063/1.123214	23	1623	1810	15	487	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 24	2000	406	6798					865	868		10.1038/35022529	http://dx.doi.org/10.1038/35022529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347AG	10972282				2022-12-28	WOS:000088903600036
J	Brahams, D				Brahams, D			"Repressed memories" and the law	LANCET			English	Editorial Material											Brahams, D (corresponding author), Old Sq Chambers,Grays Inn, London WC1R 5LQ, England.							Brandon S, 1999, Med Leg J, V67, P25	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 29	2000	356	9227					358	358		10.1016/S0140-6736(00)02525-3	http://dx.doi.org/10.1016/S0140-6736(00)02525-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339NZ	10972366				2022-12-28	WOS:000088486000006
J	Slavkin, HC; Baum, BJ				Slavkin, HC; Baum, BJ			Relationship of dental and oral pathology to systemic illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; ADULTS 30 YEARS; MYOCARDIAL-INFARCTION; UNITED-STATES; PERIODONTAL-DISEASE; ARTERY DISEASE; RISK FACTOR; INFECTION; ATHEROSCLEROSIS; CARIES		Off Director, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Slavkin, HC (corresponding author), Off Director, Bldg 31,Room 2C39,MSC-2290, Bethesda, MD 20892 USA.	SlavkinH@od31.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000336, ZIADE000336] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albandar JM, 1999, J PERIODONTOL, V70, P13, DOI 10.1902/jop.1999.70.1.13; Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540; Atkinson J C, 1992, Clin Geriatr Med, V8, P499; Baum BJ, 1999, LANCET, V354, P12; Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; Beck J D, 1998, J Dent Educ, V62, P859; Berger A M, 1998, Oncol Nurs Forum, V25, P1623; Brown LJ, 1999, J AM DENT ASSOC, V130, P1637, DOI 10.14219/jada.archive.1999.0106; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Dasanayake A P, 1998, Ann Periodontol, V3, P206, DOI 10.1902/annals.1998.3.1.206; DESTEFANO F, 1993, BRIT MED J, V306, P688, DOI 10.1136/bmj.306.6879.688; Epstein SE, 1999, CIRCULATION, V100, pE20, DOI 10.1161/01.CIR.100.4.e20; Fourrier F, 1998, CRIT CARE MED, V26, P301, DOI 10.1097/00003246-199802000-00032; Fox Robert I., 1998, Current Opinion in Rheumatology, V10, P446, DOI 10.1097/00002281-199809000-00009; Gibson S, 1999, CARIES RES, V33, P101, DOI 10.1159/000016503; Grau AJ, 1997, STROKE, V28, P1724, DOI 10.1161/01.STR.28.9.1724; GREENBERG DS, 1992, LANCET, V340, P359, DOI 10.1016/0140-6736(92)91418-8; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Hao SP, 1999, LARYNGOSCOPE, V109, P1324, DOI 10.1097/00005537-199908000-00027; Joshipura KJ, 1996, J DENT RES, V75, P1631, DOI 10.1177/00220345960750090301; Kaste LM, 1996, J DENT RES, V75, P631, DOI 10.1177/002203459607502S03; Loesche W J, 1998, Ann Periodontol, V3, P161, DOI 10.1902/annals.1998.3.1.161; Loesche WJ, 1999, CRIT REV ORAL BIOL M, V10, P245, DOI 10.1177/10454411990100030101; Loesche WJ, 1998, J AM DENT ASSOC, V129, P301, DOI 10.14219/jada.archive.1998.0204; Mattila Kimmo, 1998, P63; MATTILA KJ, 1995, CLIN INFECT DIS, V20, P588, DOI 10.1093/clinids/20.3.588; MATTILA KJ, 1993, ATHEROSCLEROSIS, V103, P205, DOI 10.1016/0021-9150(93)90263-T; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; Mattila KJ, 2000, J DENT RES, V79, P756, DOI 10.1177/00220345000790020901; Mattila KJ, 1998, CLIN INFECT DIS, V26, P719, DOI 10.1086/514570; Meurman JH, 1997, J DENT RES, V76, P1271, DOI 10.1177/00220345970760060601; Meyer DH, 1998, CURR OPIN MICROBIOL, V1, P88, DOI 10.1016/S1369-5274(98)80147-1; Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103; Scannapieco FA, 1999, J PERIODONTOL, V70, P793, DOI 10.1902/jop.1999.70.7.793; Schussheim AE, 1999, DRUGS, V57, P283, DOI 10.2165/00003495-199957030-00002; Toljanic JA, 1999, CANCER, V85, P1843, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1843::AID-CNCR26>3.3.CO;2-I; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; VALDEZ IH, 1993, INT J RADIAT ONCOL, V25, P41, DOI 10.1016/0360-3016(93)90143-J; Valtonen VV, 1999, AM HEART J, V138, pS431, DOI 10.1016/S0002-8703(99)70269-3; Vargas CM, 1998, J AM DENT ASSOC, V129, P1229, DOI 10.14219/jada.archive.1998.0420	40	71	71	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1215	1217		10.1001/jama.284.10.1215	http://dx.doi.org/10.1001/jama.284.10.1215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979082				2022-12-28	WOS:000089124600001
J	Park, H; Park, J; Lim, AKL; Anderson, EH; Alivisatos, AP; McEuen, PL				Park, H; Park, J; Lim, AKL; Anderson, EH; Alivisatos, AP; McEuen, PL			Nanomechanical oscillations in a single-C-60 transistor	NATURE			English	Article							CARBON NANOTUBES; C-60; NANOCRYSTALS; SPECTROSCOPY; MICROSCOPY; MOLECULE; WIRES	The motion of electrons through quantum dots is strongly modified by single-electron charging and the quantization of energy levels(1,2). Much effort has been directed towards extending studies of electron transport to chemical nanostructures, including molecules(3-8), nanocrystals(9-13) and nanotubes(14-17). Here we report the fabrication of single-molecule transistors based on individual C-60 molecules connected to gold electrodes. We perform transport measurements that provide evidence for a coupling between the centre-of-mass motion of the C-60 molecules and single-electron hopping(18)-a conduction mechanism that has not been observed previously in quantum dot studies. The coupling is manifest as quantized nano-mechanical oscillations of the C-60 molecule against the gold surface, with a frequency of about 1.2 THz. This value is in good agreement with a simple theoretical estimate based on van der Waals and electrostatic interactions between C-60 molecules and gold electrodes.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	McEuen, PL (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Park, Hongkun/R-9842-2019; Park, Jiwoong/C-2327-2013; Alivisatos, Paul/N-8863-2015	Park, Hongkun/0000-0001-9576-8829; Alivisatos, Paul/0000-0001-6895-9048				Banin U, 1999, NATURE, V400, P542, DOI 10.1038/22979; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; CHAVY C, 1993, CHEM PHYS LETT, V214, P569, DOI 10.1016/0009-2614(93)85685-H; Datta S, 1997, PHYS REV LETT, V79, P2530, DOI 10.1103/PhysRevLett.79.2530; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Gorelik LY, 1998, PHYS REV LETT, V80, P4526, DOI 10.1103/PhysRevLett.80.4526; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Green WH, 1996, J PHYS CHEM-US, V100, P14892, DOI 10.1021/jp960689n; Heid R, 1997, PHYS REV B, V56, P5925, DOI 10.1103/PhysRevB.56.5925; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; Kim SH, 1999, J PHYS CHEM B, V103, P10341, DOI 10.1021/jp991952y; Klein DL, 1996, APPL PHYS LETT, V68, P2574, DOI 10.1063/1.116188; Klein DL, 1997, NATURE, V389, P699, DOI 10.1038/39535; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Poncharal P, 1999, SCIENCE, V283, P1513, DOI 10.1126/science.283.5407.1513; Porath D, 1997, PHYS REV B, V56, P9829, DOI 10.1103/PhysRevB.56.9829; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; REULET B, 1999, BOLOMETRIC DETECTION; RUOFF RS, 1993, J PHYS CHEM-US, V97, P2494, DOI 10.1021/j100113a004; Schatz GC, 1993, QUANTUM MECH CHEM; Sohn L.L., 1997, MESOSCOPIC ELECT TRA; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954	26	1587	1613	8	287	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					57	60		10.1038/35024031	http://dx.doi.org/10.1038/35024031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993069				2022-12-28	WOS:000089124000038
J	Barzansky, B; Jonas, HS; Etzel, SI				Barzansky, B; Jonas, HS; Etzel, SI			Educational programs in US medical schools, 1999-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								We used data from the 1999-2000 Liaison Committee on Medical Education Annual Medical School Questionnaire, which had a 100% response rate, and other sources to describe the status of medical education programs in the United States, In 1999-2000, the number of fell-time faculty members was 102446, a 4.3% increase from 1998-1999, The number of basic science faculty increased by less than 0.5%, while the number of clinical faculty increased by about 5%. There were 38 529 medical school applicants in 1999, a 6% decrease from 1998, Women constituted 45.8% and underrepresented minorities made up 12.1% of the 1999-2000 first-year class. New content, such as alternative medicine and cultural competence, and new methods of instruction, such as computer-based learning, are being incorporated by many schools, Seventy schools (56% of the total) require students to pass both Step 1 and Step 2 of the US Medical Licensing Examination for advancement or graduation, an increase from 62 schools (50%) in 1998-1999. The use of standardized methods of assessment, such as objective structured clinical examinations, to evaluate students' clinical performance was highly variable among schools.	Amer Med Assoc, Div Undergrad Med Educ, Chicago, IL 60610 USA; Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ, 515 N State St, Chicago, IL 60610 USA.							*ASS AM MED COLL S, 1999, DAT WAR APPL MATR FI; FLEXNER A, 1910, B CARNEGIE FDN, V4; Krakower JY, 1999, JAMA-J AM MED ASSOC, V282, P847, DOI 10.1001/jama.282.9.847; Liaison Committee on Medical Education, 2000, FUNCT STRUCT MED SCH	4	58	59	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1114	1120		10.1001/jama.284.9.1114	http://dx.doi.org/10.1001/jama.284.9.1114			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974691				2022-12-28	WOS:000089037200012
J	Frader, JE				Frader, JE			Baby Doe blinders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Northwestern University	Frader, JE (corresponding author), Northwestern Univ, Sch Med, Chicago, IL 60611 USA.		Frader, Joel/A-8610-2010	Frader, Joel/0000-0001-5620-2400				PLESS JE, 1983, NEW ENGL J MED, V309, P664; 2000, EXPENDITURES PERINAT; 2000, PRETERM BIRTHS US 19; 2000, INT COMP INF MORT RA; 2000, HLTH EXPENDITURES; 2000, ADEQUACY PRENATAL CA	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1143	1143		10.1001/jama.284.9.1143	http://dx.doi.org/10.1001/jama.284.9.1143			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974698				2022-12-28	WOS:000089037200019
J	Studer-Ellis, E; Gold, JS; Jones, RF				Studer-Ellis, E; Gold, JS; Jones, RF			Trends in US medical school faculty salaries, 1988-1989 to 1998-1999	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINANCES	Expansion of managed care, intensified price competition, and the introduction of the Medicare Fee Schedule have all affected physician compensation during the past decade. We examine trends in the salaries of medical school faculty, particularly MD clinical faculty, based on a more extensive salary database than has been used previously. Data collected through the Association of American Medical Colleges' Faculty Salary Survey for the academic years 1988-1989, 1993-1994, and 1998-1999 were analyzed, and inflation-adjusted salary growth rates for clinical and basic science faculty during two 5-year periods, 1988-1993 and 1993-1998, compared across faculty ranks, departments, and various school characteristics. The comparison showed that, between 1988 and 1998, the actual median clinical faculty salary increased from $101 000 to $150 000, and the actual median basic science faculty salary increased from $52 000 to $78 000, Bivariate and multivariate analyses showed that the proportionate change in real mean salary (base year, 1988) in each 5-year period was related to department and faculty rank for clinical faculty (P<.001) and faculty rank for basic science faculty (P<.001). The inflation-adjusted annualized compound growth rate of clinical faculty salaries declined from 1.9% per year(1988-1993) to 0.2% per year (1993-1998), while the growth rate of basic science faculty salaries increased from 0.3% per year (1988-1993) to 1.3% per year(1993-1998). From 1993 to 1998, inflation-adjusted annualized salary growth rates in several clinical departments were negative (anesthesiology, -1.1%; obstetrics and gynecology, -0.5%; radiology, -0.4%; and neurology, -0.1%) hut were positive for family practice (+2.7%), Significant differences in salary growth related to school characteristics leg, geographic region, public vs private, community based vs non-community based, and research intensity) were specific to particular study periods. Overall, while actual average medical school faculty salaries are increasing, the real growth rate of average clinical faculty salaries is declining and that of basic science faculty increasing.	Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Jones, RF (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20037 USA.							*ASS AM MED COLL, 1996, FIN MED SCH REP AAMC; *ASS AM MED COLL, 1998, IMPL EV HLTH CAR SYS; Jones RF, 1998, JAMA-J AM MED ASSOC, V280, P813, DOI 10.1001/jama.280.9.813; Krakower JY, 1999, JAMA-J AM MED ASSOC, V282, P847, DOI 10.1001/jama.282.9.847; LIVELY K, 2000, CHRONICLE HIGHE 0225, pA46; *MED GROUP MAN ASS, 2000, AC PRACT FAC COMP PR; *MED GROUP MAN ASS, 1996, PHYS COMP PROD SURV; *PHYS PAYM REV COM, 1990, 1990 ANN REP C; *PHYS PAYM REV COM, 1991, 1991 ANN REP C; *PHYS PAYM REV COM, 1995, 1995 ANN REP C; Simon CJ, 1996, HEALTH AFFAIR, V15, P124, DOI 10.1377/hlthaff.15.3.124; SMITH WC, 1999, REPORT MED SCH FACUL; *US BUR LAB STAT, 1999, 1999 CPI DET REP; ZHANG P, 1999, PHYSICIAN SOCIOECONO, P5; 1997, INTERSTUDY COMP ED 3	15	24	24	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1130	1135		10.1001/jama.284.9.1130	http://dx.doi.org/10.1001/jama.284.9.1130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974694				2022-12-28	WOS:000089037200015
J	Firbank, LG; Forcella, F				Firbank, LG; Forcella, F			Agriculture - Genetically modified crops and farmland biodiversity	SCIENCE			English	Editorial Material							DYNAMICS		Ctr Ecol & Hydrol, Grange Sands LA11 6JU, Cumbria, England; USDA, Agr Res Stn, Morris, MN 56267 USA; Univ Minnesota, Dept Agron & Plant Genet, St Paul, MN 55108 USA	UK Centre for Ecology & Hydrology (UKCEH); United States Department of Agriculture (USDA); University of Minnesota System; University of Minnesota Twin Cities	Firbank, LG (corresponding author), Ctr Ecol & Hydrol, Grange Sands LA11 6JU, Cumbria, England.			Firbank, Leslie/0000-0003-1242-8293				Buhler DD, 1997, WEED SCI, V45, P329, DOI 10.1017/S0043174500092948; CAMPBELL LH, 1997, REV INDIRECT EFFECTS, P148; Culpepper AS, 2000, WEED TECHNOL, V14, P77, DOI 10.1614/0890-037X(2000)014[0077:WMIGAG]2.0.CO;2; Firbank LG, 1999, NATURE, V399, P727, DOI 10.1038/21516; Freckleton RP, 1998, J APPL ECOL, V35, P904, DOI 10.1111/j.1365-2664.1998.tb00008.x; Johnson WG, 2000, WEED TECHNOL, V14, P57, DOI 10.1614/0890-037X(2000)014[0057:EAEOWM]2.0.CO;2; Krebs JR, 1999, NATURE, V400, P611, DOI 10.1038/23127; Robinson RA, 1999, ECOGRAPHY, V22, P447, DOI 10.1111/j.1600-0587.1999.tb00581.x; Vangessel MJ, 2000, WEED TECHNOL, V14, P140, DOI 10.1614/0890-037X(2000)014[0140:OGTWOW]2.0.CO;2; Watkinson AR, 2000, SCIENCE, V289, P1554, DOI 10.1126/science.289.5484.1554	10	52	59	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1481	1482		10.1126/science.289.5484.1481	http://dx.doi.org/10.1126/science.289.5484.1481			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10991733				2022-12-28	WOS:000089071700027
J	Melov, S; Ravenscroft, J; Malik, S; Gill, MS; Walker, DW; Clayton, PE; Wallace, DC; Malfroy, B; Doctrow, SR; Lithgow, GJ				Melov, S; Ravenscroft, J; Malik, S; Gill, MS; Walker, DW; Clayton, PE; Wallace, DC; Malfroy, B; Doctrow, SR; Lithgow, GJ			Extension of life-span with superoxide dismutase/catalase mimetics	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; CATALASE; OVEREXPRESSION; SCAVENGER; EUK-8	We tested the theory that reactive oxygen species cause aging. We augmented the natural antioxidant systems of Caenorhabditis elegans with small synthetic superoxide dismutase/catalase mimetics. Treatment of wild-type worms increased their mean Life-span by a mean of 44 percent, and treatment of prematurely aging worms resulted in normalization of their life-span (a 67 percent increase). It appears that oxidative stress is a major determinant of Life-span and that it can be counteracted by pharmacological intervention.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Acad Unit Child Hlth, Manchester M13 9PT, Lancs, England; Buck Inst Age Res, Novato, CA 94949 USA; Eukarion, Bedford, MA 01730 USA; Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA	University of Manchester; University of Manchester; Buck Institute for Research on Aging; Emory University	Lithgow, GJ (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.		Melov, Simon/AAC-9469-2020	Gill, Matthew/0000-0003-0818-8792; Doctrow, Susan/0000-0003-0628-9960; Clayton, Peter/0000-0003-1225-4537; Melov, Simon/0000-0001-8554-2834	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013154] Funding Source: NIH RePORTER; NIA NIH HHS [AG-13154] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker K, 1998, J PHARMACOL EXP THER, V284, P215; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; Doctrow S R, 1997, Adv Pharmacol, V38, P247; HARRINGTON LA, 1988, MECH AGEING DEV, V43, P71, DOI 10.1016/0047-6374(88)90098-X; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Malfroy B, 1997, CELL IMMUNOL, V177, P62, DOI 10.1006/cimm.1997.1091; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; MELOV S, UNPUB; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Sun JT, 1999, MOL CELL BIOL, V19, P216; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605	21	713	751	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 1	2000	289	5484					1567	1569		10.1126/science.289.5484.1567	http://dx.doi.org/10.1126/science.289.5484.1567			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349XW	10968795				2022-12-28	WOS:000089071700051
J	Stewart, I				Stewart, I			Mathematics - The Lorenz attractor exists	NATURE			English	Editorial Material									Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England	University of Warwick	Stewart, I (corresponding author), Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England.							Morales CA, 1998, CR ACAD SCI I-MATH, V326, P81, DOI 10.1016/S0764-4442(97)82717-6; Tucker W, 1999, CR ACAD SCI I-MATH, V328, P1197, DOI 10.1016/S0764-4442(99)80439-X; Viana M, 2000, MATH INTELL, V22, P6, DOI 10.1007/BF03025276	3	163	175	1	27	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					948	949		10.1038/35023206	http://dx.doi.org/10.1038/35023206			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984036				2022-12-28	WOS:000089020200027
J	Weimerskirch, H; Wilson, RP				Weimerskirch, H; Wilson, RP			Oceanic respite for wandering albatrosses	NATURE			English	Article							SEABIRDS		CNRS, CEBC, F-79360 Villiers En Bois, France; Inst Francais Rech & Technol Polaire, F-29280 Plouzane, France	Centre National de la Recherche Scientifique (CNRS)	Weimerskirch, H (corresponding author), CNRS, CEBC, F-79360 Villiers En Bois, France.		Weimerskirch, Henri/F-5562-2013; Weimerskirch, Henri/K-7306-2019	Weimerskirch, Henri/0000-0002-0457-586X				BROTHERS N, 1991, BIOL CONSERV, V55, P255, DOI 10.1016/0006-3207(91)90031-4; Hill Roger D., 1994, P227; JOUVENTIN P, 1990, NATURE, V343, P746, DOI 10.1038/343746a0; MURPHY R.C., 1936, OCEANIC BIRDS S AM, V2; Nicholls DG, 1997, EMU, V97, P240; ROBERTSON G, 1993, ALBATROSS BIOL CONSE; WEIMERSKIRCH H, 1985, EMU, V85, P22, DOI 10.1071/MU9850022; WEIMERSKIRCH H, 1994, P ROY SOC B-BIOL SCI, V255, P91, DOI 10.1098/rspb.1994.0013; Weimerskirch H, 1997, BIOL CONSERV, V79, P257, DOI 10.1016/S0006-3207(96)00084-5; Welch DW, 1999, CAN J FISH AQUAT SCI, V56, P1317, DOI 10.1139/cjfas-56-7-1317; Wilson R.P., 1992, P131	11	104	112	0	38	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 31	2000	406	6799					955	956		10.1038/35023068	http://dx.doi.org/10.1038/35023068			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	348ZW	10984040				2022-12-28	WOS:000089020200031
J	Limaye, AP; Corey, L; Koelle, DM; Davis, CL; Boeckh, M				Limaye, AP; Corey, L; Koelle, DM; Davis, CL; Boeckh, M			Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants	LANCET			English	Article							PATIENTS RECEIVING GANCICLOVIR; ORAL GANCICLOVIR; LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; ANTIVIRAL DRUGS; RETINITIS; INFECTION; PROPHYLAXIS; THERAPY; ANTIGENEMIA	Background Concerns have been raised about emergence of ganciclovir resistance as a result of the advent of both routine oral ganciclovir prophylaxis and highly potent immunosuppression. We retrospectively assessed the occurrence of ganciclovir-resistant cytomegalovirus disease among transplant recipients who had received oral ganciclovir prophylaxis and highly potent immunosuppression, Methods We studied 240 recipients of liver, kidney, or pancreas transplants. Antiviral susceptibility testing of blood cytomegaloviral isolates was done when patients failed to respond to intravenous ganciclovir treatment for symptomatic cytomegalovirus infection. Portions of the UL97 gene associated with ganciclovir resistance were sequenced in cytomegalovirus isolates with phenotypic resistance to ganciclovir. Findings Ganciclovir-resistant cytomegalovirus disease developed in five (7%) of 67 seronegative recipients of cytomegalovirus-seropositive organs (D+/R-) com pared with none of 173 seropositive recipients (p=0.002). Among the 25 (10.4%) patients who developed cytomegalovirus disease within 1 year after transplantation, five had ganciclovir-resistant cytomegalovirus disease. Among D+/R-transplant recipients, ganciclovir-resistant cytomegalovirus disease was more common among the group receiving the most potent immunosuppression-ie, recipients of kidney and pancreas or pancreas alone (four of 19) compared with all other transplant recipients tone of 48, p=0.02). Ganciclovir-resistant cytomegalovirus disease was diagnosed at a median of 10 months after transplantation (range 7-12) after lengthened exposure to ganciclovir, was associated with previously described mutations of the UL97 gene, and led to serious clinical complications. Interpretation Ganciclovir-resistant cytomegalovirus is an important cause of late morbidity among D+/R- transplant recipients who have had lengthened exposure to ganciclovir and have received highly potent immunosuppression. Strategies to reduce this complication, especially among D+/R- patients, are warranted.	Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Limaye, AP (corresponding author), Univ Washington, Med Ctr, Dept Lab Med, Box 357110,1959 NE Pacific St, Seattle, WA 98195 USA.	limaye@u.washington.edu	Boeckh, Michael/AAA-1607-2022; Koelle, David/Q-6529-2016	Koelle, David/0000-0003-1255-9023	NCI NIH HHS [CA18029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alain S, 1997, TRANSPLANTATION, V63, P1533, DOI 10.1097/00007890-199705270-00031; Baldanti F, 1998, TRANSPLANTATION, V66, P324, DOI 10.1097/00007890-199808150-00008; Barbui Anna, 1999, Clin Microbiol Infect, V5, P23; BOECKH M, 1994, J CLIN MICROBIOL, V32, P832, DOI 10.1128/JCM.32.3.832-834.1994; BOIVIN G, 1993, J INFECT DIS, V168, P332, DOI 10.1093/infdis/168.2.332; Bowen EF, 1998, AIDS, V12, P605, DOI 10.1097/00002030-199806000-00009; Chou SW, 1998, J INFECT DIS, V178, P526, DOI 10.1086/515648; Chou SW, 1997, J INFECT DIS, V176, P786, DOI 10.1086/517302; Cope AV, 1997, J INFECT DIS, V176, P1484, DOI 10.1086/514145; CRUMPACKER CS, 1996, J ACQUIRED IMMUNE S1, V12, pS1; Drew WL, 1999, J INFECT DIS, V179, P1352, DOI 10.1086/314747; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; Erice A, 1999, CLIN MICROBIOL REV, V12, P286, DOI 10.1128/CMR.12.2.286; Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9; Goodrich J, 1997, LANCET, V350, P1718, DOI 10.1016/S0140-6736(97)22050-7; Jabs DA, 1998, J INFECT DIS, V177, P770, DOI 10.1086/514249; JABS DA, 1998, 5 C RETR OPP INF CHI; Kruger RM, 1999, TRANSPLANTATION, V68, P1272, DOI 10.1097/00007890-199911150-00010; Lowance D, 1999, NEW ENGL J MED, V340, P1462, DOI 10.1056/NEJM199905133401903; Lurain NS, 1996, TRANSPLANTATION, V62, P497, DOI 10.1097/00007890-199608270-00012; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Mendez JC, 1999, TRANSPLANTATION, V67, P755, DOI 10.1097/00007890-199903150-00020; RAZIS E, 1994, LEUKEMIA LYMPHOMA, V12, P477, DOI 10.3109/10428199409073791; Reusser P, 1996, BONE MARROW TRANSPL, V17, P813; Rosen HR, 1997, TRANSPLANTATION, V63, P476, DOI 10.1097/00007890-199702150-00026; Singh N, 1998, DIGEST DIS SCI, V43, P1190, DOI 10.1023/A:1018839320383; SLAVIN MA, 1993, ANTIMICROB AGENTS CH, V37, P1360, DOI 10.1128/AAC.37.6.1360; SMITH IL, 1998, 38 IKNT C ANT AG CHE; VANDENBERG AP, 1989, TRANSPLANTATION, V48, P991, DOI 10.1097/00007890-198912000-00019; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9	30	401	407	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2000	356	9230					645	649		10.1016/S0140-6736(00)02607-6	http://dx.doi.org/10.1016/S0140-6736(00)02607-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346RD	10968438				2022-12-28	WOS:000088884100013
J	Bothwell, M; Giniger, E				Bothwell, M; Giniger, E			Alzheimer's disease: Neurodevelopment converges with neurodegeneration	CELL			English	Review							RECEPTORS; REELIN; PROTEINS; LIGAND; CDK5; P35; TAU; RAC		Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Div Basic Sci, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Bothwell, M (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.		Giniger, Edward/C-1764-2015	Giniger, Edward/0000-0002-8340-6158				Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Liebl EC, 2000, NEURON, V26, P107, DOI 10.1016/S0896-6273(00)81142-3; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	19	84	89	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 4	2000	102	3					271	273		10.1016/S0092-8674(00)00032-5	http://dx.doi.org/10.1016/S0092-8674(00)00032-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975517	Bronze			2022-12-28	WOS:000088625600002
J	Volchuk, A; Amherdt, M; Ravazzola, M; Brugger, B; Rivera, VM; Clackson, T; Perrelet, A; Sollner, TH; Rothman, JE; Orci, L				Volchuk, A; Amherdt, M; Ravazzola, M; Brugger, B; Rivera, VM; Clackson, T; Perrelet, A; Sollner, TH; Rothman, JE; Orci, L			Megavesicles implicated in the rapid transport of intracisternal aggregates across the Golgi stack	CELL			English	Article							ENDOPLASMIC-RETICULUM; CISTERNAL MATURATION; MEMBRANE-PROTEINS; COPI VESICLES; LIVING CELLS; APPARATUS; COMPLEX; ER; SECRETION; COATOMER	Engineered protein aggregates ranging up to 400 nm in diameter were selectively deposited within the cis-most cisternae of the Golgi stack following a 15 degrees C block. These aggregates are much larger than the standard volume of Golgi vesicles, yet they are transported across the stack within 10 min after warming the cells to 20 degrees C. Serial sectioning reveals that during the peak of anterograde transport, about 20% of the aggregates were enclosed in topologically free "megavesicles" which appear to pinch off from the rims of the cisternae. These megavesicles can explain the rapid transport of aggregates without cisternal progression on this time scale.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Memorial Sloan Kettering Cancer Center; University of Geneva; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.			Rivera, Victor/0000-0002-7258-3001				Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; Bonfanti L, 1999, MOL BIOL CELL, V10, p114A; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; CLERMONT Y, 1993, ANAT REC, V235, P363, DOI 10.1002/ar.1092350305; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; ORCI L, 2000, IN PRESS J CELL BIOL; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Rollins CT, 2000, P NATL ACAD SCI USA, V97, P7096, DOI 10.1073/pnas.100101997; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIMIONESCU N, 1976, J CELL BIOL, V70, P622, DOI 10.1083/jcb.70.3.622; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015	49	83	85	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 4	2000	102	3					335	348		10.1016/S0092-8674(00)00039-8	http://dx.doi.org/10.1016/S0092-8674(00)00039-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	342BP	10975524	Bronze			2022-12-28	WOS:000088625600009
J	Fink, KS				Fink, KS			Improving survival during snow burial in avalanches	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ N Carolina, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Fink, KS (corresponding author), Univ N Carolina, Chapel Hill, NC 27514 USA.			Radwin, Martin/0000-0002-4455-414X				GRAYDON D, 1992, MOUNTAINEERING FREED, P306; Grissom CK, 2000, JAMA-J AM MED ASSOC, V283, P2266, DOI 10.1001/jama.283.17.2266; Page CE, 1999, WILD ENVIRON MED, V10, P146, DOI 10.1580/1080-6032(1999)010[0146:ADITUS]2.3.CO;2; WILLIAMS K, 1995, WILDERNESS MED MANAG, P616	4	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1242	1243		10.1001/jama.284.10.1242-a	http://dx.doi.org/10.1001/jama.284.10.1242-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979106				2022-12-28	WOS:000089124600024
J	Honig, LS				Honig, LS			Relationship between caffeine intake and Parkinson disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Honig, LS (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							GIBB WRG, 1994, MOVEMENT DISORDERS 3, P147; Honig LS, 1999, NEUROLOGY, V53, P1158, DOI 10.1212/WNL.53.5.1158; Poewe WH, 1996, NEUROLOGY, V47, pS146, DOI 10.1212/WNL.47.6_Suppl_3.146S; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Willems-Giesbergen PCLM, 2000, NEUROLOGY, V54, pA347	5	34	34	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1378	1378		10.1001/jama.284.11.1378	http://dx.doi.org/10.1001/jama.284.11.1378			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989386				2022-12-28	WOS:000089242500015
J	Kaufman, JL				Kaufman, JL			Do critically ill patients benefit from use of pulmonary artery catheters?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Vasc Serv Western New England, Springfield, MA USA		Kaufman, JL (corresponding author), Vasc Serv Western New England, Springfield, MA USA.							Hall JB, 2000, JAMA-J AM MED ASSOC, V283, P2577, DOI 10.1001/jama.283.19.2577	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1242	1242		10.1001/jama.284.10.1242	http://dx.doi.org/10.1001/jama.284.10.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979102				2022-12-28	WOS:000089124600022
J	Furlan, A; Mayberg, MR				Furlan, A; Mayberg, MR			Aspirin in acute ischemic stroke - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Furlan, A (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.								0	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1379	1379		10.1001/jama.284.11.1379	http://dx.doi.org/10.1001/jama.284.11.1379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989387				2022-12-28	WOS:000089242500018
J	Thompson, LG; Yao, T; Mosley-Thompson, E; Davis, ME; Henderson, KA; Lin, PN				Thompson, LG; Yao, T; Mosley-Thompson, E; Davis, ME; Henderson, KA; Lin, PN			A high-resolution millennial record of the South Asian Monsoon from Himalayan ice cores	SCIENCE			English	Article							EURASIAN SNOW COVER; SURFACE AIR-TEMPERATURE; TROPICAL CLIMATE; NORTH PACIFIC; RAINFALL; TRANSPORT; ENSO; DUST	A high-resolution ice core record from Dasuopu, Tibet, reveals that this site is sensitive to fluctuations in the intensity of the South Asian Monsoon. Reductions in monsoonal intensity are recorded by dust and chloride concentrations. The deeper, older sections of the Dasuopu cores suggest many other periods of drought in this region, but none have been of greater intensity than the greatest recorded drought, during 1790 to 1796 A.D. of the Last millennium. The 20th century increase in anthropogenic activity in India and Nepal, upwind from this site, is recorded by a doubling of chloride concentrations anti a fourfold increase in dust. Like other ice cores from the Tibetan Plateau, Dasuopu suggests a Large-scale, plateau-wide 20th-century warming trend that apl,ears to be amplified at higher elevations.	Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA; Chinese Acad Sci, Cold & Arid Reg Environm & Engn Inst, Lanzhou, Peoples R China; Ohio State Univ, Dept Geog, Columbus, OH 43210 USA; Ohio State Univ, Dept Geol Sci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Chinese Academy of Sciences; Cold & Arid Regions Environmental & Engineering Research Institute, CAS; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Thompson, LG (corresponding author), Ohio State Univ, Byrd Polar Res Ctr, Columbus, OH 43210 USA.		Mosley-Thompson, Ellen S/Z-2100-2018					BARNETT TP, 1988, SCIENCE, V239, P504, DOI 10.1126/science.239.4839.504; BOLZAN JF, 1985, J GEOPHYS RES-ATMOS, V90, P8111, DOI 10.1029/JD090iD05p08111; Charles CD, 1997, SCIENCE, V277, P925, DOI 10.1126/science.277.5328.925; CLEMENS S, 1991, NATURE, V353, P720, DOI 10.1038/353720a0; Cole JE, 2000, SCIENCE, V287, P617, DOI 10.1126/science.287.5453.617; DICKSON RR, 1984, J CLIM APPL METEOROL, V23, P171, DOI 10.1175/1520-0450(1984)023<0171:ESCVIM>2.0.CO;2; GAO Y, 1992, J GEOPHYS RES-ATMOS, V97, P9867, DOI 10.1029/92JD00714; GREGORY S, 1986, THEOR APPL CLIMATOL, V37, P194, DOI 10.1007/BF00867577; Grove RH, 1998, NATURE, V393, P318, DOI 10.1038/30636; HAHN DG, 1976, J ATMOS SCI, V33, P2461, DOI 10.1175/1520-0469(1976)033<2461:AARBES>2.0.CO;2; Henderson KA, 1999, J GEOPHYS RES-ATMOS, V104, P31053, DOI 10.1029/1999JD900966; JONES PD, 1994, J CLIMATE, V7, P1794, DOI 10.1175/1520-0442(1994)007<1794:HSATVA>2.0.CO;2; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Liu T.-S., 1981, GEOLOGICAL SOC AM SP, V186, P149; LIU X, IN PRESS INT J CLIMA; MERRILL JT, 1989, J GEOPHYS RES-ATMOS, V94, P8584, DOI 10.1029/JD094iD06p08584; Ortlieb L., 2000, EL NINO SO OSCILLATI, P207; PARRINGTON JR, 1983, SCIENCE, V220, P195, DOI 10.1126/science.220.4593.195; QUINN WH, 1992, NINO HIST PALEOCLIMA, P119; REEH N, 1988, J GLACIOL, V34, P46, DOI 10.3189/S0022143000009059; SIROCKO F, 1993, NATURE, V364, P322, DOI 10.1038/364322a0; SONTAKKE NA, 1993, J CLIMATE, V6, P1807, DOI 10.1175/1520-0442(1993)006<1807:COAISM>2.0.CO;2; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; THOMPSON LG, 1989, SCIENCE, V246, P474, DOI 10.1126/science.246.4929.474; THOMPSON LG, 1993, GLOBAL PLANET CHANGE, V7, P145, DOI 10.1016/0921-8181(93)90046-Q; Thompson LG, 2000, QUATERNARY SCI REV, V19, P19, DOI 10.1016/S0277-3791(99)00052-9; THOMPSON LG, 1985, SCIENCE, V229, P971, DOI 10.1126/science.229.4717.971; THOMPSON LG, 1995, SCIENCE, V269, P47; THOMPSON LG, 1997, SCIENCE, V276, P1757; TOURRE YM, 1995, J PHYS OCEANOGR, V25, P1317, DOI 10.1175/1520-0485(1995)025<1317:ESIGUO>2.0.CO;2; WALLACE JM, 1998, J GEOPHYS RES, V103, P14167; Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719; Yao TD, 1996, J GEOPHYS RES-ATMOS, V101, P29531, DOI 10.1029/96JD02683	33	685	806	16	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 15	2000	289	5486					1916	1919		10.1126/science.289.5486.1916	http://dx.doi.org/10.1126/science.289.5486.1916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354XD	11001720				2022-12-28	WOS:000089355800040
J	Braver, ER; Chen, LH; Baker, SP				Braver, ER; Chen, LH; Baker, SP			Automobile crashes and teenaged drivers - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Insurance Inst Highway Safety, Arlington, VA USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Johns Hopkins University	Braver, ER (corresponding author), Insurance Inst Highway Safety, Arlington, VA USA.		Braver, Elisa/AAT-4631-2020					*CA HIGHW PATR, 2000, ANN REP FAT INJ MOT; *FED HIGHW ADM, 1997, TOT LIC DRIV AG REP; *FED HIGHW ADM, 1998, TOT LIC DRIV AG REP; *INS I HIGHW SAF, 1999, 1998 FAT FACTS ELD; Williams A F, 1999, Inj Prev, V5, P133	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1239	1240						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979096				2022-12-28	WOS:000089124600016
J	Males, H				Males, H			Automobile crashes and teenaged drivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Calif Santa Cruz, Dept Sociol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Males, H (corresponding author), Univ Calif Santa Cruz, Dept Sociol, Santa Cruz, CA 95064 USA.		Braver, Elisa/AAT-4631-2020					Chen LH, 2000, JAMA-J AM MED ASSOC, V283, P1578, DOI 10.1001/jama.283.12.1578; *STAT INT TRAFF RE, 2000, DRIV FAT INJ COLL AG; *STAT INT TRAFF RE, 1984, ANN REP FAT INJ MOT; WESTPHAL SP, 1999, LOS ANGELES TIM 1112, pB1	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1239	1239						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979096				2022-12-28	WOS:000089124600015
J	Schwenk, TL				Schwenk, TL			Screening for depression in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Michigan, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Schwenk, TL (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.							COYNE JC, 1995, GEN HOSP PSYCHIAT, V17, P3, DOI 10.1016/0163-8343(94)00056-J; FECHNERBATES S, 1994, J CONSULT CLIN PSYCH, V62, P550, DOI 10.1037/0022-006X.62.3.550; Jacobs DG, 2000, JAMA-J AM MED ASSOC, V283, P2693, DOI 10.1001/jama.283.20.2693; Schwenk TL, 1996, J GEN INTERN MED, V11, P437, DOI 10.1007/BF02600194; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1379	1380		10.1001/jama.284.11.1379-a	http://dx.doi.org/10.1001/jama.284.11.1379-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989389				2022-12-28	WOS:000089242500019
J	Levinson, SR				Levinson, SR			Diagnosis and treatment of recurrent sinusitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Mt Sinai Med Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Levinson, SR (corresponding author), Mt Sinai Med Ctr, New York, NY 10029 USA.							Parker RA, 2000, JAMA-J AM MED ASSOC, V283, P2143, DOI 10.1001/jama.283.16.2143	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1240	1240		10.1001/jama.284.10.1240	http://dx.doi.org/10.1001/jama.284.10.1240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979097				2022-12-28	WOS:000089124600017
J	Marshall, MN; Shekelle, PG; Brook, RH; Leatherman, S				Marshall, MN; Shekelle, PG; Brook, RH; Leatherman, S			Use of performance data to change physician behavior - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England; RAND Hlth Program, Santa Monica, CA USA; United Healthcare, Minnetonka, MN USA	University of Manchester; RAND Corporation; UnitedHealth Group Incorporated	Marshall, MN (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England.							Davies HTO, 2000, QUAL HEALTH CARE, V9, P111, DOI 10.1136/qhc.9.2.111	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1079	1079		10.1001/jama.284.9.1079	http://dx.doi.org/10.1001/jama.284.9.1079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974681				2022-12-28	WOS:000089037200003
J	Ross, GW; Abbott, RD; Petrovitch, H; White, LR; Tanner, CM				Ross, GW; Abbott, RD; Petrovitch, H; White, LR; Tanner, CM			Relationship between caffeine intake and Parkinson disease - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Dept Vet Affairs, Honolulu, HI 96814 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Pacific Hlth Res Inst, Honolulu, HI USA; Parkinsons Inst, Sunnyvale, CA USA	University of Virginia; Pacific Health Research & Education Institute	Ross, GW (corresponding author), Dept Vet Affairs, Honolulu, HI 96814 USA.							Willems-Giesbergen PCLM, 2000, NEUROLOGY, V54, pA347	1	34	34	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1378	1379		10.1001/jama.284.11.1378	http://dx.doi.org/10.1001/jama.284.11.1378			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989386				2022-12-28	WOS:000089242500016
J	Hall, J				Hall, J			Do critically ill patients benefit from use of pulmonary artery catheters? Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RANDOMIZED TRIAL; SURGERY		Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University of Chicago	Hall, J (corresponding author), Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA.							Bender JS, 1997, ANN SURG, V226, P229, DOI 10.1097/00000658-199709000-00002; CONNORS AF, 1987, J CRIT CARE, V2, P174, DOI 10.1016/0883-9441(87)90004-9; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; ISAACSON IJ, 1990, J VASC SURG, V12, P754, DOI 10.1067/mva.1990.24456; Valentine RJ, 1998, J VASC SURG, V27, P203, DOI 10.1016/S0741-5214(98)70351-9	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1242	1242		10.1001/jama.284.10.1242	http://dx.doi.org/10.1001/jama.284.10.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979102				2022-12-28	WOS:000089124600023
J	Kennedy, DW				Kennedy, DW			Diagnosis and treatment of recurrent sinusitis - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kennedy, DW (corresponding author), Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA.							Burke T F, 1994, Acad Emerg Med, V1, P235; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; LINUMA T, 1994, RHINOLOGY, V32, P124; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1240	1241		10.1001/jama.284.10.1240	http://dx.doi.org/10.1001/jama.284.10.1240			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979097				2022-12-28	WOS:000089124600018
J	Smaglik, P				Smaglik, P			Climate change expert stirs new controversy	NATURE			English	News Item																			0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					7	7		10.1038/35024244	http://dx.doi.org/10.1038/35024244			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993046	Bronze			2022-12-28	WOS:000089124000010
J	Rosenstein, AH				Rosenstein, AH			Use of performance data to change physician behavior	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									VHA W Coast, Pleasanton, CA USA		Rosenstein, AH (corresponding author), VHA W Coast, Pleasanton, CA USA.							Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Rosenstein A H, 1997, Jt Comm J Qual Improv, V23, P653; ROSENSTEIN AH, 1995, MANAG CARE MED   OCT, P10	3	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2000	284	9					1079	1079		10.1001/jama.284.9.1079	http://dx.doi.org/10.1001/jama.284.9.1079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349GK	10974681				2022-12-28	WOS:000089037200002
J	Longstreth, WT				Longstreth, WT			Aspirin in acute ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Longstreth, WT (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave, Seattle, WA 98104 USA.							CANDELISE L, 1995, LANCET, V346, P1509; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mayberg MR, 2000, JAMA-J AM MED ASSOC, V283, P2440, DOI 10.1001/jama.283.18.2440; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395	5	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2000	284	11					1379	1379		10.1001/jama.284.11.1379	http://dx.doi.org/10.1001/jama.284.11.1379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	352WN	10989387				2022-12-28	WOS:000089242500017
J	Smaglik, P				Smaglik, P			US grant glues 'virtual cell' together	NATURE			English	News Item																			0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 7	2000	407	6800					7	7		10.1038/35024244	http://dx.doi.org/10.1038/35024244			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	350WE	10993046	Bronze			2022-12-28	WOS:000089124000011
J	Carley, JW				Carley, JW			A 26-year-old woman with a second abortion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		Hartman EE, 2000, JAMA-J AM MED ASSOC, V283, P2700, DOI 10.1001/jama.283.20.2700	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1244	1244		10.1001/jama.284.10.1244	http://dx.doi.org/10.1001/jama.284.10.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979108				2022-12-28	WOS:000089124600027
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 26-year-old woman with a second abortion - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Parker, RA (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.							Grimes D A, 1999, JAMA, V282, P1169, DOI 10.1001/jama.282.12.1169	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2000	284	10					1244	1244		10.1001/jama.284.10.1244	http://dx.doi.org/10.1001/jama.284.10.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350WL	10979108				2022-12-28	WOS:000089124600028
